run_guid,run_type,task_guid,agent_code,run_datetime,subscription_id,org_guid,user_guid,params,source,destination,status,create_date,modified_date
00064e05-62eb-4dc4-844a-424af32ed1d6,USA-FDA,15491157-d020-4261-b6c3-332ce4c2906e,G_MINI_SUMMARY,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002/FDA-2012-N-1239-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guideline for Industry and Food and Drug Administration Staff; Class II Special Controls Guideline: Temporary Mandibular Condyle Reconstruction Plate"", ""docket_id"": ""FDA-2012-N-1239"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-N-1239-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:31:42,2025-05-28 03:53:06
001527d2-3212-442d-a24d-6affab492ffe,USA-FDA,b2bc5cbc-8c66-4065-a6f5-0f61aeec7523,G_DETAILED_SUMMARY,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0074/FDA-2011-D-0074-0025/FDA-2011-D-0074-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Medication Guide Distribution Requirements and Inclusion of Medication Guides in Risk Evaluation and Mitigation Strategies"", ""docket_id"": ""FDA-2011-D-0074"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0074-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0074/FDA-2011-D-0074-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:00:47,2025-05-28 03:53:06
002b769b-4394-4982-acea-c1374b2cd7ed,USA-FDA,27a83884-e12c-4355-8a51-f145f8f20dae,G_FAQ,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007/FDA-2007-D-0149-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff Class II Special Controls Guidance Document: Electrocardiograph Electrodes"", ""docket_id"": ""FDA-2007-D-0149"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0149-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:32:00,2025-05-28 03:53:06
00a88a0d-e67b-44be-8fea-42442d311b60,USA-FDA,569b996d-eb45-41d4-9c7c-4eb81fd68e75,G_FAQ,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0246/FDA-2010-D-0246-0014/FDA-2010-D-0246-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Residual Drug in Transdermal and Related Drug Delivery Systems; Guidance for Industry"", ""docket_id"": ""FDA-2010-D-0246"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0246-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0246/FDA-2010-D-0246-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:02:07,2025-05-28 03:53:06
00ab0f6f-5376-4c02-bb3e-8ea2532277d2,USA-FDA,195900eb-c304-4631-bb2c-ee48f186dd64,G_IMPACT_ANALYSIS,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0533/FDA-2009-D-0533-0009/FDA-2009-D-0533-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application"", ""docket_id"": ""FDA-2009-D-0533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0533-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0533/FDA-2009-D-0533-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:00:39,2025-05-28 03:53:06
00ccd330-5633-4e1d-a40c-3018288586e1,USA-FDA,9d8ba92b-278e-4190-9522-d804aa472ac4,G_DETAILED_SUMMARY,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022/FDA-1999-D-1875-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Extra-Label Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:02:33,2025-05-28 03:53:06
00d3093f-5e88-42f8-993b-6cc1404e06e5,USA-FDA,d234097c-6ee0-4806-9a2a-30b975a2edff,G_FAQ,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003/FDA-2006-D-0231-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds"", ""docket_id"": ""FDA-2006-D-0231"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0231-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:00:59,2025-05-28 03:53:06
00fa7616-de46-412b-b29a-7e8d0480ab59,USA-FDA,ccc25d33-0fb5-48b1-a582-a96db5f1e605,G_MINI_SUMMARY,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0258/FDA-2011-D-0258-0002/FDA-2011-D-0258-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 335.700 Surgeons� Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure"", ""docket_id"": ""FDA-2011-D-0258"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0258-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0258/FDA-2011-D-0258-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:46:35,2025-05-28 03:53:06
00fbfc42-41fa-4264-871e-4bfdd5c0a472,USA-FDA,427d978d-01fc-4357-a7e2-0323d2866c85,G_MINI_SUMMARY,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0971/FDA-2016-D-0971-0002/FDA-2016-D-0971-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Infectious Disease Next Generation Sequencing Based Diagnostic Devices Microbial Identification and Detection of Antimicrobial Resistance and Virulence Markers"", ""docket_id"": ""FDA-2016-D-0971"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0971-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0971/FDA-2016-D-0971-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:45:11,2025-05-28 03:53:06
00fca77b-db08-44d5-93a7-3be9fd7269c3,CAB,9f2555d7-90ec-4358-9bc9-6c44c1715b0a,G_SUMMARY_IN,2025-05-20 12:42:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2018-N-3233-0006.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2018-N-3233-0006_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""3f21331b-4399-4219-aa7e-0a5cb7a4ba33""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3f21331b-4399-4219-aa7e-0a5cb7a4ba33"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:43:22,2025-05-28 03:53:06
010b79c3-3320-4924-b7a3-04b075666341,USA-FDA,a7a97776-cb26-4bf9-b74e-8d806387dd6c,G_FAQ,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0019/FDA-2017-D-6380-0019-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0019""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0019"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:00:24,2025-05-28 03:53:06
01226d31-c76c-46e3-99db-1890afcb9bb6,USA-FDA,ab435c41-e7be-4e33-b436-4df8cb0d9ec7,G_CONCISE_SUMMARY,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025/FDA-2004-D-0044-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:15:11,2025-05-28 03:53:06
0129521f-1a3d-4f92-b58a-265588ba1041,USA-FDA,9679177f-f327-4ef6-a32c-2575870536e5,G_KEYWORDS,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001/FDA-2018-D-3551-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Impact of Certain Provisions of Revised Common Rule on FDA-Regulated Clinical Investigations; Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2018-D-3551"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3551-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:30:53,2025-05-28 03:53:06
0147bb5c-b8a8-42b5-a573-6edaf40ee46e,USA-FDA,0632d6e5-ca07-458e-b402-3870adcbf934,G_FAQ,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610/FDA-2016-D-4414-1610-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nutrition and Supplement Facts Labels: Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals: Guidance for Industry"", ""docket_id"": ""FDA-2016-D-4414"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-4414-1610""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:15:43,2025-05-28 03:53:06
0148a4ec-b624-4f1d-b755-37d7bec87a7a,USA-FDA,aca07e51-6a57-435e-a4f0-787ab00d56ce,G_ACTION_ITEMS,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002/FDA-2012-D-1135-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidances for Industry Limiting Use of Certain Phthalates as Excipients in Center for Drug Evaluation and Research-Regulated Products"", ""docket_id"": ""FDA-2012-D-1135"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1135-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:01:43,2025-05-28 03:53:06
0152a786-57fd-4e5a-aa41-faa0a8d77cea,USA-FDA,0257b2af-3237-4fab-93c2-0fd50321190f,G_DETAILED_SUMMARY,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002/FDA-2011-D-0487-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of Acceptable Full-Length and Abbreviated Donor History Questinnaries and Accompanying Materials for Use in Screening Donors of Source Plasma Draft Guidence"", ""docket_id"": ""FDA-2011-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0487-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:31:12,2025-05-28 03:53:06
01651033-4d1e-4a1b-913b-302c78a7484c,USA-FDA,b2985e33-3360-46d8-aa82-c456b117da8e,G_ACTION_ITEMS,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002/FDA-2013-D-0920-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0920"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0920-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:31:27,2025-05-28 03:53:06
0198723a-c9eb-4d16-aa2e-9dc792d66245,USA-FDA,b4676cee-51ea-4d54-baf3-fb27ec89b479,G_FAQ,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0002/FDA-2004-D-0500-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Help Seeking and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:32:52,2025-05-28 03:53:06
01aba6cc-a881-49dd-a007-2669c8ae50cb,USA-FDA,f91e9c88-1c0c-4bab-be4e-0bae25dce427,G_MINI_SUMMARY,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0007/FDA-1992-N-0007-0005/FDA-1992-N-0007-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Industry Supported Scientific and Educational Activities:  Guidance for Industry"", ""docket_id"": ""FDA-1992-N-0007"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0007-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0007/FDA-1992-N-0007-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:16:25,2025-05-28 03:53:06
01d722ca-9261-4f59-a144-45688713b7e6,USA-FDA,cd6ae191-6b17-4be5-9754-3e289d74dc8a,G_DETAILED_SUMMARY,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006/FDA-2010-D-0500-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information"", ""docket_id"": ""FDA-2010-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0500-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:18,2025-05-28 03:53:06
01e3a978-18f0-4020-b8e8-23e7767f86b7,USA-FDA,b8da3063-6c16-45b9-b18d-d9f167a9bc18,G_FAQ,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0514/FDA-2011-D-0514-0002/FDA-2011-D-0514-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Industry and Staff; Procedures for Handling Section 522 Postmarket Surveillance Studies"", ""docket_id"": ""FDA-2011-D-0514"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0514-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0514/FDA-2011-D-0514-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:15:44,2025-05-28 03:53:06
022490cc-b985-40b0-a110-e83976b6a47d,USA-FDA,adf23480-e65e-472c-850f-a0b36f6264ab,G_IMPACT_ANALYSIS,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0893/FDA-2011-D-0893-0002/FDA-2011-D-0893-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry and Staff Center for Devices and Radiological Health Appeals Processes"", ""docket_id"": ""FDA-2011-D-0893"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0893-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0893/FDA-2011-D-0893-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:02:53,2025-05-28 03:53:06
025b8844-aeba-445f-ae12-40b54693e0f3,USA-FDA,f34b94ca-f27e-4a3c-ad23-7ce93496d4dc,G_FAQ,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0361/FDA-2008-N-0361-0002/FDA-2008-N-0361-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Standard of Identity for White Chocolate; Guidance "", ""docket_id"": ""FDA-2008-N-0361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-N-0361-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0361/FDA-2008-N-0361-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:15:20,2025-05-28 03:53:06
027cdec5-18c7-43a8-bf99-4ced5ab65361,USA-FDA,7cd0d58e-9a9d-42ec-9627-8fd22e222c42,G_DETAILED_SUMMARY,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001/FDA-2020-D-1407-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products HCT Ps Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2020-D-1407"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1407-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:32,2025-05-28 03:53:06
029979db-2550-492c-ac10-7531fe15c83a,QUEUE,36e50ad4-0646-4fbf-b5ba-01645a1383d7,G_SUMMARY_USER,2025-05-28 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""doc_title"": ""Provisions for In-vitro Diagnostic Reagent Registration (Abolished) (1).pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/detailed_summary/36e50ad4-0646-4fbf-b5ba-01645a1383d7/Provisions for In-vitro Diagnostic Reagent Registration (Abolished) (1).pdf.pdf"", ""doc_title"": ""Provisions for In-vitro Diagnostic Reagent Registration (Abolished) (1).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/detailed_summary/36e50ad4-0646-4fbf-b5ba-01645a1383d7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 22:00:17,2025-05-28 22:00:17
02a3e9f0-8d76-46d5-a5b2-7bee9fb4f5d7,USA-FDA,4ba73109-40ed-477e-a7c4-e71adc02dfc4,G_FAQ,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1318/FDA-2014-D-1318-0002/FDA-2014-D-1318-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1318"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1318-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1318/FDA-2014-D-1318-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:16:35,2025-05-28 03:53:06
02e708c2-f1c2-495d-acb5-537d63db9848,SCHEDULED,070e5000-89cd-4650-b1ca-bf8181c92255,DEVICE_ANALYST,2025-05-21 20:33:25,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/070e5000-89cd-4650-b1ca-bf8181c92255"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:43,2025-05-28 03:53:06
02e825af-8c37-4212-bae1-8968b2ab9e0e,USA-FDA,f9397e04-e15c-433b-9cfe-e8f19565c334,G_FAQ,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0128/FDA-2008-D-0128-0005/FDA-2008-D-0128-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Guidance for Industry"", ""docket_id"": ""FDA-2008-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0128-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0128/FDA-2008-D-0128-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:47:27,2025-05-28 03:53:06
02ff3b59-b5bb-468a-8e1c-b9de6de279cf,USA-FDA,9250f4a3-98d4-492a-9e89-4e8033c4159d,G_ACTION_ITEMS,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004/FDA-2002-D-0298-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition"", ""docket_id"": ""FDA-2002-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0298-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:46:47,2025-05-28 03:53:06
0322a51c-0106-451e-a467-519d222cdfd7,USA-FDA,b8095366-24e5-4baf-976b-3c3d3b52162b,G_IMPACT_ANALYSIS,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0438/FDA-2004-D-0438-0007/FDA-2004-D-0438-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Time and Extent Applications for Nonprescription Drug Products"", ""docket_id"": ""FDA-2004-D-0438"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0438-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0438/FDA-2004-D-0438-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:48:09,2025-05-28 03:53:06
0327f1c0-bba3-479b-a51b-202f0f4af6cf,USA-FDA,60538d2e-8e19-450c-948e-c1d1037aff14,G_FAQ,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004/FDA-2019-D-1372-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Elemental Impurities in Human Drug Products Questions and Answers Proposed DRAFT Guidance for Industry"", ""docket_id"": ""FDA-2019-D-1372"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-1372-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:02:15,2025-05-28 03:53:06
03364ca4-ee23-4cdb-8641-5cdcc356a007,USA-FDA,a9f34265-83f3-4703-baac-64d3bdb53bc8,G_KEYWORDS,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004/FDA-2002-D-0298-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition"", ""docket_id"": ""FDA-2002-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0298-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:47:00,2025-05-28 03:53:06
03532a04-7451-4554-842e-18306ac78c53,USA-FDA,92cd48de-2c25-402c-83e5-08e820dff4c0,G_IMPACT_ANALYSIS,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3327/FDA-2015-D-3327-0002/FDA-2015-D-3327-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry E6(R2) Good Clinical Practice"", ""docket_id"": ""FDA-2015-D-3327"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-3327-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3327/FDA-2015-D-3327-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:31:32,2025-05-28 03:53:06
03544159-d00e-4ec7-84a1-b33ea27e3626,USA-FDA,5b7930a5-f02c-4853-9ece-da24ed7f646a,G_ACTION_ITEMS,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0138/FDA-2001-D-0138-0003/FDA-2001-D-0138-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Exemptions from the Warning Label Requirement for Juice - Recommendations for Effectively Achieving a 5 -Log Pathogen Reduction"", ""docket_id"": ""FDA-2001-D-0138"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0138-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0138/FDA-2001-D-0138-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:45:33,2025-05-28 03:53:06
0357d6f4-8410-45e2-bd84-774123b1a582,USA-FDA,83802620-26dc-4099-90b2-6bec3f11be9a,G_DETAILED_SUMMARY,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0146/FDA-2010-D-0146-0012/FDA-2010-D-0146-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Irritable Bowel Syndrome Clinical Evaluation of Drugs for Treatment"", ""docket_id"": ""FDA-2010-D-0146"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0146-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0146/FDA-2010-D-0146-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:16:10,2025-05-28 03:53:06
036f4431-c04b-4b25-8b74-567549ce96ec,USA-FDA,8050275d-4e15-44e0-a73a-14dc904a6c10,G_DETAILED_SUMMARY,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0835/FDA-2011-D-0835-0002/FDA-2011-D-0835-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Considerations when Transferring Clinical Investigation Oversight to Another Institutional Review Board; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0835"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0835-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0835/FDA-2011-D-0835-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:46:39,2025-05-28 03:53:06
0377a493-5070-45aa-aede-2080fd4efad6,USA-FDA,29f3a9ce-0d09-4d6c-8303-0515da8d8243,G_CONCISE_SUMMARY,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002/FDA-2013-D-0269-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Purchasing Reef Fish Species Associated with the Hazard of Ciguatera Fish Poisoning"", ""docket_id"": ""FDA-2013-D-0269"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0269-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:31:47,2025-05-28 03:53:06
0390d9da-d801-4689-9b6b-42efb8934d6a,USA-FDA,200fb6b7-beee-4a68-b78d-cb1b84c5790b,G_IMPACT_ANALYSIS,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001/FDA-2020-D-1950-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 394.500 Importation of Television Products, Microwave Ovens, and Inherent Class I Laser Products for Investigation and Evaluation during Design Development"", ""docket_id"": ""FDA-2020-D-1950"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1950-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:47:51,2025-05-28 03:53:06
039d6a2d-61fd-4ceb-88fb-28a6337390ff,USA-FDA,f1861718-3a81-4875-9965-a39648a283ca,G_KEYWORDS,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004/FDA-2005-D-0028-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products"", ""docket_id"": ""FDA-2005-D-0028"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0028-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:02:35,2025-05-28 03:53:06
03b38423-73f2-4ba3-b479-540e5e119ba6,USA-FDA,9ac8d5ac-209f-465b-b4b0-46e60846a190,G_KEYWORDS,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008/FDA-1999-D-0128-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cooperative Manufacturing Arrangements for Licensed Biologics"", ""docket_id"": ""FDA-1999-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0128-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:32:31,2025-05-28 03:53:06
03b49cf0-eaf4-4d20-a000-9fafc7f96e6d,SCHEDULED,baa19654-fad3-4b61-acf9-46c96344cdd9,DEVICE_ANALYST,2025-05-23 00:00:04,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/baa19654-fad3-4b61-acf9-46c96344cdd9"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:12,2025-05-28 03:53:06
03b8f581-f874-48d7-88b3-09dc39d80490,USA-FDA,dcb19ef9-97d4-4a3e-a70f-a003565fe43e,G_MINI_SUMMARY,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002/FDA-2017-D-4359-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry 68 on Small Entites Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:15:07,2025-05-28 03:53:06
03c25a75-2b3f-4cd0-a461-8d20a7346005,USA-FDA,e627b0c5-fbcd-4dcd-9fdd-5fb77bcaf3c6,G_FAQ,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002/FDA-2011-D-0733-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Evaluating the Safety of Flood-affected Food Crops for Human Consumption"", ""docket_id"": ""FDA-2011-D-0733"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0733-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:30:32,2025-05-28 03:53:06
0418b48e-fd4b-4d3f-8c55-ffd807ee0804,USA-FDA,df3572af-6fd5-4e76-8fd7-d67fe7052588,G_FAQ,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001/FDA-2020-D-1408-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000; I Introduction"", ""docket_id"": ""FDA-2020-D-1408"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1408-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:54,2025-05-28 03:53:06
042304a5-1d64-4f90-9f10-e8771c7f9f2a,USA-FDA,419e2789-74cd-4390-aa80-19966c8242b7,G_IMPACT_ANALYSIS,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0730/FDA-2013-N-0730-0007/FDA-2013-N-0730-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for Industry: Submitting Requests under 21 CFR 170.39 Threshold of Regulation for Substances Used in Food-Contact Articles"", ""docket_id"": ""FDA-2013-N-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-0730-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0730/FDA-2013-N-0730-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:15:40,2025-05-28 03:53:06
0461450e-3a89-4b2a-a276-32ce745fbffd,SCHEDULED,d1b7f331-3187-4465-9563-d128f5910c6a,FDA_ALERT,2025-05-28 00:00:05,4,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-04-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/fda_alert/d1b7f331-3187-4465-9563-d128f5910c6a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:09,2025-05-28 03:53:06
0464c0f3-9405-4693-aa94-52d94b693cb4,SCHEDULED,09f070bb-2582-4900-8def-9d1786439326,DEVICE_ANALYST,2025-05-25 00:00:04,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/09f070bb-2582-4900-8def-9d1786439326"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:15,2025-05-28 03:53:06
047a277f-a54c-4c4a-a30a-7fc6a180c318,USA-FDA,b5f28e27-c033-42ac-a625-936f2063c364,G_IMPACT_ANALYSIS,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0169/FDA-2013-D-0169-0002/FDA-2013-D-0169-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Review Staff: Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling"", ""docket_id"": ""FDA-2013-D-0169"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0169-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0169/FDA-2013-D-0169-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:45:47,2025-05-28 03:53:06
0495d719-c352-4f98-be0d-c1bce941a394,USA-FDA,b9ec8b09-66ed-4b74-a651-16d405e3359d,G_FAQ,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1935/FDA-2020-D-1935-0001/FDA-2020-D-1935-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 100.550 Status and Responsibilities of Contract Sterilizers Engaged in the Sterilization of Drugs and Devices"", ""docket_id"": ""FDA-2020-D-1935"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1935-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1935/FDA-2020-D-1935-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:45:58,2025-05-28 03:53:06
04a21a3f-d9a3-4605-9891-39b5f91ca155,USA-FDA,44b3f595-347c-43cb-bc49-da72fb7db228,G_FAQ,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004/FDA-2010-D-0249-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Systemic Lupus Erythematosus � Developing Medical Products for Treatment"", ""docket_id"": ""FDA-2010-D-0249"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0249-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:02:02,2025-05-28 03:53:06
04a83e05-1491-4082-bc90-44ab26381d00,USA-FDA,8cc89106-fb40-48ac-be5e-5ddb38a138c8,G_IMPACT_ANALYSIS,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002/FDA-2018-D-3152-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Postapproval Changes to Drug Substances Guidance for Industry"", ""docket_id"": ""FDA-2018-D-3152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3152-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:46:16,2025-05-28 03:53:06
04e21f3f-893c-45a0-8329-7a9acacf52cc,USA-FDA,1532719e-dacd-4867-bab3-0526a55145e1,G_ACTION_ITEMS,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002/FDA-2015-D-1309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M8 Electronic Common Technical Document v4.0 Draft Implementation\nGuide v2.0; Electronic Common Technical Document v4.0 Implementation Package Draft Specification for Submission Formats\nv2.0; International Conference on Harmonisation; Draft Guidance for\nIndustry"", ""docket_id"": ""FDA-2015-D-1309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:46:44,2025-05-28 03:53:06
0510b338-d881-44dd-8de1-f6dbbc024bde,USA-FDA,632ed0ab-8489-4e03-b152-5ebc8ff0bdeb,G_CONCISE_SUMMARY,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004/FDA-2010-D-0249-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Systemic Lupus Erythematosus � Developing Medical Products for Treatment"", ""docket_id"": ""FDA-2010-D-0249"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0249-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:01:17,2025-05-28 03:53:06
05116094-2e27-4e40-ae8c-5dd3b3c30bdd,CAB,9df1e9c6-3449-4fc3-b65c-4deca77590d4,G_SUMMARY_IN,2025-05-27 02:30:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""Provisions for In-vitro Diagnostic Reagent Registration (Abolished) (1).pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/33ef1a3e-f632-4ce5-90e6-a74eb8d6b6eb/Provisions for In-vitro Diagnostic Reagent Registration (Abolished) (1).pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""688478d9-789c-4a07-b85a-f8ffb2a70019""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/688478d9-789c-4a07-b85a-f8ffb2a70019"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 02:30:20,2025-05-28 03:53:06
0515ef11-c6b5-4495-8fe9-9353bd978956,USA-FDA,c78255f2-7342-4017-bd02-0306ac8f93d3,G_KEYWORDS,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002/FDA-2018-D-0740-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk Guidance for Industry"", ""docket_id"": ""FDA-2018-D-0740"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0740-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:31:31,2025-05-28 03:53:06
05421361-0021-4ede-8590-159b1219008b,USA-FDA,b2af0e01-0987-4926-b8a1-2b7257d8a888,G_MINI_SUMMARY,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1962/FDA-2020-D-1962-0001/FDA-2020-D-1962-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.400 Contamination of Devices Labeled as Sterile"", ""docket_id"": ""FDA-2020-D-1962"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1962-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1962/FDA-2020-D-1962-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:16:15,2025-05-28 03:53:06
055cf962-055b-4b8d-b1ba-b079faefef9e,USA-FDA,83a07ddc-8d22-4a1e-804f-d29ef84ca394,G_CONCISE_SUMMARY,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007/FDA-2007-D-0149-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff Class II Special Controls Guidance Document: Electrocardiograph Electrodes"", ""docket_id"": ""FDA-2007-D-0149"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0149-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:31:43,2025-05-28 03:53:06
0562040b-56b6-4639-8151-756e26aeb141,USA-FDA,88b5cf00-a8af-435a-a19d-e8de1ec1de84,G_IMPACT_ANALYSIS,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005/FDA-2010-D-0163-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (VICH GL46)"", ""docket_id"": ""FDA-2010-D-0163"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0163-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:30:54,2025-05-28 03:53:06
05a06d3e-5207-447d-8fc0-d817400f33f3,CAB,c9dcac88-744b-4a83-9562-8016aa4e77f0,G_CONCISE_SUMMARY_IN,2025-05-20 10:06:57,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""__num_paragraphs__"": 3}","{""tilte"": ""Rapporto_esplicativo_revisione_ordinanze_20240607.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/Rapporto_esplicativo_revisione_ordinanze_20240607.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""fb660f3f-a153-44fa-90cf-7ed1e0478417""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/fb660f3f-a153-44fa-90cf-7ed1e0478417"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:09:15,2025-05-28 03:53:06
05a32060-1248-4759-87a7-a32744f0a0e5,SCHEDULED,d8adb97c-a670-4907-a4d0-5ae649470293,FDA_ALERT,2025-05-25 00:00:04,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/d8adb97c-a670-4907-a4d0-5ae649470293"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:17,2025-05-28 03:53:06
05e3a81e-e505-4729-9ffc-4777a27839c2,USA-FDA,1a0ec741-3ecd-4181-821e-6ed087f18b6d,G_ACTION_ITEMS,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-N-0464/FDA-2005-N-0464-0231/FDA-2005-N-0464-0231-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guideline re Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Drug Establishment Registration and Drug Listing; Availability"", ""docket_id"": ""FDA-2005-N-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-N-0464-0231""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-N-0464/FDA-2005-N-0464-0231"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:17:34,2025-05-28 03:53:06
0602817c-f5aa-43a1-b273-a61b9308c9e7,SCHEDULED,1d8f21dc-8890-49ee-b3bc-15494bb6789e,DEVICE_ANALYST,2025-05-19 17:09:17,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-19""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/1d8f21dc-8890-49ee-b3bc-15494bb6789e"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-19 21:18:44,2025-05-28 03:53:06
0603abcc-eb54-4eb9-97d4-6c95ee3675e9,USA-FDA,571f61e5-67b4-487c-901f-349ac3d7b2b2,G_KEYWORDS,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002/FDA-2009-D-0539-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins; Guidance"", ""docket_id"": ""FDA-2009-D-0539"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0539-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:32:17,2025-05-28 03:53:06
0608268c-182e-4047-b11b-0775c6bf1c78,USA-FDA,59f682e9-8ed1-43a9-94ac-b14b1d1e8868,G_FAQ,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001/FDA-2020-D-0367-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""External Guidance Document Submission from Turner Scientific, LLC re: Ototoxicity: Nonclinical Evaluation During Drug Development"", ""docket_id"": ""FDA-2020-D-0367"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-0367-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:19,2025-05-28 03:53:06
0608fff7-bfe8-40a2-8f09-460854072959,USA-FDA,77e4c5b4-4dc9-4eb6-85ed-03d4bc34812b,G_CONCISE_SUMMARY,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001/FDA-2020-D-1977-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures"", ""docket_id"": ""FDA-2020-D-1977"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1977-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:16:26,2025-05-28 03:53:06
0633ce0d-e17b-4ede-bb75-d9e91c2597b9,USA-FDA,4675e832-dea7-4ff9-b0d1-4685ac676f20,G_CONCISE_SUMMARY,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004/FDA-2007-D-0302-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Labeling for Human Prescription Drug and Biological Products � Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information"", ""docket_id"": ""FDA-2007-D-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0302-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:02:52,2025-05-28 03:53:06
0641cc11-1413-486c-bca4-1900ba1c5430,USA-FDA,6a65582f-fc15-469f-9ebe-e9340e6d33fc,G_ACTION_ITEMS,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002/FDA-2009-D-0006-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""S9 Nonclinical Evaluation for Anticancer Pharmaceuticals - Draft Guidance"", ""docket_id"": ""FDA-2009-D-0006"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0006-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:00:52,2025-05-28 03:53:06
064650a1-309a-40e1-9b67-d9dce9442f13,USA-FDA,39ad06eb-b405-402e-bccb-e10740ab2c94,G_MINI_SUMMARY,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015/FDA-1999-D-1315-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Formal Meetings With Sponsors and Applicants for PDUFA Products; Guidance Document"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:32:22,2025-05-28 03:53:06
06875993-97fb-4fce-840a-e337746ad1fd,USA-FDA,e159b5b4-c4bc-4d77-9a72-b9805e139427,G_FAQ,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0057/FDA-2011-D-0057-0021/FDA-2011-D-0057-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff ;  Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data"", ""docket_id"": ""FDA-2011-D-0057"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0057-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0057/FDA-2011-D-0057-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:02:38,2025-05-28 03:53:06
0687af85-fd62-45c2-a9be-7e2e8c7b9892,USA-FDA,3522cd14-4a13-42c2-8a25-e6d8b5a4ad04,G_MINI_SUMMARY,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0712/FDA-2016-D-0712-0002/FDA-2016-D-0712-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported  Outcome, for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use DRAFT GUIDANCE"", ""docket_id"": ""FDA-2016-D-0712"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0712-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0712/FDA-2016-D-0712-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:16:13,2025-05-28 03:53:06
068c3fff-91ce-4e97-aaed-ce4b7ed3fca6,USA-FDA,8fb93786-d3f6-4e66-a371-28c62641e828,G_DETAILED_SUMMARY,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0889/FDA-2011-D-0889-0002/FDA-2011-D-0889-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions With GFI #209"", ""docket_id"": ""FDA-2011-D-0889"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0889-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0889/FDA-2011-D-0889-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:31:01,2025-05-28 03:53:06
06a5c0e2-dd2b-46c9-acc5-5c8322e93e78,SCHEDULED,e0246fd3-6a49-49be-a736-10187f618816,FDA_ALERT,2025-05-23 00:00:04,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/e0246fd3-6a49-49be-a736-10187f618816"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:14,2025-05-28 03:53:06
06aab4fc-64b9-486a-8601-7edcec2665b1,USA-FDA,e982293b-304f-466d-96dc-3804c6ded755,G_ACTION_ITEMS,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0286/FDA-2013-D-0286-0015/FDA-2013-D-0286-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0286"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0286-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0286/FDA-2013-D-0286-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:17:01,2025-05-28 03:53:06
06c8bb03-ff94-4319-9241-8d4b4be8ed89,SCHEDULED,05257421-3c62-4afe-aef7-d61619b5b0a0,FDA_ALERT,2025-05-22 00:03:21,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/05257421-3c62-4afe-aef7-d61619b5b0a0"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:26,2025-05-28 03:53:06
06f47d8f-b3bb-495c-94da-8beef483edd3,USA-FDA,2ff87992-6126-49b7-a4cf-25b294673395,G_MINI_SUMMARY,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0490/FDA-2011-D-0490-0002/FDA-2011-D-0490-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that are Color Additives; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0490-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0490/FDA-2011-D-0490-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:15:42,2025-05-28 03:53:06
06fa09ee-b315-4141-96a8-41c3072d8903,USA-FDA,d9836f61-2f60-422f-9534-789d7cb14f3d,G_ACTION_ITEMS,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1659/FDA-2015-D-1659-0002/FDA-2015-D-1659-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Established Conditions: Reportable Chemistry, Manufacturing, and\nControls Changes for Approved Drug and Biologic Products; Draft Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1659"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1659-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1659/FDA-2015-D-1659-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:15:32,2025-05-28 03:53:06
06fd20f0-c9f7-47a1-ae1d-1603b4f2f4cd,USA-FDA,aa4cada1-e3e2-476b-892c-a14ec539dd38,G_ACTION_ITEMS,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0616/FDA-2010-D-0616-0020/FDA-2010-D-0616-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Codevelopment of Two or More New Investigational Drugs for Use in Combination"", ""docket_id"": ""FDA-2010-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0616-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0616/FDA-2010-D-0616-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:02:23,2025-05-28 03:53:06
072da5bb-f68d-4d78-9043-da05e7b499a4,USA-FDA,c08a7658-c09c-4ab7-b0b8-b96ab41be28a,G_MINI_SUMMARY,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002/FDA-1999-D-1315-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act (PDUFA) Products; Guidance for Industry; Draft Guidance for Industry"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:01:45,2025-05-28 03:53:06
073c573f-7842-4b13-995e-03c2c5768dee,USA-FDA,591e4966-7e2c-4887-a0fb-6ba6ac01af0e,G_CONCISE_SUMMARY,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001/FDA-2020-D-1398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; FDA Approval of New Animal Drugs For Minor Uses and for Minor Species; #61"", ""docket_id"": ""FDA-2020-D-1398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:46:05,2025-05-28 03:53:06
075170a3-0547-4795-9d69-8c2c1310e7bf,USA-FDA,f5e0007d-414f-4b47-805c-509458451fb4,G_DETAILED_SUMMARY,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0157/FDA-2005-D-0157-0006/FDA-2005-D-0157-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; CGMP for Phase 1 Investigational Drugs"", ""docket_id"": ""FDA-2005-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0157-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0157/FDA-2005-D-0157-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:46:29,2025-05-28 03:53:06
07525686-7f4e-45df-8dca-f096adcfd152,USA-FDA,2ba53937-6600-4e33-a3aa-06b4356a01be,G_DETAILED_SUMMARY,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3390/FDA-2015-D-3390-0002/FDA-2015-D-3390-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""eCTD TECHNICAL CONFORMANCE GUIDE"", ""docket_id"": ""FDA-2015-D-3390"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-3390-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3390/FDA-2015-D-3390-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:31:47,2025-05-28 03:53:06
075b2baa-5fe3-4117-a22d-237d70d2dc55,USA-FDA,14e6b80e-0f6c-49f0-94d7-19728ea0baa4,G_DETAILED_SUMMARY,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0166/FDA-2010-D-0166-0006/FDA-2010-D-0166-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods (VICH GL-48)"", ""docket_id"": ""FDA-2010-D-0166"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0166-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0166/FDA-2010-D-0166-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:15:43,2025-05-28 03:53:06
0773dde6-2402-4dfb-bb9a-970b6aa99397,USA-FDA,a99486e9-f35f-48f0-88fe-b27ed7776c92,G_ACTION_ITEMS,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002/FDA-2011-D-0577-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Factors To Consider When Making Benefit-Risk Determinations in Medical Device Premarket Review"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:48:13,2025-05-28 03:53:06
0780451d-cbc9-432c-8f16-39db977b4564,USA-FDA,507fdb32-b80d-491b-86d2-e9fee539ecb1,G_IMPACT_ANALYSIS,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0196/FDA-2007-D-0196-0013/FDA-2007-D-0196-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for FDA Advisory Committee Members and FDA Staff : Voting Procedures for Advisory Committee Meetings"", ""docket_id"": ""FDA-2007-D-0196"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0196-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0196/FDA-2007-D-0196-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:01:05,2025-05-28 03:53:06
0790bb7c-718c-4959-85a0-2af0ca1aeb26,USA-FDA,f5263c2d-7480-486f-bcc6-829804201c36,G_DETAILED_SUMMARY,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0002/FDA-2017-D-6526-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier"", ""docket_id"": ""FDA-2017-D-6526"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6526-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:00:25,2025-05-28 03:53:06
07abb988-6b71-43ca-a4a3-1ca67ab746e5,USA-FDA,802b46ca-23d3-4293-989b-36433e54e46f,G_MINI_SUMMARY,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002/FDA-2012-D-1002-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Questions and Answers Regarding Food Facility Registration Fifith Edition"", ""docket_id"": ""FDA-2012-D-1002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1002-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:46:05,2025-05-28 03:53:06
07b28b6f-5bd5-4bad-8445-128bf9fd205b,USA-FDA,69575d7f-5602-493b-8460-f1da2547ad2f,G_DETAILED_SUMMARY,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3443/FDA-2018-D-3443-0002/FDA-2018-D-3443-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-3443"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3443-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3443/FDA-2018-D-3443-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:46:48,2025-05-28 03:53:06
07e32f28-f8f1-4ad6-9420-1f2eae18d22a,USA-FDA,20aa06a3-8c67-4df1-a622-2b101d9a5a38,G_KEYWORDS,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009/FDA-2007-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry; Bioequivalence Recommendation for Lenalidomide Capsules"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:13:44,2025-05-28 03:53:06
08094114-2738-4e63-a7d0-53d965b05a9c,USA-FDA,be75a1d8-948b-4aa0-a119-4cd0d43bede0,G_KEYWORDS,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002/FDA-2012-D-0049-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke UnderSection 904(a)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance"", ""docket_id"": ""FDA-2012-D-0049"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0049-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:31:10,2025-05-28 03:53:06
0825bdf2-f109-4668-9750-7576efad08cf,SCHEDULED,daa946bb-c447-4c48-a29a-b7ffaa7e4181,FDA_ALERT,2025-05-25 00:00:04,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/daa946bb-c447-4c48-a29a-b7ffaa7e4181"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:19,2025-05-28 03:53:06
08546296-9660-4423-b98d-0b89c1eeb2a1,USA-FDA,2edc24f5-c1c2-4f67-bdcb-21dc9c775c71,G_ACTION_ITEMS,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1978-N-0011/FDA-1978-N-0011-0008/FDA-1978-N-0011-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidelines for Effectiveness Testing of O. T. C. Antiperspirant Drug Products"", ""docket_id"": ""FDA-1978-N-0011"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1978-N-0011-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1978-N-0011/FDA-1978-N-0011-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:46:24,2025-05-28 03:53:06
086f0e96-34e4-41f1-bd3c-4c326494422f,USA-FDA,7121f066-446e-4ecb-8774-f69b6aab0341,G_KEYWORDS,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022/FDA-1999-D-1875-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Extra-Label Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:03:02,2025-05-28 03:53:06
087a1dc5-014c-487d-bef8-aaf7265e6fb9,USA-FDA,6293119e-a95b-454a-a4cb-2a8a967502ab,G_DETAILED_SUMMARY,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010/FDA-2008-D-0623-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #192 Anesthetics for Companion Animals"", ""docket_id"": ""FDA-2008-D-0623"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0623-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:01:44,2025-05-28 03:53:06
089b0275-69a8-4689-9220-70b7624d8797,Queue,286ceb6c-fb97-4652-9e5a-1735d9e9a403,G_CONCISE_SUMMARY_USER,2025-05-30 09:12:01,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/286ceb6c-fb97-4652-9e5a-1735d9e9a403/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/286ceb6c-fb97-4652-9e5a-1735d9e9a403"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-30 03:42:04,2025-05-30 03:42:04
08a9f9f6-77d3-4169-a622-cb558afc2200,USA-FDA,13a7035b-56ed-4c6c-ac31-cccf2b44484b,G_MINI_SUMMARY,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002/FDA-2013-D-0743-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Reporting for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0743"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0743-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:15:40,2025-05-28 03:53:06
08bdd745-fa71-44b5-a03d-464500133538,USA-FDA,5ba4813d-e67c-4492-a2df-0be15096d225,G_CONCISE_SUMMARY,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008/FDA-2008-D-0642-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2008-D-0642"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0642-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:31:39,2025-05-28 03:53:06
08d19334-c124-4e0f-ab01-bc5e98c725cb,USA-FDA,c799d0ee-3e96-4059-8362-1be646888d45,G_DETAILED_SUMMARY,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002/FDA-2012-D-0307-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Revised Preventive Measures to Reduce Possible Risk of Transmission of Creutzfeldt-Jakob Disease, etc."", ""docket_id"": ""FDA-2012-D-0307"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0307-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:31:11,2025-05-28 03:53:06
08ed5786-e016-459e-ad6e-28a8d9fde2c6,USA-FDA,85f00416-615b-4dbe-a899-ec2d30dd820d,G_IMPACT_ANALYSIS,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002/FDA-2011-D-0689-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; De Novo Classification Process (Evaluation of Automatic Class III Designation)"", ""docket_id"": ""FDA-2011-D-0689"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0689-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:16:14,2025-05-28 03:53:06
08fea73b-7e78-4bee-800f-0cc4ea240e8c,USA-FDA,6c4a8f7f-611c-4124-9689-caa8b55506b0,G_ACTION_ITEMS,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010/FDA-2008-D-0623-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #192 Anesthetics for Companion Animals"", ""docket_id"": ""FDA-2008-D-0623"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0623-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:02:32,2025-05-28 03:53:06
090a3113-13ec-4269-9ac7-3880aa37fb57,USA-FDA,2ab765b8-01b1-4013-a62e-f4b024f95469,G_ACTION_ITEMS,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008/FDA-1999-D-0128-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cooperative Manufacturing Arrangements for Licensed Biologics"", ""docket_id"": ""FDA-1999-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0128-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:32:17,2025-05-28 03:53:06
0926f9e6-4cf6-4577-b576-2c5ea73e3f1a,USA-FDA,e2926d08-9611-4623-a240-d29c35899e62,G_DETAILED_SUMMARY,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004/FDA-2002-D-0298-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition"", ""docket_id"": ""FDA-2002-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0298-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:46:35,2025-05-28 03:53:06
0946347d-d6dc-4dea-ade9-1c5534accc21,USA-FDA,7b2763f7-cda2-4d69-8690-45f8fbf2b094,G_ACTION_ITEMS,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0008/FDA-2011-D-0847-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; Humanitarian Use Device (HUD) Designations"", ""docket_id"": ""FDA-2011-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0847-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:31:03,2025-05-28 03:53:06
095338a8-527b-4af3-8ac6-c0dc8d89a28b,USA-FDA,9f5060bd-a1f1-4164-8606-cb3de14ec0aa,G_DETAILED_SUMMARY,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1439/FDA-2014-D-1439-0004/FDA-2014-D-1439-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Critical Path Innovation Meetings; Guidance for Industry"", ""docket_id"": ""FDA-2014-D-1439"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1439-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1439/FDA-2014-D-1439-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:31:20,2025-05-28 03:53:06
09856469-bfe7-415f-8020-a6bccc12630b,USA-FDA,5f69ec2a-85e2-427f-ab58-bbf3e2ebc4b3,G_DETAILED_SUMMARY,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0524/FDA-2012-D-0524-0002/FDA-2012-D-0524-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: Acceptance and Filing Review for Premarket Approval Applications (PMAs) - Guidance"", ""docket_id"": ""FDA-2012-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0524-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0524/FDA-2012-D-0524-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:16:02,2025-05-28 03:53:06
0989674a-1fa9-445d-aea6-ad2343d5c13e,SCHEDULED,00fa9ff6-4182-4a73-8f0a-34302f33e5f2,FDA_ALERT,2025-05-28 00:00:05,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/00fa9ff6-4182-4a73-8f0a-34302f33e5f2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:11,2025-05-28 03:53:06
09d6985d-3a6d-4375-95da-e8df4e991f0e,CAB,3a9c8cba-a61f-4df8-a358-c572f20c84b1,G_FAQ_IN,2025-05-20 16:33:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2018-F-3757-0019.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2018-F-3757-0019_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""04cb41d6-deff-4cde-83f8-ba7f77069dd4""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/04cb41d6-deff-4cde-83f8-ba7f77069dd4"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:34:09,2025-05-28 03:53:06
09fd4df4-062d-4cee-ade1-45a486e4c2f4,USA-FDA,f1d0d681-2f53-4253-933c-2d474eda7b6d,G_DETAILED_SUMMARY,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002/FDA-2012-D-0304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Claa II Special Controls Guidance Implanted Blood Access Devices for Hemodialysis"", ""docket_id"": ""FDA-2012-D-0304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:00:35,2025-05-28 03:53:06
0a03d39b-3269-4d98-a614-73048f35bb22,USA-FDA,8fcef4f8-4011-48cb-b5a6-e67f9277a7b7,G_FAQ,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0893/FDA-2011-D-0893-0002/FDA-2011-D-0893-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry and Staff Center for Devices and Radiological Health Appeals Processes"", ""docket_id"": ""FDA-2011-D-0893"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0893-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0893/FDA-2011-D-0893-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:02:34,2025-05-28 03:53:06
0a0566ba-878d-498e-9517-15f14095d03c,USA-FDA,1cd88f89-f218-47d6-bbc1-7345cf9e752a,G_KEYWORDS,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002/FDA-2012-D-1135-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidances for Industry Limiting Use of Certain Phthalates as Excipients in Center for Drug Evaluation and Research-Regulated Products"", ""docket_id"": ""FDA-2012-D-1135"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1135-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:01:54,2025-05-28 03:53:06
0a10cc4a-3f59-4032-845c-31847a2970f3,USA-FDA,eeb4d780-f4e5-4147-a760-26990d2b1943,G_MINI_SUMMARY,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002/FDA-2010-D-0404-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use--Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0404"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0404-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:33:00,2025-05-28 03:53:06
0a275d25-043a-42a4-b85b-b870cadf13c4,USA-FDA,8e3c1a54-0175-4c82-8904-88a866e2fab3,G_ACTION_ITEMS,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0002/FDA-2010-D-0503-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Investigational New Drug Applications (INDs)�Determining Whether Human Research Studies Can Be Conducted Without an IND"", ""docket_id"": ""FDA-2010-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0503-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:48:01,2025-05-28 03:53:06
0a6448f3-06aa-4145-b556-944e31fa72a7,USA-FDA,4ea43075-9dea-4de7-8e08-e07088f1f7a9,G_MINI_SUMMARY,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0533/FDA-2009-D-0533-0009/FDA-2009-D-0533-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application"", ""docket_id"": ""FDA-2009-D-0533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0533-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0533/FDA-2009-D-0533-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:00:12,2025-05-28 03:53:06
0a7411b1-3d13-47bb-881d-e0d9936f17e7,USA-FDA,a2c2bcac-64f7-4a82-9093-5df81434dcfa,G_MINI_SUMMARY,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002/FDA-2007-D-0205-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]; Draft Guidance"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:02:13,2025-05-28 03:53:06
0a8849e0-d626-4c3f-9180-e43c65daec10,USA-FDA,e223652f-0715-480c-b861-f2e07144098a,G_ACTION_ITEMS,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001/FDA-2020-D-1608-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data"", ""docket_id"": ""FDA-2020-D-1608"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1608-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:47:03,2025-05-28 03:53:06
0aa0b703-34cc-45d7-90e1-c3a50c8fe1af,USA-FDA,21a3c96c-649f-4b51-b87e-52a23b06bcee,G_DETAILED_SUMMARY,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1659/FDA-2015-D-1659-0002/FDA-2015-D-1659-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Established Conditions: Reportable Chemistry, Manufacturing, and\nControls Changes for Approved Drug and Biologic Products; Draft Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1659"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1659-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1659/FDA-2015-D-1659-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:15:18,2025-05-28 03:53:06
0ac00501-bed2-4e07-a3fc-62a6ca152e01,USA-FDA,50ac583b-bd47-4761-b459-7fe1ebfb2427,G_DETAILED_SUMMARY,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0541/FDA-2011-D-0541-0002/FDA-2011-D-0541-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance PET Drugs ----- Current Good Manufacturing Practice (CGMP) (Small Entity Compliance Guide)"", ""docket_id"": ""FDA-2011-D-0541"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0541-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0541/FDA-2011-D-0541-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:02:19,2025-05-28 03:53:06
0aceaedd-5fd2-4c8e-9c83-1696c92088e9,SCHEDULED,be9c5d3e-4636-4eb3-be55-bc2810d09fbb,DEVICE_ANALYST,2025-05-26 00:00:07,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/be9c5d3e-4636-4eb3-be55-bc2810d09fbb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:08,2025-05-28 03:53:06
0ae1a9db-3fdd-4706-9523-10a806d2790e,SCHEDULED,7d6e484f-cd52-42eb-8da8-7fbef9d591e6,FDA_ALERT,2025-05-29 00:00:04,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/7d6e484f-cd52-42eb-8da8-7fbef9d591e6"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:10,2025-05-29 00:00:10
0b047041-c6ab-4ff4-9b8f-b72553820631,USA-FDA,db4045a5-77d9-4672-966c-fdb2e2118d42,G_FAQ,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1088/FDA-2013-D-1088-0002/FDA-2013-D-1088-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entity Compliance Guide; Declaring Color Additives in Animal Foods; #223"", ""docket_id"": ""FDA-2013-D-1088"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1088-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1088/FDA-2013-D-1088-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:00:24,2025-05-28 03:53:06
0b0d70b6-3a00-477c-81a9-4f01b4c6ce88,USA-FDA,5cba624d-df67-4423-aafc-55e66136c4d6,G_IMPACT_ANALYSIS,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001/FDA-2020-D-1407-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products HCT Ps Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2020-D-1407"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1407-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:49,2025-05-28 03:53:06
0b73128a-b69d-453e-b8ff-4be35d2e10e4,USA-FDA,c8c38b7e-8961-4ada-b59a-207f586fbe4f,G_DETAILED_SUMMARY,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0090/FDA-2003-D-0090-0002/FDA-2003-D-0090-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate � Labeling Enforcement Policy"", ""docket_id"": ""FDA-2003-D-0090"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0090-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0090/FDA-2003-D-0090-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:01:21,2025-05-28 03:53:06
0b79a55e-3055-4c6f-977f-4836b3a91c6b,USA-FDA,89923f26-d737-41e6-bcda-080ec7ef605d,G_FAQ,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0432/FDA-2011-D-0432-0002/FDA-2011-D-0432-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics"", ""docket_id"": ""FDA-2011-D-0432"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0432-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0432/FDA-2011-D-0432-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:46:10,2025-05-28 03:53:06
0b94de15-456d-43ab-89ad-ceed7abb12df,USA-FDA,ab886f99-42da-415f-b9fe-e2b402c96e80,G_KEYWORDS,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029/FDA-2009-D-0179-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0179-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:32:46,2025-05-28 03:53:06
0bd7f295-a8a3-4e8f-b38b-2042ad1c49b1,USA-FDA,6a42ecba-c17b-40aa-b5ae-d27ad8cca5aa,G_CONCISE_SUMMARY,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610/FDA-2016-D-4414-1610-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nutrition and Supplement Facts Labels: Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals: Guidance for Industry"", ""docket_id"": ""FDA-2016-D-4414"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-4414-1610""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:15:14,2025-05-28 03:53:06
0bdc4185-cf71-448e-9479-6f7bd378b3a8,USA-FDA,9a16cadf-5379-4ceb-9e67-c87860fa8f79,G_ACTION_ITEMS,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1399/FDA-2020-D-1399-0001/FDA-2020-D-1399-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part I"", ""docket_id"": ""FDA-2020-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1399-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1399/FDA-2020-D-1399-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:01:21,2025-05-28 03:53:06
0c0b9d50-a82c-4ff1-9bd3-9815ce3274ef,USA-FDA,c5b4adc9-f23a-408a-821d-304989a57646,G_ACTION_ITEMS,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0002/FDA-2014-D-1399-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Draft Guidance Document"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:16:10,2025-05-28 03:53:06
0c0d6501-5098-4dfa-9c7f-42699cbeae2c,USA-FDA,005eeb96-c7db-4eb6-9025-9c6970eb7ef3,G_KEYWORDS,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009/FDA-2011-D-0398-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Questions and Answers Regarding The Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:31:41,2025-05-28 03:53:06
0c5a6ef0-9052-47fb-864f-71b6fbd719c1,USA-FDA,b355bbb8-f764-46f2-ad11-ba005695bc88,G_IMPACT_ANALYSIS,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008/FDA-1999-D-0128-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cooperative Manufacturing Arrangements for Licensed Biologics"", ""docket_id"": ""FDA-1999-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0128-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:32:28,2025-05-28 03:53:06
0c5f7f42-4315-473f-ba57-2e5338679328,USA-FDA,ab3e01ad-6a8f-4fe6-8793-907e048dfe39,G_KEYWORDS,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011/FDA-1998-D-0035-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:01:41,2025-05-28 03:53:06
0c7a7924-b4cd-43c4-950f-75171a7bc42f,USA-FDA,7f5f5b2c-99ea-4bfe-99bd-2af872f9ff02,G_IMPACT_ANALYSIS,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0199/FDA-2008-D-0199-0002/FDA-2008-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""E15 Pharmacogenomics Definitions and Sample Coding"", ""docket_id"": ""FDA-2008-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0199/FDA-2008-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:32:31,2025-05-28 03:53:06
0c7dcdb8-eef2-482d-a0cd-8802fd46ca9c,USA-FDA,6285162e-0aac-41fa-bbde-913e408af1d2,G_FAQ,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002/FDA-2013-D-0749-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implanted Blood Access Devices for Hemodialysis; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0749"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0749-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:02:00,2025-05-28 03:53:06
0cb51675-a8d2-4601-851b-fccef30f6ab7,SCHEDULED,4cf2397f-48d5-4629-be33-54339ed9470d,DEVICE_ANALYST,2025-05-28 00:00:05,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/4cf2397f-48d5-4629-be33-54339ed9470d"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:07,2025-05-28 03:53:06
0ccfaf14-d70a-403a-ab4d-fd4997073d44,USA-FDA,678d2803-c3a4-4c47-ad13-22c31979c7d8,G_MINI_SUMMARY,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-3276/FDA-2016-D-3276-0001/FDA-2016-D-3276-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Investigational Use of Deemed, Finished Tobacco Products That Were on the U.S. Market on August 8, 2016, During the Deeming Compliance Periods; Guidance for Industry"", ""docket_id"": ""FDA-2016-D-3276"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-3276-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-3276/FDA-2016-D-3276-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:17:01,2025-05-28 03:53:06
0cd089f5-7417-4eb2-af42-71ac62a9eeb2,USA-FDA,dc9171e9-da64-4e91-9265-93627bc89727,G_FAQ,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1927/FDA-2020-D-1927-0001/FDA-2020-D-1927-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Food Security Preventive Measures Guidance for  Retail Food Stores and Food Service Establishments"", ""docket_id"": ""FDA-2020-D-1927"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1927-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1927/FDA-2020-D-1927-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:00:26,2025-05-28 03:53:06
0cd98b6a-b0f4-4e70-a9f0-f6ea15157ba3,USA-FDA,ffa2c6ad-98db-4e3c-9ca7-61578e24ec30,G_ACTION_ITEMS,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002/FDA-2009-D-0542-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Factors that Distinguish Liquid Dietary Supplements from Beverages, Considerations Regarding Novel Ingredients, and Labeling for Beverages and Other Conventional Foods; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0542"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0542-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:03:08,2025-05-28 03:53:06
0cf021db-7fea-4598-a68a-6337c99322ed,USA-FDA,0eba8ec3-ba77-44d7-b893-53820196f3a5,G_MINI_SUMMARY,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002/FDA-2012-D-0049-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke UnderSection 904(a)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance"", ""docket_id"": ""FDA-2012-D-0049"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0049-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:30:10,2025-05-28 03:53:06
0cf0c56a-0e47-4058-a70c-49af10d04435,USA-FDA,feb1fc27-fc31-4582-b3a9-3a7e8642d986,G_MINI_SUMMARY,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0848/FDA-2012-D-0848-0002/FDA-2012-D-0848-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for FDA Staff Compliance Policy Guide Sec. 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products - Hypoglycin A Toxin\nDraft Guidance"", ""docket_id"": ""FDA-2012-D-0848"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0848-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0848/FDA-2012-D-0848-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:30:08,2025-05-28 03:53:06
0cf0e611-7125-4a8b-85f0-d137c5ebd6f0,USA-FDA,d9f7817e-d81f-401e-a4d7-e88e8f793b2a,G_FAQ,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0447/FDA-2013-D-0447-0002/FDA-2013-D-0447-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Charging for Investigational Drugs Under an Investigational New Drug Application-Questions and Answers"", ""docket_id"": ""FDA-2013-D-0447"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0447-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0447/FDA-2013-D-0447-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:30:28,2025-05-28 03:53:06
0d08cad8-2c6e-436d-aa72-a73e694c15b1,USA-FDA,afcc244f-7e1b-4575-983b-f5a01112eece,G_FAQ,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001/FDA-2020-D-1398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; FDA Approval of New Animal Drugs For Minor Uses and for Minor Species; #61"", ""docket_id"": ""FDA-2020-D-1398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:46:59,2025-05-28 03:53:06
0d2b67c5-87ad-4826-aa98-86639e0b4a97,USA-FDA,b30efb92-d2f8-4e20-95bc-ac49d72cf467,G_DETAILED_SUMMARY,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002/FDA-2000-D-0129-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans - Draft Guidance"", ""docket_id"": ""FDA-2000-D-0129"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-D-0129-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:01:08,2025-05-28 03:53:06
0d3f2053-43ec-4242-9228-d49b67fa40de,USA-FDA,07b0a7a0-c8b9-49cd-915c-df25f3f8d6e1,G_IMPACT_ANALYSIS,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5960/FDA-2017-D-5960-0002/FDA-2017-D-5960-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5960"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5960-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5960/FDA-2017-D-5960-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:31:19,2025-05-28 03:53:06
0d662ec8-145c-4759-ac67-cd95278935ff,USA-FDA,a1cc9925-a8c8-401e-b824-353a7dc34247,G_CONCISE_SUMMARY,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002/FDA-2017-D-5525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Statistical Approaches to Evaluate Analytical Similarity Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:31:41,2025-05-28 03:53:06
0d8bdfd1-af26-4b48-89ce-f10257c31d50,USA-FDA,230c9393-ee1a-4082-a24d-6c1cce131bba,G_CONCISE_SUMMARY,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001/FDA-2020-D-1944-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives"", ""docket_id"": ""FDA-2020-D-1944"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1944-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:30:12,2025-05-28 03:53:06
0d8c7ec0-1286-4963-9e08-08ca4051437c,USA-FDA,9ca761d1-a0c6-46d0-93d8-17d46b97fa11,G_DETAILED_SUMMARY,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1318/FDA-2014-D-1318-0002/FDA-2014-D-1318-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1318"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1318-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1318/FDA-2014-D-1318-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:16:06,2025-05-28 03:53:06
0dc3497a-5a94-47b8-bef4-a0df3a73a236,USA-FDA,b221d2f5-a4cd-40d3-a6c8-7d4622d8dad5,G_FAQ,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0044/FDA-2009-D-0044-0009/FDA-2009-D-0044-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis "", ""docket_id"": ""FDA-2009-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0044-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0044/FDA-2009-D-0044-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:01:38,2025-05-28 03:53:06
0dcb4704-6340-4386-818f-bfef3c7120cc,USA-FDA,3e74c4c3-8284-4076-ab79-e85c1b2ba319,G_ACTION_ITEMS,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0847/FDA-2012-D-0847-0002/FDA-2012-D-0847-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for IRBs, Clinical Investigators, and Sponsors; IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed"", ""docket_id"": ""FDA-2012-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0847-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0847/FDA-2012-D-0847-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:15:32,2025-05-28 03:53:06
0dd4c882-aee2-4dde-9ddd-ac202faeed78,USA-FDA,d48ddd94-9df0-4a2a-906e-e9ba6aa9f3b6,G_IMPACT_ANALYSIS,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002/FDA-2018-D-4525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Lactation Studies: Considerations for Study Design; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2018-D-4525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-4525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:17:55,2025-05-28 03:53:06
0df791b5-aab3-4ca7-b55a-4f00b297c53a,USA-FDA,bd1d49ec-d784-4c0f-b0ff-5859de3f236c,G_MINI_SUMMARY,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002/FDA-2013-D-0168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Recommendations for Labeling Medical Products to Inform Users the Product or Product Container Is Not Made With Natural Rubber Latex"", ""docket_id"": ""FDA-2013-D-0168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:16:39,2025-05-28 03:53:06
0e33d116-3f6e-46ea-b03c-57cbb9413a60,USA-FDA,1d1b1263-6dde-47fa-8e71-1baf44d8e105,G_ACTION_ITEMS,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020/FDA-2015-D-1245-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:03:10,2025-05-28 03:53:06
0e3b0753-dfcd-4ea8-9534-bd7b8d050dd7,USA-FDA,7545aff9-4de0-4121-a04b-eb3d1ac5cd1c,G_ACTION_ITEMS,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004/FDA-2010-D-0636-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia Burgdorferi"", ""docket_id"": ""FDA-2010-D-0636"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0636-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:15:26,2025-05-28 03:53:06
0e6615d1-3ced-478b-86bf-0b64e170d66f,USA-FDA,3373c380-ca78-4a8b-943b-2e9cdcf965bf,G_CONCISE_SUMMARY,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005/FDA-2011-D-0643-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; What You Need to Know About Administrative Detention of Foods; Small Entity Compliance Guide; Final Guidance"", ""docket_id"": ""FDA-2011-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0643-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:30:59,2025-05-28 03:53:06
0e6d0152-f12a-4a8c-8bca-f1d271e9f6db,USA-FDA,e298be34-aa4a-49f4-8d49-19690468da6e,G_IMPACT_ANALYSIS,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002/FDA-2007-D-0205-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]; Draft Guidance"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:03:13,2025-05-28 03:53:06
0e7c6fe1-a14f-4697-ba69-caa952a4449c,USA-FDA,fc06d154-fd85-443e-8521-1f9020f46748,G_KEYWORDS,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016/FDA-2014-D-1399-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:15:46,2025-05-28 03:53:06
0e8b70bc-b1c4-47b1-8d0b-22ba2109a014,USA-FDA,62880b3f-2ccb-4b2e-8dc5-49a0da3b5a8c,G_DETAILED_SUMMARY,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020/FDA-2015-D-1245-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:02:52,2025-05-28 03:53:06
0eb82f54-981d-4217-a798-cae424b94f35,USA-FDA,9f1b8a45-55d3-4460-94c0-a11e1180fb6a,G_MINI_SUMMARY,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009/FDA-2006-D-0157-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry:  Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2006-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0157-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:00:12,2025-05-28 03:53:06
0ecfc7f8-eb0b-43bf-8d18-563385576717,USA-FDA,2fef963e-4987-4eb1-8243-8eb010f3965e,G_ACTION_ITEMS,2025-05-19 23:42:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001/FDA-2017-D-5478-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""MRCT Draft FDA Guidance Return of Aggregate Results"", ""docket_id"": ""FDA-2017-D-5478"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5478-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 03:43:41,2025-05-28 03:53:06
0eeebcce-5116-4738-9dea-d2bf5c3cb9cc,USA-FDA,1c0e57cd-7c35-44e8-9927-37d47b7557ad,G_ACTION_ITEMS,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017/FDA-2010-D-0426-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Bar Code Label Requirements�Questions and Answers"", ""docket_id"": ""FDA-2010-D-0426"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0426-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:33:37,2025-05-28 03:53:06
0eefff3c-b6b4-4912-b19c-2a8ce6fe722a,USA-FDA,ae669d86-ecd8-4f75-a01b-111d10cd237f,G_FAQ,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1439/FDA-2014-D-1439-0004/FDA-2014-D-1439-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Critical Path Innovation Meetings; Guidance for Industry"", ""docket_id"": ""FDA-2014-D-1439"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1439-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1439/FDA-2014-D-1439-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:31:27,2025-05-28 03:53:06
0f2580ac-e01d-4726-941c-6784adbc9199,USA-FDA,5ba45587-c307-4439-be45-faa9d934768d,G_ACTION_ITEMS,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022/FDA-1998-N-0050-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 540.375 Canned Salmon - Adulteration Involving Decomposition Withdrawn 3-22-2010"", ""docket_id"": ""FDA-1998-N-0050"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-N-0050-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:23,2025-05-28 03:53:06
0f2850a5-04e9-476b-a4e6-bdf03d1dca35,USA-FDA,67ee3235-cc77-4c17-b175-6874cb649e1e,G_KEYWORDS,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002/FDA-2003-D-0416-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS"", ""docket_id"": ""FDA-2003-D-0416"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0416-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:47:52,2025-05-28 03:53:06
0f3bf8e8-6a2c-4c5f-90f2-7a587d269299,USA-FDA,defc773e-7f26-4607-b668-fbf203e22cd2,G_DETAILED_SUMMARY,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0438/FDA-2004-D-0438-0007/FDA-2004-D-0438-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Time and Extent Applications for Nonprescription Drug Products"", ""docket_id"": ""FDA-2004-D-0438"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0438-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0438/FDA-2004-D-0438-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:47:30,2025-05-28 03:53:06
0f804f9e-bf89-42a1-87b9-a02d71f588c4,QUEUE,52d02302-1782-4c2e-b5a1-6deabaacb16f,G_CONCISE_SUMMARY_USER,2025-05-29 07:00:14,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/52d02302-1782-4c2e-b5a1-6deabaacb16f/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/52d02302-1782-4c2e-b5a1-6deabaacb16f"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 07:00:19,2025-05-29 07:00:19
0f99363e-d3b2-4b07-a55d-c8923c793cc9,USA-FDA,a814e8a8-d302-4c54-a1c3-f11329f1302a,G_CONCISE_SUMMARY,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002/FDA-2017-D-2462-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:00:57,2025-05-28 03:53:06
0fb59e78-5e7f-4bf5-8098-d018da2395a3,USA-FDA,8ff0d626-7b2a-4ec5-9d96-0f918a3512a0,G_ACTION_ITEMS,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004/FDA-2005-D-0208-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency"", ""docket_id"": ""FDA-2005-D-0208"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0208-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:33:32,2025-05-28 03:53:06
0fc12fae-f1ee-41a1-9c04-975ec67d2879,USA-FDA,633a4ec9-e3e7-46ad-95dc-baded0aa7a24,G_MINI_SUMMARY,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3327/FDA-2015-D-3327-0002/FDA-2015-D-3327-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry E6(R2) Good Clinical Practice"", ""docket_id"": ""FDA-2015-D-3327"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-3327-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3327/FDA-2015-D-3327-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:30:10,2025-05-28 03:53:06
0feade91-cb5a-430e-932c-cb9572d85fe2,USA-FDA,a37bea53-87cb-42ac-8f71-fc9a260bfb06,G_CONCISE_SUMMARY,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022/FDA-2011-D-0082-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry , Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling"", ""docket_id"": ""FDA-2011-D-0082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0082-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:02:55,2025-05-28 03:53:06
0fef7773-be9c-4876-9549-f1819a4a9751,USA-FDA,3bf7e443-2b92-4eba-8a91-6d22dbc16185,G_DETAILED_SUMMARY,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001/FDA-2020-D-1944-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives"", ""docket_id"": ""FDA-2020-D-1944"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1944-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:30:18,2025-05-28 03:53:06
1,,cbf9dad6-aa31-45ec-92cb-a8f4c49ee7cf,G_DETAILED_SUMMARY,2025-05-09 01:48:53,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 08:49:48,2025-05-28 03:53:06
10,,3bb8db0a-b830-4815-ba4a-27dbd23eea50,G_COMPARE_DOCUMENTS,2025-05-09 01:55:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0002/FDA-2024-D-3863-0002-guidance.pdf"", ""aws_bucket"": ""lexim-ai-dev""}","{""format"": ""md"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/AGENT/3bb8db0a-b830-4815-ba4a-27dbd23eea50"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-09 08:55:27,2025-05-28 03:53:06
100,,70fd021f-fbc9-4765-a36b-742242ab1166,G_IMPACT_ANALYSIS_IN,2025-05-12 22:32:34,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:32:34,2025-05-28 03:53:06
1004ef32-6187-478d-8ff0-45cf741284c7,USA-FDA,4560d62f-f6d1-4c9d-9135-c49a31a1eac5,G_MINI_SUMMARY,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0096/FDA-2012-D-0096-0002/FDA-2012-D-0096-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations"", ""docket_id"": ""FDA-2012-D-0096"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0096-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0096/FDA-2012-D-0096-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:46:31,2025-05-28 03:53:06
101,,ff9d9122-4e9c-413d-9f8c-db169cefe42a,G_MINI_SUMMARY_IN,2025-05-12 22:33:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:33:06,2025-05-28 03:53:06
101aac7d-dfa0-4efb-b527-a527faae1c8a,USA-FDA,450221e1-ae29-4bf9-89ad-258af34fc57b,G_ACTION_ITEMS,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4561/FDA-2015-D-4561-0005/FDA-2015-D-4561-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Head Lice Infestation: Developing Drugs for Topical Treatment Guidance for Industry"", ""docket_id"": ""FDA-2015-D-4561"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4561-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4561/FDA-2015-D-4561-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:17:22,2025-05-28 03:53:06
102,,9f886c6d-04df-4550-aad2-21189607349f,G_CONCISE_SUMMARY_IN,2025-05-12 22:33:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:33:10,2025-05-28 03:53:06
1023f44e-403d-4d1e-a5c6-41a3ffbd5999,SCHEDULED,30453908-e886-4f14-8ec7-f73c48a18b54,FDA_ALERT,2025-05-28 00:00:05,33,22e9cbee-8ffd-40b1-ac72-354a385b80f8,c151cd9d-a4ea-462e-baf0-37da703a0484,"{""user_id"": 174, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""weekly"", ""last_name"": ""Mannan"", ""user_guid"": ""c151cd9d-a4ea-462e-baf0-37da703a0484"", ""first_name"": ""Naeem "", ""start_date"": ""2025-02-26"", ""user_email"": ""nmannan97@gmail.com"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/c151cd9d-a4ea-462e-baf0-37da703a0484/AGENTS/fda_alert/30453908-e886-4f14-8ec7-f73c48a18b54"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:39,2025-05-28 03:53:06
103,,6654bcf7-a494-4ae2-a6aa-b95be0570f36,G_FAQ_IN,2025-05-12 22:33:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:33:28,2025-05-28 03:53:06
10320f20-44a0-4fee-9adf-4765918d9947,USA-FDA,1b3098c9-b038-4e18-a54c-69ab19a38b15,G_DETAILED_SUMMARY,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0002/FDA-2011-D-0847-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Humanitarian Use Device Designations"", ""docket_id"": ""FDA-2011-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0847-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:45:20,2025-05-28 03:53:06
104,,ee522e66-0887-4857-b027-a18168917789,G_ACTION_ITEMS_IN,2025-05-12 22:33:35,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:33:35,2025-05-28 03:53:06
105,,503cc791-d882-483d-9b62-531995924093,G_IMPACT_ANALYSIS_IN,2025-05-12 22:33:44,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:33:44,2025-05-28 03:53:06
105c6003-b24e-40bb-b4f0-1f777c4a651d,USA-FDA,476e3d50-106e-47ac-b953-e35ff39d5c2b,G_ACTION_ITEMS,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002/FDA-2016-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Enforcement Policy on National Health Related Item Code and National Drug Code Numbers Assigned to Devices"", ""docket_id"": ""FDA-2016-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:45:36,2025-05-28 03:53:06
106,,1730baa2-bcff-48ba-857a-202b0b9f4ec9,G_MINI_SUMMARY_IN,2025-05-12 22:33:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:33:48,2025-05-28 03:53:06
107,,097db1fa-ea18-403f-9472-d6ef7bc7ffa0,G_CONCISE_SUMMARY_IN,2025-05-12 22:33:52,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:33:52,2025-05-28 03:53:06
107bcb9c-9522-45f3-95a7-2562ae21c736,USA-FDA,39a9df4c-c0fd-4621-bc52-ca485f4d70b7,G_MINI_SUMMARY,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-3528/FDA-1999-D-3528-0002/FDA-1999-D-3528-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture"", ""docket_id"": ""FDA-1999-D-3528"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-3528-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-3528/FDA-1999-D-3528-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:00:41,2025-05-28 03:53:06
108,,bedafa96-6604-468c-96cf-a71710106c35,G_FAQ_IN,2025-05-12 22:34:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:34:10,2025-05-28 03:53:06
109,,1e6c27e8-b6ef-4721-8fb5-f913ef2f4b6b,G_ACTION_ITEMS_IN,2025-05-12 22:34:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:34:17,2025-05-28 03:53:06
10a3a5ec-5103-48dd-bffc-a438c1ecccd2,USA-FDA,862950e5-d01f-4012-b3ef-554204e2fa65,G_FAQ,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002/FDA-2012-D-0179-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens"", ""docket_id"": ""FDA-2012-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0179-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:00:46,2025-05-28 03:53:06
11,,b54f67d6-aba4-4cbf-9b28-7df4c234e983,G_COMPARE_DOCUMENTS,2025-05-09 01:55:26,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0002/FDA-2024-D-3863-0002-guidance.pdf"", ""aws_bucket"": ""lexim-ai-dev""}","{""format"": ""md"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/AGENT/b54f67d6-aba4-4cbf-9b28-7df4c234e983"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-09 08:55:37,2025-05-28 03:53:06
110,,da835d97-f08f-4a04-8f67-4e5c7c298821,G_IMPACT_ANALYSIS_IN,2025-05-12 22:34:26,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:34:27,2025-05-28 03:53:06
11030aa6-3c2e-4092-a91f-728a1406406d,USA-FDA,f93ac6e9-67bf-4e39-860e-bfbf5b156182,G_DETAILED_SUMMARY,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0848/FDA-2012-D-0848-0002/FDA-2012-D-0848-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for FDA Staff Compliance Policy Guide Sec. 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products - Hypoglycin A Toxin\nDraft Guidance"", ""docket_id"": ""FDA-2012-D-0848"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0848-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0848/FDA-2012-D-0848-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:30:14,2025-05-28 03:53:06
1103548d-fe76-4b55-8a9f-16c0311e2c39,USA-FDA,967cb72e-2be7-4ec2-82a3-03817156ec78,G_CONCISE_SUMMARY,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005/FDA-1999-D-4079-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling"", ""docket_id"": ""FDA-1999-D-4079"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4079-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:31:53,2025-05-28 03:53:06
1107f406-e131-4e08-bcfc-101290d8005c,USA-FDA,31607aa4-b712-4698-8233-f431f448fb88,G_MINI_SUMMARY,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001/FDA-2020-D-1385-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Drug Stability Guidelines; #5"", ""docket_id"": ""FDA-2020-D-1385"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1385-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:31:30,2025-05-28 03:53:06
110dd54c-9891-4a7d-8ac9-956bb41f13c0,USA-FDA,275d2fe7-2aac-4a5b-8001-6570e5f4a752,G_IMPACT_ANALYSIS,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002/FDA-1997-D-0444-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""FDA Approval of Animal Drugs for Minor Uses and Minor Species; Draft Guidance Document"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:01:09,2025-05-28 03:53:06
111,,650bd5ce-6699-4b3d-ac2b-8bd015be92d8,G_MINI_SUMMARY_IN,2025-05-12 22:34:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:34:30,2025-05-28 03:53:06
1117dd80-92c0-46ae-9082-55cf805b3fa7,SCHEDULED,bcb4c883-cb4c-4b2d-a59a-bf784f56d7bc,FDA_ALERT,2025-05-23 00:00:04,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/bcb4c883-cb4c-4b2d-a59a-bf784f56d7bc"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:26,2025-05-28 03:53:06
112,,81f0956a-a11f-4bd0-a02f-b5fec7263e19,G_CONCISE_SUMMARY_IN,2025-05-12 22:34:34,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:34:35,2025-05-28 03:53:06
112832d4-9593-458c-8cd8-b84cb5024924,USA-FDA,0291fbf9-cfa5-4779-a8e5-40e01f98bf50,G_DETAILED_SUMMARY,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002/FDA-2011-D-0733-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Evaluating the Safety of Flood-affected Food Crops for Human Consumption"", ""docket_id"": ""FDA-2011-D-0733"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0733-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:30:21,2025-05-28 03:53:06
113,,c883e73d-1995-4bfc-8304-d7bd2263bab7,G_FAQ_IN,2025-05-12 22:34:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:34:48,2025-05-28 03:53:06
1137e06f-e3ba-42a8-a5c5-fda9a28ee8f1,USA-FDA,50d602ae-670b-4e2d-8acb-0886abf0d9c7,G_IMPACT_ANALYSIS,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002/FDA-2014-N-1108-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products--Considerations, Content, and Format"", ""docket_id"": ""FDA-2014-N-1108"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1108-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:02:03,2025-05-28 03:53:06
113c63a7-bd8d-4a36-8120-322453c111d7,USA-FDA,8e7d11ae-4357-4024-9325-afa4f8e086ac,G_KEYWORDS,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009/FDA-2006-D-0157-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry:  Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2006-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0157-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:01:26,2025-05-28 03:53:06
114,,4bfad373-f33d-4bdb-b014-69d00ccce243,G_ACTION_ITEMS_IN,2025-05-12 22:34:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:34:56,2025-05-28 03:53:06
115,,1d71d2d9-471b-45ea-b456-ee5a3a30b873,G_IMPACT_ANALYSIS_IN,2025-05-12 22:35:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:35:04,2025-05-28 03:53:06
116,,76f99d69-deb1-4507-ba2b-4e25b7f79432,G_MINI_SUMMARY_IN,2025-05-12 22:37:26,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11/Regulation_(EU)_2017/746_-_application_of_IVDR_requirements_to_�legacy_devices�_and_to_devices_placed_on_the_market_prior_to_26_May_2022_in_accordance_with_Directive_98/79/EC.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Regulation (EU) 2017/746 - application of IVDR requirements to �legacy devices� and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-11""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:37:27,2025-05-28 03:53:06
11671bf6-aeea-43fb-9870-3cf01ec032fb,USA-FDA,6f91ebbc-b01d-4b6d-a643-6b1c9758bf40,G_IMPACT_ANALYSIS,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0643/FDA-2010-D-0643-0092/FDA-2010-D-0643-0092-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Electronic Source Data in Clinical Investigations"", ""docket_id"": ""FDA-2010-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0643-0092""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0643/FDA-2010-D-0643-0092"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:01:02,2025-05-28 03:53:06
117,,fd77e891-de3e-4628-9eec-1c9915973c2b,G_CONCISE_SUMMARY_IN,2025-05-12 22:37:52,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11/Regulation_(EU)_2017/746_-_application_of_IVDR_requirements_to_�legacy_devices�_and_to_devices_placed_on_the_market_prior_to_26_May_2022_in_accordance_with_Directive_98/79/EC.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Regulation (EU) 2017/746 - application of IVDR requirements to �legacy devices� and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-11""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:37:52,2025-05-28 03:53:06
118,,ac886583-8d80-416c-b92c-8fdaec3754e8,G_CONCISE_SUMMARY_IN,2025-05-12 22:40:19,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11/Regulation_(EU)_2017/746_-_application_of_IVDR_requirements_to_�legacy_devices�_and_to_devices_placed_on_the_market_prior_to_26_May_2022_in_accordance_with_Directive_98/79/EC.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Regulation (EU) 2017/746 - application of IVDR requirements to �legacy devices� and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-11""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:40:20,2025-05-28 03:53:06
119,,670c37ec-c5e8-4b8c-b419-d001fe2068b1,G_CONCISE_SUMMARY_IN,2025-05-12 22:40:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12/Guidance_on_significant_changes_regarding_the_transitional_provision_under_Article_110(3)_of_the_IVDR.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-12""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:40:25,2025-05-28 03:53:06
119ab675-5496-4880-a8e4-56a3a27b09d9,USA-FDA,afe1caea-3209-4984-a883-43bdd98b0057,G_FAQ,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3390/FDA-2015-D-3390-0002/FDA-2015-D-3390-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""eCTD TECHNICAL CONFORMANCE GUIDE"", ""docket_id"": ""FDA-2015-D-3390"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-3390-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3390/FDA-2015-D-3390-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:32:05,2025-05-28 03:53:06
11ac665c-7ba9-4ce6-8826-b8877d286995,USA-FDA,94054e01-fd16-4b8b-9522-ff0913cbea58,G_ACTION_ITEMS,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0013/FDA-2003-D-0186-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""DRAFT GUIDANCE FOR INDUSTRY COSMETICS PROCESSORS AND TRANSPORTERS: COSMETICS SECURITY PREVENTIVE MEASURES GUIDANCE"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:31:42,2025-05-28 03:53:06
11c8382b-2777-4924-b1eb-aca4a4861cef,USA-FDA,0f1706a6-5081-453b-b188-305f0b7bdd4d,G_DETAILED_SUMMARY,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002/FDA-2012-D-0049-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke UnderSection 904(a)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance"", ""docket_id"": ""FDA-2012-D-0049"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0049-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:30:26,2025-05-28 03:53:06
11ec44cb-946d-4289-ac6f-cef59bb4ae76,USA-FDA,ab2cc8ea-faed-406d-8727-3dc7a944c780,G_ACTION_ITEMS,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-0298/FDA-2019-D-0298-0002/FDA-2019-D-0298-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Quality Considerations for Continuous Manufacturing; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2019-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-0298-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-0298/FDA-2019-D-0298-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:46:03,2025-05-28 03:53:06
11ef0846-22b8-4f58-af20-5eaa1000d30f,USA-FDA,c8ce5df4-37d0-43bb-82e6-d888068cc98f,G_MINI_SUMMARY,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002/FDA-2009-D-0006-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""S9 Nonclinical Evaluation for Anticancer Pharmaceuticals - Draft Guidance"", ""docket_id"": ""FDA-2009-D-0006"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0006-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:00:11,2025-05-28 03:53:06
11f61680-0cb5-4e16-95f4-1b66dd9bdae1,USA-FDA,d160f039-f1d8-4414-a9f2-35fe67cc7216,G_MINI_SUMMARY,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002/FDA-2020-D-1877-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Necessary Automated External Defibrillator Accessories: Policy Regarding Compliance Date; Guidance for Industry, Stakeholders, Health Care Professionals, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2020-D-1877"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1877-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:00:50,2025-05-28 03:53:06
12,,53719680-3b4a-45f7-a7b1-97ca2171a1f5,G_CONCISE_SUMMARY,2025-05-09 01:56:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 08:56:30,2025-05-28 03:53:06
120,,d31863bf-e770-4290-a5b1-ac92e3e6775e,G_CONCISE_SUMMARY_IN,2025-05-12 22:46:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:46:48,2025-05-28 03:53:06
120fd800-e3aa-4e2d-9993-07d2ccea660c,USA-FDA,52735481-1fe9-4003-bd65-0df380968d93,G_IMPACT_ANALYSIS,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0057/FDA-2011-D-0057-0021/FDA-2011-D-0057-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff ;  Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data"", ""docket_id"": ""FDA-2011-D-0057"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0057-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0057/FDA-2011-D-0057-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:02:51,2025-05-28 03:53:06
121,,356c63d9-288f-4a8d-8d3f-8733f967daa7,G_CONCISE_SUMMARY_IN,2025-05-12 22:46:53,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:46:53,2025-05-28 03:53:06
122,,3934ba29-bd5e-4afc-afe2-15b34d64dc6d,G_CONCISE_SUMMARY_IN,2025-05-12 22:46:58,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:46:58,2025-05-28 03:53:06
1228758c-024a-483a-a05e-ecc60f7d6bb7,USA-FDA,ceba742a-a965-4226-aa9e-fdc245c02a41,G_CONCISE_SUMMARY,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001/FDA-2020-D-1430-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents"", ""docket_id"": ""FDA-2020-D-1430"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1430-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:17:16,2025-05-28 03:53:06
123,,bcf8cdd8-bd5f-4d6d-a501-d6237c7e3e14,G_CONCISE_SUMMARY_IN,2025-05-12 22:47:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:47:03,2025-05-28 03:53:06
1239bd9d-d386-4852-b10c-094eb96534b2,USA-FDA,33948049-47f3-41c6-8371-83c43d022318,G_MINI_SUMMARY,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003/FDA-2008-D-0180-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Coronary Drug Eluting Stents- Nonclincal and Clinical Studies; Draft Guidance"", ""docket_id"": ""FDA-2008-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0180-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:00:11,2025-05-28 03:53:06
124,,cb276c1d-f3d9-4dad-9224-f8ed78c53f03,G_CONCISE_SUMMARY_IN,2025-05-12 22:47:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:47:08,2025-05-28 03:53:06
125,,f017ac84-9736-4411-a3ef-1c5f702cfc5e,G_CONCISE_SUMMARY_IN,2025-05-12 22:47:12,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11/Regulation_(EU)_2017/746_-_application_of_IVDR_requirements_to_�legacy_devices�_and_to_devices_placed_on_the_market_prior_to_26_May_2022_in_accordance_with_Directive_98/79/EC.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Regulation (EU) 2017/746 - application of IVDR requirements to �legacy devices� and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-11""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:47:12,2025-05-28 03:53:06
125f201f-068b-4b72-84d0-2d65651ba4ec,USA-FDA,0ec008fc-593a-4759-98c9-745a66e175a0,G_ACTION_ITEMS,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002/FDA-2011-D-0733-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Evaluating the Safety of Flood-affected Food Crops for Human Consumption"", ""docket_id"": ""FDA-2011-D-0733"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0733-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:30:38,2025-05-28 03:53:06
126,,40687a7f-014f-4cf2-87ad-50b4e448d14b,G_CONCISE_SUMMARY_IN,2025-05-12 22:47:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12/Guidance_on_significant_changes_regarding_the_transitional_provision_under_Article_110(3)_of_the_IVDR.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-12""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:47:17,2025-05-28 03:53:06
126599da-76de-45e2-93d9-099a698d64a7,USA-FDA,6060e674-ea1a-45c1-9731-f1e3fe5eb4fd,G_MINI_SUMMARY,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4561/FDA-2015-D-4561-0005/FDA-2015-D-4561-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Head Lice Infestation: Developing Drugs for Topical Treatment Guidance for Industry"", ""docket_id"": ""FDA-2015-D-4561"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4561-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4561/FDA-2015-D-4561-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:16:41,2025-05-28 03:53:06
127,,df017ff7-b83b-4b2c-aa39-84e9263ccad8,G_MINI_SUMMARY_IN,2025-05-12 23:03:37,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:03:38,2025-05-28 03:53:06
128,,b7c6cb2b-4928-43bb-b23b-043d5d7da5ec,G_CONCISE_SUMMARY_IN,2025-05-12 23:03:41,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:03:42,2025-05-28 03:53:06
129,,4e586b49-65fd-4e62-af50-bb8441f64768,G_FAQ_IN,2025-05-12 23:03:49,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:03:49,2025-05-28 03:53:06
12be7fce-8a1e-4086-91b6-e60cb09973ce,USA-FDA,71619e9a-3213-48e7-bebc-88f3d68c801d,G_DETAILED_SUMMARY,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0938/FDA-2012-D-0938-0024/FDA-2012-D-0938-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Guidance on Abbreviated New Drug Applications: Stability Testing of Drug Substances and Products"", ""docket_id"": ""FDA-2012-D-0938"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0938-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0938/FDA-2012-D-0938-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:15:13,2025-05-28 03:53:06
12ca8381-887b-487a-8c57-07ce889612c6,USA-FDA,947f4ea7-c029-4ea5-a42a-83ad3fc59f0b,G_CONCISE_SUMMARY,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002/FDA-2008-D-0576-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sponsors, Clinical Investigators, and IRBs - Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials"", ""docket_id"": ""FDA-2008-D-0576"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0576-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:16:26,2025-05-28 03:53:06
12e76a8b-2635-4833-83a0-4d250b531c0b,USA-FDA,a3f813e0-8373-49d9-a273-831d958a571a,G_MINI_SUMMARY,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002/FDA-2013-D-0616-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0616-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:32:50,2025-05-28 03:53:06
12f5cb5c-afbb-46f7-a36b-a5cf79dc5325,QUEUE,1a9f0d0f-e581-44c2-b3f7-292e08db615d,G_IMPACT_ANALYSIS_USER,2025-05-20 10:42:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__doc_title__"": ""FDA-2005-D-0027-0016-guidance.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/1a9f0d0f-e581-44c2-b3f7-292e08db615d/SRC/1a9f0d0f-e581-44c2-b3f7-292e08db615d.pdf"", ""doc_title"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/1a9f0d0f-e581-44c2-b3f7-292e08db615d/DEST/impact_analysis.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:42:22,2025-05-28 03:53:06
12fb5f7c-c74e-40d9-a539-ee0afcdc2e3d,SCHEDULED,a1aa641d-0bf8-46a7-bcec-6b1339c3895c,DEVICE_ANALYST,2025-05-27 00:00:04,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/a1aa641d-0bf8-46a7-bcec-6b1339c3895c"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:15,2025-05-28 03:53:06
13,,8a8d225a-c132-4199-909c-68b971178329,G_CONCISE_SUMMARY,2025-05-09 02:16:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 09:16:43,2025-05-28 03:53:06
130,,df71cc3e-b59d-4e97-abb5-3eb43225928e,G_ACTION_ITEMS_IN,2025-05-12 23:03:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:03:55,2025-05-28 03:53:06
131,,989d3cac-eabe-4225-9f37-0d165100a31f,G_IMPACT_ANALYSIS_IN,2025-05-12 23:04:01,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:04:02,2025-05-28 03:53:06
1318d50e-b25c-44fd-898c-2891bff49eb9,USA-FDA,97eaf062-2030-44e5-8f85-87ecab57415d,G_CONCISE_SUMMARY,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011/FDA-1998-D-0035-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:00:14,2025-05-28 03:53:06
132,,2ba9a66c-411b-454d-a7c7-0d08c328cecb,G_MINI_SUMMARY_IN,2025-05-12 23:09:21,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:09:22,2025-05-28 03:53:06
1323e9b4-19fe-4820-9a41-0e26dff3f433,USA-FDA,7d1a646f-1d90-4aed-80f7-79b6ec997632,G_IMPACT_ANALYSIS,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1279/FDA-2013-D-1279-0002/FDA-2013-D-1279-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Development Tools; Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-1279"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1279-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1279/FDA-2013-D-1279-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:01:32,2025-05-28 03:53:06
133,,85f49f57-9c9a-4634-818e-21f2613f51e9,G_CONCISE_SUMMARY_IN,2025-05-12 23:10:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:10:23,2025-05-28 03:53:06
134,,b4d44442-571b-4ac5-a8bc-cf044ec2b0ae,G_MINI_SUMMARY_IN,2025-05-12 23:11:21,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:11:21,2025-05-28 03:53:06
13401fba-74a1-4f28-97a3-9d09171d9f4b,USA-FDA,087fcdc9-7ed6-40eb-800f-b75794c124d9,G_KEYWORDS,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001/FDA-2020-D-1407-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products HCT Ps Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2020-D-1407"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1407-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:52,2025-05-28 03:53:06
135,,1dbcf078-9550-443a-92a1-31dc02ef2990,G_CONCISE_SUMMARY_IN,2025-05-12 23:11:32,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:11:32,2025-05-28 03:53:06
136,,04da09c5-0a74-43f3-906a-99e72ea2ea16,G_SUMMARY_IN,2025-05-12 23:11:45,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:11:45,2025-05-28 03:53:06
137,,d528e22c-80ab-4bc0-b590-91658f6e490f,G_FAQ_IN,2025-05-12 23:12:01,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:12:01,2025-05-28 03:53:06
13763e25-2dc2-49eb-91c7-67fe6ba5cc6b,SCHEDULED,41fe10eb-e00b-42aa-98a3-76715576ace6,DEVICE_ANALYST,2025-05-25 00:00:04,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/41fe10eb-e00b-42aa-98a3-76715576ace6"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:06,2025-05-28 03:53:06
138,,112757e3-c2b8-4bdc-a6b9-cf0de582d6e7,G_ACTION_ITEMS_IN,2025-05-12 23:12:20,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:12:20,2025-05-28 03:53:06
139,,80e773aa-5cf7-409e-a174-79af76125a76,G_IMPACT_ANALYSIS_IN,2025-05-12 23:12:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:12:56,2025-05-28 03:53:06
139786db-15f0-47b7-821a-706ea200db40,USA-FDA,7feb6cea-d4f7-4e74-98d1-f23cb267dad1,G_ACTION_ITEMS,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002/FDA-2013-D-0168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Recommendations for Labeling Medical Products to Inform Users the Product or Product Container Is Not Made With Natural Rubber Latex"", ""docket_id"": ""FDA-2013-D-0168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:17:03,2025-05-28 03:53:06
13b2c553-abfb-47fa-9e49-1c5ed3c53f52,USA-FDA,b3534138-85e2-4f12-9c82-c4ad1f7d83fa,G_KEYWORDS,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001/FDA-2020-D-1444-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Safety Information - FDA's Communication to the Public"", ""docket_id"": ""FDA-2020-D-1444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1444-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:17:07,2025-05-28 03:53:06
13b9f5b3-bf5f-4e29-900f-e89afeefda51,SCHEDULED,18453e26-f4dd-458c-ae76-03169db5d432,FDA_ALERT,2025-05-28 00:00:05,36,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,922d0502-12bf-496f-8290-4dcff6453e7c,"{""user_id"": 77, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""weekly"", ""last_name"": ""Chandawarkar"", ""user_guid"": ""922d0502-12bf-496f-8290-4dcff6453e7c"", ""first_name"": ""Aseem"", ""start_date"": ""2025-02-26"", ""user_email"": ""Aseem.Chandawarkar@gmail.com"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/922d0502-12bf-496f-8290-4dcff6453e7c/AGENTS/fda_alert/18453e26-f4dd-458c-ae76-03169db5d432"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:14,2025-05-28 03:53:06
13d6399c-0c6c-4f3e-8d62-ef6c0025c89c,USA-FDA,3e6902be-3222-40d8-bd54-0adf28bc6970,G_ACTION_ITEMS,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0722/FDA-2011-D-0722-0002/FDA-2011-D-0722-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Implementation of Acceptable Abbreviated Donor History Questionnaire, etc."", ""docket_id"": ""FDA-2011-D-0722"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0722-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0722/FDA-2011-D-0722-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:48:11,2025-05-28 03:53:06
13d6bf35-1aab-45a8-9d08-ef90461ec28b,USA-FDA,e7f310b5-0009-42ec-93ba-4d48664c078c,G_IMPACT_ANALYSIS,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0310/FDA-2014-D-0310-0002/FDA-2014-D-0310-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Immunogenicity-Related\nConsiderations for the Approval of Low Molecular Weight Heparin for New Drug Applications and Abbreviated New Drug Applications"", ""docket_id"": ""FDA-2014-D-0310"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-0310-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0310/FDA-2014-D-0310-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:31:36,2025-05-28 03:53:06
13ee3a15-c837-40f0-8146-844ceb9fcdc1,SCHEDULED,64b8f579-d7ae-4304-a5cf-5a567bc9ffa2,FDA_ALERT,2025-05-22 00:03:21,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/64b8f579-d7ae-4304-a5cf-5a567bc9ffa2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:30,2025-05-28 03:53:06
14,,efcbcf85-a747-41cf-b903-f7a78c3273c0,G_COMPARE_DOCUMENTS,2025-05-09 02:16:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145/FDA-2024-D-3863-0145-guidance.pdf"", ""aws_bucket"": ""lexim-ai-dev""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0002/FDA-2024-D-3863-0002-guidance.pdf"", ""aws_bucket"": ""lexim-ai-dev""}","{""format"": ""md"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/AGENT/efcbcf85-a747-41cf-b903-f7a78c3273c0"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-09 09:17:12,2025-05-28 03:53:06
140,,0c32d886-3686-410c-b68a-682e86cabf40,G_MINI_SUMMARY_IN,2025-05-12 23:14:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:14:09,2025-05-28 03:53:06
140237a5-44cc-445a-ab0f-5724ee494d64,USA-FDA,3b76757f-9232-4290-ace2-c7b6f64d0963,G_FAQ,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002/FDA-2003-D-0416-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS"", ""docket_id"": ""FDA-2003-D-0416"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0416-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:47:33,2025-05-28 03:53:06
140f25a3-ef9c-48c3-baa6-98d28119f45b,USA-FDA,053a574c-6a74-4675-8320-c65100f51be6,G_FAQ,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0056/FDA-1997-D-0056-0002/FDA-1997-D-0056-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Iron-Containing Supplements and Drugs: Label Warning Statements and Unit-Dose Packaging Requirements Small Entity Compliance Guide"", ""docket_id"": ""FDA-1997-D-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0056-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0056/FDA-1997-D-0056-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:16:27,2025-05-28 03:53:06
141,,8efc5378-f8f8-40bd-9c48-dce0dbf50ff9,G_MINI_SUMMARY_IN,2025-05-12 23:16:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:16:07,2025-05-28 03:53:06
141bdeca-1109-4918-ab25-0405eba7597f,USA-FDA,d10f4510-a72c-450a-bb46-c53283fbabe4,G_ACTION_ITEMS,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0260/FDA-2009-D-0260-0029/FDA-2009-D-0260-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2)"", ""docket_id"": ""FDA-2009-D-0260"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0260-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0260/FDA-2009-D-0260-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:47:39,2025-05-28 03:53:06
142,,e753f054-ae4f-4196-906a-920c7c6d3ad6,G_CONCISE_SUMMARY_IN,2025-05-12 23:16:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:16:10,2025-05-28 03:53:06
143,,b5ee931e-e758-46d8-b977-0f5ffd85e356,G_SUMMARY_IN,2025-05-12 23:16:14,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:16:15,2025-05-28 03:53:06
144,,197fc80d-48c1-49db-a5be-fa760ba32df0,G_FAQ_IN,2025-05-12 23:16:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:16:24,2025-05-28 03:53:06
145,,c626cf3e-331a-4338-847b-1943438ab004,G_ACTION_ITEMS_IN,2025-05-12 23:16:29,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:16:30,2025-05-28 03:53:06
146,,7b6826cf-8459-4eb2-a0d8-de49d3718e63,G_IMPACT_ANALYSIS_IN,2025-05-12 23:16:36,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:16:36,2025-05-28 03:53:06
147,,b28cde53-337f-46d9-a19c-fe1af9250c29,G_MINI_SUMMARY_IN,2025-05-12 23:17:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:17:18,2025-05-28 03:53:06
1475a51e-c56a-4003-ab87-5085c1fe25a5,USA-FDA,567b8012-77cf-495a-91e3-71bb7b7abbae,G_MINI_SUMMARY,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-N-0083/FDA-1999-N-0083-0015/FDA-1999-N-0083-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Availability: Reproductive and Developmental Toxicities - Integrating Study Results to Assess Concerns"", ""docket_id"": ""FDA-1999-N-0083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-N-0083-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-N-0083/FDA-1999-N-0083-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:46:13,2025-05-28 03:53:06
148,,f9326e8c-909a-495d-bf16-8e357a6c36f4,G_CONCISE_SUMMARY_IN,2025-05-12 23:17:21,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:17:22,2025-05-28 03:53:06
1485b77a-31c2-4531-b52b-bd249a6ab761,USA-FDA,0fe1323f-8fef-488e-883e-cdeba392f774,G_MINI_SUMMARY,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1935/FDA-2020-D-1935-0001/FDA-2020-D-1935-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 100.550 Status and Responsibilities of Contract Sterilizers Engaged in the Sterilization of Drugs and Devices"", ""docket_id"": ""FDA-2020-D-1935"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1935-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1935/FDA-2020-D-1935-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:45:39,2025-05-28 03:53:06
149,,06b883c8-c58c-4f25-8680-484c13440c6e,G_SUMMARY_IN,2025-05-12 23:17:27,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:17:27,2025-05-28 03:53:06
149e4fce-fb56-4c29-a6c8-4cea71a87222,USA-FDA,c0fd689c-cd57-4b29-87cb-97df3b0fee2c,G_MINI_SUMMARY,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009/FDA-2011-D-0398-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Questions and Answers Regarding The Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:30:44,2025-05-28 03:53:06
14abbc7e-7fdb-4f1c-b1a7-e8d5d5128062,USA-FDA,91269770-ab71-4402-9ca9-d1194778ddfd,G_IMPACT_ANALYSIS,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1439/FDA-2014-D-1439-0004/FDA-2014-D-1439-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Critical Path Innovation Meetings; Guidance for Industry"", ""docket_id"": ""FDA-2014-D-1439"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1439-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1439/FDA-2014-D-1439-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:31:39,2025-05-28 03:53:06
14af130e-79d9-48dc-b2e8-bb6959a380b1,USA-FDA,a212e3ad-3930-43fc-9b05-c551dd9f0675,G_IMPACT_ANALYSIS,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004/FDA-2018-N-4735-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""GFI Safety Labeling Changes Implementation of Section 505(o)(4) of the FDC Act"", ""docket_id"": ""FDA-2018-N-4735"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-N-4735-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:16:58,2025-05-28 03:53:06
14ca5e1f-da9d-434c-9e61-8d6f00f8a3ff,USA-FDA,8fc6cbbb-3426-4ea5-aa63-7fcde23d2828,G_IMPACT_ANALYSIS,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002/FDA-2000-D-0129-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans - Draft Guidance"", ""docket_id"": ""FDA-2000-D-0129"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-D-0129-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:02:02,2025-05-28 03:53:06
14cc75fc-360f-44ee-a261-e0426bcc4328,USA-FDA,a249c8ba-2204-4b97-a480-13b0ce56ec86,G_DETAILED_SUMMARY,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001/FDA-2020-D-1397-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Q3A Impurities in New Drug Substances"", ""docket_id"": ""FDA-2020-D-1397"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1397-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:45:23,2025-05-28 03:53:06
14d5ebfd-88d3-477e-a3b5-4bf0f352e4cd,USA-FDA,98f69400-b3e7-4d58-957e-564d9ac49390,G_CONCISE_SUMMARY,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001/FDA-2020-D-1397-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Q3A Impurities in New Drug Substances"", ""docket_id"": ""FDA-2020-D-1397"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1397-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:45:12,2025-05-28 03:53:06
15,,e0eaf2b3-55b2-4f89-90f2-828cd9ed9fb8,G_DETAILED_SUMMARY,2025-05-09 02:17:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 09:17:19,2025-05-28 03:53:06
150,,6fe42351-f36a-4a7b-9616-91e83fb54e27,G_FAQ_IN,2025-05-12 23:17:37,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:17:38,2025-05-28 03:53:06
151,,7b7121e3-1907-4831-be70-b96650663216,G_ACTION_ITEMS_IN,2025-05-12 23:17:44,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:17:44,2025-05-28 03:53:06
152,,8d3e83af-735c-4779-a255-112971207387,G_IMPACT_ANALYSIS_IN,2025-05-12 23:17:53,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:17:53,2025-05-28 03:53:06
153,,29b321ef-fed7-496e-8588-b6aa3a3cfba1,G_MINI_SUMMARY_IN,2025-05-12 23:18:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:18:03,2025-05-28 03:53:06
154,,6d79754d-2edc-4521-af1e-e3661237974b,G_CONCISE_SUMMARY_IN,2025-05-12 23:18:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:18:08,2025-05-28 03:53:06
15477947-5f0d-4d21-a797-12dfa99b3851,QUEUE,a9c66105-6845-46e2-b76b-2cefa5817b1c,G_FAQ_USER,2025-05-20 10:57:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""__doc_title__"": ""FDA-2023-D-0488-0002-guidance (1).pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/a9c66105-6845-46e2-b76b-2cefa5817b1c/SRC/a9c66105-6845-46e2-b76b-2cefa5817b1c.pdf"", ""doc_title"": ""FDA-2023-D-0488-0002-guidance (1).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/a9c66105-6845-46e2-b76b-2cefa5817b1c/DEST/faq.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:58:01,2025-05-28 03:53:06
155,,6541e7bb-f352-4aca-bfb9-ebb4fd1a8a07,G_SUMMARY_IN,2025-05-12 23:18:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:18:23,2025-05-28 03:53:06
155c66f8-f740-45f5-83c7-4dc02a7e6bbf,USA-FDA,6e01e080-0346-439b-ae5f-b602253890a7,G_FAQ,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001/FDA-2020-D-1977-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures"", ""docket_id"": ""FDA-2020-D-1977"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1977-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:16:53,2025-05-28 03:53:06
156,,4dfee76c-aaf2-4d92-b525-569567fc95cb,G_FAQ_IN,2025-05-12 23:18:44,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:18:44,2025-05-28 03:53:06
157,,3724be70-0e6d-4a2b-8f69-4f704154d2ce,G_ACTION_ITEMS_IN,2025-05-12 23:18:50,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:18:51,2025-05-28 03:53:06
1577e01a-97d9-4fc3-a1cb-3063418121f9,USA-FDA,fbadff87-f60f-4ba6-9aeb-fa06ad8614f9,G_KEYWORDS,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002/FDA-2009-D-0195-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Uranium"", ""docket_id"": ""FDA-2009-D-0195"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0195-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:31:30,2025-05-28 03:53:06
157d79d6-c20f-4b56-b59e-63c8f4641b21,USA-FDA,cecca3c4-afcb-4cd0-9ba5-1508109d3a9f,G_ACTION_ITEMS,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0044/FDA-2009-D-0044-0009/FDA-2009-D-0044-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis "", ""docket_id"": ""FDA-2009-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0044-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0044/FDA-2009-D-0044-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:01:42,2025-05-28 03:53:06
158,,ee5c6fde-7924-498b-b51d-8c50a9f198dc,G_IMPACT_ANALYSIS_IN,2025-05-12 23:19:01,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1/Guidance_on_the_health_institution_exemption_under_Article_5(5)_of_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-10"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-10-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-10/MDCG-10-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:19:02,2025-05-28 03:53:06
159,,395a9798-b9ad-4a97-a588-547a30532d67,G_MINI_SUMMARY_IN,2025-05-12 23:19:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:19:05,2025-05-28 03:53:06
159fcd35-9fbc-4eac-ad86-c30a1961c876,USA-FDA,3568170b-ecfe-49d0-92db-12ed29804609,G_DETAILED_SUMMARY,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0138/FDA-2001-D-0138-0003/FDA-2001-D-0138-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Exemptions from the Warning Label Requirement for Juice - Recommendations for Effectively Achieving a 5 -Log Pathogen Reduction"", ""docket_id"": ""FDA-2001-D-0138"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0138-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0138/FDA-2001-D-0138-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:45:18,2025-05-28 03:53:06
15c901ff-8dd3-45ac-bf04-8803a973fc7e,USA-FDA,a550c93b-e11c-420e-ab5b-926e73306758,G_ACTION_ITEMS,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002/FDA-2017-D-5525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Statistical Approaches to Evaluate Analytical Similarity Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:32:16,2025-05-28 03:53:06
15dc22f6-dc83-4cb2-a046-dc9f0435157f,USA-FDA,77cb42a7-814a-419f-b942-7043b625187b,G_FAQ,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0971/FDA-2016-D-0971-0002/FDA-2016-D-0971-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Infectious Disease Next Generation Sequencing Based Diagnostic Devices Microbial Identification and Detection of Antimicrobial Resistance and Virulence Markers"", ""docket_id"": ""FDA-2016-D-0971"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0971-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0971/FDA-2016-D-0971-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:46:19,2025-05-28 03:53:06
15e867be-2db8-4d21-95aa-7e47b64c91da,USA-FDA,ef516be1-4dab-49f4-994b-b278ccc1d432,G_FAQ,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015/FDA-1999-D-1315-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Formal Meetings With Sponsors and Applicants for PDUFA Products; Guidance Document"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:32:47,2025-05-28 03:53:06
15f60067-ddd8-4b28-b961-3841c6af6afa,USA-FDA,f4c12650-91f1-4daf-be70-e53456c85b1e,G_ACTION_ITEMS,2025-05-20 12:08:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002/FDA-2011-D-0597-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring"", ""docket_id"": ""FDA-2011-D-0597"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0597-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:10:09,2025-05-28 03:53:06
16,,12599bec-4ce5-447e-b62d-aef9bc2283b0,G_MINI_SUMMARY,2025-05-12 18:34:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 01:34:49,2025-05-28 03:53:06
160,,b6ccf6ec-be50-496c-84d1-ee4736975e03,G_CONCISE_SUMMARY_IN,2025-05-12 23:19:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:19:09,2025-05-28 03:53:06
161,,475f11df-24b0-47c6-af15-d154687cc08a,G_SUMMARY_IN,2025-05-12 23:19:20,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:19:20,2025-05-28 03:53:06
161e8a69-a607-4171-b217-5af0951a3e26,USA-FDA,1ae32ec0-6854-48d6-ad70-7027e6c0642f,G_MINI_SUMMARY,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0432/FDA-2011-D-0432-0002/FDA-2011-D-0432-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics"", ""docket_id"": ""FDA-2011-D-0432"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0432-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0432/FDA-2011-D-0432-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:45:43,2025-05-28 03:53:06
162,,c68933e9-6896-40bd-8f69-bf27b1af4d51,G_FAQ_IN,2025-05-12 23:19:50,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:19:50,2025-05-28 03:53:06
1620136b-80c7-4b85-b082-bd254aa0cc9c,USA-FDA,e12f213f-2a52-4c27-98c3-59f02785e8d3,G_MINI_SUMMARY,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0005/FDA-2007-D-0433-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bieoquivalence Recommendations for Specific Products"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:00:43,2025-05-28 03:53:06
163,,fda17bfe-3bdc-4704-b0fe-4860322a38e8,G_ACTION_ITEMS_IN,2025-05-12 23:19:57,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:19:58,2025-05-28 03:53:06
164,,0ea0b656-67fc-487e-aeb0-68135c82be54,G_IMPACT_ANALYSIS_IN,2025-05-12 23:20:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2/Guidance_on_Authorised_Representatives_Regulation_(EU)_2017/745_and_Regulation_(EU)_2017/746.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746"", ""docket_id"": ""MDCG-11"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-11-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-11/MDCG-11-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:20:08,2025-05-28 03:53:06
16406639-0b8e-490f-a0e6-9f42558a0824,USA-FDA,33aac874-d866-486d-99a6-63ab92f43c63,G_KEYWORDS,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002/FDA-2011-D-0730-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff; Class II Special Controls Guidance Documents: In Vitro Diagnostic Devices for Yersinia Species Detection"", ""docket_id"": ""FDA-2011-D-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0730-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:01:08,2025-05-28 03:53:06
165,,7a4a19fa-56f3-44fb-a3a2-ee060bf22d2a,G_MINI_SUMMARY_IN,2025-05-12 23:20:11,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:20:12,2025-05-28 03:53:06
166,,a579524d-d6b5-4e98-8379-cb9515cc611f,G_CONCISE_SUMMARY_IN,2025-05-12 23:20:16,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:20:17,2025-05-28 03:53:06
167,,8e342d27-5b98-4167-891a-c5eb6d2f204d,G_SUMMARY_IN,2025-05-12 23:20:27,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:20:27,2025-05-28 03:53:06
1677b8a5-8e0b-4e8a-bab9-9e611c70eaf6,USA-FDA,1d99ef01-31de-4c4a-a7ff-38652d7af6b7,G_DETAILED_SUMMARY,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002/FDA-2011-D-0398-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:31:12,2025-05-28 03:53:06
167faa0f-21a8-45e6-b418-d897405559a3,USA-FDA,394578db-fbc7-4951-9021-bde4d2cc76c0,G_IMPACT_ANALYSIS,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002/FDA-2011-D-0147-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Staff Demonstrating Substantial Equivalence of New Tobacco Product; Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2011-D-0147"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0147-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:30:59,2025-05-28 03:53:06
168,,f40094ca-d351-475d-86e4-bb68c417d14b,G_FAQ_IN,2025-05-12 23:20:44,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:20:44,2025-05-28 03:53:06
16802afb-006c-4864-a1d4-693d5342a5de,USA-FDA,e3401a1b-1e5d-4d58-97b7-cf8812987724,G_MINI_SUMMARY,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0436/FDA-2011-D-0436-0002/FDA-2011-D-0436-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Q11 Development and Manufacture of Drug Substances; International Conference on Harmonisation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0436"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0436-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0436/FDA-2011-D-0436-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:30:33,2025-05-28 03:53:06
169,,6b9ec295-1ef9-4e75-ac22-e3a9a35b9bf4,G_ACTION_ITEMS_IN,2025-05-12 23:20:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:20:51,2025-05-28 03:53:06
16bae920-ab99-40cf-9b8c-8d2dbda37d2e,USA-FDA,d2a8f279-f8a6-4a53-bf69-777673e87852,G_ACTION_ITEMS,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002/FDA-2014-N-1108-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products--Considerations, Content, and Format"", ""docket_id"": ""FDA-2014-N-1108"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1108-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:01:55,2025-05-28 03:53:06
16cec175-dc72-48aa-a179-656ea0a306cd,USA-FDA,038ec92a-995e-4721-abd6-4e5128000ed6,G_ACTION_ITEMS,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0212/FDA-2009-D-0212-0025/FDA-2009-D-0212-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting - Guidance for Industry"", ""docket_id"": ""FDA-2009-D-0212"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0212-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0212/FDA-2009-D-0212-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:47:27,2025-05-28 03:53:06
16d31edf-4fbc-4f92-81e0-961b05d3282f,USA-FDA,21496c54-3298-4267-b5cb-b4a1cb2a7c7a,G_IMPACT_ANALYSIS,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002/FDA-2011-D-0733-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Evaluating the Safety of Flood-affected Food Crops for Human Consumption"", ""docket_id"": ""FDA-2011-D-0733"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0733-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:30:47,2025-05-28 03:53:06
16e71c5b-7a6c-4313-8145-72b08a7ce58a,USA-FDA,b0461e30-4680-4a72-aa5f-2da3c2aa8c27,G_MINI_SUMMARY,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0182/FDA-2004-D-0182-0004/FDA-2004-D-0182-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; ANDAs: Pharmaceutical Solid Polymorphism;\nChemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-2004-D-0182"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0182-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0182/FDA-2004-D-0182-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:30:07,2025-05-28 03:53:06
16f26863-d54f-43e6-96b7-7aaed420127d,USA-FDA,1553799c-f258-4d81-babb-ec185ea26479,G_CONCISE_SUMMARY,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002/FDA-2010-D-0395-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Adminstration Staff Recommendation for Premarket Notification for Lamotrigine and Zonisamide Assays"", ""docket_id"": ""FDA-2010-D-0395"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0395-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:00:13,2025-05-28 03:53:06
17,,7317f739-7576-4d29-9fa4-5b33e5de65ba,G_CONCISE_SUMMARY,2025-05-12 18:35:02,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 01:35:04,2025-05-28 03:53:06
170,,69f64dca-1a85-410c-b54d-baa360b68d5b,G_IMPACT_ANALYSIS_IN,2025-05-12 23:21:00,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1/Guidance_on_qualification_of_in_vitro_diagnostic_medical_devices.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification of in vitro diagnostic medical devices"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:21:01,2025-05-28 03:53:06
171,,9594f1e5-659a-4e32-b963-ec5e7e4ef551,G_MINI_SUMMARY_IN,2025-05-12 23:21:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11/Regulation_(EU)_2017/746_-_application_of_IVDR_requirements_to_�legacy_devices�_and_to_devices_placed_on_the_market_prior_to_26_May_2022_in_accordance_with_Directive_98/79/EC.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Regulation (EU) 2017/746 - application of IVDR requirements to �legacy devices� and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-11""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:21:04,2025-05-28 03:53:06
1718f825-47e4-4cb6-8db1-7f4ab3cb94b7,USA-FDA,0b8c797d-7a69-4f83-a6ae-149584e1bffb,G_CONCISE_SUMMARY,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010/FDA-2008-D-0623-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #192 Anesthetics for Companion Animals"", ""docket_id"": ""FDA-2008-D-0623"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0623-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:01:20,2025-05-28 03:53:06
172,,535dd413-6763-4615-80c9-d597c067729c,G_CONCISE_SUMMARY_IN,2025-05-12 23:21:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11/Regulation_(EU)_2017/746_-_application_of_IVDR_requirements_to_�legacy_devices�_and_to_devices_placed_on_the_market_prior_to_26_May_2022_in_accordance_with_Directive_98/79/EC.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Regulation (EU) 2017/746 - application of IVDR requirements to �legacy devices� and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-11""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:21:09,2025-05-28 03:53:06
173,,15ef3b6d-8691-459a-811d-93b02abcd6b9,G_SUMMARY_IN,2025-05-12 23:21:15,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11/Regulation_(EU)_2017/746_-_application_of_IVDR_requirements_to_�legacy_devices�_and_to_devices_placed_on_the_market_prior_to_26_May_2022_in_accordance_with_Directive_98/79/EC.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Regulation (EU) 2017/746 - application of IVDR requirements to �legacy devices� and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-11""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:21:15,2025-05-28 03:53:06
17326b7f-8e7d-4d30-882a-380a370c024d,USA-FDA,7051364d-c7d6-4f92-a506-836be12efb45,G_IMPACT_ANALYSIS,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002/FDA-2018-D-0740-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk Guidance for Industry"", ""docket_id"": ""FDA-2018-D-0740"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0740-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:31:24,2025-05-28 03:53:06
174,,19081ddf-5dd2-4b06-99f3-1d5b644b8926,G_FAQ_IN,2025-05-12 23:21:25,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11/Regulation_(EU)_2017/746_-_application_of_IVDR_requirements_to_�legacy_devices�_and_to_devices_placed_on_the_market_prior_to_26_May_2022_in_accordance_with_Directive_98/79/EC.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Regulation (EU) 2017/746 - application of IVDR requirements to �legacy devices� and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-11""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:21:26,2025-05-28 03:53:06
174364bc-21c9-4087-9cd7-73f03a659936,USA-FDA,0025f99e-a4aa-44d0-8364-896788dcec50,G_ACTION_ITEMS,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1005/FDA-2012-D-1005-0002/FDA-2012-D-1005-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Considerations for Product Design to Minimize Medication Errors - Draft Guidance"", ""docket_id"": ""FDA-2012-D-1005"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1005-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1005/FDA-2012-D-1005-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:45:44,2025-05-28 03:53:06
175,,b8299bfb-635c-43a9-a170-4b75dac2aa45,G_ACTION_ITEMS_IN,2025-05-12 23:21:32,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11/Regulation_(EU)_2017/746_-_application_of_IVDR_requirements_to_�legacy_devices�_and_to_devices_placed_on_the_market_prior_to_26_May_2022_in_accordance_with_Directive_98/79/EC.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Regulation (EU) 2017/746 - application of IVDR requirements to �legacy devices� and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-11""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:21:32,2025-05-28 03:53:06
17500d7f-0483-4d0a-a01a-c44527580c64,USA-FDA,4493c0ae-442f-464d-859d-16276a136392,G_CONCISE_SUMMARY,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009/FDA-2006-D-0157-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry:  Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2006-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0157-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:00:18,2025-05-28 03:53:06
176,,2aafe795-fd06-4e43-8e30-89905895f2c5,G_IMPACT_ANALYSIS_IN,2025-05-12 23:21:40,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11/Regulation_(EU)_2017/746_-_application_of_IVDR_requirements_to_�legacy_devices�_and_to_devices_placed_on_the_market_prior_to_26_May_2022_in_accordance_with_Directive_98/79/EC.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Regulation (EU) 2017/746 - application of IVDR requirements to �legacy devices� and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-11""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-11"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:21:40,2025-05-28 03:53:06
176010c0-cd24-4f49-8a3a-55dcdc12c6d3,USA-FDA,21440990-68c4-4a3f-8b30-ec9aa7cab2b6,G_MINI_SUMMARY,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003/FDA-1999-D-0030-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-1999-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0030-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:31:46,2025-05-28 03:53:06
177,,cf273675-e912-450e-bdcd-8a83e6011c8b,G_MINI_SUMMARY_IN,2025-05-12 23:21:44,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12/Guidance_on_significant_changes_regarding_the_transitional_provision_under_Article_110(3)_of_the_IVDR.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-12""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:21:44,2025-05-28 03:53:06
178,,d438591f-0a08-4326-a040-57c4c8065eb5,G_CONCISE_SUMMARY_IN,2025-05-12 23:21:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12/Guidance_on_significant_changes_regarding_the_transitional_provision_under_Article_110(3)_of_the_IVDR.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-12""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:21:48,2025-05-28 03:53:06
179,,51f21051-7d55-437f-8055-e6a705fb7b05,G_SUMMARY_IN,2025-05-12 23:21:58,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12/Guidance_on_significant_changes_regarding_the_transitional_provision_under_Article_110(3)_of_the_IVDR.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-12""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:21:59,2025-05-28 03:53:06
1796551c-39ac-4651-995e-3cfbc3a11b07,USA-FDA,4ec7629b-3876-477c-aca1-272eeb6ea80f,G_ACTION_ITEMS,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002/FDA-2009-D-0198-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain Cochineal Extract and Carmine"", ""docket_id"": ""FDA-2009-D-0198"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0198-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:58,2025-05-28 03:53:06
17a163c9-9618-4ef7-94d7-26ed7bfb1c3f,CAB,2bf866ff-5db4-40bd-bb38-e691efd7c5f5,G_FAQ_IN,2025-05-27 02:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-2910-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2024-N-2910-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b3efc128-de32-4064-8905-ee749b8e53b7""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b3efc128-de32-4064-8905-ee749b8e53b7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 02:00:39,2025-05-28 03:53:06
17ab0a1e-c525-4a9e-873d-8f2a497fdc78,USA-FDA,c7d24691-76c3-4852-b2bb-604827bf4c04,G_IMPACT_ANALYSIS,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1459/FDA-2018-D-1459-0049/FDA-2018-D-1459-0049-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Food Labeling: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics: Guidance for Industry"", ""docket_id"": ""FDA-2018-D-1459"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-1459-0049""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1459/FDA-2018-D-1459-0049"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:30:54,2025-05-28 03:53:06
17ab6937-8cc2-491d-a59a-b6b9fe9680fa,USA-FDA,afaef6fb-f017-44be-90df-73271a3915d1,G_KEYWORDS,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002/FDA-1997-D-0444-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""FDA Approval of Animal Drugs for Minor Uses and Minor Species; Draft Guidance Document"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:01:12,2025-05-28 03:53:06
17b66c5d-e104-4dc0-806e-ba0369c30ab9,USA-FDA,312cb5cc-3333-4ace-9861-832799cba1ae,G_CONCISE_SUMMARY,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025/FDA-2009-D-0524-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Listing of Ingredients in Tobacco Products"", ""docket_id"": ""FDA-2009-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0524-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:01:21,2025-05-28 03:53:06
17c262d8-45d9-40e6-8817-bbc8af20c1ab,USA-FDA,cb661bb4-9351-4192-b020-2dde3f180902,G_FAQ,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002/FDA-2014-N-0829-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Reporting Drug Sample Information\nUnder Section 6004 of the Affordable Care Act"", ""docket_id"": ""FDA-2014-N-0829"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-0829-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:30:36,2025-05-28 03:53:06
18,,87ad40e0-a019-4b0d-894c-17799eaa2eac,G_DETAILED_SUMMARY,2025-05-12 18:35:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 01:35:18,2025-05-28 03:53:06
180,,7e358773-1836-4e47-8d65-01d15ea409f8,G_FAQ_IN,2025-05-12 23:22:14,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12/Guidance_on_significant_changes_regarding_the_transitional_provision_under_Article_110(3)_of_the_IVDR.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-12""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:22:14,2025-05-28 03:53:06
1803f4c2-3aee-41a3-9f64-aba6e3562448,SCHEDULED,9f981d81-f308-4442-9d24-084d52eed47a,FDA_ALERT,2025-06-01 00:00:04,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/9f981d81-f308-4442-9d24-084d52eed47a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:13,2025-06-01 00:00:13
181,,e0659476-58df-4d6b-ab71-e207c81793c1,G_ACTION_ITEMS_IN,2025-05-12 23:22:21,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12/Guidance_on_significant_changes_regarding_the_transitional_provision_under_Article_110(3)_of_the_IVDR.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-12""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:22:21,2025-05-28 03:53:06
18189e37-b376-425b-ae61-08d153b09082,USA-FDA,0b2da950-95cf-4ed8-9c69-df969c58d803,G_MINI_SUMMARY,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005/FDA-2011-D-0112-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Chemistry, Manufacturing, and Controls (CMC)\nInformation � Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use"", ""docket_id"": ""FDA-2011-D-0112"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0112-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:30:08,2025-05-28 03:53:06
182,,37bd2471-df7a-43f7-ae26-d36fde81b196,G_IMPACT_ANALYSIS_IN,2025-05-12 23:22:29,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12/Guidance_on_significant_changes_regarding_the_transitional_provision_under_Article_110(3)_of_the_IVDR.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR"", ""docket_id"": ""MDCG-12"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-12-12""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-12/MDCG-12-12"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 06:22:29,2025-05-28 03:53:06
183,,fe2596bd-5c6c-4d95-8d7b-bc38a00176f5,G_MINI_SUMMARY_IN,2025-05-13 18:35:50,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 01:35:51,2025-05-28 03:53:06
183610c0-7b5c-4d82-b999-b2ac7691736d,USA-FDA,f0cc1c63-49ef-4789-a169-4ddba359acf6,G_MINI_SUMMARY,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0188/FDA-1999-D-0188-0002/FDA-1999-D-0188-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Effect of Anthelmintics : Specific Recommendations for Ovine  VICH GL13 -  Final Guidance 96"", ""docket_id"": ""FDA-1999-D-0188"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0188-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0188/FDA-1999-D-0188-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:16:39,2025-05-28 03:53:06
184,,fb00ddfa-eb66-472a-a91a-4f5322e8bf1a,G_SUMMARY_IN,2025-05-13 18:39:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 01:39:09,2025-05-28 03:53:06
185,,2912e6d7-9eb7-40b1-bdbc-4da91b8af494,G_KEYWORDS,2025-05-13 21:02:59,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:03:00,2025-05-28 03:53:06
185095c9-5754-4d5b-867c-cc39393c02e4,USA-FDA,f6fdfd30-fce1-457d-b0b5-c2e7e693d6e7,G_MINI_SUMMARY,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0002/FDA-2017-D-6526-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier"", ""docket_id"": ""FDA-2017-D-6526"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6526-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:00:12,2025-05-28 03:53:06
185fafcb-f1d4-4c2e-b0f2-190ef30dbf08,USA-FDA,50718806-d3ab-4724-90c5-c2a54fdf1577,G_ACTION_ITEMS,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002/FDA-2010-D-0395-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Adminstration Staff Recommendation for Premarket Notification for Lamotrigine and Zonisamide Assays"", ""docket_id"": ""FDA-2010-D-0395"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0395-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:00,2025-05-28 03:53:06
186,,9407bbd4-d72f-4dcf-bde8-62b675393462,G_KEYWORDS,2025-05-13 21:06:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:06:52,2025-05-28 03:53:06
187,,1d0c95c5-5aff-4881-bb9f-d9127c08b116,G_TRANSLATE,2025-05-13 21:10:13,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:10:15,2025-05-28 03:53:06
187d6953-7128-4acb-ac1c-15aa580cb6ad,USA-FDA,f3f5d242-d1d9-40a2-a785-a8eda23cd32d,G_FAQ,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0616/FDA-2010-D-0616-0020/FDA-2010-D-0616-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Codevelopment of Two or More New Investigational Drugs for Use in Combination"", ""docket_id"": ""FDA-2010-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0616-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0616/FDA-2010-D-0616-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:02:16,2025-05-28 03:53:06
188,,1ea3ed1e-5e73-4d1b-a189-eb1e21551f30,G_TRANSLATE,2025-05-13 21:12:19,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:12:21,2025-05-28 03:53:06
188e144c-5f07-40ca-89e6-6c5fb69f2ec1,SCHEDULED,6faa48f3-0390-4c94-bb0c-36a0d5c3ef50,DEVICE_ANALYST,2025-06-01 00:00:04,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/6faa48f3-0390-4c94-bb0c-36a0d5c3ef50"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:23,2025-06-01 00:00:23
189,,8f0c7556-5dfb-459c-82fe-20ccf0360caf,G_KEYWORDS,2025-05-13 21:13:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:13:48,2025-05-28 03:53:06
18926637-beb2-4da4-9a3d-b21b454c3443,USA-FDA,208a353a-cb70-4d4e-b5bf-d4b948992b59,G_DETAILED_SUMMARY,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002/FDA-2018-D-2583-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products; Guidance for Industry;  Draft Guidance"", ""docket_id"": ""FDA-2018-D-2583"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2583-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:02:47,2025-05-28 03:53:06
18c2ce1b-3eb3-4f2c-8f2b-53bcdcee38d9,USA-FDA,8ea876bb-002a-41f0-8bab-29158874cf35,G_ACTION_ITEMS,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0310/FDA-2014-D-0310-0002/FDA-2014-D-0310-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Immunogenicity-Related\nConsiderations for the Approval of Low Molecular Weight Heparin for New Drug Applications and Abbreviated New Drug Applications"", ""docket_id"": ""FDA-2014-D-0310"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-0310-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0310/FDA-2014-D-0310-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:31:28,2025-05-28 03:53:06
18d0a8f6-0e30-4340-b715-31e0d89867f0,USA-FDA,9e47234c-2fac-4dc0-a2ec-129955f7b7f2,G_MINI_SUMMARY,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0790/FDA-2011-D-0790-0002/FDA-2011-D-0790-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff, FDA Decisions for Investigational Device Exemption Clinical Investigations"", ""docket_id"": ""FDA-2011-D-0790"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0790-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0790/FDA-2011-D-0790-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:45:43,2025-05-28 03:53:06
18d50793-ec12-4182-9d04-5e6a35d26742,USA-FDA,e82f162d-255b-4ac9-879b-4a1ad0e89a47,G_KEYWORDS,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008/FDA-2009-D-0448-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry, MQSA Inspectors and FDA Staffl The Mammography Quality Standards Act Final Regulations: Modifications and Additions to Policy Guidance Help System #13"", ""docket_id"": ""FDA-2009-D-0448"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0448-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:03:41,2025-05-28 03:53:06
18dff177-f443-4ae0-8025-13bee4665b01,USA-FDA,dca66778-81d5-4d0e-bacf-1f40d26d79ce,G_ACTION_ITEMS,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0002/FDA-2009-D-0568-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:47:11,2025-05-28 03:53:06
18edfd2a-1dd4-44b8-8728-27165e04d137,USA-FDA,1153b896-a3bc-48ca-b0ee-9b0c663bc9b5,G_ACTION_ITEMS,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004/FDA-2005-D-0028-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products"", ""docket_id"": ""FDA-2005-D-0028"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0028-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:02:21,2025-05-28 03:53:06
19,,f0d579bc-3bf0-4a98-b082-3cfd49d6dd0f,G_FAQ,2025-05-12 18:35:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 01:35:31,2025-05-28 03:53:06
190,,f1ba2143-7255-42f4-8183-104e783cde4a,G_TRANSLATE,2025-05-13 21:14:32,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:14:33,2025-05-28 03:53:06
191,,a36c75dc-24d5-470f-8023-ea9425e290b7,G_TRANSLATE,2025-05-13 21:15:21,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:15:22,2025-05-28 03:53:06
191a8ce1-f00b-4eb5-8354-b3e0f53edcb4,USA-FDA,1aa3a2ea-dbaf-40b5-8b82-7dd6fa464555,G_DETAILED_SUMMARY,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012/FDA-2008-D-0610-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic"", ""docket_id"": ""FDA-2008-D-0610"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0610-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:32:08,2025-05-28 03:53:06
192,,bbc49e05-b6da-4e16-b195-c9a3a80bad63,G_KEYWORDS,2025-05-13 21:17:53,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:17:55,2025-05-28 03:53:06
19248683-43c3-4b5f-8a1f-bb989ef000f2,USA-FDA,f70ceb3a-02ec-40d5-a646-eb0418a1c257,G_DETAILED_SUMMARY,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002/FDA-2011-D-0649-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Class II Special Controls; External Pacemaker Pulse Generator"", ""docket_id"": ""FDA-2011-D-0649"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0649-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:00:49,2025-05-28 03:53:06
1928339f-b9e3-43e4-8062-accc9fdd370f,USA-FDA,f33ca883-5806-47a2-bd80-8ea6b33d505e,G_KEYWORDS,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164/FDA-2006-D-0102-1164-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry"", ""docket_id"": ""FDA-2006-D-0102"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0102-1164""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:47:21,2025-05-28 03:53:06
193,,3ca3ffa8-ae47-483f-9a20-af44d8429d24,G_TRANSLATE,2025-05-13 21:18:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:18:40,2025-05-28 03:53:06
194,,d8c68879-57e0-4786-838c-f5600e92601c,G_TRANSLATE,2025-05-13 21:19:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:19:29,2025-05-28 03:53:06
195,,4e310084-c397-42da-91c4-b7d14b5cd74f,G_KEYWORDS,2025-05-13 21:26:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:26:52,2025-05-28 03:53:06
19581f75-77c5-477d-af3c-e883a74c64fe,USA-FDA,ec89b19a-1b30-48f5-9762-959885ddfba3,G_DETAILED_SUMMARY,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005/FDA-2011-D-0643-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; What You Need to Know About Administrative Detention of Foods; Small Entity Compliance Guide; Final Guidance"", ""docket_id"": ""FDA-2011-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0643-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:31:04,2025-05-28 03:53:06
196,,f901cda1-9a6f-423b-a98e-da766504ecf0,G_TRANSLATE,2025-05-13 21:27:37,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:27:38,2025-05-28 03:53:06
19662ea1-1b3c-44bc-bdd3-1c6285361eec,USA-FDA,8e92dea3-ed47-42de-8f1b-287c761533ec,G_IMPACT_ANALYSIS,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0567/FDA-2011-D-0567-0002/FDA-2011-D-0567-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry, Clinical Investigators and Staff; Design Considerations for Pivotal Clinical Investigations for Medical Devices"", ""docket_id"": ""FDA-2011-D-0567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0567-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0567/FDA-2011-D-0567-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:01:24,2025-05-28 03:53:06
1966d54d-0720-4baf-92f7-2fba5a0ff2c9,USA-FDA,4cf5c20d-ecad-4047-8a74-98e5dae7b3b9,G_IMPACT_ANALYSIS,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009/FDA-2007-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry; Bioequivalence Recommendation for Lenalidomide Capsules"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:13:41,2025-05-28 03:53:06
197,,38c89516-f75c-40b5-8fe4-a22bcc997f9c,G_TRANSLATE,2025-05-13 21:28:27,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:28:28,2025-05-28 03:53:06
19752187-447e-489d-a0c0-f344eaed8c43,USA-FDA,d1e2abef-316d-44d3-9c3d-6163fe7c92e4,G_DETAILED_SUMMARY,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007/FDA-2011-D-0691-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs"", ""docket_id"": ""FDA-2011-D-0691"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0691-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:02:49,2025-05-28 03:53:06
198,,d05c0aae-bba1-4e8d-8020-7d9661072049,G_MINI_SUMMARY_IN,2025-05-13 21:34:35,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:34:36,2025-05-28 03:53:06
199,,95666941-e840-4d3a-b09e-28568188b632,G_CONCISE_SUMMARY_IN,2025-05-13 21:34:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:34:40,2025-05-28 03:53:06
1999bd12-eab7-42b4-b1dd-37b7b7e12639,USA-FDA,c917c6a3-3702-4c16-a473-79828101e0ad,G_MINI_SUMMARY,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009/FDA-2011-D-0164-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Safety Labeling Changes--Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:00:11,2025-05-28 03:53:06
19daddff-f66f-4302-bd49-7a8204c58695,USA-FDA,1a57351a-d1ec-4478-bd31-0148666d6324,G_MINI_SUMMARY,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002/FDA-2009-D-0539-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins; Guidance"", ""docket_id"": ""FDA-2009-D-0539"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0539-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:31:03,2025-05-28 03:53:06
1a04ee89-c702-4afd-97f9-f77948d7ddd8,USA-FDA,debcf273-f75d-4a01-afbb-6bb456652885,G_KEYWORDS,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001/FDA-2020-D-2015-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Devices Without a Premarket Notification (510(k)) or an Approved Premarket Approval Application (PMA) REVOKED DOCUMENT"", ""docket_id"": ""FDA-2020-D-2015"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-2015-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:51,2025-05-28 03:53:06
1a1281df-f79e-4099-bb10-6ea478098549,USA-FDA,7febe809-b401-4315-ab14-3f38280749bf,G_FAQ,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002/FDA-2017-D-4359-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry 68 on Small Entites Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:15:29,2025-05-28 03:53:06
1a20e514-2cf6-43a1-8986-3b3c35b22b28,USA-FDA,12b5415a-79a2-4b57-b1d9-9384dca3f265,G_MINI_SUMMARY,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1958/FDA-2020-D-1958-0001/FDA-2020-D-1958-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Seafood HACCP Transition Guidance"", ""docket_id"": ""FDA-2020-D-1958"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1958-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1958/FDA-2020-D-1958-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:02:35,2025-05-28 03:53:06
1a2f23b5-7981-42da-8fc1-2f46a2f9d2b4,USA-FDA,826a6eac-a7e6-458c-be02-b847faf1805d,G_MINI_SUMMARY,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0246/FDA-2010-D-0246-0014/FDA-2010-D-0246-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Residual Drug in Transdermal and Related Drug Delivery Systems; Guidance for Industry"", ""docket_id"": ""FDA-2010-D-0246"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0246-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0246/FDA-2010-D-0246-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:01:54,2025-05-28 03:53:06
1a4139ba-4b0a-4ffc-a1f7-c43010b8a0ca,USA-FDA,631937d4-9371-4eeb-ba3e-df89a8ec6220,G_MINI_SUMMARY,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0044/FDA-2009-D-0044-0009/FDA-2009-D-0044-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis "", ""docket_id"": ""FDA-2009-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0044-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0044/FDA-2009-D-0044-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:01:27,2025-05-28 03:53:06
1a5ce6b8-27d1-45af-9fa4-2413ff8d5713,USA-FDA,04c839ff-f80c-42d3-a534-1e5c6d7d6170,G_FAQ,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1529/FDA-2013-N-1529-0023/FDA-2013-N-1529-0023-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""03 Reference 2 Open Public Hearings Guidance - Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: The Open Public Hearing at FDA Advisory Committee Meetings"", ""docket_id"": ""FDA-2013-N-1529"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1529-0023""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1529/FDA-2013-N-1529-0023"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:32:15,2025-05-28 03:53:06
1a6a2a0a-d535-4b27-b1ee-fe99e7bffb9d,SCHEDULED,f7d9eedf-3e32-44f7-824c-84d0bae5e848,DEVICE_ANALYST,2025-05-20 13:40:01,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-03-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/f7d9eedf-3e32-44f7-824c-84d0bae5e848"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:40:13,2025-05-28 03:53:06
1a8048b9-adf3-4d34-ad8d-4c992a7f6e0d,USA-FDA,a7e6a71b-b870-48ef-b277-4f53f684842c,G_IMPACT_ANALYSIS,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-0298/FDA-2019-D-0298-0002/FDA-2019-D-0298-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Quality Considerations for Continuous Manufacturing; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2019-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-0298-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-0298/FDA-2019-D-0298-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:46:14,2025-05-28 03:53:06
1aa21814-28be-4d26-89aa-e7549df256a1,USA-FDA,7107daf5-19d6-4b9a-b9ee-32cc05a23030,G_IMPACT_ANALYSIS,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002/FDA-2015-D-1309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M8 Electronic Common Technical Document v4.0 Draft Implementation\nGuide v2.0; Electronic Common Technical Document v4.0 Implementation Package Draft Specification for Submission Formats\nv2.0; International Conference on Harmonisation; Draft Guidance for\nIndustry"", ""docket_id"": ""FDA-2015-D-1309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:46:59,2025-05-28 03:53:06
1aaac3f3-b8c0-46e0-b6a9-d1fe9388e435,USA-FDA,67d53eea-1fba-422a-9965-aa9ffa1ae804,G_FAQ,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002/FDA-2005-G-0193-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Low Energy Ultrasound Wound Cleaner"", ""docket_id"": ""FDA-2005-G-0193"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-G-0193-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:12:45,2025-05-28 03:53:06
1abd98e8-0169-4e5e-a636-b363aab4c9eb,USA-FDA,5f875c74-aecb-4b75-acbb-f0bdd343d5f3,G_KEYWORDS,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001/FDA-2020-D-1977-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures"", ""docket_id"": ""FDA-2020-D-1977"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1977-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:17:21,2025-05-28 03:53:06
1aed2d5c-2e04-490e-a1f9-d114f6667150,USA-FDA,6760633b-0f3e-43c5-a7b9-2f6897b400d1,G_DETAILED_SUMMARY,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0096/FDA-2012-D-0096-0002/FDA-2012-D-0096-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations"", ""docket_id"": ""FDA-2012-D-0096"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0096-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0096/FDA-2012-D-0096-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:46:41,2025-05-28 03:53:06
1afde15c-2fd8-4c62-9165-1d8341c1c87c,USA-FDA,41575b7d-4334-494c-b4b4-86b5487869c2,G_MINI_SUMMARY,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001/FDA-2023-D-2508-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products"", ""docket_id"": ""FDA-2023-D-2508"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2508-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:00:07,2025-05-28 03:53:06
1b255e5f-7c65-4175-8508-a8d31095ec38,USA-FDA,1ee75974-6a2e-4539-bb1b-80f46a5db1f4,G_ACTION_ITEMS,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005/FDA-1999-D-4079-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling"", ""docket_id"": ""FDA-1999-D-4079"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4079-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:32:14,2025-05-28 03:53:06
1b54c7fb-fd75-442a-9615-cf887db0ee82,USA-FDA,2460b115-0db3-4170-afcd-5e7f48f7b67b,G_MINI_SUMMARY,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016/FDA-2013-D-0369-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in\nPharmaceuticals to Limit Potential Carcinogenic Risk; International\nConference on Harmonisation; Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0369"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0369-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:11:14,2025-05-28 03:53:06
1b667455-1c99-43ed-b80e-9d37f81eb928,USA-FDA,66e6c09a-1623-404c-a858-457071670315,G_IMPACT_ANALYSIS,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012/FDA-2016-D-1533-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma - Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:47:58,2025-05-28 03:53:06
1b9e50c5-24f4-4104-a8e8-068d47597b81,USA-FDA,5d3b5c95-9b6e-44de-9b44-453a8d684ea3,G_DETAILED_SUMMARY,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0007/FDA-1992-N-0007-0005/FDA-1992-N-0007-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Industry Supported Scientific and Educational Activities:  Guidance for Industry"", ""docket_id"": ""FDA-1992-N-0007"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0007-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0007/FDA-1992-N-0007-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:16:34,2025-05-28 03:53:06
1b9e9e7b-2460-4746-aa0a-c58ce875d72c,USA-FDA,4d8fbb61-591e-449c-8530-77985d148bcc,G_FAQ,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0031/FDA-2006-D-0031-0006/FDA-2006-D-0031-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Frequently Asked Questions About Medical Devices:  Guidance For IRBs, Clinical Investigators, and Sponsors"", ""docket_id"": ""FDA-2006-D-0031"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0031-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0031/FDA-2006-D-0031-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:16:18,2025-05-28 03:53:06
1ba66b7f-b0c1-4cef-bd3e-bf320c0165e0,USA-FDA,4d9eb847-9be9-4097-9c24-f9c920c59f1d,G_DETAILED_SUMMARY,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1067/FDA-2013-D-1067-0002/FDA-2013-D-1067-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products--Content and Format"", ""docket_id"": ""FDA-2013-D-1067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1067-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1067/FDA-2013-D-1067-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:01:19,2025-05-28 03:53:06
1bb94ef5-4510-48d5-905f-3a443dabbd27,USA-FDA,7d66e4d4-1890-46ec-95b6-d27e934b8ed0,G_KEYWORDS,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010/FDA-2004-D-0500-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Consumer-Directed Broadcast Advertising of Restricted Devices; Draft Guidance for Industry"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:02:21,2025-05-28 03:53:06
1bbab44e-9b07-41b0-8ba2-0dbcf6aa8e1a,USA-FDA,8ea291ce-2956-422e-98a4-b6627b7f4ace,G_ACTION_ITEMS,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-3276/FDA-2016-D-3276-0001/FDA-2016-D-3276-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Investigational Use of Deemed, Finished Tobacco Products That Were on the U.S. Market on August 8, 2016, During the Deeming Compliance Periods; Guidance for Industry"", ""docket_id"": ""FDA-2016-D-3276"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-3276-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-3276/FDA-2016-D-3276-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:17:18,2025-05-28 03:53:06
1bd6c75e-1eb6-4886-a784-e8eb827a590b,USA-FDA,b1275ff0-f750-4e47-ab2b-4df2b32738c2,G_IMPACT_ANALYSIS,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164/FDA-2006-D-0102-1164-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry"", ""docket_id"": ""FDA-2006-D-0102"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0102-1164""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:47:17,2025-05-28 03:53:06
1be3f87f-eec0-41c6-9e6f-6ecb3b5169d9,USA-FDA,f07510ba-4c7f-49a0-ab38-38e448572536,G_FAQ,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0045/FDA-2013-D-0045-0030/FDA-2013-D-0045-0030-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abuse-Deterrent Opioids-Evaluation and Labeling"", ""docket_id"": ""FDA-2013-D-0045"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0045-0030""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0045/FDA-2013-D-0045-0030"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:45:47,2025-05-28 03:53:06
1c014812-5d63-4c15-a0df-c409369bda81,USA-FDA,4ba3542b-8948-4ec5-905e-b68e5a5f49e9,G_MINI_SUMMARY,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0298/FDA-2006-D-0298-0005/FDA-2006-D-0298-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff: Whole Grain Label Statements"", ""docket_id"": ""FDA-2006-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0298-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0298/FDA-2006-D-0298-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:16:42,2025-05-28 03:53:06
1c1c35d7-7b21-419d-b83a-b8204782132f,USA-FDA,ad55f6e4-6a3b-4934-94e6-388178eab91e,G_CONCISE_SUMMARY,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006/FDA-2010-D-0500-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information"", ""docket_id"": ""FDA-2010-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0500-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:14,2025-05-28 03:53:06
1c2547e2-704e-4b57-987d-be61d4843cce,USA-FDA,34e279c9-c359-4dde-9d83-846f0aa75ab5,G_IMPACT_ANALYSIS,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001/FDA-2020-D-1430-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents"", ""docket_id"": ""FDA-2020-D-1430"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1430-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:18:11,2025-05-28 03:53:06
1c277d95-0383-42f3-b7d3-4f98235de4d8,USA-FDA,5f2e45aa-5a62-4664-b080-286e676a5f40,G_ACTION_ITEMS,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002/FDA-2015-D-4380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Best Practices for Communication Between IND Sponsors and FDA\nDuring Drug Development Guidance for Industry and Review Staff"", ""docket_id"": ""FDA-2015-D-4380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:17:06,2025-05-28 03:53:06
1c2e85fe-9ccc-4dbb-836d-e6d1bfec8df8,USA-FDA,e3f6a8b4-91cf-478d-9861-aac3fe858623,G_MINI_SUMMARY,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004/FDA-2019-D-1372-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Elemental Impurities in Human Drug Products Questions and Answers Proposed DRAFT Guidance for Industry"", ""docket_id"": ""FDA-2019-D-1372"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-1372-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:54,2025-05-28 03:53:06
1c2e98d7-5ae6-42b5-82a3-f6a095b49f70,USA-FDA,4411f26b-6417-4c26-bfcf-8da13e904248,G_ACTION_ITEMS,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029/FDA-2009-D-0179-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0179-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:32:34,2025-05-28 03:53:06
1c358686-dbe5-44ed-8401-46613e3c8e67,USA-FDA,68f9c865-f5f8-4051-8d85-767333673ba0,G_IMPACT_ANALYSIS,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0008/FDA-2012-D-1083-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff Civil Money Penalties for Tobacco Retailers: Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2012-D-1083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1083-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:16:09,2025-05-28 03:53:06
1c425a9b-d5c7-43f2-bf62-0c4e4a8783d9,USA-FDA,0a2743b5-41b7-4e94-8510-2a9cb4843768,G_IMPACT_ANALYSIS,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002/FDA-2017-D-5525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Statistical Approaches to Evaluate Analytical Similarity Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:32:25,2025-05-28 03:53:06
1c54d72d-e6a5-4bfa-b2be-79da6ba9f547,USA-FDA,2148b66b-0b7d-4c94-ac9f-a6c5695efab5,G_IMPACT_ANALYSIS,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1918/FDA-2020-D-1918-0001/FDA-2020-D-1918-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Food Additive Petition Expedited Review"", ""docket_id"": ""FDA-2020-D-1918"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1918-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1918/FDA-2020-D-1918-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:48:16,2025-05-28 03:53:06
1c5e9951-c2a4-452a-ac68-618826d1c833,SCHEDULED,04f7bab4-e49d-4261-bca4-423645325839,DEVICE_ANALYST,2025-06-02 00:00:04,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/04f7bab4-e49d-4261-bca4-423645325839"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:11,2025-06-02 00:00:11
1d0559b0-cc61-4e72-bbc8-1b42540c0b20,USA-FDA,0cb61cfe-1048-49ce-8bb6-63cb97235978,G_ACTION_ITEMS,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025/FDA-2009-D-0524-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Listing of Ingredients in Tobacco Products"", ""docket_id"": ""FDA-2009-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0524-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:01:49,2025-05-28 03:53:06
1d233d5d-6521-4a6d-8c36-477daf02f9eb,USA-FDA,c1234c60-7b71-451a-8fa1-2c44bbe9c22d,G_IMPACT_ANALYSIS,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007/FDA-2011-D-0691-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs"", ""docket_id"": ""FDA-2011-D-0691"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0691-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:03:14,2025-05-28 03:53:06
1d58dbff-fa54-4b65-a9b7-d8788b8c117e,SCHEDULED,3b74bc67-9af1-4fc7-a88d-a804ed64052b,FDA_ALERT,2025-05-25 00:00:04,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/3b74bc67-9af1-4fc7-a88d-a804ed64052b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:13,2025-05-28 03:53:06
1d5d51a1-4f70-4409-9c12-54f81b9c9e01,USA-FDA,95ff2029-c040-4141-a170-2c0a2e903b99,G_CONCISE_SUMMARY,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015/FDA-2010-D-0281-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; ��Harmful and Potentially Harmful Constituents� in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act�"", ""docket_id"": ""FDA-2010-D-0281"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0281-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:11,2025-05-28 03:53:06
1da15499-bf0e-4194-8933-f86cd9a60dca,USA-FDA,e6a5b39c-bd50-4b1b-816c-2736e5efc9d3,G_FAQ,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-N-0121/FDA-2011-N-0121-0009/FDA-2011-N-0121-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products; Small Entity Compliance Guide"", ""docket_id"": ""FDA-2011-N-0121"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-N-0121-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-N-0121/FDA-2011-N-0121-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:15:21,2025-05-28 03:53:06
1dc9ade6-d6f8-4d9a-846c-28c87aaa4a39,USA-FDA,6528e0ce-5a62-4ed2-a5dc-4b8cbacd456c,G_KEYWORDS,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020/FDA-2015-D-1245-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:03:22,2025-05-28 03:53:06
1de77eab-10d6-46ad-9ba4-d2c1f030edb3,USA-FDA,31ec05c8-3bef-46d0-b2c4-231f6511ae68,G_KEYWORDS,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011/FDA-2001-D-0137-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children"", ""docket_id"": ""FDA-2001-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0137-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:32:52,2025-05-28 03:53:06
1deaa1c6-935c-48dc-81c9-31e0c926eeaf,USA-FDA,ba75a422-6db5-4c6a-8f15-eed3a6ae7b11,G_DETAILED_SUMMARY,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016/FDA-2014-D-1399-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:15:20,2025-05-28 03:53:06
1dee12ed-181c-424c-a647-3886f5fed1cf,USA-FDA,7941649a-6b26-406f-8d48-417ab2c6fccb,G_ACTION_ITEMS,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025/FDA-2004-D-0044-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:15:36,2025-05-28 03:53:06
1dfedfe3-4b39-40fc-9f0e-ccd39d40e8b8,USA-FDA,b91ab048-f6f7-48e7-bfa9-9da60d2337b7,G_DETAILED_SUMMARY,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0057/FDA-2011-D-0057-0021/FDA-2011-D-0057-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff ;  Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data"", ""docket_id"": ""FDA-2011-D-0057"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0057-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0057/FDA-2011-D-0057-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:02:07,2025-05-28 03:53:06
1e1fe94b-8b16-4dd2-a91f-59fd4b20838c,USA-FDA,a1bda1e7-fb1b-43c0-9e7b-5f99ea1afefb,G_MINI_SUMMARY,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022/FDA-2011-D-0082-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry , Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling"", ""docket_id"": ""FDA-2011-D-0082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0082-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:02:50,2025-05-28 03:53:06
1e303dd3-ff68-4422-b18c-6573cc71b3db,USA-FDA,1015e2bd-558c-4130-b942-fe544ded25e3,G_FAQ,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002/FDA-2014-D-1891-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD"", ""docket_id"": ""FDA-2014-D-1891"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1891-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:16:08,2025-05-28 03:53:06
1e46ad1d-afe2-47ce-bb6d-a4460f75d7eb,USA-FDA,9a5d1192-0078-4451-a59e-f43f6d8dfd76,G_IMPACT_ANALYSIS,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001/FDA-2023-D-2508-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products"", ""docket_id"": ""FDA-2023-D-2508"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2508-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:00:44,2025-05-28 03:53:06
1e8c1db8-ceda-439f-8ab8-1f00787fc235,USA-FDA,b2547f17-cd7e-429d-ad57-4f15a2077595,G_MINI_SUMMARY,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002/FDA-2018-D-4525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Lactation Studies: Considerations for Study Design; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2018-D-4525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-4525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:17:07,2025-05-28 03:53:06
1e98008f-a1fb-4a65-855a-ac5c95441d0e,USA-FDA,b7ee8a08-6f3b-4563-9de1-97e4ce66850d,G_CONCISE_SUMMARY,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002/FDA-2012-D-0179-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens"", ""docket_id"": ""FDA-2012-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0179-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:00:15,2025-05-28 03:53:06
1e981c8a-1c0e-4209-82d1-8f16d71d0f1b,USA-FDA,0ac08971-18e2-4658-bb20-49a7a16df087,G_ACTION_ITEMS,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1264/FDA-2014-D-1264-0003/FDA-2014-D-1264-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment over the Spectrum of Disease"", ""docket_id"": ""FDA-2014-D-1264"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1264-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1264/FDA-2014-D-1264-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:48:15,2025-05-28 03:53:06
1f13c6b1-efe3-45dc-a6f1-e1a28cce0777,USA-FDA,f7ab3ae5-b359-4ba1-b8bc-f24d8a84978c,G_FAQ,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022/FDA-1998-N-0050-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 540.375 Canned Salmon - Adulteration Involving Decomposition Withdrawn 3-22-2010"", ""docket_id"": ""FDA-1998-N-0050"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-N-0050-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:20,2025-05-28 03:53:06
1f254bd3-8c2a-4f40-b243-535103466726,USA-FDA,edc3f4f7-db86-4247-9fe3-935efd8cb579,G_IMPACT_ANALYSIS,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006/FDA-2005-D-0086-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""uidance for Industry; Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals"", ""docket_id"": ""FDA-2005-D-0086"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0086-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:02:10,2025-05-28 03:53:06
1f31c3de-2bb4-49ff-a0d2-4fa74475a8f6,USA-FDA,d7f916e7-e67c-48ce-843b-094f2a57dc16,G_IMPACT_ANALYSIS,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002/FDA-2020-D-1640-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance on Cannabidiol"", ""docket_id"": ""FDA-2020-D-1640"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1640-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:16:15,2025-05-28 03:53:06
1f68298d-2c4d-4fbb-bbac-3927e92e4727,USA-FDA,130ee1ce-1698-455c-98e1-217fda3a41a2,G_DETAILED_SUMMARY,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0489/FDA-2011-D-0489-0002/FDA-2011-D-0489-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety of Nanomaterials in Cosmetic Products; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0489"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0489-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0489/FDA-2011-D-0489-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:45:17,2025-05-28 03:53:06
1f829080-73d1-435d-8b71-c9b122ad93d6,USA-FDA,90d76b26-27c0-4be7-be94-1e7d7eaa6809,G_MINI_SUMMARY,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009/FDA-2016-D-2569-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""01 Final Guidance for Industry - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals-Questions and Answers"", ""docket_id"": ""FDA-2016-D-2569"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2569-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:32:34,2025-05-28 03:53:06
1fc9ccee-28fa-4d4e-83f9-83d8b95f922f,USA-FDA,26290491-dd75-461d-9af3-7210a258fb80,G_CONCISE_SUMMARY,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001/FDA-2020-D-1444-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Safety Information - FDA's Communication to the Public"", ""docket_id"": ""FDA-2020-D-1444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1444-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:16:17,2025-05-28 03:53:06
1fdeec0c-403b-4afb-b185-55e12ea5b48a,USA-FDA,ba107f0e-1905-4f78-9425-c8059528bccf,G_DETAILED_SUMMARY,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004/FDA-2018-N-4735-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""GFI Safety Labeling Changes Implementation of Section 505(o)(4) of the FDC Act"", ""docket_id"": ""FDA-2018-N-4735"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-N-4735-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:16:30,2025-05-28 03:53:06
2,,caac39b7-db02-4d8a-b71e-ea63a86d92db,G_CONCISE_SUMMARY,2025-05-09 01:49:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 08:50:15,2025-05-28 03:53:06
20,,984b1d6b-d41c-4ca8-8c2c-316b32b1418a,G_MINI_SUMMARY,2025-05-12 18:43:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 01:43:40,2025-05-28 03:53:06
200,,aa7ab115-d496-4ad2-8a0b-c4c5ebf85788,G_SUMMARY_IN,2025-05-13 21:34:44,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:34:45,2025-05-28 03:53:06
201,,ae45ed12-7ef2-4f0d-bcf4-d522f0f0050f,G_FAQ_IN,2025-05-13 21:34:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:34:57,2025-05-28 03:53:06
20150903-2ea6-4258-a1c8-a5eb9f77f3fe,USA-FDA,180dc395-861f-44fa-b5ce-8176bc059101,G_ACTION_ITEMS,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3443/FDA-2018-D-3443-0002/FDA-2018-D-3443-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-3443"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3443-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3443/FDA-2018-D-3443-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:47:43,2025-05-28 03:53:06
202,,a01c6ab2-d2cf-4922-9d96-3995515aec48,G_ACTION_ITEMS_IN,2025-05-13 21:35:02,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:35:03,2025-05-28 03:53:06
203,,86df6962-0ffb-4617-8e13-011600ee3cc8,G_IMPACT_ANALYSIS_IN,2025-05-13 21:35:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:35:10,2025-05-28 03:53:06
20396f11-1f2f-4262-bc06-a703a543d7b1,CAB,9e5b1474-575f-4eb9-b88b-a64fcef3bb49,G_KEYWORDS,2025-05-20 09:28:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2023-N-4225-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""be71a183-8124-4a8f-984c-ce1233023d0a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/be71a183-8124-4a8f-984c-ce1233023d0a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:28:50,2025-05-28 03:53:06
204,,374e6d85-27f5-46a9-84ac-ffbe00b09d6b,G_KEYWORDS,2025-05-13 21:35:13,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:35:14,2025-05-28 03:53:06
204afe9b-49f2-4dc4-bfff-cf8408ab84f3,USA-FDA,ad540f45-beb6-45bc-9778-40d2044e1d48,G_DETAILED_SUMMARY,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002/FDA-2017-D-6380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric\nSubpopulations of Common Diseases Draft Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:01:51,2025-05-28 03:53:06
205,,ac78be08-af17-4a12-a987-c897a4b4ec82,G_TRANSLATE,2025-05-13 21:36:00,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:36:02,2025-05-28 03:53:06
20502571-32a9-4880-a8a8-79d9c899de6b,USA-FDA,d919e7de-8bf6-4fd4-bf8d-fea74dbc5790,G_DETAILED_SUMMARY,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001/FDA-2020-D-1398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; FDA Approval of New Animal Drugs For Minor Uses and for Minor Species; #61"", ""docket_id"": ""FDA-2020-D-1398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:46:34,2025-05-28 03:53:06
206,,771b8d0e-6768-479f-a097-6ded4aa84b6d,G_TRANSLATE,2025-05-13 21:36:50,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:36:51,2025-05-28 03:53:06
207,,3840b87c-7ece-49fa-a41f-6ea7e0ef940b,G_MINI_SUMMARY_IN,2025-05-13 21:57:37,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""549dd9f7-cd97-4f19-9415-874050fdb79a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/549dd9f7-cd97-4f19-9415-874050fdb79a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:57:38,2025-05-28 03:53:06
208,,f8e6a3ae-ba39-4531-ba5a-e94d2ddd4c72,G_CONCISE_SUMMARY_IN,2025-05-13 21:57:41,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2024-N-0002-0003.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""549dd9f7-cd97-4f19-9415-874050fdb79a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/549dd9f7-cd97-4f19-9415-874050fdb79a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:57:42,2025-05-28 03:53:06
208370b4-b473-4589-9f1b-fbb68e369a43,USA-FDA,e01d6b72-e1c2-41fc-81a0-c11e80f185a2,G_IMPACT_ANALYSIS,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002/FDA-2013-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abbreviated New Drug Application Submissions--Refuse-to-Receive Standards"", ""docket_id"": ""FDA-2013-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:32:55,2025-05-28 03:53:06
209,,e2985a70-877e-4a22-ae57-273f5d71127f,G_SUMMARY_IN,2025-05-13 21:57:45,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""549dd9f7-cd97-4f19-9415-874050fdb79a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/549dd9f7-cd97-4f19-9415-874050fdb79a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:57:47,2025-05-28 03:53:06
20b2197a-98cd-4a18-9786-760cc1071788,USA-FDA,3a547101-d40c-413d-9729-ff969806dd49,G_MINI_SUMMARY,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009/FDA-2011-D-0916-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Classification Product Codes; Guidance for Industry and  Food and Drug Administration Staff"", ""docket_id"": ""FDA-2011-D-0916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0916-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:31:44,2025-05-28 03:53:06
20c1e9f3-8203-4590-86a3-7b01d400ade7,USA-FDA,12153434-e36f-426c-b793-0ded70a33b13,G_DETAILED_SUMMARY,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-2441/FDA-1999-D-2441-0002/FDA-1999-D-2441-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Dioxin in Anti-Caking Agents Used in Animal Feed and Feed Ingredients"", ""docket_id"": ""FDA-1999-D-2441"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-2441-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-2441/FDA-1999-D-2441-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:00:15,2025-05-28 03:53:06
20d88d09-a074-4e28-843a-ee5ce0762661,USA-FDA,e630ba32-6949-4507-92f1-ec601be30549,G_ACTION_ITEMS,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0096/FDA-2012-D-0096-0002/FDA-2012-D-0096-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations"", ""docket_id"": ""FDA-2012-D-0096"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0096-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0096/FDA-2012-D-0096-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:47:02,2025-05-28 03:53:06
20ff955a-374f-4a8f-8b00-a61d2110fb21,SCHEDULED,fd17ab2a-57c7-4718-b04b-7b89402c539d,FDA_ALERT,2025-05-28 00:00:05,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/fd17ab2a-57c7-4718-b04b-7b89402c539d"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:20,2025-05-28 03:53:06
21,,99b6cdd4-98c0-4a9f-a1a3-f610592009a9,G_CONCISE_SUMMARY,2025-05-12 18:44:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 01:44:08,2025-05-28 03:53:06
210,,234ab67f-38bb-48a1-a213-fedb4dda6446,G_FAQ_IN,2025-05-13 21:57:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""549dd9f7-cd97-4f19-9415-874050fdb79a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/549dd9f7-cd97-4f19-9415-874050fdb79a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:57:57,2025-05-28 03:53:06
211,,d8c0120f-2034-4a57-923e-4686b489d524,G_ACTION_ITEMS_IN,2025-05-13 21:58:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""549dd9f7-cd97-4f19-9415-874050fdb79a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/549dd9f7-cd97-4f19-9415-874050fdb79a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:58:04,2025-05-28 03:53:06
2119cd57-5152-47d9-80dd-d25ea0493f4d,SCHEDULED,adeb9da3-5b9e-4230-a559-a1752f017631,DEVICE_ANALYST,2025-05-26 00:00:07,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/adeb9da3-5b9e-4230-a559-a1752f017631"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:14,2025-05-28 03:53:06
212,,d32d3750-9895-43fe-840a-61c8feae061d,G_IMPACT_ANALYSIS_IN,2025-05-13 21:58:11,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""549dd9f7-cd97-4f19-9415-874050fdb79a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/549dd9f7-cd97-4f19-9415-874050fdb79a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:58:12,2025-05-28 03:53:06
213,,479940c9-564d-444e-9f40-56b2d23f20a3,G_KEYWORDS,2025-05-13 21:58:15,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-0002-0003.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""549dd9f7-cd97-4f19-9415-874050fdb79a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/549dd9f7-cd97-4f19-9415-874050fdb79a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:58:16,2025-05-28 03:53:06
214,,e78e77e6-6a73-43fb-95f4-c40b1239476e,G_TRANSLATE,2025-05-13 21:59:00,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2024-N-0002-0003.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""549dd9f7-cd97-4f19-9415-874050fdb79a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/549dd9f7-cd97-4f19-9415-874050fdb79a/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:59:01,2025-05-28 03:53:06
214bec7d-dca0-4b53-9aa3-633dd8d1c7b6,USA-FDA,1628a6ce-9f60-47c0-8f07-e175d593649c,G_KEYWORDS,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010/FDA-2008-D-0623-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #192 Anesthetics for Companion Animals"", ""docket_id"": ""FDA-2008-D-0623"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0623-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:02:45,2025-05-28 03:53:06
215,,6fe03a5e-fb82-4c80-b295-56eac04ed842,G_TRANSLATE,2025-05-13 21:59:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-2024-N-0002-0003.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""549dd9f7-cd97-4f19-9415-874050fdb79a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/549dd9f7-cd97-4f19-9415-874050fdb79a/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:59:48,2025-05-28 03:53:06
2152044c-f998-4fb2-a6c2-118a786bc5dd,CAB,31e6424a-b3be-493b-9de9-edce58e6d901,G_SUMMARY_IN,2025-05-20 16:33:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2018-F-3757-0019.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2018-F-3757-0019_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""04cb41d6-deff-4cde-83f8-ba7f77069dd4""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/04cb41d6-deff-4cde-83f8-ba7f77069dd4"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:34:00,2025-05-28 03:53:06
215f1110-3dba-490d-a3f0-fd4d5184048f,USA-FDA,f30af229-af2c-4196-b360-977f923807a8,G_IMPACT_ANALYSIS,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0002/FDA-2004-D-0500-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Help Seeking and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:33:05,2025-05-28 03:53:06
216,,e81613b5-cb4d-42c1-8e58-6a2f72ea50fd,G_MINI_SUMMARY_IN,2025-05-13 21:59:50,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-5976-0001_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5976-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""49762bb4-0c1f-45c4-954d-2942e59811cd""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/49762bb4-0c1f-45c4-954d-2942e59811cd"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:59:51,2025-05-28 03:53:06
217,,801abc11-13e1-4ca6-9e83-ee62c3bf624c,G_CONCISE_SUMMARY_IN,2025-05-13 21:59:54,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2024-N-5976-0001_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5976-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""49762bb4-0c1f-45c4-954d-2942e59811cd""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/49762bb4-0c1f-45c4-954d-2942e59811cd"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 04:59:55,2025-05-28 03:53:06
217c33b8-850b-4f5b-938f-8ee1db7678c7,USA-FDA,52e61b15-bb3f-40d6-ad60-6eae059ec1de,G_MINI_SUMMARY,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1918/FDA-2020-D-1918-0001/FDA-2020-D-1918-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Food Additive Petition Expedited Review"", ""docket_id"": ""FDA-2020-D-1918"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1918-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1918/FDA-2020-D-1918-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:47:49,2025-05-28 03:53:06
218,,bc0bc545-a99a-43b2-af71-6294a7a2b1de,G_SUMMARY_IN,2025-05-13 22:00:01,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-5976-0001_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5976-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""49762bb4-0c1f-45c4-954d-2942e59811cd""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/49762bb4-0c1f-45c4-954d-2942e59811cd"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:00:02,2025-05-28 03:53:06
2187a4a1-4d9a-41c5-83e8-78c6ac9e08c8,USA-FDA,a8a2b7d0-ac93-4ecc-a194-1e93f3fcf624,G_MINI_SUMMARY,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0074/FDA-2011-D-0074-0025/FDA-2011-D-0074-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Medication Guide Distribution Requirements and Inclusion of Medication Guides in Risk Evaluation and Mitigation Strategies"", ""docket_id"": ""FDA-2011-D-0074"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0074-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0074/FDA-2011-D-0074-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:00:40,2025-05-28 03:53:06
219,,0b5d925e-e1b7-4fa9-a303-0ffb1042fb19,G_FAQ_IN,2025-05-13 22:00:11,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-5976-0001_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5976-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""49762bb4-0c1f-45c4-954d-2942e59811cd""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/49762bb4-0c1f-45c4-954d-2942e59811cd"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:00:12,2025-05-28 03:53:06
21a16ebd-2e44-43ec-ae3b-4196f151cbad,USA-FDA,9e0b39f9-394f-49e0-a193-a3ed91f0a2be,G_IMPACT_ANALYSIS,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001/FDA-2020-D-1608-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data"", ""docket_id"": ""FDA-2020-D-1608"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1608-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:47:14,2025-05-28 03:53:06
21ffcf6a-6593-4a4c-aa25-486103e2ebe1,USA-FDA,b358e450-6cfa-443d-8cb2-353c0d68cbd1,G_KEYWORDS,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008/FDA-2010-D-0431-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Food and Drug Administration Staff and Tobacco Retailers on Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Revised"", ""docket_id"": ""FDA-2010-D-0431"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0431-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:46:00,2025-05-28 03:53:06
22,,36fe561b-b503-4887-8e62-4fced0cbbd8d,G_DETAILED_SUMMARY,2025-05-12 18:44:27,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 01:44:28,2025-05-28 03:53:06
220,,193588a3-dbd0-4c96-bc98-5dacd22306c9,G_ACTION_ITEMS_IN,2025-05-13 22:00:16,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-5976-0001_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5976-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""49762bb4-0c1f-45c4-954d-2942e59811cd""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/49762bb4-0c1f-45c4-954d-2942e59811cd"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:00:17,2025-05-28 03:53:06
221,,59b98c61-b467-46ba-bf64-741914e8e104,G_IMPACT_ANALYSIS_IN,2025-05-13 22:00:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-5976-0001_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5976-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""49762bb4-0c1f-45c4-954d-2942e59811cd""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/49762bb4-0c1f-45c4-954d-2942e59811cd"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:00:29,2025-05-28 03:53:06
222,,8dba13a1-9001-436a-ac8a-c02b4943a4b5,G_KEYWORDS,2025-05-13 22:00:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-5976-0001_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5976-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""49762bb4-0c1f-45c4-954d-2942e59811cd""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/49762bb4-0c1f-45c4-954d-2942e59811cd"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:00:32,2025-05-28 03:53:06
2226d97c-3f7e-4640-a344-1c82c784f08d,USA-FDA,df2bfef3-8698-4057-83f1-0de0f3ea6d4d,G_CONCISE_SUMMARY,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002/FDA-2011-D-0469-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and the Food and Drug Administration Staff: Applying Human Factors and Usability Engineering to Optimize Medical Device Design - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0469"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0469-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:16,2025-05-28 03:53:06
223,,b26f0431-26be-43dc-9dd2-193579c73567,G_TRANSLATE,2025-05-13 22:01:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2024-N-5976-0001_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5976-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""49762bb4-0c1f-45c4-954d-2942e59811cd""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/49762bb4-0c1f-45c4-954d-2942e59811cd/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:01:08,2025-05-28 03:53:06
224,,efb18507-c37b-4741-a375-92b961afcb34,G_TRANSLATE,2025-05-13 22:01:46,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-2024-N-5976-0001_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5976-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""49762bb4-0c1f-45c4-954d-2942e59811cd""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/49762bb4-0c1f-45c4-954d-2942e59811cd/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:01:47,2025-05-28 03:53:06
225,,9fac54a8-0fdc-446e-bb3c-94f12310d242,G_MINI_SUMMARY_IN,2025-05-13 22:01:49,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""7d3dd55f-336d-4893-a375-0a6ad1ed4a81""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/7d3dd55f-336d-4893-a375-0a6ad1ed4a81"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:01:50,2025-05-28 03:53:06
226,,51e1c2dd-5bc7-4d09-a763-588519e0053e,G_CONCISE_SUMMARY_IN,2025-05-13 22:01:53,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""7d3dd55f-336d-4893-a375-0a6ad1ed4a81""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/7d3dd55f-336d-4893-a375-0a6ad1ed4a81"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:01:54,2025-05-28 03:53:06
227,,d4203de9-32c2-4fcb-a268-7b39603599db,G_SUMMARY_IN,2025-05-13 22:01:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""7d3dd55f-336d-4893-a375-0a6ad1ed4a81""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/7d3dd55f-336d-4893-a375-0a6ad1ed4a81"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:01:58,2025-05-28 03:53:06
227e66db-4cbc-46f1-a46f-77d3ac5c559b,USA-FDA,472de84a-bcdc-4cae-b71f-535a9198c609,G_IMPACT_ANALYSIS,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0309/FDA-2002-D-0309-0002/FDA-2002-D-0309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been ReconditionedDraft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been Reconditioned"", ""docket_id"": ""FDA-2002-D-0309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0309/FDA-2002-D-0309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:15:41,2025-05-28 03:53:06
228,,0139b023-b149-4c0f-ae65-0adb2417c019,G_FAQ_IN,2025-05-13 22:02:01,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""7d3dd55f-336d-4893-a375-0a6ad1ed4a81""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/7d3dd55f-336d-4893-a375-0a6ad1ed4a81"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:02,2025-05-28 03:53:06
229,,ebb1eae5-ffc9-4dbd-a909-fae08110fd4e,G_ACTION_ITEMS_IN,2025-05-13 22:02:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""7d3dd55f-336d-4893-a375-0a6ad1ed4a81""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/7d3dd55f-336d-4893-a375-0a6ad1ed4a81"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:06,2025-05-28 03:53:06
2299475e-ba0e-40d0-bd5e-5a79fe64a9bb,USA-FDA,18f9db12-2069-4865-be1a-f7283e4d52a4,G_MINI_SUMMARY,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002/FDA-2011-D-0689-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; De Novo Classification Process (Evaluation of Automatic Class III Designation)"", ""docket_id"": ""FDA-2011-D-0689"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0689-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:15:08,2025-05-28 03:53:06
22b22f29-42ea-4475-aa02-f1dd01288c9d,USA-FDA,666bb80d-3712-4d6d-8c67-dd896104cd42,G_ACTION_ITEMS,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024/FDA-2011-D-0577-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications  - Guidance"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:32:29,2025-05-28 03:53:06
22df94b9-587b-4dcf-93d6-93ac6c784b8f,USA-FDA,c9f39717-6a39-42c6-b060-ba162c543c4e,G_CONCISE_SUMMARY,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002/FDA-2016-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Enforcement Policy on National Health Related Item Code and National Drug Code Numbers Assigned to Devices"", ""docket_id"": ""FDA-2016-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:45:13,2025-05-28 03:53:06
22dff8c1-33ea-4add-adc0-f2d0a7c334fc,USA-FDA,9e86693f-b848-4403-8fc7-cfa52cd5771d,G_IMPACT_ANALYSIS,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002/FDA-2017-D-4359-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry 68 on Small Entites Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:15:42,2025-05-28 03:53:06
22e04a61-6bdb-41dc-9e3a-8ce6ed91034a,SCHEDULED,02a40a93-9cbd-49f9-a01e-f8615c1f3133,DEVICE_ANALYST,2025-05-22 00:03:21,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": """", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": """", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/02a40a93-9cbd-49f9-a01e-f8615c1f3133"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:43,2025-05-28 03:53:06
22e618b2-9fa1-43d5-a3f2-d587edf45390,USA-FDA,392ef282-8a06-4057-866b-1bf73e9942bf,G_MINI_SUMMARY,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0002/FDA-2011-D-0620-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2011-D-0620"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0620-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:16:12,2025-05-28 03:53:06
23,,4326f033-298f-40c9-a660-f997b9f3488f,G_FAQ,2025-05-12 18:44:43,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 01:44:44,2025-05-28 03:53:06
230,,85b4dfb6-9a0c-4f81-94e4-900f7c24fec7,G_IMPACT_ANALYSIS_IN,2025-05-13 22:02:12,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""7d3dd55f-336d-4893-a375-0a6ad1ed4a81""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/7d3dd55f-336d-4893-a375-0a6ad1ed4a81"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:13,2025-05-28 03:53:06
230272e0-bf20-42e9-90c9-790a5053afb4,USA-FDA,bda37baa-7812-44f8-ac38-48816e4af4a6,G_FAQ,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002/FDA-2012-D-0022-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Direct-to-Consumer Television Advertisements, etc."", ""docket_id"": ""FDA-2012-D-0022"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0022-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:30:35,2025-05-28 03:53:06
2306a29c-f92a-499d-8d30-97442d3ae471,USA-FDA,31e855ae-0c4d-4d9b-b606-354ea6db9e0b,G_MINI_SUMMARY,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1960/FDA-2020-D-1960-0001/FDA-2020-D-1960-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on HACCP Regulation for Fish and Fishery Products"", ""docket_id"": ""FDA-2020-D-1960"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1960-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1960/FDA-2020-D-1960-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:01:08,2025-05-28 03:53:06
231,,8e71bf69-c13f-42e4-ac24-d8c82a0035ba,G_KEYWORDS,2025-05-13 22:02:14,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""7d3dd55f-336d-4893-a375-0a6ad1ed4a81""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/7d3dd55f-336d-4893-a375-0a6ad1ed4a81"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:15,2025-05-28 03:53:06
232,,ec2aae1e-b5d5-44f8-b9ec-4a7ef5cf65ba,G_TRANSLATE,2025-05-13 22:02:19,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""7d3dd55f-336d-4893-a375-0a6ad1ed4a81""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/7d3dd55f-336d-4893-a375-0a6ad1ed4a81/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:20,2025-05-28 03:53:06
232fa53b-afd4-4f3c-82af-c6665f651533,SCHEDULED,568816d6-fd57-4f93-8443-a488826bf336,DEVICE_ANALYST,2025-05-19 17:09:17,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-19""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/568816d6-fd57-4f93-8443-a488826bf336"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-19 21:18:30,2025-05-28 03:53:06
233,,1844e8f7-6d62-4813-911b-0bc985c22c67,G_TRANSLATE,2025-05-13 22:02:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""7d3dd55f-336d-4893-a375-0a6ad1ed4a81""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/7d3dd55f-336d-4893-a375-0a6ad1ed4a81/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:25,2025-05-28 03:53:06
234,,c6a669f7-eeda-4e3d-976d-a06be8e354ce,G_MINI_SUMMARY_IN,2025-05-13 22:02:27,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:28,2025-05-28 03:53:06
2340f62d-63f4-41d3-abb4-279e791c1274,USA-FDA,35e91d2e-5729-46ac-b5c1-4296265ea773,G_IMPACT_ANALYSIS,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-3276/FDA-2016-D-3276-0001/FDA-2016-D-3276-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Investigational Use of Deemed, Finished Tobacco Products That Were on the U.S. Market on August 8, 2016, During the Deeming Compliance Periods; Guidance for Industry"", ""docket_id"": ""FDA-2016-D-3276"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-3276-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-3276/FDA-2016-D-3276-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:17:24,2025-05-28 03:53:06
235,,b130477e-ddf3-4cc3-b965-e59087bd8e8f,G_CONCISE_SUMMARY_IN,2025-05-13 22:02:31,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:32,2025-05-28 03:53:06
235cb9ab-de20-4cb4-8a6f-5beb59d8afa3,USA-FDA,b11c91e1-28f7-480a-8ea9-cc117b021f54,G_ACTION_ITEMS,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0019/FDA-2017-D-6380-0019-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0019""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0019"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:00:28,2025-05-28 03:53:06
236,,49d3248a-661d-4aef-96ad-ce0e1c92ec19,G_SUMMARY_IN,2025-05-13 22:02:36,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:38,2025-05-28 03:53:06
237,,384d2c04-da2b-487f-84ce-4526d7d8ce6a,G_FAQ_IN,2025-05-13 22:02:49,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:50,2025-05-28 03:53:06
238,,ffa0b56c-ff7a-4990-aa4e-3ca3448416c2,G_ACTION_ITEMS_IN,2025-05-13 22:02:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:02:57,2025-05-28 03:53:06
239,,cc966c14-a6fc-4424-922b-426d986ca519,G_IMPACT_ANALYSIS_IN,2025-05-13 22:03:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:03:06,2025-05-28 03:53:06
2395a930-a5cd-41ae-97b2-0de9457a2b74,USA-FDA,d25ea65b-77eb-450e-8a34-0046cee1766b,G_ACTION_ITEMS,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001/FDA-2020-D-1925-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations)"", ""docket_id"": ""FDA-2020-D-1925"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1925-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:47:06,2025-05-28 03:53:06
23b68348-fe15-4e6f-af88-7b0730bf078d,USA-FDA,05ed77d6-fe7e-46cf-bfc0-bbd1377285cc,G_DETAILED_SUMMARY,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0300/FDA-2004-D-0300-0005/FDA-2004-D-0300-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Quality Systems Approach to Pharmaceutical CGMP Regulations"", ""docket_id"": ""FDA-2004-D-0300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0300-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0300/FDA-2004-D-0300-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:00:24,2025-05-28 03:53:06
23da72ee-5dba-4a3a-baed-2f914a3afa6f,USA-FDA,2156c185-3f38-420b-9929-59b0e4a70362,G_FAQ,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1161/FDA-2012-D-1161-0002/FDA-2012-D-1161-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Design Considerations for Devices Intended for Home Use - Draft Guidance"", ""docket_id"": ""FDA-2012-D-1161"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1161-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1161/FDA-2012-D-1161-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:32:59,2025-05-28 03:53:06
23f8124a-9612-4242-b27a-a67a1bf03004,USA-FDA,c9650f10-665c-47f2-91b3-87aeb884c047,G_CONCISE_SUMMARY,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001/FDA-2016-D-1533-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:02:30,2025-05-28 03:53:06
24,,5eabba30-3ee1-49d6-993e-076a3134cb89,G_ACTION_ITEMS,2025-05-12 19:09:16,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:09:18,2025-05-28 03:53:06
240,,b6253dbf-9220-43d0-8c0a-8a25a8b9b367,G_TRANSLATE,2025-05-13 22:03:31,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:03:32,2025-05-28 03:53:06
241,,7be1153f-7aa3-4fa5-91a8-b5ab7f5b3ab8,G_TRANSLATE,2025-05-13 22:03:59,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:04:00,2025-05-28 03:53:06
242,,15865a36-e5a6-43bd-8144-af159bf3bb26,G_MINI_SUMMARY_IN,2025-05-13 22:04:01,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:04:03,2025-05-28 03:53:06
242fa0e7-aeef-4bc5-9fe5-52607e3a9bed,USA-FDA,333293dc-4633-4ec4-bd31-fa0bcd05b149,G_KEYWORDS,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007/FDA-2011-D-0691-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs"", ""docket_id"": ""FDA-2011-D-0691"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0691-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:03:17,2025-05-28 03:53:06
243,,d15ba15a-4f0a-43ae-a879-9ce5bdf7f1e2,G_CONCISE_SUMMARY_IN,2025-05-13 22:04:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:04:07,2025-05-28 03:53:06
2432c411-b0bc-4a90-8a4a-50a220abcba1,USA-FDA,9a4848c5-7bb9-4465-a050-055f8d6e070a,G_DETAILED_SUMMARY,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002/FDA-2011-D-0689-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; De Novo Classification Process (Evaluation of Automatic Class III Designation)"", ""docket_id"": ""FDA-2011-D-0689"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0689-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:15:24,2025-05-28 03:53:06
244,,27a20f70-7188-401d-ae78-173f17328dc7,G_SUMMARY_IN,2025-05-13 22:04:18,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:04:19,2025-05-28 03:53:06
244f655c-7d04-4ffc-b42b-19a0c37b3a1b,USA-FDA,3f94837b-4abc-4bf9-80cd-1ee407540d06,G_MINI_SUMMARY,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003/FDA-2006-D-0231-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds"", ""docket_id"": ""FDA-2006-D-0231"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0231-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:00:15,2025-05-28 03:53:06
245,,a95b9b9f-485b-492b-94c9-3cdf0b01c332,G_FAQ_IN,2025-05-13 22:04:38,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:04:40,2025-05-28 03:53:06
246,,6b152efe-950a-4010-a1be-64c6d713837d,G_ACTION_ITEMS_IN,2025-05-13 22:04:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:04:49,2025-05-28 03:53:06
247,,e49fdb2f-a73e-4f57-a382-37e2da662a00,G_IMPACT_ANALYSIS_IN,2025-05-13 22:04:58,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:04:59,2025-05-28 03:53:06
248,,b0084540-2b64-459d-a978-bd017325f15c,G_KEYWORDS,2025-05-13 22:05:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:05:04,2025-05-28 03:53:06
24869c7f-e04d-447d-b115-b78c652c95b6,USA-FDA,e8669089-d082-4422-8ce6-a9f23ece3140,G_ACTION_ITEMS,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005/FDA-2010-D-0165-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies (VICH GL49)"", ""docket_id"": ""FDA-2010-D-0165"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0165-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:02:15,2025-05-28 03:53:06
24892c48-d905-4d02-ba9e-ae67d4d74e18,USA-FDA,aa4f539e-00a5-4031-b6f9-32bca92c69fd,G_IMPACT_ANALYSIS,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002/FDA-2016-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Enforcement Policy on National Health Related Item Code and National Drug Code Numbers Assigned to Devices"", ""docket_id"": ""FDA-2016-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:45:45,2025-05-28 03:53:06
248b108c-b344-4d1f-8385-d93fe1b1810b,USA-FDA,e144ee36-c477-4758-a25b-3dcd365b288c,G_DETAILED_SUMMARY,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002/FDA-2018-D-0740-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk Guidance for Industry"", ""docket_id"": ""FDA-2018-D-0740"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0740-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:30:46,2025-05-28 03:53:06
248d9ab9-8406-4ae8-af5d-6c207ef5b286,USA-FDA,36ffcd57-cdd7-4e7f-a63d-11000c094d8f,G_MINI_SUMMARY,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-N-0121/FDA-2011-N-0121-0009/FDA-2011-N-0121-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products; Small Entity Compliance Guide"", ""docket_id"": ""FDA-2011-N-0121"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-N-0121-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-N-0121/FDA-2011-N-0121-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:15:08,2025-05-28 03:53:06
249,,f3a6f8ce-a2e1-43ac-8304-7235c6595f54,G_TRANSLATE,2025-05-13 22:05:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:05:52,2025-05-28 03:53:06
24a80b36-765f-4eb3-a684-f97c5f9333e8,USA-FDA,c9a6a009-05e5-4ea0-9475-b0f83fb3eff8,G_ACTION_ITEMS,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002/FDA-2013-D-0269-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Purchasing Reef Fish Species Associated with the Hazard of Ciguatera Fish Poisoning"", ""docket_id"": ""FDA-2013-D-0269"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0269-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:32:15,2025-05-28 03:53:06
24ddd0df-413c-4c83-a172-5d4acecaa113,USA-FDA,9d1c9d99-fd33-4c07-aa18-178be50ff18e,G_ACTION_ITEMS,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0429/FDA-2011-D-0429-0002/FDA-2011-D-0429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry and Staff: Classification of Products as Drugs and Devices and Additional Product Classification Issues"", ""docket_id"": ""FDA-2011-D-0429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0429/FDA-2011-D-0429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:46:21,2025-05-28 03:53:06
24dfa05b-2268-4ec7-8f92-62221096c368,SCHEDULED,e05f136f-7a5b-45c6-b4aa-99202e6271de,FDA_ALERT,2025-06-01 00:00:04,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/e05f136f-7a5b-45c6-b4aa-99202e6271de"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:17,2025-06-01 00:00:17
25,,20f0519b-cd18-4d97-9b6d-e1fdbbe08a13,G_IMPACT_ANALYSIS,2025-05-12 19:09:33,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:09:35,2025-05-28 03:53:06
250,,11f5ed8b-4692-4ef4-abad-140365488b65,G_TRANSLATE,2025-05-13 22:06:41,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-14 05:06:42,2025-05-28 03:53:06
251,,c41b52a4-5417-46de-b8dd-005fbd6a7a95,G_MINI_SUMMARY,2025-05-14 18:41:35,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Part 73"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Listing of Color Additives Exempt From Certification; Myoglobin"", ""docket_id"": ""FDA-2022-C-0098"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2022-C-0098-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:41:35,2025-05-28 03:53:06
252,,526638a0-bf66-4136-82ce-18eb34696c83,G_CONCISE_SUMMARY,2025-05-14 18:41:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Part 73"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Listing of Color Additives Exempt From Certification; Myoglobin"", ""docket_id"": ""FDA-2022-C-0098"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2022-C-0098-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:41:39,2025-05-28 03:53:06
253,,b725651e-74ce-40ee-ae38-6c99d8fdb091,G_DETAILED_SUMMARY,2025-05-14 18:41:43,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Part 73"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Listing of Color Additives Exempt From Certification; Myoglobin"", ""docket_id"": ""FDA-2022-C-0098"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2022-C-0098-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:41:44,2025-05-28 03:53:06
253b10f8-566f-462b-a3bd-fdad5a9d7384,USA-FDA,ed9f063d-00cd-4541-8164-43db43ccd6ab,G_DETAILED_SUMMARY,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013/FDA-2009-D-0503-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in - Premarket Notification (510(k)) Submissions; Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0503-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:00:33,2025-05-28 03:53:06
254,,f5f134b6-271f-4306-b32a-0f2d2825dd45,G_FAQ,2025-05-14 18:41:52,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Part 73"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Listing of Color Additives Exempt From Certification; Myoglobin"", ""docket_id"": ""FDA-2022-C-0098"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2022-C-0098-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:41:52,2025-05-28 03:53:06
255,,203f1f3b-bb4a-4d46-a863-84792b59a5df,G_ACTION_ITEMS,2025-05-14 18:41:57,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Part 73"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Listing of Color Additives Exempt From Certification; Myoglobin"", ""docket_id"": ""FDA-2022-C-0098"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2022-C-0098-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:41:57,2025-05-28 03:53:06
25526b33-9f96-4e6b-b35e-f7c6afc709bc,USA-FDA,4598f0f1-e69e-4ea5-b1e9-cab10afd189b,G_FAQ,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0531/FDA-2004-D-0531-0001/FDA-2004-D-0531-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations to Processors of Apple Juice or Cider on the Use of Ozone for Pathogen Reduction Purposes"", ""docket_id"": ""FDA-2004-D-0531"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0531-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0531/FDA-2004-D-0531-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:15:31,2025-05-28 03:53:06
256,,412ff14e-2c30-4c7a-8b04-5064a9c9a4d7,G_IMPACT_ANALYSIS,2025-05-14 18:42:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Part 73"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Listing of Color Additives Exempt From Certification; Myoglobin"", ""docket_id"": ""FDA-2022-C-0098"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2022-C-0098-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:42:04,2025-05-28 03:53:06
2561640f-2eb1-49a2-9ad2-9055c3924db1,USA-FDA,7a1040e4-8f85-4b4d-947e-d4656bbabde9,G_MINI_SUMMARY,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002/FDA-2011-D-0398-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:30:57,2025-05-28 03:53:06
257,,b73f4295-39d2-435c-9d8a-22b30dca249c,G_KEYWORDS,2025-05-14 18:42:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Part 73"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Listing of Color Additives Exempt From Certification; Myoglobin"", ""docket_id"": ""FDA-2022-C-0098"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2022-C-0098-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2022-C-0098/FDA-2022-C-0098-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:42:07,2025-05-28 03:53:06
258,,e6876299-0db4-4eb4-b2a2-9d285f8aa5db,G_MINI_SUMMARY,2025-05-14 18:45:36,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002/FDA-2024-D-5663-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology; Draft Guidance for Industry"", ""docket_id"": ""FDA-2024-D-5663"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-5663-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:45:36,2025-05-28 03:53:06
259,,0ef2cb78-7bea-42c3-99be-ab757ac57082,G_CONCISE_SUMMARY,2025-05-14 18:45:40,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002/FDA-2024-D-5663-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology; Draft Guidance for Industry"", ""docket_id"": ""FDA-2024-D-5663"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-5663-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:45:40,2025-05-28 03:53:06
2593b665-5d3c-458b-857a-aa3eb786cdc7,USA-FDA,9676e516-b9ba-4aae-bb8b-14ed1ab309a5,G_FAQ,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005/FDA-2011-D-0643-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; What You Need to Know About Administrative Detention of Foods; Small Entity Compliance Guide; Final Guidance"", ""docket_id"": ""FDA-2011-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0643-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:31:22,2025-05-28 03:53:06
25959693-7fc7-45c0-b9b9-fd6f4289d003,USA-FDA,7ac95c2c-ee3b-474d-8b28-993da324c3a1,G_DETAILED_SUMMARY,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0012/FDA-1998-D-0035-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:15:29,2025-05-28 03:53:06
2597fc01-701e-4027-9bee-27745abdd133,QUEUE,286ceb6c-fb97-4652-9e5a-1735d9e9a403,G_CONCISE_SUMMARY_USER,2025-05-30 03:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/286ceb6c-fb97-4652-9e5a-1735d9e9a403/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/286ceb6c-fb97-4652-9e5a-1735d9e9a403"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-30 03:45:10,2025-05-30 03:45:10
25d7c21e-68d9-4c79-b3ab-593b2c8108d5,USA-FDA,e3f0c75e-9375-49cc-833d-884327fd97ed,G_IMPACT_ANALYSIS,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1005/FDA-2012-D-1005-0002/FDA-2012-D-1005-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Considerations for Product Design to Minimize Medication Errors - Draft Guidance"", ""docket_id"": ""FDA-2012-D-1005"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1005-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1005/FDA-2012-D-1005-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:45:54,2025-05-28 03:53:06
26,,542bc023-ee68-42ba-8ca8-0969a79848d7,G_MINI_SUMMARY,2025-05-12 19:17:13,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:17:15,2025-05-28 03:53:06
260,,166fc736-2928-4634-8836-05fc3df33d0c,G_DETAILED_SUMMARY,2025-05-14 18:45:46,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002/FDA-2024-D-5663-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology; Draft Guidance for Industry"", ""docket_id"": ""FDA-2024-D-5663"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-5663-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:45:47,2025-05-28 03:53:06
26012283-832c-4044-9dca-967554ab5f13,USA-FDA,bf7e14a1-244c-4859-9adf-df6af1878b78,G_CONCISE_SUMMARY,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021/FDA-2004-D-0044-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for the Early Food Safety\nEvaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties\nIntended for Food Use; Availability"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:00:16,2025-05-28 03:53:06
2604d4fd-5ece-47c2-8e55-c2e0ec52b6c2,USA-FDA,b84fcd8e-98d0-4d77-a04d-686a17d0bf82,G_MINI_SUMMARY,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0008/FDA-2011-D-0847-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; Humanitarian Use Device (HUD) Designations"", ""docket_id"": ""FDA-2011-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0847-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:30:08,2025-05-28 03:53:06
261,,a304f953-dacb-4d20-b7e8-8cfc003875f6,G_FAQ,2025-05-14 18:45:57,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002/FDA-2024-D-5663-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology; Draft Guidance for Industry"", ""docket_id"": ""FDA-2024-D-5663"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-5663-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:45:57,2025-05-28 03:53:06
262,,66ca346d-d235-4ebb-9517-dd7b48bb6707,G_ACTION_ITEMS,2025-05-14 18:46:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002/FDA-2024-D-5663-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology; Draft Guidance for Industry"", ""docket_id"": ""FDA-2024-D-5663"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-5663-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:46:03,2025-05-28 03:53:06
262653c2-8d19-4331-949f-699a5d74c6ed,USA-FDA,2bbcdf79-cb92-4f68-bf73-f5533f450af8,G_MINI_SUMMARY,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0643/FDA-2010-D-0643-0092/FDA-2010-D-0643-0092-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Electronic Source Data in Clinical Investigations"", ""docket_id"": ""FDA-2010-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0643-0092""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0643/FDA-2010-D-0643-0092"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:00:07,2025-05-28 03:53:06
262ed815-f23b-4cdc-9e1f-5e34769f6808,USA-FDA,b89666f8-ec22-48be-b33f-013e8069952e,G_IMPACT_ANALYSIS,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0031/FDA-2007-D-0031-0005/FDA-2007-D-0031-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Integrated Summaries of Effectiveness and Safety:  Location Within the Common Technical Document"", ""docket_id"": ""FDA-2007-D-0031"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0031-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0031/FDA-2007-D-0031-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:00:45,2025-05-28 03:53:06
263,,24865cbc-596e-4496-8a4f-541a210d2f67,G_IMPACT_ANALYSIS,2025-05-14 18:46:12,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002/FDA-2024-D-5663-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology; Draft Guidance for Industry"", ""docket_id"": ""FDA-2024-D-5663"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-5663-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:46:12,2025-05-28 03:53:06
263d348a-9742-4954-bc62-5ac20cb69689,SCHEDULED,c48477c3-d24e-4718-908f-a8863b1c7e24,FDA_ALERT,2025-05-23 00:00:04,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/c48477c3-d24e-4718-908f-a8863b1c7e24"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:20,2025-05-28 03:53:06
264,,650ebb61-0078-4271-8b66-62fd1911e951,G_KEYWORDS,2025-05-14 18:46:14,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002/FDA-2024-D-5663-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology; Draft Guidance for Industry"", ""docket_id"": ""FDA-2024-D-5663"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-5663-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-5663/FDA-2024-D-5663-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:46:15,2025-05-28 03:53:06
265,,d7e2bcea-129b-46b8-b33a-fb7d9989572a,G_MINI_SUMMARY,2025-05-14 18:46:31,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057/FDA-2017-D-2462-0057-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Comment from Fidelis Pharmaceuticals, Inc."", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0057""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:46:32,2025-05-28 03:53:06
266,,6d102193-9ffa-41a6-b9ab-1c0a3f52c71e,G_CONCISE_SUMMARY,2025-05-14 18:46:35,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057/FDA-2017-D-2462-0057-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Comment from Fidelis Pharmaceuticals, Inc."", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0057""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:46:35,2025-05-28 03:53:06
267,,93aafb3c-4019-492e-ab72-0b6a247910e9,G_DETAILED_SUMMARY,2025-05-14 18:46:40,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057/FDA-2017-D-2462-0057-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Comment from Fidelis Pharmaceuticals, Inc."", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0057""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:46:40,2025-05-28 03:53:06
268,,b1bb0bad-036c-4d95-848a-cf3a44ebccdc,G_FAQ,2025-05-14 18:46:44,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057/FDA-2017-D-2462-0057-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Comment from Fidelis Pharmaceuticals, Inc."", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0057""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:46:44,2025-05-28 03:53:06
269,,41bdd8d6-cb31-4ba0-94a0-23ea1e3b1eba,G_ACTION_ITEMS,2025-05-14 18:46:49,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057/FDA-2017-D-2462-0057-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Comment from Fidelis Pharmaceuticals, Inc."", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0057""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:46:49,2025-05-28 03:53:06
26d8fac5-3be6-4a05-9a04-5e80f41438cd,USA-FDA,3686ec11-140a-4616-b60c-f8968655e41c,G_FAQ,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0196/FDA-2009-D-0196-0002/FDA-2009-D-0196-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Arsenic"", ""docket_id"": ""FDA-2009-D-0196"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0196-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0196/FDA-2009-D-0196-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:30:59,2025-05-28 03:53:06
26e16778-62e7-462d-bc62-0bf5e46d6050,USA-FDA,2299ec27-e390-4081-9510-21d29705ab45,G_KEYWORDS,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008/FDA-2008-D-0642-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2008-D-0642"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0642-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:33:49,2025-05-28 03:53:06
27,,01467859-2b36-47c7-9210-da455c268f85,G_CONCISE_SUMMARY,2025-05-12 19:17:18,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:17:19,2025-05-28 03:53:06
270,,d35c0066-dcfa-44b9-ae2d-3b2e29771795,G_IMPACT_ANALYSIS,2025-05-14 18:46:54,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057/FDA-2017-D-2462-0057-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Comment from Fidelis Pharmaceuticals, Inc."", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0057""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:46:54,2025-05-28 03:53:06
271,,8f8d8cdd-cec4-4b43-b968-5942ae5e4d9e,G_KEYWORDS,2025-05-14 18:46:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057/FDA-2017-D-2462-0057-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Comment from Fidelis Pharmaceuticals, Inc."", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0057""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0057"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:46:57,2025-05-28 03:53:06
271f3991-7ef4-47fc-a2ea-03ae3a9f1791,USA-FDA,c35e2a5e-616c-4652-a21b-eba310b6e6f0,G_KEYWORDS,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020/FDA-1992-N-0056-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prescription Drug Marketing Act (PDMA) Requirements; Questions and Answers"", ""docket_id"": ""FDA-1992-N-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0056-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:16:09,2025-05-28 03:53:06
272,,815af987-eb18-43d9-a334-0274c7fb6a09,G_MINI_SUMMARY,2025-05-14 18:46:59,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004/FDA-2003-D-0152-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance"", ""docket_id"": ""FDA-2003-D-0152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0152-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:00,2025-05-28 03:53:06
273,,6f575f3d-af2f-473c-b9b3-5c3b2e3518f0,G_CONCISE_SUMMARY,2025-05-14 18:47:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004/FDA-2003-D-0152-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance"", ""docket_id"": ""FDA-2003-D-0152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0152-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:04,2025-05-28 03:53:06
273b7eeb-60e5-476f-8fb8-7241b55f61a5,USA-FDA,ab6400b9-67e7-488e-a9e1-a953589ccd00,G_MINI_SUMMARY,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001/FDA-2020-D-1407-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products HCT Ps Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2020-D-1407"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1407-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:24,2025-05-28 03:53:06
274,,5cfb72b8-a445-4ae3-9c1c-79f4202040a7,G_DETAILED_SUMMARY,2025-05-14 18:47:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004/FDA-2003-D-0152-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance"", ""docket_id"": ""FDA-2003-D-0152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0152-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:10,2025-05-28 03:53:06
274d9652-1903-4393-84e8-5841ecf0c5e3,CAB,31b5ee4f-15ad-4912-a09c-c50c7b774d92,G_FAQ_IN,2025-05-28 21:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,{},"{""tilte"": ""EU regulations on medical devices � Update November 2022.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/EU regulations on medical devices � Update November 2022.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""0a2f2db4-b308-43a4-9ab5-7be5666e97bb""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/0a2f2db4-b308-43a4-9ab5-7be5666e97bb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 21:30:27,2025-05-28 21:30:27
275,,9e1f4d63-5572-486d-a542-a166a5d12f1f,G_FAQ,2025-05-14 18:47:22,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004/FDA-2003-D-0152-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance"", ""docket_id"": ""FDA-2003-D-0152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0152-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:22,2025-05-28 03:53:06
276,,e3410c9c-199b-4c1b-9158-72da206ea5dc,G_ACTION_ITEMS,2025-05-14 18:47:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004/FDA-2003-D-0152-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance"", ""docket_id"": ""FDA-2003-D-0152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0152-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:29,2025-05-28 03:53:06
2762b4e6-ae6b-475e-8613-67c29cce83fd,USA-FDA,21972213-71c3-4642-a14e-cc7fe3220fa9,G_DETAILED_SUMMARY,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002/FDA-2014-N-0829-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Reporting Drug Sample Information\nUnder Section 6004 of the Affordable Care Act"", ""docket_id"": ""FDA-2014-N-0829"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-0829-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:30:27,2025-05-28 03:53:06
277,,dac41270-9116-40f1-b5f7-d3ee9b663eb7,G_IMPACT_ANALYSIS,2025-05-14 18:47:35,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004/FDA-2003-D-0152-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance"", ""docket_id"": ""FDA-2003-D-0152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0152-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:35,2025-05-28 03:53:06
278,,5d4544ac-72aa-41fc-8c81-fa9311c369f0,G_KEYWORDS,2025-05-14 18:47:37,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004/FDA-2003-D-0152-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance"", ""docket_id"": ""FDA-2003-D-0152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0152-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0152/FDA-2003-D-0152-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:38,2025-05-28 03:53:06
278c86d7-2e3e-4ca2-b7c4-f1fee33b004b,USA-FDA,7c4671fb-cc03-41eb-ba45-7221c6d2fc84,G_DETAILED_SUMMARY,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004/FDA-2002-D-0180-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Q1E Evaluation of Stability Data"", ""docket_id"": ""FDA-2002-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0180-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:45:55,2025-05-28 03:53:06
279,,2c149254-19b3-48d2-9d71-aea9dce0209a,G_MINI_SUMMARY,2025-05-14 18:47:40,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011/FDA-2009-D-0568-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Planning for Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:40,2025-05-28 03:53:06
27a93ad7-bea2-42ff-87ef-59caa0decfb4,USA-FDA,cfb13e7f-c1ff-4038-b3e2-d65d7d7f4774,G_MINI_SUMMARY,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032/FDA-2002-D-0094-0032-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0032""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:02:06,2025-05-28 03:53:06
27b234ef-480a-4021-9ae1-23ffb81e430e,USA-FDA,a66bcbb2-0fd1-49f2-ad8c-7bb4ae7a7de5,G_IMPACT_ANALYSIS,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0313/FDA-2010-D-0313-0018/FDA-2010-D-0313-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2010-D-0313"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0313-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0313/FDA-2010-D-0313-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:46:01,2025-05-28 03:53:06
27b634c0-3fc8-446b-b7d1-03d9d8bc746a,USA-FDA,d0cf3007-e380-4d4a-9cbc-7841ae12d6bd,G_KEYWORDS,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002/FDA-2011-D-0398-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:31:51,2025-05-28 03:53:06
28,,6f17c71e-feff-4d03-99ab-3ba292812a68,G_DETAILED_SUMMARY,2025-05-12 19:17:38,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:17:39,2025-05-28 03:53:06
280,,4b8cb1c3-6c95-41e4-b545-888e47e063fa,G_CONCISE_SUMMARY,2025-05-14 18:47:42,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011/FDA-2009-D-0568-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Planning for Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:42,2025-05-28 03:53:06
280ca36e-9bf8-414f-b30b-049102b32dc2,USA-FDA,018e6278-12ea-484d-8e83-f84568921d88,G_ACTION_ITEMS,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002/FDA-2012-D-0022-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Direct-to-Consumer Television Advertisements, etc."", ""docket_id"": ""FDA-2012-D-0022"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0022-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:30:42,2025-05-28 03:53:06
281,,d2525cf8-c052-4501-bcad-bc1cef683526,G_DETAILED_SUMMARY,2025-05-14 18:47:46,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011/FDA-2009-D-0568-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Planning for Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:47,2025-05-28 03:53:06
2812f966-9c63-4e81-ba8f-33c86177dd7c,QUEUE,472d078d-c42b-4c34-bc02-89dbc9b114b7,G_COMPARE_DOCUMENTS,2025-05-23 20:45:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/compare_documents/472d078d-c42b-4c34-bc02-89dbc9b114b7/FDA-2024-N-1111-0001_content.pdf.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""child_document_title"": ""FDA-2024-N-1111-0001.pdf"", ""master_document_title"": ""FDA-2024-N-5976-0001.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/compare_documents/472d078d-c42b-4c34-bc02-89dbc9b114b7/FDA-2024-N-5976-0001_content.pdf.pdf"", ""doc_title"": ""FDA-2024-N-5976-0001.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/compare_documents/472d078d-c42b-4c34-bc02-89dbc9b114b7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 20:45:17,2025-05-28 03:53:06
282,,7d134cda-63dd-42cd-bd57-679a6f9406f2,G_FAQ,2025-05-14 18:47:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011/FDA-2009-D-0568-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Planning for Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:51,2025-05-28 03:53:06
2826234e-58dd-4e62-8f98-439cba3b77b3,SCHEDULED,1999b193-2e4f-4b0c-843d-9ab8b4cb886e,DEVICE_ANALYST,2025-05-28 00:00:05,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Patel"", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": ""Abhishek"", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/1999b193-2e4f-4b0c-843d-9ab8b4cb886e"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:31,2025-05-28 03:53:06
283,,749a453e-5071-4484-9f53-26fe7ae0fcfa,G_ACTION_ITEMS,2025-05-14 18:47:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011/FDA-2009-D-0568-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Planning for Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:47:56,2025-05-28 03:53:06
28315194-44f6-44f2-ad15-6a87d5a845ff,USA-FDA,d244dd79-94a7-489c-9fa5-0790ffb302ae,G_ACTION_ITEMS,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021/FDA-2004-D-0044-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for the Early Food Safety\nEvaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties\nIntended for Food Use; Availability"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:00:34,2025-05-28 03:53:06
284,,d27cff34-6854-4a77-8dcf-eb3c6a8945b8,G_IMPACT_ANALYSIS,2025-05-14 18:48:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011/FDA-2009-D-0568-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Planning for Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:48:05,2025-05-28 03:53:06
284a8b95-ea44-402b-8bf2-28d891cc489f,USA-FDA,c0983e33-f833-4cb0-967e-9f75c410444e,G_FAQ,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112/FDA-2000-N-0190-0112-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Outdoor Access)"", ""docket_id"": ""FDA-2000-N-0190"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-N-0190-0112""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:03:43,2025-05-28 03:53:06
285,,dafcc61f-9711-419f-854a-1a34936acbbd,G_KEYWORDS,2025-05-14 18:48:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011/FDA-2009-D-0568-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Planning for Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 01:48:07,2025-05-28 03:53:06
286,,42000bfc-fccd-49a0-ab53-d0c522a111c6,G_MINI_SUMMARY_IN,2025-05-14 18:56:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:56:51,2025-05-28 03:53:06
287,,2d00df62-5e93-4bfd-9d3b-ab3d2ecef16b,G_CONCISE_SUMMARY_IN,2025-05-14 18:56:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:56:55,2025-05-28 03:53:06
28722ccd-ce3c-4613-a058-3e8c751ea9a1,USA-FDA,a08be397-ac12-49ab-a729-4f2d96e8dfcd,G_MINI_SUMMARY,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112/FDA-2000-N-0190-0112-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Outdoor Access)"", ""docket_id"": ""FDA-2000-N-0190"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-N-0190-0112""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:03:11,2025-05-28 03:53:06
287ee61c-7d9c-4488-b2b1-dd9dc16585f2,SCHEDULED,b8510048-4e47-4ec4-9fa4-83d4fd1a7c37,DEVICE_ANALYST,2025-05-19 16:57:48,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-19""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/b8510048-4e47-4ec4-9fa4-83d4fd1a7c37"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-19 21:02:04,2025-05-28 03:53:06
288,,3773d325-b3de-4e65-a560-92e9b8e4ed7d,G_SUMMARY_IN,2025-05-14 18:56:59,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:56:59,2025-05-28 03:53:06
289,,091d0955-48a0-4464-a773-a5e64f35b14d,G_FAQ_IN,2025-05-14 18:57:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:57:09,2025-05-28 03:53:06
2891c0e2-ba75-492d-9fa3-faebaa36de5b,USA-FDA,676e4beb-eef3-4818-b34b-843fc2685834,G_FAQ,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1918/FDA-2020-D-1918-0001/FDA-2020-D-1918-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Food Additive Petition Expedited Review"", ""docket_id"": ""FDA-2020-D-1918"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1918-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1918/FDA-2020-D-1918-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:48:03,2025-05-28 03:53:06
289b743b-7ede-4203-a3ac-ea2386aad440,USA-FDA,ea81ed5a-4984-4b06-98cb-13f9f7940ad3,G_CONCISE_SUMMARY,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002/FDA-2011-D-0733-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Evaluating the Safety of Flood-affected Food Crops for Human Consumption"", ""docket_id"": ""FDA-2011-D-0733"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0733-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:30:14,2025-05-28 03:53:06
28a5c1e5-869c-4434-8b74-9e781176d28a,USA-FDA,25622cc2-976f-4bef-a803-2fc5f3dbe6cd,G_DETAILED_SUMMARY,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001/FDA-2016-D-1533-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:02:37,2025-05-28 03:53:06
28bce7c5-f038-49cf-804c-2af848f52cc0,USA-FDA,8e129cc2-9c45-48d7-b960-44dd867418ea,G_DETAILED_SUMMARY,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022/FDA-2011-D-0082-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry , Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling"", ""docket_id"": ""FDA-2011-D-0082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0082-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:03:04,2025-05-28 03:53:06
28d67657-857e-4724-913f-5c65449b87fc,USA-FDA,e19cae50-7e88-4fec-a404-b25cf4b36afa,G_CONCISE_SUMMARY,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002/FDA-2012-D-0544-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Toll Free Number Labeling and Related Requirements for Over the Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide"", ""docket_id"": ""FDA-2012-D-0544"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0544-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:30:12,2025-05-28 03:53:06
28daec56-298a-4a90-8b0b-4b9623abae55,USA-FDA,23d784cc-57b0-46aa-b7bc-f899dd551535,G_MINI_SUMMARY,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0514/FDA-2011-D-0514-0002/FDA-2011-D-0514-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Industry and Staff; Procedures for Handling Section 522 Postmarket Surveillance Studies"", ""docket_id"": ""FDA-2011-D-0514"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0514-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0514/FDA-2011-D-0514-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:15:11,2025-05-28 03:53:06
29,,3c1f24fb-ebbd-4313-a3b4-fb60a06997f7,G_ACTION_ITEMS,2025-05-12 19:18:27,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:18:28,2025-05-28 03:53:06
290,,c135b479-fe95-40bb-a1ab-57b99aa2445b,G_ACTION_ITEMS_IN,2025-05-14 18:57:16,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:57:16,2025-05-28 03:53:06
291,,ecd24a4f-5f7f-4c5a-aee9-dccbbb24588d,G_IMPACT_ANALYSIS_IN,2025-05-14 18:57:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:57:25,2025-05-28 03:53:06
2916e1c8-0a9e-45a9-b1fb-1d128d8c23ed,USA-FDA,c2c7735b-f39b-4df6-8765-56b40927a262,G_FAQ,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002/FDA-2012-D-0304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Claa II Special Controls Guidance Implanted Blood Access Devices for Hemodialysis"", ""docket_id"": ""FDA-2012-D-0304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:00:52,2025-05-28 03:53:06
292,,e4cc486a-c996-4bd2-a1d5-5a5d7edbb9eb,G_KEYWORDS,2025-05-14 18:57:27,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:57:28,2025-05-28 03:53:06
293,,6dca6415-95c3-4bf8-ba0c-87a3bd726422,G_TRANSLATE,2025-05-14 18:58:16,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2024-N-0002-0002_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0002_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""44f41c78-fdd8-4d66-ba83-ced9abcdbea2""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/44f41c78-fdd8-4d66-ba83-ced9abcdbea2/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:58:16,2025-05-28 03:53:06
29336f91-3bc0-4438-adb5-46d9329fe921,USA-FDA,f7a84617-df00-4c00-b1be-7c8ea604a913,G_MINI_SUMMARY,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0025/FDA-1999-D-1875-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sec.615.115 Extralabel Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:32:44,2025-05-28 03:53:06
294,,57ca4c42-bd6f-4afc-aa4f-96ba4fb73fb3,G_MINI_SUMMARY_IN,2025-05-14 18:58:45,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:58:45,2025-05-28 03:53:06
295,,1ed5828b-6635-42ae-a993-258d5025d0f0,G_CONCISE_SUMMARY_IN,2025-05-14 18:58:49,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:58:49,2025-05-28 03:53:06
296,,52bc5b3f-a995-493c-b38e-e25579799bd7,G_SUMMARY_IN,2025-05-14 18:58:53,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:58:53,2025-05-28 03:53:06
297,,0cc24471-dc1b-4398-b752-3ff10711e2af,G_FAQ_IN,2025-05-14 18:59:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:59:05,2025-05-28 03:53:06
297bfb7d-d3fc-4549-bae2-cc69732eb0fc,USA-FDA,03384c7e-8b5d-4be7-9f7a-7476aef17906,G_FAQ,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015/FDA-2010-D-0281-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; ��Harmful and Potentially Harmful Constituents� in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act�"", ""docket_id"": ""FDA-2010-D-0281"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0281-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:19,2025-05-28 03:53:06
298,,4ee6a7f8-91d7-46a1-bdf8-34fd6dbd32a2,G_ACTION_ITEMS_IN,2025-05-14 18:59:13,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:59:13,2025-05-28 03:53:06
299,,d9bd8601-2945-4351-a8a1-015b9545f1aa,G_IMPACT_ANALYSIS_IN,2025-05-14 18:59:19,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:59:20,2025-05-28 03:53:06
29b4d9b6-aea8-4da6-a626-4ea59927192a,USA-FDA,8f411f24-d4a9-49f7-be15-1d75057a1021,G_ACTION_ITEMS,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002/FDA-1999-D-1875-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:30:41,2025-05-28 03:53:06
29c2ebba-3514-466e-897a-3ca72270fca2,USA-FDA,6691a839-24bf-42d1-a561-db06b3b17f56,G_IMPACT_ANALYSIS,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-2441/FDA-1999-D-2441-0002/FDA-1999-D-2441-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Dioxin in Anti-Caking Agents Used in Animal Feed and Feed Ingredients"", ""docket_id"": ""FDA-1999-D-2441"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-2441-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-2441/FDA-1999-D-2441-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:00:36,2025-05-28 03:53:06
29f9a843-6b09-4abd-b7f8-144955fdae3a,USA-FDA,f2a5086b-0f45-4305-8e5b-caac9b209337,G_FAQ,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0003/FDA-2014-D-1525-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Draft Guidance"", ""docket_id"": ""FDA-2014-D-1525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1525-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:02:13,2025-05-28 03:53:06
29fba1e2-2c5a-4a06-80a9-60fcbab1023a,USA-FDA,83ef201c-2872-452d-8f92-fb7dd3aab431,G_MINI_SUMMARY,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002/FDA-2009-D-0542-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Factors that Distinguish Liquid Dietary Supplements from Beverages, Considerations Regarding Novel Ingredients, and Labeling for Beverages and Other Conventional Foods; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0542"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0542-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:02:39,2025-05-28 03:53:06
2a02c6d3-0b23-46b0-a045-fc966ed5c0fa,USA-FDA,5825bd02-04ee-452e-859e-0eb81c3115ed,G_IMPACT_ANALYSIS,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001/FDA-2018-D-0398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions Guidance for Industry and\nFood and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:01:33,2025-05-28 03:53:06
2a36431c-127c-4ca1-b3e8-bfe8b79399ab,USA-FDA,bbc93a1b-7248-4f11-b103-b1c3297e31b4,G_IMPACT_ANALYSIS,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3443/FDA-2018-D-3443-0002/FDA-2018-D-3443-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-3443"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3443-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3443/FDA-2018-D-3443-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:47:54,2025-05-28 03:53:06
2a8c7d29-baf2-4593-82a2-793542a9a560,SCHEDULED,d7515129-3aae-4deb-858a-e062afcdbaa1,FDA_ALERT,2025-05-28 00:00:05,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/d7515129-3aae-4deb-858a-e062afcdbaa1"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:22,2025-05-28 03:53:06
2a968675-7b94-4b67-a92b-7bf52e12e470,CAB,a196d367-4984-47d6-8267-e11c700afe93,G_TRANSLATE,2025-05-27 02:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""to_language"": ""Italian""}","{""tilte"": ""FDA-2024-N-2910-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2024-N-2910-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b3efc128-de32-4064-8905-ee749b8e53b7""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b3efc128-de32-4064-8905-ee749b8e53b7/Italian"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 02:01:32,2025-05-28 03:53:06
2ab70ad1-88db-42da-b167-919e19f8d6e9,USA-FDA,a0266bca-5059-47a7-8229-92353ad861ee,G_DETAILED_SUMMARY,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0730/FDA-2013-N-0730-0007/FDA-2013-N-0730-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for Industry: Submitting Requests under 21 CFR 170.39 Threshold of Regulation for Substances Used in Food-Contact Articles"", ""docket_id"": ""FDA-2013-N-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-0730-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0730/FDA-2013-N-0730-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:15:17,2025-05-28 03:53:06
2ad27fa9-b7a9-45f0-8353-ba6581dbd8e4,USA-FDA,3d335f20-e0dd-441a-8378-ac51e15a1564,G_MINI_SUMMARY,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1399/FDA-2020-D-1399-0001/FDA-2020-D-1399-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part I"", ""docket_id"": ""FDA-2020-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1399-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1399/FDA-2020-D-1399-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:01:09,2025-05-28 03:53:06
2adf6399-207d-465e-8607-febafdcc870c,USA-FDA,405dd353-aae5-4e8a-9ddf-fddf5d7c3a0a,G_KEYWORDS,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002/FDA-2011-D-0649-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Class II Special Controls; External Pacemaker Pulse Generator"", ""docket_id"": ""FDA-2011-D-0649"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0649-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:01:23,2025-05-28 03:53:06
2b0de5db-d04d-4ec5-8056-9329ee3641eb,USA-FDA,f8c092d6-35d8-4382-8cdf-15932e7add88,G_IMPACT_ANALYSIS,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0872/FDA-2011-D-0872-0002/FDA-2011-D-0872-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies"", ""docket_id"": ""FDA-2011-D-0872"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0872-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0872/FDA-2011-D-0872-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:00:56,2025-05-28 03:53:06
2b31a060-4599-49d8-a088-a8d292daf0e2,USA-FDA,8cfce574-52f7-424d-a931-7794c67ae258,G_IMPACT_ANALYSIS,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0268/FDA-2009-D-0268-0005/FDA-2009-D-0268-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0268"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0268-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0268/FDA-2009-D-0268-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:30:41,2025-05-28 03:53:06
2b5d7a8c-013a-4f37-9432-881225d18462,USA-FDA,4c06ce37-9a22-43ea-a3d9-575dbe352a4c,G_MINI_SUMMARY,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0196/FDA-2009-D-0196-0002/FDA-2009-D-0196-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Arsenic"", ""docket_id"": ""FDA-2009-D-0196"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0196-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0196/FDA-2009-D-0196-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:30:46,2025-05-28 03:53:06
2b9c7261-4e91-428a-9980-77de116b35df,USA-FDA,d556a287-6880-4702-a0be-b308f03db6fa,G_DETAILED_SUMMARY,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1960/FDA-2020-D-1960-0001/FDA-2020-D-1960-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on HACCP Regulation for Fish and Fishery Products"", ""docket_id"": ""FDA-2020-D-1960"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1960-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1960/FDA-2020-D-1960-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:01:29,2025-05-28 03:53:06
2bddb9a5-283b-4b2a-bacb-2d73ed35e116,USA-FDA,8150163b-68c9-4f6e-b2f1-9bc0fc185b04,G_ACTION_ITEMS,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0077/FDA-2007-D-0077-0003/FDA-2007-D-0077-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Providing Regulatory Submissions in Electronic Format - Receipt Date - Draft Guidance Document"", ""docket_id"": ""FDA-2007-D-0077"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0077-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0077/FDA-2007-D-0077-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:31:08,2025-05-28 03:53:06
2c10026d-3277-4f37-a070-67da5bcbd5eb,QUEUE,69a02fa3-3b2b-4ace-ae01-541af7c0f281,G_IMPACT_ANALYSIS_USER,2025-05-20 10:43:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__doc_title__"": ""FDA-2023-N-4225-0001_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/69a02fa3-3b2b-4ace-ae01-541af7c0f281/SRC/69a02fa3-3b2b-4ace-ae01-541af7c0f281.pdf"", ""doc_title"": ""FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/69a02fa3-3b2b-4ace-ae01-541af7c0f281/DEST/impact_analysis.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:43:33,2025-05-28 03:53:06
2c3376ad-8ed0-41b2-9a78-6ac4b0fc66ad,USA-FDA,01c82878-2b79-4655-88d7-7b0544837937,G_FAQ,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0295/FDA-2013-D-0295-0002/FDA-2013-D-0295-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Scale-Up and Post-Approval Changes, Manufacturing Equipment Addendum"", ""docket_id"": ""FDA-2013-D-0295"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0295-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0295/FDA-2013-D-0295-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:30:37,2025-05-28 03:53:06
2c3fa666-d018-426e-a98d-3fefb5636ddd,Queue,ac42199b-7f78-4853-9370-d34ddaefe108,G_TRANSLATE,2025-05-29 22:18:58,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""to_language"": ""Dutch""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/translation/ac42199b-7f78-4853-9370-d34ddaefe108/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/translation/ac42199b-7f78-4853-9370-d34ddaefe108"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 16:49:02,2025-05-29 16:49:02
2c59fadf-284a-4543-88d9-4f6964b567eb,USA-FDA,eeba5c31-55bb-4e5e-8a82-0d3b905d7cd4,G_IMPACT_ANALYSIS,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016/FDA-2013-D-0369-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in\nPharmaceuticals to Limit Potential Carcinogenic Risk; International\nConference on Harmonisation; Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0369"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0369-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:12:09,2025-05-28 03:53:06
2c67c91e-10cd-44c1-b667-32c66d45e918,USA-FDA,fdf452f0-ea13-4918-8b29-fdfae3a1bda6,G_KEYWORDS,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024/FDA-2011-D-0577-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications  - Guidance"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:32:42,2025-05-28 03:53:06
2c73f09f-840d-4035-a4c5-0cb48ce38161,SCHEDULED,829a355f-de92-4d0b-b0ed-45b5ede28776,FDA_ALERT,2025-05-31 00:00:05,30,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/fda_alert/829a355f-de92-4d0b-b0ed-45b5ede28776"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:32,2025-05-31 00:00:32
2c87577d-4e2a-4585-8c30-ef190455473d,CAB,0f1bfd6a-6b54-493b-b22f-ac2e63675e99,G_SUMMARY_IN,2025-05-20 10:13:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2022-F-1108-0001"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2022-F-1108-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""48b24e3f-2c7d-446d-8ef2-9a788b5abc48""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/48b24e3f-2c7d-446d-8ef2-9a788b5abc48"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:13:35,2025-05-28 03:53:06
2c9c0baf-75eb-47b1-ba84-81059d7dd074,USA-FDA,e5c3b98a-39ea-4118-9ffa-f1d66d95428b,G_FAQ,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0364/FDA-2007-D-0364-0014/FDA-2007-D-0364-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Indexing Structured Product Labeling"", ""docket_id"": ""FDA-2007-D-0364"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0364-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0364/FDA-2007-D-0364-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:01:42,2025-05-28 03:53:06
2ca34b3f-8ef7-44ca-bcea-b171add43e42,USA-FDA,fedc8a21-eb1c-47b3-823c-aaa3e2080b17,G_DETAILED_SUMMARY,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1399/FDA-2020-D-1399-0001/FDA-2020-D-1399-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part I"", ""docket_id"": ""FDA-2020-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1399-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1399/FDA-2020-D-1399-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:01:13,2025-05-28 03:53:06
2ca66f96-c87a-474a-a8a6-43c6a2c71a4f,USA-FDA,f25eb392-a3fa-4205-a83a-03c882b5cc6b,G_MINI_SUMMARY,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0013/FDA-1998-D-0035-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis and Interpretation of Clinical Studies"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:16:46,2025-05-28 03:53:06
2cb30287-c613-4042-89be-798f7c70f9df,USA-FDA,ae0a3ad3-21c6-4fc3-b379-483e6baa9e17,G_ACTION_ITEMS,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0157/FDA-2005-D-0157-0006/FDA-2005-D-0157-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; CGMP for Phase 1 Investigational Drugs"", ""docket_id"": ""FDA-2005-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0157-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0157/FDA-2005-D-0157-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:46:54,2025-05-28 03:53:06
2ce146ce-420c-4fd8-bacd-9115bccfc045,SCHEDULED,39e4d5bb-d211-495f-a053-71d08b1cc042,DEVICE_ANALYST,2025-05-19 16:57:48,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-19""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/39e4d5bb-d211-495f-a053-71d08b1cc042"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-19 21:07:43,2025-05-28 03:53:06
2d00b36d-51ab-4176-88ca-2584ded5c3c4,SCHEDULED,e45819f0-39c8-4e00-921d-8dcd6c351cc2,DEVICE_ANALYST,2025-05-24 00:00:05,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": """", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": """", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/e45819f0-39c8-4e00-921d-8dcd6c351cc2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:27,2025-05-28 03:53:06
2d1b8fd9-5b1a-4c0f-8bc0-3dd17921c882,USA-FDA,7ac5791e-b815-4227-acf6-2291f5851480,G_DETAILED_SUMMARY,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025/FDA-2004-D-0044-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:15:19,2025-05-28 03:53:06
2d2026c1-6221-41f4-9609-6025c369be91,SCHEDULED,37e39749-13c4-4035-8d92-5a4e8c87b0fb,DEVICE_ANALYST,2025-05-28 00:00:05,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/37e39749-13c4-4035-8d92-5a4e8c87b0fb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:26,2025-05-28 03:53:06
2d2eef56-2579-480e-a949-aff8036df1ff,QUEUE,532adee4-4963-45bd-b260-da81935346e0,G_SUMMARY_USER,2025-05-20 10:43:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__doc_title__"": ""FDA-2018-N-3233-0006.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/532adee4-4963-45bd-b260-da81935346e0/SRC/532adee4-4963-45bd-b260-da81935346e0.pdf"", ""doc_title"": ""FDA-2018-N-3233-0006.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/532adee4-4963-45bd-b260-da81935346e0/DEST/detailed_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:43:12,2025-05-28 03:53:06
2d3e5408-4f8a-4cd9-bb29-1386b98f04ad,USA-FDA,1b3e13d9-8092-4a33-a7b9-7837873b24cf,G_CONCISE_SUMMARY,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002/FDA-2012-D-1002-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Questions and Answers Regarding Food Facility Registration Fifith Edition"", ""docket_id"": ""FDA-2012-D-1002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1002-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:46:10,2025-05-28 03:53:06
2d4b9b09-03e4-448b-8f8d-a653bf2e675f,USA-FDA,fa0133fd-8fec-4de9-8c91-a43f0cda5b37,G_ACTION_ITEMS,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0074/FDA-2011-D-0074-0025/FDA-2011-D-0074-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Medication Guide Distribution Requirements and Inclusion of Medication Guides in Risk Evaluation and Mitigation Strategies"", ""docket_id"": ""FDA-2011-D-0074"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0074-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0074/FDA-2011-D-0074-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:01:00,2025-05-28 03:53:06
2d528bb7-490d-4a30-bc9b-34fc761a88a8,USA-FDA,3c5435df-4081-480b-8e93-1edc67b5435a,G_CONCISE_SUMMARY,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002/FDA-2015-D-1309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M8 Electronic Common Technical Document v4.0 Draft Implementation\nGuide v2.0; Electronic Common Technical Document v4.0 Implementation Package Draft Specification for Submission Formats\nv2.0; International Conference on Harmonisation; Draft Guidance for\nIndustry"", ""docket_id"": ""FDA-2015-D-1309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:45:27,2025-05-28 03:53:06
2d8dba5f-9357-4b6d-bfe6-6df18216ba7d,USA-FDA,36db2a02-0f74-452e-9b7f-c36dc260146b,G_IMPACT_ANALYSIS,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009/FDA-2011-D-0398-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Questions and Answers Regarding The Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:31:38,2025-05-28 03:53:06
2d97beb9-668c-4948-baf7-38f4fcf2d120,USA-FDA,2d98de65-cd46-4f92-895e-e738c5042dc8,G_CONCISE_SUMMARY,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002/FDA-2011-D-0649-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Class II Special Controls; External Pacemaker Pulse Generator"", ""docket_id"": ""FDA-2011-D-0649"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0649-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:00:39,2025-05-28 03:53:06
2daab99d-fd29-43aa-98f0-1bab3ac4300f,USA-FDA,ed268077-4526-40b0-8045-8246ef28cfe6,G_DETAILED_SUMMARY,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003/FDA-1999-D-0030-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-1999-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0030-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:32:05,2025-05-28 03:53:06
2db44935-afff-49d2-a13c-54e711529bf0,USA-FDA,4fbba9f6-8fa0-452a-8be0-aa9368ae7565,G_MINI_SUMMARY,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164/FDA-2006-D-0102-1164-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry"", ""docket_id"": ""FDA-2006-D-0102"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0102-1164""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:46:26,2025-05-28 03:53:06
2db874bc-ce1c-4342-a6b9-7992024a15d7,USA-FDA,cece3fbb-7488-4649-b601-5d527a0ce225,G_IMPACT_ANALYSIS,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008/FDA-2004-D-0181-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA)"", ""docket_id"": ""FDA-2004-D-0181"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0181-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:32:53,2025-05-28 03:53:06
2db88e52-ae1f-4da4-b093-dabed6ab7550,SCHEDULED,ede15943-e8c3-4b41-be4b-b369c06b7ee8,DEVICE_ANALYST,2025-05-31 00:00:05,32,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/device_analyst/ede15943-e8c3-4b41-be4b-b369c06b7ee8"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:30,2025-05-31 00:00:30
2dfa3994-c60d-4bf7-b1ee-fd223bdf476d,USA-FDA,bfbf10af-81fd-4845-92d2-cf8740d2d3ae,G_MINI_SUMMARY,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1010/FDA-2012-D-1010-0002/FDA-2012-D-1010-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Initial Completeness Assessments for Type II Active Pharmaceutical Ingredient Drug Master Files under Generic Drug User Fee"", ""docket_id"": ""FDA-2012-D-1010"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1010-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1010/FDA-2012-D-1010-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:47:33,2025-05-28 03:53:06
2e2da4da-7633-404d-87bf-6183ed8621f3,USA-FDA,dfe53cbc-b7d6-479a-b995-42f910349574,G_DETAILED_SUMMARY,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016/FDA-2013-D-0369-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in\nPharmaceuticals to Limit Potential Carcinogenic Risk; International\nConference on Harmonisation; Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0369"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0369-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:11:34,2025-05-28 03:53:06
2e40abad-fe1a-4689-a13d-a58bfc340ee8,USA-FDA,8be0cd0e-9824-4e47-ad0d-a5c4df6a2806,G_DETAILED_SUMMARY,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004/FDA-2010-D-0249-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Systemic Lupus Erythematosus � Developing Medical Products for Treatment"", ""docket_id"": ""FDA-2010-D-0249"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0249-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:01:43,2025-05-28 03:53:06
2e49875b-05d1-44be-84d3-187c7f18d7f7,USA-FDA,40c430e3-8a32-4a01-9893-b9b04069fa78,G_IMPACT_ANALYSIS,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002/FDA-2009-D-0195-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Uranium"", ""docket_id"": ""FDA-2009-D-0195"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0195-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:31:27,2025-05-28 03:53:06
2e66cd39-9cba-41d5-b7ea-3914ad827a84,USA-FDA,4d58ebe0-7e51-4339-ada4-ad8426f146b6,G_FAQ,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016/FDA-2013-D-0369-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in\nPharmaceuticals to Limit Potential Carcinogenic Risk; International\nConference on Harmonisation; Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0369"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0369-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:11:47,2025-05-28 03:53:06
2e76ee17-052f-4210-ae58-e5e099ea2ae2,USA-FDA,3e06d67c-4b29-44c0-b701-b20b4ec10131,G_IMPACT_ANALYSIS,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0386/FDA-2009-D-0386-0010/FDA-2009-D-0386-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection, etc., of Human Papillomaviruses"", ""docket_id"": ""FDA-2009-D-0386"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0386-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0386/FDA-2009-D-0386-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:30:26,2025-05-28 03:53:06
2e852ae7-ac0f-4fd3-9c2b-87f6b7b52f36,USA-FDA,daf6f92d-10a9-4e46-8409-0642f212ea64,G_MINI_SUMMARY,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002/FDA-2014-N-1108-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products--Considerations, Content, and Format"", ""docket_id"": ""FDA-2014-N-1108"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1108-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:01:11,2025-05-28 03:53:06
2e8c9bc6-4c1d-46d7-917e-005574335d93,USA-FDA,f680ed40-f4eb-420b-bdcf-604f27c94531,G_FAQ,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0489/FDA-2011-D-0489-0002/FDA-2011-D-0489-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety of Nanomaterials in Cosmetic Products; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0489"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0489-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0489/FDA-2011-D-0489-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:45:25,2025-05-28 03:53:06
2e9edc07-750f-4f65-bbc2-7047d8a2b560,USA-FDA,6d2667d0-9cf4-4be6-ac85-8a3ccd9ae0ed,G_ACTION_ITEMS,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009/FDA-2006-D-0157-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry:  Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2006-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0157-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:01:07,2025-05-28 03:53:06
2e9f9fcd-0350-4a0d-bcda-0d809ae1ad54,USA-FDA,312e69e1-dbc8-4e56-9e37-e933ed81357a,G_IMPACT_ANALYSIS,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002/FDA-2013-D-0920-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0920"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0920-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:31:35,2025-05-28 03:53:06
2eada0f9-42d4-4710-9fa4-98a0ce2d25f0,USA-FDA,b6842a33-1344-4055-9f0c-ad9ed3fcbbd9,G_ACTION_ITEMS,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0592/FDA-2008-D-0592-0010/FDA-2008-D-0592-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Contents of a Complete Submission for the Evaluation ofProprietary Names - Guidance for Industry "", ""docket_id"": ""FDA-2008-D-0592"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0592-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0592/FDA-2008-D-0592-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:17:57,2025-05-28 03:53:06
2ed16cd9-3438-4d6f-b6e8-e1b210891a8a,USA-FDA,7d4b41ec-688c-4c51-9d0f-7782b4407d73,G_IMPACT_ANALYSIS,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004/FDA-2010-D-0249-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Systemic Lupus Erythematosus � Developing Medical Products for Treatment"", ""docket_id"": ""FDA-2010-D-0249"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0249-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:02:19,2025-05-28 03:53:06
2ed5c03d-fe40-4053-b897-16a9b7e2a1d2,USA-FDA,b7e1c8d2-6a37-425b-9cb9-9b3a66e60fcb,G_DETAILED_SUMMARY,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0652/FDA-2011-D-0652-0002/FDA-2011-D-0652-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff The 510(k) Program Evaluating Substantial Equivalence in Premarket Notifications [510(k)]"", ""docket_id"": ""FDA-2011-D-0652"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0652-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0652/FDA-2011-D-0652-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:45:37,2025-05-28 03:53:06
2ef47399-51a9-4e07-a0d3-c25f7391d737,USA-FDA,89218bfe-55e1-4433-aed5-e5219ba4d266,G_IMPACT_ANALYSIS,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0432/FDA-2011-D-0432-0002/FDA-2011-D-0432-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics"", ""docket_id"": ""FDA-2011-D-0432"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0432-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0432/FDA-2011-D-0432-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:46:25,2025-05-28 03:53:06
2f0f4bb6-31e0-48d7-9787-76b1f3c6cbb0,USA-FDA,c4459ac0-b695-4853-9dfe-7f703428ee23,G_DETAILED_SUMMARY,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005/FDA-2010-D-0163-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (VICH GL46)"", ""docket_id"": ""FDA-2010-D-0163"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0163-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:30:21,2025-05-28 03:53:06
2f178d62-9f8e-47db-bd44-a2a3719e527e,USA-FDA,dfb14e57-c4e3-464b-90ad-2d824708fe5c,G_KEYWORDS,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002/FDA-2011-D-0376-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues"", ""docket_id"": ""FDA-2011-D-0376"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0376-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:01:37,2025-05-28 03:53:06
2f1ee84f-bab4-489f-aa19-ce1297f635f1,USA-FDA,70d6096e-8008-4a34-8ed2-c95e8f6570fc,G_CONCISE_SUMMARY,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004/FDA-2005-D-0028-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products"", ""docket_id"": ""FDA-2005-D-0028"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0028-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:01:30,2025-05-28 03:53:06
2f284ab9-4679-442e-a6c6-10068f8cc759,USA-FDA,fd634130-7c11-4b06-bff7-a26b640cde33,G_FAQ,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002/FDA-2013-D-0269-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Purchasing Reef Fish Species Associated with the Hazard of Ciguatera Fish Poisoning"", ""docket_id"": ""FDA-2013-D-0269"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0269-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:32:08,2025-05-28 03:53:06
2f30d044-9572-4b00-a268-9657b375dc38,SCHEDULED,8df48dc1-94a7-4e76-944a-7c0745bdd827,FDA_ALERT,2025-06-02 00:00:04,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/8df48dc1-94a7-4e76-944a-7c0745bdd827"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:19,2025-06-02 00:00:19
2f3c854f-825f-42d3-9c5e-c960292a6da5,USA-FDA,0470580b-8ecb-46af-80b7-9bb19c371a52,G_MINI_SUMMARY,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0157/FDA-2005-D-0157-0006/FDA-2005-D-0157-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; CGMP for Phase 1 Investigational Drugs"", ""docket_id"": ""FDA-2005-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0157-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0157/FDA-2005-D-0157-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:46:17,2025-05-28 03:53:06
2f534964-8d18-4685-ad32-2c934f00fbb1,USA-FDA,925d3040-9470-492c-bf2b-e2759925481f,G_IMPACT_ANALYSIS,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002/FDA-1999-D-0063-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling"", ""docket_id"": ""FDA-1999-D-0063"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0063-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:48:10,2025-05-28 03:53:06
2f5a6466-8e38-41e6-a5e6-0025abbd31e1,USA-FDA,909473f2-c05d-4cf0-a673-1ac8ac6b7292,G_KEYWORDS,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002/FDA-2009-D-0006-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""S9 Nonclinical Evaluation for Anticancer Pharmaceuticals - Draft Guidance"", ""docket_id"": ""FDA-2009-D-0006"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0006-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:01:05,2025-05-28 03:53:06
2f5dd1a0-7f5e-4b3f-a7a6-747ff036d9f1,SCHEDULED,22e849a5-99f8-4a92-9673-63ef44bf0c52,FDA_ALERT,2025-05-26 00:00:07,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/22e849a5-99f8-4a92-9673-63ef44bf0c52"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:16,2025-05-28 03:53:06
2f97a750-33d1-4b4a-91fc-001a47dcb356,USA-FDA,423ea2c7-aad4-4fd1-ad70-9bcef7596bc7,G_IMPACT_ANALYSIS,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001/FDA-2020-D-1961-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling"", ""docket_id"": ""FDA-2020-D-1961"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1961-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:31:55,2025-05-28 03:53:06
2f99fc20-a019-4836-854a-7e37643a6624,USA-FDA,72bd7a9a-ee18-4ea8-9ed8-af27a843ec61,G_CONCISE_SUMMARY,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020/FDA-1992-N-0056-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prescription Drug Marketing Act (PDMA) Requirements; Questions and Answers"", ""docket_id"": ""FDA-1992-N-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0056-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:15:13,2025-05-28 03:53:06
2fcdea46-acc7-4147-a382-b79272e778ab,USA-FDA,f9bf77ce-cd9b-4185-9b0e-a1ec997d307d,G_FAQ,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0029/FDA-2003-D-0029-0003/FDA-2003-D-0029-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Federal Agencies and State and Local Governments Potassium Iodide Tablets Shelf Life Extension"", ""docket_id"": ""FDA-2003-D-0029"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0029-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0029/FDA-2003-D-0029-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:30:25,2025-05-28 03:53:06
2ff18be3-16d3-47bb-9bb7-ff7cf46b7de3,USA-FDA,8cc80d91-9f16-4888-b2e4-0cf33de504b7,G_ACTION_ITEMS,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001/FDA-2020-D-1951-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on Juice HACCP Regulation (2003)"", ""docket_id"": ""FDA-2020-D-1951"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1951-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:31:16,2025-05-28 03:53:06
2ff691e0-ea89-4611-b27f-5806bc2f4fa6,USA-FDA,263918a0-22e1-4519-a55c-127f5c6e03d6,G_KEYWORDS,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015/FDA-2010-D-0281-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; ��Harmful and Potentially Harmful Constituents� in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act�"", ""docket_id"": ""FDA-2010-D-0281"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0281-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:33,2025-05-28 03:53:06
3,,46e2cbe7-e68a-4048-b97e-9b4cf70da1d5,G_DETAILED_SUMMARY,2025-05-09 01:50:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 08:50:40,2025-05-28 03:53:06
30,,827c17dd-e42a-4275-8330-59bdd3941110,G_IMPACT_ANALYSIS,2025-05-12 19:18:36,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:18:37,2025-05-28 03:53:06
300,,9eaddadb-f426-4867-aad7-db30e8cabed0,G_KEYWORDS,2025-05-14 18:59:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 01:59:24,2025-05-28 03:53:06
300d7778-2235-4c0e-9fcb-6ba31b26f9c9,SCHEDULED,16182a0e-8b8d-4a4c-a4b2-83207a1b99fe,FDA_ALERT,2025-06-02 00:00:04,4,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-04-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/fda_alert/16182a0e-8b8d-4a4c-a4b2-83207a1b99fe"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:08,2025-06-02 00:00:08
301,,5164e521-1817-4442-99b4-2fe113ee6b92,G_TRANSLATE,2025-05-14 19:00:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""German""}","{""tilte"": ""FDA-2024-N-0002-0003_content.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-0002-0003_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b4bca1ff-3762-4cee-a95d-7054097040ef""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b4bca1ff-3762-4cee-a95d-7054097040ef/German"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-15 02:00:17,2025-05-28 03:53:06
302,,28edd9d7-1360-49aa-8663-99d8bd82ac8b,G_FAQ_USER,2025-05-14 19:00:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/28edd9d7-1360-49aa-8663-99d8bd82ac8b/SRC/28edd9d7-1360-49aa-8663-99d8bd82ac8b.pdf"", ""aws_bucket"": ""lexim-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/28edd9d7-1360-49aa-8663-99d8bd82ac8b/DEST/faq.md"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 02:00:33,2025-05-28 03:53:06
303,,94cef418-48e9-417c-93ae-1696517dda62,G_IMPACT_ANALYSIS_USER,2025-05-14 19:00:33,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/94cef418-48e9-417c-93ae-1696517dda62/SRC/94cef418-48e9-417c-93ae-1696517dda62.pdf"", ""aws_bucket"": ""lexim-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/94cef418-48e9-417c-93ae-1696517dda62/DEST/impact_analysis.md"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 02:00:42,2025-05-28 03:53:06
304,,28cb4a8d-8b00-4c23-a2f1-53e929a2d628,G_ACTION_ITEMS_USER,2025-05-14 19:00:42,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/28cb4a8d-8b00-4c23-a2f1-53e929a2d628/SRC/28cb4a8d-8b00-4c23-a2f1-53e929a2d628.pdf"", ""aws_bucket"": ""lexim-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/28cb4a8d-8b00-4c23-a2f1-53e929a2d628/DEST/action_items.md"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 02:00:53,2025-05-28 03:53:06
305,,a2b8e630-e386-4add-904e-69733d4a964f,G_MINI_SUMMARY_USER,2025-05-14 19:00:53,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/a2b8e630-e386-4add-904e-69733d4a964f/SRC/a2b8e630-e386-4add-904e-69733d4a964f.pdf"", ""aws_bucket"": ""lexim-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/a2b8e630-e386-4add-904e-69733d4a964f/DEST/mini_summary.md"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 02:00:56,2025-05-28 03:53:06
305d1987-2286-47eb-ad0e-78df8068b45f,USA-FDA,346b0827-c6e9-4131-bc62-44e1fb1e976e,G_ACTION_ITEMS,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002/FDA-2012-D-1002-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Questions and Answers Regarding Food Facility Registration Fifith Edition"", ""docket_id"": ""FDA-2012-D-1002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1002-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:47:14,2025-05-28 03:53:06
306,,125a98d1-2f7d-4f6c-ab21-a3709bd21ee8,G_CONCISE_SUMMARY,2025-05-14 19:01:02,0,ced2d237-300d-11f0-840d-02ffca30ba2d,b7cb73bf-300d-11f0-840d-02ffca30ba2d,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""AI in Healthcare""}","{""aws_key"": ""ORGANIZATION/ced2d237-300d-11f0-840d-02ffca30ba2d/USERS/b7cb73bf-300d-11f0-840d-02ffca30ba2d/125a98d1-2f7d-4f6c-ab21-a3709bd21ee8/SRC/125a98d1-2f7d-4f6c-ab21-a3709bd21ee8.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/ced2d237-300d-11f0-840d-02ffca30ba2d/USERS/b7cb73bf-300d-11f0-840d-02ffca30ba2d/125a98d1-2f7d-4f6c-ab21-a3709bd21ee8/DEST/concise_summary.md"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-15 02:01:07,2025-05-28 03:53:06
306a7b21-3043-44c9-ab39-507ba7b31f3f,USA-FDA,eddd530a-a660-4056-b0e4-e2f825c7084d,G_ACTION_ITEMS,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016/FDA-2013-D-0369-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in\nPharmaceuticals to Limit Potential Carcinogenic Risk; International\nConference on Harmonisation; Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0369"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0369-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:11:58,2025-05-28 03:53:06
307,,366955ae-9024-45f5-9f56-f801f26af4d5,G_CONCISE_SUMMARY,2025-05-14 19:01:08,0,ced2d237-300d-11f0-840d-02ffca30ba2d,b7cb73bf-300d-11f0-840d-02ffca30ba2d,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""AI in Healthcare""}","{""aws_key"": ""ORGANIZATION/ced2d237-300d-11f0-840d-02ffca30ba2d/USERS/b7cb73bf-300d-11f0-840d-02ffca30ba2d/366955ae-9024-45f5-9f56-f801f26af4d5/SRC/366955ae-9024-45f5-9f56-f801f26af4d5.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/ced2d237-300d-11f0-840d-02ffca30ba2d/USERS/b7cb73bf-300d-11f0-840d-02ffca30ba2d/366955ae-9024-45f5-9f56-f801f26af4d5/DEST/concise_summary.md"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-15 02:01:13,2025-05-28 03:53:06
308,,67cb3886-f0c9-4233-bbe0-91055b61662b,G_SUMMARY_USER,2025-05-14 19:01:14,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/67cb3886-f0c9-4233-bbe0-91055b61662b/SRC/67cb3886-f0c9-4233-bbe0-91055b61662b.pdf"", ""aws_bucket"": ""lexim-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/67cb3886-f0c9-4233-bbe0-91055b61662b/DEST/detailed_summary.md"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 02:01:21,2025-05-28 03:53:06
309,,4721fa8b-3142-430a-b81c-9857f83f3434,G_FAQ_USER,2025-05-14 19:01:21,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/4721fa8b-3142-430a-b81c-9857f83f3434/SRC/4721fa8b-3142-430a-b81c-9857f83f3434.pdf"", ""aws_bucket"": ""lexim-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/4721fa8b-3142-430a-b81c-9857f83f3434/DEST/faq.md"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 02:01:34,2025-05-28 03:53:06
30b73851-9332-40c8-9089-900f01ef4433,USA-FDA,b61b0bf4-93cc-455e-a876-8340580db29b,G_ACTION_ITEMS,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0035/FDA-2003-D-0035-0002/FDA-2003-D-0035-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims"", ""docket_id"": ""FDA-2003-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0035-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0035/FDA-2003-D-0035-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:02:38,2025-05-28 03:53:06
30fe9d3c-a622-423b-b4ce-9cd74166a4c7,QUEUE,68517fdc-99e6-483f-9353-0a0531c5eb41,G_ACTION_ITEMS_USER,2025-05-20 10:42:53,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__doc_title__"": ""FDA-2011-D-0514-0013-guidance.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/68517fdc-99e6-483f-9353-0a0531c5eb41/SRC/68517fdc-99e6-483f-9353-0a0531c5eb41.pdf"", ""doc_title"": ""FDA-2011-D-0514-0013-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/68517fdc-99e6-483f-9353-0a0531c5eb41/DEST/action_items.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:43:01,2025-05-28 03:53:06
31,,f36dd1b3-bb8c-493c-8402-914ce868523a,G_MINI_SUMMARY,2025-05-12 19:18:45,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:18:46,2025-05-28 03:53:06
310,,3168eaab-edec-46f3-9c4b-80266f1becf0,G_MINI_SUMMARY,2025-05-15 09:11:32,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001/FDA-2020-D-1947-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b)"", ""docket_id"": ""FDA-2020-D-1947"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1947-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:11:32,2025-05-28 03:53:06
310174c8-7c6d-48e3-bc43-c61da549d155,USA-FDA,2dfd8ca0-19b6-424c-b32c-4495e210e3f1,G_DETAILED_SUMMARY,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0258/FDA-2011-D-0258-0002/FDA-2011-D-0258-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 335.700 Surgeons� Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure"", ""docket_id"": ""FDA-2011-D-0258"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0258-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0258/FDA-2011-D-0258-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:46:41,2025-05-28 03:53:06
31024ba0-43b9-4190-a4dc-8f53d5d22109,USA-FDA,a9fb8ede-5eab-44e6-9949-6be8e87e4e93,G_DETAILED_SUMMARY,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038/FDA-2008-D-0406-0038-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs; Frequently Asked Questions - Statement of Investigator (Form FDA 1572)"", ""docket_id"": ""FDA-2008-D-0406"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0406-0038""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:17:16,2025-05-28 03:53:06
311,,b04d63bf-4a64-4cf4-9f81-4e70681d57f2,G_CONCISE_SUMMARY,2025-05-15 09:11:40,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001/FDA-2020-D-1947-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b)"", ""docket_id"": ""FDA-2020-D-1947"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1947-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:11:41,2025-05-28 03:53:06
311ff8a0-362c-4a2f-ab04-226616c5ba81,USA-FDA,cec97c13-c3e4-4b18-b89c-037429c008c8,G_IMPACT_ANALYSIS,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0183/FDA-2004-D-0183-0003/FDA-2004-D-0183-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System Guidance for Industry\nand FDA Staff"", ""docket_id"": ""FDA-2004-D-0183"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0183-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0183/FDA-2004-D-0183-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:47:23,2025-05-28 03:53:06
312,,a112625a-e4a1-4f55-bcea-2935c6bfbd03,G_DETAILED_SUMMARY,2025-05-15 09:11:45,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001/FDA-2020-D-1947-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b)"", ""docket_id"": ""FDA-2020-D-1947"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1947-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:11:46,2025-05-28 03:53:06
313,,764449eb-1d3f-4997-b9f1-c61d786e213b,G_FAQ,2025-05-15 09:11:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001/FDA-2020-D-1947-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b)"", ""docket_id"": ""FDA-2020-D-1947"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1947-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:11:52,2025-05-28 03:53:06
3132749a-259c-40e2-9e77-6a9eba23018d,CAB,da6ccdcd-6d05-4c81-9bd7-ca011294b1d8,G_CONCISE_SUMMARY_IN,2025-05-20 09:28:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2023-N-4225-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""be71a183-8124-4a8f-984c-ce1233023d0a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/be71a183-8124-4a8f-984c-ce1233023d0a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:28:11,2025-05-28 03:53:06
31367d74-e4e0-458d-8e53-b55a5466852d,USA-FDA,d31411d2-e315-4941-bbd7-63285594b35e,G_ACTION_ITEMS,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004/FDA-2018-N-4735-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""GFI Safety Labeling Changes Implementation of Section 505(o)(4) of the FDC Act"", ""docket_id"": ""FDA-2018-N-4735"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-N-4735-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:16:48,2025-05-28 03:53:06
314,,d28beaa0-7b19-45ab-b891-89b9d838ca61,G_ACTION_ITEMS,2025-05-15 09:11:57,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001/FDA-2020-D-1947-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b)"", ""docket_id"": ""FDA-2020-D-1947"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1947-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:11:58,2025-05-28 03:53:06
31474deb-090d-45de-9fba-442b0a6a00f7,USA-FDA,aab3d821-df6e-4a2c-97a2-4abb513e2dbc,G_FAQ,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001/FDA-2020-D-1950-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 394.500 Importation of Television Products, Microwave Ovens, and Inherent Class I Laser Products for Investigation and Evaluation during Design Development"", ""docket_id"": ""FDA-2020-D-1950"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1950-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:47:41,2025-05-28 03:53:06
315,,b91c6fb0-f0b3-484b-aab5-ffe8bd8da595,G_IMPACT_ANALYSIS,2025-05-15 09:12:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001/FDA-2020-D-1947-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b)"", ""docket_id"": ""FDA-2020-D-1947"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1947-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:06,2025-05-28 03:53:06
3150cfde-2cf6-4cbf-9b9c-d23348621c84,SCHEDULED,f635e656-25d9-4340-a13d-763fc1871bb2,FDA_ALERT,2025-05-30 00:00:04,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/f635e656-25d9-4340-a13d-763fc1871bb2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:26,2025-05-30 00:00:26
316,,8ea4902d-624c-429b-88d3-0436ee52e7fe,G_KEYWORDS,2025-05-15 09:12:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001/FDA-2020-D-1947-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b)"", ""docket_id"": ""FDA-2020-D-1947"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1947-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1947/FDA-2020-D-1947-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:09,2025-05-28 03:53:06
3164c8eb-901e-4cb6-b8c6-62ea15a18423,USA-FDA,a2899552-b6ed-4074-b628-6a582a375681,G_ACTION_ITEMS,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0386/FDA-2009-D-0386-0010/FDA-2009-D-0386-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection, etc., of Human Papillomaviruses"", ""docket_id"": ""FDA-2009-D-0386"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0386-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0386/FDA-2009-D-0386-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:30:19,2025-05-28 03:53:06
317,,10096454-a2c5-494f-984f-b14c4fc26f3d,G_MINI_SUMMARY,2025-05-15 09:12:11,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001/FDA-2020-D-1953-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 391.100 Advertisement Literature for High-Intensity Mercury Vapor Discharge Lamps - revoked 6/20/02"", ""docket_id"": ""FDA-2020-D-1953"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1953-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:11,2025-05-28 03:53:06
318,,144e2771-135d-4b9f-955a-319fa551b9c5,G_CONCISE_SUMMARY,2025-05-15 09:12:14,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001/FDA-2020-D-1953-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 391.100 Advertisement Literature for High-Intensity Mercury Vapor Discharge Lamps - revoked 6/20/02"", ""docket_id"": ""FDA-2020-D-1953"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1953-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:15,2025-05-28 03:53:06
31807633-4934-41c3-a369-014ce93d9d1a,USA-FDA,0cf0de29-8d8a-4ba1-9233-6b3d4c3923ab,G_IMPACT_ANALYSIS,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0081/FDA-2012-D-0081-0002/FDA-2012-D-0081-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance; Investigational New Drug Applications for Positron Emission Tomography Drugs"", ""docket_id"": ""FDA-2012-D-0081"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0081-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0081/FDA-2012-D-0081-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:46:00,2025-05-28 03:53:06
3181dcaf-04b6-43a0-adb7-c08d32b38bd5,SCHEDULED,98b74534-767c-4ef2-89af-cf9dd0064905,FDA_ALERT,2025-05-19 14:48:33,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-18""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/98b74534-767c-4ef2-89af-cf9dd0064905"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-19 18:48:50,2025-05-28 03:53:06
319,,70c26016-3607-48bc-8a1d-01f1d5b7fe36,G_DETAILED_SUMMARY,2025-05-15 09:12:18,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001/FDA-2020-D-1953-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 391.100 Advertisement Literature for High-Intensity Mercury Vapor Discharge Lamps - revoked 6/20/02"", ""docket_id"": ""FDA-2020-D-1953"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1953-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:19,2025-05-28 03:53:06
31959edc-2c13-4ff2-a3eb-00a7783fe4f7,USA-FDA,e889fdd6-b0f1-4bfd-b08e-427e19ebbeb4,G_MINI_SUMMARY,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0029/FDA-2003-D-0029-0003/FDA-2003-D-0029-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Federal Agencies and State and Local Governments Potassium Iodide Tablets Shelf Life Extension"", ""docket_id"": ""FDA-2003-D-0029"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0029-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0029/FDA-2003-D-0029-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:30:08,2025-05-28 03:53:06
31a0cf03-da3d-46a2-a54b-01ca247f44e3,USA-FDA,41b8ce57-9d87-4da8-be65-eb4eb8eaea08,G_IMPACT_ANALYSIS,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0429/FDA-2011-D-0429-0002/FDA-2011-D-0429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry and Staff: Classification of Products as Drugs and Devices and Additional Product Classification Issues"", ""docket_id"": ""FDA-2011-D-0429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0429/FDA-2011-D-0429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:46:30,2025-05-28 03:53:06
31ba1cf4-a46f-4f4a-995a-4929c09f5f5e,USA-FDA,b822231d-d757-42e7-864d-00579b20e067,G_DETAILED_SUMMARY,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0056/FDA-1997-D-0056-0002/FDA-1997-D-0056-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Iron-Containing Supplements and Drugs: Label Warning Statements and Unit-Dose Packaging Requirements Small Entity Compliance Guide"", ""docket_id"": ""FDA-1997-D-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0056-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0056/FDA-1997-D-0056-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:16:22,2025-05-28 03:53:06
31dfb1b7-369a-4f6b-b78c-3199c8a7f365,USA-FDA,61f6b7c9-a966-45dd-aa20-d8a15c3f7657,G_MINI_SUMMARY,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002/FDA-2012-D-0307-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Revised Preventive Measures to Reduce Possible Risk of Transmission of Creutzfeldt-Jakob Disease, etc."", ""docket_id"": ""FDA-2012-D-0307"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0307-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:31:02,2025-05-28 03:53:06
31ebc42e-d5db-4442-8bc9-80b5f1c855e1,USA-FDA,7d4704b9-3354-4215-9ffc-ebf3ac451db1,G_CONCISE_SUMMARY,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001/FDA-2018-D-0398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions Guidance for Industry and\nFood and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:00:15,2025-05-28 03:53:06
32,,d9e9990c-0a64-4761-aad2-7ea668bc34dc,G_CONCISE_SUMMARY,2025-05-12 19:18:50,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:18:51,2025-05-28 03:53:06
320,,21bfaeb6-3b9c-4a16-96ee-8d7bf1b18477,G_FAQ,2025-05-15 09:12:25,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001/FDA-2020-D-1953-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 391.100 Advertisement Literature for High-Intensity Mercury Vapor Discharge Lamps - revoked 6/20/02"", ""docket_id"": ""FDA-2020-D-1953"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1953-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:25,2025-05-28 03:53:06
321,,63f37ce9-e7cb-4e80-b8b8-de3b7ceaf606,G_ACTION_ITEMS,2025-05-15 09:12:29,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001/FDA-2020-D-1953-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 391.100 Advertisement Literature for High-Intensity Mercury Vapor Discharge Lamps - revoked 6/20/02"", ""docket_id"": ""FDA-2020-D-1953"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1953-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:29,2025-05-28 03:53:06
321c58ba-d112-4d26-a439-71f8e33bc8fb,USA-FDA,b671b873-fb14-4f0f-b910-a8a9a11bc28e,G_FAQ,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009/FDA-2011-D-0164-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Safety Labeling Changes--Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:00:45,2025-05-28 03:53:06
322,,742f588b-8257-4fc4-ab64-476ff228db21,G_IMPACT_ANALYSIS,2025-05-15 09:12:36,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001/FDA-2020-D-1953-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 391.100 Advertisement Literature for High-Intensity Mercury Vapor Discharge Lamps - revoked 6/20/02"", ""docket_id"": ""FDA-2020-D-1953"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1953-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:37,2025-05-28 03:53:06
323,,677d0bcc-6e6a-4d4a-99d8-023fa652897c,G_KEYWORDS,2025-05-15 09:12:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001/FDA-2020-D-1953-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 391.100 Advertisement Literature for High-Intensity Mercury Vapor Discharge Lamps - revoked 6/20/02"", ""docket_id"": ""FDA-2020-D-1953"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1953-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1953/FDA-2020-D-1953-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:39,2025-05-28 03:53:06
323ab9f6-771c-4b60-8815-73af0c3f7426,USA-FDA,334ca1d4-8269-40af-bf86-7af7d3ccc94c,G_ACTION_ITEMS,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0002/FDA-2011-D-0847-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Humanitarian Use Device Designations"", ""docket_id"": ""FDA-2011-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0847-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:45:42,2025-05-28 03:53:06
324,,29dc931c-ac83-4eaf-ab50-854e35f18b92,G_MINI_SUMMARY,2025-05-15 09:12:42,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001/FDA-2020-D-1939-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.750 Class III Devices Subject to 515(b) Requirements"", ""docket_id"": ""FDA-2020-D-1939"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1939-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:43,2025-05-28 03:53:06
32463c89-5cd6-4e5e-8fc7-ec599adfe2c4,USA-FDA,e8a307fb-089e-4b7e-86e6-3ed00710147c,G_FAQ,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0509/FDA-2010-D-0509-0002/FDA-2010-D-0509-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Enforcement Policy - OTC Sunscreen Drug Products Marketed Without an Approved Application"", ""docket_id"": ""FDA-2010-D-0509"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0509-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0509/FDA-2010-D-0509-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:01:23,2025-05-28 03:53:06
325,,707bc165-7c4a-411e-8048-fcc9120de4d1,G_CONCISE_SUMMARY,2025-05-15 09:12:46,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001/FDA-2020-D-1939-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.750 Class III Devices Subject to 515(b) Requirements"", ""docket_id"": ""FDA-2020-D-1939"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1939-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:47,2025-05-28 03:53:06
326,,c41e795f-fe17-4bd4-b0b4-e617622c1b25,G_DETAILED_SUMMARY,2025-05-15 09:12:52,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001/FDA-2020-D-1939-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.750 Class III Devices Subject to 515(b) Requirements"", ""docket_id"": ""FDA-2020-D-1939"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1939-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:12:53,2025-05-28 03:53:06
327,,11f1f96c-6ac2-4c51-a2a7-04c5bc4d6269,G_FAQ,2025-05-15 09:13:00,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001/FDA-2020-D-1939-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.750 Class III Devices Subject to 515(b) Requirements"", ""docket_id"": ""FDA-2020-D-1939"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1939-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:00,2025-05-28 03:53:06
327969d1-31e0-4ee7-9349-d8906b83d516,USA-FDA,cd309063-6e5b-4f53-81db-8a061f527b6f,G_DETAILED_SUMMARY,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0721/FDA-2011-D-0721-0002/FDA-2011-D-0721-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act"", ""docket_id"": ""FDA-2011-D-0721"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0721-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0721/FDA-2011-D-0721-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:30:45,2025-05-28 03:53:06
327eb5a1-378a-42c2-8a8f-3294a0272246,USA-FDA,e17b7a69-56a5-4cc7-80b4-b121f943950c,G_MINI_SUMMARY,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001/FDA-2020-D-1944-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives"", ""docket_id"": ""FDA-2020-D-1944"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1944-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:30:08,2025-05-28 03:53:06
328,,cad36b19-42c2-465d-ad60-78ab2397020a,G_ACTION_ITEMS,2025-05-15 09:13:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001/FDA-2020-D-1939-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.750 Class III Devices Subject to 515(b) Requirements"", ""docket_id"": ""FDA-2020-D-1939"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1939-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:06,2025-05-28 03:53:06
329,,ae1f83f1-fdae-437f-a644-dee8e5aa31f9,G_IMPACT_ANALYSIS,2025-05-15 09:13:14,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001/FDA-2020-D-1939-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.750 Class III Devices Subject to 515(b) Requirements"", ""docket_id"": ""FDA-2020-D-1939"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1939-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:15,2025-05-28 03:53:06
329571c1-9efd-479f-8c16-4ce9581e7999,SCHEDULED,50f13e59-32f8-4d59-a9db-c6649195b9e0,DEVICE_ANALYST,2025-05-23 00:00:04,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": """", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": """", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/50f13e59-32f8-4d59-a9db-c6649195b9e0"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:27,2025-05-28 03:53:06
3299414d-b52d-408e-9b0e-c4c00dfb384a,USA-FDA,bbddb9e1-cf8a-4c16-aee5-269dee82a5a5,G_IMPACT_ANALYSIS,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0487/FDA-2007-D-0487-0005/FDA-2007-D-0487-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec 110.310 Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002"", ""docket_id"": ""FDA-2007-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0487-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0487/FDA-2007-D-0487-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:01:24,2025-05-28 03:53:06
329beeb2-72d6-4be9-8bc3-d8909f2a539f,USA-FDA,b325a082-4935-467a-b815-c135c10c7e6e,G_MINI_SUMMARY,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0005/FDA-2004-D-0301-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Fixed Dose Combinations, Co-Packaged Drug Products, and Single-EntityVersions of Previously Approved\nAntiretrovirals for the Treatment of HIV"", ""docket_id"": ""FDA-2004-D-0301"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0301-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:01:23,2025-05-28 03:53:06
329e0436-330d-4a80-913a-8335da4e549a,USA-FDA,ce84e274-6859-49dc-8eb8-4807c4e69a2c,G_DETAILED_SUMMARY,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4090/FDA-1999-D-4090-0005/FDA-1999-D-4090-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and for FDA Reviewers Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer"", ""docket_id"": ""FDA-1999-D-4090"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4090-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4090/FDA-1999-D-4090-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:31:27,2025-05-28 03:53:06
32cf6c82-0b48-43f5-bcc8-9d112e4d8ed9,USA-FDA,eedbf34e-ff6f-47d9-82fc-a8679ba50d1c,G_KEYWORDS,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002/FDA-2014-N-1082-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Multiplexed Microbiological/Medical Countermeasure In Vitro \nNucleic Acid Based Diagnostic Devices; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-N-1082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1082-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:02:02,2025-05-28 03:53:06
32d501a9-fec3-4536-b273-58ea1d92b999,USA-FDA,9ff22eda-907a-4723-8353-bc876f940f24,G_IMPACT_ANALYSIS,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002/FDA-2012-D-1002-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Questions and Answers Regarding Food Facility Registration Fifith Edition"", ""docket_id"": ""FDA-2012-D-1002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1002-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:47:21,2025-05-28 03:53:06
32d62574-9f2c-4583-adb4-a9aee2805a97,USA-FDA,d04a114c-150f-438d-897f-76465507b7f4,G_ACTION_ITEMS,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0545/FDA-2016-D-0545-0099/FDA-2016-D-0545-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components; Guidance for Industry"", ""docket_id"": ""FDA-2016-D-0545"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0545-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0545/FDA-2016-D-0545-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:30:43,2025-05-28 03:53:06
32dbceed-b2d8-4be7-839f-f3ddbc94bc80,USA-FDA,3a8f5b6f-37b8-44fe-a088-0499e77e9f6b,G_FAQ,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012/FDA-2008-D-0610-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic"", ""docket_id"": ""FDA-2008-D-0610"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0610-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:32:21,2025-05-28 03:53:06
33,,d5fa283d-b99e-4c7e-9e36-77de0c6570a4,G_DETAILED_SUMMARY,2025-05-12 19:19:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:19:05,2025-05-28 03:53:06
330,,64976772-7858-407e-ad11-0e3e7dde529f,G_KEYWORDS,2025-05-15 09:13:16,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001/FDA-2020-D-1939-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.750 Class III Devices Subject to 515(b) Requirements"", ""docket_id"": ""FDA-2020-D-1939"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1939-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1939/FDA-2020-D-1939-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:17,2025-05-28 03:53:06
3305e052-4f61-4cdd-b261-4202b8f0d49d,SCHEDULED,27601dde-1b7e-4a1c-909b-dbe1ac8a70e9,DEVICE_ANALYST,2025-05-23 00:00:04,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/27601dde-1b7e-4a1c-909b-dbe1ac8a70e9"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:06,2025-05-28 03:53:06
330cfe45-a9f2-4843-8c51-4bc9add0ed8b,USA-FDA,bc3ff5e4-1faf-41f0-8e65-59cd7f84ab6a,G_IMPACT_ANALYSIS,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002/FDA-1997-D-0380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation; Guidance"", ""docket_id"": ""FDA-1997-D-0380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:31:36,2025-05-28 03:53:06
331,,9fa42582-c689-41bd-818e-67141e65b2a7,G_MINI_SUMMARY,2025-05-15 09:13:19,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001/FDA-2020-D-1968-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 355.300 Ion Generating Devices"", ""docket_id"": ""FDA-2020-D-1968"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1968-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:20,2025-05-28 03:53:06
331082a9-2cdc-4549-91c9-00f0daf9ef94,USA-FDA,86f64fe9-ed25-49c9-bc9f-22d20eaedc79,G_KEYWORDS,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002/FDA-2013-D-0269-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Purchasing Reef Fish Species Associated with the Hazard of Ciguatera Fish Poisoning"", ""docket_id"": ""FDA-2013-D-0269"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0269-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:32:26,2025-05-28 03:53:06
3312f699-5d2a-49c7-b9e7-852c62455016,USA-FDA,f334d98e-3394-4d63-bb15-c922a2873882,G_CONCISE_SUMMARY,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002/FDA-2014-D-1351-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Flow Cytometric Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1351"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1351-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:01:51,2025-05-28 03:53:06
331b5a0c-3f05-4583-adba-94b3a2236d11,USA-FDA,07117114-118c-4f24-aad3-8d0786a58bcc,G_CONCISE_SUMMARY,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002/FDA-2018-D-4525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Lactation Studies: Considerations for Study Design; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2018-D-4525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-4525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:17:11,2025-05-28 03:53:06
332,,a88d44e3-b818-4d8d-8559-9dc7d38bad1c,G_CONCISE_SUMMARY,2025-05-15 09:13:22,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001/FDA-2020-D-1968-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 355.300 Ion Generating Devices"", ""docket_id"": ""FDA-2020-D-1968"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1968-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:23,2025-05-28 03:53:06
332d3c9b-791c-4bc3-b736-7263f634061b,USA-FDA,00b19572-57bd-48a1-8b69-d8eaf42daf82,G_CONCISE_SUMMARY,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002/FDA-2009-D-0198-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain Cochineal Extract and Carmine"", ""docket_id"": ""FDA-2009-D-0198"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0198-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:41,2025-05-28 03:53:06
333,,f2d188c1-2aae-4350-8f3d-90e7be677254,G_DETAILED_SUMMARY,2025-05-15 09:13:26,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001/FDA-2020-D-1968-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 355.300 Ion Generating Devices"", ""docket_id"": ""FDA-2020-D-1968"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1968-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:26,2025-05-28 03:53:06
33349c80-8655-40cd-a253-8fda3affa7c5,USA-FDA,c4813ecc-3a74-47c0-be39-05898056b5a1,G_KEYWORDS,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002/FDA-2014-N-0829-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Reporting Drug Sample Information\nUnder Section 6004 of the Affordable Care Act"", ""docket_id"": ""FDA-2014-N-0829"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-0829-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:30:54,2025-05-28 03:53:06
334,,1c82edf0-16af-4d47-80b4-8830f8ac6a97,G_FAQ,2025-05-15 09:13:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001/FDA-2020-D-1968-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 355.300 Ion Generating Devices"", ""docket_id"": ""FDA-2020-D-1968"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1968-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:31,2025-05-28 03:53:06
335,,e9aa508a-9faf-40c8-b723-eb9b3155a518,G_ACTION_ITEMS,2025-05-15 09:13:35,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001/FDA-2020-D-1968-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 355.300 Ion Generating Devices"", ""docket_id"": ""FDA-2020-D-1968"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1968-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:35,2025-05-28 03:53:06
336,,6c2441ff-72d9-4637-96e4-3dab565074b7,G_IMPACT_ANALYSIS,2025-05-15 09:13:42,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001/FDA-2020-D-1968-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 355.300 Ion Generating Devices"", ""docket_id"": ""FDA-2020-D-1968"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1968-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:42,2025-05-28 03:53:06
3363f5e9-48f0-4754-b693-ce770257e035,USA-FDA,618cff18-10af-46f4-b88f-1949971bb12a,G_ACTION_ITEMS,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002/FDA-2011-D-0469-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and the Food and Drug Administration Staff: Applying Human Factors and Usability Engineering to Optimize Medical Device Design - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0469"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0469-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:28,2025-05-28 03:53:06
337,,f96b37bd-f4ca-4a39-8a9c-9dd3401127be,G_KEYWORDS,2025-05-15 09:13:44,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001/FDA-2020-D-1968-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 355.300 Ion Generating Devices"", ""docket_id"": ""FDA-2020-D-1968"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1968-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1968/FDA-2020-D-1968-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:45,2025-05-28 03:53:06
33797314-69c6-4afd-99f3-ae504dd83699,QUEUE,365c6b20-a888-48cf-8c52-634329b8fc9f,G_CONCISE_SUMMARY_USER,2025-05-29 16:00:25,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/365c6b20-a888-48cf-8c52-634329b8fc9f/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/365c6b20-a888-48cf-8c52-634329b8fc9f"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 16:00:29,2025-05-29 16:00:29
338,,336bd094-6ba9-4a60-ab14-d07184192399,G_MINI_SUMMARY,2025-05-15 09:13:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001/FDA-2020-D-1930-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims"", ""docket_id"": ""FDA-2020-D-1930"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1930-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:48,2025-05-28 03:53:06
339,,7921a2cf-1750-46b7-a52d-fc5f93719c51,G_CONCISE_SUMMARY,2025-05-15 09:13:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001/FDA-2020-D-1930-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims"", ""docket_id"": ""FDA-2020-D-1930"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1930-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:52,2025-05-28 03:53:06
33943bbc-23f7-40f5-af1e-c29cd54028cf,USA-FDA,e4a5e5b5-3a24-4060-aa3b-420defa1c495,G_IMPACT_ANALYSIS,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0031/FDA-2006-D-0031-0006/FDA-2006-D-0031-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Frequently Asked Questions About Medical Devices:  Guidance For IRBs, Clinical Investigators, and Sponsors"", ""docket_id"": ""FDA-2006-D-0031"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0031-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0031/FDA-2006-D-0031-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:16:38,2025-05-28 03:53:06
33948e2b-2459-47d9-a5bd-00b8ffb70375,USA-FDA,3d5817f2-3c8f-47c3-8c3d-797f2e5b10e2,G_KEYWORDS,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001/FDA-2023-D-2510-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)"", ""docket_id"": ""FDA-2023-D-2510"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2510-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:31:50,2025-05-28 03:53:06
339db8dd-edf0-4621-a0bd-17882a2d196a,USA-FDA,825b028d-632f-4127-a4e4-152794c78c4a,G_IMPACT_ANALYSIS,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003/FDA-2006-D-0231-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds"", ""docket_id"": ""FDA-2006-D-0231"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0231-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:01:18,2025-05-28 03:53:06
33d033e6-271b-4918-bbbc-85241c2e74cf,USA-FDA,18a7d9d8-0029-451f-b7b7-78989cdc5f93,G_KEYWORDS,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001/FDA-2020-D-1430-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents"", ""docket_id"": ""FDA-2020-D-1430"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1430-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:18:15,2025-05-28 03:53:06
33ed6b07-1ad3-4309-a6c7-08ccc19f7ab3,USA-FDA,33a8f5a2-8a45-40e9-8d5d-873054e274ac,G_IMPACT_ANALYSIS,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004/FDA-2005-D-0028-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products"", ""docket_id"": ""FDA-2005-D-0028"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0028-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:02:31,2025-05-28 03:53:06
33fce3be-03f4-406a-9061-3343885b2874,USA-FDA,4468aa49-bad2-44d7-a5c0-6249cc5bb909,G_IMPACT_ANALYSIS,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0433/FDA-2012-D-0433-0002/FDA-2012-D-0433-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""mHealth Regulatory Coalition (Epstein Becker & Green) - Guidance"", ""docket_id"": ""FDA-2012-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0433-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0433/FDA-2012-D-0433-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:15:56,2025-05-28 03:53:06
34,,d3f134b3-ac70-4258-8217-4e246ce646c4,G_FAQ,2025-05-12 19:20:32,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:20:39,2025-05-28 03:53:06
340,,308348e0-17f2-4c4b-ae5d-d89dea7336aa,G_DETAILED_SUMMARY,2025-05-15 09:13:58,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001/FDA-2020-D-1930-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims"", ""docket_id"": ""FDA-2020-D-1930"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1930-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:13:58,2025-05-28 03:53:06
340ae0cc-6730-400d-90c4-a7bc745178fc,USA-FDA,13e32fb3-fc6c-4e81-87e9-2b210e6d90a3,G_FAQ,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0157/FDA-2005-D-0157-0006/FDA-2005-D-0157-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; CGMP for Phase 1 Investigational Drugs"", ""docket_id"": ""FDA-2005-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0157-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0157/FDA-2005-D-0157-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:46:45,2025-05-28 03:53:06
341,,85c6dd3f-7317-4c5e-993c-6c46aae9edd0,G_FAQ,2025-05-15 09:14:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001/FDA-2020-D-1930-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims"", ""docket_id"": ""FDA-2020-D-1930"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1930-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:14:08,2025-05-28 03:53:06
342,,b25b76bc-4faa-4ef3-a352-a2b126c2d22d,G_ACTION_ITEMS,2025-05-15 09:14:12,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001/FDA-2020-D-1930-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims"", ""docket_id"": ""FDA-2020-D-1930"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1930-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:14:13,2025-05-28 03:53:06
342089c1-5cf9-4108-ab98-53af4972f2e4,USA-FDA,88e09c99-1117-4491-99f6-1f202aca7545,G_IMPACT_ANALYSIS,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0013/FDA-2003-D-0186-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""DRAFT GUIDANCE FOR INDUSTRY COSMETICS PROCESSORS AND TRANSPORTERS: COSMETICS SECURITY PREVENTIVE MEASURES GUIDANCE"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:31:51,2025-05-28 03:53:06
343,,2b05b392-019b-4e4e-b105-c8390516ef28,G_IMPACT_ANALYSIS,2025-05-15 09:14:21,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001/FDA-2020-D-1930-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims"", ""docket_id"": ""FDA-2020-D-1930"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1930-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:14:22,2025-05-28 03:53:06
34350288-b721-497f-803a-2bdb560787fc,USA-FDA,f5518a07-036d-411b-abb9-11d8ee23347b,G_FAQ,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001/FDA-2020-D-1925-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations)"", ""docket_id"": ""FDA-2020-D-1925"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1925-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:46:57,2025-05-28 03:53:06
3438f428-160c-4455-bffd-32ec24e514d9,USA-FDA,b40cf99d-9d35-4e54-995a-40e5eba52bc0,G_FAQ,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001/FDA-2020-D-1397-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Q3A Impurities in New Drug Substances"", ""docket_id"": ""FDA-2020-D-1397"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1397-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:45:32,2025-05-28 03:53:06
344,,02a2eaad-d7eb-4534-8e83-5f76b401c0c8,G_KEYWORDS,2025-05-15 09:14:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001/FDA-2020-D-1930-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims"", ""docket_id"": ""FDA-2020-D-1930"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1930-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1930/FDA-2020-D-1930-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-15 16:14:24,2025-05-28 03:53:06
34437145-497c-4451-ac35-5d78d71b0578,USA-FDA,45cdbee5-0d4d-4969-9ca1-2875e6915be2,G_KEYWORDS,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011/FDA-1997-D-0444-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance on FDA Approval of New Animal Drugs for Minor Uses and for Minor Species; Guidance Document (Revised May 29, 2008)"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:01:10,2025-05-28 03:53:06
345,USA-FDA,a6048536-7aa2-4092-9365-2ec7e2ed1d32,G_MINI_SUMMARY,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001/FDA-2020-D-1361-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part V Food Contact Substance Submissions"", ""docket_id"": ""FDA-2020-D-1361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1361-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 01:57:39,2025-05-28 03:53:06
345ad573-1228-4a2d-b4cf-8c6bcd021bc0,USA-FDA,e4648cfa-a7c0-4287-86f1-2b1286e2ea78,G_ACTION_ITEMS,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004/FDA-2007-D-0375-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Acute Bacterial Sinusitis; Developing Drugs for Treatment"", ""docket_id"": ""FDA-2007-D-0375"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0375-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:30:59,2025-05-28 03:53:06
346,USA-FDA,d11eaa0e-48f5-4be0-83d8-9bbeaf3def64,G_CONCISE_SUMMARY,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001/FDA-2020-D-1361-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part V Food Contact Substance Submissions"", ""docket_id"": ""FDA-2020-D-1361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1361-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 01:57:50,2025-05-28 03:53:06
347,USA-FDA,ac5d606f-80bd-4c6f-bd30-ea06041363d4,G_DETAILED_SUMMARY,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001/FDA-2020-D-1361-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part V Food Contact Substance Submissions"", ""docket_id"": ""FDA-2020-D-1361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1361-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 01:57:57,2025-05-28 03:53:06
348,USA-FDA,4d2455e7-72ef-4664-a17b-430414e506ca,G_FAQ,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001/FDA-2020-D-1361-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part V Food Contact Substance Submissions"", ""docket_id"": ""FDA-2020-D-1361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1361-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 01:58:27,2025-05-28 03:53:06
348a0b46-de85-4b5e-8dc7-3a37c529c171,USA-FDA,30848725-90b5-4d74-8387-d18bdd39062b,G_FAQ,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002/FDA-2011-D-0464-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Low Glucose Suspend (LGS) Device Systems - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0464-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:32:33,2025-05-28 03:53:06
349,USA-FDA,5bc11ea3-e53a-4375-a3e8-d8bab8f17679,G_ACTION_ITEMS,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001/FDA-2020-D-1361-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part V Food Contact Substance Submissions"", ""docket_id"": ""FDA-2020-D-1361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1361-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 01:58:32,2025-05-28 03:53:06
34935442-781c-42d4-b211-39b1c920afb2,Queue,365c6b20-a888-48cf-8c52-634329b8fc9f,G_CONCISE_SUMMARY_USER,2025-05-29 21:29:34,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/365c6b20-a888-48cf-8c52-634329b8fc9f/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/365c6b20-a888-48cf-8c52-634329b8fc9f"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 15:59:42,2025-05-29 15:59:42
34a814e2-29d0-4d2a-918b-1a2f17cd8400,USA-FDA,1991018a-c746-444d-bcda-e79f9ca33252,G_IMPACT_ANALYSIS,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002/FDA-1999-D-1315-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act (PDUFA) Products; Guidance for Industry; Draft Guidance for Industry"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:02:35,2025-05-28 03:53:06
34e2555a-38cb-47da-824b-22b1e9627e45,USA-FDA,fc9fe2ff-9511-46b3-933e-3d3740695834,G_CONCISE_SUMMARY,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002/FDA-2002-P-0302-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices"", ""docket_id"": ""FDA-2002-P-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-P-0302-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:30:13,2025-05-28 03:53:06
35,,a1996aef-edf2-439b-96d8-370d217118a0,G_MINI_SUMMARY,2025-05-12 19:23:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:23:32,2025-05-28 03:53:06
350,USA-FDA,4452958c-0054-4c69-8b11-c25a4e62b628,G_IMPACT_ANALYSIS,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001/FDA-2020-D-1361-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part V Food Contact Substance Submissions"", ""docket_id"": ""FDA-2020-D-1361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1361-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 01:58:40,2025-05-28 03:53:06
350c7c57-7ce0-4b16-9f6a-a01074ba7d17,USA-FDA,28bd66bb-3aec-4326-adda-e8c0449dece8,G_DETAILED_SUMMARY,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015/FDA-2010-D-0350-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Tobacco Retailers on Tobacco Retailer Training Programs"", ""docket_id"": ""FDA-2010-D-0350"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0350-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:02:32,2025-05-28 03:53:06
351,USA-FDA,45390c61-f940-45ec-934f-256fd8ae3870,G_KEYWORDS,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001/FDA-2020-D-1361-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part V Food Contact Substance Submissions"", ""docket_id"": ""FDA-2020-D-1361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1361-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1361/FDA-2020-D-1361-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 01:58:43,2025-05-28 03:53:06
352,USA-FDA,7dfb17aa-57f9-4dfb-a166-33839f987ae1,G_MINI_SUMMARY,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001/FDA-2020-D-1363-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VII Biotechnology Final Consultations"", ""docket_id"": ""FDA-2020-D-1363"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1363-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:04:04,2025-05-28 03:53:06
353,USA-FDA,b5e6f2b4-d712-450c-bd1b-097d1fa913c9,G_CONCISE_SUMMARY,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001/FDA-2020-D-1363-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VII Biotechnology Final Consultations"", ""docket_id"": ""FDA-2020-D-1363"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1363-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:04:08,2025-05-28 03:53:06
353d1fb1-d095-433e-8cd7-8c199e06d051,USA-FDA,2227f752-1313-4eae-9cdb-a871543801a2,G_FAQ,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001/FDA-2020-D-1916-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect -21 CFR 1003.11"", ""docket_id"": ""FDA-2020-D-1916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1916-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:45:23,2025-05-28 03:53:06
354,USA-FDA,5e2c1b26-965e-4cce-b8f9-85cf92ab52e5,G_DETAILED_SUMMARY,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001/FDA-2020-D-1363-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VII Biotechnology Final Consultations"", ""docket_id"": ""FDA-2020-D-1363"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1363-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:04:13,2025-05-28 03:53:06
355,USA-FDA,516f7dc8-730c-4377-88de-869accf05961,G_FAQ,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001/FDA-2020-D-1363-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VII Biotechnology Final Consultations"", ""docket_id"": ""FDA-2020-D-1363"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1363-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:04:24,2025-05-28 03:53:06
356,USA-FDA,4172a094-3240-412d-9fb6-1496824822de,G_ACTION_ITEMS,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001/FDA-2020-D-1363-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VII Biotechnology Final Consultations"", ""docket_id"": ""FDA-2020-D-1363"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1363-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:04:30,2025-05-28 03:53:06
356183f1-78d2-430c-9989-94a892a31dd7,USA-FDA,e9b555bd-d850-4e8c-abf0-dc59ed09b534,G_FAQ,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009/FDA-2011-D-0916-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Classification Product Codes; Guidance for Industry and  Food and Drug Administration Staff"", ""docket_id"": ""FDA-2011-D-0916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0916-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:32:35,2025-05-28 03:53:06
357,USA-FDA,c0ac7999-5490-4507-baf4-8cb3160027b5,G_IMPACT_ANALYSIS,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001/FDA-2020-D-1363-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VII Biotechnology Final Consultations"", ""docket_id"": ""FDA-2020-D-1363"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1363-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:04:36,2025-05-28 03:53:06
358,USA-FDA,b67d3289-7dc9-4dd5-8ae4-6d185a38e2c4,G_KEYWORDS,2025-05-15 18:57:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001/FDA-2020-D-1363-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VII Biotechnology Final Consultations"", ""docket_id"": ""FDA-2020-D-1363"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1363-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1363/FDA-2020-D-1363-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:04:39,2025-05-28 03:53:06
359,CAB,3ee3557e-f5b2-42fd-928f-9385b99bf841,G_MINI_SUMMARY_IN,2025-05-15 19:16:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:16:50,2025-05-28 03:53:06
35d54c42-ffb8-4406-ab04-1684255b1978,USA-FDA,6cce0f43-0d4e-4af2-95cc-55f5b50f5179,G_FAQ,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018/FDA-2012-D-1038-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:31:01,2025-05-28 03:53:06
35ec09b1-78f4-4f41-9b4e-802d055ba2e0,USA-FDA,979abb64-340b-4961-af62-2b3d68633a97,G_ACTION_ITEMS,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005/FDA-2007-D-0205-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:33:21,2025-05-28 03:53:06
36,,99217f83-713f-4359-a3d2-ddaf0d090909,G_CONCISE_SUMMARY,2025-05-12 19:23:34,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:23:36,2025-05-28 03:53:06
360,CAB,4d986a08-acf2-4ff9-90f7-21846d1fe87b,G_CONCISE_SUMMARY_IN,2025-05-15 19:16:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:16:55,2025-05-28 03:53:06
361,CAB,d6eddea1-6c5a-4014-aecd-ca5f0d8accd7,G_SUMMARY_IN,2025-05-15 19:16:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:16:59,2025-05-28 03:53:06
361c0ceb-83b5-400e-8efd-f9de9fb7eb2a,USA-FDA,8e15da35-4a89-4cb9-a418-3ba8f406faa6,G_ACTION_ITEMS,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001/FDA-2020-D-0367-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""External Guidance Document Submission from Turner Scientific, LLC re: Ototoxicity: Nonclinical Evaluation During Drug Development"", ""docket_id"": ""FDA-2020-D-0367"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-0367-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:22,2025-05-28 03:53:06
362,CAB,0dbd12f1-5a3f-42e4-b88d-aed1b52550ab,G_FAQ_IN,2025-05-15 19:16:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:17:07,2025-05-28 03:53:06
363,CAB,3b3cfc10-8899-49e5-b4af-5d8fcfebb09b,G_ACTION_ITEMS_IN,2025-05-15 19:16:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:17:13,2025-05-28 03:53:06
364,CAB,a59731fa-c4de-4712-a374-74f9f074ab17,G_IMPACT_ANALYSIS_IN,2025-05-15 19:16:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:17:22,2025-05-28 03:53:06
365,CAB,39e01673-238d-4e9d-af22-1d4489953db0,G_KEYWORDS,2025-05-15 19:16:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:17:25,2025-05-28 03:53:06
366,CAB,e0cb3e09-1f2f-42ea-9246-e66ba10e9e7c,G_TRANSLATE,2025-05-15 19:16:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/05421ecc-6e7d-4075-b9c1-77a5e0d4f6ae/FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""240bf566-dc5f-463b-a794-1e968881db49""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/240bf566-dc5f-463b-a794-1e968881db49/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:17:50,2025-05-28 03:53:06
366909de-54ec-46cf-85b8-6979a2223c1d,USA-FDA,f47c64b7-9525-4a91-bd05-f908ac09c6ab,G_MINI_SUMMARY,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004/FDA-2002-D-0298-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition"", ""docket_id"": ""FDA-2002-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0298-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:46:27,2025-05-28 03:53:06
367,USA-FDA,70a800fa-5e5a-46e1-8f4e-93e7662732ae,G_MINI_SUMMARY,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010/FDA-2005-D-0154-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Q8 R2-Pharmaceutical-Development"", ""docket_id"": ""FDA-2005-D-0154"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0154-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:36:33,2025-05-28 03:53:06
368,USA-FDA,6177c01d-86bb-40d0-bb2d-f789808bb15f,G_CONCISE_SUMMARY,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010/FDA-2005-D-0154-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Q8 R2-Pharmaceutical-Development"", ""docket_id"": ""FDA-2005-D-0154"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0154-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:36:37,2025-05-28 03:53:06
369,USA-FDA,9babe8b4-caf9-45df-917e-d599cbf3c769,G_DETAILED_SUMMARY,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010/FDA-2005-D-0154-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Q8 R2-Pharmaceutical-Development"", ""docket_id"": ""FDA-2005-D-0154"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0154-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:37:12,2025-05-28 03:53:06
36abbbc7-b122-4aa6-9e2a-ae6579cff41f,CAB,26ed473e-bcf3-4d42-8d56-41e02b680d37,G_TRANSLATE,2025-05-20 18:32:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""__to_language__"": ""English""}","{""tilte"": ""Erlaeuternder_Bericht_20130821.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/Erlaeuternder_Bericht_20130821.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""c20a850b-c6a6-43b1-a92a-d6c621908a53""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/c20a850b-c6a6-43b1-a92a-d6c621908a53/English"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 18:33:31,2025-05-28 03:53:06
36d4d0b5-9c60-4a78-8d65-e7cf23ce1b8a,USA-FDA,2537288a-06de-4819-b18e-1489093185eb,G_IMPACT_ANALYSIS,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0847/FDA-2012-D-0847-0002/FDA-2012-D-0847-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for IRBs, Clinical Investigators, and Sponsors; IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed"", ""docket_id"": ""FDA-2012-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0847-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0847/FDA-2012-D-0847-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:15:38,2025-05-28 03:53:06
37,,d56bb4c9-191c-485b-9b46-659f9b8152dd,G_DETAILED_SUMMARY,2025-05-12 19:23:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:23:57,2025-05-28 03:53:06
370,USA-FDA,afffdaa8-8800-4e09-97ab-0708b0724fea,G_FAQ,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010/FDA-2005-D-0154-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Q8 R2-Pharmaceutical-Development"", ""docket_id"": ""FDA-2005-D-0154"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0154-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:37:23,2025-05-28 03:53:06
37093517-9399-47af-8941-590ab7557435,USA-FDA,6f6fbe56-7cc5-4645-a5f8-0e355bd24da1,G_IMPACT_ANALYSIS,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034/FDA-2002-D-0094-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Food and Drug Administration Advisory\nCommittee Members, and Food and Drug Administration Staff: Public\nAvailability of Advisory Committee Members� Financial Interest\nInformation and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:30:44,2025-05-28 03:53:06
371,USA-FDA,4323beec-a1dc-4e79-987e-d8df070def4f,G_ACTION_ITEMS,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010/FDA-2005-D-0154-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Q8 R2-Pharmaceutical-Development"", ""docket_id"": ""FDA-2005-D-0154"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0154-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:37:31,2025-05-28 03:53:06
372,USA-FDA,28c486b8-6adc-47a6-96cd-9d83bb7efce0,G_IMPACT_ANALYSIS,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010/FDA-2005-D-0154-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Q8 R2-Pharmaceutical-Development"", ""docket_id"": ""FDA-2005-D-0154"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0154-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:37:39,2025-05-28 03:53:06
373,USA-FDA,e5744798-1886-4d03-8b31-e710f6ddf789,G_KEYWORDS,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010/FDA-2005-D-0154-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Q8 R2-Pharmaceutical-Development"", ""docket_id"": ""FDA-2005-D-0154"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0154-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0154/FDA-2005-D-0154-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:37:44,2025-05-28 03:53:06
373627d0-a6b9-4885-a5fd-1b66cd08e78d,USA-FDA,bf2ef1b5-70a1-49da-b719-2b17aba4d09b,G_ACTION_ITEMS,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002/FDA-2011-D-0674-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry FDA Records Access Authority under Section 414 and 704 of the Federal Food, Drug, & Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0674"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0674-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:41,2025-05-28 03:53:06
3737592b-63ee-4239-bc4d-fe7c50acc51d,USA-FDA,f687ab94-f774-4405-9c7e-c207f35b1e1c,G_DETAILED_SUMMARY,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002/FDA-2002-P-0302-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices"", ""docket_id"": ""FDA-2002-P-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-P-0302-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:30:23,2025-05-28 03:53:06
373a182c-be52-4493-9fbf-905de214fbf1,USA-FDA,80c1c9e3-8fd8-4c1f-9958-ec2fa40cbaf5,G_IMPACT_ANALYSIS,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0436/FDA-2011-D-0436-0002/FDA-2011-D-0436-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Q11 Development and Manufacture of Drug Substances; International Conference on Harmonisation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0436"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0436-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0436/FDA-2011-D-0436-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:31:43,2025-05-28 03:53:06
374,USA-FDA,0b848a0a-8c07-4d96-b84d-15ef9a4d60c9,G_MINI_SUMMARY,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001/FDA-2020-D-1377-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations; # 70"", ""docket_id"": ""FDA-2020-D-1377"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1377-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:37:47,2025-05-28 03:53:06
374ee1e5-7ef1-4ed8-a68a-19407dd68036,USA-FDA,f452f3dd-2629-4a0d-a2da-7e4e598e016e,G_IMPACT_ANALYSIS,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0476/FDA-2011-D-0476-0010/FDA-2011-D-0476-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Enforcement Policy for Premarket Notification Requirements for Certain In Vitro Diagnostic and Radiology Devices"", ""docket_id"": ""FDA-2011-D-0476"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0476-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0476/FDA-2011-D-0476-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:31:50,2025-05-28 03:53:06
375,USA-FDA,f80a25d4-0b73-48ed-aa3a-959a57b8f97e,G_CONCISE_SUMMARY,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001/FDA-2020-D-1377-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations; # 70"", ""docket_id"": ""FDA-2020-D-1377"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1377-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:37:50,2025-05-28 03:53:06
376,USA-FDA,63a442e8-1564-4e58-9fe3-e42211bd3869,G_DETAILED_SUMMARY,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001/FDA-2020-D-1377-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations; # 70"", ""docket_id"": ""FDA-2020-D-1377"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1377-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:37:57,2025-05-28 03:53:06
377,USA-FDA,6a97524e-ed72-43a6-aa94-be80b5cb0613,G_FAQ,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001/FDA-2020-D-1377-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations; # 70"", ""docket_id"": ""FDA-2020-D-1377"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1377-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:38:10,2025-05-28 03:53:06
377c13d7-73a1-4e25-8f43-465fb0c0b6f1,USA-FDA,6760d106-402e-497c-8b20-a0e467a2441c,G_FAQ,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0002/FDA-2004-D-0301-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Fixed Dose Combination and Co-Packaged Drug Products for Treatment of HIV - DRAFT GUIDANCE"", ""docket_id"": ""FDA-2004-D-0301"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0301-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:32:30,2025-05-28 03:53:06
378,USA-FDA,12e9c8be-b088-4aba-80aa-3f3528bb0c78,G_ACTION_ITEMS,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001/FDA-2020-D-1377-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations; # 70"", ""docket_id"": ""FDA-2020-D-1377"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1377-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:38:15,2025-05-28 03:53:06
379,USA-FDA,de34306f-0fd0-44c2-931e-a60ab636252d,G_IMPACT_ANALYSIS,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001/FDA-2020-D-1377-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations; # 70"", ""docket_id"": ""FDA-2020-D-1377"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1377-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:38:20,2025-05-28 03:53:06
37a5906f-aa00-4878-9728-aa9acfadc2f0,USA-FDA,2a0fe004-2157-40bd-b972-eaa7e0e2a09b,G_FAQ,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001/FDA-2020-D-1430-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents"", ""docket_id"": ""FDA-2020-D-1430"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1430-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:17:50,2025-05-28 03:53:06
37e5c4f3-6be9-4d47-87fa-d44902347228,USA-FDA,a39dbbe7-3f89-4724-928c-3ce99a956813,G_ACTION_ITEMS,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-3528/FDA-1999-D-3528-0002/FDA-1999-D-3528-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture"", ""docket_id"": ""FDA-1999-D-3528"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-3528-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-3528/FDA-1999-D-3528-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:01:43,2025-05-28 03:53:06
37f12616-60fc-46f4-90ce-3a2ce8d220ac,USA-FDA,b2d17db9-1ea7-4e8d-8245-bca67e2aa937,G_MINI_SUMMARY,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025/FDA-2009-D-0524-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Listing of Ingredients in Tobacco Products"", ""docket_id"": ""FDA-2009-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0524-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:01:16,2025-05-28 03:53:06
37f9c410-454f-4665-a3ab-774bea23ad42,USA-FDA,d2190aac-a338-46fd-8be6-a1072ef58e6f,G_MINI_SUMMARY,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-2001/FDA-2015-D-2001-0002/FDA-2015-D-2001-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance Assessment of Male-Mediated Developmental Risk for Pharmaceuticals"", ""docket_id"": ""FDA-2015-D-2001"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-2001-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-2001/FDA-2015-D-2001-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:31:41,2025-05-28 03:53:06
38,,ae9ba7bd-c1a4-4fdf-bda8-e8332b0c106e,G_FAQ,2025-05-12 19:24:21,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:24:22,2025-05-28 03:53:06
380,USA-FDA,840d9279-b9aa-43b1-913c-de621ed62ef5,G_KEYWORDS,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001/FDA-2020-D-1377-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations; # 70"", ""docket_id"": ""FDA-2020-D-1377"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1377-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1377/FDA-2020-D-1377-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:38:23,2025-05-28 03:53:06
380c59ff-b3f1-4a51-8d89-a19508ed590e,USA-FDA,c0f0c91c-ca9d-4e79-ba09-19c61841986a,G_MINI_SUMMARY,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0008/FDA-2012-D-1083-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff Civil Money Penalties for Tobacco Retailers: Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2012-D-1083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1083-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:15:08,2025-05-28 03:53:06
381,USA-FDA,04aaca39-9566-4bdf-825f-2260384fc63c,G_MINI_SUMMARY,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001/FDA-2017-D-4359-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Small Entitles Compliance Guide for Renderers"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:38:26,2025-05-28 03:53:06
382,USA-FDA,0645825c-1be6-4e59-b047-420835762886,G_CONCISE_SUMMARY,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001/FDA-2017-D-4359-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Small Entitles Compliance Guide for Renderers"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:38:29,2025-05-28 03:53:06
3821f9a0-f397-44fb-9dd8-81778d77f7d2,USA-FDA,5c186175-3a45-4af1-ba2b-8be5b694d4ed,G_FAQ,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002/FDA-2018-D-2238-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""2018-125 Guidance GT for Hemophilia_7-09-2018 -508 Compliant"", ""docket_id"": ""FDA-2018-D-2238"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2238-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:30:34,2025-05-28 03:53:06
383,USA-FDA,497a87a4-7548-44d1-bec4-90549c637099,G_DETAILED_SUMMARY,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001/FDA-2017-D-4359-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Small Entitles Compliance Guide for Renderers"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:38:41,2025-05-28 03:53:06
384,USA-FDA,bbdcee6d-4df1-4c14-9c3d-00e1fb2577e5,G_FAQ,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001/FDA-2017-D-4359-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Small Entitles Compliance Guide for Renderers"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:38:49,2025-05-28 03:53:06
3842e97a-06d3-4bd1-8bd0-d5431aaeb8ad,USA-FDA,fadbe670-1ee0-40c0-bb4a-01d7960400d8,G_ACTION_ITEMS,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0080/FDA-2012-D-0080-0005/FDA-2012-D-0080-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Oversight of Positron Emission Tomography Drug Products - Questions and Answers"", ""docket_id"": ""FDA-2012-D-0080"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0080-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0080/FDA-2012-D-0080-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:32:35,2025-05-28 03:53:06
38473f38-0b3e-45cc-bbf5-c30d581295cc,SCHEDULED,023a0a1d-4680-453d-8ab6-d4cabe899c6d,FDA_ALERT,2025-05-27 00:00:04,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/023a0a1d-4680-453d-8ab6-d4cabe899c6d"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:24,2025-05-28 03:53:06
384855b3-eec0-4a0c-a083-60caf7009337,USA-FDA,2c8b5589-f18e-4a4c-b3d2-2c7c4fa70283,G_DETAILED_SUMMARY,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008/FDA-2004-D-0181-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA)"", ""docket_id"": ""FDA-2004-D-0181"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0181-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:32:22,2025-05-28 03:53:06
384e6063-aea8-451d-b59e-c490270d50db,USA-FDA,0d6e5186-dd67-4430-9c0c-d66eb15ff6e7,G_ACTION_ITEMS,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002/FDA-2011-D-0147-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Staff Demonstrating Substantial Equivalence of New Tobacco Product; Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2011-D-0147"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0147-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:30:50,2025-05-28 03:53:06
385,USA-FDA,c2e168bb-0d18-4d4e-97a4-b822fda8e534,G_ACTION_ITEMS,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001/FDA-2017-D-4359-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Small Entitles Compliance Guide for Renderers"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:38:54,2025-05-28 03:53:06
386,USA-FDA,410636c4-905d-4df9-8386-6ca389937129,G_IMPACT_ANALYSIS,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001/FDA-2017-D-4359-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Small Entitles Compliance Guide for Renderers"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:39:01,2025-05-28 03:53:06
387,USA-FDA,013768c0-d0f4-4dcf-bd6b-0e68cc198212,G_KEYWORDS,2025-05-15 19:36:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001/FDA-2017-D-4359-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Small Entitles Compliance Guide for Renderers"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:39:05,2025-05-28 03:53:06
387c6af4-1f72-4d22-8b81-83f198d82ba9,USA-FDA,3bfecee2-7580-443b-a8d5-807a95711d23,G_ACTION_ITEMS,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0196/FDA-2007-D-0196-0013/FDA-2007-D-0196-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for FDA Advisory Committee Members and FDA Staff : Voting Procedures for Advisory Committee Meetings"", ""docket_id"": ""FDA-2007-D-0196"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0196-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0196/FDA-2007-D-0196-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:00:58,2025-05-28 03:53:06
388,CAB,63e6625e-c001-454c-ab19-592dad0ca890,G_MINI_SUMMARY_IN,2025-05-15 19:39:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:39:09,2025-05-28 03:53:06
389,CAB,3fbcffd4-7ed6-43b3-b573-5b229c51fd14,G_CONCISE_SUMMARY_IN,2025-05-15 19:39:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:39:13,2025-05-28 03:53:06
38987dec-8fc5-4d5a-8bf8-bfc6331c304d,SCHEDULED,52db9bec-81bc-4c8b-abe0-cb5f83721181,DEVICE_ANALYST,2025-05-25 00:00:04,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/52db9bec-81bc-4c8b-abe0-cb5f83721181"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:23,2025-05-28 03:53:06
389e36c2-f8d8-4a7b-95ca-9a1489ffc17b,USA-FDA,7f27f4cf-fba8-46e6-bf79-47b86b8a24e3,G_DETAILED_SUMMARY,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0246/FDA-2010-D-0246-0014/FDA-2010-D-0246-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Residual Drug in Transdermal and Related Drug Delivery Systems; Guidance for Industry"", ""docket_id"": ""FDA-2010-D-0246"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0246-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0246/FDA-2010-D-0246-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:02:01,2025-05-28 03:53:06
38a0b5c5-a7cc-4d5a-8a66-f7a712142c34,USA-FDA,94fcd174-d313-4211-b67e-0af35d3d173a,G_ACTION_ITEMS,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0742/FDA-1999-D-0742-0014/FDA-1999-D-0742-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Financial Disclosure by Clinical Investigators - Draft Guidance"", ""docket_id"": ""FDA-1999-D-0742"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0742-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0742/FDA-1999-D-0742-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:47:15,2025-05-28 03:53:06
39,,5edafa8a-5d96-4a88-a460-75b2210b01e1,G_ACTION_ITEMS,2025-05-12 19:24:26,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:24:28,2025-05-28 03:53:06
390,CAB,55b32648-f8d9-4a3b-83e4-b57cdc1ad39b,G_SUMMARY_IN,2025-05-15 19:39:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:39:27,2025-05-28 03:53:06
391,CAB,69588394-d02f-4d3c-9812-717133c0ce36,G_FAQ_IN,2025-05-15 19:39:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:39:42,2025-05-28 03:53:06
391f439a-1478-4d23-8648-6d598876afb7,USA-FDA,89314aee-acee-491d-86c9-9bc1e7098877,G_CONCISE_SUMMARY,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002/FDA-1997-D-0380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation; Guidance"", ""docket_id"": ""FDA-1997-D-0380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:31:13,2025-05-28 03:53:06
392,CAB,6fd50547-8a6d-47b3-b668-9198ae6ab5c6,G_ACTION_ITEMS_IN,2025-05-15 19:39:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:39:51,2025-05-28 03:53:06
393,CAB,8a5f696b-4d9e-4788-9f34-26ee15155eb9,G_IMPACT_ANALYSIS_IN,2025-05-15 19:39:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:40:01,2025-05-28 03:53:06
394,CAB,43b8a60b-3d30-4dc5-b83b-4d467b02c661,G_KEYWORDS,2025-05-15 19:39:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:40:05,2025-05-28 03:53:06
395,CAB,6b04be2f-bdd4-41ad-8d0b-7dd7e238dfda,G_TRANSLATE,2025-05-15 19:39:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2005-D-0027-0016-guidance.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2005-D-0027-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b877e90c-3bc0-415d-9d1c-32618d99f246""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b877e90c-3bc0-415d-9d1c-32618d99f246/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 02:40:52,2025-05-28 03:53:06
3951aa3b-6d46-4b24-af24-28ecb1db54b9,USA-FDA,b50a19e3-5e17-4c09-adf8-848144c36f98,G_CONCISE_SUMMARY,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009/FDA-2011-D-0398-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Questions and Answers Regarding The Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:30:49,2025-05-28 03:53:06
396,USA-FDA,27b563ab-5538-4e94-8360-55ccdf77167d,G_MINI_SUMMARY,2025-05-15 19:46:54,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001/FDA-2017-D-5478-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""MRCT Draft FDA Guidance Return of Aggregate Results"", ""docket_id"": ""FDA-2017-D-5478"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5478-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:46:58,2025-05-28 03:53:06
397,USA-FDA,9112987f-0dd6-4021-a134-259ab009f42b,G_CONCISE_SUMMARY,2025-05-15 19:46:54,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001/FDA-2017-D-5478-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""MRCT Draft FDA Guidance Return of Aggregate Results"", ""docket_id"": ""FDA-2017-D-5478"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5478-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-16 02:47:03,2025-05-28 03:53:06
398,SCHEDULED,14aa8ba2-0462-4fe0-824d-8c0b88188d92,FDA_ALERT,2025-05-15 19:59:42,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-04-16""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/fda_alert/14aa8ba2-0462-4fe0-824d-8c0b88188d92"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-16 03:01:11,2025-05-28 03:53:06
39bd7edb-d1e6-40ef-baf8-03e516300de3,USA-FDA,48bd19f8-3e1b-4c78-bedb-cedb320c80c9,G_CONCISE_SUMMARY,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002/FDA-2011-D-0674-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry FDA Records Access Authority under Section 414 and 704 of the Federal Food, Drug, & Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0674"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0674-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:20,2025-05-28 03:53:06
3a2faceb-cc50-4020-8e7c-bfffcc1a0fc7,USA-FDA,2575c4c0-2f28-47a3-99ed-9de5c28396ea,G_MINI_SUMMARY,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002/FDA-2010-D-0395-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Adminstration Staff Recommendation for Premarket Notification for Lamotrigine and Zonisamide Assays"", ""docket_id"": ""FDA-2010-D-0395"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0395-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:00:09,2025-05-28 03:53:06
3a36e7fa-0be8-4e39-afb2-f2cadfb21589,USA-FDA,058748f6-dd5b-4a92-929e-7a52dbb61870,G_KEYWORDS,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002/FDA-2012-D-0022-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Direct-to-Consumer Television Advertisements, etc."", ""docket_id"": ""FDA-2012-D-0022"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0022-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:30:51,2025-05-28 03:53:06
3a38e0e9-0c9d-411a-ad58-d2612ccb4c1f,USA-FDA,89798d1e-b86c-4b56-8584-41a296c24004,G_IMPACT_ANALYSIS,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1924/FDA-2020-D-1924-0001/FDA-2020-D-1924-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry:  Dear Manufacturer Letter Regarding Front-of-Package Symbols"", ""docket_id"": ""FDA-2020-D-1924"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1924-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1924/FDA-2020-D-1924-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:45:35,2025-05-28 03:53:06
3a6126ef-8062-4ba4-852a-5e1975912bfa,USA-FDA,14303b94-4ccd-4330-9039-88a8c12ceeff,G_DETAILED_SUMMARY,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0298/FDA-2006-D-0298-0005/FDA-2006-D-0298-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff: Whole Grain Label Statements"", ""docket_id"": ""FDA-2006-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0298-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0298/FDA-2006-D-0298-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:16:48,2025-05-28 03:53:06
3b1f863e-8fed-4007-829a-ac4f6381df20,SCHEDULED,64e8a509-c805-478d-bedb-e3e89172903a,FDA_ALERT,2025-05-29 00:00:04,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/64e8a509-c805-478d-bedb-e3e89172903a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:19,2025-05-29 00:00:19
3b51575f-0ed6-40ec-a5cd-a6be16ba3279,USA-FDA,a1ae7ef1-9ff8-4b75-8e66-f1f992717766,G_DETAILED_SUMMARY,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0742/FDA-1999-D-0742-0014/FDA-1999-D-0742-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Financial Disclosure by Clinical Investigators - Draft Guidance"", ""docket_id"": ""FDA-1999-D-0742"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0742-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0742/FDA-1999-D-0742-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:46:33,2025-05-28 03:53:06
3bb35870-362a-4e6c-83af-c2e8157d4f16,QUEUE,968c7c01-fb02-434d-9911-174101584bbf,G_TRANSLATE,2025-05-30 03:31:01,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""c_986569 (9).pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/968c7c01-fb02-434d-9911-174101584bbf/c_986569 (9).pdf.pdf"", ""doc_title"": ""c_986569 (9).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/968c7c01-fb02-434d-9911-174101584bbf"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 03:31:06,2025-05-30 03:31:06
3bf2cd19-dfec-4de9-8c2b-0f5842b4359f,USA-FDA,d81aa51a-e4c3-4d74-87c0-6ac3d678781f,G_CONCISE_SUMMARY,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002/FDA-2011-D-0577-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Factors To Consider When Making Benefit-Risk Determinations in Medical Device Premarket Review"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:47,2025-05-28 03:53:06
3c030805-4ff5-4db0-86d7-0fb1f519f6fa,USA-FDA,19859053-3558-4e25-93d3-1deb28606e35,G_KEYWORDS,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011/FDA-2014-D-2300-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Drug Effects on the Ability to Operate a Motor Vehicle\nGuidance for Industry"", ""docket_id"": ""FDA-2014-D-2300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-2300-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:32:41,2025-05-28 03:53:06
3c2c28b8-7e3e-40bf-ba4e-f668e4e1c23e,USA-FDA,4e069c1d-2742-425f-b7d9-2b86272b8ec4,G_MINI_SUMMARY,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038/FDA-2008-D-0406-0038-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs; Frequently Asked Questions - Statement of Investigator (Form FDA 1572)"", ""docket_id"": ""FDA-2008-D-0406"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0406-0038""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:17:04,2025-05-28 03:53:06
3c9e539f-5546-456e-8581-919f74373ff0,USA-FDA,718fb798-7773-45a6-844d-52847a4349e3,G_ACTION_ITEMS,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0358/FDA-2014-D-1525-0358-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application"", ""docket_id"": ""FDA-2014-D-1525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1525-0358""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0358"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:02:08,2025-05-28 03:53:06
3cb03cd1-d99e-4503-9f2f-838bc8e4f116,USA-FDA,2ccbd98e-bfe5-45a1-99d4-3702a2a5c5dc,G_FAQ,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0169/FDA-2013-D-0169-0002/FDA-2013-D-0169-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Review Staff: Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling"", ""docket_id"": ""FDA-2013-D-0169"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0169-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0169/FDA-2013-D-0169-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:45:32,2025-05-28 03:53:06
3d771d40-1ee8-4358-887b-19fa313d7388,SCHEDULED,38711726-4840-4a12-a2ec-e8eb21594e74,DEVICE_ANALYST,2025-06-02 00:00:04,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/38711726-4840-4a12-a2ec-e8eb21594e74"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:06,2025-06-02 00:00:06
3d9e46d8-10c0-49a9-aca9-25cbe815d975,USA-FDA,fb6d6c4e-962b-46ec-bb8c-7a192ec286ee,G_IMPACT_ANALYSIS,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002/FDA-2013-D-0168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Recommendations for Labeling Medical Products to Inform Users the Product or Product Container Is Not Made With Natural Rubber Latex"", ""docket_id"": ""FDA-2013-D-0168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:17:09,2025-05-28 03:53:06
3ddf26d7-7319-4940-8b52-34f87863b598,SCHEDULED,5ac7af3d-514f-4305-a0dc-3ab5368ea470,FDA_ALERT,2025-05-25 00:00:04,30,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/fda_alert/5ac7af3d-514f-4305-a0dc-3ab5368ea470"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:30,2025-05-28 03:53:06
3de277bf-7ed4-4ea7-adf9-654ecf39b6ed,USA-FDA,7eb546cf-a3d9-4cb3-af0d-0099dabc5664,G_MINI_SUMMARY,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0212/FDA-2009-D-0212-0025/FDA-2009-D-0212-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting - Guidance for Industry"", ""docket_id"": ""FDA-2009-D-0212"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0212-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0212/FDA-2009-D-0212-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:47:02,2025-05-28 03:53:06
3e001cc9-633d-4e6a-b884-5398012f8917,USA-FDA,39a266df-3828-40ae-94a4-de071a473482,G_IMPACT_ANALYSIS,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005/FDA-2012-D-0419-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for Use in Companion Animals"", ""docket_id"": ""FDA-2012-D-0419"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0419-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:31:49,2025-05-28 03:53:06
3e1a9d7d-e792-43d7-8fa0-f4e8b3d0fd57,USA-FDA,d592d05b-47cc-4293-8c33-0b53aab6c5dc,G_IMPACT_ANALYSIS,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1304/FDA-1999-D-1304-0002/FDA-1999-D-1304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Possible Dioxin/PCB Contamination of Drug and Biological Products"", ""docket_id"": ""FDA-1999-D-1304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1304/FDA-1999-D-1304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:32:03,2025-05-28 03:53:06
3e87d8f2-05dd-4b6c-9471-213c1f33628b,USA-FDA,d828462e-2c7a-4f21-8e47-33430bb3cfcc,G_IMPACT_ANALYSIS,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0096/FDA-2012-D-0096-0002/FDA-2012-D-0096-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations"", ""docket_id"": ""FDA-2012-D-0096"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0096-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0096/FDA-2012-D-0096-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:47:13,2025-05-28 03:53:06
3e9b522b-d00b-4237-8438-abac2a3adb1e,USA-FDA,7ef566f1-600f-4a34-9f3c-73b296300244,G_ACTION_ITEMS,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002/FDA-2011-D-0398-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:31:36,2025-05-28 03:53:06
3eb37cb9-5833-4648-a4b3-f177865be64a,CAB,a99eff47-edc1-49cd-9e5e-0d762f57ed04,G_TRANSLATE,2025-05-20 17:03:42,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__to_language__"": ""English""}","{""tilte"": ""Rapporto_esplicativo_revisione_ordinanze.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/e3cb8c44-0dbd-45b0-864d-6032ea109472/Rapporto_esplicativo_revisione_ordinanze.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""51b62d2e-ed87-4d5b-bcb8-387d08a21028""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/51b62d2e-ed87-4d5b-bcb8-387d08a21028/English"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:04:19,2025-05-28 03:53:06
3ec6cc2c-261b-4fa5-ad9d-9b5287cb63e4,USA-FDA,f8933e3a-55fc-49de-ab27-81deaf058032,G_ACTION_ITEMS,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0433/FDA-2012-D-0433-0002/FDA-2012-D-0433-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""mHealth Regulatory Coalition (Epstein Becker & Green) - Guidance"", ""docket_id"": ""FDA-2012-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0433-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0433/FDA-2012-D-0433-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:15:46,2025-05-28 03:53:06
3ed84bad-7c85-45d4-a3a1-b338998c9df1,USA-FDA,38fdce4f-dbda-401b-9cc0-2a8740d39c03,G_MINI_SUMMARY,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002/FDA-2012-D-0544-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Toll Free Number Labeling and Related Requirements for Over the Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide"", ""docket_id"": ""FDA-2012-D-0544"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0544-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:30:08,2025-05-28 03:53:06
3f08f015-2f33-48fc-be03-49d8c7f9813a,USA-FDA,d78af2e3-a02f-45d6-87f2-b507e6941d17,G_MINI_SUMMARY,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1439/FDA-2014-D-1439-0004/FDA-2014-D-1439-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Critical Path Innovation Meetings; Guidance for Industry"", ""docket_id"": ""FDA-2014-D-1439"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1439-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1439/FDA-2014-D-1439-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:31:14,2025-05-28 03:53:06
3f247a1c-a2f1-4b41-915f-54d271247288,SCHEDULED,3d6bcc39-5af1-435c-ae06-04bf17ae39ad,DEVICE_ANALYST,2025-05-28 00:00:05,32,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/device_analyst/3d6bcc39-5af1-435c-ae06-04bf17ae39ad"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:33,2025-05-28 03:53:06
3f316647-a291-4a76-9ae5-ae62ed85d566,CAB,1f93efb9-5ccb-4606-a572-53f5004f107c,G_ACTION_ITEMS_IN,2025-05-20 09:28:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2023-N-4225-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""be71a183-8124-4a8f-984c-ce1233023d0a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/be71a183-8124-4a8f-984c-ce1233023d0a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:28:37,2025-05-28 03:53:06
3f36b7ea-4860-4cb4-acd0-1822e5cc3b88,USA-FDA,74be4277-7841-45d8-906d-2f415f611f87,G_IMPACT_ANALYSIS,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1935/FDA-2020-D-1935-0001/FDA-2020-D-1935-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 100.550 Status and Responsibilities of Contract Sterilizers Engaged in the Sterilization of Drugs and Devices"", ""docket_id"": ""FDA-2020-D-1935"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1935-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1935/FDA-2020-D-1935-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:46:12,2025-05-28 03:53:06
3f680171-21b2-4761-9860-dc7c3749c8bd,USA-FDA,65e9c945-8405-48ab-a59f-5eca77db867d,G_FAQ,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0730/FDA-2013-N-0730-0007/FDA-2013-N-0730-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for Industry: Submitting Requests under 21 CFR 170.39 Threshold of Regulation for Substances Used in Food-Contact Articles"", ""docket_id"": ""FDA-2013-N-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-0730-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0730/FDA-2013-N-0730-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:15:27,2025-05-28 03:53:06
3f99ba4a-73cc-4886-a76a-8c4397825a0f,USA-FDA,bd408c1e-93d9-4f14-bcd1-f4575df037d6,G_ACTION_ITEMS,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001/FDA-2020-D-1397-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Q3A Impurities in New Drug Substances"", ""docket_id"": ""FDA-2020-D-1397"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1397-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:45:43,2025-05-28 03:53:06
3fab6609-8f7c-491e-8bf8-c3142df013e3,USA-FDA,b48dbe4f-681b-4e0c-aec8-563d98f53b8a,G_MINI_SUMMARY,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0814/FDA-2013-D-0814-0002/FDA-2013-D-0814-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Pediatric Study Plans:  Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans"", ""docket_id"": ""FDA-2013-D-0814"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0814-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0814/FDA-2013-D-0814-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:45:52,2025-05-28 03:53:06
3fb186d4-8070-47b7-b6fa-02a2ad932ce4,USA-FDA,1bbe8137-aa15-42fd-8cac-e5629fe3d055,G_FAQ,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0300/FDA-2004-D-0300-0005/FDA-2004-D-0300-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Quality Systems Approach to Pharmaceutical CGMP Regulations"", ""docket_id"": ""FDA-2004-D-0300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0300-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0300/FDA-2004-D-0300-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:00:54,2025-05-28 03:53:06
3fccb7a5-167f-4cfa-a160-83d779be64d9,USA-FDA,3c3a9f1f-e45a-4419-84a0-d3caff4e715d,G_DETAILED_SUMMARY,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005/FDA-2012-D-0419-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for Use in Companion Animals"", ""docket_id"": ""FDA-2012-D-0419"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0419-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:31:10,2025-05-28 03:53:06
3fd0ed53-a3d2-4bb8-ac06-37032782a1cf,USA-FDA,a4807dcb-ad1b-49b8-a2e7-390a7cda0462,G_KEYWORDS,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002/FDA-2017-D-5525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Statistical Approaches to Evaluate Analytical Similarity Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:32:28,2025-05-28 03:53:06
3fe37600-7805-47f7-932e-404211a71a73,USA-FDA,d571f58a-af79-490a-bff6-5d796d27200a,G_IMPACT_ANALYSIS,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001/FDA-2020-D-1945-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a)"", ""docket_id"": ""FDA-2020-D-1945"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1945-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:31:00,2025-05-28 03:53:06
4,,4f4ddcdf-25da-481c-9b15-03e2b5191ddb,G_FAQ,2025-05-09 01:50:42,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 08:51:05,2025-05-28 03:53:06
40,,abe50318-992e-489e-8054-af6ab54d30c3,G_IMPACT_ANALYSIS,2025-05-12 19:24:37,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:24:38,2025-05-28 03:53:06
4014ad76-5d77-49ba-841e-5aec8ad629d1,USA-FDA,b99dd70d-cd5d-4792-a136-e35e91bef264,G_FAQ,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011/FDA-1997-D-0444-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance on FDA Approval of New Animal Drugs for Minor Uses and for Minor Species; Guidance Document (Revised May 29, 2008)"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:00:45,2025-05-28 03:53:06
4015e337-8a90-4458-a5fa-925143ac5036,Queue,8fd65a0b-3fb6-49f2-9ec4-fb669cf3ab9e,G_TRANSLATE,2025-05-30 03:23:21,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""Provisions for In-vitro Diagnostic Reagent Registration and Filing.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/8fd65a0b-3fb6-49f2-9ec4-fb669cf3ab9e/Provisions for In-vitro Diagnostic Reagent Registration and Filing.pdf.pdf"", ""doc_title"": ""Provisions for In-vitro Diagnostic Reagent Registration and Filing.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/8fd65a0b-3fb6-49f2-9ec4-fb669cf3ab9e"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 03:23:20,2025-05-30 03:23:20
40380603-d4be-403b-a209-2bccedd188b8,USA-FDA,c59f1f77-8ef9-445d-978d-60fa62d5bc60,G_CONCISE_SUMMARY,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001/FDA-2020-D-1961-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling"", ""docket_id"": ""FDA-2020-D-1961"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1961-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:31:13,2025-05-28 03:53:06
404b3c69-84c4-4ca9-adc2-2a39222f3275,USA-FDA,f2c13ec9-8028-4753-b1a7-0cb6990150ea,G_CONCISE_SUMMARY,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001/FDA-2020-D-2015-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Devices Without a Premarket Notification (510(k)) or an Approved Premarket Approval Application (PMA) REVOKED DOCUMENT"", ""docket_id"": ""FDA-2020-D-2015"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-2015-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:30,2025-05-28 03:53:06
404ba2ff-7f81-4954-9751-94d5bc6fee9c,CAB,e8f23fb4-50a4-4800-9979-862728130631,G_CONCISE_SUMMARY_IN,2025-05-20 12:42:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2018-N-3233-0006.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2018-N-3233-0006_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""3f21331b-4399-4219-aa7e-0a5cb7a4ba33""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3f21331b-4399-4219-aa7e-0a5cb7a4ba33"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:43:13,2025-05-28 03:53:06
404e38e1-4f8c-439e-a6a0-9d4e922715bc,USA-FDA,81748f5c-8e66-4a8d-b3fb-c5e237f60aa0,G_FAQ,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0586/FDA-2011-D-0586-0002/FDA-2011-D-0586-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Standards for Clinical Trial Imaging Endpoints; Draft Guidance Document"", ""docket_id"": ""FDA-2011-D-0586"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0586-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0586/FDA-2011-D-0586-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:01:32,2025-05-28 03:53:06
4082f174-ec3b-4501-a0d6-205a6a3206f5,USA-FDA,ad415ade-cc67-471c-a6a3-a32105b73254,G_IMPACT_ANALYSIS,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008/FDA-2018-D-2936-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; CDRH Standard Operating Procedures for the Identification and Evaluation of Candidate Consensus Standards for Recognition"", ""docket_id"": ""FDA-2018-D-2936"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2936-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:00:44,2025-05-28 03:53:06
40c81c34-1cbe-4fba-bdc8-74313e8caa4a,USA-FDA,7ecd2f94-a3e2-4a6f-8a69-90799ec10f98,G_ACTION_ITEMS,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001/FDA-2018-D-3551-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Impact of Certain Provisions of Revised Common Rule on FDA-Regulated Clinical Investigations; Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2018-D-3551"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3551-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:30:41,2025-05-28 03:53:06
40d7c624-e518-4eec-bada-5e95c1646e3b,USA-FDA,921a021d-7529-48bf-84d2-cffdf79d8a91,G_CONCISE_SUMMARY,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009/FDA-2016-D-2569-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""01 Final Guidance for Industry - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals-Questions and Answers"", ""docket_id"": ""FDA-2016-D-2569"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2569-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:32:40,2025-05-28 03:53:06
40dcf202-f548-4225-bfb3-92de62c11fb5,USA-FDA,a3ec3929-89ee-4030-b64d-79025c4be025,G_ACTION_ITEMS,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0183/FDA-2004-D-0183-0003/FDA-2004-D-0183-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System Guidance for Industry\nand FDA Staff"", ""docket_id"": ""FDA-2004-D-0183"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0183-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0183/FDA-2004-D-0183-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:47:16,2025-05-28 03:53:06
41,,212259fb-a9ff-460d-82b1-4d22efb58f7b,G_MINI_SUMMARY,2025-05-12 19:24:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:24:58,2025-05-28 03:53:06
411ea6c6-557b-459b-9a03-31f286a6d076,USA-FDA,76a1d00b-fe9d-4db5-939c-2103da497b9f,G_MINI_SUMMARY,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1189/FDA-2018-D-1189-0002/FDA-2018-D-1189-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Concentrated Caffeine in Dietary Supplements: Guidance for Industry"", ""docket_id"": ""FDA-2018-D-1189"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-1189-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1189/FDA-2018-D-1189-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:33:01,2025-05-28 03:53:06
41243a45-ac40-470a-9821-d6a4b48aa668,USA-FDA,12051b2d-ae30-4bf1-9669-7f5d5e10025b,G_IMPACT_ANALYSIS,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0563/FDA-1996-N-0270-0563-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations"", ""docket_id"": ""FDA-1996-N-0270"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1996-N-0270-0563""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0563"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:31:01,2025-05-28 03:53:06
41359e5f-a964-4d0a-af78-cbb274703ee9,USA-FDA,3eb9c2c8-2470-41f1-995e-ef931958a61d,G_CONCISE_SUMMARY,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002/FDA-2018-D-2238-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""2018-125 Guidance GT for Hemophilia_7-09-2018 -508 Compliant"", ""docket_id"": ""FDA-2018-D-2238"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2238-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:30:14,2025-05-28 03:53:06
413606c8-718e-4454-a6ff-2000f28e9799,USA-FDA,3f20ea36-a6a9-4fbe-b969-41d5997d04e2,G_ACTION_ITEMS,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013/FDA-2009-D-0490-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff:  Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2009-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0490-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:48:15,2025-05-28 03:53:06
413a8654-e038-43c8-baba-cc29201b40b9,USA-FDA,986a7482-8afd-451d-8597-ddce806d5230,G_MINI_SUMMARY,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0364/FDA-2007-D-0364-0014/FDA-2007-D-0364-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Indexing Structured Product Labeling"", ""docket_id"": ""FDA-2007-D-0364"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0364-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0364/FDA-2007-D-0364-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:01:29,2025-05-28 03:53:06
414757bf-18a6-4009-ae48-59a3e77ea46b,USA-FDA,3b098fa9-fc49-47e7-be79-5d2180769756,G_CONCISE_SUMMARY,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008/FDA-2018-D-2936-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; CDRH Standard Operating Procedures for the Identification and Evaluation of Candidate Consensus Standards for Recognition"", ""docket_id"": ""FDA-2018-D-2936"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2936-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:00:14,2025-05-28 03:53:06
4181c2ad-a616-4734-8e61-c650f2bb5ab4,USA-FDA,68ac1852-6ffc-4405-94b6-cc4173e34f4e,G_MINI_SUMMARY,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0166/FDA-2010-D-0166-0006/FDA-2010-D-0166-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods (VICH GL-48)"", ""docket_id"": ""FDA-2010-D-0166"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0166-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0166/FDA-2010-D-0166-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:15:37,2025-05-28 03:53:06
418c45ec-63a2-45ac-b1bb-b88b33caf023,USA-FDA,2eb78c37-5539-494a-b1f3-40d88811236b,G_DETAILED_SUMMARY,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0712/FDA-2016-D-0712-0002/FDA-2016-D-0712-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported  Outcome, for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use DRAFT GUIDANCE"", ""docket_id"": ""FDA-2016-D-0712"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0712-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0712/FDA-2016-D-0712-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:16:19,2025-05-28 03:53:06
41a77e75-d316-4b22-bc5e-d0d3e05a56b0,USA-FDA,bcf06cc7-e474-42d5-8394-1f6755e9f7a0,G_FAQ,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1984-D-0020/FDA-1984-D-0020-0002/FDA-1984-D-0020-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics"", ""docket_id"": ""FDA-1984-D-0020"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1984-D-0020-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1984-D-0020/FDA-1984-D-0020-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:17:38,2025-05-28 03:53:06
41e4eca1-d29b-44d2-a45a-5ed1c24cd529,USA-FDA,57cd5a58-3eed-4354-a6f7-e690b3ef3b08,G_FAQ,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0487/FDA-2007-D-0487-0005/FDA-2007-D-0487-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec 110.310 Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002"", ""docket_id"": ""FDA-2007-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0487-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0487/FDA-2007-D-0487-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:01:12,2025-05-28 03:53:06
41f9fa93-2338-4ae1-ad13-089c7882be79,USA-FDA,c3291354-e756-4264-ac09-f54b072caaa1,G_MINI_SUMMARY,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0616/FDA-2010-D-0616-0020/FDA-2010-D-0616-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Codevelopment of Two or More New Investigational Drugs for Use in Combination"", ""docket_id"": ""FDA-2010-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0616-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0616/FDA-2010-D-0616-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:01:45,2025-05-28 03:53:06
41fe4e4d-5765-48f3-b1ea-30969c809d0e,USA-FDA,143c5058-b6a2-4c2d-9cd0-20d40a92f060,G_KEYWORDS,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001/FDA-2020-D-1398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; FDA Approval of New Animal Drugs For Minor Uses and for Minor Species; #61"", ""docket_id"": ""FDA-2020-D-1398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:47:22,2025-05-28 03:53:06
42,,1b7d5399-bbdc-4cac-8f5a-bc65ad4bc355,G_CONCISE_SUMMARY,2025-05-12 19:25:00,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:25:02,2025-05-28 03:53:06
422d55ba-b3e9-4c85-8b48-80c709c61570,USA-FDA,45b37a17-45cb-41b1-a1ca-0a3fbe043eb3,G_KEYWORDS,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022/FDA-1998-N-0050-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 540.375 Canned Salmon - Adulteration Involving Decomposition Withdrawn 3-22-2010"", ""docket_id"": ""FDA-1998-N-0050"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-N-0050-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:31,2025-05-28 03:53:06
4233712c-3034-449f-ac3b-099803174609,USA-FDA,0afd0649-c02c-4bf7-91b7-336289766f29,G_FAQ,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0188/FDA-1999-D-0188-0002/FDA-1999-D-0188-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Effect of Anthelmintics : Specific Recommendations for Ovine  VICH GL13 -  Final Guidance 96"", ""docket_id"": ""FDA-1999-D-0188"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0188-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0188/FDA-1999-D-0188-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:17:03,2025-05-28 03:53:06
4257e3be-8f86-4098-9348-a4b64b29818a,USA-FDA,9a946301-6b15-42a6-9fc5-7dc9f16da5e4,G_ACTION_ITEMS,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5960/FDA-2017-D-5960-0002/FDA-2017-D-5960-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5960"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5960-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5960/FDA-2017-D-5960-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:31:09,2025-05-28 03:53:06
4276e619-c5d1-4a32-98d2-4658f13639cd,USA-FDA,c9c031bc-8460-4041-9854-18161cc8c924,G_ACTION_ITEMS,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009/FDA-2016-D-2569-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""01 Final Guidance for Industry - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals-Questions and Answers"", ""docket_id"": ""FDA-2016-D-2569"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2569-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:33:19,2025-05-28 03:53:06
428e6bae-88a4-46a8-bf84-58e8d45c3c6b,USA-FDA,bac5bae3-0c07-483b-ab68-afb02d0563cb,G_CONCISE_SUMMARY,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022/FDA-1998-N-0050-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 540.375 Canned Salmon - Adulteration Involving Decomposition Withdrawn 3-22-2010"", ""docket_id"": ""FDA-1998-N-0050"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-N-0050-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:12,2025-05-28 03:53:06
43,,d2a7a93e-edda-446c-8f61-4cfdeec5549b,G_DETAILED_SUMMARY,2025-05-12 19:25:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:25:10,2025-05-28 03:53:06
438142bf-0114-46ab-928f-b0b48cbff375,USA-FDA,4fef2e7f-ebc8-49d0-a7f9-08fcc7e2a351,G_FAQ,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002/FDA-2009-D-0198-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain Cochineal Extract and Carmine"", ""docket_id"": ""FDA-2009-D-0198"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0198-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:53,2025-05-28 03:53:06
44,,686575c6-b069-4abb-871d-877f5180e66d,G_FAQ,2025-05-12 19:25:26,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:25:28,2025-05-28 03:53:06
44372292-7ac8-4a06-a4c2-6227f0ac16bf,USA-FDA,65b69617-6788-41bc-ba79-9752441b2c7e,G_FAQ,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0138/FDA-2001-D-0138-0003/FDA-2001-D-0138-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Exemptions from the Warning Label Requirement for Juice - Recommendations for Effectively Achieving a 5 -Log Pathogen Reduction"", ""docket_id"": ""FDA-2001-D-0138"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0138-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0138/FDA-2001-D-0138-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:45:27,2025-05-28 03:53:06
445e68de-0570-49ec-a548-1e5ec6cf1f1c,USA-FDA,5d5e6946-76af-420a-bd74-8415a5c06991,G_MINI_SUMMARY,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0386/FDA-2009-D-0386-0010/FDA-2009-D-0386-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection, etc., of Human Papillomaviruses"", ""docket_id"": ""FDA-2009-D-0386"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0386-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0386/FDA-2009-D-0386-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:30:07,2025-05-28 03:53:06
4477cb29-10f2-4392-9894-a9e94d2ab591,USA-FDA,301a196c-df89-4318-9fc7-5880e91473ec,G_IMPACT_ANALYSIS,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002/FDA-2013-D-0743-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Reporting for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0743"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0743-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:16:30,2025-05-28 03:53:06
447ee7ae-e46b-4d84-bc33-4fac18741b1d,USA-FDA,0faab654-a6c5-4e78-9ce1-99cd8338dc7a,G_KEYWORDS,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002/FDA-2012-D-0544-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Toll Free Number Labeling and Related Requirements for Over the Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide"", ""docket_id"": ""FDA-2012-D-0544"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0544-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:30:40,2025-05-28 03:53:06
44a1ed30-0cd1-4161-8389-5d8d640af9ba,USA-FDA,c144934f-9f62-468e-a456-2007f7e612c7,G_MINI_SUMMARY,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001/FDA-2020-D-1950-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 394.500 Importation of Television Products, Microwave Ovens, and Inherent Class I Laser Products for Investigation and Evaluation during Design Development"", ""docket_id"": ""FDA-2020-D-1950"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1950-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:47:26,2025-05-28 03:53:06
44a652d4-d729-4009-9d59-0f434209dd06,USA-FDA,5193fd9b-2984-496b-9348-c9236db10d4a,G_MINI_SUMMARY,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002/FDA-2011-D-0464-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Low Glucose Suspend (LGS) Device Systems - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0464-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:31:19,2025-05-28 03:53:06
44a6b5c8-18d9-451a-b3c4-bf7dc38a4c51,USA-FDA,f8d73e25-00a9-4364-8c6d-870bd1ac7e98,G_ACTION_ITEMS,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0814/FDA-2013-D-0814-0002/FDA-2013-D-0814-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Pediatric Study Plans:  Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans"", ""docket_id"": ""FDA-2013-D-0814"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0814-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0814/FDA-2013-D-0814-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:46:24,2025-05-28 03:53:06
44a6e9ee-bb24-41f2-bde7-ef914f6c52fe,USA-FDA,84ff76ba-d910-4f0c-ab26-99a09da4f22e,G_DETAILED_SUMMARY,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011/FDA-2014-D-2300-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Drug Effects on the Ability to Operate a Motor Vehicle\nGuidance for Industry"", ""docket_id"": ""FDA-2014-D-2300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-2300-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:32:11,2025-05-28 03:53:06
44ec2f0f-2bd7-4750-8ef3-940c7959d83e,SCHEDULED,348ec1e7-b4c2-4b34-85a4-89875c20e69e,FDA_ALERT,2025-06-01 00:00:04,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/348ec1e7-b4c2-4b34-85a4-89875c20e69e"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:19,2025-06-01 00:00:19
45,,40771d97-48c2-4b81-a826-d075b24e37dd,G_ACTION_ITEMS,2025-05-12 19:25:38,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:25:40,2025-05-28 03:53:06
4552a234-5ccb-4b8f-b30c-046c06c0688d,USA-FDA,f88f78f7-b77f-4319-a888-69abd369d84f,G_ACTION_ITEMS,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002/FDA-2002-P-0302-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices"", ""docket_id"": ""FDA-2002-P-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-P-0302-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:30:45,2025-05-28 03:53:06
45539e7e-88ca-4b4a-af84-c9efac47944f,USA-FDA,4f129b1c-45fe-4f15-be03-fec307e028bf,G_DETAILED_SUMMARY,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1304/FDA-1999-D-1304-0002/FDA-1999-D-1304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Possible Dioxin/PCB Contamination of Drug and Biological Products"", ""docket_id"": ""FDA-1999-D-1304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1304/FDA-1999-D-1304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:31:45,2025-05-28 03:53:06
455c55d9-4a8c-4365-bcec-dc6dea8ce088,USA-FDA,5e83ff2f-c272-457d-a344-74d0e85c5c1a,G_DETAILED_SUMMARY,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1362/FDA-2020-D-1362-0001/FDA-2020-D-1362-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VI GRAS Notices"", ""docket_id"": ""FDA-2020-D-1362"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1362-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1362/FDA-2020-D-1362-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:30:16,2025-05-28 03:53:06
45698830-a5c2-42a9-aca4-975789a7aca4,USA-FDA,f430a247-0030-405f-a631-2447017bc1db,G_CONCISE_SUMMARY,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002/FDA-2011-D-0480-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products"", ""docket_id"": ""FDA-2011-D-0480"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0480-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:30:13,2025-05-28 03:53:06
45b0719a-a55f-418e-a8ea-762ce8e5ddee,QUEUE,bc49bc23-d66f-427f-86d0-2ef223a1752e,G_IMPACT_ANALYSIS_USER,2025-05-20 10:43:35,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__doc_title__"": ""FDA-2024-N-1111-0001_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/bc49bc23-d66f-427f-86d0-2ef223a1752e/SRC/bc49bc23-d66f-427f-86d0-2ef223a1752e.pdf"", ""doc_title"": ""FDA-2024-N-1111-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/bc49bc23-d66f-427f-86d0-2ef223a1752e/DEST/impact_analysis.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:43:43,2025-05-28 03:53:06
45d248f6-bae7-4f06-b836-b52bffcb7208,USA-FDA,bded1e2d-5e58-43da-a12b-c2589aac7554,G_MINI_SUMMARY,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1529/FDA-2013-N-1529-0023/FDA-2013-N-1529-0023-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""03 Reference 2 Open Public Hearings Guidance - Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: The Open Public Hearing at FDA Advisory Committee Meetings"", ""docket_id"": ""FDA-2013-N-1529"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1529-0023""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1529/FDA-2013-N-1529-0023"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:31:54,2025-05-28 03:53:06
45fec5f0-5b29-4b97-ac7e-46566d13ed24,SCHEDULED,1f94f04b-e90b-4072-ba2e-4b582c2e006f,FDA_ALERT,2025-05-25 00:00:04,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/1f94f04b-e90b-4072-ba2e-4b582c2e006f"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:10,2025-05-28 03:53:06
46,,ec8c3875-9427-4df0-9e70-190756eac5ad,G_IMPACT_ANALYSIS,2025-05-12 19:25:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147/FDA-2015-D-1211-0147-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0147""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0147"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:25:48,2025-05-28 03:53:06
46036cf6-8e3a-4528-a9de-cf35372cc1c4,USA-FDA,35583d6a-5e6f-4b77-9d06-e82f92063f54,G_MINI_SUMMARY,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0002/FDA-2011-D-0847-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Humanitarian Use Device Designations"", ""docket_id"": ""FDA-2011-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0847-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:45:08,2025-05-28 03:53:06
4608f826-dc3d-4095-a998-556743c6fa7d,USA-FDA,d72306b4-bad9-4cad-8204-cbd3e95c379a,G_CONCISE_SUMMARY,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002/FDA-2014-D-1891-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD"", ""docket_id"": ""FDA-2014-D-1891"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1891-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:15:54,2025-05-28 03:53:06
46171548-594f-4675-904f-d1161a174938,USA-FDA,e112c175-f8b1-46d5-9233-d49dd6464d83,G_MINI_SUMMARY,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017/FDA-2010-D-0426-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Bar Code Label Requirements�Questions and Answers"", ""docket_id"": ""FDA-2010-D-0426"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0426-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:33:02,2025-05-28 03:53:06
462d2960-a302-48ff-9683-e1035c4c59c9,USA-FDA,b6062ad4-ae2d-428c-928a-01b21137c89a,G_DETAILED_SUMMARY,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001/FDA-2020-D-1977-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures"", ""docket_id"": ""FDA-2020-D-1977"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1977-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:16:34,2025-05-28 03:53:06
4636cefd-6244-4b8f-bb5f-ad1632dd1839,USA-FDA,dfb3d354-0688-4269-8666-1d7c6ce1ec56,G_MINI_SUMMARY,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0125/FDA-2013-N-0125-0025/FDA-2013-N-0125-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Alternative to Certain Prescription Device Labeling Requirements"", ""docket_id"": ""FDA-2013-N-0125"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-0125-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0125/FDA-2013-N-0125-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:00:10,2025-05-28 03:53:06
464a933d-aae7-4a88-8c97-4eac182dfd9c,USA-FDA,eaf72e24-60ac-41cf-97b9-c99e797f27d7,G_FAQ,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0093/FDA-2002-D-0093-0022/FDA-2002-D-0093-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry"", ""docket_id"": ""FDA-2002-D-0093"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0093-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0093/FDA-2002-D-0093-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:32:25,2025-05-28 03:53:06
46560c1b-eed5-4d2a-bb0e-09fc47458128,USA-FDA,4a45043d-b89c-4809-b75f-42faf3ccc550,G_IMPACT_ANALYSIS,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0002/FDA-2012-D-1083-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff; Civil Responses to Frequently Asked Question"", ""docket_id"": ""FDA-2012-D-1083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1083-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:04:32,2025-05-28 03:53:06
46629b28-bf31-41ba-b5e2-040d1024faf0,USA-FDA,e994b397-636d-45bb-9533-f6ebf2be8b17,G_DETAILED_SUMMARY,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0169/FDA-2013-D-0169-0002/FDA-2013-D-0169-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Review Staff: Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling"", ""docket_id"": ""FDA-2013-D-0169"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0169-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0169/FDA-2013-D-0169-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:45:21,2025-05-28 03:53:06
46a94e73-28f6-44bc-bf20-0da9de7b0c18,USA-FDA,7f02f2e6-a83b-4baa-98a9-1b2a4dce9a11,G_FAQ,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002/FDA-2011-D-0164-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:00:18,2025-05-28 03:53:06
46f93b06-5d37-4310-b148-d1c32a9b4830,USA-FDA,59d29328-6eab-4785-ad83-0fe0192c09c0,G_KEYWORDS,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002/FDA-1999-D-1315-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act (PDUFA) Products; Guidance for Industry; Draft Guidance for Industry"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:02:38,2025-05-28 03:53:06
47,,9b870453-85c4-4419-9890-85349d04add0,G_MINI_SUMMARY,2025-05-12 19:25:49,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 201 and 314"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonprescription Drug Product With an Additional Condition for Nonprescription Use"", ""docket_id"": ""FDA-2021-N-0862"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-N-0862-0235""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:25:51,2025-05-28 03:53:06
473eb337-8e21-436b-9a74-07927f976e4c,USA-FDA,c80b0ef0-d945-4a4a-abc4-3299aee8b3f7,G_MINI_SUMMARY,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021/FDA-2004-D-0044-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for the Early Food Safety\nEvaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties\nIntended for Food Use; Availability"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:00:12,2025-05-28 03:53:06
47420e18-edca-45a8-9bc3-64b38b461a96,CAB,6976a9ff-54f2-442f-89a2-d9552ffc5e9a,G_TRANSLATE,2025-05-20 12:42:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Spanish""}","{""tilte"": ""FDA-2018-N-3233-0006.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2018-N-3233-0006_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""3f21331b-4399-4219-aa7e-0a5cb7a4ba33""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3f21331b-4399-4219-aa7e-0a5cb7a4ba33/Spanish"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:44:40,2025-05-28 03:53:06
4751637c-5386-44f7-949b-a17e33a4828f,USA-FDA,cb064bf2-e6bf-44d1-a3ea-f8a464df1620,G_ACTION_ITEMS,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0196/FDA-2009-D-0196-0002/FDA-2009-D-0196-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Arsenic"", ""docket_id"": ""FDA-2009-D-0196"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0196-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0196/FDA-2009-D-0196-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:31:04,2025-05-28 03:53:06
477fb8c8-7e71-46f2-b2de-e992778b1854,USA-FDA,2c56ea34-4361-4eda-88e9-16f0566725c8,G_IMPACT_ANALYSIS,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1958/FDA-2020-D-1958-0001/FDA-2020-D-1958-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Seafood HACCP Transition Guidance"", ""docket_id"": ""FDA-2020-D-1958"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1958-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1958/FDA-2020-D-1958-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:03:08,2025-05-28 03:53:06
478f5387-c326-4b86-ac41-c0426a2bc812,USA-FDA,322f1850-7a3a-4637-83ea-e3d398659bf1,G_DETAILED_SUMMARY,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002/FDA-2009-D-0136-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0136"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0136-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:30:49,2025-05-28 03:53:06
47be39f8-8269-4f69-b84a-a473cc14ff06,USA-FDA,49b73afc-d3cf-4112-bdf3-5442d880a640,G_ACTION_ITEMS,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1010/FDA-2012-D-1010-0002/FDA-2012-D-1010-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Initial Completeness Assessments for Type II Active Pharmaceutical Ingredient Drug Master Files under Generic Drug User Fee"", ""docket_id"": ""FDA-2012-D-1010"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1010-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1010/FDA-2012-D-1010-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:48:16,2025-05-28 03:53:06
47ccbb61-8c40-4294-8ccb-131714c20ad7,USA-FDA,70bc9e87-96bd-4947-b9a8-82e2855f6fec,G_DETAILED_SUMMARY,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0514/FDA-2011-D-0514-0002/FDA-2011-D-0514-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Industry and Staff; Procedures for Handling Section 522 Postmarket Surveillance Studies"", ""docket_id"": ""FDA-2011-D-0514"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0514-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0514/FDA-2011-D-0514-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:15:25,2025-05-28 03:53:06
47d5d967-579a-40dd-a1c1-717a6c3269c0,USA-FDA,2a154d64-b702-421d-9337-76c052f06a86,G_CONCISE_SUMMARY,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002/FDA-2005-G-0193-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Low Energy Ultrasound Wound Cleaner"", ""docket_id"": ""FDA-2005-G-0193"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-G-0193-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:12:23,2025-05-28 03:53:06
47dc4930-1c61-4766-8c00-699e75fb7e98,USA-FDA,f0610654-9bd3-4265-97b3-40c45d87fd13,G_MINI_SUMMARY,2025-05-22 18:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0243/FDA-2003-D-0243-0021/FDA-2003-D-0243-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #169 Drug Substance Chemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-2003-D-0243"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0243-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0243/FDA-2003-D-0243-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:30:10,2025-05-28 03:53:06
47dc96b6-7bd5-43e5-bcb3-146f2f60bf00,USA-FDA,d9658fdc-0033-4abb-aab3-09cda22ea5c0,G_MINI_SUMMARY,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002/FDA-1999-D-0063-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling"", ""docket_id"": ""FDA-1999-D-0063"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0063-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:47:25,2025-05-28 03:53:06
47e28f6d-9468-44db-8827-4e5cc0b9ff20,USA-FDA,2a0d23df-65ff-47d5-b0fc-2dde834b0175,G_IMPACT_ANALYSIS,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0033/FDA-2003-D-0033-0003/FDA-2003-D-0033-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff: Food and Drug Administration and Industry Actions on Premarket Notification Submissions: Effect on Food and Drug Administration Review Clock and Performance Assessment"", ""docket_id"": ""FDA-2003-D-0033"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0033-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0033/FDA-2003-D-0033-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:32:29,2025-05-28 03:53:06
47fd1aa0-5dd1-4271-8d45-a0429859f15d,USA-FDA,3e0521ce-30c7-441b-bd89-d9f7738ecb94,G_DETAILED_SUMMARY,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002/FDA-2012-D-0179-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens"", ""docket_id"": ""FDA-2012-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0179-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:00:27,2025-05-28 03:53:06
48,,ab9f9157-e411-4c0f-9017-680055dbcabd,G_CONCISE_SUMMARY,2025-05-12 19:25:53,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 201 and 314"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonprescription Drug Product With an Additional Condition for Nonprescription Use"", ""docket_id"": ""FDA-2021-N-0862"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-N-0862-0235""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:25:55,2025-05-28 03:53:06
4807d493-3d80-4040-af18-90cbd0c21952,USA-FDA,baa4d852-3258-4abf-af96-eae3d1fdbca5,G_IMPACT_ANALYSIS,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002/FDA-2011-D-0398-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:31:46,2025-05-28 03:53:06
481b9d7e-c418-46b1-a722-011ebb07f0ef,USA-FDA,c4506dc4-aad4-44bc-a726-efa62e720d01,G_ACTION_ITEMS,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0533/FDA-2009-D-0533-0009/FDA-2009-D-0533-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application"", ""docket_id"": ""FDA-2009-D-0533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0533-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0533/FDA-2009-D-0533-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:00:33,2025-05-28 03:53:06
481cebc7-24b3-4aa5-b569-16a8e7f15fd9,USA-FDA,cac00fa3-f645-4c15-bff3-b5ca387da8f1,G_CONCISE_SUMMARY,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002/FDA-2014-N-1108-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products--Considerations, Content, and Format"", ""docket_id"": ""FDA-2014-N-1108"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1108-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:01:15,2025-05-28 03:53:06
4842f0ca-b23a-41c3-8ca5-d8c111bda8c4,USA-FDA,c378b788-ebe1-4f00-90b0-71270f94cf4b,G_DETAILED_SUMMARY,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001/FDA-2020-D-1430-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents"", ""docket_id"": ""FDA-2020-D-1430"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1430-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:17:24,2025-05-28 03:53:06
48552541-fc4b-4928-bda2-3ccf35949120,USA-FDA,975b5cbf-625d-492a-b4f8-0318ff0ad492,G_ACTION_ITEMS,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0013/FDA-1998-D-0035-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis and Interpretation of Clinical Studies"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:18:03,2025-05-28 03:53:06
48760d03-680a-480d-9840-35d038bee527,USA-FDA,a06f3fbb-5ee9-48b4-8a54-8f6c7da8965c,G_MINI_SUMMARY,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0300/FDA-2004-D-0300-0005/FDA-2004-D-0300-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Quality Systems Approach to Pharmaceutical CGMP Regulations"", ""docket_id"": ""FDA-2004-D-0300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0300-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0300/FDA-2004-D-0300-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:00:09,2025-05-28 03:53:06
489afc92-c433-462b-b303-dde0050869a2,USA-FDA,01453497-9f0a-40b4-938c-1ca409eff465,G_IMPACT_ANALYSIS,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002/FDA-2011-D-0376-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues"", ""docket_id"": ""FDA-2011-D-0376"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0376-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:01:32,2025-05-28 03:53:06
48aed2a5-b637-4daf-b68c-37e8ede6f1d3,USA-FDA,22019ff8-8557-4f43-a809-2bea56cf0bbd,G_IMPACT_ANALYSIS,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0889/FDA-2011-D-0889-0002/FDA-2011-D-0889-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions With GFI #209"", ""docket_id"": ""FDA-2011-D-0889"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0889-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0889/FDA-2011-D-0889-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:31:35,2025-05-28 03:53:06
48b473a7-7771-4690-b7e1-fbdaaabb95ed,USA-FDA,94444afe-db9d-43bc-bf2b-aaeffbeb2f36,G_FAQ,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009/FDA-2006-D-0157-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry:  Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2006-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0157-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:00:55,2025-05-28 03:53:06
48b92c48-f792-44d6-a0c9-45895ff64cd3,USA-FDA,901bcaa3-b22e-416c-b222-f0190103278e,G_CONCISE_SUMMARY,2025-05-19 23:42:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001/FDA-2017-D-5478-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""MRCT Draft FDA Guidance Return of Aggregate Results"", ""docket_id"": ""FDA-2017-D-5478"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5478-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 03:42:59,2025-05-28 03:53:06
48c8e3e6-3571-45ff-83b4-a66f394d4db0,USA-FDA,32b6f6fd-2539-4bf0-b7ec-e80ff019b87f,G_MINI_SUMMARY,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1353/FDA-2020-D-1353-0001/FDA-2020-D-1353-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part IX FDA References"", ""docket_id"": ""FDA-2020-D-1353"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1353-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1353/FDA-2020-D-1353-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:15:50,2025-05-28 03:53:06
48d96079-458a-4118-b754-1208074116e3,USA-FDA,16adde43-7cc8-43b7-b06b-fa4abb47766c,G_DETAILED_SUMMARY,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0358/FDA-2014-D-1525-0358-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application"", ""docket_id"": ""FDA-2014-D-1525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1525-0358""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0358"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:01:42,2025-05-28 03:53:06
48fa94d5-2364-4305-a3df-10f096600d38,USA-FDA,075b563f-0fc4-4e72-a7ed-f675e284ab53,G_KEYWORDS,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002/FDA-2013-N-1429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2013-N-1429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:02:33,2025-05-28 03:53:06
48ffe7dc-1497-4dfa-b501-699549e759b6,USA-FDA,a3b54d6d-8ce0-410c-ada5-49ad1aeb4561,G_ACTION_ITEMS,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0489/FDA-2011-D-0489-0002/FDA-2011-D-0489-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety of Nanomaterials in Cosmetic Products; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0489"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0489-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0489/FDA-2011-D-0489-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:45:30,2025-05-28 03:53:06
49,,3312fd90-dfde-49bf-a0ad-ec5983700205,G_DETAILED_SUMMARY,2025-05-12 19:25:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 201 and 314"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonprescription Drug Product With an Additional Condition for Nonprescription Use"", ""docket_id"": ""FDA-2021-N-0862"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-N-0862-0235""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:25:58,2025-05-28 03:53:06
4913f010-c5f9-498f-b0f7-52dd723e2942,USA-FDA,4558df5c-14c0-4a0f-a82f-7231cef94179,G_FAQ,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0183/FDA-2010-D-0183-0002/FDA-2010-D-0183-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance of Industry; Prevention of Salmonella Enteritidis in Shell Eggs During Production, Transportation, and Storage; Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0183"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0183-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0183/FDA-2010-D-0183-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:00:47,2025-05-28 03:53:06
49428823-97f2-4176-a73b-89a45faaa2b4,USA-FDA,71de4d39-4a4a-4e8a-8492-8e23f771f331,G_MINI_SUMMARY,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0531/FDA-2004-D-0531-0001/FDA-2004-D-0531-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations to Processors of Apple Juice or Cider on the Use of Ozone for Pathogen Reduction Purposes"", ""docket_id"": ""FDA-2004-D-0531"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0531-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0531/FDA-2004-D-0531-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:15:07,2025-05-28 03:53:06
4948b255-4b67-4c71-9838-7dc77ea7433f,USA-FDA,bacc980c-9a66-4a13-93da-0f983b450d6c,G_MINI_SUMMARY,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0652/FDA-2011-D-0652-0002/FDA-2011-D-0652-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff The 510(k) Program Evaluating Substantial Equivalence in Premarket Notifications [510(k)]"", ""docket_id"": ""FDA-2011-D-0652"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0652-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0652/FDA-2011-D-0652-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:45:12,2025-05-28 03:53:06
4979da8e-30de-4e50-b963-159ace3990d1,USA-FDA,1f6b9b54-e260-4924-8c43-19948de19e94,G_ACTION_ITEMS,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0541/FDA-2011-D-0541-0002/FDA-2011-D-0541-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance PET Drugs ----- Current Good Manufacturing Practice (CGMP) (Small Entity Compliance Guide)"", ""docket_id"": ""FDA-2011-D-0541"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0541-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0541/FDA-2011-D-0541-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:03:13,2025-05-28 03:53:06
49806cac-d751-4911-acf6-a3a47a290f80,USA-FDA,c118b7e9-ad0f-4617-a128-72a3857be65e,G_ACTION_ITEMS,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0432/FDA-2011-D-0432-0002/FDA-2011-D-0432-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics"", ""docket_id"": ""FDA-2011-D-0432"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0432-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0432/FDA-2011-D-0432-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:46:16,2025-05-28 03:53:06
49943a79-6786-4ef5-9f40-dfb646dd4f33,USA-FDA,0800f3ea-3e6f-4122-b464-09abb1173115,G_KEYWORDS,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001/FDA-2020-D-1951-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on Juice HACCP Regulation (2003)"", ""docket_id"": ""FDA-2020-D-1951"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1951-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:31:26,2025-05-28 03:53:06
49963157-9e86-4f94-8ff8-9fa81507641e,USA-FDA,ecdf45cf-69d4-4871-8239-65f1c55d911b,G_ACTION_ITEMS,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002/FDA-2011-D-0376-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues"", ""docket_id"": ""FDA-2011-D-0376"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0376-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:01:23,2025-05-28 03:53:06
4996af73-c31a-49f3-a938-c9d0c9a42aa2,SCHEDULED,5d1b22df-177a-480d-87ac-58d839124eac,FDA_ALERT,2025-05-31 00:00:05,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/5d1b22df-177a-480d-87ac-58d839124eac"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:19,2025-05-31 00:00:19
4997e267-c1a3-4149-80e5-e0fd3a82d64d,USA-FDA,23474f69-9a36-420f-864d-3cbc2576f2c5,G_FAQ,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002/FDA-1999-D-0063-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling"", ""docket_id"": ""FDA-1999-D-0063"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0063-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:47:53,2025-05-28 03:53:06
49b6858e-4057-4b77-9d5e-e03983203d65,USA-FDA,195545cc-f1aa-46b8-a1f8-655fbd9164c1,G_MINI_SUMMARY,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002/FDA-2014-N-0829-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Reporting Drug Sample Information\nUnder Section 6004 of the Affordable Care Act"", ""docket_id"": ""FDA-2014-N-0829"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-0829-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:30:10,2025-05-28 03:53:06
4a2a2d3d-759e-4a92-9b4d-9b66473333a5,USA-FDA,a0bcd56a-a9f8-4be9-89ff-e71ae00cc309,G_DETAILED_SUMMARY,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0002/FDA-2014-D-1399-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Draft Guidance Document"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:15:52,2025-05-28 03:53:06
4a607745-0cf7-424d-b1d6-7ea875913f2d,USA-FDA,f07a6788-4368-4bd9-aeb1-715868283312,G_IMPACT_ANALYSIS,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032/FDA-2002-D-0094-0032-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0032""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:02:43,2025-05-28 03:53:06
4a77bba9-959d-42a6-9c85-21dcacb0cd2f,SCHEDULED,8e83be8c-843c-476e-899a-d872937756ca,FDA_ALERT,2025-05-24 00:00:05,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/8e83be8c-843c-476e-899a-d872937756ca"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:18,2025-05-28 03:53:06
4a88caa2-32bd-4185-843e-de0c848105ad,USA-FDA,6b876d13-8829-4fa1-b87a-959715665f8b,G_MINI_SUMMARY,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025/FDA-2004-D-0044-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:15:07,2025-05-28 03:53:06
4a8eafd7-fa1c-4627-a307-748bd7284a95,USA-FDA,e0845999-ff01-459f-978e-095c6d71db32,G_KEYWORDS,2025-05-19 23:42:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001/FDA-2017-D-5478-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""MRCT Draft FDA Guidance Return of Aggregate Results"", ""docket_id"": ""FDA-2017-D-5478"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5478-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 03:44:01,2025-05-28 03:53:06
4abb93e8-3693-4d6c-b09c-c8b624b5b64b,USA-FDA,f453cf98-5b56-4c62-a926-b1c6b0daab26,G_IMPACT_ANALYSIS,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002/FDA-2011-D-0730-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff; Class II Special Controls Guidance Documents: In Vitro Diagnostic Devices for Yersinia Species Detection"", ""docket_id"": ""FDA-2011-D-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0730-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:01:04,2025-05-28 03:53:06
4ac45221-ec70-40cf-8824-07d7f1e8d62c,USA-FDA,442834fa-de88-4459-87af-7468e2c0eaa1,G_MINI_SUMMARY,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0138/FDA-2001-D-0138-0003/FDA-2001-D-0138-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Exemptions from the Warning Label Requirement for Juice - Recommendations for Effectively Achieving a 5 -Log Pathogen Reduction"", ""docket_id"": ""FDA-2001-D-0138"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0138-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0138/FDA-2001-D-0138-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:45:10,2025-05-28 03:53:06
4ac89d76-19d4-4936-a55c-15ba6d212255,USA-FDA,e13d4dcd-e991-48ae-8d77-5c4919e191c0,G_MINI_SUMMARY,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0562/FDA-1996-N-0270-0562-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #69 Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations"", ""docket_id"": ""FDA-1996-N-0270"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1996-N-0270-0562""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0562"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:31:05,2025-05-28 03:53:06
4ad16285-ad9a-43fe-825e-7100f4757fda,USA-FDA,48e10926-672c-46ee-b36d-05f659f97322,G_MINI_SUMMARY,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0334/FDA-2008-N-0334-0010/FDA-2008-N-0334-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Providing Submissions in Electronic Format - Postmarketing Safety Reports-Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements"", ""docket_id"": ""FDA-2008-N-0334"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-N-0334-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0334/FDA-2008-N-0334-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:01:12,2025-05-28 03:53:06
4ad7f27a-b4a1-4ab4-8731-99b374562fea,USA-FDA,96b1b558-c284-4d23-ac53-8c35ff71df19,G_IMPACT_ANALYSIS,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002/FDA-2011-D-0602-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industryon Quality Considerations in Demonstrating Biosimilarity to Reference Protein Product"", ""docket_id"": ""FDA-2011-D-0602"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0602-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:34:56,2025-05-28 03:53:06
4afca183-72ea-4df9-b021-12662fe3a88e,SCHEDULED,c32ce536-4df5-4bac-b327-65cdabc4730d,FDA_ALERT,2025-05-31 00:00:05,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/c32ce536-4df5-4bac-b327-65cdabc4730d"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:21,2025-05-31 00:00:21
4b12bd56-6cde-4b7e-893f-7a2fb954f1f2,CAB,1080112f-e8b0-495f-82e2-7e534b61f768,G_FAQ_IN,2025-05-20 09:28:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2023-N-4225-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""be71a183-8124-4a8f-984c-ce1233023d0a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/be71a183-8124-4a8f-984c-ce1233023d0a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:28:29,2025-05-28 03:53:06
4b1a0bda-6e59-4ba1-9914-f83cb7f9f9cf,USA-FDA,c4f2bdb3-18be-471f-92f5-904ef8fc7a53,G_CONCISE_SUMMARY,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003/FDA-2006-D-0231-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds"", ""docket_id"": ""FDA-2006-D-0231"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0231-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:00:20,2025-05-28 03:53:06
4b1bb651-17a9-4691-b208-110c68a680be,USA-FDA,3bbdebab-b0e3-4eb9-af1a-758f5b3cf572,G_DETAILED_SUMMARY,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001/FDA-2020-D-1916-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect -21 CFR 1003.11"", ""docket_id"": ""FDA-2020-D-1916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1916-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:45:17,2025-05-28 03:53:06
4b1ea452-1f7f-46d4-9b36-88ce5242c4fc,USA-FDA,d6a469b3-04b9-4089-bdbc-e896bd7d681f,G_FAQ,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0790/FDA-2011-D-0790-0002/FDA-2011-D-0790-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff, FDA Decisions for Investigational Device Exemption Clinical Investigations"", ""docket_id"": ""FDA-2011-D-0790"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0790-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0790/FDA-2011-D-0790-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:46:09,2025-05-28 03:53:06
4b2906cc-bc7d-4765-9ba6-fdaeb7776669,USA-FDA,4f0f480d-0c80-4b3d-a94c-b0c7fd0c21ae,G_ACTION_ITEMS,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0182/FDA-2004-D-0182-0004/FDA-2004-D-0182-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; ANDAs: Pharmaceutical Solid Polymorphism;\nChemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-2004-D-0182"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0182-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0182/FDA-2004-D-0182-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:30:32,2025-05-28 03:53:06
4b3423f5-c135-4398-a276-cfb4af13907a,USA-FDA,e74cb110-ea8b-4e6c-b3ba-aa1e46161780,G_FAQ,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004/FDA-2002-D-0180-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Q1E Evaluation of Stability Data"", ""docket_id"": ""FDA-2002-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0180-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:46:05,2025-05-28 03:53:06
4b3b9fb8-1a91-4782-a131-e81aacc4fb45,USA-FDA,7705a00b-9fa5-4385-964b-b5799c93f189,G_ACTION_ITEMS,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0562/FDA-1996-N-0270-0562-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #69 Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations"", ""docket_id"": ""FDA-1996-N-0270"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1996-N-0270-0562""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0562"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:31:21,2025-05-28 03:53:06
4b4cb303-6a13-4e46-82ac-693f8676b2da,USA-FDA,5d2100bc-a8c4-46ae-a501-26c3b40c0e01,G_KEYWORDS,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002/FDA-2011-D-0147-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Staff Demonstrating Substantial Equivalence of New Tobacco Product; Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2011-D-0147"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0147-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:31:03,2025-05-28 03:53:06
4b5e7ae7-23dd-4659-ac05-fd618652b6b6,USA-FDA,9d50c8f0-dbfc-4eb6-bb34-9c7adc9276cb,G_KEYWORDS,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006/FDA-2005-D-0086-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""uidance for Industry; Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals"", ""docket_id"": ""FDA-2005-D-0086"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0086-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:02:15,2025-05-28 03:53:06
4b692310-54cd-4c45-b75f-60dc38f70fe7,USA-FDA,39f1a04f-87c5-433b-8831-dd90be4dabbe,G_ACTION_ITEMS,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002/FDA-1999-D-0063-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling"", ""docket_id"": ""FDA-1999-D-0063"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0063-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:48:01,2025-05-28 03:53:06
4b724623-dbce-49a3-804c-2532fc8a6bf3,USA-FDA,0c6b1010-529d-4243-8895-b4539d910309,G_DETAILED_SUMMARY,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0893/FDA-2011-D-0893-0002/FDA-2011-D-0893-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry and Staff Center for Devices and Radiological Health Appeals Processes"", ""docket_id"": ""FDA-2011-D-0893"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0893-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0893/FDA-2011-D-0893-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:02:14,2025-05-28 03:53:06
4b924d91-0223-4b58-94e7-bad5e9b7de54,USA-FDA,ac46dfd3-5724-4c7e-a6d6-3cda61b155a2,G_CONCISE_SUMMARY,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002/FDA-2011-D-0398-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:31:04,2025-05-28 03:53:06
4bee757f-4f45-423f-a853-66ba47b944e3,USA-FDA,5d064294-94b7-4136-95bc-0ce87ffdb9d4,G_ACTION_ITEMS,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0017/FDA-2017-D-6526-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6526"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6526-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:46:21,2025-05-28 03:53:06
4bef7959-6829-4fb7-a5e8-fd9428bbbe35,USA-FDA,aa9e524f-7309-424d-b55a-3724cd44aa1c,G_MINI_SUMMARY,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001/FDA-2018-D-0398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions Guidance for Industry and\nFood and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:00:10,2025-05-28 03:53:06
4c0a66ab-0a66-4ba9-afbb-210d3ae389d0,USA-FDA,31e2fb04-3fed-407c-9d2e-88153b5cbac2,G_MINI_SUMMARY,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002/FDA-2012-D-0304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Claa II Special Controls Guidance Implanted Blood Access Devices for Hemodialysis"", ""docket_id"": ""FDA-2012-D-0304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:00:14,2025-05-28 03:53:06
4c680e86-52ad-4c90-905e-c0065774abbe,USA-FDA,8a4c2ead-d310-4826-8132-cfa8091bd02d,G_MINI_SUMMARY,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013/FDA-2009-D-0503-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in - Premarket Notification (510(k)) Submissions; Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0503-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:00:10,2025-05-28 03:53:06
4c6e798e-1fc1-4e34-9652-66518cab8781,USA-FDA,219295f0-686d-409a-ba19-6ccd608cc6db,G_DETAILED_SUMMARY,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012/FDA-2016-D-1533-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma - Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:47:37,2025-05-28 03:53:06
4ca164b7-dc03-47ed-9d66-f18fe457254c,USA-FDA,7079dec0-126a-48ee-b665-da4f04075fbc,G_MINI_SUMMARY,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0567/FDA-2011-D-0567-0002/FDA-2011-D-0567-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry, Clinical Investigators and Staff; Design Considerations for Pivotal Clinical Investigations for Medical Devices"", ""docket_id"": ""FDA-2011-D-0567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0567-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0567/FDA-2011-D-0567-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:00:13,2025-05-28 03:53:06
4cd656d7-f8cc-43e7-8a2c-9418c9c29628,USA-FDA,70311407-d46f-41b6-b6be-ddae238af468,G_CONCISE_SUMMARY,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002/FDA-2011-D-0147-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Staff Demonstrating Substantial Equivalence of New Tobacco Product; Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2011-D-0147"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0147-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:30:14,2025-05-28 03:53:06
4cdf828f-efa1-460f-b824-54bc74ec14cd,USA-FDA,aa726d0f-61cf-4e27-b439-aef1865f0e2d,G_DETAILED_SUMMARY,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003/FDA-2008-D-0180-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Coronary Drug Eluting Stents- Nonclincal and Clinical Studies; Draft Guidance"", ""docket_id"": ""FDA-2008-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0180-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:00:27,2025-05-28 03:53:06
4cfebe61-b9f8-497b-b5f6-561d36649dfc,SCHEDULED,ac08d9d0-5d83-4d55-b4fd-0d0fbf4c73fa,DEVICE_ANALYST,2025-05-30 00:00:04,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/ac08d9d0-5d83-4d55-b4fd-0d0fbf4c73fa"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:12,2025-05-30 00:00:12
4d14a139-8c01-4f7a-aa1f-bf5690ae6059,USA-FDA,b1e15975-274e-4f7b-8936-778767306173,G_MINI_SUMMARY,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001/FDA-2020-D-1397-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Q3A Impurities in New Drug Substances"", ""docket_id"": ""FDA-2020-D-1397"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1397-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:45:07,2025-05-28 03:53:06
4d1fbd7c-2502-468a-a0de-c67e7c2d8809,USA-FDA,3dda71f8-d542-4cab-a015-516c4cea0b6c,G_IMPACT_ANALYSIS,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0358/FDA-2014-D-1525-0358-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application"", ""docket_id"": ""FDA-2014-D-1525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1525-0358""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0358"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:02:17,2025-05-28 03:53:06
4d2f5ead-85d4-402b-b918-fe8b6928a146,USA-FDA,e957e62b-df07-4bd7-b28c-3be623bc8d10,G_KEYWORDS,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038/FDA-2008-D-0406-0038-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs; Frequently Asked Questions - Statement of Investigator (Form FDA 1572)"", ""docket_id"": ""FDA-2008-D-0406"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0406-0038""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:18:01,2025-05-28 03:53:06
4d6a5e6a-e05c-4802-8794-7103bd063643,USA-FDA,4f76a3e8-6caf-453e-9c4a-85033afa12cc,G_ACTION_ITEMS,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005/FDA-2011-D-0112-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Chemistry, Manufacturing, and Controls (CMC)\nInformation � Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use"", ""docket_id"": ""FDA-2011-D-0112"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0112-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:31:29,2025-05-28 03:53:06
4d6d7f99-2d0f-448f-8f23-da62a66311bf,USA-FDA,77758775-e2a5-4a65-a388-e223b4d43c71,G_CONCISE_SUMMARY,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016/FDA-2014-D-1399-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:15:14,2025-05-28 03:53:06
4d744439-b916-48d9-aaa7-d1b55cee7fee,USA-FDA,f0a424c2-6830-4926-a53c-9cadaa4229ec,G_MINI_SUMMARY,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002/FDA-2011-D-0577-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Factors To Consider When Making Benefit-Risk Determinations in Medical Device Premarket Review"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:43,2025-05-28 03:53:06
4d93cfea-a95f-4dcf-a2e2-531b7d1736ca,USA-FDA,3a07ca93-c44d-408a-9a55-1133636a1d60,G_ACTION_ITEMS,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004/FDA-2010-D-0249-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Systemic Lupus Erythematosus � Developing Medical Products for Treatment"", ""docket_id"": ""FDA-2010-D-0249"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0249-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:02:11,2025-05-28 03:53:06
4ddbd469-288f-4ee7-a7f5-54a30cfcf07a,SCHEDULED,2c9c3cb1-7390-4108-b066-a9d4880e1580,FDA_ALERT,2025-05-26 00:00:07,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/2c9c3cb1-7390-4108-b066-a9d4880e1580"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:27,2025-05-28 03:53:06
4def360b-9358-42eb-8481-7f738bfb7d4d,USA-FDA,126e13b9-f6b9-4bd2-b996-377e1f6bc2bb,G_MINI_SUMMARY,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1005/FDA-2012-D-1005-0002/FDA-2012-D-1005-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Considerations for Product Design to Minimize Medication Errors - Draft Guidance"", ""docket_id"": ""FDA-2012-D-1005"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1005-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1005/FDA-2012-D-1005-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:45:07,2025-05-28 03:53:06
4e65c5e7-35bf-4059-a7bb-2bda22178460,USA-FDA,a56bc03a-8fda-4c66-bb74-ce60e480e01b,G_MINI_SUMMARY,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004/FDA-2005-D-0208-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency"", ""docket_id"": ""FDA-2005-D-0208"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0208-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:32:32,2025-05-28 03:53:06
4eb2c639-9a46-427f-a091-4715bf81f3ca,USA-FDA,09f19008-71f0-46be-8b36-9ce2cde349a8,G_MINI_SUMMARY,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0295/FDA-2013-D-0295-0002/FDA-2013-D-0295-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Scale-Up and Post-Approval Changes, Manufacturing Equipment Addendum"", ""docket_id"": ""FDA-2013-D-0295"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0295-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0295/FDA-2013-D-0295-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:30:09,2025-05-28 03:53:06
4ec49fe7-d8be-46da-9965-8e8cc30f8c8c,USA-FDA,ec1baa1f-b321-40e8-8037-3cde3aeb1116,G_MINI_SUMMARY,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0030/FDA-2007-D-0030-0002/FDA-2007-D-0030-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Refrigerated Carrot Juice and Other Refrigerated\nLow-Acid Juices"", ""docket_id"": ""FDA-2007-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0030-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0030/FDA-2007-D-0030-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:15:07,2025-05-28 03:53:06
4ed56bc1-e1d5-4327-b0f9-f81f819bb86e,USA-FDA,4edc926c-b5f9-49d6-80ec-abb9f267da7f,G_MINI_SUMMARY,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011/FDA-2001-D-0137-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children"", ""docket_id"": ""FDA-2001-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0137-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:32:10,2025-05-28 03:53:06
4f3ed69e-d5d6-4233-8add-5ac22f1d1089,QUEUE,9f591146-c684-48cd-aec4-3d00d59c7e05,G_CONCISE_SUMMARY_USER,2025-05-29 16:45:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/9f591146-c684-48cd-aec4-3d00d59c7e05/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/9f591146-c684-48cd-aec4-3d00d59c7e05"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 16:45:12,2025-05-29 16:45:12
4f5437e8-0321-4168-8db0-4e2db06918bd,QUEUE,df62ae53-165f-4d5c-ba00-5d91d0d21e5c,G_FAQ_USER,2025-05-20 10:42:26,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__doc_title__"": ""FDA-2023-N-4225-0001.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/df62ae53-165f-4d5c-ba00-5d91d0d21e5c/SRC/df62ae53-165f-4d5c-ba00-5d91d0d21e5c.pdf"", ""doc_title"": ""FDA-2023-N-4225-0001.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/df62ae53-165f-4d5c-ba00-5d91d0d21e5c/DEST/faq.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:42:38,2025-05-28 03:53:06
4f6a6fd0-6342-44bd-bf0f-a59e057f5cf9,USA-FDA,1eeb5c58-61a6-4c74-9d24-400542443e4b,G_DETAILED_SUMMARY,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0025/FDA-1999-D-1875-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sec.615.115 Extralabel Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:33:03,2025-05-28 03:53:06
4f730fdf-448e-4120-b9b9-11237c0432ab,USA-FDA,fa223239-0571-401d-aaca-f70234126867,G_MINI_SUMMARY,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1659/FDA-2015-D-1659-0002/FDA-2015-D-1659-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Established Conditions: Reportable Chemistry, Manufacturing, and\nControls Changes for Approved Drug and Biologic Products; Draft Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1659"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1659-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1659/FDA-2015-D-1659-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:15:09,2025-05-28 03:53:06
4f886627-cc9a-46d7-9834-b0a7ca795100,USA-FDA,e9aee314-b10d-4be8-b1bf-48364881e7a0,G_MINI_SUMMARY,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021/FDA-2005-D-0282-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:31:01,2025-05-28 03:53:06
4f8d3aad-194e-4ad8-b077-e60ad390cb46,SCHEDULED,17d2ccf0-25b5-468a-adac-a9584e1b89f1,FDA_ALERT,2025-05-26 00:00:07,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/17d2ccf0-25b5-468a-adac-a9584e1b89f1"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:20,2025-05-28 03:53:06
4f91f48e-a1e8-482d-8625-d987084d86a1,CAB,20da9eaf-bca5-4ac9-85c0-c0f881f37d2b,G_CONCISE_SUMMARY_IN,2025-05-27 02:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""num_paragraphs"": 3}","{""tilte"": ""FDA-2024-N-2910-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2024-N-2910-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b3efc128-de32-4064-8905-ee749b8e53b7""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b3efc128-de32-4064-8905-ee749b8e53b7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 02:00:14,2025-05-28 03:53:06
4fa1014f-4561-4678-8d68-fd2a01088060,USA-FDA,de4fe372-4b0d-4774-90af-1c0d5bf27a97,G_IMPACT_ANALYSIS,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002/FDA-2017-D-6380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric\nSubpopulations of Common Diseases Draft Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:02:13,2025-05-28 03:53:06
4faa04b9-e442-403d-9bbd-5a2d9de5a7da,USA-FDA,1641e74b-0f85-4ce0-9216-9085f8923953,G_IMPACT_ANALYSIS,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008/FDA-2008-D-0642-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2008-D-0642"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0642-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:33:36,2025-05-28 03:53:06
4fb14f3c-9738-442f-8133-1f85596192af,USA-FDA,39409ec3-2c32-4595-a05c-c7d55e21f35a,G_FAQ,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0567/FDA-2011-D-0567-0002/FDA-2011-D-0567-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry, Clinical Investigators and Staff; Design Considerations for Pivotal Clinical Investigations for Medical Devices"", ""docket_id"": ""FDA-2011-D-0567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0567-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0567/FDA-2011-D-0567-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:01:07,2025-05-28 03:53:06
4ff4f85d-4950-49b7-8aef-2a38adc52ac6,USA-FDA,ea925bee-dc06-446d-af0d-80077a0b7060,G_ACTION_ITEMS,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2635/FDA-2016-D-2635-0269/FDA-2016-D-2635-0269-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Potential Approach for Defining Durations of Use for Medically Important Antimicrobial Drugs Intended for Use In or On Feed: A Concept Paper"", ""docket_id"": ""FDA-2016-D-2635"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2635-0269""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2635/FDA-2016-D-2635-0269"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:30:58,2025-05-28 03:53:06
5,,048ef63e-88e5-4bed-811f-f63916686e57,G_CONCISE_SUMMARY,2025-05-09 01:51:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 08:51:09,2025-05-28 03:53:06
50,,8a644245-d40b-4b25-8497-aa8db8f375c3,G_FAQ,2025-05-12 19:26:01,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 201 and 314"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonprescription Drug Product With an Additional Condition for Nonprescription Use"", ""docket_id"": ""FDA-2021-N-0862"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-N-0862-0235""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:26:02,2025-05-28 03:53:06
50182c92-5b01-4a89-9fae-0f9f03eac8b1,USA-FDA,37001e1d-417e-431a-89a8-b4bcaa9c0439,G_MINI_SUMMARY,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004/FDA-2007-D-0302-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Labeling for Human Prescription Drug and Biological Products � Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information"", ""docket_id"": ""FDA-2007-D-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0302-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:02:48,2025-05-28 03:53:06
50184487-1b95-4ed0-bf97-051eaa58c58b,USA-FDA,6be5a1c3-e7b9-4f09-8c43-10913b56373e,G_DETAILED_SUMMARY,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1358/FDA-2013-D-1358-0002/FDA-2013-D-1358-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation"", ""docket_id"": ""FDA-2013-D-1358"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1358-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1358/FDA-2013-D-1358-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:01:51,2025-05-28 03:53:06
502ce282-2a7a-47e5-8415-69d6220fb759,USA-FDA,79270688-fd8a-4c09-b25e-b6d28cbf83e5,G_KEYWORDS,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015/FDA-1999-D-1315-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Formal Meetings With Sponsors and Applicants for PDUFA Products; Guidance Document"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:33:08,2025-05-28 03:53:06
50334d1e-cf79-4fa5-956a-0af3a47b1a84,SCHEDULED,4f812b11-9356-49e0-95f0-af0e9b2fc302,DEVICE_ANALYST,2025-05-20 04:13:45,17,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,86583d6a-2c86-4f76-9cb3-2bc933de2ebc,"{""user_id"": 127, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""weekly"", ""last_name"": ""Mandadapu"", ""user_guid"": ""86583d6a-2c86-4f76-9cb3-2bc933de2ebc"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""mandadapu.nandakishore@gmail.com"", ""next_run_date"": ""2025-05-20""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/86583d6a-2c86-4f76-9cb3-2bc933de2ebc/AGENTS/device_analyst/4f812b11-9356-49e0-95f0-af0e9b2fc302"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 04:13:56,2025-05-28 03:53:06
5040e25b-d60c-4316-abe6-0c4b0db9f7e6,USA-FDA,53cc16dc-3f53-4779-b7f3-52f67eb4c589,G_IMPACT_ANALYSIS,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002/FDA-1999-D-1875-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:30:49,2025-05-28 03:53:06
5054a6df-053d-4752-8eef-bba4e4cb219b,USA-FDA,f772bee2-8c30-4a80-96a9-88469b1d1c85,G_IMPACT_ANALYSIS,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002/FDA-2012-D-0307-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Revised Preventive Measures to Reduce Possible Risk of Transmission of Creutzfeldt-Jakob Disease, etc."", ""docket_id"": ""FDA-2012-D-0307"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0307-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:31:33,2025-05-28 03:53:06
509a1dd2-028b-4fd5-99c6-11e6c2604236,USA-FDA,aafa8a2d-e9dc-4159-97e7-9f9d83322784,G_ACTION_ITEMS,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002/FDA-2011-D-0487-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of Acceptable Full-Length and Abbreviated Donor History Questinnaries and Accompanying Materials for Use in Screening Donors of Source Plasma Draft Guidence"", ""docket_id"": ""FDA-2011-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0487-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:31:23,2025-05-28 03:53:06
50ab343b-2bf4-45ff-9208-553a4f99c55d,USA-FDA,6e79699f-97a0-4a78-8962-cd25bc814009,G_DETAILED_SUMMARY,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004/FDA-2010-D-0636-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia Burgdorferi"", ""docket_id"": ""FDA-2010-D-0636"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0636-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:15:16,2025-05-28 03:53:06
50b87f38-987a-47de-8fd0-15846813b8a3,USA-FDA,22ff5683-9013-4ff0-9514-b010ae5028bc,G_MINI_SUMMARY,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001/FDA-2020-D-2015-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Devices Without a Premarket Notification (510(k)) or an Approved Premarket Approval Application (PMA) REVOKED DOCUMENT"", ""docket_id"": ""FDA-2020-D-2015"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-2015-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:27,2025-05-28 03:53:06
50de2617-c3b4-4d3e-ae07-ef59b3021672,USA-FDA,2e593bd7-26ca-46c9-9e30-1b957dc96e9c,G_KEYWORDS,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002/FDA-2013-D-0743-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Reporting for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0743"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0743-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:16:35,2025-05-28 03:53:06
51,,63cae160-a4e9-44c4-a4ee-4acf09868852,G_ACTION_ITEMS,2025-05-12 19:26:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 201 and 314"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonprescription Drug Product With an Additional Condition for Nonprescription Use"", ""docket_id"": ""FDA-2021-N-0862"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-N-0862-0235""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:26:05,2025-05-28 03:53:06
51360f1a-89aa-49d7-bb4f-7669d62e3c84,USA-FDA,455c7d31-9c3f-46a8-a183-dba6f758737b,G_MINI_SUMMARY,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002/FDA-2007-D-0202-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting Improving Human Subject Protection"", ""docket_id"": ""FDA-2007-D-0202"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0202-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:01:24,2025-05-28 03:53:06
514aacf2-b0be-4168-bda5-378cf41358d1,QUEUE,a124dd56-7b36-47de-8467-e49b9caf4c74,G_MINI_SUMMARY_USER,2025-05-20 10:43:43,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__doc_title__"": ""FDA-2023-N-4225-0001_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/a124dd56-7b36-47de-8467-e49b9caf4c74/SRC/a124dd56-7b36-47de-8467-e49b9caf4c74.pdf"", ""doc_title"": ""FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/a124dd56-7b36-47de-8467-e49b9caf4c74/DEST/mini_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:43:47,2025-05-28 03:53:06
51674cae-b944-4975-a797-a2abc4247810,USA-FDA,7d5237e8-c7ab-45a7-b764-3b2c1b0d1bcd,G_DETAILED_SUMMARY,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002/FDA-2010-D-0395-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Adminstration Staff Recommendation for Premarket Notification for Lamotrigine and Zonisamide Assays"", ""docket_id"": ""FDA-2010-D-0395"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0395-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:00:20,2025-05-28 03:53:06
5179fa45-c5c3-4a1a-980d-fc1eaf3b520d,USA-FDA,741afd88-bd47-46a4-a31b-e8c9f06201a0,G_FAQ,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002/FDA-2011-D-0469-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and the Food and Drug Administration Staff: Applying Human Factors and Usability Engineering to Optimize Medical Device Design - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0469"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0469-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:24,2025-05-28 03:53:06
517dcbda-f425-4c0b-a5c8-efc88144cdd4,SCHEDULED,5cce0d93-e3ba-401c-889f-37596207cab5,DEVICE_ANALYST,2025-05-20 04:13:45,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-20""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/5cce0d93-e3ba-401c-889f-37596207cab5"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 04:13:46,2025-05-28 03:53:06
519c263f-6af5-46b2-b1b7-a1a66ac24c07,SCHEDULED,3261b66a-fa0d-46fc-8a3f-c2686459db3b,DEVICE_ANALYST,2025-05-27 00:00:04,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/3261b66a-fa0d-46fc-8a3f-c2686459db3b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:21,2025-05-28 03:53:06
51b5178e-f599-4975-a38d-5f1ec5ed5f4d,USA-FDA,910dc747-7783-4053-81e7-16ec5c3b968a,G_CONCISE_SUMMARY,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021/FDA-2005-D-0282-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:31:06,2025-05-28 03:53:06
51bae793-1a49-470a-ba7d-47faa34fe991,USA-FDA,978c042a-d208-4027-9bfb-d9d17e482afc,G_ACTION_ITEMS,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0146/FDA-2010-D-0146-0012/FDA-2010-D-0146-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Irritable Bowel Syndrome Clinical Evaluation of Drugs for Treatment"", ""docket_id"": ""FDA-2010-D-0146"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0146-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0146/FDA-2010-D-0146-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:16:28,2025-05-28 03:53:06
51d3b809-8acf-4f3b-b32d-34936f8a98b7,USA-FDA,c5e548e5-de39-4bb4-b06c-bf1ec26f83d4,G_KEYWORDS,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001/FDA-2020-D-1408-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000; I Introduction"", ""docket_id"": ""FDA-2020-D-1408"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1408-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:01:09,2025-05-28 03:53:06
51da3508-c54d-4210-98c7-1a8fffdcb53a,USA-FDA,3726a884-dd90-4757-851a-b52ea0efbc04,G_FAQ,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0835/FDA-2011-D-0835-0002/FDA-2011-D-0835-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Considerations when Transferring Clinical Investigation Oversight to Another Institutional Review Board; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0835"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0835-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0835/FDA-2011-D-0835-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:46:52,2025-05-28 03:53:06
51ec7aa7-a14d-4207-9812-f583a98c6b17,USA-FDA,1b589617-0e72-44a3-83a2-edc717f0ce33,G_FAQ,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0429/FDA-2012-D-0429-0003/FDA-2012-D-0429-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Investigators Meetings with Industry and Investigators on the Research and Development of Tobacco Products"", ""docket_id"": ""FDA-2012-D-0429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0429-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0429/FDA-2012-D-0429-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:00:37,2025-05-28 03:53:06
52,,8336ce64-a213-43eb-b25c-09bcc0a05fce,G_IMPACT_ANALYSIS,2025-05-12 19:26:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 201 and 314"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonprescription Drug Product With an Additional Condition for Nonprescription Use"", ""docket_id"": ""FDA-2021-N-0862"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-N-0862-0235""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-N-0862/FDA-2021-N-0862-0235"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:26:10,2025-05-28 03:53:06
520ece2f-55ca-4ef7-95c1-3f90faedbec9,USA-FDA,4e827251-c133-4017-918e-bc701166ff2c,G_ACTION_ITEMS,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0848/FDA-2012-D-0848-0002/FDA-2012-D-0848-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for FDA Staff Compliance Policy Guide Sec. 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products - Hypoglycin A Toxin\nDraft Guidance"", ""docket_id"": ""FDA-2012-D-0848"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0848-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0848/FDA-2012-D-0848-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:30:27,2025-05-28 03:53:06
528fc4b8-6b3b-4632-bb8d-b752493a0a4c,USA-FDA,b1bc3ab8-a74a-4001-ae3d-086813d3ea37,G_DETAILED_SUMMARY,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0563/FDA-1996-N-0270-0563-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations"", ""docket_id"": ""FDA-1996-N-0270"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1996-N-0270-0563""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0563"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:30:46,2025-05-28 03:53:06
52a707bf-e83c-4c5c-b341-695717044495,QUEUE,fafc2489-ee07-4b4a-a21d-a0a4c23d45d1,G_IMPACT_ANALYSIS_USER,2025-05-20 10:44:38,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__doc_title__"": ""FDA-2024-N-1111-0001_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/fafc2489-ee07-4b4a-a21d-a0a4c23d45d1/SRC/fafc2489-ee07-4b4a-a21d-a0a4c23d45d1.pdf"", ""doc_title"": ""FDA-2024-N-1111-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/fafc2489-ee07-4b4a-a21d-a0a4c23d45d1/DEST/impact_analysis.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:44:46,2025-05-28 03:53:06
52a7e34c-f926-4343-b532-54beaa8fc77f,SCHEDULED,8df7f8aa-17df-4262-8344-f16a750d52f3,FDA_ALERT,2025-06-01 00:00:04,4,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-04-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/fda_alert/8df7f8aa-17df-4262-8344-f16a750d52f3"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:08,2025-06-01 00:00:08
52c2d075-f463-489f-afb6-fe178554e3ae,USA-FDA,52221698-1f51-487f-bc8e-8bb2282c6414,G_MINI_SUMMARY,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006/FDA-2005-D-0086-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""uidance for Industry; Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals"", ""docket_id"": ""FDA-2005-D-0086"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0086-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:01:27,2025-05-28 03:53:06
52cf5341-3fae-4153-912f-791c44346b4a,USA-FDA,7c13bc9a-9c1b-4f7e-9e42-03a91f07e2a5,G_MINI_SUMMARY,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002/FDA-1999-D-1875-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:30:09,2025-05-28 03:53:06
52ea4a76-d403-4869-a7d6-05ebee92e56b,USA-FDA,aa38375f-411a-462c-ad90-e7111e690f0d,G_IMPACT_ANALYSIS,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009/FDA-2003-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI"", ""docket_id"": ""FDA-2003-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:31:10,2025-05-28 03:53:06
53,,27668dde-531c-4341-a419-8e41d0997b20,G_MINI_SUMMARY,2025-05-12 19:26:12,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Providing Submissions in Electronic Format--Standardized Study Data"", ""docket_id"": ""FDA-2012-D-0097"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0097-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:26:14,2025-05-28 03:53:06
531986a1-671a-4041-bb53-0ab70f8b5036,USA-FDA,fc1812b6-fe3a-451a-9d37-32d161cc7010,G_DETAILED_SUMMARY,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0268/FDA-2009-D-0268-0005/FDA-2009-D-0268-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0268"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0268-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0268/FDA-2009-D-0268-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:30:15,2025-05-28 03:53:06
533dfa58-5a50-41a4-b788-56dc79801cea,USA-FDA,62448f47-9b50-462e-aad4-e51a2846a43f,G_MINI_SUMMARY,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002/FDA-2009-D-0137-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Guidance"", ""docket_id"": ""FDA-2009-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0137-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:31:39,2025-05-28 03:53:06
53452ec8-0f59-4d48-bd73-9108b62be3c0,USA-FDA,1b20d6bb-7a5a-45cf-bf9a-e0221ac78394,G_DETAILED_SUMMARY,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-2001/FDA-2015-D-2001-0002/FDA-2015-D-2001-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance Assessment of Male-Mediated Developmental Risk for Pharmaceuticals"", ""docket_id"": ""FDA-2015-D-2001"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-2001-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-2001/FDA-2015-D-2001-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:31:52,2025-05-28 03:53:06
5365d4ac-5511-4ad9-b57e-7bc9632f4bbb,USA-FDA,3d4da742-1ab9-478e-aebf-4bce1b885de3,G_IMPACT_ANALYSIS,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002/FDA-2009-D-0539-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins; Guidance"", ""docket_id"": ""FDA-2009-D-0539"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0539-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:32:13,2025-05-28 03:53:06
53688e84-4571-47a4-ad46-364548b19a5e,USA-FDA,7c05b95a-ee15-417d-9fa3-f9191fa50723,G_DETAILED_SUMMARY,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002/FDA-2012-D-1135-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidances for Industry Limiting Use of Certain Phthalates as Excipients in Center for Drug Evaluation and Research-Regulated Products"", ""docket_id"": ""FDA-2012-D-1135"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1135-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:01:26,2025-05-28 03:53:06
53a674e8-fe8b-4884-ab8d-d74fb7e55d72,USA-FDA,0d24c821-a5bc-4515-ac72-b140cc78f3ec,G_FAQ,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013/FDA-2016-D-2567-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""02-Final Guidance for Industry-E17 General Principles for Planning and Design of Multiregional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:03:24,2025-05-28 03:53:06
53c84c88-0cab-4ff0-92f3-d78e15e8fffa,USA-FDA,94c6ddbd-170a-4375-b593-fd20f470d815,G_DETAILED_SUMMARY,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0616/FDA-2010-D-0616-0020/FDA-2010-D-0616-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Codevelopment of Two or More New Investigational Drugs for Use in Combination"", ""docket_id"": ""FDA-2010-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0616-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0616/FDA-2010-D-0616-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:02:04,2025-05-28 03:53:06
54,,933a3378-3867-4d89-9e7f-8fcfbf77abf0,G_CONCISE_SUMMARY,2025-05-12 19:26:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Providing Submissions in Electronic Format--Standardized Study Data"", ""docket_id"": ""FDA-2012-D-0097"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0097-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:26:18,2025-05-28 03:53:06
54002ba7-d61e-4639-a91d-937906d6891f,USA-FDA,befbc6a5-6274-4f6d-b5ba-0ab4c286c863,G_FAQ,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002/FDA-2002-P-0302-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices"", ""docket_id"": ""FDA-2002-P-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-P-0302-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:30:36,2025-05-28 03:53:06
540a0409-39c1-4f10-8b56-72602429c52a,USA-FDA,3b9d26d1-076f-48db-8477-4ecc7acbfa26,G_FAQ,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002/FDA-2011-D-0730-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff; Class II Special Controls Guidance Documents: In Vitro Diagnostic Devices for Yersinia Species Detection"", ""docket_id"": ""FDA-2011-D-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0730-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:00:45,2025-05-28 03:53:06
543e684d-7cb8-4b76-8f18-52e0cdb63f5d,CAB,f2134875-9fbc-40ac-9c25-cccb8e0241f0,G_FAQ_IN,2025-05-20 12:42:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2018-N-3233-0006.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2018-N-3233-0006_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""3f21331b-4399-4219-aa7e-0a5cb7a4ba33""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3f21331b-4399-4219-aa7e-0a5cb7a4ba33"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:43:39,2025-05-28 03:53:06
5462e7ab-3142-473f-807b-e08dad373c8f,USA-FDA,3c0280ca-99a1-46bd-a323-d7160f9ecb66,G_IMPACT_ANALYSIS,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610/FDA-2016-D-4414-1610-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nutrition and Supplement Facts Labels: Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals: Guidance for Industry"", ""docket_id"": ""FDA-2016-D-4414"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-4414-1610""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:16:06,2025-05-28 03:53:06
549ef024-a9a6-4932-815f-55bbff800c11,USA-FDA,5f1763d6-712e-4657-af44-9b53b15f87e8,G_MINI_SUMMARY,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-0298/FDA-2019-D-0298-0002/FDA-2019-D-0298-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Quality Considerations for Continuous Manufacturing; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2019-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-0298-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-0298/FDA-2019-D-0298-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:45:09,2025-05-28 03:53:06
54a7f36c-705c-4294-8a36-51f69c3b6d07,USA-FDA,32d1be26-46e9-48f2-9dc8-fe4bb2a71b39,G_DETAILED_SUMMARY,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009/FDA-2016-D-2569-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""01 Final Guidance for Industry - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals-Questions and Answers"", ""docket_id"": ""FDA-2016-D-2569"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2569-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:32:49,2025-05-28 03:53:06
54b2d0b0-06c7-4244-aadd-d169454503ec,USA-FDA,9863576b-735c-4ad7-9d68-305046b413e2,G_ACTION_ITEMS,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002/FDA-2000-D-0129-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans - Draft Guidance"", ""docket_id"": ""FDA-2000-D-0129"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-D-0129-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:01:50,2025-05-28 03:53:06
54d6ee6c-9fdb-4ec5-8ed6-2c5a34173c01,USA-FDA,5ea93e1f-3884-44eb-813e-a1f0cfa4c75e,G_KEYWORDS,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009/FDA-2016-D-2569-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""01 Final Guidance for Industry - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals-Questions and Answers"", ""docket_id"": ""FDA-2016-D-2569"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2569-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:33:36,2025-05-28 03:53:06
55,,e679db8a-0cc9-4778-9c9c-997251023629,G_DETAILED_SUMMARY,2025-05-12 19:26:31,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Providing Submissions in Electronic Format--Standardized Study Data"", ""docket_id"": ""FDA-2012-D-0097"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0097-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:26:33,2025-05-28 03:53:06
5509720a-db03-4780-abdd-53c62895749b,SCHEDULED,34e6e0b5-6af2-4195-b417-44901ef64bbf,FDA_ALERT,2025-06-02 00:00:04,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/34e6e0b5-6af2-4195-b417-44901ef64bbf"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:10,2025-06-02 00:00:10
550b83e5-2955-4112-aa0e-8972864f0eff,USA-FDA,b20cc667-0c25-4f44-b1a0-33094fb761b3,G_FAQ,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002/FDA-2012-D-0049-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke UnderSection 904(a)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance"", ""docket_id"": ""FDA-2012-D-0049"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0049-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:30:47,2025-05-28 03:53:06
55231836-4d4e-4f36-920e-86e6aba80e5b,USA-FDA,faf81860-60b5-45b0-9b7b-32c8a263e3b3,G_ACTION_ITEMS,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1088/FDA-2013-D-1088-0002/FDA-2013-D-1088-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entity Compliance Guide; Declaring Color Additives in Animal Foods; #223"", ""docket_id"": ""FDA-2013-D-1088"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1088-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1088/FDA-2013-D-1088-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:00:31,2025-05-28 03:53:06
55297d9c-9c5b-4b96-bb71-76b6bed368e5,USA-FDA,b63bc33e-fd14-4bc7-83e1-ca8767e6bc4d,G_FAQ,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002/FDA-2017-D-6380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric\nSubpopulations of Common Diseases Draft Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:02:00,2025-05-28 03:53:06
55424670-548b-4fa5-b7c4-5085db22ecf0,USA-FDA,e7177a4b-44f3-4d89-be5d-ac9531b7ee1b,G_MINI_SUMMARY,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010/FDA-2008-D-0623-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #192 Anesthetics for Companion Animals"", ""docket_id"": ""FDA-2008-D-0623"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0623-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:01:15,2025-05-28 03:53:06
5542ecf1-772f-4fea-a157-218f140635b0,USA-FDA,52a03856-ac6a-48d1-93b0-a954601206bf,G_DETAILED_SUMMARY,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0605/FDA-2011-D-0605-0002/FDA-2011-D-0605-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Scientific Considerations in Demonstrating Biosimilarity to Reference Product"", ""docket_id"": ""FDA-2011-D-0605"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0605-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0605/FDA-2011-D-0605-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:16:10,2025-05-28 03:53:06
555496d8-262e-4244-8450-b0e7d4b89262,USA-FDA,c446a3f3-812c-433c-928c-e8e8b3559a28,G_KEYWORDS,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017/FDA-2010-D-0426-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Bar Code Label Requirements�Questions and Answers"", ""docket_id"": ""FDA-2010-D-0426"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0426-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:33:49,2025-05-28 03:53:06
5561c470-440d-40f5-8fa9-ba8fbb9e81b2,USA-FDA,bbf2ca11-c190-4291-94f3-dd6f096ca1cf,G_IMPACT_ANALYSIS,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0016/FDA-2010-D-0503-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Clinical Investigators, Sponsors, and Institutional Review Boards on Investigational New Drug Applications--Determining Whether Human Research Studies Can Be Conducted Without an Investigational New Drug Application"", ""docket_id"": ""FDA-2010-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0503-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:45:55,2025-05-28 03:53:06
556ba0e5-8fba-4963-859a-a20c317bfd7b,USA-FDA,bce43ce2-db16-4161-b695-d46cde50f342,G_ACTION_ITEMS,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1960/FDA-2020-D-1960-0001/FDA-2020-D-1960-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on HACCP Regulation for Fish and Fishery Products"", ""docket_id"": ""FDA-2020-D-1960"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1960-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1960/FDA-2020-D-1960-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:02:22,2025-05-28 03:53:06
557eaa56-19d4-404a-a8e4-66080b6dc066,USA-FDA,7d7b6660-c261-4271-a7d0-b6194328e845,G_FAQ,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0433/FDA-2012-D-0433-0002/FDA-2012-D-0433-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""mHealth Regulatory Coalition (Epstein Becker & Green) - Guidance"", ""docket_id"": ""FDA-2012-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0433-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0433/FDA-2012-D-0433-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:15:39,2025-05-28 03:53:06
55a839ae-4e57-4fae-a7f1-2e49aa95b181,USA-FDA,8dde90cb-acf3-4df4-9273-200b51eaa2ae,G_MINI_SUMMARY,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004/FDA-2007-D-0375-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Acute Bacterial Sinusitis; Developing Drugs for Treatment"", ""docket_id"": ""FDA-2007-D-0375"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0375-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:30:08,2025-05-28 03:53:06
55ae0792-fcf0-4905-8450-1c8cd595828a,USA-FDA,3e345552-2a48-434e-9f56-0caafd8adce4,G_FAQ,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0286/FDA-2013-D-0286-0015/FDA-2013-D-0286-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0286"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0286-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0286/FDA-2013-D-0286-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:16:53,2025-05-28 03:53:06
55b9afd4-c5f2-48d0-9ec3-c5ab36ee97f0,USA-FDA,12f16b0b-0d20-49e9-b153-60ca9b17dfd0,G_MINI_SUMMARY,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0199/FDA-2008-D-0199-0002/FDA-2008-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""E15 Pharmacogenomics Definitions and Sample Coding"", ""docket_id"": ""FDA-2008-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0199/FDA-2008-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:31:53,2025-05-28 03:53:06
55f1acec-8172-4f4a-b5aa-b98ff0f64c12,USA-FDA,9f2ab71b-e9f8-4cd0-95a4-c5f4218428a6,G_DETAILED_SUMMARY,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002/FDA-2011-D-0480-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products"", ""docket_id"": ""FDA-2011-D-0480"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0480-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:30:20,2025-05-28 03:53:06
56,,891ae851-726f-41c0-bd91-008dda9115df,G_FAQ,2025-05-12 19:27:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Providing Submissions in Electronic Format--Standardized Study Data"", ""docket_id"": ""FDA-2012-D-0097"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0097-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:27:05,2025-05-28 03:53:06
56226f6d-b76d-4dbe-9aed-44df6a934759,CAB,72f9aadc-652b-4b85-b363-f7bfe39f008f,G_KEYWORDS,2025-05-20 10:13:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2022-F-1108-0001"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2022-F-1108-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""48b24e3f-2c7d-446d-8ef2-9a788b5abc48""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/48b24e3f-2c7d-446d-8ef2-9a788b5abc48"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:13:57,2025-05-28 03:53:06
5655db0c-959b-4b07-80fd-5cf60b9b0746,USA-FDA,7a4a7528-2b3c-4be8-8f9e-08abedbba9b7,G_CONCISE_SUMMARY,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002/FDA-2020-D-1640-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance on Cannabidiol"", ""docket_id"": ""FDA-2020-D-1640"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1640-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:15:53,2025-05-28 03:53:06
5665bf5a-eb14-4b66-b7ae-510702ec5844,USA-FDA,c83776a5-18e1-4b6a-b8e4-0b6fbb8e4457,G_KEYWORDS,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005/FDA-2007-D-0205-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:33:34,2025-05-28 03:53:06
567836ee-3a3c-428d-b0e5-bb63801d7200,USA-FDA,01da244b-07c1-4d8d-8d89-f2ed606e00dd,G_ACTION_ITEMS,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002/FDA-2018-D-0740-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk Guidance for Industry"", ""docket_id"": ""FDA-2018-D-0740"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0740-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:31:12,2025-05-28 03:53:06
568909e3-0316-4474-bceb-95b51f666ba2,USA-FDA,191a0866-c333-4ee5-9e85-da5977f858fe,G_IMPACT_ANALYSIS,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0545/FDA-2016-D-0545-0099/FDA-2016-D-0545-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components; Guidance for Industry"", ""docket_id"": ""FDA-2016-D-0545"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0545-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0545/FDA-2016-D-0545-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:30:53,2025-05-28 03:53:06
56c3d2a7-4ced-479a-bac9-2d3c677cefff,USA-FDA,37581f9e-2313-4fe2-aa84-38dbdd35c572,G_IMPACT_ANALYSIS,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002/FDA-2002-P-0302-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices"", ""docket_id"": ""FDA-2002-P-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-P-0302-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:30:54,2025-05-28 03:53:06
56e8973f-d80d-45da-9315-ecc392a37532,USA-FDA,72181392-3f27-4e87-86ad-0ad337ccc654,G_MINI_SUMMARY,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002/FDA-2002-P-0302-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices"", ""docket_id"": ""FDA-2002-P-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-P-0302-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:30:08,2025-05-28 03:53:06
56ee4f55-3eb4-4d57-bd9d-a25852060225,USA-FDA,b5bff9e0-052e-442e-9e49-46c429a45a92,G_MINI_SUMMARY,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002/FDA-2011-D-0674-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry FDA Records Access Authority under Section 414 and 704 of the Federal Food, Drug, & Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0674"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0674-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:16,2025-05-28 03:53:06
56f54d43-ba5f-4973-a78f-03a3afa786aa,Queue,6f6876cd-1cc0-47c0-883a-00c46a20bdec,G_SUMMARY_USER,2025-05-30 04:08:32,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""c_986569 (11).pdf""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/detailed_summary/6f6876cd-1cc0-47c0-883a-00c46a20bdec/c_986569 (11).pdf.pdf"", ""doc_title"": ""c_986569 (11).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/detailed_summary/6f6876cd-1cc0-47c0-883a-00c46a20bdec"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 04:08:32,2025-05-30 04:08:32
57,,3258a62c-4cd9-4042-9976-1829a8b9b368,G_ACTION_ITEMS,2025-05-12 19:27:12,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Providing Submissions in Electronic Format--Standardized Study Data"", ""docket_id"": ""FDA-2012-D-0097"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0097-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:27:13,2025-05-28 03:53:06
574783f0-ab28-47f5-9a99-236f1adcddd6,USA-FDA,477f06c5-8685-4de6-b4c3-e87acae20b1d,G_MINI_SUMMARY,2025-05-19 23:42:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016/FDA-2013-D-0369-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in\nPharmaceuticals to Limit Potential Carcinogenic Risk; International\nConference on Harmonisation; Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0369"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0369-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 03:44:10,2025-05-28 03:53:06
5762ec38-abe4-4019-ba40-3bbce7e13bc8,USA-FDA,a3c376f3-d566-483b-85c0-63971b8d452e,G_IMPACT_ANALYSIS,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002/FDA-2011-D-0649-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Class II Special Controls; External Pacemaker Pulse Generator"", ""docket_id"": ""FDA-2011-D-0649"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0649-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:01:20,2025-05-28 03:53:06
57780c10-63e5-40d0-b808-731266076e38,USA-FDA,69236b2f-2b49-417f-ba07-1afd4f327ab7,G_KEYWORDS,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034/FDA-2002-D-0094-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Food and Drug Administration Advisory\nCommittee Members, and Food and Drug Administration Staff: Public\nAvailability of Advisory Committee Members� Financial Interest\nInformation and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:30:47,2025-05-28 03:53:06
58,,c1082fc3-798b-4812-848e-ed8b1df726c4,G_IMPACT_ANALYSIS,2025-05-12 19:27:19,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Providing Submissions in Electronic Format--Standardized Study Data"", ""docket_id"": ""FDA-2012-D-0097"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0097-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0097/FDA-2012-D-0097-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:27:21,2025-05-28 03:53:06
582ef5a0-86f4-47d3-861a-39ff3a44a94b,USA-FDA,3791b2f0-e52f-4c53-adcb-1ae6b58b5200,G_KEYWORDS,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021/FDA-2005-D-0282-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:32:05,2025-05-28 03:53:06
5840e9d2-7ff6-41da-9a6a-b4fce4720578,USA-FDA,dd8aeb32-ddb8-46cf-895e-cf434e030dd9,G_IMPACT_ANALYSIS,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1010/FDA-2012-D-1010-0002/FDA-2012-D-1010-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Initial Completeness Assessments for Type II Active Pharmaceutical Ingredient Drug Master Files under Generic Drug User Fee"", ""docket_id"": ""FDA-2012-D-1010"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1010-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1010/FDA-2012-D-1010-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:48:24,2025-05-28 03:53:06
58454761-a347-4470-8253-542f30f78dbf,USA-FDA,64e4d24c-30b4-4952-8778-089148934b72,G_FAQ,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020/FDA-2015-D-1245-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:03:03,2025-05-28 03:53:06
585a11e1-c948-45dc-a033-70dc6645c5c2,USA-FDA,457d8619-c137-4b56-973c-dc75d78afc2d,G_FAQ,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0721/FDA-2011-D-0721-0002/FDA-2011-D-0721-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act"", ""docket_id"": ""FDA-2011-D-0721"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0721-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0721/FDA-2011-D-0721-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:30:51,2025-05-28 03:53:06
58d612ba-f19d-433a-825a-14febe929f98,USA-FDA,cbd5d506-f3be-4f5c-92d1-46ae4ed5a8ed,G_FAQ,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0005/FDA-2007-D-0433-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bieoquivalence Recommendations for Specific Products"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:00:57,2025-05-28 03:53:06
59,,99af6d92-4063-402f-9434-5a0eb5fae24a,G_MINI_SUMMARY,2025-05-12 19:27:23,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002/FDA-2013-D-0114-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls from Product Enhancements; Reporting Requirements; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:27:24,2025-05-28 03:53:06
5925fe1f-aa25-4097-bbc0-ee308c218328,USA-FDA,c3adbd26-2944-4a3c-a161-3cb7ad42c703,G_MINI_SUMMARY,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0721/FDA-2011-D-0721-0002/FDA-2011-D-0721-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act"", ""docket_id"": ""FDA-2011-D-0721"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0721-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0721/FDA-2011-D-0721-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:30:39,2025-05-28 03:53:06
59351c28-33b4-4bfb-9bca-01165df9caf5,USA-FDA,cab3431a-f5c9-4507-bab0-ba5604e81dd8,G_KEYWORDS,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002/FDA-2005-G-0193-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Low Energy Ultrasound Wound Cleaner"", ""docket_id"": ""FDA-2005-G-0193"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-G-0193-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:13:09,2025-05-28 03:53:06
594765e8-5562-4e44-b9bc-5223b1fc9f8b,USA-FDA,1614f4f8-b7ad-46cd-86db-6224028504b7,G_DETAILED_SUMMARY,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0286/FDA-2013-D-0286-0015/FDA-2013-D-0286-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0286"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0286-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0286/FDA-2013-D-0286-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:16:38,2025-05-28 03:53:06
5957ae3b-9a9b-4849-89be-dbe9b50b9824,USA-FDA,a901bc5b-1b5b-4588-b369-6ac4460a0501,G_IMPACT_ANALYSIS,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0938/FDA-2012-D-0938-0024/FDA-2012-D-0938-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Guidance on Abbreviated New Drug Applications: Stability Testing of Drug Substances and Products"", ""docket_id"": ""FDA-2012-D-0938"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0938-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0938/FDA-2012-D-0938-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:15:33,2025-05-28 03:53:06
59599bed-2c77-4cc0-9e89-9f66761bfae2,USA-FDA,4962acaa-9944-450f-b970-987d33e4ba75,G_ACTION_ITEMS,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015/FDA-1999-D-1315-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Formal Meetings With Sponsors and Applicants for PDUFA Products; Guidance Document"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:32:54,2025-05-28 03:53:06
596420ec-77a7-4d75-bb1d-e289c1e8ea81,USA-FDA,0c75a9cc-a068-419c-a76e-76eb58157f09,G_MINI_SUMMARY,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018/FDA-2012-D-1038-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:30:12,2025-05-28 03:53:06
59819a04-9837-4680-89f4-cbcf96b33a2b,USA-FDA,e3fbd2d2-7d5f-479b-815e-bd1ba4c4fc1e,G_DETAILED_SUMMARY,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0033/FDA-2003-D-0033-0003/FDA-2003-D-0033-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff: Food and Drug Administration and Industry Actions on Premarket Notification Submissions: Effect on Food and Drug Administration Review Clock and Performance Assessment"", ""docket_id"": ""FDA-2003-D-0033"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0033-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0033/FDA-2003-D-0033-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:32:03,2025-05-28 03:53:06
59a335a0-867f-4041-b3bb-538b9d5e13df,USA-FDA,37716d22-f47a-4fc0-b734-668d1b657019,G_KEYWORDS,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002/FDA-2015-D-1309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M8 Electronic Common Technical Document v4.0 Draft Implementation\nGuide v2.0; Electronic Common Technical Document v4.0 Implementation Package Draft Specification for Submission Formats\nv2.0; International Conference on Harmonisation; Draft Guidance for\nIndustry"", ""docket_id"": ""FDA-2015-D-1309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:11,2025-05-28 03:53:06
59a9859d-19d9-47c4-9f70-af8deac3ead2,USA-FDA,d5a1c932-7995-491f-a091-2cda83f5a713,G_DETAILED_SUMMARY,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001/FDA-2020-D-1925-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations)"", ""docket_id"": ""FDA-2020-D-1925"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1925-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:46:29,2025-05-28 03:53:06
59fd5327-2178-46dc-913f-ef4ae81ffbd9,USA-FDA,45d275b5-e226-4a94-a86c-8def9eeea091,G_CONCISE_SUMMARY,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010/FDA-2011-D-0799-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components Including Source Plasma to Reduce the Risk of Transmission of Hepatitis B Virus"", ""docket_id"": ""FDA-2011-D-0799"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0799-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:01:13,2025-05-28 03:53:06
5a15255e-89c7-4414-bfa1-8e2943f532c5,USA-FDA,4b55a766-2073-498d-954c-da905b4ed390,G_FAQ,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0013/FDA-2003-D-0186-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""DRAFT GUIDANCE FOR INDUSTRY COSMETICS PROCESSORS AND TRANSPORTERS: COSMETICS SECURITY PREVENTIVE MEASURES GUIDANCE"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:31:13,2025-05-28 03:53:06
5a1a8656-567a-41cc-9496-3f6d6e919123,USA-FDA,fc4640b3-27f8-4853-bf63-e59bfb3ab73d,G_FAQ,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0524/FDA-2012-D-0524-0002/FDA-2012-D-0524-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: Acceptance and Filing Review for Premarket Approval Applications (PMAs) - Guidance"", ""docket_id"": ""FDA-2012-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0524-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0524/FDA-2012-D-0524-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:16:21,2025-05-28 03:53:06
5a3abafa-090e-48a2-8793-8e5a79a4bb9f,USA-FDA,2a1c6000-75d9-429c-a73e-4c15aada1522,G_IMPACT_ANALYSIS,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1399/FDA-2020-D-1399-0001/FDA-2020-D-1399-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part I"", ""docket_id"": ""FDA-2020-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1399-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1399/FDA-2020-D-1399-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:01:27,2025-05-28 03:53:06
5a3e6014-dce0-41d3-a510-45a1e5e6f178,USA-FDA,a69be1eb-722b-48e2-ad04-edbe1cf1ca78,G_FAQ,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001/FDA-2020-D-1407-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products HCT Ps Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2020-D-1407"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1407-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:37,2025-05-28 03:53:06
5a4d3146-004d-497a-b152-7240bddda968,USA-FDA,f36d8516-8c9b-4488-ace0-f171dcc4e15f,G_IMPACT_ANALYSIS,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0334/FDA-2008-N-0334-0010/FDA-2008-N-0334-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Providing Submissions in Electronic Format - Postmarketing Safety Reports-Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements"", ""docket_id"": ""FDA-2008-N-0334"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-N-0334-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0334/FDA-2008-N-0334-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:01:54,2025-05-28 03:53:06
5a85c949-d7b1-4641-882e-6934da36b347,USA-FDA,f1c276fc-5380-40ab-b52f-54a3fe75a0b3,G_MINI_SUMMARY,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0045/FDA-2013-D-0045-0030/FDA-2013-D-0045-0030-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abuse-Deterrent Opioids-Evaluation and Labeling"", ""docket_id"": ""FDA-2013-D-0045"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0045-0030""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0045/FDA-2013-D-0045-0030"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:45:08,2025-05-28 03:53:06
5aa1d6e3-9096-482f-917f-a2f2e117fc89,USA-FDA,4e27f1e4-6f89-4f67-afe8-f4b938873616,G_DETAILED_SUMMARY,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0586/FDA-2011-D-0586-0002/FDA-2011-D-0586-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Standards for Clinical Trial Imaging Endpoints; Draft Guidance Document"", ""docket_id"": ""FDA-2011-D-0586"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0586-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0586/FDA-2011-D-0586-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:01:13,2025-05-28 03:53:06
5aad3e64-1e53-4f52-b1f3-99310021ed20,USA-FDA,205067ec-5bab-4755-95f0-a53dc599f4cd,G_ACTION_ITEMS,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1304/FDA-1999-D-1304-0002/FDA-1999-D-1304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Possible Dioxin/PCB Contamination of Drug and Biological Products"", ""docket_id"": ""FDA-1999-D-1304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1304/FDA-1999-D-1304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:31:56,2025-05-28 03:53:06
5ace2961-1218-4549-9f9d-9f770f184d97,USA-FDA,85dbe5c2-9163-444b-9ae8-859c15b04b6b,G_KEYWORDS,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002/FDA-2012-N-1239-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guideline for Industry and Food and Drug Administration Staff; Class II Special Controls Guideline: Temporary Mandibular Condyle Reconstruction Plate"", ""docket_id"": ""FDA-2012-N-1239"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-N-1239-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:32:33,2025-05-28 03:53:06
5ad26a75-bfc5-439a-b337-a73cd1130918,USA-FDA,087fcfc2-8a02-4019-a8d6-2df5dd47a060,G_ACTION_ITEMS,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1958/FDA-2020-D-1958-0001/FDA-2020-D-1958-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Seafood HACCP Transition Guidance"", ""docket_id"": ""FDA-2020-D-1958"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1958-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1958/FDA-2020-D-1958-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:03:01,2025-05-28 03:53:06
5b1f0779-537e-4656-b648-a203e8dd34a6,USA-FDA,84dfd76a-1853-40ba-a90d-2f7f8c96127f,G_DETAILED_SUMMARY,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0077/FDA-2007-D-0077-0003/FDA-2007-D-0077-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Providing Regulatory Submissions in Electronic Format - Receipt Date - Draft Guidance Document"", ""docket_id"": ""FDA-2007-D-0077"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0077-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0077/FDA-2007-D-0077-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:30:51,2025-05-28 03:53:06
5b4feffb-5039-47bf-b5e2-983dd9a9aad4,USA-FDA,6c1ef3d5-c477-4ef9-887c-2393ca1a687f,G_IMPACT_ANALYSIS,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0007/FDA-1992-N-0007-0005/FDA-1992-N-0007-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Industry Supported Scientific and Educational Activities:  Guidance for Industry"", ""docket_id"": ""FDA-1992-N-0007"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0007-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0007/FDA-1992-N-0007-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:16:54,2025-05-28 03:53:06
5b656b98-09cd-4b97-9659-8c5baa5042c8,USA-FDA,7640fd68-b2a2-4f3c-a40a-9ee4015cb7d6,G_FAQ,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004/FDA-2018-N-4735-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""GFI Safety Labeling Changes Implementation of Section 505(o)(4) of the FDC Act"", ""docket_id"": ""FDA-2018-N-4735"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-N-4735-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:16:41,2025-05-28 03:53:06
5b928517-852f-4248-bc4c-92254be711f0,SCHEDULED,752711e3-8f40-4744-9a1b-03459338d02f,DEVICE_ANALYST,2025-05-19 16:19:25,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-18""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/752711e3-8f40-4744-9a1b-03459338d02f"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-19 20:20:37,2025-05-28 03:53:06
5b9500cc-0a89-4a07-96e6-8429039d40ba,USA-FDA,db94e428-94a6-462b-ad6f-4f3f63b755a8,G_IMPACT_ANALYSIS,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002/FDA-2014-D-1351-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Flow Cytometric Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1351"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1351-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:03:02,2025-05-28 03:53:06
5ba0be29-860f-475a-83b6-6bd73b95584d,USA-FDA,e6a3150d-359d-44a9-a56b-c742b1828469,G_IMPACT_ANALYSIS,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002/FDA-2011-D-0674-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry FDA Records Access Authority under Section 414 and 704 of the Federal Food, Drug, & Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0674"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0674-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:48,2025-05-28 03:53:06
5ba7a270-7683-4afd-9869-a7900b87b034,QUEUE,1727d558-d238-43ef-8080-73dee2f8d168,G_ACTION_ITEMS_USER,2025-05-20 10:41:52,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__doc_title__"": ""FDA-2023-N-4225-0001_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/1727d558-d238-43ef-8080-73dee2f8d168/SRC/1727d558-d238-43ef-8080-73dee2f8d168.pdf"", ""doc_title"": ""FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/1727d558-d238-43ef-8080-73dee2f8d168/DEST/action_items.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:42:00,2025-05-28 03:53:06
5bb6b56f-1586-453a-8fc8-4ee38187d372,USA-FDA,c417b14b-0b8d-411e-86c2-fc502383ceef,G_ACTION_ITEMS,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0364/FDA-2007-D-0364-0014/FDA-2007-D-0364-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Indexing Structured Product Labeling"", ""docket_id"": ""FDA-2007-D-0364"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0364-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0364/FDA-2007-D-0364-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:01:47,2025-05-28 03:53:06
5bba0e7d-1804-418b-a763-5639f8b709f8,USA-FDA,4b243dd1-729b-4351-9b34-8778aac63189,G_MINI_SUMMARY,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0476/FDA-2011-D-0476-0010/FDA-2011-D-0476-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Enforcement Policy for Premarket Notification Requirements for Certain In Vitro Diagnostic and Radiology Devices"", ""docket_id"": ""FDA-2011-D-0476"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0476-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0476/FDA-2011-D-0476-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:31:18,2025-05-28 03:53:06
5bba8eb7-f27a-44e0-89ab-aaadd30a5ad2,CAB,c2b4a7de-4f4e-4d8b-bce2-05d58fc00122,G_MINI_SUMMARY_IN,2025-05-27 02:30:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""Provisions for In-vitro Diagnostic Reagent Registration (Abolished) (1).pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/33ef1a3e-f632-4ce5-90e6-a74eb8d6b6eb/Provisions for In-vitro Diagnostic Reagent Registration (Abolished) (1).pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""688478d9-789c-4a07-b85a-f8ffb2a70019""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/688478d9-789c-4a07-b85a-f8ffb2a70019"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 02:30:08,2025-05-28 03:53:06
5bf09fbc-1459-4631-85f0-4cf05758f812,USA-FDA,77ff8c1d-863a-46ea-901a-acb346a5fe61,G_FAQ,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013/FDA-2009-D-0490-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff:  Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2009-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0490-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:48:01,2025-05-28 03:53:06
5c0b3230-489c-47a0-86e1-2e00b2c629dc,USA-FDA,08f298c1-32cb-4ec9-acb8-6eef401cf8a5,G_FAQ,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009/FDA-2007-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry; Bioequivalence Recommendation for Lenalidomide Capsules"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:13:28,2025-05-28 03:53:06
5c1726ff-3625-431e-a050-b5d08c499a28,CAB,e6e75962-60ef-4031-bdf0-2d4f922a6bfe,G_MINI_SUMMARY_IN,2025-05-27 02:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-2910-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2024-N-2910-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b3efc128-de32-4064-8905-ee749b8e53b7""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b3efc128-de32-4064-8905-ee749b8e53b7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 02:00:08,2025-05-28 03:53:06
5c5b9619-a8fa-4544-9133-e33580c62124,SCHEDULED,5e51098c-4387-4e4f-b095-2a31b0786ac0,DEVICE_ANALYST,2025-05-31 00:00:05,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/5e51098c-4387-4e4f-b095-2a31b0786ac0"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:13,2025-05-31 00:00:13
5c644703-0f43-458a-be50-232065b1348b,USA-FDA,d185cd82-f6be-45e5-9742-bdb0bcab0e73,G_CONCISE_SUMMARY,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002/FDA-2009-D-0539-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins; Guidance"", ""docket_id"": ""FDA-2009-D-0539"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0539-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:31:08,2025-05-28 03:53:06
5c76e715-9669-48d6-8de4-1294d1e0fd59,USA-FDA,42a4fab1-99c8-413e-ac3c-1f99e95932f9,G_KEYWORDS,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002/FDA-2009-D-0354-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Pharmaceutical Components at Risk for Melamine Contamination"", ""docket_id"": ""FDA-2009-D-0354"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0354-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:02:49,2025-05-28 03:53:06
5c8581f5-a410-465b-9b75-9dc34ab2661d,USA-FDA,f98947b2-19d4-48da-9052-e3b87bf1f557,G_KEYWORDS,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005/FDA-2012-D-0419-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for Use in Companion Animals"", ""docket_id"": ""FDA-2012-D-0419"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0419-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:31:53,2025-05-28 03:53:06
5c970577-5923-4c1a-9779-34ae1e7406e0,SCHEDULED,62262c03-f48d-4f72-89c5-4e2655a414fb,FDA_ALERT,2025-05-31 00:00:05,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/62262c03-f48d-4f72-89c5-4e2655a414fb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:15,2025-05-31 00:00:15
5c9edf89-0a5d-4f47-b07b-659faf714e69,USA-FDA,6f060cc1-8fb1-40ae-8827-cd53ed470bcd,G_DETAILED_SUMMARY,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009/FDA-2006-D-0157-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry:  Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2006-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0157-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:00:30,2025-05-28 03:53:06
5ca01a92-2723-458f-80e6-f329bbc86e02,USA-FDA,a497fc6a-7d60-4997-82fb-7a61317e853d,G_ACTION_ITEMS,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0205/FDA-2008-D-0205-0034/FDA-2008-D-0205-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"", ""docket_id"": ""FDA-2008-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0205-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0205/FDA-2008-D-0205-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:47:32,2025-05-28 03:53:06
5ca51a4f-9955-41f5-9ac3-ea2424a26699,USA-FDA,9834f9af-2d39-4ac7-99c4-04722bfcb67e,G_CONCISE_SUMMARY,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001/FDA-2020-D-1608-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data"", ""docket_id"": ""FDA-2020-D-1608"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1608-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:46:38,2025-05-28 03:53:06
5ca80ca9-07c7-4770-ace4-9437c28d0732,USA-FDA,48cb829f-5e8a-4404-ae8f-ff5734508594,G_DETAILED_SUMMARY,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004/FDA-2007-D-0375-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Acute Bacterial Sinusitis; Developing Drugs for Treatment"", ""docket_id"": ""FDA-2007-D-0375"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0375-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:30:33,2025-05-28 03:53:06
5cd9d5c5-33e6-491e-b491-137c26306152,USA-FDA,07a64b9d-12d3-4b70-a43a-63b8906e4e41,G_FAQ,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0090/FDA-2003-D-0090-0002/FDA-2003-D-0090-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate � Labeling Enforcement Policy"", ""docket_id"": ""FDA-2003-D-0090"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0090-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0090/FDA-2003-D-0090-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:01:27,2025-05-28 03:53:06
5ce8e5bb-0107-4b4c-9436-e22fde65bf6f,USA-FDA,16dea49f-8ea5-43cb-88b1-f2a80157e1d8,G_MINI_SUMMARY,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002/FDA-2012-D-0179-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens"", ""docket_id"": ""FDA-2012-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0179-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:00:10,2025-05-28 03:53:06
5cf4d1b4-c1c2-4ba4-ae78-29f2faabd47a,USA-FDA,4806c3e0-72b7-467c-ac98-d9269baeac92,G_ACTION_ITEMS,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0605/FDA-2011-D-0605-0002/FDA-2011-D-0605-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Scientific Considerations in Demonstrating Biosimilarity to Reference Product"", ""docket_id"": ""FDA-2011-D-0605"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0605-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0605/FDA-2011-D-0605-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:16:36,2025-05-28 03:53:06
5d02a0c5-6392-4bce-9d5f-ae2f2649d461,USA-FDA,3ddcbb52-1ef5-45f9-aaf8-b86325889b2b,G_MINI_SUMMARY,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012/FDA-2016-D-1533-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma - Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:47:25,2025-05-28 03:53:06
5d239ce6-2615-4ea7-b2e6-bcc101f2f112,SCHEDULED,8585e57d-75ef-410f-8653-91a2f3901f18,DEVICE_ANALYST,2025-06-02 00:00:04,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/8585e57d-75ef-410f-8653-91a2f3901f18"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:15,2025-06-02 00:00:15
5d9c6198-3c3a-405f-98e3-8e5a77d0bbe7,SCHEDULED,fb263cfa-a6aa-4439-8d44-3b2c51069749,DEVICE_ANALYST,2025-05-24 00:00:05,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/fb263cfa-a6aa-4439-8d44-3b2c51069749"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:16,2025-05-28 03:53:06
5db8a5c3-9491-458c-b428-15e899056897,USA-FDA,cf4dc409-e0f2-4f6d-8b74-d4636b8cd2a4,G_ACTION_ITEMS,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0872/FDA-2011-D-0872-0002/FDA-2011-D-0872-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies"", ""docket_id"": ""FDA-2011-D-0872"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0872-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0872/FDA-2011-D-0872-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:00:46,2025-05-28 03:53:06
5dbf70ad-325d-4de5-bada-fd0c11d09947,USA-FDA,00bb1826-25b0-4c38-8ee7-64efd9751973,G_KEYWORDS,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002/FDA-2011-D-0487-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of Acceptable Full-Length and Abbreviated Donor History Questinnaries and Accompanying Materials for Use in Screening Donors of Source Plasma Draft Guidence"", ""docket_id"": ""FDA-2011-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0487-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:31:34,2025-05-28 03:53:06
5e0bbcf6-1193-4202-817a-a5aa9ece0b7f,SCHEDULED,a1bb8ef5-2e4b-42c7-a81c-38099677cd01,FDA_ALERT,2025-05-30 00:00:04,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/a1bb8ef5-2e4b-42c7-a81c-38099677cd01"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:10,2025-05-30 00:00:10
5e18393d-110a-40d1-b78d-4d69b7fa7e74,USA-FDA,f4a413a5-fa0a-4fa9-9f6c-d8b444ccb911,G_DETAILED_SUMMARY,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002/FDA-2009-D-0539-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins; Guidance"", ""docket_id"": ""FDA-2009-D-0539"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0539-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:31:17,2025-05-28 03:53:06
5e1d973b-7a78-411e-a522-954187d0faad,USA-FDA,2052930a-2897-4f09-89ef-d5d7d2b1ded4,G_FAQ,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002/FDA-2013-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abbreviated New Drug Application Submissions--Refuse-to-Receive Standards"", ""docket_id"": ""FDA-2013-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:32:26,2025-05-28 03:53:06
5e32b60d-3f2a-4e13-81e1-84c0ec510b8d,USA-FDA,357be12a-9f9b-4d4a-a32a-6e1deca9c79c,G_CONCISE_SUMMARY,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002/FDA-2012-D-1135-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidances for Industry Limiting Use of Certain Phthalates as Excipients in Center for Drug Evaluation and Research-Regulated Products"", ""docket_id"": ""FDA-2012-D-1135"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1135-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:01:16,2025-05-28 03:53:06
5e4d0daa-2879-43a6-b880-1c133e47c66d,USA-FDA,71b0b937-b348-422b-a2fb-f7db39849c24,G_MINI_SUMMARY,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1459/FDA-2018-D-1459-0049/FDA-2018-D-1459-0049-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Food Labeling: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics: Guidance for Industry"", ""docket_id"": ""FDA-2018-D-1459"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-1459-0049""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1459/FDA-2018-D-1459-0049"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:30:08,2025-05-28 03:53:06
5e586fe8-bbe2-4b90-abaf-c571cbe30cdd,USA-FDA,ab0ff80f-4448-4594-847a-903c20076359,G_IMPACT_ANALYSIS,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0814/FDA-2013-D-0814-0002/FDA-2013-D-0814-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Pediatric Study Plans:  Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans"", ""docket_id"": ""FDA-2013-D-0814"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0814-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0814/FDA-2013-D-0814-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:46:31,2025-05-28 03:53:06
5e70fc62-93f5-44bb-a26f-8418bf9ed750,USA-FDA,64a8fa94-9975-42ec-9be2-333676cbe59f,G_MINI_SUMMARY,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0002/FDA-2016-D-2567-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on E17 General Principles for Planning and Design of Multi-Regional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:15:09,2025-05-28 03:53:06
5e743663-5493-4b36-b523-c290ccdd6a0c,USA-FDA,5d8354f1-1ca1-4f66-9f8d-6f3c10dfbbc6,G_ACTION_ITEMS,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002/FDA-2011-D-0480-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products"", ""docket_id"": ""FDA-2011-D-0480"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0480-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:30:43,2025-05-28 03:53:06
5e760efb-1bb4-41de-9f58-e68c3a94996c,USA-FDA,68bfd3bf-c7db-4186-9741-ace40e799a5a,G_DETAILED_SUMMARY,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009/FDA-2011-D-0164-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Safety Labeling Changes--Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:00:26,2025-05-28 03:53:06
5ed1d2b5-6d1a-4707-bb11-3ce2177addea,USA-FDA,174cab23-fc77-44c1-a10c-1cb8200f9e49,G_KEYWORDS,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022/FDA-2011-D-0082-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry , Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling"", ""docket_id"": ""FDA-2011-D-0082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0082-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:03:51,2025-05-28 03:53:06
5ef21d0d-7d77-43f1-8c02-4d5e3c8e7823,USA-FDA,9ece275a-9b7a-4ab0-8faa-60052d08bfe1,G_MINI_SUMMARY,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002/FDA-2018-D-3152-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Postapproval Changes to Drug Substances Guidance for Industry"", ""docket_id"": ""FDA-2018-D-3152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3152-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:45:10,2025-05-28 03:53:06
5f04c725-7afa-4db5-a59f-5f90d06e32b9,USA-FDA,4e46743a-85cd-41a1-8455-66d51565cdfa,G_FAQ,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0017/FDA-2017-D-6526-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6526"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6526-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:46:16,2025-05-28 03:53:06
5f2020d3-9a4b-40e9-b48d-cc7986feaf38,USA-FDA,0b17b542-6a17-4e00-a09c-24dabc66d89d,G_FAQ,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1279/FDA-2013-D-1279-0002/FDA-2013-D-1279-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Development Tools; Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-1279"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1279-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1279/FDA-2013-D-1279-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:01:15,2025-05-28 03:53:06
5f8086dc-ea17-49f7-b27c-4bf3b908b282,USA-FDA,f260f350-06b5-4547-be97-828c9a04634f,G_FAQ,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1362/FDA-2020-D-1362-0001/FDA-2020-D-1362-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VI GRAS Notices"", ""docket_id"": ""FDA-2020-D-1362"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1362-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1362/FDA-2020-D-1362-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:30:23,2025-05-28 03:53:06
5f8a608f-c228-45b8-bf2a-f5562222ea22,USA-FDA,dbdd3c1f-a02c-4417-bbc2-28e9d7007112,G_KEYWORDS,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002/FDA-2020-D-1877-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Necessary Automated External Defibrillator Accessories: Policy Regarding Compliance Date; Guidance for Industry, Stakeholders, Health Care Professionals, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2020-D-1877"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1877-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:20,2025-05-28 03:53:06
5faf7503-c174-42ec-a696-09b4e756fa8d,USA-FDA,c8665713-d7d3-448c-b7e7-e19ab33696b1,G_FAQ,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0722/FDA-2011-D-0722-0002/FDA-2011-D-0722-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Implementation of Acceptable Abbreviated Donor History Questionnaire, etc."", ""docket_id"": ""FDA-2011-D-0722"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0722-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0722/FDA-2011-D-0722-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:48:06,2025-05-28 03:53:06
5fcf0cb0-f84b-454b-8543-5c142f19c352,USA-FDA,07fbbf84-2b35-45d1-ade0-6da25a64e4a7,G_ACTION_ITEMS,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002/FDA-2018-D-2238-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""2018-125 Guidance GT for Hemophilia_7-09-2018 -508 Compliant"", ""docket_id"": ""FDA-2018-D-2238"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2238-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:30:44,2025-05-28 03:53:06
5fdab3fa-ffe8-4628-8510-52391c6e4989,USA-FDA,4e21be7e-2a3a-46a3-b0b4-f353df8bad97,G_KEYWORDS,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002/FDA-2011-D-0674-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry FDA Records Access Authority under Section 414 and 704 of the Federal Food, Drug, & Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0674"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0674-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:51,2025-05-28 03:53:06
5fdc19ea-9a0e-40ce-83ec-9c351cdafa96,USA-FDA,d59f5d4c-6ba5-472d-a12a-716ce9095c28,G_CONCISE_SUMMARY,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002/FDA-1999-D-0063-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling"", ""docket_id"": ""FDA-1999-D-0063"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0063-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:47:30,2025-05-28 03:53:06
6,,249550e0-4da8-40ef-a977-89100b74a82e,G_FAQ,2025-05-09 01:51:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 08:51:30,2025-05-28 03:53:06
60,,a671f838-2fc9-4d46-a029-52feaab86b5c,G_CONCISE_SUMMARY,2025-05-12 19:27:27,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002/FDA-2013-D-0114-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls from Product Enhancements; Reporting Requirements; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:27:28,2025-05-28 03:53:06
6008d56f-a8b9-4152-98c5-fa3888431735,SCHEDULED,90784826-3977-4590-8813-4afb03635214,DEVICE_ANALYST,2025-05-26 00:00:07,32,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/device_analyst/90784826-3977-4590-8813-4afb03635214"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:31,2025-05-28 03:53:06
600f9364-8a0b-4f08-9a42-ed4058371828,USA-FDA,8c3d3d76-a4bb-45e2-a368-1f00fccc9ace,G_FAQ,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164/FDA-2006-D-0102-1164-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry"", ""docket_id"": ""FDA-2006-D-0102"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0102-1164""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:47:02,2025-05-28 03:53:06
6022cedc-45b5-4982-b29d-7ee6b6ba471c,USA-FDA,56131038-c440-47fc-9cfe-90e45f7a0580,G_ACTION_ITEMS,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009/FDA-2011-D-0398-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Questions and Answers Regarding The Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:31:29,2025-05-28 03:53:06
603cf6c4-9046-4ad1-8ccb-d166e277e772,USA-FDA,44513f74-a955-4471-bd88-dfdd31d60202,G_KEYWORDS,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006/FDA-2010-D-0500-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information"", ""docket_id"": ""FDA-2010-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0500-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:42,2025-05-28 03:53:06
60468482-6d24-4a18-baa4-3de0dc1ca0fd,USA-FDA,c6c329f5-00cb-47ea-869c-7c07107c6b47,G_DETAILED_SUMMARY,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002/FDA-2013-D-0743-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Reporting for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0743"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0743-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:15:56,2025-05-28 03:53:06
6046f33a-171e-4d81-97e4-240e36f42018,SCHEDULED,f290e6d6-534b-46d0-9e54-0b8f0fcefec4,FDA_ALERT,2025-05-29 00:00:04,4,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-04-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/fda_alert/f290e6d6-534b-46d0-9e54-0b8f0fcefec4"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:08,2025-05-29 00:00:08
6050ad0c-861c-4bf9-9129-fae63d6b96e1,USA-FDA,a54ad8c3-471c-4124-8314-382852b77dac,G_CONCISE_SUMMARY,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001/FDA-2020-D-1950-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 394.500 Importation of Television Products, Microwave Ovens, and Inherent Class I Laser Products for Investigation and Evaluation during Design Development"", ""docket_id"": ""FDA-2020-D-1950"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1950-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:47:29,2025-05-28 03:53:06
6078f62d-f300-492e-b43d-f1df850d6550,USA-FDA,0062c540-1915-420d-8304-a04873a72f94,G_MINI_SUMMARY,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0002/FDA-2004-D-0500-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Help Seeking and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:32:36,2025-05-28 03:53:06
60c04b5f-7db0-498b-8218-db347a7ab7ab,USA-FDA,f14ef647-bf33-4107-9f05-5805b3d826c8,G_DETAILED_SUMMARY,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1010/FDA-2012-D-1010-0002/FDA-2012-D-1010-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Initial Completeness Assessments for Type II Active Pharmaceutical Ingredient Drug Master Files under Generic Drug User Fee"", ""docket_id"": ""FDA-2012-D-1010"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1010-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1010/FDA-2012-D-1010-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:47:46,2025-05-28 03:53:06
60db278b-8863-49fc-9b5c-4f8ae8f9002f,USA-FDA,de698879-9272-47f6-8593-cbc24a497216,G_ACTION_ITEMS,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1455/FDA-2020-D-1455-0001/FDA-2020-D-1455-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; Early Development Considerations for Innovative Combination Products"", ""docket_id"": ""FDA-2020-D-1455"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1455-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1455/FDA-2020-D-1455-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:17:07,2025-05-28 03:53:06
61,,ead1cef3-b17b-42e4-876b-2e59ace1ff2c,G_DETAILED_SUMMARY,2025-05-12 19:27:37,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002/FDA-2013-D-0114-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls from Product Enhancements; Reporting Requirements; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:27:38,2025-05-28 03:53:06
61049b93-0375-4696-b82e-abb85a3391a1,USA-FDA,ec2bf159-cde8-4ecc-a0f4-9f058e07774a,G_ACTION_ITEMS,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0016/FDA-2010-D-0503-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Clinical Investigators, Sponsors, and Institutional Review Boards on Investigational New Drug Applications--Determining Whether Human Research Studies Can Be Conducted Without an Investigational New Drug Application"", ""docket_id"": ""FDA-2010-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0503-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:45:44,2025-05-28 03:53:06
613d8a7a-237b-4a8d-8148-41efb263c024,USA-FDA,a19f366b-09ec-4663-b2c7-4961e9282179,G_ACTION_ITEMS,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011/FDA-2001-D-0137-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children"", ""docket_id"": ""FDA-2001-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0137-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:32:40,2025-05-28 03:53:06
614ecae9-4e94-4a1d-b1ce-e5f44854b263,USA-FDA,60483866-aad2-4f9b-95d7-c895b7809057,G_FAQ,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0074/FDA-2011-D-0074-0025/FDA-2011-D-0074-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Medication Guide Distribution Requirements and Inclusion of Medication Guides in Risk Evaluation and Mitigation Strategies"", ""docket_id"": ""FDA-2011-D-0074"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0074-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0074/FDA-2011-D-0074-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:00:53,2025-05-28 03:53:06
6161d1e5-c113-4d42-bd27-63f40e8d57b5,USA-FDA,11143505-4e9b-4e8d-9317-128120a90f9f,G_IMPACT_ANALYSIS,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025/FDA-2004-D-0044-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:15:43,2025-05-28 03:53:06
61b17784-bdcd-436d-9f0c-9dfb8127dd96,SCHEDULED,0cc423fc-002f-466b-a0fc-105fd061e1a4,DEVICE_ANALYST,2025-05-23 00:00:04,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/0cc423fc-002f-466b-a0fc-105fd061e1a4"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:16,2025-05-28 03:53:06
61caef01-9cc4-4359-a181-475a2da7fb04,USA-FDA,4e56030f-be32-43d6-aa41-8d0c181eacf5,G_DETAILED_SUMMARY,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0013/FDA-1998-D-0035-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis and Interpretation of Clinical Studies"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:17:22,2025-05-28 03:53:06
61cb34a3-9bd8-41e2-8e62-c1fcfe57456c,USA-FDA,ee4f73c2-29bb-46da-9386-90393d516868,G_FAQ,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1353/FDA-2020-D-1353-0001/FDA-2020-D-1353-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part IX FDA References"", ""docket_id"": ""FDA-2020-D-1353"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1353-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1353/FDA-2020-D-1353-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:16:05,2025-05-28 03:53:06
61e08360-424f-4a2f-b73d-f2c76d2903a9,USA-FDA,5a659f3a-e728-4e22-9782-78e163686bab,G_DETAILED_SUMMARY,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1353/FDA-2020-D-1353-0001/FDA-2020-D-1353-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part IX FDA References"", ""docket_id"": ""FDA-2020-D-1353"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1353-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1353/FDA-2020-D-1353-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:15:57,2025-05-28 03:53:06
61f012f0-89d1-425e-9b2f-1f5cf8eba0df,USA-FDA,3b1bc4a6-1736-4903-a43e-5ded4c46c32f,G_FAQ,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0030/FDA-2007-D-0030-0002/FDA-2007-D-0030-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Refrigerated Carrot Juice and Other Refrigerated\nLow-Acid Juices"", ""docket_id"": ""FDA-2007-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0030-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0030/FDA-2007-D-0030-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:15:23,2025-05-28 03:53:06
61f43c36-5144-411c-8f53-9983824dee20,USA-FDA,8aa3d451-b331-457b-aff6-9b0712d9938c,G_IMPACT_ANALYSIS,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016/FDA-2014-D-1399-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:15:43,2025-05-28 03:53:06
61fbebb3-67e6-4ccc-90bd-0e2c5028c7d1,USA-FDA,304104c2-aaf8-456d-847e-e60739627a9c,G_DETAILED_SUMMARY,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0205/FDA-2008-D-0205-0034/FDA-2008-D-0205-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"", ""docket_id"": ""FDA-2008-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0205-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0205/FDA-2008-D-0205-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:46:35,2025-05-28 03:53:06
61fd34aa-8c25-4036-b84e-071f0605efa0,CAB,1e50518d-6cce-4e58-abf8-db323bfd52ee,G_ACTION_ITEMS_IN,2025-05-20 10:13:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2022-F-1108-0001"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2022-F-1108-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""48b24e3f-2c7d-446d-8ef2-9a788b5abc48""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/48b24e3f-2c7d-446d-8ef2-9a788b5abc48"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:13:49,2025-05-28 03:53:06
62,,6b6ecbcd-8712-4ba7-be0c-2bb91260d5fc,G_FAQ,2025-05-12 19:27:50,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002/FDA-2013-D-0114-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls from Product Enhancements; Reporting Requirements; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:27:51,2025-05-28 03:53:06
6237675d-7139-4b0f-8b7a-0c87722e9f58,USA-FDA,83946010-465f-42f3-bc92-24fbccfbbb9d,G_FAQ,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0490/FDA-2011-D-0490-0002/FDA-2011-D-0490-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that are Color Additives; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0490-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0490/FDA-2011-D-0490-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:16:38,2025-05-28 03:53:06
626e7f0c-1a4e-46ff-b86f-edeb612683e3,USA-FDA,e8837a57-6a88-46f2-a7bd-f4da8bc7aa12,G_MINI_SUMMARY,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0012/FDA-1998-D-0035-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:15:11,2025-05-28 03:53:06
6282d54f-8f4a-4282-a038-eb6ed9fabf95,USA-FDA,189f5b39-f061-4af3-bf39-e9de879102fb,G_DETAILED_SUMMARY,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002/FDA-2013-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abbreviated New Drug Application Submissions--Refuse-to-Receive Standards"", ""docket_id"": ""FDA-2013-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:32:01,2025-05-28 03:53:06
62e03371-cbaf-476a-9707-fd19085834a9,USA-FDA,0d4c7f20-affd-40aa-a87c-99f74b27b27e,G_MINI_SUMMARY,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002/FDA-2016-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Enforcement Policy on National Health Related Item Code and National Drug Code Numbers Assigned to Devices"", ""docket_id"": ""FDA-2016-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:45:09,2025-05-28 03:53:06
63,,86a64f6f-e221-4c36-a7a4-65476a3c9eae,G_ACTION_ITEMS,2025-05-12 19:27:56,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002/FDA-2013-D-0114-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls from Product Enhancements; Reporting Requirements; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:27:57,2025-05-28 03:53:06
633608c3-68aa-4718-b74d-e00887db20a0,USA-FDA,4a2cc008-c91c-45c1-b4f8-f0538c351281,G_DETAILED_SUMMARY,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002/FDA-2013-D-0616-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0616-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:33:01,2025-05-28 03:53:06
63563410-e232-4bfa-bc9b-70d8d6b6cca5,SCHEDULED,70ce4eba-b1c9-4054-90c5-55e3f5ab9ed0,FDA_ALERT,2025-06-01 00:00:04,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/70ce4eba-b1c9-4054-90c5-55e3f5ab9ed0"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:10,2025-06-01 00:00:10
638bed2b-6908-461f-bfa9-295630c59ba3,USA-FDA,63e87b26-007e-4ca9-80c8-c7e59017216a,G_IMPACT_ANALYSIS,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-2001/FDA-2015-D-2001-0002/FDA-2015-D-2001-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance Assessment of Male-Mediated Developmental Risk for Pharmaceuticals"", ""docket_id"": ""FDA-2015-D-2001"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-2001-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-2001/FDA-2015-D-2001-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:32:21,2025-05-28 03:53:06
63e99385-0642-41c3-bc6e-bb879d17da66,USA-FDA,f7b5dffc-c167-46b7-9c64-e22fa8426d61,G_MINI_SUMMARY,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3390/FDA-2015-D-3390-0002/FDA-2015-D-3390-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""eCTD TECHNICAL CONFORMANCE GUIDE"", ""docket_id"": ""FDA-2015-D-3390"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-3390-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3390/FDA-2015-D-3390-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:31:39,2025-05-28 03:53:06
64,,72522606-e394-4ab9-bcd3-34f8eb007224,G_IMPACT_ANALYSIS,2025-05-12 19:28:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002/FDA-2013-D-0114-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls from Product Enhancements; Reporting Requirements; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:28:06,2025-05-28 03:53:06
641f2448-f226-436b-959a-7feedb0e0a10,USA-FDA,596a9979-5b6b-489f-bd36-16d4114a60a6,G_IMPACT_ANALYSIS,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0298/FDA-2006-D-0298-0005/FDA-2006-D-0298-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff: Whole Grain Label Statements"", ""docket_id"": ""FDA-2006-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0298-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0298/FDA-2006-D-0298-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:17:17,2025-05-28 03:53:06
64278f8a-eef2-4177-8843-764ed798dfa2,USA-FDA,6c7f3ea3-9fe2-481a-9584-1901e458de4b,G_MINI_SUMMARY,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001/FDA-2020-D-1430-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents"", ""docket_id"": ""FDA-2020-D-1430"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1430-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:17:11,2025-05-28 03:53:06
6429feca-2c9c-4cb7-b75a-c965f0eb895d,USA-FDA,c228744c-ee6b-432c-820e-524a7b0960a4,G_IMPACT_ANALYSIS,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001/FDA-2018-D-3551-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Impact of Certain Provisions of Revised Common Rule on FDA-Regulated Clinical Investigations; Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2018-D-3551"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3551-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:30:50,2025-05-28 03:53:06
647ea7ea-adbc-4c0c-bc3a-6644d8ed02df,USA-FDA,0fb0ad35-8c6d-4279-9ffe-d97d1ee819a2,G_IMPACT_ANALYSIS,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0002/FDA-2016-D-2567-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on E17 General Principles for Planning and Design of Multi-Regional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:16:34,2025-05-28 03:53:06
64ad5536-f6f3-426d-93d7-8f33179349c5,USA-FDA,1666f58e-416e-4631-ae31-3f7188da9f5e,G_DETAILED_SUMMARY,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009/FDA-2011-D-0916-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Classification Product Codes; Guidance for Industry and  Food and Drug Administration Staff"", ""docket_id"": ""FDA-2011-D-0916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0916-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:32:00,2025-05-28 03:53:06
64b7a79a-cd9a-4a33-abcb-5647746de66c,USA-FDA,ec6f045e-adff-48a0-a18a-341368dad0fa,G_MINI_SUMMARY,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1358/FDA-2013-D-1358-0002/FDA-2013-D-1358-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation"", ""docket_id"": ""FDA-2013-D-1358"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1358-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1358/FDA-2013-D-1358-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:01:37,2025-05-28 03:53:06
64bd763d-e26a-48a7-9605-8b834e4c2081,USA-FDA,c4b8cf94-ca73-4580-8b8a-121bb6c6fbf0,G_MINI_SUMMARY,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002/FDA-2011-D-0598-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers Regarding Establishment, Maintenance of Records by Persons Who Manufacture of Records by Persons Who Manufacture, Process, Pack, Transport,Distribute Receive, Hold or Import Food (Edition 5)"", ""docket_id"": ""FDA-2011-D-0598"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0598-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:30:56,2025-05-28 03:53:06
64e48c01-1803-49ae-9549-4308e7bfa8a5,USA-FDA,f08b8396-91b1-447d-ae3f-d0ba4173542d,G_DETAILED_SUMMARY,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002/FDA-2011-D-0674-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry FDA Records Access Authority under Section 414 and 704 of the Federal Food, Drug, & Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0674"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0674-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:25,2025-05-28 03:53:06
64e6b022-37a7-4119-a419-cd0213f21a66,CAB,aad7a08c-9d74-4990-990a-c0f5a01d6c58,G_CONCISE_SUMMARY_IN,2025-05-20 10:13:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2022-F-1108-0001"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2022-F-1108-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""48b24e3f-2c7d-446d-8ef2-9a788b5abc48""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/48b24e3f-2c7d-446d-8ef2-9a788b5abc48"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:13:31,2025-05-28 03:53:06
64f4ee33-d887-40ee-bc24-2a44ab849aa1,USA-FDA,9a5846f7-5a7a-496b-96aa-bc1bba866ad3,G_ACTION_ITEMS,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002/FDA-1997-D-0444-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""FDA Approval of Animal Drugs for Minor Uses and Minor Species; Draft Guidance Document"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:01:00,2025-05-28 03:53:06
64f8cf2a-2382-4172-a22e-912540cace7e,USA-FDA,1dc6f917-c8c5-4c30-bf3b-8c1ef4a6ca6d,G_KEYWORDS,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002/FDA-1999-D-1875-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:30:52,2025-05-28 03:53:06
65,,d1e660fa-6461-4bfb-a0b7-6f7a866b2041,G_MINI_SUMMARY,2025-05-12 19:28:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026/FDA-2013-D-0114-0026-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls From Medical Device Enhancements; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0026""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:28:09,2025-05-28 03:53:06
6504070f-89a5-422a-ba76-46c9668bd926,USA-FDA,eabad0af-e6bc-437d-a148-1f8f387e9a7c,G_ACTION_ITEMS,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002/FDA-2009-D-0136-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0136"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0136-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:31:31,2025-05-28 03:53:06
6511f281-86c2-42c5-a743-b71d3dcd80f4,USA-FDA,e0218c6a-3c23-45e4-a779-10c8e9e45f0e,G_CONCISE_SUMMARY,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004/FDA-2002-D-0298-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition"", ""docket_id"": ""FDA-2002-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0298-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:46:31,2025-05-28 03:53:06
659603cc-cf9e-40d2-9e31-e42ccbbe8699,USA-FDA,cebd3093-64bc-4826-b00a-12df0f342193,G_MINI_SUMMARY,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024/FDA-2011-D-0577-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications  - Guidance"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:31:57,2025-05-28 03:53:06
659d5b52-17c0-461d-9bb7-535a9a416926,USA-FDA,f05466c5-0474-4453-81d7-234f030c0ceb,G_IMPACT_ANALYSIS,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001/FDA-2020-D-1944-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives"", ""docket_id"": ""FDA-2020-D-1944"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1944-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:30:37,2025-05-28 03:53:06
65ab4ce1-8186-4d64-870b-28072785a8e6,USA-FDA,d9c29c44-4f1c-454f-a742-743b75d30920,G_FAQ,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1168/FDA-2012-D-1168-0002/FDA-2012-D-1168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Providing Submissions in Electronic Format Summary Level Clinical Site Data for CDER's Inspection Planning"", ""docket_id"": ""FDA-2012-D-1168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1168/FDA-2012-D-1168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:45:22,2025-05-28 03:53:06
65ac228d-6511-4ec7-98c1-692375c43978,USA-FDA,85dd31ee-14f5-42d8-86d1-74ed6554d89b,G_FAQ,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002/FDA-2011-D-0689-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; De Novo Classification Process (Evaluation of Automatic Class III Designation)"", ""docket_id"": ""FDA-2011-D-0689"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0689-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:15:58,2025-05-28 03:53:06
65d2c565-6a3e-4aec-9e82-3d5ef03189c1,USA-FDA,b7a36d1a-86db-41a5-b0f4-848cc8413cd7,G_ACTION_ITEMS,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002/FDA-2020-D-1640-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance on Cannabidiol"", ""docket_id"": ""FDA-2020-D-1640"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1640-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:16:07,2025-05-28 03:53:06
65dd3811-f8ab-4458-a673-5e6124bccda4,USA-FDA,f189ffd5-5989-4547-87dc-88e83093d7e0,G_IMPACT_ANALYSIS,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002/FDA-2020-D-1877-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Necessary Automated External Defibrillator Accessories: Policy Regarding Compliance Date; Guidance for Industry, Stakeholders, Health Care Professionals, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2020-D-1877"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1877-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:17,2025-05-28 03:53:06
65df8057-1586-49c2-872d-d06223c44dba,USA-FDA,499febf9-cdf5-4183-bdc9-23de62f7b3b8,G_DETAILED_SUMMARY,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002/FDA-2018-D-2238-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""2018-125 Guidance GT for Hemophilia_7-09-2018 -508 Compliant"", ""docket_id"": ""FDA-2018-D-2238"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2238-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:30:26,2025-05-28 03:53:06
66,,36c70892-4400-400b-9de0-2aa10472bd97,G_CONCISE_SUMMARY,2025-05-12 19:28:12,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026/FDA-2013-D-0114-0026-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls From Medical Device Enhancements; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0026""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:28:13,2025-05-28 03:53:06
6616d6af-fdd6-4528-98af-2030d448c873,USA-FDA,3bee4c8c-22fd-4ee3-b649-d7ed481a21e2,G_FAQ,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0533/FDA-2009-D-0533-0009/FDA-2009-D-0533-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application"", ""docket_id"": ""FDA-2009-D-0533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0533-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0533/FDA-2009-D-0533-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:00:28,2025-05-28 03:53:06
664c4936-9466-4d2d-99da-2f778c6b6b72,USA-FDA,128e8fcb-259f-493a-b5ac-4f62a475bd47,G_IMPACT_ANALYSIS,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007/FDA-2007-D-0149-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff Class II Special Controls Guidance Document: Electrocardiograph Electrodes"", ""docket_id"": ""FDA-2007-D-0149"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0149-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:32:18,2025-05-28 03:53:06
6650f73f-11b6-4d1a-a308-82f35ee8ee92,USA-FDA,b02956d5-e1af-4c58-a696-b3b8b597d445,G_IMPACT_ANALYSIS,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009/FDA-2006-D-0157-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry:  Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2006-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0157-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0157/FDA-2006-D-0157-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:01:21,2025-05-28 03:53:06
667a399f-90f4-411e-af3d-6aad69e5334e,USA-FDA,014f26f1-c35c-4914-b6d1-dd13d8f5822e,G_KEYWORDS,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002/FDA-2000-D-0129-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans - Draft Guidance"", ""docket_id"": ""FDA-2000-D-0129"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-D-0129-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:02:08,2025-05-28 03:53:06
668770ee-6a36-4286-80c4-3ab450f792b6,USA-FDA,14537360-1e3a-42a2-adfa-b928bda42677,G_MINI_SUMMARY,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002/FDA-2020-D-1640-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance on Cannabidiol"", ""docket_id"": ""FDA-2020-D-1640"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1640-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:15:49,2025-05-28 03:53:06
66aead2c-7c50-4d5b-a62d-7614b36037d6,USA-FDA,27e91ed7-26b5-4dab-bfe3-477f708e41f0,G_IMPACT_ANALYSIS,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005/FDA-2007-D-0205-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:33:30,2025-05-28 03:53:06
66ccf683-dd88-4f5a-81a5-8abb7570604a,USA-FDA,930d83af-21b4-4217-a403-d4899fdf8d5a,G_ACTION_ITEMS,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002/FDA-2014-N-0829-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Reporting Drug Sample Information\nUnder Section 6004 of the Affordable Care Act"", ""docket_id"": ""FDA-2014-N-0829"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-0829-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:30:42,2025-05-28 03:53:06
66d0a494-05b1-4791-9dd4-fefc6af33fce,USA-FDA,5bb3b06a-051a-4b7d-a00a-8b744585bc05,G_MINI_SUMMARY,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0872/FDA-2011-D-0872-0002/FDA-2011-D-0872-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies"", ""docket_id"": ""FDA-2011-D-0872"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0872-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0872/FDA-2011-D-0872-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:00:10,2025-05-28 03:53:06
66efa290-ea20-4975-8af4-57daf55b6578,USA-FDA,105ede38-0278-4a70-93f9-e37c0dc09d71,G_IMPACT_ANALYSIS,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009/FDA-2011-D-0916-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Classification Product Codes; Guidance for Industry and  Food and Drug Administration Staff"", ""docket_id"": ""FDA-2011-D-0916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0916-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:32:52,2025-05-28 03:53:06
66f6c214-1315-4f30-8970-92fc55eae4c6,USA-FDA,7e31e84d-f8ed-4672-b061-be1b57e6bb65,G_MINI_SUMMARY,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022/FDA-1998-N-0050-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 540.375 Canned Salmon - Adulteration Involving Decomposition Withdrawn 3-22-2010"", ""docket_id"": ""FDA-1998-N-0050"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-N-0050-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:09,2025-05-28 03:53:06
67,,a72b066d-ab5c-444d-9648-98c00628a84a,G_DETAILED_SUMMARY,2025-05-12 19:28:20,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026/FDA-2013-D-0114-0026-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls From Medical Device Enhancements; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0026""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:28:22,2025-05-28 03:53:06
67224842-a436-4cb6-ac25-a99d0dd02060,USA-FDA,e73c3957-7a53-479c-aeff-21124b91a53e,G_FAQ,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0132/FDA-2009-D-0132-0012/FDA-2009-D-0132-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cellular Therapy for Cardiac Disease "", ""docket_id"": ""FDA-2009-D-0132"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0132-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0132/FDA-2009-D-0132-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:47:20,2025-05-28 03:53:06
67336d7e-d499-49d3-bc5b-9fd54dc50d4c,SCHEDULED,70b0f752-4767-47f1-a0b2-f82f8dc4c38e,FDA_ALERT,2025-05-31 00:00:05,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/70b0f752-4767-47f1-a0b2-f82f8dc4c38e"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:11,2025-05-31 00:00:11
6735a70e-213e-410d-8cc2-611d2a1c3198,USA-FDA,3fb42074-0c23-465e-96ee-7e578d89c8c8,G_ACTION_ITEMS,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0132/FDA-2009-D-0132-0012/FDA-2009-D-0132-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cellular Therapy for Cardiac Disease "", ""docket_id"": ""FDA-2009-D-0132"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0132-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0132/FDA-2009-D-0132-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:47:44,2025-05-28 03:53:06
6737c65e-fd83-4f19-a0f2-147f4c9dc35e,USA-FDA,b10c56ce-3e91-4d78-819a-9d5a1c6b665d,G_MINI_SUMMARY,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002/FDA-2018-D-2583-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products; Guidance for Industry;  Draft Guidance"", ""docket_id"": ""FDA-2018-D-2583"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2583-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:02:33,2025-05-28 03:53:06
673dd0ae-c7d5-43bb-ba8b-5f4d381398a8,USA-FDA,fcacde8d-d78b-4c8c-8066-21ea0a932ed9,G_FAQ,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001/FDA-2023-D-2510-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)"", ""docket_id"": ""FDA-2023-D-2510"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2510-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:31:31,2025-05-28 03:53:06
67553f58-038a-4081-9526-95a849747201,USA-FDA,4a4ef7e4-e501-4984-b421-113b936d141c,G_ACTION_ITEMS,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0090/FDA-2003-D-0090-0002/FDA-2003-D-0090-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate � Labeling Enforcement Policy"", ""docket_id"": ""FDA-2003-D-0090"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0090-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0090/FDA-2003-D-0090-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:01:32,2025-05-28 03:53:06
676e50c9-d334-4ebd-8b06-7eeff345bf09,USA-FDA,24a5e805-9f29-4159-a48a-c9e24ae9f543,G_ACTION_ITEMS,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002/FDA-2020-D-1877-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Necessary Automated External Defibrillator Accessories: Policy Regarding Compliance Date; Guidance for Industry, Stakeholders, Health Care Professionals, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2020-D-1877"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1877-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:11,2025-05-28 03:53:06
67b1cda0-11c4-4bac-9eb6-9a5ec4b1f9e3,USA-FDA,24e5b305-ac85-4f26-b6c2-2d1d5b29c642,G_DETAILED_SUMMARY,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001/FDA-2020-D-2015-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Devices Without a Premarket Notification (510(k)) or an Approved Premarket Approval Application (PMA) REVOKED DOCUMENT"", ""docket_id"": ""FDA-2020-D-2015"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-2015-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:34,2025-05-28 03:53:06
67d667f5-f655-44f4-9b6c-6668aa5dcdf9,USA-FDA,1bc49e19-be65-44df-8417-0784666a8d0b,G_KEYWORDS,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002/FDA-2009-D-0542-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Factors that Distinguish Liquid Dietary Supplements from Beverages, Considerations Regarding Novel Ingredients, and Labeling for Beverages and Other Conventional Foods; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0542"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0542-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:03:22,2025-05-28 03:53:06
67ebdd34-9bac-4674-9f7b-19a576396197,USA-FDA,23e710c3-4e7f-4a3d-91f8-88d5c6759a8e,G_KEYWORDS,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010/FDA-2011-D-0799-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components Including Source Plasma to Reduce the Risk of Transmission of Hepatitis B Virus"", ""docket_id"": ""FDA-2011-D-0799"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0799-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:02:14,2025-05-28 03:53:06
68,,02ef81f6-6198-419b-8350-3502219e660b,G_FAQ,2025-05-12 19:28:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026/FDA-2013-D-0114-0026-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls From Medical Device Enhancements; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0026""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:28:53,2025-05-28 03:53:06
682c9536-dd4f-4a03-80e0-cc75f3447a89,USA-FDA,0c8e7f8b-7a21-41d7-8cf8-b05f3da4ea1d,G_ACTION_ITEMS,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0971/FDA-2016-D-0971-0002/FDA-2016-D-0971-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Infectious Disease Next Generation Sequencing Based Diagnostic Devices Microbial Identification and Detection of Antimicrobial Resistance and Virulence Markers"", ""docket_id"": ""FDA-2016-D-0971"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0971-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0971/FDA-2016-D-0971-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:46:33,2025-05-28 03:53:06
684c647d-0551-48de-aade-508fbbf490d5,USA-FDA,35478543-fa58-4a0d-b3f4-2aaf771889d7,G_KEYWORDS,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001/FDA-2020-D-1961-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling"", ""docket_id"": ""FDA-2020-D-1961"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1961-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:31:59,2025-05-28 03:53:06
68509a50-e686-4f29-a8e1-1042a08759e6,USA-FDA,3a4f3626-f09a-4475-9ac8-dc0a7ce26c76,G_CONCISE_SUMMARY,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002/FDA-2012-D-0049-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke UnderSection 904(a)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance"", ""docket_id"": ""FDA-2012-D-0049"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0049-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:30:16,2025-05-28 03:53:06
686cc741-7c92-489e-9e08-263600a2cfee,USA-FDA,3f3ae15a-fae2-473a-a9fa-fd8b32df4c19,G_IMPACT_ANALYSIS,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1318/FDA-2014-D-1318-0002/FDA-2014-D-1318-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1318"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1318-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1318/FDA-2014-D-1318-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:16:56,2025-05-28 03:53:06
689e14c1-cffc-4323-a4f0-41b9f7b35061,USA-FDA,e9f45aa3-422a-4890-ac03-e47246d61edd,G_KEYWORDS,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002/FDA-2017-D-4359-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry 68 on Small Entites Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:15:45,2025-05-28 03:53:06
68d398d4-4abb-45f0-8b68-38dc2c6961ff,USA-FDA,84766111-fd73-4d24-9094-5749b520c81b,G_IMPACT_ANALYSIS,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011/FDA-2014-D-2300-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Drug Effects on the Ability to Operate a Motor Vehicle\nGuidance for Industry"", ""docket_id"": ""FDA-2014-D-2300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-2300-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:32:37,2025-05-28 03:53:06
68dea274-6884-4b6f-845f-78ba69544a67,USA-FDA,ec1578af-200f-477e-b65e-934451309716,G_IMPACT_ANALYSIS,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0030/FDA-2007-D-0030-0002/FDA-2007-D-0030-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Refrigerated Carrot Juice and Other Refrigerated\nLow-Acid Juices"", ""docket_id"": ""FDA-2007-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0030-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0030/FDA-2007-D-0030-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:15:35,2025-05-28 03:53:06
68f2604e-41c5-45d8-955b-7603a3950d87,USA-FDA,5a3c5193-6326-41d9-871f-ae0d8c48ac98,G_MINI_SUMMARY,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0545/FDA-2016-D-0545-0099/FDA-2016-D-0545-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components; Guidance for Industry"", ""docket_id"": ""FDA-2016-D-0545"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0545-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0545/FDA-2016-D-0545-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:30:10,2025-05-28 03:53:06
69,,e309c66b-b493-4d74-932f-3925f691a0e5,G_ACTION_ITEMS,2025-05-12 19:28:57,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026/FDA-2013-D-0114-0026-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls From Medical Device Enhancements; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0026""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:28:58,2025-05-28 03:53:06
69066841-fcf3-4dcd-88bb-af713b2fdb60,USA-FDA,8595390a-255e-4eac-a0e3-2dcc7a1de9f8,G_DETAILED_SUMMARY,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4561/FDA-2015-D-4561-0005/FDA-2015-D-4561-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Head Lice Infestation: Developing Drugs for Topical Treatment Guidance for Industry"", ""docket_id"": ""FDA-2015-D-4561"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4561-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4561/FDA-2015-D-4561-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:17:05,2025-05-28 03:53:06
692157de-841a-479a-aa01-1aa67df59a64,USA-FDA,53e8d443-3d0a-4da4-83c6-fc01d2b49ac0,G_DETAILED_SUMMARY,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0125/FDA-2013-N-0125-0025/FDA-2013-N-0125-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Alternative to Certain Prescription Device Labeling Requirements"", ""docket_id"": ""FDA-2013-N-0125"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-0125-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0125/FDA-2013-N-0125-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:00:16,2025-05-28 03:53:06
6928628d-6592-4682-9415-26513c3a9f6b,USA-FDA,3d45eb99-d028-4002-9d65-aa8df703fa35,G_ACTION_ITEMS,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0093/FDA-2002-D-0093-0022/FDA-2002-D-0093-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry"", ""docket_id"": ""FDA-2002-D-0093"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0093-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0093/FDA-2002-D-0093-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:32:32,2025-05-28 03:53:06
6937082d-7a3d-482a-8c7c-e2575c0248cd,USA-FDA,0226d49e-0a55-4512-8ab4-1be18937a741,G_FAQ,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002/FDA-1999-D-1875-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:30:36,2025-05-28 03:53:06
69393540-92f7-4c51-b699-054d419f8392,USA-FDA,42680db9-6945-4a38-b4a2-92168f56398e,G_FAQ,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0541/FDA-2011-D-0541-0002/FDA-2011-D-0541-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance PET Drugs ----- Current Good Manufacturing Practice (CGMP) (Small Entity Compliance Guide)"", ""docket_id"": ""FDA-2011-D-0541"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0541-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0541/FDA-2011-D-0541-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:02:56,2025-05-28 03:53:06
697834de-9392-41b6-b20e-14f8fa7498ff,USA-FDA,818f449a-8fb8-4a2b-92a4-b8524baf45f7,G_MINI_SUMMARY,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007/FDA-2007-D-0149-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff Class II Special Controls Guidance Document: Electrocardiograph Electrodes"", ""docket_id"": ""FDA-2007-D-0149"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0149-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:31:39,2025-05-28 03:53:06
698e8731-cba5-4af0-9280-aa2f3f2f22c5,USA-FDA,a76b2cff-b387-4b57-851d-655e46392071,G_KEYWORDS,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002/FDA-2018-D-2238-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""2018-125 Guidance GT for Hemophilia_7-09-2018 -508 Compliant"", ""docket_id"": ""FDA-2018-D-2238"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2238-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:30:58,2025-05-28 03:53:06
699d0d9b-791f-4c56-80b0-b0bc049bcde5,USA-FDA,1159df0f-418c-4e10-8bdb-57d3faa94e92,G_IMPACT_ANALYSIS,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006/FDA-2010-D-0500-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information"", ""docket_id"": ""FDA-2010-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0500-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:39,2025-05-28 03:53:06
69b61902-e580-471a-8420-9c708b10b208,USA-FDA,da7765c5-e567-49c1-80de-c6b315589fe3,G_DETAILED_SUMMARY,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002/FDA-2018-D-3152-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Postapproval Changes to Drug Substances Guidance for Industry"", ""docket_id"": ""FDA-2018-D-3152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3152-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:45:32,2025-05-28 03:53:06
69cc8189-59de-4583-896c-e2267a055117,USA-FDA,dd664682-d8a9-4745-a921-072be37b0a65,G_IMPACT_ANALYSIS,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0138/FDA-2001-D-0138-0003/FDA-2001-D-0138-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Exemptions from the Warning Label Requirement for Juice - Recommendations for Effectively Achieving a 5 -Log Pathogen Reduction"", ""docket_id"": ""FDA-2001-D-0138"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0138-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0138/FDA-2001-D-0138-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:45:41,2025-05-28 03:53:06
69d13e1a-df5b-4bb7-9ece-b218b1ce15b5,USA-FDA,4911a9ab-3071-4371-b438-c6a50c332f4d,G_FAQ,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0260/FDA-2009-D-0260-0029/FDA-2009-D-0260-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2)"", ""docket_id"": ""FDA-2009-D-0260"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0260-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0260/FDA-2009-D-0260-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:47:30,2025-05-28 03:53:06
69fd14a3-c73f-4ca5-b35a-59d23af37727,USA-FDA,fe8f5cdc-44b5-4249-b688-43cf1793a9cb,G_ACTION_ITEMS,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015/FDA-2010-D-0350-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Tobacco Retailers on Tobacco Retailer Training Programs"", ""docket_id"": ""FDA-2010-D-0350"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0350-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:03:06,2025-05-28 03:53:06
6a221396-fc56-41eb-92bc-ea9e653917a6,USA-FDA,f7ea7a9a-50e4-49e7-bb51-04d432e963f2,G_MINI_SUMMARY,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0524/FDA-2012-D-0524-0002/FDA-2012-D-0524-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: Acceptance and Filing Review for Premarket Approval Applications (PMAs) - Guidance"", ""docket_id"": ""FDA-2012-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0524-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0524/FDA-2012-D-0524-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:15:47,2025-05-28 03:53:06
6a334c59-eccf-4f4e-8503-24cdb644f006,USA-FDA,3b5c5abf-9e92-40ac-9a4b-aae8ec1e5011,G_MINI_SUMMARY,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1380/FDA-2020-D-1380-0001/FDA-2020-D-1380-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products"", ""docket_id"": ""FDA-2020-D-1380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1380-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1380/FDA-2020-D-1380-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:30:58,2025-05-28 03:53:06
6a446ee8-3574-46b9-affe-6060fe0b0c0d,SCHEDULED,a301e3c3-d76a-4aa9-8aad-4aa41882c951,DEVICE_ANALYST,2025-06-02 00:00:04,32,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/device_analyst/a301e3c3-d76a-4aa9-8aad-4aa41882c951"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:28,2025-06-02 00:00:28
6a484964-3b78-4df3-9bf5-c20d0e649f24,USA-FDA,dbff2294-4774-40e7-9625-4d47868bd232,G_CONCISE_SUMMARY,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002/FDA-2009-D-0354-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Pharmaceutical Components at Risk for Melamine Contamination"", ""docket_id"": ""FDA-2009-D-0354"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0354-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:02:21,2025-05-28 03:53:06
6a52f416-9141-4fec-b36f-dabe34971565,SCHEDULED,e23be63e-b11a-4d80-a76e-29c3a7cdccfb,DEVICE_ANALYST,2025-06-01 00:00:04,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/e23be63e-b11a-4d80-a76e-29c3a7cdccfb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:21,2025-06-01 00:00:21
6a68e490-9c2c-492a-8dce-d96b317b8e4a,USA-FDA,f4606537-1a92-4fce-8d49-006b88966a3d,G_DETAILED_SUMMARY,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0196/FDA-2007-D-0196-0013/FDA-2007-D-0196-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for FDA Advisory Committee Members and FDA Staff : Voting Procedures for Advisory Committee Meetings"", ""docket_id"": ""FDA-2007-D-0196"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0196-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0196/FDA-2007-D-0196-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:00:46,2025-05-28 03:53:06
6a8c17f5-e0a3-4672-a2d6-80287f238ed4,USA-FDA,42fc221a-3c93-4c6d-bcce-2f71ec5c7d16,G_MINI_SUMMARY,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5140/FDA-2017-D-5140-0002/FDA-2017-D-5140-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Display Devices for Diagnostic Radiology"", ""docket_id"": ""FDA-2017-D-5140"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5140-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5140/FDA-2017-D-5140-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:16:25,2025-05-28 03:53:06
6aaddc94-30f7-490f-8224-a7e8dee28b78,USA-FDA,3e600359-b779-41d3-b5b5-38ee0c7180c1,G_FAQ,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002/FDA-2008-D-0576-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sponsors, Clinical Investigators, and IRBs - Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials"", ""docket_id"": ""FDA-2008-D-0576"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0576-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:16:41,2025-05-28 03:53:06
6ab806ff-e5f7-4fb5-aa59-088f611dee14,USA-FDA,3c124bd2-e316-4b36-bda5-f77ef57b61b7,G_MINI_SUMMARY,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0744/FDA-2013-D-0744-0002/FDA-2013-D-0744-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Antibacterial Therapies for Patients With Unmet Medical Need for the Treatment of Serious Bacterial Diseases"", ""docket_id"": ""FDA-2013-D-0744"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0744-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0744/FDA-2013-D-0744-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:16:53,2025-05-28 03:53:06
6b244676-38ce-4637-815e-6c578fb421c6,USA-FDA,e39818c1-8102-4be2-a56c-27e93a77f1ba,G_CONCISE_SUMMARY,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009/FDA-2003-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI"", ""docket_id"": ""FDA-2003-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:30:14,2025-05-28 03:53:06
6b4de981-d6f9-4bb2-8947-4e3e7d34e2e0,USA-FDA,bc081b11-cb4c-4ee5-9dce-35b15ac00b5d,G_DETAILED_SUMMARY,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001/FDA-2020-D-1408-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000; I Introduction"", ""docket_id"": ""FDA-2020-D-1408"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1408-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:45,2025-05-28 03:53:06
6b85dcf1-edb1-47d5-814f-9defc2dfd039,USA-FDA,68b8117e-7dda-4c77-9b57-3dc8fa8dfd46,G_KEYWORDS,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004/FDA-2019-D-1372-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Elemental Impurities in Human Drug Products Questions and Answers Proposed DRAFT Guidance for Industry"", ""docket_id"": ""FDA-2019-D-1372"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-1372-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:02:35,2025-05-28 03:53:06
6b8927f4-9deb-4831-abc9-79cbead8df94,USA-FDA,1e3193d5-817b-45df-9325-0dd7bf5a29bf,G_KEYWORDS,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016/FDA-2013-D-0369-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in\nPharmaceuticals to Limit Potential Carcinogenic Risk; International\nConference on Harmonisation; Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0369"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0369-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:12:14,2025-05-28 03:53:06
6b8ad8af-147d-4508-9d8d-8cc75e4f387a,USA-FDA,4ecb12ce-af7b-4f6b-bd29-006ab64b6a77,G_KEYWORDS,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012/FDA-2016-D-1533-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma - Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:48:01,2025-05-28 03:53:06
6b91197e-620b-42a5-8157-99a92f6b8151,USA-FDA,e763ba45-bfca-4a22-93e0-1e2895647469,G_IMPACT_ANALYSIS,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1984-D-0020/FDA-1984-D-0020-0002/FDA-1984-D-0020-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics"", ""docket_id"": ""FDA-1984-D-0020"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1984-D-0020-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1984-D-0020/FDA-1984-D-0020-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:18:11,2025-05-28 03:53:06
6bd07b6d-5b02-4564-a88b-25a52fb22926,USA-FDA,4d852761-cf26-425d-b3cf-34e54e088b8a,G_DETAILED_SUMMARY,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0035/FDA-2003-D-0035-0002/FDA-2003-D-0035-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims"", ""docket_id"": ""FDA-2003-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0035-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0035/FDA-2003-D-0035-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:02:22,2025-05-28 03:53:06
6be8f18d-55cd-40e8-89da-5192a2981c1b,USA-FDA,10242417-abe0-4883-847c-8124b79bb352,G_DETAILED_SUMMARY,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1264/FDA-2014-D-1264-0003/FDA-2014-D-1264-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment over the Spectrum of Disease"", ""docket_id"": ""FDA-2014-D-1264"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1264-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1264/FDA-2014-D-1264-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:47:42,2025-05-28 03:53:06
6c006cdc-2bf1-4fd7-a2e5-58d40f67a0cd,QUEUE,fc4dc73d-b4cf-429b-886b-4b874b76ba28,G_SUMMARY_USER,2025-05-29 16:00:13,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/detailed_summary/fc4dc73d-b4cf-429b-886b-4b874b76ba28/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/detailed_summary/fc4dc73d-b4cf-429b-886b-4b874b76ba28"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 16:00:19,2025-05-29 16:00:19
6c5ef886-ad8d-43ee-bdad-5fcc4e819384,USA-FDA,6fa9bfc6-fced-4c22-a5b7-e526577dc883,G_IMPACT_ANALYSIS,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0029/FDA-2003-D-0029-0003/FDA-2003-D-0029-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Federal Agencies and State and Local Governments Potassium Iodide Tablets Shelf Life Extension"", ""docket_id"": ""FDA-2003-D-0029"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0029-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0029/FDA-2003-D-0029-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:30:38,2025-05-28 03:53:06
6c697550-1558-4869-8d6f-d7a4cbe0f3c1,QUEUE,9b3d8ad0-e5ea-4184-9bc6-7192356c0fe2,G_FAQ_USER,2025-05-20 10:44:58,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__doc_title__"": ""FDA-2014-D-1399-0016-guidance.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/9b3d8ad0-e5ea-4184-9bc6-7192356c0fe2/SRC/9b3d8ad0-e5ea-4184-9bc6-7192356c0fe2.pdf"", ""doc_title"": ""FDA-2014-D-1399-0016-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/9b3d8ad0-e5ea-4184-9bc6-7192356c0fe2/DEST/faq.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:45:07,2025-05-28 03:53:06
6c82c057-6872-4ac2-91c3-74a267a87a66,USA-FDA,54a7c765-4091-4d2e-b3de-772e65c6011f,G_FAQ,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001/FDA-2020-D-1944-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives"", ""docket_id"": ""FDA-2020-D-1944"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1944-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:30:26,2025-05-28 03:53:06
6c876f98-8d4f-47c7-a0ef-7aca381e4cec,USA-FDA,be8c5a8d-d91c-4919-9eab-58d48c57bfe4,G_KEYWORDS,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025/FDA-2009-D-0524-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Listing of Ingredients in Tobacco Products"", ""docket_id"": ""FDA-2009-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0524-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:02:00,2025-05-28 03:53:06
6cb1e2b3-b8fa-44e2-8f91-2def16b8902d,USA-FDA,fc6d5291-ec66-49fa-a216-65e631f91cf1,G_FAQ,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4090/FDA-1999-D-4090-0005/FDA-1999-D-4090-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and for FDA Reviewers Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer"", ""docket_id"": ""FDA-1999-D-4090"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4090-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4090/FDA-1999-D-4090-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:32:02,2025-05-28 03:53:06
6cf7951f-35de-4d39-8b2b-569346daec05,USA-FDA,95a9a62a-6144-4c96-9881-455763b24c4d,G_DETAILED_SUMMARY,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0183/FDA-2010-D-0183-0002/FDA-2010-D-0183-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance of Industry; Prevention of Salmonella Enteritidis in Shell Eggs During Production, Transportation, and Storage; Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0183"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0183-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0183/FDA-2010-D-0183-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:00:27,2025-05-28 03:53:06
6d11444c-1ed2-49f6-b0b8-0a9d2826f768,USA-FDA,9baed3f3-c2b0-42a9-afbd-4a0f219d3e52,G_CONCISE_SUMMARY,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003/FDA-2008-D-0180-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Coronary Drug Eluting Stents- Nonclincal and Clinical Studies; Draft Guidance"", ""docket_id"": ""FDA-2008-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0180-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:00:16,2025-05-28 03:53:06
6d2e0168-2252-4b29-b3a5-fb7160dbdcf2,USA-FDA,84f47154-1159-462c-b09f-da0a6981fbf9,G_MINI_SUMMARY,2025-05-22 18:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0363/FDA-2014-D-0363-0002/FDA-2014-D-0363-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Expedited Access for Premarket Approval Medical Devices Intended for\nUnmet Medical Need for Life Threatening or Irreversibly Debilitating\nDisease or Conditions; Draft Guidance for Industry and Food and Drug\nAdministration Staff"", ""docket_id"": ""FDA-2014-D-0363"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-0363-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0363/FDA-2014-D-0363-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:30:24,2025-05-28 03:53:06
6d364857-2692-4c0e-8eeb-50477665a75d,USA-FDA,7972102f-fb92-4b88-a1f7-fde5afb96399,G_MINI_SUMMARY,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0586/FDA-2011-D-0586-0002/FDA-2011-D-0586-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Standards for Clinical Trial Imaging Endpoints; Draft Guidance Document"", ""docket_id"": ""FDA-2011-D-0586"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0586-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0586/FDA-2011-D-0586-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:00:58,2025-05-28 03:53:06
6d3d6dc3-dfa7-470d-81f7-a750f99a49d0,SCHEDULED,4c3329d3-73a8-43ad-a16b-bbc83d4adb79,DEVICE_ANALYST,2025-05-30 00:00:04,32,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/device_analyst/4c3329d3-73a8-43ad-a16b-bbc83d4adb79"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:29,2025-05-30 00:00:29
6d4aede6-ae1d-4a56-8de5-77a777a99e8b,USA-FDA,7b6fc6cf-bea4-4705-a4dc-5e3cf42f48ba,G_KEYWORDS,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002/FDA-2007-D-0202-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting Improving Human Subject Protection"", ""docket_id"": ""FDA-2007-D-0202"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0202-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:02:17,2025-05-28 03:53:06
6d5dda70-73b8-4e1a-9921-573774fbe009,SCHEDULED,b484c4ec-3d0d-4c2d-ad9c-440716f49a64,FDA_ALERT,2025-05-26 00:00:07,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/b484c4ec-3d0d-4c2d-ad9c-440716f49a64"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:12,2025-05-28 03:53:06
6db2d972-50c0-4ea6-a586-50bf00a8595c,USA-FDA,b21e0fb2-db11-42f6-9134-b13c690f509b,G_ACTION_ITEMS,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164/FDA-2006-D-0102-1164-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry"", ""docket_id"": ""FDA-2006-D-0102"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0102-1164""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:47:09,2025-05-28 03:53:06
6e0473cd-8e83-4336-8cb0-4190edda7c33,SCHEDULED,92fde110-fd3f-4143-bc7d-6d913ad5c3f9,GLOBAL_ALERT,2025-05-27 10:34:56,5,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/int_alert/92fde110-fd3f-4143-bc7d-6d913ad5c3f9"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 17:35:31,2025-05-28 03:53:06
6e32ec6a-cbda-41df-9ec0-84d15a67ea54,USA-FDA,5d7be256-e4c3-4030-88b3-7bc7e87539d9,G_MINI_SUMMARY,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002/FDA-2013-D-0349-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format"", ""docket_id"": ""FDA-2013-D-0349"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0349-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:01:16,2025-05-28 03:53:06
6e39ab72-2007-4a7b-a260-67a1813b6520,USA-FDA,c4b26e53-1f27-42f9-a6c3-e96ebe7262b9,G_CONCISE_SUMMARY,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002/FDA-2012-D-0022-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Direct-to-Consumer Television Advertisements, etc."", ""docket_id"": ""FDA-2012-D-0022"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0022-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:30:12,2025-05-28 03:53:06
6e3fb7e1-2600-478f-9662-e2a45ada1a95,USA-FDA,3492e1d6-bad4-4059-8cf1-d1e63fc81b28,G_IMPACT_ANALYSIS,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002/FDA-2018-D-2583-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products; Guidance for Industry;  Draft Guidance"", ""docket_id"": ""FDA-2018-D-2583"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2583-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:03:11,2025-05-28 03:53:06
6e47394c-25d6-46d0-baaa-7386a8f05407,USA-FDA,725d3eec-ba19-4b99-ad07-cfda64698f83,G_IMPACT_ANALYSIS,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0286/FDA-2013-D-0286-0015/FDA-2013-D-0286-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0286"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0286-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0286/FDA-2013-D-0286-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:17:10,2025-05-28 03:53:06
6e86a449-35de-4dfc-a10a-61d77caa6602,USA-FDA,792a9647-6e15-497c-a789-083fd1f2e04f,G_DETAILED_SUMMARY,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0019/FDA-2017-D-6380-0019-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0019""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0019"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:00:16,2025-05-28 03:53:06
6ea6eb2f-3c2d-40d3-b6ba-c5c47c257fd2,USA-FDA,43edebdd-970c-415c-ba4f-398a3f9748e7,G_FAQ,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007/FDA-2011-D-0691-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs"", ""docket_id"": ""FDA-2011-D-0691"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0691-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:03:00,2025-05-28 03:53:06
6eaeacf4-fe3c-4215-a0e6-fcbd51a6abe2,USA-FDA,e49b72d8-b242-40aa-82a2-437f5cb31703,G_KEYWORDS,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004/FDA-2007-D-0302-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Labeling for Human Prescription Drug and Biological Products � Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information"", ""docket_id"": ""FDA-2007-D-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0302-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:03:23,2025-05-28 03:53:06
6eb077e0-0dc7-4aa8-a1b5-6b27af451c29,USA-FDA,ed412d2c-a9f6-4f36-85a6-7057ed0bbfd3,G_KEYWORDS,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002/FDA-2012-D-0304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Claa II Special Controls Guidance Implanted Blood Access Devices for Hemodialysis"", ""docket_id"": ""FDA-2012-D-0304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:01:12,2025-05-28 03:53:06
6efde3a0-8406-406e-94b5-5cc8383d33c3,USA-FDA,9c3453b6-7ed8-460b-ab96-ac9a88c58402,G_MINI_SUMMARY,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4090/FDA-1999-D-4090-0005/FDA-1999-D-4090-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and for FDA Reviewers Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer"", ""docket_id"": ""FDA-1999-D-4090"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4090-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4090/FDA-1999-D-4090-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:31:10,2025-05-28 03:53:06
6f44d249-81b5-4e25-8da6-debfcabc3efe,USA-FDA,4f1a27fb-e971-45e1-9f51-a6fa3a5d4df3,G_MINI_SUMMARY,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002/FDA-2017-D-5525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Statistical Approaches to Evaluate Analytical Similarity Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:31:36,2025-05-28 03:53:06
6f457ef6-dc9c-44bb-a4b2-b37cc4b91308,USA-FDA,e3f76954-67ae-47f4-b5c2-ba9ea5547de9,G_ACTION_ITEMS,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0336/FDA-2005-D-0336-0004/FDA-2005-D-0336-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #176 (VICH GL39) Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances"", ""docket_id"": ""FDA-2005-D-0336"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0336-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0336/FDA-2005-D-0336-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:31:38,2025-05-28 03:53:06
6f53df69-abb3-485c-b201-511a27cabf07,USA-FDA,505510a0-1259-4d0c-9c4e-b27a16a951ff,G_FAQ,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1304/FDA-1999-D-1304-0002/FDA-1999-D-1304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Possible Dioxin/PCB Contamination of Drug and Biological Products"", ""docket_id"": ""FDA-1999-D-1304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1304/FDA-1999-D-1304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:31:51,2025-05-28 03:53:06
6f8537e4-7195-4638-a25e-6ccb287d043e,USA-FDA,ea76eaf1-623f-462a-a518-487dce1f540a,G_ACTION_ITEMS,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1927/FDA-2020-D-1927-0001/FDA-2020-D-1927-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Food Security Preventive Measures Guidance for  Retail Food Stores and Food Service Establishments"", ""docket_id"": ""FDA-2020-D-1927"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1927-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1927/FDA-2020-D-1927-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:00:55,2025-05-28 03:53:06
6f8d5cd3-b34a-42b5-9c72-42b31955b19f,SCHEDULED,98099b38-e53b-4152-8fb2-59347876f7a1,DEVICE_ANALYST,2025-05-26 00:00:07,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/98099b38-e53b-4152-8fb2-59347876f7a1"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:24,2025-05-28 03:53:06
6fc67541-ce73-40b7-97c4-1f6b2039dae8,USA-FDA,3b9aa9a4-9f52-42b1-bc59-c8e00a0cd586,G_FAQ,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1005/FDA-2012-D-1005-0002/FDA-2012-D-1005-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Considerations for Product Design to Minimize Medication Errors - Draft Guidance"", ""docket_id"": ""FDA-2012-D-1005"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1005-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1005/FDA-2012-D-1005-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:45:35,2025-05-28 03:53:06
6fc67584-aacc-481e-99ce-f860023c9034,USA-FDA,b64786af-a78c-4742-9b84-4e7a2d954d1e,G_FAQ,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1958/FDA-2020-D-1958-0001/FDA-2020-D-1958-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Seafood HACCP Transition Guidance"", ""docket_id"": ""FDA-2020-D-1958"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1958-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1958/FDA-2020-D-1958-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:02:54,2025-05-28 03:53:06
7,,9aeb66b8-618f-4f86-a7c5-51f99dceee68,G_CONCISE_SUMMARY,2025-05-09 01:53:01,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 08:53:08,2025-05-28 03:53:06
70,,0f951fc5-5074-4b4b-9a2b-757d70854d1c,G_IMPACT_ANALYSIS,2025-05-12 19:29:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026/FDA-2013-D-0114-0026-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Distinguishing Medical Device Recalls From Medical Device Enhancements; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0114"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0114-0026""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0114/FDA-2013-D-0114-0026"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:29:06,2025-05-28 03:53:06
701b0546-f202-49b9-81c0-7229ae1e0a7f,SCHEDULED,b76ffdb8-347b-4dc9-95df-3127c1d593b1,DEVICE_ANALYST,2025-05-24 00:00:05,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/b76ffdb8-347b-4dc9-95df-3127c1d593b1"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:22,2025-05-28 03:53:06
70200eef-794d-47bb-9721-160aa52ca029,USA-FDA,c1ed154c-f980-4ffd-80c8-46bcfcadecdc,G_MINI_SUMMARY,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0429/FDA-2011-D-0429-0002/FDA-2011-D-0429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry and Staff: Classification of Products as Drugs and Devices and Additional Product Classification Issues"", ""docket_id"": ""FDA-2011-D-0429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0429/FDA-2011-D-0429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:45:47,2025-05-28 03:53:06
7020a188-2ebd-4c1e-87bc-b43d3b569756,USA-FDA,ba3c951b-00e8-46c2-9d4a-614b6f065adc,G_DETAILED_SUMMARY,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1005/FDA-2012-D-1005-0002/FDA-2012-D-1005-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Considerations for Product Design to Minimize Medication Errors - Draft Guidance"", ""docket_id"": ""FDA-2012-D-1005"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1005-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1005/FDA-2012-D-1005-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:45:20,2025-05-28 03:53:06
704a7f66-1609-4a9a-b4ba-b5344caf5f9a,CAB,e8dd4edd-4d43-4f49-98f7-62f85a8ae446,G_TRANSLATE,2025-05-20 16:33:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Italian""}","{""tilte"": ""FDA-2018-F-3757-0019.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2018-F-3757-0019_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""04cb41d6-deff-4cde-83f8-ba7f77069dd4""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/04cb41d6-deff-4cde-83f8-ba7f77069dd4/Italian"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:34:56,2025-05-28 03:53:06
70532ab8-f22e-4d59-9569-5f42611eabd9,USA-FDA,53b0400b-c0a3-47b8-aa22-b39e74f99cca,G_IMPACT_ANALYSIS,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004/FDA-2007-D-0375-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Acute Bacterial Sinusitis; Developing Drugs for Treatment"", ""docket_id"": ""FDA-2007-D-0375"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0375-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:31:08,2025-05-28 03:53:06
705ad2bc-edf4-46fb-9594-ada3619c5ba1,USA-FDA,f46024e6-1990-4473-a232-6552899464ca,G_CONCISE_SUMMARY,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002/FDA-2013-D-0749-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implanted Blood Access Devices for Hemodialysis; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0749"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0749-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:01:35,2025-05-28 03:53:06
7077ba2d-1d84-4617-8b48-a7ad8e8fb905,USA-FDA,f84b486d-6aaa-490b-8918-6bb760f5f40a,G_FAQ,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0589/FDA-2013-D-0589-0002/FDA-2013-D-0589-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Human Immunodeficiency Virus-1 Infection:  Developing Antiretroviral Drugs for Treatment"", ""docket_id"": ""FDA-2013-D-0589"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0589-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0589/FDA-2013-D-0589-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:01:26,2025-05-28 03:53:06
7096c867-a424-4ddd-ba24-0c94ed8984a0,USA-FDA,67ba383b-5d23-4992-bc8c-3ff5bd9bac6e,G_ACTION_ITEMS,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002/FDA-2011-D-0598-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers Regarding Establishment, Maintenance of Records by Persons Who Manufacture of Records by Persons Who Manufacture, Process, Pack, Transport,Distribute Receive, Hold or Import Food (Edition 5)"", ""docket_id"": ""FDA-2011-D-0598"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0598-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:31:52,2025-05-28 03:53:06
70976aca-bc27-42c7-9793-b16d4b8663bc,Queue,394e89ad-3f57-4c4a-8883-f5338eb92d35,G_TRANSLATE,2025-05-29 21:35:20,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""FDA-2008-N-0567-0011_content.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/394e89ad-3f57-4c4a-8883-f5338eb92d35/FDA-2008-N-0567-0011_content.pdf.pdf"", ""doc_title"": ""FDA-2008-N-0567-0011_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/394e89ad-3f57-4c4a-8883-f5338eb92d35"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 21:35:20,2025-05-29 21:35:20
70cfba5e-2438-4eb4-ba02-ebbbed581151,USA-FDA,639bba62-f5e7-4c00-94eb-7e235ebc5c2c,G_IMPACT_ANALYSIS,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0300/FDA-2004-D-0300-0005/FDA-2004-D-0300-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Quality Systems Approach to Pharmaceutical CGMP Regulations"", ""docket_id"": ""FDA-2004-D-0300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0300-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0300/FDA-2004-D-0300-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:01:17,2025-05-28 03:53:06
70e78847-12f0-4ca5-8c56-b621bc21ccb3,USA-FDA,59d00fac-6dc2-43fd-8872-20c0a1a82106,G_DETAILED_SUMMARY,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1978/FDA-2020-D-1978-0001/FDA-2020-D-1978-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects"", ""docket_id"": ""FDA-2020-D-1978"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1978-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1978/FDA-2020-D-1978-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:15:50,2025-05-28 03:53:06
70f16433-a6f7-4b89-98ee-908b6929f307,SCHEDULED,f8d599eb-5136-400c-8625-d69dae0d3e31,DEVICE_ANALYST,2025-05-31 00:00:05,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/f8d599eb-5136-400c-8625-d69dae0d3e31"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:25,2025-05-31 00:00:25
71,,edbd417e-d248-4e4f-a21e-f4399b8487bb,G_MINI_SUMMARY,2025-05-12 19:29:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002/FDA-2010-D-0571-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; The Safety of Imported Traditional Pottery Intended for Use With Food and the Use of the Term \""Lead Free\"" in the Labeling of Pottery; and Proper Identification of Ornamental and Decorative Ceramicware"", ""docket_id"": ""FDA-2010-D-0571"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0571-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:29:09,2025-05-28 03:53:06
711074f0-b798-4552-b1ec-5cebb70573be,USA-FDA,7df1fbde-bd5f-4e36-8e2f-04a411fcd997,G_DETAILED_SUMMARY,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008/FDA-2008-D-0642-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2008-D-0642"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0642-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:32:30,2025-05-28 03:53:06
711b1d35-8cc5-4510-8140-c51b8475351d,USA-FDA,5aa7db08-5787-4777-a6f1-3f641f54714e,G_ACTION_ITEMS,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018/FDA-2012-D-1038-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:31:09,2025-05-28 03:53:06
7154f0eb-637d-4087-af9c-a6d6833464f0,USA-FDA,c54b78da-4af2-4ee0-8e10-121f0f97ef24,G_DETAILED_SUMMARY,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0260/FDA-2009-D-0260-0029/FDA-2009-D-0260-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2)"", ""docket_id"": ""FDA-2009-D-0260"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0260-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0260/FDA-2009-D-0260-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:47:10,2025-05-28 03:53:06
717d276a-eef4-4c56-9168-9454073d8f2d,USA-FDA,36590138-458e-4ffa-9a29-cafa0ecdca4e,G_IMPACT_ANALYSIS,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0128/FDA-2008-D-0128-0005/FDA-2008-D-0128-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Guidance for Industry"", ""docket_id"": ""FDA-2008-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0128-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0128/FDA-2008-D-0128-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:47:42,2025-05-28 03:53:06
7191905e-1b30-4ae0-80ed-a52a309a5bdc,USA-FDA,80fc8c2e-289f-480c-88cb-23c49391030f,G_MINI_SUMMARY,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002/FDA-2013-N-1429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2013-N-1429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:01:58,2025-05-28 03:53:06
719d1c0f-4c63-4a42-99ba-7c85bd428913,USA-FDA,b9017a5b-d130-4773-b580-606bfdcdfbf7,G_MINI_SUMMARY,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0002/FDA-2004-D-0301-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Fixed Dose Combination and Co-Packaged Drug Products for Treatment of HIV - DRAFT GUIDANCE"", ""docket_id"": ""FDA-2004-D-0301"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0301-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:31:56,2025-05-28 03:53:06
71e45057-dbfc-4414-9756-d9c9f1096102,QUEUE,6f6876cd-1cc0-47c0-883a-00c46a20bdec,G_SUMMARY_USER,2025-05-30 04:15:05,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""c_986569 (11).pdf""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/detailed_summary/6f6876cd-1cc0-47c0-883a-00c46a20bdec/c_986569 (11).pdf.pdf"", ""doc_title"": ""c_986569 (11).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/detailed_summary/6f6876cd-1cc0-47c0-883a-00c46a20bdec"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 04:15:09,2025-05-30 04:15:09
71e8cc14-93c9-4701-9dc8-502d14c86074,QUEUE,72492f06-eb4b-4be9-9cbf-9707806c0cf5,G_MINI_SUMMARY_USER,2025-05-20 10:44:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""__doc_title__"": ""FDA-2024-N-2910-0001_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/72492f06-eb4b-4be9-9cbf-9707806c0cf5/SRC/72492f06-eb4b-4be9-9cbf-9707806c0cf5.pdf"", ""doc_title"": ""FDA-2024-N-2910-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/72492f06-eb4b-4be9-9cbf-9707806c0cf5/DEST/mini_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:44:29,2025-05-28 03:53:06
71f66b1a-b860-464d-8c81-30d2beac50dc,USA-FDA,9176c31c-e16d-4b80-822f-d16b0d48701c,G_ACTION_ITEMS,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012/FDA-2003-D-0186-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for InduGuidance for Industry: Cosmetics Processors and Transporters of Cosmetics Security Preventive Measures Guidance"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:12,2025-05-28 03:53:06
72,,3a0aa880-3fce-49da-9355-5c31f4708ad4,G_CONCISE_SUMMARY,2025-05-12 19:29:12,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002/FDA-2010-D-0571-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; The Safety of Imported Traditional Pottery Intended for Use With Food and the Use of the Term \""Lead Free\"" in the Labeling of Pottery; and Proper Identification of Ornamental and Decorative Ceramicware"", ""docket_id"": ""FDA-2010-D-0571"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0571-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:29:13,2025-05-28 03:53:06
722e335e-4e8e-4c41-bade-e672d8f69dfe,CAB,58bcbdd6-37a1-448b-9f5b-5c5b3582fbed,G_CONCISE_SUMMARY_IN,2025-05-20 16:33:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_paragraphs__"": 3}","{""tilte"": ""FDA-2018-F-3757-0019.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2018-F-3757-0019_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""04cb41d6-deff-4cde-83f8-ba7f77069dd4""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/04cb41d6-deff-4cde-83f8-ba7f77069dd4"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:33:56,2025-05-28 03:53:06
725eac40-9c89-4419-88ac-7fe1e7daba01,USA-FDA,1c0d495d-7dac-4403-8950-d183c0d0a905,G_IMPACT_ANALYSIS,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1353/FDA-2020-D-1353-0001/FDA-2020-D-1353-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part IX FDA References"", ""docket_id"": ""FDA-2020-D-1353"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1353-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1353/FDA-2020-D-1353-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:16:18,2025-05-28 03:53:06
72673144-fd26-48c7-8837-8d5943b8b2de,QUEUE,5e10fbd0-6680-40e7-937f-16e1fb4c68eb,G_TRANSLATE,2025-05-29 22:30:06,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""MDCG_Position_Paper_on_the_application_of_Article_97_MDR_to_legacy_devices_for_which_the_MDD_or_AIMDD_certificate_expires_before_the_issuance_of_a_MDR_certificate.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/5e10fbd0-6680-40e7-937f-16e1fb4c68eb/MDCG_Position_Paper_on_the_application_of_Article_97_MDR_to_legacy_devices_for_which_the_MDD_or_AIMDD_certificate_expires_before_the_issuance_of_a_MDR_certificate.pdf.pdf"", ""doc_title"": ""MDCG_Position_Paper_on_the_application_of_Article_97_MDR_to_legacy_devices_for_which_the_MDD_or_AIMDD_certificate_expires_before_the_issuance_of_a_MDR_certificate.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/5e10fbd0-6680-40e7-937f-16e1fb4c68eb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 22:30:36,2025-05-29 22:30:36
728383f4-8e91-4390-8e56-6603dbf440f8,SCHEDULED,97b51d5a-71dd-4e58-8746-0f055eb53d5b,FDA_ALERT,2025-05-24 00:00:05,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/97b51d5a-71dd-4e58-8746-0f055eb53d5b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:11,2025-05-28 03:53:06
728d1611-0ab5-41f7-858c-b6668c4b1016,USA-FDA,1e1e68d0-1f0b-48c2-8fd0-b8563d071495,G_MINI_SUMMARY,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002/FDA-2011-D-0469-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and the Food and Drug Administration Staff: Applying Human Factors and Usability Engineering to Optimize Medical Device Design - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0469"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0469-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:14,2025-05-28 03:53:06
73,,f46f0581-5d4a-489f-ae0d-bfe56822eb65,G_DETAILED_SUMMARY,2025-05-12 19:29:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002/FDA-2010-D-0571-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; The Safety of Imported Traditional Pottery Intended for Use With Food and the Use of the Term \""Lead Free\"" in the Labeling of Pottery; and Proper Identification of Ornamental and Decorative Ceramicware"", ""docket_id"": ""FDA-2010-D-0571"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0571-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:29:19,2025-05-28 03:53:06
7300bdd5-80a0-497f-a210-55ffb58f5b28,USA-FDA,014b4d33-c299-49fd-aeff-b42a0cab8280,G_ACTION_ITEMS,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1362/FDA-2020-D-1362-0001/FDA-2020-D-1362-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VI GRAS Notices"", ""docket_id"": ""FDA-2020-D-1362"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1362-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1362/FDA-2020-D-1362-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:30:28,2025-05-28 03:53:06
730d290d-05cb-41c3-8410-0bfa8c7e9696,USA-FDA,ce503943-1a93-4dba-874d-231440007c39,G_FAQ,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001/FDA-2020-D-1385-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Drug Stability Guidelines; #5"", ""docket_id"": ""FDA-2020-D-1385"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1385-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:32:38,2025-05-28 03:53:06
73308cec-8d9f-4058-ad82-7f5bca69b292,USA-FDA,268700c0-c21e-4e03-8cc3-75438498db7b,G_FAQ,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0016/FDA-2010-D-0503-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Clinical Investigators, Sponsors, and Institutional Review Boards on Investigational New Drug Applications--Determining Whether Human Research Studies Can Be Conducted Without an Investigational New Drug Application"", ""docket_id"": ""FDA-2010-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0503-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:45:38,2025-05-28 03:53:06
735bee3e-cf24-4419-bdc5-7340002f792c,USA-FDA,83e50188-d0c3-4203-a00c-9d911648b235,G_FAQ,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0002/FDA-2010-D-0503-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Investigational New Drug Applications (INDs)�Determining Whether Human Research Studies Can Be Conducted Without an IND"", ""docket_id"": ""FDA-2010-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0503-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:47:55,2025-05-28 03:53:06
73886985-4624-4a1c-959c-5a89f89dd79a,USA-FDA,373c8d11-b901-4d13-83b1-c60d6773c800,G_IMPACT_ANALYSIS,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0056/FDA-1997-D-0056-0002/FDA-1997-D-0056-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Iron-Containing Supplements and Drugs: Label Warning Statements and Unit-Dose Packaging Requirements Small Entity Compliance Guide"", ""docket_id"": ""FDA-1997-D-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0056-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0056/FDA-1997-D-0056-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:16:39,2025-05-28 03:53:06
738b40e1-7ef4-4da9-836b-ec9445e825ed,USA-FDA,d7406817-7948-4597-91a5-ffd6f10138d9,G_IMPACT_ANALYSIS,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-N-0121/FDA-2011-N-0121-0009/FDA-2011-N-0121-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products; Small Entity Compliance Guide"", ""docket_id"": ""FDA-2011-N-0121"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-N-0121-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-N-0121/FDA-2011-N-0121-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:15:36,2025-05-28 03:53:06
73adafff-98a6-4d60-b38f-9fc914e8a59d,USA-FDA,cb888141-7b33-4f49-ba25-32532aa107c8,G_DETAILED_SUMMARY,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021/FDA-2005-D-0282-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:31:29,2025-05-28 03:53:06
73df1efb-725a-4aec-92ea-7452e9dfbf81,CAB,7ee2adc7-732a-427b-9727-b75ff33ea9b3,G_KEYWORDS,2025-05-27 02:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""num_keywords"": 10}","{""tilte"": ""FDA-2024-N-2910-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2024-N-2910-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b3efc128-de32-4064-8905-ee749b8e53b7""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b3efc128-de32-4064-8905-ee749b8e53b7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 02:00:59,2025-05-28 03:53:06
73e62536-d365-4de6-a895-b6671d53d0c1,USA-FDA,70ef82b3-f92e-4e73-b89e-49d8c7beebde,G_CONCISE_SUMMARY,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002/FDA-2018-D-3152-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Postapproval Changes to Drug Substances Guidance for Industry"", ""docket_id"": ""FDA-2018-D-3152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3152-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:45:15,2025-05-28 03:53:06
74,,e6e14e89-029c-48dc-a069-21c1dd3ce614,G_FAQ,2025-05-12 19:29:26,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002/FDA-2010-D-0571-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; The Safety of Imported Traditional Pottery Intended for Use With Food and the Use of the Term \""Lead Free\"" in the Labeling of Pottery; and Proper Identification of Ornamental and Decorative Ceramicware"", ""docket_id"": ""FDA-2010-D-0571"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0571-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:29:27,2025-05-28 03:53:06
740153f8-d829-4fb9-b056-1bdab0cd0198,USA-FDA,aa024d45-0ba2-4d00-8ce9-63d3c25322e0,G_IMPACT_ANALYSIS,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0132/FDA-2009-D-0132-0012/FDA-2009-D-0132-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cellular Therapy for Cardiac Disease "", ""docket_id"": ""FDA-2009-D-0132"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0132-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0132/FDA-2009-D-0132-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:47:53,2025-05-28 03:53:06
741831f6-e970-41a0-a850-b7bf6b6ee3a3,USA-FDA,3984314f-9f71-4bad-823a-6381c90f1ceb,G_ACTION_ITEMS,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5140/FDA-2017-D-5140-0002/FDA-2017-D-5140-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Display Devices for Diagnostic Radiology"", ""docket_id"": ""FDA-2017-D-5140"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5140-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5140/FDA-2017-D-5140-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:17:02,2025-05-28 03:53:06
7423bdf9-e277-4dc7-8961-369bdb3d9bf0,USA-FDA,ebbb46c2-62f6-4006-9486-13ea777e9d8a,G_ACTION_ITEMS,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001/FDA-2023-D-2510-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)"", ""docket_id"": ""FDA-2023-D-2510"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2510-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:31:37,2025-05-28 03:53:06
7428a200-41ef-4685-b28b-5ef2d82d6123,USA-FDA,c765afa5-ba6f-42ff-bd77-0611d91bdc45,G_MINI_SUMMARY,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0361/FDA-2008-N-0361-0002/FDA-2008-N-0361-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Standard of Identity for White Chocolate; Guidance "", ""docket_id"": ""FDA-2008-N-0361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-N-0361-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0361/FDA-2008-N-0361-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:15:07,2025-05-28 03:53:06
74349357-0712-4697-9661-3794ac8ced47,USA-FDA,7bd0bd9f-25d5-4210-8eb1-fd9a7e9dd7a0,G_DETAILED_SUMMARY,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002/FDA-2003-D-0416-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS"", ""docket_id"": ""FDA-2003-D-0416"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0416-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:47:18,2025-05-28 03:53:06
74371767-c86c-4912-b08c-8fefce55a1fe,USA-FDA,113cb3dc-b8a1-4731-99e8-5b78569ceaf4,G_IMPACT_ANALYSIS,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005/FDA-2010-D-0165-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies (VICH GL49)"", ""docket_id"": ""FDA-2010-D-0165"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0165-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:02:25,2025-05-28 03:53:06
743b21d7-0ce0-4398-b69f-c809672883bd,SCHEDULED,cce060d2-da8c-4eac-863a-cf6aa66b84b6,GLOBAL_ALERT,2025-05-27 10:34:56,24,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-03-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/int_alert/cce060d2-da8c-4eac-863a-cf6aa66b84b6"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 17:36:52,2025-05-28 03:53:06
744040c9-e69c-4545-b05a-f54a829f6a9e,USA-FDA,913c3e49-137d-4a9d-8b88-32b65976ff14,G_MINI_SUMMARY,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001/FDA-2020-D-1925-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations)"", ""docket_id"": ""FDA-2020-D-1925"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1925-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:45:41,2025-05-28 03:53:06
7442567d-efe0-47d5-8c2f-9c9a095fbbfb,USA-FDA,9fe226de-f0e7-49e3-9e54-b2f874451ad1,G_CONCISE_SUMMARY,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011/FDA-2001-D-0137-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children"", ""docket_id"": ""FDA-2001-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0137-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:32:14,2025-05-28 03:53:06
744e6024-2320-4412-a689-6ce090001b7d,USA-FDA,5e5a9735-2ad8-4c32-990e-9860faa0473a,G_ACTION_ITEMS,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0309/FDA-2002-D-0309-0002/FDA-2002-D-0309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been ReconditionedDraft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been Reconditioned"", ""docket_id"": ""FDA-2002-D-0309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0309/FDA-2002-D-0309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:15:34,2025-05-28 03:53:06
746b32ea-b2fc-4199-b336-da2ee214de8f,USA-FDA,fe72cbdd-d348-4559-ba72-946a0cddbce7,G_DETAILED_SUMMARY,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005/FDA-2011-D-0112-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Chemistry, Manufacturing, and Controls (CMC)\nInformation � Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use"", ""docket_id"": ""FDA-2011-D-0112"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0112-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:30:43,2025-05-28 03:53:06
7498bdf5-dbad-480d-8946-744bfce11693,SCHEDULED,f041776e-fbfa-4810-93a6-7f00f1dc22d8,GLOBAL_ALERT,2025-05-27 11:51:52,5,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/int_alert/f041776e-fbfa-4810-93a6-7f00f1dc22d8"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 18:52:16,2025-05-28 03:53:06
74b4e256-2e3f-44cf-9ff6-f346456144a5,USA-FDA,69084e87-828f-46b3-aa43-5341150fb718,G_FAQ,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004/FDA-2010-D-0636-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia Burgdorferi"", ""docket_id"": ""FDA-2010-D-0636"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0636-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:15:22,2025-05-28 03:53:06
74f240f9-ed8f-4166-8bb0-d1ad3b1df3d9,USA-FDA,4f65f4c2-48b3-4dc2-8e64-86af34b14612,G_MINI_SUMMARY,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0008/FDA-2017-D-2462-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species Guidance for Industry"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:31:25,2025-05-28 03:53:06
74fd0574-e97f-474a-b723-3ea7ac1b65ab,USA-FDA,22ec9ed5-9261-41a4-b782-c34feca63e90,G_ACTION_ITEMS,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008/FDA-2009-D-0448-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry, MQSA Inspectors and FDA Staffl The Mammography Quality Standards Act Final Regulations: Modifications and Additions to Policy Guidance Help System #13"", ""docket_id"": ""FDA-2009-D-0448"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0448-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:03:15,2025-05-28 03:53:06
75,,86c2e72e-7324-414c-afbb-c3378d310bb9,G_ACTION_ITEMS,2025-05-12 19:29:31,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002/FDA-2010-D-0571-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; The Safety of Imported Traditional Pottery Intended for Use With Food and the Use of the Term \""Lead Free\"" in the Labeling of Pottery; and Proper Identification of Ornamental and Decorative Ceramicware"", ""docket_id"": ""FDA-2010-D-0571"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0571-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:29:32,2025-05-28 03:53:06
751b0d63-8d9c-4361-bf52-c58a0cdbc612,USA-FDA,48e24907-6955-4551-a8dc-7b1206bc5a29,G_FAQ,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005/FDA-2011-D-0112-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Chemistry, Manufacturing, and Controls (CMC)\nInformation � Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use"", ""docket_id"": ""FDA-2011-D-0112"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0112-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:31:16,2025-05-28 03:53:06
7540f454-b668-47cc-8de2-30d59a4fdead,USA-FDA,faf544af-530c-4326-9531-976d6a409aaf,G_DETAILED_SUMMARY,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0013/FDA-2003-D-0186-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""DRAFT GUIDANCE FOR INDUSTRY COSMETICS PROCESSORS AND TRANSPORTERS: COSMETICS SECURITY PREVENTIVE MEASURES GUIDANCE"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:30:53,2025-05-28 03:53:06
755b39f4-c18a-46a9-bf50-3d650ec23fb6,USA-FDA,1fe28f87-a98d-48fd-b9cd-eb28cb269a07,G_MINI_SUMMARY,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004/FDA-2018-N-4735-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""GFI Safety Labeling Changes Implementation of Section 505(o)(4) of the FDC Act"", ""docket_id"": ""FDA-2018-N-4735"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-N-4735-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:16:14,2025-05-28 03:53:06
758f2eb2-417f-4aae-82c8-c191d6e223a3,USA-FDA,019c885b-18ae-4afa-bd65-07aeb3fa7f83,G_IMPACT_ANALYSIS,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0166/FDA-2010-D-0166-0006/FDA-2010-D-0166-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods (VICH GL-48)"", ""docket_id"": ""FDA-2010-D-0166"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0166-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0166/FDA-2010-D-0166-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:16:21,2025-05-28 03:53:06
75ccb051-4370-4c4e-98ae-0788799b4d17,QUEUE,d1da2bf8-6a7b-4294-a292-18dd2b42a343,G_SUMMARY_USER,2025-05-20 10:42:45,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""__doc_title__"": ""EU regulations on medical devices � Update November 2022.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/d1da2bf8-6a7b-4294-a292-18dd2b42a343/SRC/d1da2bf8-6a7b-4294-a292-18dd2b42a343.pdf"", ""doc_title"": ""EU regulations on medical devices � Update November 2022.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/d1da2bf8-6a7b-4294-a292-18dd2b42a343/DEST/detailed_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:42:53,2025-05-28 03:53:06
75ce8dde-7b2f-49fc-bf46-cf3f8e789f46,USA-FDA,2793a8f7-a4c0-4e3d-8e27-5d3e19f6ecec,G_ACTION_ITEMS,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002/FDA-2012-D-0307-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Revised Preventive Measures to Reduce Possible Risk of Transmission of Creutzfeldt-Jakob Disease, etc."", ""docket_id"": ""FDA-2012-D-0307"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0307-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:31:25,2025-05-28 03:53:06
75cfed7c-a49f-4e98-83e4-78c1b5eab363,USA-FDA,5593f2eb-696e-4058-84e1-06cf2efe830f,G_CONCISE_SUMMARY,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022/FDA-1999-D-1875-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Extra-Label Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:02:25,2025-05-28 03:53:06
75d0a813-d7f0-48c9-ba35-12b6c56ad7d8,USA-FDA,0d0559d0-15d2-4d79-86c2-1c4bcca6c0c4,G_FAQ,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002/FDA-2011-D-0487-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of Acceptable Full-Length and Abbreviated Donor History Questinnaries and Accompanying Materials for Use in Screening Donors of Source Plasma Draft Guidence"", ""docket_id"": ""FDA-2011-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0487-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:31:19,2025-05-28 03:53:06
75e9f2de-a248-451a-8991-e00fa3eded8f,USA-FDA,aaf617a0-52b3-4485-90bc-3b3a89fe16df,G_IMPACT_ANALYSIS,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0045/FDA-2013-D-0045-0030/FDA-2013-D-0045-0030-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abuse-Deterrent Opioids-Evaluation and Labeling"", ""docket_id"": ""FDA-2013-D-0045"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0045-0030""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0045/FDA-2013-D-0045-0030"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:46:03,2025-05-28 03:53:06
75f83a79-1aeb-4305-90cb-2db20cb38ce9,SCHEDULED,72cf71cc-b0df-4464-8cb2-27728e9f26ca,FDA_ALERT,2025-05-23 00:00:04,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/72cf71cc-b0df-4464-8cb2-27728e9f26ca"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:10,2025-05-28 03:53:06
76,,8bb36262-93bd-475d-afa2-f6c0d844d30f,G_IMPACT_ANALYSIS,2025-05-12 19:29:38,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002/FDA-2010-D-0571-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; The Safety of Imported Traditional Pottery Intended for Use With Food and the Use of the Term \""Lead Free\"" in the Labeling of Pottery; and Proper Identification of Ornamental and Decorative Ceramicware"", ""docket_id"": ""FDA-2010-D-0571"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0571-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0571/FDA-2010-D-0571-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:29:39,2025-05-28 03:53:06
763fcd7d-e8ad-4c05-88fe-7df5af53bbd7,USA-FDA,5f553849-583a-4fe4-bd4e-0731be6449ce,G_MINI_SUMMARY,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0893/FDA-2011-D-0893-0002/FDA-2011-D-0893-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry and Staff Center for Devices and Radiological Health Appeals Processes"", ""docket_id"": ""FDA-2011-D-0893"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0893-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0893/FDA-2011-D-0893-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:02:00,2025-05-28 03:53:06
7684bb07-b548-40d2-aff3-572fecf5c706,SCHEDULED,846445d0-2730-4d3d-b1ec-f8dc3432a0f1,DEVICE_ANALYST,2025-05-24 00:00:05,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/846445d0-2730-4d3d-b1ec-f8dc3432a0f1"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:24,2025-05-28 03:53:06
76854490-9d91-429e-8298-f721115257b0,USA-FDA,2269cb27-c6c2-4a56-a106-ead2a7d96166,G_IMPACT_ANALYSIS,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002/FDA-2010-D-0395-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Adminstration Staff Recommendation for Premarket Notification for Lamotrigine and Zonisamide Assays"", ""docket_id"": ""FDA-2010-D-0395"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0395-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:09,2025-05-28 03:53:06
769765fb-c957-4110-a001-539e4a6be4f7,USA-FDA,ee903b20-5d7a-441b-bf11-e46183aba1c2,G_ACTION_ITEMS,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002/FDA-2011-D-0464-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Low Glucose Suspend (LGS) Device Systems - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0464-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:32:41,2025-05-28 03:53:06
76b49467-02b5-4ae8-9d32-0b5ea8905b85,USA-FDA,ec4b0d7f-57ee-40ae-b550-143920f3c9af,G_ACTION_ITEMS,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1984-D-0020/FDA-1984-D-0020-0002/FDA-1984-D-0020-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics"", ""docket_id"": ""FDA-1984-D-0020"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1984-D-0020-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1984-D-0020/FDA-1984-D-0020-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:17:57,2025-05-28 03:53:06
76b581ec-8c1a-4d06-a5b8-fa43a7ae7545,USA-FDA,cdf64495-dcda-403c-9574-db473fcd40af,G_CONCISE_SUMMARY,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002/FDA-2015-D-4380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Best Practices for Communication Between IND Sponsors and FDA\nDuring Drug Development Guidance for Industry and Review Staff"", ""docket_id"": ""FDA-2015-D-4380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:16:33,2025-05-28 03:53:06
76f8cef8-a9e6-4d57-923a-f3ab10bcffb6,USA-FDA,0c31cbc1-b267-436e-97d0-15be597b9802,G_DETAILED_SUMMARY,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1984-D-0020/FDA-1984-D-0020-0002/FDA-1984-D-0020-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics"", ""docket_id"": ""FDA-1984-D-0020"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1984-D-0020-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1984-D-0020/FDA-1984-D-0020-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:17:13,2025-05-28 03:53:06
76fe091d-e440-4e0d-a819-75d68744b077,QUEUE,8fd65a0b-3fb6-49f2-9ec4-fb669cf3ab9e,G_TRANSLATE,2025-05-30 03:30:06,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""Provisions for In-vitro Diagnostic Reagent Registration and Filing.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/8fd65a0b-3fb6-49f2-9ec4-fb669cf3ab9e/Provisions for In-vitro Diagnostic Reagent Registration and Filing.pdf.pdf"", ""doc_title"": ""Provisions for In-vitro Diagnostic Reagent Registration and Filing.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/8fd65a0b-3fb6-49f2-9ec4-fb669cf3ab9e"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 03:31:01,2025-05-30 03:31:01
77,,75ebdacd-c911-4840-a109-8b9870dd6abe,G_MINI_SUMMARY,2025-05-12 19:29:41,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 510, 520, 522, 524, 529, and 558"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal\nof Approval of New Animal Drug Applications; Change of Sponsor;\nChange of Sponsor Address"", ""docket_id"": ""FDA-2024-N-0002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-N-0002-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:29:42,2025-05-28 03:53:06
770bb2be-5061-4261-8fbe-addd99388983,USA-FDA,7e545a27-4862-4e20-81ba-013786262a07,G_DETAILED_SUMMARY,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0364/FDA-2007-D-0364-0014/FDA-2007-D-0364-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Indexing Structured Product Labeling"", ""docket_id"": ""FDA-2007-D-0364"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0364-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0364/FDA-2007-D-0364-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:01:35,2025-05-28 03:53:06
77275408-214f-4ea1-8f5a-1970dcbd13aa,USA-FDA,3ab7719b-cdc5-489b-bd73-e605c59a364b,G_CONCISE_SUMMARY,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002/FDA-1999-D-1875-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:30:14,2025-05-28 03:53:06
77398bbc-e525-436f-924d-69ba974dd6f6,USA-FDA,33392934-5794-405c-b6f7-d758310749b3,G_CONCISE_SUMMARY,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002/FDA-2009-D-0137-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Guidance"", ""docket_id"": ""FDA-2009-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0137-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:31:45,2025-05-28 03:53:06
773fc665-ba4c-4062-88da-ae6dd5211b6b,USA-FDA,3e07850c-8ca6-4339-b543-6d889c8f1e2e,G_MINI_SUMMARY,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001/FDA-2020-D-1916-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect -21 CFR 1003.11"", ""docket_id"": ""FDA-2020-D-1916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1916-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:45:08,2025-05-28 03:53:06
775135a5-0ea3-442a-8dc1-912e14933c22,USA-FDA,77c8f5d4-f7f6-484a-9828-ec4769610f21,G_IMPACT_ANALYSIS,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002/FDA-2011-D-0480-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products"", ""docket_id"": ""FDA-2011-D-0480"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0480-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:30:51,2025-05-28 03:53:06
77530c87-efaa-43c5-b56c-ebbad30ef94c,USA-FDA,5abe628c-34c0-480c-8f9e-6269a6ccd7d6,G_ACTION_ITEMS,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0361/FDA-2008-N-0361-0002/FDA-2008-N-0361-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Standard of Identity for White Chocolate; Guidance "", ""docket_id"": ""FDA-2008-N-0361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-N-0361-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0361/FDA-2008-N-0361-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:15:25,2025-05-28 03:53:06
776439a2-14cd-4a43-962e-99e12bea157e,USA-FDA,6b73baaa-f8c0-41db-9495-30216225edd8,G_FAQ,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022/FDA-1999-D-1875-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Extra-Label Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:02:43,2025-05-28 03:53:06
778cb339-9e24-4771-8bff-fe74bab1d863,CAB,3cf493af-22ab-40b6-a3f1-25d86615d12e,G_IMPACT_ANALYSIS_IN,2025-05-20 10:13:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2022-F-1108-0001"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2022-F-1108-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""48b24e3f-2c7d-446d-8ef2-9a788b5abc48""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/48b24e3f-2c7d-446d-8ef2-9a788b5abc48"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:13:55,2025-05-28 03:53:06
778f6495-f0a0-4af3-83ca-74dec46f5a70,USA-FDA,ead4d9ab-9f30-4c5a-9bba-56b2cc1108b2,G_MINI_SUMMARY,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1455/FDA-2020-D-1455-0001/FDA-2020-D-1455-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; Early Development Considerations for Innovative Combination Products"", ""docket_id"": ""FDA-2020-D-1455"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1455-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1455/FDA-2020-D-1455-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:16:23,2025-05-28 03:53:06
7790cd49-fc0a-4c31-978e-b68483271fd0,USA-FDA,67ec9595-b6fc-4259-ad59-b87aad5dbd4c,G_FAQ,2025-05-20 12:08:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002/FDA-2011-D-0597-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring"", ""docket_id"": ""FDA-2011-D-0597"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0597-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:09:55,2025-05-28 03:53:06
77b79c21-6087-43bd-9730-0b6a5a640ba0,USA-FDA,21cebbf1-2c2a-42e0-af5c-8675df5588c4,G_IMPACT_ANALYSIS,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0721/FDA-2011-D-0721-0002/FDA-2011-D-0721-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act"", ""docket_id"": ""FDA-2011-D-0721"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0721-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0721/FDA-2011-D-0721-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:31:04,2025-05-28 03:53:06
77ebd06f-d53d-4842-b001-cec3ce02cab4,USA-FDA,b59b4fdf-c358-438c-abc1-bd679c6883ab,G_DETAILED_SUMMARY,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0432/FDA-2011-D-0432-0002/FDA-2011-D-0432-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics"", ""docket_id"": ""FDA-2011-D-0432"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0432-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0432/FDA-2011-D-0432-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:45:53,2025-05-28 03:53:06
77eca3bb-af24-42b1-8d73-fd715856d4a6,USA-FDA,28292bb3-1ac8-4b4e-9767-424192303793,G_DETAILED_SUMMARY,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0429/FDA-2011-D-0429-0002/FDA-2011-D-0429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry and Staff: Classification of Products as Drugs and Devices and Additional Product Classification Issues"", ""docket_id"": ""FDA-2011-D-0429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0429/FDA-2011-D-0429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:46:02,2025-05-28 03:53:06
77f6d3ce-c92d-4b6a-a8f2-9d8b0c2ceb43,USA-FDA,227a7e6a-569f-48ac-86a6-66a8336f36c4,G_DETAILED_SUMMARY,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0295/FDA-2013-D-0295-0002/FDA-2013-D-0295-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Scale-Up and Post-Approval Changes, Manufacturing Equipment Addendum"", ""docket_id"": ""FDA-2013-D-0295"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0295-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0295/FDA-2013-D-0295-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:30:23,2025-05-28 03:53:06
77f8d1b9-69a5-4914-83ca-9045a05d9527,USA-FDA,75aa738f-ec23-4c4f-82d4-f7184de27f84,G_MINI_SUMMARY,2025-05-22 18:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0902/FDA-2014-D-0902-0002/FDA-2014-D-0902-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry ANDA Submissions  Amendments and Easily Correctable Deficiencies Under GDUFA"", ""docket_id"": ""FDA-2014-D-0902"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-0902-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0902/FDA-2014-D-0902-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:45:35,2025-05-28 03:53:06
78,,92398248-4b2f-4eed-8b06-82b8ff7a2de7,G_CONCISE_SUMMARY,2025-05-12 19:29:45,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 510, 520, 522, 524, 529, and 558"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal\nof Approval of New Animal Drug Applications; Change of Sponsor;\nChange of Sponsor Address"", ""docket_id"": ""FDA-2024-N-0002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-N-0002-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:29:46,2025-05-28 03:53:06
780545d9-1cb4-4d43-9796-558ff5a88322,CAB,5fe0ae74-3068-42b7-a4f4-f35e95969465,G_MINI_SUMMARY_IN,2025-05-20 11:45:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,{},"{""tilte"": ""FDA-1993-D-0285-0014_attachment_1.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/dd7f6201-f981-4d40-8289-1dadcf8b4715/FDA-1993-D-0285-0014_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""1cc4a4c6-e41f-42b6-b8cb-eacbb3415f01""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/1cc4a4c6-e41f-42b6-b8cb-eacbb3415f01"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 18:45:55,2025-05-28 03:53:06
7834edfc-a8ee-41af-8907-b0b488d1a7a9,USA-FDA,54d63093-404a-4b25-9a2e-c46478e8d831,G_FAQ,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029/FDA-2009-D-0179-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0179-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:32:21,2025-05-28 03:53:06
7839f5df-6967-4f5e-b1e8-d4c6348c0f92,USA-FDA,af293ab2-ddd4-4720-8004-15ba01827744,G_KEYWORDS,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013/FDA-2009-D-0490-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff:  Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2009-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0490-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:48:27,2025-05-28 03:53:06
78488a5b-bf0c-42a6-a6c7-961e4130dfe9,USA-FDA,e6b2974d-7ea7-4e39-9255-2a8d27fb36f1,G_FAQ,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002/FDA-2009-D-0137-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Guidance"", ""docket_id"": ""FDA-2009-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0137-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:32:28,2025-05-28 03:53:06
784b71ca-6ea5-4c24-a304-a796b9451db2,USA-FDA,473fe99c-f203-42d7-ba8e-3f79de93c9c1,G_KEYWORDS,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008/FDA-2004-D-0181-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA)"", ""docket_id"": ""FDA-2004-D-0181"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0181-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:32:57,2025-05-28 03:53:06
788357e9-caa8-40da-986f-2328f8549fea,USA-FDA,c9473354-0d5d-4ea9-af43-6ebde60b3e81,G_MINI_SUMMARY,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1984-D-0020/FDA-1984-D-0020-0002/FDA-1984-D-0020-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics"", ""docket_id"": ""FDA-1984-D-0020"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1984-D-0020-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1984-D-0020/FDA-1984-D-0020-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:16:47,2025-05-28 03:53:06
788d68cc-a954-4971-9e2f-a659bf2a5b97,USA-FDA,ca559a0d-064c-4614-a854-647271ac72e8,G_DETAILED_SUMMARY,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002/FDA-2014-N-1108-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products--Considerations, Content, and Format"", ""docket_id"": ""FDA-2014-N-1108"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1108-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:01:34,2025-05-28 03:53:06
78c06d64-f445-4be6-89ab-21d696880c3e,USA-FDA,949c3680-0273-4af4-87f6-d2c9d4f21253,G_ACTION_ITEMS,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012/FDA-2016-D-1533-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma - Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:47:50,2025-05-28 03:53:06
78c441cc-01b4-44bc-bef8-bc74b36170aa,USA-FDA,d7438703-3046-4bcf-877c-c6dc78a730d1,G_IMPACT_ANALYSIS,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005/FDA-1999-D-4079-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling"", ""docket_id"": ""FDA-1999-D-4079"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4079-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:32:24,2025-05-28 03:53:06
79,,5cf046a2-fcde-4399-9f75-3ec9c92bc51f,G_DETAILED_SUMMARY,2025-05-12 19:29:54,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 510, 520, 522, 524, 529, and 558"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal\nof Approval of New Animal Drug Applications; Change of Sponsor;\nChange of Sponsor Address"", ""docket_id"": ""FDA-2024-N-0002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-N-0002-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:29:55,2025-05-28 03:53:06
791a9045-4e5e-42df-918d-7d66ae9a9013,USA-FDA,450826fe-9fbb-4955-a152-0ecf4af51699,G_DETAILED_SUMMARY,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002/FDA-1997-D-0444-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""FDA Approval of Animal Drugs for Minor Uses and Minor Species; Draft Guidance Document"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:52,2025-05-28 03:53:06
7923b355-156d-4ffa-a2c2-a4e919bc05bf,USA-FDA,d7b26c53-906f-42cc-a2d9-a93d2822049c,G_FAQ,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002/FDA-2012-D-0307-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Revised Preventive Measures to Reduce Possible Risk of Transmission of Creutzfeldt-Jakob Disease, etc."", ""docket_id"": ""FDA-2012-D-0307"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0307-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:31:20,2025-05-28 03:53:06
794539b8-081c-4529-8827-b2facc8beabc,USA-FDA,1fc7a74f-4fc8-4013-ad85-25d97343ef19,G_CONCISE_SUMMARY,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002/FDA-2013-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abbreviated New Drug Application Submissions--Refuse-to-Receive Standards"", ""docket_id"": ""FDA-2013-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:31:19,2025-05-28 03:53:06
794c26a6-ca0f-4cd0-8fea-4a687541248b,USA-FDA,90e93343-51fe-4ec4-bfd3-4ce3a88d37bd,G_KEYWORDS,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018/FDA-2012-D-1038-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:31:24,2025-05-28 03:53:06
797284f9-4dc7-4dc8-a28f-0d0752091a7e,USA-FDA,97ab8e7f-3663-4d73-89bb-4fede6bbd94d,G_FAQ,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0889/FDA-2011-D-0889-0002/FDA-2011-D-0889-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions With GFI #209"", ""docket_id"": ""FDA-2011-D-0889"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0889-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0889/FDA-2011-D-0889-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:31:17,2025-05-28 03:53:06
79adaf2b-6746-4ff5-bb8c-35477b9deb89,USA-FDA,c01980ab-cf5b-4d19-a682-4b4efe258f01,G_DETAILED_SUMMARY,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-3276/FDA-2016-D-3276-0001/FDA-2016-D-3276-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Investigational Use of Deemed, Finished Tobacco Products That Were on the U.S. Market on August 8, 2016, During the Deeming Compliance Periods; Guidance for Industry"", ""docket_id"": ""FDA-2016-D-3276"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-3276-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-3276/FDA-2016-D-3276-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:17:06,2025-05-28 03:53:06
79af2283-b8ad-4e52-9e44-50e37bdcbfb3,USA-FDA,73640014-ceab-4c42-a350-323fbaf7d506,G_FAQ,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0002/FDA-2011-D-0620-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2011-D-0620"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0620-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:16:41,2025-05-28 03:53:06
79faa000-bcd2-4c3d-8661-f0644cc2d7b0,USA-FDA,c3cd6bb3-2757-42eb-9561-f869be566c9e,G_FAQ,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2635/FDA-2016-D-2635-0269/FDA-2016-D-2635-0269-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Potential Approach for Defining Durations of Use for Medically Important Antimicrobial Drugs Intended for Use In or On Feed: A Concept Paper"", ""docket_id"": ""FDA-2016-D-2635"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2635-0269""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2635/FDA-2016-D-2635-0269"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:30:50,2025-05-28 03:53:06
7a0476de-2fde-4714-9654-1333814d76e3,USA-FDA,b7ad2d22-841b-4d03-8e0d-dfde82c6e4a7,G_FAQ,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004/FDA-2007-D-0375-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Acute Bacterial Sinusitis; Developing Drugs for Treatment"", ""docket_id"": ""FDA-2007-D-0375"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0375-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:30:51,2025-05-28 03:53:06
7a09a02f-5f94-4ad1-9fe1-3e0a2994aa87,QUEUE,f82f6a49-b382-4ff1-96da-8ea6f53ed53d,G_SUMMARY_USER,2025-05-20 10:57:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""__doc_title__"": ""FDA-2023-D-0488-0002-guidance (1).pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/f82f6a49-b382-4ff1-96da-8ea6f53ed53d/SRC/f82f6a49-b382-4ff1-96da-8ea6f53ed53d.pdf"", ""doc_title"": ""FDA-2023-D-0488-0002-guidance (1).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/f82f6a49-b382-4ff1-96da-8ea6f53ed53d/DEST/detailed_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:57:16,2025-05-28 03:53:06
7a1424c4-22ff-41ad-881d-f73671ac7321,USA-FDA,9908ed45-364d-40fc-91a1-1467c3abf3df,G_CONCISE_SUMMARY,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002/FDA-2000-D-0129-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans - Draft Guidance"", ""docket_id"": ""FDA-2000-D-0129"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-D-0129-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:00:57,2025-05-28 03:53:06
7a39951c-6804-4421-9274-5743683a4f96,USA-FDA,3f8c4a3a-5b7e-4971-8679-7abe68640445,G_ACTION_ITEMS,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1353/FDA-2020-D-1353-0001/FDA-2020-D-1353-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part IX FDA References"", ""docket_id"": ""FDA-2020-D-1353"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1353-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1353/FDA-2020-D-1353-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:16:12,2025-05-28 03:53:06
7a4489b8-e7cc-4adc-a27e-804d8fe849bc,USA-FDA,d5f179be-f9f6-4f96-9bdb-4f6814d847d7,G_KEYWORDS,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022/FDA-2005-D-0282-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Antiviral Product Development - Conducting and Submitting Virology Studies to the Agency Guidance for Submitting Influenza Resistance Data"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:46:29,2025-05-28 03:53:06
7a4e68ab-967d-4d93-aa2a-872c8e998943,USA-FDA,73a0fca3-3d92-42b0-aa5b-d75edbca64a4,G_MINI_SUMMARY,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0306/FDA-2003-D-0306-0002/FDA-2003-D-0306-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Powder Blends and Finished Dosage Units Stratified In-Process Dosage Unit Sampling and Assessment"", ""docket_id"": ""FDA-2003-D-0306"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0306-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0306/FDA-2003-D-0306-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:16:40,2025-05-28 03:53:06
7a5b3334-431f-4acf-a35b-ec072fbb940f,USA-FDA,f9bd87b8-a99b-4271-a780-2fa2d92a0cbb,G_IMPACT_ANALYSIS,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0024/FDA-2011-D-0024-0012/FDA-2011-D-0024-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Size of Beads in Drug Products Labeled for Sprinkle"", ""docket_id"": ""FDA-2011-D-0024"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0024-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0024/FDA-2011-D-0024-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:31:49,2025-05-28 03:53:06
7ad12353-47a2-4710-9e47-e16f94115167,USA-FDA,1806ab7f-4806-470e-947e-17edeac1e685,G_IMPACT_ANALYSIS,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0002/FDA-2015-D-1245-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; Draft Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:32:31,2025-05-28 03:53:06
7afe8e5d-f6a4-4ba1-b38b-edf3954ccef5,USA-FDA,adef125a-f87d-4cfc-b0e3-9f79dfa0548b,G_MINI_SUMMARY,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1924/FDA-2020-D-1924-0001/FDA-2020-D-1924-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry:  Dear Manufacturer Letter Regarding Front-of-Package Symbols"", ""docket_id"": ""FDA-2020-D-1924"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1924-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1924/FDA-2020-D-1924-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:45:09,2025-05-28 03:53:06
7aff7f51-0257-466e-872c-4427c26237f6,USA-FDA,d845b0e1-4077-4505-b5ed-43ea4e1f508f,G_MINI_SUMMARY,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002/FDA-2013-D-0269-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Purchasing Reef Fish Species Associated with the Hazard of Ciguatera Fish Poisoning"", ""docket_id"": ""FDA-2013-D-0269"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0269-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:31:42,2025-05-28 03:53:06
7b017b15-d348-4c30-9d68-1363a40fae52,USA-FDA,dbf6d152-e2ca-482b-9806-31bd2cb0cde5,G_IMPACT_ANALYSIS,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0012/FDA-1998-D-0035-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:16:10,2025-05-28 03:53:06
7b0d97bb-1e0c-4f18-a94a-76454337091f,USA-FDA,996d1c6d-34e0-4cf9-9da7-d91597b5b49e,G_IMPACT_ANALYSIS,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0005/FDA-2007-D-0433-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bieoquivalence Recommendations for Specific Products"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:01:11,2025-05-28 03:53:06
7b468edb-66d0-4a4b-bfff-bd069aa7322c,USA-FDA,9c0afbba-a57a-4059-ad91-ed414ac041ae,G_CONCISE_SUMMARY,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164/FDA-2006-D-0102-1164-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry"", ""docket_id"": ""FDA-2006-D-0102"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0102-1164""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:46:30,2025-05-28 03:53:06
7bb15768-34bc-431d-a779-d6d7d3720c35,USA-FDA,18ea78db-6a79-423b-9420-dfcaa0148ce6,G_KEYWORDS,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001/FDA-2023-D-2508-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products"", ""docket_id"": ""FDA-2023-D-2508"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2508-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:00:46,2025-05-28 03:53:06
7bf9de10-417b-4c76-934b-c4fe1f2c1681,USA-FDA,95666548-cb1b-438e-afda-1830170253e4,G_MINI_SUMMARY,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002/FDA-2009-D-0354-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Pharmaceutical Components at Risk for Melamine Contamination"", ""docket_id"": ""FDA-2009-D-0354"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0354-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:02:17,2025-05-28 03:53:06
7c0621c7-e6a7-4493-9a82-2e4c9a76bc3f,USA-FDA,597d1f55-6a48-4e16-abbd-9ff4c8ead7b2,G_FAQ,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0002/FDA-2017-D-6526-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier"", ""docket_id"": ""FDA-2017-D-6526"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6526-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:00:36,2025-05-28 03:53:06
7c0ce2e5-8b76-493b-a36a-7dd0c141a21c,USA-FDA,ce65e60c-3e57-4cbb-8c31-caeb29cf26df,G_FAQ,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009/FDA-2003-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI"", ""docket_id"": ""FDA-2003-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:30:49,2025-05-28 03:53:06
7c288f20-7b14-450b-a71a-7c85bb5f37e6,QUEUE,aa65d668-7d85-425a-b285-b502c81e1a8f,G_CONCISE_SUMMARY_USER,2025-05-30 04:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/aa65d668-7d85-425a-b285-b502c81e1a8f/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/aa65d668-7d85-425a-b285-b502c81e1a8f"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 04:00:11,2025-05-30 04:00:11
7c52e3d5-1574-4833-aaab-313daa5ebac6,USA-FDA,37c31028-b2fe-44e1-a711-f5ef76436927,G_IMPACT_ANALYSIS,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0562/FDA-1996-N-0270-0562-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #69 Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations"", ""docket_id"": ""FDA-1996-N-0270"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1996-N-0270-0562""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0562"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:31:28,2025-05-28 03:53:06
7c695162-4c73-4110-8a0c-15a00610d53c,USA-FDA,b64e7ce2-944e-4c15-abd4-e55b98455080,G_DETAILED_SUMMARY,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002/FDA-2020-D-1877-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Necessary Automated External Defibrillator Accessories: Policy Regarding Compliance Date; Guidance for Industry, Stakeholders, Health Care Professionals, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2020-D-1877"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1877-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:00:59,2025-05-28 03:53:06
7c6f68c1-2282-49d0-975e-af49407a7020,USA-FDA,6605df71-d5ce-43fa-9251-7c9ed6218a53,G_DETAILED_SUMMARY,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1168/FDA-2012-D-1168-0002/FDA-2012-D-1168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Providing Submissions in Electronic Format Summary Level Clinical Site Data for CDER's Inspection Planning"", ""docket_id"": ""FDA-2012-D-1168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1168/FDA-2012-D-1168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:45:15,2025-05-28 03:53:06
7c7160e4-3fad-4002-9b7e-7622f5a84392,USA-FDA,84426a01-7222-45b5-8263-8f044a50880a,G_IMPACT_ANALYSIS,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002/FDA-2003-D-0416-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS"", ""docket_id"": ""FDA-2003-D-0416"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0416-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:47:48,2025-05-28 03:53:06
7c9946fe-d537-491e-be59-97741c1a2173,QUEUE,067e7e83-9395-4996-aa97-197c8da37687,G_SUMMARY_USER,2025-05-29 16:00:19,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/detailed_summary/067e7e83-9395-4996-aa97-197c8da37687/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/detailed_summary/067e7e83-9395-4996-aa97-197c8da37687"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 16:00:25,2025-05-29 16:00:25
7c9ba80a-72db-4743-8ca0-9ca9d2376a8b,USA-FDA,112ed54f-82c8-4822-aa99-955cebe75f94,G_CONCISE_SUMMARY,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004/FDA-2005-D-0208-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency"", ""docket_id"": ""FDA-2005-D-0208"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0208-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:32:36,2025-05-28 03:53:06
7ca1c889-ee08-4ca3-a791-5116a6e636f2,USA-FDA,d3d4e276-2fbe-4616-86cb-19d40afd33e7,G_FAQ,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004/FDA-2005-D-0208-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency"", ""docket_id"": ""FDA-2005-D-0208"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0208-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:33:18,2025-05-28 03:53:06
7ca629ad-2295-4aaf-b8f4-9856d9c8c386,USA-FDA,02e87413-81b9-45c0-816f-56dc14973c57,G_DETAILED_SUMMARY,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0562/FDA-1996-N-0270-0562-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #69 Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations"", ""docket_id"": ""FDA-1996-N-0270"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1996-N-0270-0562""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0562"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:31:14,2025-05-28 03:53:06
7caadc68-2fa3-493d-ab3d-f6c6924bc863,USA-FDA,83911c51-a724-4d6c-bc21-b46df75ca619,G_IMPACT_ANALYSIS,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001/FDA-2020-D-1977-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures"", ""docket_id"": ""FDA-2020-D-1977"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1977-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:17:18,2025-05-28 03:53:06
7cdec6d9-dfe4-45d4-bda7-2c7386ba83e1,USA-FDA,5d67e3d3-4713-4d8a-aab6-79c3b491bded,G_KEYWORDS,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002/FDA-2011-D-0598-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers Regarding Establishment, Maintenance of Records by Persons Who Manufacture of Records by Persons Who Manufacture, Process, Pack, Transport,Distribute Receive, Hold or Import Food (Edition 5)"", ""docket_id"": ""FDA-2011-D-0598"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0598-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:32:06,2025-05-28 03:53:06
7d03c179-5ad0-472d-a012-1624882b06b7,USA-FDA,c0e82547-a327-4174-a70f-6e284e578325,G_ACTION_ITEMS,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0002/FDA-2015-D-1245-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; Draft Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:32:23,2025-05-28 03:53:06
7d0686f6-7e1a-4ea1-87ce-15a0794b3562,USA-FDA,b890af2e-0513-4563-b591-511bc1f65a5a,G_FAQ,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002/FDA-2013-D-0920-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0920"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0920-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:31:20,2025-05-28 03:53:06
7d112fdc-8125-4c39-82b2-19f03ad3920f,SCHEDULED,13ccbf54-f830-4735-bcbd-7dda24e0500d,DEVICE_ANALYST,2025-05-27 00:00:04,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/13ccbf54-f830-4735-bcbd-7dda24e0500d"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:05,2025-05-28 03:53:06
7d3553b6-50d1-411a-896c-92ce8fe4715b,USA-FDA,9dd0b0ca-9fed-4cd5-8a4d-ec46fed0d98c,G_ACTION_ITEMS,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0008/FDA-2017-D-2462-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species Guidance for Industry"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:32:45,2025-05-28 03:53:06
7d4b1901-05fd-4b2a-9d16-cdc10e847160,USA-FDA,6180941b-204d-43e8-a280-7ce92f631c3b,G_FAQ,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-3528/FDA-1999-D-3528-0002/FDA-1999-D-3528-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture"", ""docket_id"": ""FDA-1999-D-3528"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-3528-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-3528/FDA-1999-D-3528-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:01:32,2025-05-28 03:53:06
7dc00157-608a-4a4b-9f06-0f63c5ee1384,USA-FDA,d318193c-4637-4dd5-a6da-ab41d1679e6c,G_IMPACT_ANALYSIS,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0283/FDA-2009-D-0283-0021/FDA-2009-D-0283-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Postmarketing Stuides and Clinical Trials - Implementation of Section 505 (o)(3) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2009-D-0283"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0283-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0283/FDA-2009-D-0283-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:01:24,2025-05-28 03:53:06
7de85b23-1d6e-406b-b88e-71a3089e4496,USA-FDA,28c0c1d0-648a-4a22-9e5a-c40d61babcad,G_IMPACT_ANALYSIS,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0080/FDA-2012-D-0080-0005/FDA-2012-D-0080-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Oversight of Positron Emission Tomography Drug Products - Questions and Answers"", ""docket_id"": ""FDA-2012-D-0080"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0080-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0080/FDA-2012-D-0080-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:32:46,2025-05-28 03:53:06
7deb7402-b123-49e6-9cb8-f49f5cb6d600,USA-FDA,35e9c61b-a0b4-4614-8265-55994ac69874,G_ACTION_ITEMS,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0719/FDA-2018-D-0719-0002/FDA-2018-D-0719-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)\nGuidance for Industry"", ""docket_id"": ""FDA-2018-D-0719"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0719-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0719/FDA-2018-D-0719-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:31:43,2025-05-28 03:53:06
7dffcc19-6186-4d96-b589-5317a5db6209,CAB,eb96ed14-a122-4fc7-b420-2009c1dac574,G_TRANSLATE,2025-05-20 09:31:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Italian""}","{""tilte"": ""FDA-2024-N-5471-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5471-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""efc4cee5-eb06-4edf-b5ae-42564def83b6""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/efc4cee5-eb06-4edf-b5ae-42564def83b6/Italian"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:32:29,2025-05-28 03:53:06
7e0ca5fa-dcb4-40ce-bc6f-dfc698252a89,SCHEDULED,bdc2b503-85ad-444b-bd34-c51d3eca2248,DEVICE_ANALYST,2025-05-25 00:00:04,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/bdc2b503-85ad-444b-bd34-c51d3eca2248"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:21,2025-05-28 03:53:06
7e1d2c12-7cef-451f-94a5-539d58dfdb2b,QUEUE,fa34754c-fcbb-42ab-a16d-3db2ab726897,G_CONCISE_SUMMARY_USER,2025-05-30 03:45:11,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/fa34754c-fcbb-42ab-a16d-3db2ab726897/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/fa34754c-fcbb-42ab-a16d-3db2ab726897"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-30 03:45:15,2025-05-30 03:45:15
7e339606-3389-48b2-b47d-e22538273619,SCHEDULED,ae1b0648-ac18-4bf1-a598-37e57ce6843e,DEVICE_ANALYST,2025-05-28 00:00:05,35,22e9cbee-8ffd-40b1-ac72-354a385b80f8,c151cd9d-a4ea-462e-baf0-37da703a0484,"{""user_id"": 174, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""monthly"", ""last_name"": ""Mannan"", ""user_guid"": ""c151cd9d-a4ea-462e-baf0-37da703a0484"", ""first_name"": ""Naeem "", ""start_date"": ""2025-02-26"", ""user_email"": ""nmannan97@gmail.com"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/c151cd9d-a4ea-462e-baf0-37da703a0484/AGENTS/device_analyst/ae1b0648-ac18-4bf1-a598-37e57ce6843e"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:37,2025-05-28 03:53:06
7e441b17-6939-4405-90af-45a94d1a5213,USA-FDA,f3272bec-b6d9-4623-b9b4-13ecd0487592,G_KEYWORDS,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009/FDA-2011-D-0164-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Safety Labeling Changes--Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:01:07,2025-05-28 03:53:06
7e5008f2-381d-4994-a169-8cd2763594fc,USA-FDA,a1d0f0d4-2364-423e-9771-858d4825eb1e,G_KEYWORDS,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001/FDA-2020-D-1925-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations)"", ""docket_id"": ""FDA-2020-D-1925"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1925-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:47:22,2025-05-28 03:53:06
7e85e850-bff0-40d0-b59f-6642243b1c13,SCHEDULED,1196aff2-31eb-42a6-b3a3-8a6bf6ed78ea,DEVICE_ANALYST,2025-06-01 00:00:04,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/1196aff2-31eb-42a6-b3a3-8a6bf6ed78ea"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:15,2025-06-01 00:00:15
7e9624cd-0e8f-42c4-aab5-21f8edb3b9e1,USA-FDA,ed51421c-f2a2-4f29-a92d-3390d5bf468d,G_CONCISE_SUMMARY,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015/FDA-2010-D-0350-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Tobacco Retailers on Tobacco Retailer Training Programs"", ""docket_id"": ""FDA-2010-D-0350"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0350-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:02:18,2025-05-28 03:53:06
7e9e4b38-2373-416c-a98d-ff3b77d11b70,USA-FDA,a051d2c5-b171-4655-bab3-11f311b75ea2,G_CONCISE_SUMMARY,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002/FDA-2013-D-0168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Recommendations for Labeling Medical Products to Inform Users the Product or Product Container Is Not Made With Natural Rubber Latex"", ""docket_id"": ""FDA-2013-D-0168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:16:43,2025-05-28 03:53:06
7e9f1074-5538-49fe-97de-a36fae1bfe9b,SCHEDULED,2e39ea79-3905-45ca-b410-49189501eef4,FDA_ALERT,2025-05-24 00:00:05,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/2e39ea79-3905-45ca-b410-49189501eef4"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:26,2025-05-28 03:53:06
7ec1afdf-14bb-48ac-826d-c436a620ed37,USA-FDA,013b4f42-2910-483c-b97b-850a65259fe5,G_CONCISE_SUMMARY,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002/FDA-2011-D-0464-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Low Glucose Suspend (LGS) Device Systems - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0464-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:31:24,2025-05-28 03:53:06
7ed7206c-44c4-44a4-9b86-40497cfa8e9d,USA-FDA,9b930274-2b3a-4414-8a53-23b7dddd8df1,G_FAQ,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0562/FDA-1996-N-0270-0562-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #69 Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations"", ""docket_id"": ""FDA-1996-N-0270"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1996-N-0270-0562""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0562"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:31:18,2025-05-28 03:53:06
7f188f93-d71c-48e1-ac81-35551d64f53b,QUEUE,bdf58601-9d8e-4153-9af2-7092a1a2f104,G_SUMMARY_USER,2025-05-20 10:44:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""__doc_title__"": ""MHRA -367-1.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/bdf58601-9d8e-4153-9af2-7092a1a2f104/SRC/bdf58601-9d8e-4153-9af2-7092a1a2f104.pdf"", ""doc_title"": ""MHRA -367-1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/bdf58601-9d8e-4153-9af2-7092a1a2f104/DEST/detailed_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:44:13,2025-05-28 03:53:06
7f80e18b-736d-43fb-a5d0-e10afd12de1a,USA-FDA,6b9cfab2-9bd5-42fe-8c58-e2beadbf6b68,G_DETAILED_SUMMARY,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0008/FDA-2011-D-0847-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; Humanitarian Use Device (HUD) Designations"", ""docket_id"": ""FDA-2011-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0847-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:30:25,2025-05-28 03:53:06
7fa01c0f-57f6-430a-8524-da162e775003,USA-FDA,cf5f416e-8ce3-4ad5-a853-96f384768adc,G_IMPACT_ANALYSIS,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0025/FDA-1999-D-1875-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sec.615.115 Extralabel Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:33:32,2025-05-28 03:53:06
7fa425f1-48e6-4946-9b8d-2e5a9487792d,USA-FDA,3197599e-9acc-45e9-b920-a3f9f6e8fef0,G_ACTION_ITEMS,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001/FDA-2020-D-1950-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 394.500 Importation of Television Products, Microwave Ovens, and Inherent Class I Laser Products for Investigation and Evaluation during Design Development"", ""docket_id"": ""FDA-2020-D-1950"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1950-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:47:46,2025-05-28 03:53:06
7fb83602-4bb8-48e0-b0e2-42a24402c2fb,USA-FDA,232ee6a5-129c-4482-b751-39df8a9f1ae2,G_CONCISE_SUMMARY,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112/FDA-2000-N-0190-0112-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Outdoor Access)"", ""docket_id"": ""FDA-2000-N-0190"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-N-0190-0112""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:03:16,2025-05-28 03:53:06
7fe9b612-7c13-444c-863a-54fcb2718302,USA-FDA,a726706f-9dda-434f-bdb1-e45e7ce80845,G_MINI_SUMMARY,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011/FDA-1998-D-0035-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:00:09,2025-05-28 03:53:06
8,,8244e60e-2a32-453b-aefe-ec9d872fc319,G_CONCISE_SUMMARY,2025-05-09 01:54:37,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 08:54:42,2025-05-28 03:53:06
80,,74b59011-75b7-4a6b-99d2-5e44cda2ae93,G_FAQ,2025-05-12 19:30:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 510, 520, 522, 524, 529, and 558"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal\nof Approval of New Animal Drug Applications; Change of Sponsor;\nChange of Sponsor Address"", ""docket_id"": ""FDA-2024-N-0002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-N-0002-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:30:19,2025-05-28 03:53:06
8015162c-224c-4933-bf7f-a50d2eaf149f,USA-FDA,1d030f2a-d1eb-43ee-b3c8-f2832c3f2930,G_IMPACT_ANALYSIS,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002/FDA-2013-D-0616-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0616-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:33:21,2025-05-28 03:53:06
802241af-1121-43b2-876d-16f9f0364329,USA-FDA,0d4c75a3-052b-43e8-8888-095a722cf7a2,G_IMPACT_ANALYSIS,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001/FDA-2020-D-0367-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""External Guidance Document Submission from Turner Scientific, LLC re: Ototoxicity: Nonclinical Evaluation During Drug Development"", ""docket_id"": ""FDA-2020-D-0367"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-0367-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:30,2025-05-28 03:53:06
803107f0-5077-4b90-b6a9-4c2d6bf4e483,USA-FDA,46e023f2-8626-4648-af02-56a3e4e79f50,G_MINI_SUMMARY,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1120/FDA-2012-D-1120-0002/FDA-2012-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Vaginal Microbicides: Development for the Prevention of Human Immunodeficiency Virus Infection"", ""docket_id"": ""FDA-2012-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1120/FDA-2012-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:46:08,2025-05-28 03:53:06
803b5615-2f4a-4d7d-9044-7724bf52eaa7,SCHEDULED,7deae2ec-f83e-4e2b-ae35-141b03ae83cc,DEVICE_ANALYST,2025-05-29 00:00:04,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/7deae2ec-f83e-4e2b-ae35-141b03ae83cc"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:21,2025-05-29 00:00:21
803dff44-90d7-45c5-863b-51ef91aa2da8,USA-FDA,695eb2db-8dd7-4462-8701-e9a74118e5d1,G_FAQ,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0199/FDA-2008-D-0199-0002/FDA-2008-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""E15 Pharmacogenomics Definitions and Sample Coding"", ""docket_id"": ""FDA-2008-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0199/FDA-2008-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:32:16,2025-05-28 03:53:06
8043dde6-ca0d-429a-a060-b9436ef43a78,USA-FDA,f8b2fa86-cda0-416a-b5ac-b9cbf5507e76,G_DETAILED_SUMMARY,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002/FDA-2017-D-4359-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry 68 on Small Entites Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:15:18,2025-05-28 03:53:06
8048eeeb-afff-452c-8252-75007a62c8b1,SCHEDULED,3a4d8ace-d628-4ab1-91b0-9258ebbba532,FDA_ALERT,2025-05-22 00:03:21,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/3a4d8ace-d628-4ab1-91b0-9258ebbba532"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:34,2025-05-28 03:53:06
804b4f19-755b-483a-8cda-36d653ec912f,USA-FDA,ef92fd52-1467-4a20-8edc-6460070aab7b,G_ACTION_ITEMS,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002/FDA-2012-N-1239-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guideline for Industry and Food and Drug Administration Staff; Class II Special Controls Guideline: Temporary Mandibular Condyle Reconstruction Plate"", ""docket_id"": ""FDA-2012-N-1239"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-N-1239-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:32:21,2025-05-28 03:53:06
807ca904-cbe3-4b25-a5dc-d5f1d8255438,USA-FDA,c26d5e86-f361-40b8-9379-86c4699d1dbd,G_ACTION_ITEMS,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0531/FDA-2004-D-0531-0001/FDA-2004-D-0531-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations to Processors of Apple Juice or Cider on the Use of Ozone for Pathogen Reduction Purposes"", ""docket_id"": ""FDA-2004-D-0531"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0531-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0531/FDA-2004-D-0531-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:15:36,2025-05-28 03:53:06
807cf86a-83e3-4a03-be77-5a967d7570bc,USA-FDA,a079e401-6b33-4b62-b5cb-cb8552c5e177,G_ACTION_ITEMS,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001/FDA-2020-D-1916-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect -21 CFR 1003.11"", ""docket_id"": ""FDA-2020-D-1916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1916-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:45:27,2025-05-28 03:53:06
80882500-08c1-4872-8f9d-13b312585345,USA-FDA,5044fb2b-c4d7-4f06-8f00-16fca0e97104,G_ACTION_ITEMS,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-N-0083/FDA-1999-N-0083-0015/FDA-1999-N-0083-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Availability: Reproductive and Developmental Toxicities - Integrating Study Results to Assess Concerns"", ""docket_id"": ""FDA-1999-N-0083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-N-0083-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-N-0083/FDA-1999-N-0083-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:47:06,2025-05-28 03:53:06
80b0b52c-f7f9-4516-abe0-6fe3291c61a2,QUEUE,33945ff6-7631-4a61-9339-1d6f1ffbc930,G_CONCISE_SUMMARY_USER,2025-05-29 07:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/33945ff6-7631-4a61-9339-1d6f1ffbc930/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/33945ff6-7631-4a61-9339-1d6f1ffbc930"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 07:00:14,2025-05-29 07:00:14
80b4b54d-a399-4edb-8dbd-3f5e99160f60,USA-FDA,316fd0cf-77c7-4d76-abb2-df6aa61e7d95,G_MINI_SUMMARY,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002/FDA-2008-D-0576-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sponsors, Clinical Investigators, and IRBs - Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials"", ""docket_id"": ""FDA-2008-D-0576"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0576-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:16:22,2025-05-28 03:53:06
80cb824c-74b7-4723-ae67-84f9a83c1f9b,USA-FDA,f5b07d40-32fa-4a50-b944-fc24998296e4,G_MINI_SUMMARY,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0260/FDA-2009-D-0260-0029/FDA-2009-D-0260-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2)"", ""docket_id"": ""FDA-2009-D-0260"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0260-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0260/FDA-2009-D-0260-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:46:53,2025-05-28 03:53:06
80d85bff-7ccf-45be-bd53-a716347b4541,USA-FDA,4dc2601b-fb15-44c6-bf7d-d6ae0cf8c32b,G_FAQ,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009/FDA-2011-D-0398-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Questions and Answers Regarding The Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:31:21,2025-05-28 03:53:06
80f7f303-d9fb-4536-aed4-909f0d043090,USA-FDA,82545bd8-f01f-45da-bbbd-80e1ccd5c08a,G_MINI_SUMMARY,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002/FDA-2017-D-3235-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2017-D-3235"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-3235-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:15:48,2025-05-28 03:53:06
81,,c211e2b9-c980-405a-bd72-ffc6ea24ab2a,G_ACTION_ITEMS,2025-05-12 19:30:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 510, 520, 522, 524, 529, and 558"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal\nof Approval of New Animal Drug Applications; Change of Sponsor;\nChange of Sponsor Address"", ""docket_id"": ""FDA-2024-N-0002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-N-0002-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:30:31,2025-05-28 03:53:06
8138a9e8-edce-44f7-ba67-e0a18292ef98,USA-FDA,72a86b3b-0994-4709-9997-24bd22543fbe,G_ACTION_ITEMS,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1962/FDA-2020-D-1962-0001/FDA-2020-D-1962-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.400 Contamination of Devices Labeled as Sterile"", ""docket_id"": ""FDA-2020-D-1962"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1962-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1962/FDA-2020-D-1962-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:16:30,2025-05-28 03:53:06
813e3604-d166-4d73-8dc4-9d90d2f0f87b,USA-FDA,fbab8ae1-bd78-4058-90fa-8255fe140c47,G_ACTION_ITEMS,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002/FDA-2005-G-0193-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Low Energy Ultrasound Wound Cleaner"", ""docket_id"": ""FDA-2005-G-0193"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-G-0193-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:12:57,2025-05-28 03:53:06
81700735-0ceb-43a7-a55b-ea2a85de29d2,USA-FDA,0a4a128c-907e-4b05-93cb-be7f3c7d2d9b,G_MINI_SUMMARY,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002/FDA-2011-D-0487-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of Acceptable Full-Length and Abbreviated Donor History Questinnaries and Accompanying Materials for Use in Screening Donors of Source Plasma Draft Guidence"", ""docket_id"": ""FDA-2011-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0487-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:31:07,2025-05-28 03:53:06
8182d4c0-e67b-4dbf-95a7-ad346aee2867,USA-FDA,fc45eecf-aadd-4732-a35b-db78c6a13232,G_KEYWORDS,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002/FDA-2013-D-0920-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0920"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0920-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:31:38,2025-05-28 03:53:06
81af53a1-f851-46a9-ac4b-59a242a879d3,SCHEDULED,d2925a7d-d968-415b-aa88-9afc5fea84b8,FDA_ALERT,2025-05-31 00:00:05,4,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-04-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/fda_alert/d2925a7d-d968-415b-aa88-9afc5fea84b8"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:10,2025-05-31 00:00:10
81afcf34-79f9-4310-94a5-2ca7e5a0784c,USA-FDA,43851563-db56-4e05-8b7c-e08c1f1fec1b,G_ACTION_ITEMS,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002/FDA-2018-D-2583-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products; Guidance for Industry;  Draft Guidance"", ""docket_id"": ""FDA-2018-D-2583"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2583-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:03:01,2025-05-28 03:53:06
82,,67bca86a-12e9-4ac5-8146-2c6d1a010e8b,G_IMPACT_ANALYSIS,2025-05-12 19:30:37,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004.pdf"", ""country"": ""USA"", ""cfr_part"": ""21 CFR Parts 510, 520, 522, 524, 529, and 558"", ""doc_type"": ""Rule"", ""agency_id"": ""FDA"", ""doc_title"": ""New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal\nof Approval of New Animal Drug Applications; Change of Sponsor;\nChange of Sponsor Address"", ""docket_id"": ""FDA-2024-N-0002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-N-0002-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-N-0002/FDA-2024-N-0002-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:30:38,2025-05-28 03:53:06
8220ec3d-cb6e-4146-84b4-c6d20e058fea,USA-FDA,7bb39fbd-d6b6-4433-ba79-4ca8bb352088,G_ACTION_ITEMS,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002/FDA-2018-D-3152-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Postapproval Changes to Drug Substances Guidance for Industry"", ""docket_id"": ""FDA-2018-D-3152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3152-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:46:05,2025-05-28 03:53:06
8231c3ab-a1a3-4350-a5b4-6974d0bf9a48,USA-FDA,7db35ead-7958-4a29-b29e-80347e7801d2,G_IMPACT_ANALYSIS,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0589/FDA-2013-D-0589-0002/FDA-2013-D-0589-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Human Immunodeficiency Virus-1 Infection:  Developing Antiretroviral Drugs for Treatment"", ""docket_id"": ""FDA-2013-D-0589"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0589-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0589/FDA-2013-D-0589-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:01:41,2025-05-28 03:53:06
8265db7f-d437-4b4f-991d-fa9a90cc9776,USA-FDA,c2f4b22e-61d8-4f80-b2b1-f3debbd954d8,G_ACTION_ITEMS,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002/FDA-2009-D-0137-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Guidance"", ""docket_id"": ""FDA-2009-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0137-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:32:36,2025-05-28 03:53:06
826cca83-a805-404d-9fd0-7dad7faa0e26,USA-FDA,f13732e5-3fd0-45b7-8b12-ba275d6e315d,G_MINI_SUMMARY,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0938/FDA-2012-D-0938-0024/FDA-2012-D-0938-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Guidance on Abbreviated New Drug Applications: Stability Testing of Drug Substances and Products"", ""docket_id"": ""FDA-2012-D-0938"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0938-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0938/FDA-2012-D-0938-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:15:08,2025-05-28 03:53:06
829121f0-fc9b-4aef-8a7a-04347acdb126,SCHEDULED,bee07fbb-0f3d-4c78-8718-6b708a142ff1,FDA_ALERT,2025-05-31 00:00:05,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/bee07fbb-0f3d-4c78-8718-6b708a142ff1"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:27,2025-05-31 00:00:27
82df9a7b-94f9-4f27-87ba-22d0cb333f5b,USA-FDA,443086bd-44d0-43f0-9d53-d8a22d7ffdf0,G_MINI_SUMMARY,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002/FDA-2013-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abbreviated New Drug Application Submissions--Refuse-to-Receive Standards"", ""docket_id"": ""FDA-2013-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:31:14,2025-05-28 03:53:06
82f30388-03df-4618-8bd4-68cc56fbedce,SCHEDULED,63da5e75-d2fa-421e-8bc6-68f08fb2b7a3,FDA_ALERT,2025-05-21 20:33:25,29,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""weekly"", ""last_name"": """", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": """", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/fda_alert/63da5e75-d2fa-421e-8bc6-68f08fb2b7a3"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:48,2025-05-28 03:53:06
83,,c2f247dc-d2b1-4221-9899-0fb39c936ef5,G_MINI_SUMMARY,2025-05-12 19:30:40,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035/FDA-2024-D-3067-0035-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3067-0035""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:30:41,2025-05-28 03:53:06
8317f0d2-5da5-4ed0-b62a-4aff59677a04,USA-FDA,30cf5e93-398e-4a72-b106-709c9ac9dc2a,G_DETAILED_SUMMARY,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0334/FDA-2008-N-0334-0010/FDA-2008-N-0334-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Providing Submissions in Electronic Format - Postmarketing Safety Reports-Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements"", ""docket_id"": ""FDA-2008-N-0334"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-N-0334-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0334/FDA-2008-N-0334-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:01:21,2025-05-28 03:53:06
8324e881-37f3-4c3e-810d-5ea652b27544,USA-FDA,fa731eb9-3e2a-42e3-abe4-19611f848f42,G_DETAILED_SUMMARY,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1380/FDA-2020-D-1380-0001/FDA-2020-D-1380-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products"", ""docket_id"": ""FDA-2020-D-1380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1380-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1380/FDA-2020-D-1380-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:31:05,2025-05-28 03:53:06
832cff34-fb63-435c-a0cf-01414c6b7484,USA-FDA,f5e5be74-133b-4ede-9523-5b098448f4fe,G_KEYWORDS,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002/FDA-2011-D-0733-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Evaluating the Safety of Flood-affected Food Crops for Human Consumption"", ""docket_id"": ""FDA-2011-D-0733"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0733-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:30:50,2025-05-28 03:53:06
83374aa8-758a-4a77-a598-feedc8dbc62e,USA-FDA,f340e36a-d90f-4f94-9f90-5884c5b2f75b,G_CONCISE_SUMMARY,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002/FDA-2013-D-0743-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Reporting for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0743"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0743-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:15:46,2025-05-28 03:53:06
8367cb58-f0d1-4173-a0d2-897e7113d8e3,USA-FDA,65a7e818-34ff-4094-a187-595f0feb6208,G_IMPACT_ANALYSIS,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001/FDA-2020-D-1951-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on Juice HACCP Regulation (2003)"", ""docket_id"": ""FDA-2020-D-1951"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1951-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:31:23,2025-05-28 03:53:06
83919d8b-11da-4e10-9f8a-2712300e28a6,USA-FDA,811165f9-a53c-4442-9f39-9e66d0181ce6,G_DETAILED_SUMMARY,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011/FDA-2001-D-0137-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children"", ""docket_id"": ""FDA-2001-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0137-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:32:22,2025-05-28 03:53:06
83a928ad-21a0-4555-8184-66811ceb07e9,USA-FDA,7fa72773-27eb-4f9f-a3e3-3a17f5a726b6,G_FAQ,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002/FDA-2014-N-1108-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products--Considerations, Content, and Format"", ""docket_id"": ""FDA-2014-N-1108"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1108-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:01:47,2025-05-28 03:53:06
83e18d62-3439-4588-9fbe-8473e5fc9ad0,USA-FDA,7fc16997-f11e-4635-8250-e7f548b68b8a,G_DETAILED_SUMMARY,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-3528/FDA-1999-D-3528-0002/FDA-1999-D-3528-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture"", ""docket_id"": ""FDA-1999-D-3528"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-3528-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-3528/FDA-1999-D-3528-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:01:05,2025-05-28 03:53:06
83e7d286-7e64-4b7f-a6c0-d42b363b616d,USA-FDA,4bca3f12-6184-444f-86f8-06c06d2436cb,G_FAQ,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002/FDA-2012-D-0544-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Toll Free Number Labeling and Related Requirements for Over the Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide"", ""docket_id"": ""FDA-2012-D-0544"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0544-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:30:24,2025-05-28 03:53:06
83eefa6e-56f3-4860-a344-9beec411e4d7,SCHEDULED,32ebf636-51d2-4b1f-a5f5-e99fdf088591,FDA_ALERT,2025-05-27 00:00:04,30,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/fda_alert/32ebf636-51d2-4b1f-a5f5-e99fdf088591"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:32,2025-05-28 03:53:06
84,,b3cf2181-456e-4353-8dd3-5fbf58d02b76,G_CONCISE_SUMMARY,2025-05-12 19:30:44,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035/FDA-2024-D-3067-0035-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3067-0035""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:30:45,2025-05-28 03:53:06
8403f27d-a7b7-4727-8f4f-6704f405760c,USA-FDA,84039e20-116d-4fd1-9092-6a45743a29d8,G_MINI_SUMMARY,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1318/FDA-2014-D-1318-0002/FDA-2014-D-1318-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1318"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1318-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1318/FDA-2014-D-1318-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:15:38,2025-05-28 03:53:06
8404fd7c-effd-4e14-8816-802c8bfdb30d,SCHEDULED,b6e58e12-9dfb-4495-bfed-0a5ae2977368,DEVICE_ANALYST,2025-05-21 20:33:25,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": """", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": """", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/b6e58e12-9dfb-4495-bfed-0a5ae2977368"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:50,2025-05-28 03:53:06
8414d8f5-a38e-4476-8273-e6912ae33933,QUEUE,68875a2b-3915-4968-a2a7-ef492ebacda5,G_SUMMARY_USER,2025-05-20 10:44:51,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__doc_title__"": ""FDA-1983-P-0373-0002_attachment_1.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/68875a2b-3915-4968-a2a7-ef492ebacda5/SRC/68875a2b-3915-4968-a2a7-ef492ebacda5.pdf"", ""doc_title"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/68875a2b-3915-4968-a2a7-ef492ebacda5/DEST/detailed_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:44:55,2025-05-28 03:53:06
841db44a-05cf-4dc0-95a4-91bac9acb673,USA-FDA,17de9103-7c71-4bc1-b2e1-a7b91c108e6f,G_MINI_SUMMARY,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016/FDA-2014-D-1399-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:15:10,2025-05-28 03:53:06
842ad001-5fe7-4749-aa8f-2ab77953bb8f,USA-FDA,f03c7784-9b4c-41ba-8ccc-cba4396e6cc4,G_FAQ,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002/FDA-2013-N-1429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2013-N-1429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:02:16,2025-05-28 03:53:06
844d4e4d-c52d-46ed-b0fb-29a8183aa56a,USA-FDA,aeb474df-0336-478f-8578-f068a6d16722,G_DETAILED_SUMMARY,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1935/FDA-2020-D-1935-0001/FDA-2020-D-1935-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 100.550 Status and Responsibilities of Contract Sterilizers Engaged in the Sterilization of Drugs and Devices"", ""docket_id"": ""FDA-2020-D-1935"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1935-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1935/FDA-2020-D-1935-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:45:49,2025-05-28 03:53:06
84597108-ba1f-4c7a-a073-bc9b043fa387,USA-FDA,ab6c6724-fd9d-481f-b888-5699d96412d2,G_DETAILED_SUMMARY,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003/FDA-2006-D-0231-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds"", ""docket_id"": ""FDA-2006-D-0231"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0231-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:00:33,2025-05-28 03:53:06
84928368-8ae6-404e-912b-f59f61c70b0a,USA-FDA,3577335c-3041-4f6f-acdb-ed1e12623014,G_FAQ,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001/FDA-2020-D-1444-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Safety Information - FDA's Communication to the Public"", ""docket_id"": ""FDA-2020-D-1444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1444-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:16:44,2025-05-28 03:53:06
84a94c20-74c0-443a-bcbd-cc329cca5f9d,USA-FDA,4cd3af64-1065-496a-8fe6-0665f0d2ba72,G_ACTION_ITEMS,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0007/FDA-1992-N-0007-0005/FDA-1992-N-0007-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Industry Supported Scientific and Educational Activities:  Guidance for Industry"", ""docket_id"": ""FDA-1992-N-0007"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0007-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0007/FDA-1992-N-0007-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:16:46,2025-05-28 03:53:06
84baaf5d-11f9-4ca2-85ac-b325254b60e2,USA-FDA,0a0b1b4f-f5d6-4a8a-bb3a-711ecc05da86,G_KEYWORDS,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003/FDA-2008-D-0180-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Coronary Drug Eluting Stents- Nonclincal and Clinical Studies; Draft Guidance"", ""docket_id"": ""FDA-2008-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0180-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:01:21,2025-05-28 03:53:06
84c9b025-128f-45e1-924a-5287f3251dbd,USA-FDA,71300fc8-b253-4f9d-ac42-01d464dd16a7,G_IMPACT_ANALYSIS,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004/FDA-2007-D-0302-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Labeling for Human Prescription Drug and Biological Products � Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information"", ""docket_id"": ""FDA-2007-D-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0302-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:03:21,2025-05-28 03:53:06
84cc2b41-18dc-4877-980c-8b72b22ea970,USA-FDA,6f1a201b-29c4-4565-b8d2-5c5fd1a689c9,G_CONCISE_SUMMARY,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004/FDA-2010-D-0636-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia Burgdorferi"", ""docket_id"": ""FDA-2010-D-0636"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0636-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:15:11,2025-05-28 03:53:06
84e76165-d333-4e2c-917c-1080a77c2f4c,USA-FDA,f6b0c968-e8fe-41cf-a369-45136bc95ef4,G_MINI_SUMMARY,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0605/FDA-2011-D-0605-0002/FDA-2011-D-0605-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Scientific Considerations in Demonstrating Biosimilarity to Reference Product"", ""docket_id"": ""FDA-2011-D-0605"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0605-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0605/FDA-2011-D-0605-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:15:45,2025-05-28 03:53:06
84fc5a3f-2648-4fe7-986c-85d4ffad6f70,USA-FDA,971540fd-c2ef-4baf-98ed-4e8992b10c1c,G_MINI_SUMMARY,2025-05-22 18:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1566/FDA-2013-D-1566-0002/FDA-2013-D-1566-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Naming of Drug Products Containing Salt Drug Substances"", ""docket_id"": ""FDA-2013-D-1566"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1566-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1566/FDA-2013-D-1566-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:30:39,2025-05-28 03:53:06
85,,18ed79fb-62bc-464f-9e9e-8821e12e153a,G_DETAILED_SUMMARY,2025-05-12 19:30:53,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035/FDA-2024-D-3067-0035-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3067-0035""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:30:54,2025-05-28 03:53:06
85065acb-0fb5-45fa-8900-69089480c4e1,SCHEDULED,a3ad1ed6-8801-45d3-a4ad-77876ea70a22,FDA_ALERT,2025-05-30 00:00:04,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/a3ad1ed6-8801-45d3-a4ad-77876ea70a22"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:18,2025-05-30 00:00:18
850ed7e9-f8e0-419f-adc5-db44bca1b3d4,USA-FDA,d8dca5d3-546b-4fb8-aeac-7ec54b4e3a54,G_IMPACT_ANALYSIS,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001/FDA-2020-D-1925-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations)"", ""docket_id"": ""FDA-2020-D-1925"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1925-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:47:18,2025-05-28 03:53:06
8513d61c-b89a-44b3-acd7-e4dbeb9708bf,USA-FDA,0c7bf3ab-8ca1-4f2f-abbe-566ead35d845,G_ACTION_ITEMS,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032/FDA-2002-D-0094-0032-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0032""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:02:36,2025-05-28 03:53:06
8527a91b-372d-4d84-882c-6484b068925c,USA-FDA,aea98dba-bec9-4aa7-a11a-10e0b708e5aa,G_MINI_SUMMARY,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0132/FDA-2009-D-0132-0012/FDA-2009-D-0132-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cellular Therapy for Cardiac Disease "", ""docket_id"": ""FDA-2009-D-0132"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0132-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0132/FDA-2009-D-0132-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:46:29,2025-05-28 03:53:06
852c0963-fb3b-405f-a82a-d0a7d3a50349,CAB,1d5bcad6-b918-41bb-8ae8-4a3608c08770,G_IMPACT_ANALYSIS_IN,2025-05-20 09:28:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2023-N-4225-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""be71a183-8124-4a8f-984c-ce1233023d0a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/be71a183-8124-4a8f-984c-ce1233023d0a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:28:46,2025-05-28 03:53:06
853ffc60-c615-4ed0-8aab-29af1048aa6a,USA-FDA,dfd62a98-86be-44f0-869d-bac097c7f59c,G_MINI_SUMMARY,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0019/FDA-2017-D-6380-0019-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0019""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0019"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:00:09,2025-05-28 03:53:06
8545e2ac-1176-4dea-ac0c-bb4f00af9c64,USA-FDA,6465a972-8b0b-4ed5-91c7-cea7874d7acb,G_FAQ,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001/FDA-2020-D-1608-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data"", ""docket_id"": ""FDA-2020-D-1608"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1608-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:46:55,2025-05-28 03:53:06
8556f057-be03-4046-8110-a1fe1571e620,USA-FDA,91475fe8-cda0-4b60-9b39-cea03f5f9ef4,G_KEYWORDS,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021/FDA-2004-D-0044-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for the Early Food Safety\nEvaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties\nIntended for Food Use; Availability"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:00:45,2025-05-28 03:53:06
855e7653-fe1f-47a8-8164-0a1b1f9e20d3,USA-FDA,f29daa4a-c375-4b1d-999d-a76e7d89b075,G_MINI_SUMMARY,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0438/FDA-2004-D-0438-0007/FDA-2004-D-0438-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Time and Extent Applications for Nonprescription Drug Products"", ""docket_id"": ""FDA-2004-D-0438"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0438-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0438/FDA-2004-D-0438-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:47:20,2025-05-28 03:53:06
85675b93-1a0a-47d5-8c95-353658857b4e,USA-FDA,8485be9f-35ea-4857-a725-dd7c4cd7ed4f,G_MINI_SUMMARY,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1978-N-0011/FDA-1978-N-0011-0008/FDA-1978-N-0011-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidelines for Effectiveness Testing of O. T. C. Antiperspirant Drug Products"", ""docket_id"": ""FDA-1978-N-0011"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1978-N-0011-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1978-N-0011/FDA-1978-N-0011-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:45:59,2025-05-28 03:53:06
856c3b55-d524-44e2-98a3-1ebe0e5bc463,USA-FDA,fd90d277-baa3-46cd-bf3f-f3964636af2f,G_CONCISE_SUMMARY,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006/FDA-2005-D-0086-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""uidance for Industry; Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals"", ""docket_id"": ""FDA-2005-D-0086"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0086-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:01:32,2025-05-28 03:53:06
8573fc93-1436-44ed-b117-5ef53d3e52cb,USA-FDA,babda2a7-c683-46d1-a13f-356ec22d7903,G_MINI_SUMMARY,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1362/FDA-2020-D-1362-0001/FDA-2020-D-1362-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VI GRAS Notices"", ""docket_id"": ""FDA-2020-D-1362"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1362-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1362/FDA-2020-D-1362-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:30:09,2025-05-28 03:53:06
85ac8814-8803-47a3-bee2-d2b636223adc,SCHEDULED,3a2f6463-8535-431b-b533-2e4de97ef0ff,DEVICE_ANALYST,2025-05-31 00:00:05,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/3a2f6463-8535-431b-b533-2e4de97ef0ff"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:17,2025-05-31 00:00:17
85b7a83c-af34-4d3e-af1b-a41390033785,SCHEDULED,c2f67f9c-3fdf-428c-9afb-a0f15f13ea71,FDA_ALERT,2025-05-28 00:00:05,30,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/fda_alert/c2f67f9c-3fdf-428c-9afb-a0f15f13ea71"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:35,2025-05-28 03:53:06
85eb3e6e-cf4b-4279-9214-55c841f95edc,USA-FDA,66412706-34c1-4219-a9a8-e01d7a52898c,G_FAQ,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0002/FDA-2015-D-1245-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; Draft Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:32:16,2025-05-28 03:53:06
85eec2cb-d33a-4183-bb3f-0c9735906302,USA-FDA,d137300a-8583-41ad-b8fa-377f632d0c13,G_FAQ,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009/FDA-2016-D-2569-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""01 Final Guidance for Industry - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals-Questions and Answers"", ""docket_id"": ""FDA-2016-D-2569"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2569-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:33:10,2025-05-28 03:53:06
86,,26e87e94-4119-46fb-881e-be1dd6c3b6f4,G_FAQ,2025-05-12 19:31:00,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035/FDA-2024-D-3067-0035-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3067-0035""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:31:01,2025-05-28 03:53:06
862c0245-1ea5-47a3-9797-b0cd1276f8fa,SCHEDULED,0ebfc220-1f26-4fae-8743-9874d180e575,DEVICE_ANALYST,2025-05-31 00:00:05,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/0ebfc220-1f26-4fae-8743-9874d180e575"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:23,2025-05-31 00:00:23
864e7436-3513-4858-9547-ffc39eaf8eae,USA-FDA,e7b80f97-b5e5-4642-a035-2453d681beba,G_FAQ,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1380/FDA-2020-D-1380-0001/FDA-2020-D-1380-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products"", ""docket_id"": ""FDA-2020-D-1380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1380-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1380/FDA-2020-D-1380-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:31:13,2025-05-28 03:53:06
865adb4f-ffc2-4d8e-8062-6c832f8c03be,USA-FDA,3f8d5c2e-c7dd-4d2c-94c9-f0d32d8f1cee,G_FAQ,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002/FDA-2011-D-0398-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:31:26,2025-05-28 03:53:06
869f5f25-2f0c-41e8-873c-0a9eee2e094b,QUEUE,be85e5e0-740f-4a6f-971b-ff92fdb67134,G_IMPACT_ANALYSIS_USER,2025-05-20 10:44:00,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""__doc_title__"": ""FDA-2024-N-5471-0004_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/be85e5e0-740f-4a6f-971b-ff92fdb67134/SRC/be85e5e0-740f-4a6f-971b-ff92fdb67134.pdf"", ""doc_title"": ""FDA-2024-N-5471-0004_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/be85e5e0-740f-4a6f-971b-ff92fdb67134/DEST/impact_analysis.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:44:08,2025-05-28 03:53:06
86a7713c-e1e1-47b6-a776-8be407417140,USA-FDA,1f7492b8-8418-4fe8-b85a-a6a7b0182a9e,G_KEYWORDS,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012/FDA-2003-D-0186-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for InduGuidance for Industry: Cosmetics Processors and Transporters of Cosmetics Security Preventive Measures Guidance"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:24,2025-05-28 03:53:06
86bffc72-8b69-479d-b206-ee195026866e,USA-FDA,9bdb923e-460f-4540-987f-81537998f74e,G_MINI_SUMMARY,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005/FDA-2012-D-0419-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for Use in Companion Animals"", ""docket_id"": ""FDA-2012-D-0419"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0419-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:30:57,2025-05-28 03:53:06
86e6ab39-829e-44c4-948a-63fcd285628b,USA-FDA,65f599be-fb43-4172-8938-bd61f0793598,G_IMPACT_ANALYSIS,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0019/FDA-2017-D-6380-0019-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0019""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0019"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:00:35,2025-05-28 03:53:06
87,,9c11befb-b575-430d-bebb-4df8c137bce0,G_ACTION_ITEMS,2025-05-12 19:31:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035/FDA-2024-D-3067-0035-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3067-0035""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:31:06,2025-05-28 03:53:06
8711b96d-f79e-42d0-8c04-5048bbff48a1,USA-FDA,536777e2-4197-4090-975e-91557512bbb1,G_DETAILED_SUMMARY,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164/FDA-2006-D-0102-1164-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry"", ""docket_id"": ""FDA-2006-D-0102"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0102-1164""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0102/FDA-2006-D-0102-1164"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:46:46,2025-05-28 03:53:06
8728e2e8-bbcb-406e-802d-9958768d98be,USA-FDA,ed1643ff-7d4f-46d8-8ec5-a59eb6eeeb3e,G_DETAILED_SUMMARY,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004/FDA-2005-D-0208-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency"", ""docket_id"": ""FDA-2005-D-0208"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0208-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:32:49,2025-05-28 03:53:06
87405d4a-8ffa-474c-902d-d32a0c57ab3b,USA-FDA,5f0d8a48-cdcb-4a3a-a541-d3b3efe962ad,G_ACTION_ITEMS,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0246/FDA-2010-D-0246-0014/FDA-2010-D-0246-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Residual Drug in Transdermal and Related Drug Delivery Systems; Guidance for Industry"", ""docket_id"": ""FDA-2010-D-0246"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0246-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0246/FDA-2010-D-0246-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:02:13,2025-05-28 03:53:06
875d762f-59b4-4171-ab82-af69aeab1be4,USA-FDA,6f877b3b-544d-44fd-95ef-85559f3e07b1,G_DETAILED_SUMMARY,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0002/FDA-2004-D-0301-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Fixed Dose Combination and Co-Packaged Drug Products for Treatment of HIV - DRAFT GUIDANCE"", ""docket_id"": ""FDA-2004-D-0301"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0301-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:32:13,2025-05-28 03:53:06
8762afe3-d899-4a51-91ff-6a16670b2869,USA-FDA,c568cc8b-101e-4ca3-a686-18760fb9735e,G_IMPACT_ANALYSIS,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018/FDA-2012-D-1038-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:31:20,2025-05-28 03:53:06
876e09f5-ba54-4f17-b718-9030e6965ca6,USA-FDA,766e034d-b388-4f0b-9893-5084018a2585,G_CONCISE_SUMMARY,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002/FDA-2009-D-0542-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Factors that Distinguish Liquid Dietary Supplements from Beverages, Considerations Regarding Novel Ingredients, and Labeling for Beverages and Other Conventional Foods; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0542"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0542-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:02:44,2025-05-28 03:53:06
87d2078b-639b-459b-b363-9d1c3d0ddd88,USA-FDA,5f4cb95c-046a-4da0-8310-e658ac69ffef,G_FAQ,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006/FDA-2005-D-0086-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""uidance for Industry; Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals"", ""docket_id"": ""FDA-2005-D-0086"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0086-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:01:56,2025-05-28 03:53:06
87ef3fb3-7b97-4d1a-9038-c3dd265466d6,USA-FDA,1ef4b5b9-1c0d-46ef-aa63-a9500e406199,G_MINI_SUMMARY,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0283/FDA-2009-D-0283-0021/FDA-2009-D-0283-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Postmarketing Stuides and Clinical Trials - Implementation of Section 505 (o)(3) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2009-D-0283"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0283-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0283/FDA-2009-D-0283-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:01:04,2025-05-28 03:53:06
88,,9bac53f6-3dd7-4d0f-acc7-63ee20ae6553,G_IMPACT_ANALYSIS,2025-05-12 19:31:13,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035/FDA-2024-D-3067-0035-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3067-0035""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3067/FDA-2024-D-3067-0035"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:31:14,2025-05-28 03:53:06
883242d8-648e-4813-88b2-e8cf4868ad82,USA-FDA,222f3f99-0183-4e64-aa03-c7f19d28d8da,G_ACTION_ITEMS,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0002/FDA-2012-D-1038-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:17:31,2025-05-28 03:53:06
886cef0e-3672-4537-9b19-5cbb9027d109,USA-FDA,581cad51-002b-4e9d-bc6d-afc5041f8200,G_IMPACT_ANALYSIS,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002/FDA-2011-D-0577-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Factors To Consider When Making Benefit-Risk Determinations in Medical Device Premarket Review"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:48:22,2025-05-28 03:53:06
8876004d-4980-4f6f-8d5f-95ea65c46827,USA-FDA,d486da42-ab30-408a-aabb-2339d9f13ee4,G_DETAILED_SUMMARY,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001/FDA-2020-D-1444-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Safety Information - FDA's Communication to the Public"", ""docket_id"": ""FDA-2020-D-1444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1444-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:16:33,2025-05-28 03:53:06
887b274e-e34b-4277-b7e5-8a52ff5d59f2,CAB,43354110-ca62-4553-8898-c89786e3d76c,G_KEYWORDS,2025-05-20 09:31:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2024-N-5471-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5471-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""efc4cee5-eb06-4edf-b5ae-42564def83b6""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/efc4cee5-eb06-4edf-b5ae-42564def83b6"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:31:48,2025-05-28 03:53:06
887d61ee-4bf1-4a3b-a5ee-845b3a89f32f,USA-FDA,eab153fd-c46c-4595-b267-45cb1026d8fd,G_CONCISE_SUMMARY,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002/FDA-2011-D-0598-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers Regarding Establishment, Maintenance of Records by Persons Who Manufacture of Records by Persons Who Manufacture, Process, Pack, Transport,Distribute Receive, Hold or Import Food (Edition 5)"", ""docket_id"": ""FDA-2011-D-0598"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0598-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:31:01,2025-05-28 03:53:06
88c03736-fd7a-4edb-91e6-e4e771b2203c,SCHEDULED,9866026a-c5c2-4d72-95ab-a87a8c20b5b5,DEVICE_ANALYST,2025-05-22 00:03:21,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/9866026a-c5c2-4d72-95ab-a87a8c20b5b5"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:22,2025-05-28 03:53:06
88d9ed02-e42c-40f5-89d5-fe9d99a60cd1,USA-FDA,bfe74f5a-f897-4e2d-86d6-08d5aed6fc70,G_DETAILED_SUMMARY,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002/FDA-2014-D-1891-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD"", ""docket_id"": ""FDA-2014-D-1891"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1891-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:16:00,2025-05-28 03:53:06
88f0cdc9-7f6b-4587-9ac7-2eb2879cc3ed,USA-FDA,a5add0af-f3c0-41a5-af8e-9125154bc922,G_ACTION_ITEMS,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001/FDA-2023-D-2508-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products"", ""docket_id"": ""FDA-2023-D-2508"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2508-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:00:34,2025-05-28 03:53:06
89,,3e4b45d5-3a40-43af-a047-9457701b9746,G_MINI_SUMMARY,2025-05-12 19:31:16,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145/FDA-2024-D-3863-0145-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3863"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3863-0145""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:31:17,2025-05-28 03:53:06
89297687-78b0-4070-ad88-16e0a200c966,SCHEDULED,fce2027e-0644-49b1-a794-ac4a3ed9efba,FDA_ALERT,2025-05-29 00:00:04,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/fce2027e-0644-49b1-a794-ac4a3ed9efba"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:17,2025-05-29 00:00:17
892adf74-5c81-4aa9-bd21-2f45eadcd4d4,USA-FDA,d87578b8-c990-4c78-adc0-496efd2f025f,G_IMPACT_ANALYSIS,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0848/FDA-2012-D-0848-0002/FDA-2012-D-0848-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for FDA Staff Compliance Policy Guide Sec. 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products - Hypoglycin A Toxin\nDraft Guidance"", ""docket_id"": ""FDA-2012-D-0848"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0848-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0848/FDA-2012-D-0848-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:30:36,2025-05-28 03:53:06
89316ac6-9cb6-402a-9a48-605254fda3b8,USA-FDA,73d07de4-9401-4f7c-a647-6d7ec7fad194,G_DETAILED_SUMMARY,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0003/FDA-2014-D-1525-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Draft Guidance"", ""docket_id"": ""FDA-2014-D-1525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1525-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:01:52,2025-05-28 03:53:06
89366ede-018c-4d29-804a-e2ab676d10b9,USA-FDA,8d1a1ab7-2496-48e2-b152-78666d5a20ca,G_CONCISE_SUMMARY,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013/FDA-2009-D-0503-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in - Premarket Notification (510(k)) Submissions; Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0503-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:00:16,2025-05-28 03:53:06
8968a962-a89d-44da-9da6-b5bf8ba55663,USA-FDA,6bdc9ea8-6e5d-4b75-9e69-3259a8a1d00b,G_KEYWORDS,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002/FDA-2011-D-0689-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; De Novo Classification Process (Evaluation of Automatic Class III Designation)"", ""docket_id"": ""FDA-2011-D-0689"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0689-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:16:18,2025-05-28 03:53:06
89a8cd03-d39f-45a7-bb48-3772080deb71,USA-FDA,df2f2535-5139-44d6-9933-5b16d1a6cde8,G_FAQ,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0268/FDA-2009-D-0268-0005/FDA-2009-D-0268-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0268"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0268-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0268/FDA-2009-D-0268-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:30:29,2025-05-28 03:53:06
89b73b6d-16d9-4d30-a084-bee92ddc4bee,SCHEDULED,4e95e74c-fdb8-465d-996e-af69d2df0c74,FDA_ALERT,2025-05-28 00:00:05,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/4e95e74c-fdb8-465d-996e-af69d2df0c74"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:16,2025-05-28 03:53:06
89bb2a4b-bfd0-4db3-b0a9-3ce854962ea5,USA-FDA,56249a5e-13ec-47dd-884d-83a366594424,G_DETAILED_SUMMARY,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0008/FDA-2017-D-2462-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species Guidance for Industry"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:32:08,2025-05-28 03:53:06
8a15c0dd-f1c3-4f13-af8c-f03ee42e86ba,USA-FDA,960fa0fb-4b36-4068-b4c7-a6bcf50d8e4e,G_FAQ,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012/FDA-2003-D-0186-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for InduGuidance for Industry: Cosmetics Processors and Transporters of Cosmetics Security Preventive Measures Guidance"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:00:37,2025-05-28 03:53:06
8a260606-e7b6-4612-97f9-af5ea52fe73f,USA-FDA,4d1e5346-4ec9-4a9f-8c72-851b3baf7313,G_FAQ,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0814/FDA-2013-D-0814-0002/FDA-2013-D-0814-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Pediatric Study Plans:  Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans"", ""docket_id"": ""FDA-2013-D-0814"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0814-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0814/FDA-2013-D-0814-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:46:17,2025-05-28 03:53:06
8a6c4156-33e7-48eb-803d-282ab0184986,USA-FDA,78e4cf83-58fc-40ef-ad03-2609efaae66c,G_IMPACT_ANALYSIS,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0509/FDA-2010-D-0509-0002/FDA-2010-D-0509-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Enforcement Policy - OTC Sunscreen Drug Products Marketed Without an Approved Application"", ""docket_id"": ""FDA-2010-D-0509"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0509-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0509/FDA-2010-D-0509-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:01:38,2025-05-28 03:53:06
8a7f2fc8-f137-4440-8e93-047c571fdd67,USA-FDA,1c6efb31-6aad-4109-9688-84ad903125c9,G_KEYWORDS,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002/FDA-2016-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Enforcement Policy on National Health Related Item Code and National Drug Code Numbers Assigned to Devices"", ""docket_id"": ""FDA-2016-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:45:48,2025-05-28 03:53:06
8aa9fdf6-945d-42fa-8877-c6092018d0bb,USA-FDA,f2247766-49b8-4e11-bddc-f5536fdb8262,G_MINI_SUMMARY,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0433/FDA-2012-D-0433-0002/FDA-2012-D-0433-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""mHealth Regulatory Coalition (Epstein Becker & Green) - Guidance"", ""docket_id"": ""FDA-2012-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0433-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0433/FDA-2012-D-0433-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:15:09,2025-05-28 03:53:06
8ab427a3-af2d-42b5-9af1-7a342895bb71,USA-FDA,2913111c-4c34-435b-8600-5a6f22db3f7f,G_IMPACT_ANALYSIS,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022/FDA-1998-N-0050-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 540.375 Canned Salmon - Adulteration Involving Decomposition Withdrawn 3-22-2010"", ""docket_id"": ""FDA-1998-N-0050"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-N-0050-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:28,2025-05-28 03:53:06
8ac70414-822c-4056-8dc1-508b36780a5a,USA-FDA,4e5effc2-9d6e-4135-a39b-718c2c1bf358,G_MINI_SUMMARY,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002/FDA-2013-D-0749-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implanted Blood Access Devices for Hemodialysis; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0749"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0749-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:01:30,2025-05-28 03:53:06
8b1266f4-74eb-42ba-96a9-440048dc3efc,SCHEDULED,31e01326-47e6-44a6-a1a4-81ffc8c26e2d,FDA_ALERT,2025-05-21 20:33:25,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/31e01326-47e6-44a6-a1a4-81ffc8c26e2d"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:41,2025-05-28 03:53:06
8b2db68c-3c00-401e-bfd7-bbfeb1069e79,USA-FDA,f4c6949a-4a05-4f14-b01b-e0644ebb39aa,G_DETAILED_SUMMARY,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5960/FDA-2017-D-5960-0002/FDA-2017-D-5960-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5960"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5960-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5960/FDA-2017-D-5960-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:30:38,2025-05-28 03:53:06
8b704215-ad61-4d3f-8a80-75bff0f7a992,USA-FDA,262d201d-dfe7-4adc-b8ca-74b45bde5e31,G_ACTION_ITEMS,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0009/FDA-2011-D-0620-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2011-D-0620"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0620-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:00:37,2025-05-28 03:53:06
8b7a0a1d-f067-4e15-9a79-13bf9b51741c,USA-FDA,268a8d66-ce23-495c-89f2-458d9b13a7d9,G_MINI_SUMMARY,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002/FDA-2015-D-1309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M8 Electronic Common Technical Document v4.0 Draft Implementation\nGuide v2.0; Electronic Common Technical Document v4.0 Implementation Package Draft Specification for Submission Formats\nv2.0; International Conference on Harmonisation; Draft Guidance for\nIndustry"", ""docket_id"": ""FDA-2015-D-1309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:45:16,2025-05-28 03:53:06
8b7e6420-463b-4546-a813-8adcc22b3d52,USA-FDA,9aff54e7-30bc-482b-bb2e-9aa3579ebc84,G_ACTION_ITEMS,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0045/FDA-2013-D-0045-0030/FDA-2013-D-0045-0030-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abuse-Deterrent Opioids-Evaluation and Labeling"", ""docket_id"": ""FDA-2013-D-0045"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0045-0030""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0045/FDA-2013-D-0045-0030"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:45:54,2025-05-28 03:53:06
8ba293dd-d528-45b1-a08d-a1c070e4298f,USA-FDA,164f1bc4-14de-49e3-8db7-a5e511488510,G_DETAILED_SUMMARY,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3327/FDA-2015-D-3327-0002/FDA-2015-D-3327-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry E6(R2) Good Clinical Practice"", ""docket_id"": ""FDA-2015-D-3327"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-3327-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3327/FDA-2015-D-3327-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:30:24,2025-05-28 03:53:06
8bd214e2-6542-44c7-86b1-2b1e0eeca9a8,USA-FDA,423dba1e-33a1-43b3-ba77-d5c211bfb3d0,G_IMPACT_ANALYSIS,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002/FDA-2013-D-0749-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implanted Blood Access Devices for Hemodialysis; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0749"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0749-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:02:17,2025-05-28 03:53:06
8c04c4b1-0d5e-45a7-9966-a83d13500268,USA-FDA,4b754f9d-7462-4615-aee7-56cae6cc069f,G_MINI_SUMMARY,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002/FDA-2005-G-0193-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Low Energy Ultrasound Wound Cleaner"", ""docket_id"": ""FDA-2005-G-0193"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-G-0193-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:12:18,2025-05-28 03:53:06
8c0c34fe-7b66-41d7-8ffd-5bbc5dd10005,USA-FDA,cd7b44aa-ed4f-47d8-a75e-6b92a0733180,G_CONCISE_SUMMARY,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011/FDA-2014-D-2300-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Drug Effects on the Ability to Operate a Motor Vehicle\nGuidance for Industry"", ""docket_id"": ""FDA-2014-D-2300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-2300-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:31:58,2025-05-28 03:53:06
8c573a1b-6025-45ad-8999-21e2a0af10e4,USA-FDA,cb92d0d1-8caf-42d0-8929-880db0881f80,G_MINI_SUMMARY,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002/FDA-2011-D-0602-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industryon Quality Considerations in Demonstrating Biosimilarity to Reference Protein Product"", ""docket_id"": ""FDA-2011-D-0602"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0602-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:33:53,2025-05-28 03:53:06
8c66d331-9f51-4808-b5e4-22eb062aa2b2,SCHEDULED,9e4ebe78-7d77-4ca2-b614-f03abcdd18ed,FDA_ALERT,2025-05-27 00:00:04,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/9e4ebe78-7d77-4ca2-b614-f03abcdd18ed"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:13,2025-05-28 03:53:06
8c845636-f9fd-4acb-b0d6-71e19a72c369,USA-FDA,4dfe8c87-1307-47b3-8c09-59ab9729ac3f,G_DETAILED_SUMMARY,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002/FDA-2012-D-0022-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Direct-to-Consumer Television Advertisements, etc."", ""docket_id"": ""FDA-2012-D-0022"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0022-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:30:22,2025-05-28 03:53:06
8caf4359-2b70-4744-bd96-a128a57b8034,USA-FDA,5ef2d930-3e28-4308-9236-12a1bf1ac1ad,G_FAQ,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0031/FDA-2007-D-0031-0005/FDA-2007-D-0031-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Integrated Summaries of Effectiveness and Safety:  Location Within the Common Technical Document"", ""docket_id"": ""FDA-2007-D-0031"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0031-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0031/FDA-2007-D-0031-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:00:34,2025-05-28 03:53:06
8cd4cf49-98c9-441e-a64b-8ca843b95f17,USA-FDA,28be168b-facf-47d7-bcf3-29e0b5a4a45b,G_ACTION_ITEMS,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1439/FDA-2014-D-1439-0004/FDA-2014-D-1439-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Critical Path Innovation Meetings; Guidance for Industry"", ""docket_id"": ""FDA-2014-D-1439"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1439-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1439/FDA-2014-D-1439-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:31:32,2025-05-28 03:53:06
8cec5da3-9004-4cb4-ab40-5d2014d909ef,USA-FDA,62cf4df9-325e-4e83-8cbb-83fae5cf3f9a,G_MINI_SUMMARY,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002/FDA-2003-D-0416-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS"", ""docket_id"": ""FDA-2003-D-0416"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0416-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:47:04,2025-05-28 03:53:06
8ceedfb8-40e2-41a7-8e25-3a5b390f697d,USA-FDA,0920356c-5d42-4317-afe4-b74df2dbaae1,G_FAQ,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5140/FDA-2017-D-5140-0002/FDA-2017-D-5140-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Display Devices for Diagnostic Radiology"", ""docket_id"": ""FDA-2017-D-5140"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5140-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5140/FDA-2017-D-5140-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:16:55,2025-05-28 03:53:06
8cf9d758-1bc9-4014-9a76-a5b7b5a1286b,SCHEDULED,7f723415-408a-480c-99a5-48ad3245a7f8,DEVICE_ANALYST,2025-05-26 00:00:07,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": """", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": """", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/7f723415-408a-480c-99a5-48ad3245a7f8"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:29,2025-05-28 03:53:06
8d23cfac-dee0-4fda-abdb-931b4618a7d6,USA-FDA,5fc44044-6e10-4989-8866-a5c87c8329ac,G_KEYWORDS,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002/FDA-2012-D-1002-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Questions and Answers Regarding Food Facility Registration Fifith Edition"", ""docket_id"": ""FDA-2012-D-1002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1002-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:47:25,2025-05-28 03:53:06
8d2b6dd5-08e9-4e39-85f7-cae96e6abe4a,CAB,a065a826-f48f-4cc5-a9a9-76049f9487c6,G_CONCISE_SUMMARY_IN,2025-05-28 21:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""num_paragraphs"": 3}","{""tilte"": ""EU regulations on medical devices � Update November 2022.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/EU regulations on medical devices � Update November 2022.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""0a2f2db4-b308-43a4-9ab5-7be5666e97bb""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/0a2f2db4-b308-43a4-9ab5-7be5666e97bb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 21:30:09,2025-05-28 21:30:09
8d746a4f-60fe-48b8-b584-b0d66b526f32,USA-FDA,c4f81ecb-c818-4387-a5b5-141012cf8398,G_DETAILED_SUMMARY,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002/FDA-2012-N-1239-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guideline for Industry and Food and Drug Administration Staff; Class II Special Controls Guideline: Temporary Mandibular Condyle Reconstruction Plate"", ""docket_id"": ""FDA-2012-N-1239"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-N-1239-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:31:56,2025-05-28 03:53:06
8d9bbbdb-6269-4e7c-8d3a-861c0e45e91b,USA-FDA,db2b5230-974c-47af-b92b-50f9dd2d7032,G_IMPACT_ANALYSIS,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0971/FDA-2016-D-0971-0002/FDA-2016-D-0971-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Infectious Disease Next Generation Sequencing Based Diagnostic Devices Microbial Identification and Detection of Antimicrobial Resistance and Virulence Markers"", ""docket_id"": ""FDA-2016-D-0971"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0971-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0971/FDA-2016-D-0971-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:46:45,2025-05-28 03:53:06
8dcb6b91-8d80-4e82-82eb-e6de58cae963,USA-FDA,ad6f8143-e2a9-40f2-aec5-72681be95be7,G_DETAILED_SUMMARY,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002/FDA-2013-D-0749-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implanted Blood Access Devices for Hemodialysis; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0749"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0749-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:01:46,2025-05-28 03:53:06
8dcc5024-4374-48cf-a916-387849eb757a,USA-FDA,bfbf238d-1cc4-41fe-9887-aacfd9689223,G_ACTION_ITEMS,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022/FDA-2011-D-0082-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry , Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling"", ""docket_id"": ""FDA-2011-D-0082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0082-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:03:40,2025-05-28 03:53:06
8de7b250-75fc-46f2-8385-00dea6602b9a,USA-FDA,6d4c8725-434b-4300-86d1-df837531bb4c,G_FAQ,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005/FDA-1999-D-4079-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling"", ""docket_id"": ""FDA-1999-D-4079"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4079-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:32:08,2025-05-28 03:53:06
8e0d76d7-55d7-42a6-bff9-ab0d68b41761,USA-FDA,0d9725c9-542c-47ed-bc68-ff61ed68bc93,G_FAQ,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0012/FDA-1998-D-0035-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:15:52,2025-05-28 03:53:06
8e14e815-c3af-42b7-9922-0ef77369cec1,USA-FDA,643cda39-a30e-4e8f-94b8-99a6d3898977,G_DETAILED_SUMMARY,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024/FDA-2011-D-0577-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications  - Guidance"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:32:12,2025-05-28 03:53:06
8e2b9e8a-42ee-40a9-beb9-787211c696a0,USA-FDA,8ce1e956-547e-48a0-81f4-991090acd6f3,G_MINI_SUMMARY,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0286/FDA-2013-D-0286-0015/FDA-2013-D-0286-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0286"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0286-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0286/FDA-2013-D-0286-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:16:23,2025-05-28 03:53:06
8e33fa5e-9ec8-4d9d-88e3-7b2282cdc7be,USA-FDA,9a3fbb72-53c8-4d66-ae15-957457568829,G_IMPACT_ANALYSIS,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002/FDA-2005-G-0193-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Low Energy Ultrasound Wound Cleaner"", ""docket_id"": ""FDA-2005-G-0193"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-G-0193-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:13:05,2025-05-28 03:53:06
8e4c8b5f-e92d-4c47-82e4-c779b328d324,SCHEDULED,a3d9613d-00fa-41cc-bf7b-6a7c6f61408b,FDA_ALERT,2025-06-01 00:00:04,30,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/fda_alert/a3d9613d-00fa-41cc-bf7b-6a7c6f61408b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:30,2025-06-01 00:00:30
8e5ddf93-3439-4f47-9b85-1885dbcccc14,USA-FDA,291db3ef-be4d-47f1-9554-856690a3cd48,G_IMPACT_ANALYSIS,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002/FDA-2018-D-2238-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""2018-125 Guidance GT for Hemophilia_7-09-2018 -508 Compliant"", ""docket_id"": ""FDA-2018-D-2238"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2238-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:30:53,2025-05-28 03:53:06
8e6867fa-3763-4e4d-809d-baf562972f8a,SCHEDULED,42eb5365-dfd8-4973-b179-c7529ace5233,FDA_ALERT,2025-06-02 00:00:04,30,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/fda_alert/42eb5365-dfd8-4973-b179-c7529ace5233"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:30,2025-06-02 00:00:30
8e7b7623-cf75-4c64-8ff1-1c1934ec87cd,SCHEDULED,c9cd744c-3685-4763-b1d1-06dfeab12930,FDA_ALERT,2025-05-28 00:00:05,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/c9cd744c-3685-4763-b1d1-06dfeab12930"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:27,2025-05-28 03:53:06
8e87aa6b-bfa3-4a29-8757-5186f5dfa099,USA-FDA,b2537717-a639-45ea-a6f8-b31db26d6c05,G_DETAILED_SUMMARY,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002/FDA-2009-D-0137-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Guidance"", ""docket_id"": ""FDA-2009-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0137-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:32:01,2025-05-28 03:53:06
8e931977-1119-48ca-bf7d-f738da6ae37d,USA-FDA,25b57a1f-3a72-43d0-9ae6-91705e709880,G_FAQ,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0077/FDA-2007-D-0077-0003/FDA-2007-D-0077-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Providing Regulatory Submissions in Electronic Format - Receipt Date - Draft Guidance Document"", ""docket_id"": ""FDA-2007-D-0077"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0077-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0077/FDA-2007-D-0077-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:31:02,2025-05-28 03:53:06
8ecb01f2-c347-4b02-848d-6e7e83ba9211,USA-FDA,463303a2-2ce4-492f-bc6d-0820c30d3d45,G_MINI_SUMMARY,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1168/FDA-2012-D-1168-0002/FDA-2012-D-1168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Providing Submissions in Electronic Format Summary Level Clinical Site Data for CDER's Inspection Planning"", ""docket_id"": ""FDA-2012-D-1168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1168/FDA-2012-D-1168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:45:07,2025-05-28 03:53:06
8f006e74-453b-4df7-b12d-02b8fc72405f,USA-FDA,a9ec3d81-8dd1-4910-a8d7-a0931d9cd469,G_DETAILED_SUMMARY,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001/FDA-2020-D-1951-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on Juice HACCP Regulation (2003)"", ""docket_id"": ""FDA-2020-D-1951"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1951-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:30:58,2025-05-28 03:53:06
8f1eba55-9650-4b90-b8a3-3cf33b785552,USA-FDA,3abb6521-1559-411e-b32c-33eaf2116e6d,G_ACTION_ITEMS,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0306/FDA-2003-D-0306-0002/FDA-2003-D-0306-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Powder Blends and Finished Dosage Units Stratified In-Process Dosage Unit Sampling and Assessment"", ""docket_id"": ""FDA-2003-D-0306"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0306-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0306/FDA-2003-D-0306-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:17:36,2025-05-28 03:53:06
8f332552-5bda-46c0-9ca4-9f27bbd48177,SCHEDULED,1cddd771-eb04-4e6d-b0b7-272f1a521a98,FDA_ALERT,2025-05-23 00:00:04,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/1cddd771-eb04-4e6d-b0b7-272f1a521a98"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:18,2025-05-28 03:53:06
8f3399b0-5ce7-4b90-9d94-1865e89fc919,USA-FDA,df46da30-329b-43a8-84ce-3465ac6c9df1,G_FAQ,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0310/FDA-2014-D-0310-0002/FDA-2014-D-0310-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Immunogenicity-Related\nConsiderations for the Approval of Low Molecular Weight Heparin for New Drug Applications and Abbreviated New Drug Applications"", ""docket_id"": ""FDA-2014-D-0310"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-0310-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0310/FDA-2014-D-0310-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:31:19,2025-05-28 03:53:06
8f35a0c2-9212-4ec3-993a-a6862cadfa2a,USA-FDA,d02bdbf9-f9a8-4027-9402-71ca29a4b91c,G_KEYWORDS,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032/FDA-2002-D-0094-0032-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0032""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:02:46,2025-05-28 03:53:06
8f3d96f6-e085-44df-b24e-11190cddf972,USA-FDA,ffee9cbc-ab0b-409a-a26b-0c943ce5eb9a,G_MINI_SUMMARY,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0487/FDA-2007-D-0487-0005/FDA-2007-D-0487-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec 110.310 Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002"", ""docket_id"": ""FDA-2007-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0487-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0487/FDA-2007-D-0487-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:00:50,2025-05-28 03:53:06
8f47037b-0c63-41aa-a33d-eb5c4a2b5655,USA-FDA,019327a6-c01f-46cf-8ce2-2b71b3ef97fa,G_ACTION_ITEMS,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002/FDA-2009-D-0539-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins; Guidance"", ""docket_id"": ""FDA-2009-D-0539"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0539-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:32:04,2025-05-28 03:53:06
8f47a73b-654f-43a7-8121-1021d021b8fe,USA-FDA,9a46699d-38ce-4cc1-abb7-6c3336de6d64,G_KEYWORDS,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002/FDA-2018-D-4525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Lactation Studies: Considerations for Study Design; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2018-D-4525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-4525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:17:58,2025-05-28 03:53:06
8f4e21cc-8577-4702-bbdb-4179493a7981,USA-FDA,99ede23c-2acf-4cdc-aab0-1012a23def60,G_MINI_SUMMARY,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1088/FDA-2013-D-1088-0002/FDA-2013-D-1088-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entity Compliance Guide; Declaring Color Additives in Animal Foods; #223"", ""docket_id"": ""FDA-2013-D-1088"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1088-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1088/FDA-2013-D-1088-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:00:07,2025-05-28 03:53:06
8f77c535-3dc3-4372-aba2-ca0ea2ce442e,USA-FDA,f60f5277-39eb-48c7-bc7d-5afaecd8beb1,G_MINI_SUMMARY,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0035/FDA-2003-D-0035-0002/FDA-2003-D-0035-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims"", ""docket_id"": ""FDA-2003-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0035-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0035/FDA-2003-D-0035-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:02:16,2025-05-28 03:53:06
8f86e635-51b3-4a2f-b2f6-c4d0c5408550,USA-FDA,180445a3-9d92-4933-92d8-1a86c9ce55a6,G_DETAILED_SUMMARY,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002/FDA-2011-D-0577-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Factors To Consider When Making Benefit-Risk Determinations in Medical Device Premarket Review"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:54,2025-05-28 03:53:06
8f8909f3-a6f8-4484-961a-4b7a38eda888,USA-FDA,6550a7c1-11e3-4fd1-8921-cff4da03b30b,G_CONCISE_SUMMARY,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002/FDA-2013-D-0349-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format"", ""docket_id"": ""FDA-2013-D-0349"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0349-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:01:20,2025-05-28 03:53:06
8fc02382-5795-4d33-b838-49fbba9ceca3,USA-FDA,00636329-7962-4111-bac3-a4ec28f33633,G_ACTION_ITEMS,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0313/FDA-2010-D-0313-0018/FDA-2010-D-0313-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2010-D-0313"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0313-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0313/FDA-2010-D-0313-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:45:51,2025-05-28 03:53:06
8fca65ef-978e-4031-a286-4349222b3403,USA-FDA,fb25d921-36dd-44ee-8f3d-024a98e7f737,G_DETAILED_SUMMARY,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002/FDA-1999-D-1875-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:30:20,2025-05-28 03:53:06
8ffbb754-4a01-405d-b98f-1a2e3dcc569c,SCHEDULED,79ad6819-1506-4407-a512-20d770f0ba51,DEVICE_ANALYST,2025-05-30 00:00:04,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/79ad6819-1506-4407-a512-20d770f0ba51"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:22,2025-05-30 00:00:22
9,,4b536e74-645f-4f4e-b0f9-0cbf684b6724,G_FAQ,2025-05-09 01:54:41,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,null,"{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099/FDA-2015-D-1211-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Guidance"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1211"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1211-0099""}","{""format"": ""md"", ""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1211/FDA-2015-D-1211-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-09 08:55:18,2025-05-28 03:53:06
90,,b76f317f-593d-4df9-9496-0ec0c87419f0,G_CONCISE_SUMMARY,2025-05-12 19:31:20,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145/FDA-2024-D-3863-0145-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3863"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3863-0145""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:31:21,2025-05-28 03:53:06
9034ef5b-c4a2-4493-a7af-9c27af197563,USA-FDA,ebd1948b-6d8e-4416-aafc-3411ea3d32e3,G_DETAILED_SUMMARY,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0306/FDA-2003-D-0306-0002/FDA-2003-D-0306-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Powder Blends and Finished Dosage Units Stratified In-Process Dosage Unit Sampling and Assessment"", ""docket_id"": ""FDA-2003-D-0306"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0306-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0306/FDA-2003-D-0306-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:16:53,2025-05-28 03:53:06
903c1a53-bd09-4d6e-9ec2-764e6c1fb75b,USA-FDA,53fa1508-60f3-494f-99bd-d6c24fc2d5c5,G_CONCISE_SUMMARY,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001/FDA-2020-D-1916-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect -21 CFR 1003.11"", ""docket_id"": ""FDA-2020-D-1916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1916-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:45:12,2025-05-28 03:53:06
908802fe-77ef-459f-8d1a-f6bf077800e2,SCHEDULED,13d4601e-a2ec-42cd-b659-0d5e35c743fa,DEVICE_ANALYST,2025-05-21 20:33:25,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/13d4601e-a2ec-42cd-b659-0d5e35c743fa"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:32,2025-05-28 03:53:06
90a87eb2-e9e6-48b2-b2ac-dca188eb8c66,USA-FDA,cd405353-2d6c-402a-80f0-3a61947164fa,G_MINI_SUMMARY,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002/FDA-2011-D-0164-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:00:08,2025-05-28 03:53:06
90c4196f-f129-4d27-967f-cb9475407657,USA-FDA,5f8aaa10-2195-45c6-a329-702bec3c5554,G_MINI_SUMMARY,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002/FDA-2011-D-0649-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Class II Special Controls; External Pacemaker Pulse Generator"", ""docket_id"": ""FDA-2011-D-0649"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0649-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:00:35,2025-05-28 03:53:06
91,,0afb5b80-b8fa-41f6-a88a-5639c39a6e3c,G_DETAILED_SUMMARY,2025-05-12 19:31:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145/FDA-2024-D-3863-0145-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3863"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3863-0145""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:31:32,2025-05-28 03:53:06
9119ebd8-4f5d-4636-9804-a1d8aceb29ca,USA-FDA,d2968373-0ac4-4da5-a2e9-26ebb1aeb2e5,G_FAQ,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005/FDA-2012-D-0419-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for Use in Companion Animals"", ""docket_id"": ""FDA-2012-D-0419"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0419-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:31:32,2025-05-28 03:53:06
91327d29-f39c-4be8-a589-622f773fe4b7,USA-FDA,5946f2d0-e1b0-4776-8345-5aa50d124816,G_MINI_SUMMARY,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002/FDA-2011-D-0730-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff; Class II Special Controls Guidance Documents: In Vitro Diagnostic Devices for Yersinia Species Detection"", ""docket_id"": ""FDA-2011-D-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0730-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:00:11,2025-05-28 03:53:06
9135bd48-ed24-4b88-ad21-f99e8549a3df,USA-FDA,2c4a1cf9-e7c3-4922-aff0-9aa01c82b3d1,G_DETAILED_SUMMARY,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1962/FDA-2020-D-1962-0001/FDA-2020-D-1962-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.400 Contamination of Devices Labeled as Sterile"", ""docket_id"": ""FDA-2020-D-1962"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1962-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1962/FDA-2020-D-1962-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:16:20,2025-05-28 03:53:06
91443dd0-fba5-44c4-8b0a-50661d0ba44b,USA-FDA,dd0584dc-d6bf-498d-9be9-3b17292bc091,G_KEYWORDS,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004/FDA-2002-D-0180-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Q1E Evaluation of Stability Data"", ""docket_id"": ""FDA-2002-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0180-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:46:23,2025-05-28 03:53:06
916f225c-66fb-4147-b730-0ae7bc176b4a,QUEUE,ae149f97-a383-47a4-9ee4-1ccc9aaab61f,G_IMPACT_ANALYSIS_USER,2025-05-20 11:46:15,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""__doc_title__"": ""FDA-2023-D-0488-0002-guidance (1).pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/ae149f97-a383-47a4-9ee4-1ccc9aaab61f/SRC/ae149f97-a383-47a4-9ee4-1ccc9aaab61f.pdf"", ""doc_title"": ""FDA-2023-D-0488-0002-guidance (1).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/ae149f97-a383-47a4-9ee4-1ccc9aaab61f/DEST/impact_analysis.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 18:46:24,2025-05-28 03:53:06
91f3791c-322d-43f1-98c8-ce4ac2be03ae,USA-FDA,5b6526d8-d66f-47bc-ac42-5a823f13b459,G_MINI_SUMMARY,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009/FDA-2007-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry; Bioequivalence Recommendation for Lenalidomide Capsules"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:13:13,2025-05-28 03:53:06
92,,27eb9ada-4baf-4e5f-8563-e37d9c980d37,G_FAQ,2025-05-12 19:31:45,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145/FDA-2024-D-3863-0145-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3863"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3863-0145""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:31:47,2025-05-28 03:53:06
921064b2-4607-4bf7-9675-c8c8e8752c71,Queue,aa65d668-7d85-425a-b285-b502c81e1a8f,G_CONCISE_SUMMARY_USER,2025-05-30 03:51:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/aa65d668-7d85-425a-b285-b502c81e1a8f/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/aa65d668-7d85-425a-b285-b502c81e1a8f"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 03:51:39,2025-05-30 03:51:39
92192c61-8abe-4f15-b85b-dafbcaf1a093,USA-FDA,0a88ba0b-2135-49d2-977a-88b7558a880f,G_CONCISE_SUMMARY,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002/FDA-2011-D-0376-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues"", ""docket_id"": ""FDA-2011-D-0376"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0376-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:00:16,2025-05-28 03:53:06
921b530a-9641-4f38-8c15-8d577862df18,USA-FDA,75ef4aac-33b1-4aac-9293-fa1b455aa39c,G_MINI_SUMMARY,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0489/FDA-2011-D-0489-0002/FDA-2011-D-0489-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety of Nanomaterials in Cosmetic Products; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0489"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0489-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0489/FDA-2011-D-0489-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:45:08,2025-05-28 03:53:06
9263f552-8240-4fcb-be8c-40a92852cda3,USA-FDA,a267ce6c-e9f3-438b-b774-9a4e8be8a64e,G_ACTION_ITEMS,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002/FDA-2013-D-0749-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implanted Blood Access Devices for Hemodialysis; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0749"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0749-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:02:08,2025-05-28 03:53:06
927e9963-46f2-4365-aef1-3205adf40ae1,USA-FDA,9e6f671e-223b-4c81-ac74-59d437288106,G_CONCISE_SUMMARY,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009/FDA-2011-D-0916-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Classification Product Codes; Guidance for Industry and  Food and Drug Administration Staff"", ""docket_id"": ""FDA-2011-D-0916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0916-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:31:49,2025-05-28 03:53:06
92c00d25-448e-4964-8636-72e2e8544f9b,SCHEDULED,794400f9-eef0-40bf-804e-6ccbec9a6775,DEVICE_ANALYST,2025-05-30 00:00:04,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/794400f9-eef0-40bf-804e-6ccbec9a6775"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:06,2025-05-30 00:00:06
92db10dc-7333-46e2-9359-f5e778c25e08,USA-FDA,c6f3cbb3-9bbf-40f9-afc9-dd13445942aa,G_IMPACT_ANALYSIS,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0336/FDA-2005-D-0336-0004/FDA-2005-D-0336-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #176 (VICH GL39) Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances"", ""docket_id"": ""FDA-2005-D-0336"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0336-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0336/FDA-2005-D-0336-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:31:48,2025-05-28 03:53:06
92ec86f7-474f-4f88-b315-916834215982,QUEUE,1e506c86-32eb-4ebf-a247-dfc873327d63,G_FAQ_USER,2025-05-20 10:42:37,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""__doc_title__"": ""FDA-2024-N-5471-0004_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/1e506c86-32eb-4ebf-a247-dfc873327d63/SRC/1e506c86-32eb-4ebf-a247-dfc873327d63.pdf"", ""doc_title"": ""FDA-2024-N-5471-0004_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/1e506c86-32eb-4ebf-a247-dfc873327d63/DEST/faq.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:42:45,2025-05-28 03:53:06
92f78e28-681e-45e1-ab63-98af6e28ec81,USA-FDA,c3ec5897-e024-46ce-9d47-130c1c0d686f,G_FAQ,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1455/FDA-2020-D-1455-0001/FDA-2020-D-1455-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; Early Development Considerations for Innovative Combination Products"", ""docket_id"": ""FDA-2020-D-1455"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1455-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1455/FDA-2020-D-1455-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:16:56,2025-05-28 03:53:06
93,,b55e378b-3da5-45c2-b6bb-5e51bc55635e,G_ACTION_ITEMS,2025-05-12 19:31:50,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145/FDA-2024-D-3863-0145-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3863"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3863-0145""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:31:52,2025-05-28 03:53:06
931722b5-c0d0-4fce-864d-6bca7b14c671,USA-FDA,5435afe9-4522-4a5f-815c-ed74be8c0c92,G_FAQ,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002/FDA-2009-D-0136-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0136"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0136-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:31:15,2025-05-28 03:53:06
9322fff5-7d9f-415a-97ba-ff8255d5dc84,USA-FDA,40651ff9-12a8-45d0-adc1-6da73a62dd54,G_DETAILED_SUMMARY,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1088/FDA-2013-D-1088-0002/FDA-2013-D-1088-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entity Compliance Guide; Declaring Color Additives in Animal Foods; #223"", ""docket_id"": ""FDA-2013-D-1088"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1088-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1088/FDA-2013-D-1088-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:00:14,2025-05-28 03:53:06
939a239a-7595-4f37-ada5-41fa81d51175,USA-FDA,8adeda87-9d4d-436b-8600-677ac05017cb,G_FAQ,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1399/FDA-2020-D-1399-0001/FDA-2020-D-1399-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part I"", ""docket_id"": ""FDA-2020-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1399-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1399/FDA-2020-D-1399-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:01:18,2025-05-28 03:53:06
93a6f86d-5ed4-4bbe-8f90-d6c765cd11c3,USA-FDA,1aa54f3d-82be-42e5-a290-10d335ddd344,G_FAQ,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0847/FDA-2012-D-0847-0002/FDA-2012-D-0847-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for IRBs, Clinical Investigators, and Sponsors; IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed"", ""docket_id"": ""FDA-2012-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0847-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0847/FDA-2012-D-0847-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:15:27,2025-05-28 03:53:06
93b4ddf5-7ca5-487b-bcd3-33002c0ef8ad,USA-FDA,d6bb5619-49a3-4eea-b731-ca77d4bf71f9,G_CONCISE_SUMMARY,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002/FDA-2009-D-0006-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""S9 Nonclinical Evaluation for Anticancer Pharmaceuticals - Draft Guidance"", ""docket_id"": ""FDA-2009-D-0006"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0006-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:00:16,2025-05-28 03:53:06
93c3cc2b-a436-4d5c-aeb9-6e19fcd33185,USA-FDA,b338365e-b244-4202-a99f-c2ad56ea31ed,G_IMPACT_ANALYSIS,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003/FDA-1999-D-0030-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-1999-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0030-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:32:46,2025-05-28 03:53:06
93d0bec3-a478-416d-8996-a730f034d22a,QUEUE,f24dbea3-283d-462d-b3bb-f6ff7e7ac15b,G_TRANSLATE,2025-05-23 14:15:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""doc_title"": ""Presentaciones-Regulatorias-en-Formato-Electr�nico---Registro-de-Establecimientos-Farmac�uticos-y-Listado-de-F�rmacos.pdf"", ""to_language"": ""English""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/translation/f24dbea3-283d-462d-b3bb-f6ff7e7ac15b/Presentaciones-Regulatorias-en-Formato-Electr�nico---Registro-de-Establecimientos-Farmac�uticos-y-Listado-de-F�rmacos.pdf.pdf"", ""doc_title"": ""Presentaciones-Regulatorias-en-Formato-Electr�nico---Registro-de-Establecimientos-Farmac�uticos-y-Listado-de-F�rmacos.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/translation/f24dbea3-283d-462d-b3bb-f6ff7e7ac15b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 14:15:59,2025-05-28 03:53:06
93dca598-11c6-4e24-8ac0-7e02468964ca,USA-FDA,65bcc435-2522-46d6-9139-95d39944543e,G_FAQ,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008/FDA-2004-D-0181-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA)"", ""docket_id"": ""FDA-2004-D-0181"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0181-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:32:39,2025-05-28 03:53:06
93e60431-4f3d-4975-9260-e0ab88c5ce76,USA-FDA,71374462-7d7d-4592-acbe-9d27da6979b5,G_ACTION_ITEMS,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0334/FDA-2008-N-0334-0010/FDA-2008-N-0334-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Providing Submissions in Electronic Format - Postmarketing Safety Reports-Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements"", ""docket_id"": ""FDA-2008-N-0334"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-N-0334-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0334/FDA-2008-N-0334-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:01:47,2025-05-28 03:53:06
93f7b160-e8a0-4009-b57b-e824f6fdacde,USA-FDA,5bb58674-1110-418d-bf09-65381a189d8a,G_KEYWORDS,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002/FDA-2015-D-4380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Best Practices for Communication Between IND Sponsors and FDA\nDuring Drug Development Guidance for Industry and Review Staff"", ""docket_id"": ""FDA-2015-D-4380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:17:20,2025-05-28 03:53:06
93fc2c0a-216d-4229-aed0-a3c85ad7c11c,USA-FDA,417095db-9975-40f7-af22-9b7b5c8c2aa6,G_CONCISE_SUMMARY,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005/FDA-2012-D-0419-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for Use in Companion Animals"", ""docket_id"": ""FDA-2012-D-0419"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0419-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:31:02,2025-05-28 03:53:06
94,,2d54c3b0-8aa0-4944-8115-d0164fed1175,G_IMPACT_ANALYSIS,2025-05-12 19:31:57,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145/FDA-2024-D-3863-0145-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents\nAssociated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products"", ""docket_id"": ""FDA-2024-D-3863"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2024-D-3863-0145""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2024-D-3863/FDA-2024-D-3863-0145"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 02:31:58,2025-05-28 03:53:06
940a110f-3a5d-456e-8c16-9413acbd7f7b,SCHEDULED,1b37ad56-5977-4565-b7bd-bb501aff5f43,DEVICE_ANALYST,2025-05-20 04:13:45,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-20""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/1b37ad56-5977-4565-b7bd-bb501aff5f43"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 04:13:54,2025-05-28 03:53:06
94391eed-00c4-4c3c-b33c-8ddcca59d325,USA-FDA,3f09dccc-e39b-4ec6-a7ef-80f542044398,G_DETAILED_SUMMARY,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002/FDA-2011-D-0598-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers Regarding Establishment, Maintenance of Records by Persons Who Manufacture of Records by Persons Who Manufacture, Process, Pack, Transport,Distribute Receive, Hold or Import Food (Edition 5)"", ""docket_id"": ""FDA-2011-D-0598"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0598-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:31:12,2025-05-28 03:53:06
944c8c96-446d-4870-be9e-ee50799b69e8,USA-FDA,9d194ca1-12c6-469a-9d32-3c63ff04086b,G_ACTION_ITEMS,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3327/FDA-2015-D-3327-0002/FDA-2015-D-3327-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry E6(R2) Good Clinical Practice"", ""docket_id"": ""FDA-2015-D-3327"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-3327-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3327/FDA-2015-D-3327-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:31:23,2025-05-28 03:53:06
945c4c39-c78a-4e0c-bf67-271a61bd953b,USA-FDA,0e52a436-5432-407b-9ed3-afb3a15e8230,G_MINI_SUMMARY,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001/FDA-2020-D-1608-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data"", ""docket_id"": ""FDA-2020-D-1608"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1608-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:46:34,2025-05-28 03:53:06
94637c27-2996-4aee-af83-3b31338c7b52,USA-FDA,0519d9d4-be16-4e45-bddb-14de92f63ec0,G_IMPACT_ANALYSIS,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001/FDA-2020-D-1444-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Safety Information - FDA's Communication to the Public"", ""docket_id"": ""FDA-2020-D-1444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1444-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:17:01,2025-05-28 03:53:06
94732832-d3b7-4493-8ce2-71a7b6b5ef04,SCHEDULED,430b9457-ab90-4982-9860-661761bbf61b,FDA_ALERT,2025-06-02 00:00:04,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/430b9457-ab90-4982-9860-661761bbf61b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:13,2025-06-02 00:00:13
94a7e3a6-a10e-4b8e-a4e2-8aabc44e6cc2,USA-FDA,de701ee4-32fc-415d-8dba-f8a77d1962f2,G_IMPACT_ANALYSIS,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002/FDA-2017-D-2462-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:02:24,2025-05-28 03:53:06
94db93f8-2c73-4c09-b196-c3db4939c4f4,USA-FDA,22feb049-4310-43d2-8799-8b30cc669719,G_ACTION_ITEMS,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0429/FDA-2012-D-0429-0003/FDA-2012-D-0429-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Investigators Meetings with Industry and Investigators on the Research and Development of Tobacco Products"", ""docket_id"": ""FDA-2012-D-0429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0429-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0429/FDA-2012-D-0429-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:00:45,2025-05-28 03:53:06
95,,4f315eb5-e920-461c-b785-c1fd1707dfcd,G_MINI_SUMMARY,2025-05-12 21:04:12,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1/Guidance_on_demonstration_of_equivalence_for_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on demonstration of equivalence for Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-1""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-1"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 04:04:14,2025-05-28 03:53:06
950edf4c-4da3-4245-99b2-f672b912d48d,USA-FDA,157057b0-be34-4f83-9530-f3ad865e9b7f,G_IMPACT_ANALYSIS,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002/FDA-2011-D-0469-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and the Food and Drug Administration Staff: Applying Human Factors and Usability Engineering to Optimize Medical Device Design - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0469"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0469-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:36,2025-05-28 03:53:06
953afc14-2ce8-44bc-ad69-9396126ee58d,USA-FDA,14ee4a35-2488-4e76-a551-c7e7dc4f1faa,G_KEYWORDS,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002/FDA-2002-P-0302-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices"", ""docket_id"": ""FDA-2002-P-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-P-0302-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-P-0302/FDA-2002-P-0302-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:30:57,2025-05-28 03:53:06
956513ee-16a8-4a41-88c6-a8d949a15468,USA-FDA,0c77e3f4-f988-464e-8e78-c0933d2042d3,G_FAQ,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0212/FDA-2009-D-0212-0025/FDA-2009-D-0212-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting - Guidance for Industry"", ""docket_id"": ""FDA-2009-D-0212"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0212-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0212/FDA-2009-D-0212-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:47:21,2025-05-28 03:53:06
956c8181-8c83-431f-bcfd-313376b49845,USA-FDA,332524d7-fd35-4314-96fc-fad62fd2c73a,G_DETAILED_SUMMARY,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007/FDA-2007-D-0149-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff Class II Special Controls Guidance Document: Electrocardiograph Electrodes"", ""docket_id"": ""FDA-2007-D-0149"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0149-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:31:52,2025-05-28 03:53:06
95ab858e-cc3e-4440-a383-dc42bd5a93d3,USA-FDA,6d084b11-f44c-4571-80d5-be26e9045847,G_CONCISE_SUMMARY,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002/FDA-2003-D-0416-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS"", ""docket_id"": ""FDA-2003-D-0416"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0416-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:47:07,2025-05-28 03:53:06
96,,64e0c962-e0fa-452f-b6af-6cb903a24fed,G_MINI_SUMMARY_IN,2025-05-12 22:32:00,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:32:00,2025-05-28 03:53:06
960f5004-3560-43b8-b16e-32f57602b1b6,USA-FDA,5365e64d-ef04-4fe7-beb1-2304a6517703,G_CONCISE_SUMMARY,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001/FDA-2023-D-2508-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products"", ""docket_id"": ""FDA-2023-D-2508"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2508-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:00:12,2025-05-28 03:53:06
96107391-f876-4da1-99c0-863d5958618e,USA-FDA,bcc03dec-9fd6-4e88-817c-eb2d9565cb4b,G_DETAILED_SUMMARY,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009/FDA-2003-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI"", ""docket_id"": ""FDA-2003-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:30:37,2025-05-28 03:53:06
96203890-4c42-4953-ba69-5b723a9af38e,USA-FDA,b5208da9-757d-49a5-aa33-9112111ac96c,G_CONCISE_SUMMARY,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034/FDA-2002-D-0094-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Food and Drug Administration Advisory\nCommittee Members, and Food and Drug Administration Staff: Public\nAvailability of Advisory Committee Members� Financial Interest\nInformation and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:30:13,2025-05-28 03:53:06
96245d9c-aa26-4662-9f59-d35c35f81e94,USA-FDA,7ce131f8-296e-48f4-abad-ec91371fdd94,G_ACTION_ITEMS,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002/FDA-2014-N-1082-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Multiplexed Microbiological/Medical Countermeasure In Vitro \nNucleic Acid Based Diagnostic Devices; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-N-1082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1082-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:01:47,2025-05-28 03:53:06
96334a89-dd49-431b-af95-b57cb67946e6,USA-FDA,9cc1c8a5-b06a-4580-8fe4-72186bf68a88,G_IMPACT_ANALYSIS,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002/FDA-2012-D-0049-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke UnderSection 904(a)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance"", ""docket_id"": ""FDA-2012-D-0049"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0049-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:31:05,2025-05-28 03:53:06
96453bb0-969c-40fc-87bf-414b6fc5aaf5,USA-FDA,9f4ea42c-6b49-4e36-a2c3-677cfab33dc6,G_IMPACT_ANALYSIS,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022/FDA-1999-D-1875-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Extra-Label Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:02:58,2025-05-28 03:53:06
965f51a8-88ad-4e9c-86a0-afdca12fb794,USA-FDA,92d111f9-cf6f-4e2a-99f3-f3291bee1cde,G_FAQ,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015/FDA-2010-D-0350-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Tobacco Retailers on Tobacco Retailer Training Programs"", ""docket_id"": ""FDA-2010-D-0350"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0350-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:02:58,2025-05-28 03:53:06
966abb0f-2f03-4684-82b4-918c6e94c66b,USA-FDA,e46bdf08-c5b3-4e42-84e5-fe26953e4430,G_FAQ,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-N-0083/FDA-1999-N-0083-0015/FDA-1999-N-0083-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Availability: Reproductive and Developmental Toxicities - Integrating Study Results to Assess Concerns"", ""docket_id"": ""FDA-1999-N-0083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-N-0083-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-N-0083/FDA-1999-N-0083-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:46:44,2025-05-28 03:53:06
9676ff22-244b-4de0-8f33-413b8080a7dd,USA-FDA,b5bff929-c73b-426d-807d-776d77962290,G_IMPACT_ANALYSIS,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001/FDA-2020-D-1385-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Drug Stability Guidelines; #5"", ""docket_id"": ""FDA-2020-D-1385"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1385-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:32:55,2025-05-28 03:53:06
967e104d-f8d0-4bfb-a1b7-e7acaab1c5e2,USA-FDA,0e3d4039-d0ad-4aa2-bc3c-ce21bdfcbf42,G_MINI_SUMMARY,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001/FDA-2018-D-3551-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Impact of Certain Provisions of Revised Common Rule on FDA-Regulated Clinical Investigations; Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2018-D-3551"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3551-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:30:08,2025-05-28 03:53:06
96b59c39-21a7-4523-abe4-9e21ff48a259,USA-FDA,3791a134-0184-4321-bb1e-70d9dab56f8d,G_FAQ,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022/FDA-2005-D-0282-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Antiviral Product Development - Conducting and Submitting Virology Studies to the Agency Guidance for Submitting Influenza Resistance Data"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:46:11,2025-05-28 03:53:06
96bfad32-ab78-4f34-8967-96b4f66cf97c,USA-FDA,5b354651-ee0e-4f52-bb5a-cb1a4843c8c5,G_IMPACT_ANALYSIS,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0835/FDA-2011-D-0835-0002/FDA-2011-D-0835-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Considerations when Transferring Clinical Investigation Oversight to Another Institutional Review Board; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0835"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0835-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0835/FDA-2011-D-0835-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:47:06,2025-05-28 03:53:06
96e668b6-611b-449f-99b4-ab9564e318fa,USA-FDA,433694c7-a923-474f-8057-d38bec9b9b7e,G_FAQ,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1120/FDA-2012-D-1120-0002/FDA-2012-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Vaginal Microbicides: Development for the Prevention of Human Immunodeficiency Virus Infection"", ""docket_id"": ""FDA-2012-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1120/FDA-2012-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:47:00,2025-05-28 03:53:06
97,,f5fc0fe2-883b-4abf-9a8a-a6d73a929434,G_CONCISE_SUMMARY_IN,2025-05-12 22:32:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:32:09,2025-05-28 03:53:06
9723bbc9-9386-44bd-9f9a-16151fe075b4,USA-FDA,9b381d84-da64-4712-b57f-84a1dd6ab50e,G_KEYWORDS,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002/FDA-2014-N-1108-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products--Considerations, Content, and Format"", ""docket_id"": ""FDA-2014-N-1108"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1108-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1108/FDA-2014-N-1108-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:02:07,2025-05-28 03:53:06
972c9218-0e8f-4cbc-9cb9-97e10c377130,USA-FDA,41b2083c-af5c-447d-bc55-d12e8f690c0b,G_MINI_SUMMARY,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002/FDA-2017-D-2462-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:00:51,2025-05-28 03:53:06
9757eaed-6953-46c3-b06e-ead83b9c8bea,USA-FDA,9c856429-2cda-4242-917b-4aae9d3d92a1,G_IMPACT_ANALYSIS,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0005/FDA-2004-D-0301-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Fixed Dose Combinations, Co-Packaged Drug Products, and Single-EntityVersions of Previously Approved\nAntiretrovirals for the Treatment of HIV"", ""docket_id"": ""FDA-2004-D-0301"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0301-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:02:11,2025-05-28 03:53:06
9786b158-54bf-4a84-886a-ea7775b45ff0,USA-FDA,8618298c-9782-40d8-b260-b150e5ac0ba2,G_FAQ,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0283/FDA-2009-D-0283-0021/FDA-2009-D-0283-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Postmarketing Stuides and Clinical Trials - Implementation of Section 505 (o)(3) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2009-D-0283"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0283-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0283/FDA-2009-D-0283-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:01:12,2025-05-28 03:53:06
97cd7994-d048-4fba-a968-4835a99cab55,USA-FDA,3eaa6859-a2ce-4738-9cfe-35806dd631b9,G_IMPACT_ANALYSIS,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015/FDA-1999-D-1315-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Formal Meetings With Sponsors and Applicants for PDUFA Products; Guidance Document"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:33:03,2025-05-28 03:53:06
97e74113-0f0a-4d9a-8e79-47540eaac27c,USA-FDA,914bd9d8-0bbb-4b78-a70c-b500a24ae887,G_FAQ,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022/FDA-2011-D-0082-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry , Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling"", ""docket_id"": ""FDA-2011-D-0082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0082-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:03:33,2025-05-28 03:53:06
97e8b0f6-c348-4868-901e-e675fbc0c350,USA-FDA,101b3f24-6489-4191-8692-bd310a449eb7,G_MINI_SUMMARY,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0541/FDA-2011-D-0541-0002/FDA-2011-D-0541-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance PET Drugs ----- Current Good Manufacturing Practice (CGMP) (Small Entity Compliance Guide)"", ""docket_id"": ""FDA-2011-D-0541"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0541-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0541/FDA-2011-D-0541-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:01:30,2025-05-28 03:53:06
97f3c47e-adeb-42a0-a474-a764b236cd25,USA-FDA,3ec24720-d090-4553-980a-61878634939d,G_IMPACT_ANALYSIS,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002/FDA-2013-N-1429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2013-N-1429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:02:30,2025-05-28 03:53:06
98,,d087f4de-f431-4bf2-af0d-f09202f8adf1,G_FAQ_IN,2025-05-12 22:32:20,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:32:20,2025-05-28 03:53:06
980078e5-9958-46ad-adb9-969d008f8bda,USA-FDA,da5354e8-24e6-43fe-91b0-8cb7614640d1,G_DETAILED_SUMMARY,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0814/FDA-2013-D-0814-0002/FDA-2013-D-0814-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Pediatric Study Plans:  Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans"", ""docket_id"": ""FDA-2013-D-0814"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0814-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0814/FDA-2013-D-0814-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:46:04,2025-05-28 03:53:06
9803436f-e57c-41dd-a79a-0a00ed1f1f96,USA-FDA,8d9a3a72-8c14-4661-a2ba-5bda60039bbf,G_FAQ,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0196/FDA-2007-D-0196-0013/FDA-2007-D-0196-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for FDA Advisory Committee Members and FDA Staff : Voting Procedures for Advisory Committee Meetings"", ""docket_id"": ""FDA-2007-D-0196"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0196-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0196/FDA-2007-D-0196-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:00:54,2025-05-28 03:53:06
9825da5d-69af-462a-912e-6e0a8df5eba0,USA-FDA,3696e608-fc4e-4fa8-b508-4e7ed4c9d1ce,G_FAQ,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002/FDA-2017-D-5525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Statistical Approaches to Evaluate Analytical Similarity Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:32:05,2025-05-28 03:53:06
98314026-3f5c-4b8a-ba90-53c5cb4643c2,USA-FDA,89a1d954-e958-4a5c-8476-ed60d93c9551,G_FAQ,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002/FDA-2018-D-3152-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Postapproval Changes to Drug Substances Guidance for Industry"", ""docket_id"": ""FDA-2018-D-3152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3152-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:45:58,2025-05-28 03:53:06
98344fea-7c57-4bcc-9352-65a7a5ff5751,USA-FDA,9f1fe104-129d-4f4f-b468-014b5d03f047,G_ACTION_ITEMS,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020/FDA-1992-N-0056-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prescription Drug Marketing Act (PDMA) Requirements; Questions and Answers"", ""docket_id"": ""FDA-1992-N-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0056-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:15:57,2025-05-28 03:53:06
986bd48f-bd14-47a6-a066-90869975751c,USA-FDA,509d6368-65e7-4190-a20e-d7399a79ef5d,G_ACTION_ITEMS,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008/FDA-2010-D-0431-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Food and Drug Administration Staff and Tobacco Retailers on Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Revised"", ""docket_id"": ""FDA-2010-D-0431"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0431-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:45:48,2025-05-28 03:53:06
987b6b54-6a5b-491d-8e08-03d3304b6f79,USA-FDA,cf744807-48e6-4ba3-bbfe-6c34ab7f40c0,G_DETAILED_SUMMARY,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021/FDA-2004-D-0044-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for the Early Food Safety\nEvaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties\nIntended for Food Use; Availability"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:00:22,2025-05-28 03:53:06
9896b23d-4775-417b-aeb4-19ec866a8099,USA-FDA,e5053af0-262b-42a5-8747-5aa27d0bb008,G_IMPACT_ANALYSIS,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0742/FDA-1999-D-0742-0014/FDA-1999-D-0742-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Financial Disclosure by Clinical Investigators - Draft Guidance"", ""docket_id"": ""FDA-1999-D-0742"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0742-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0742/FDA-1999-D-0742-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:47:26,2025-05-28 03:53:06
989c7b12-81d3-4c55-8112-ec53d749fb9f,USA-FDA,9158e0db-db40-4703-b45c-61ce83913e8e,G_MINI_SUMMARY,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0090/FDA-2003-D-0090-0002/FDA-2003-D-0090-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate � Labeling Enforcement Policy"", ""docket_id"": ""FDA-2003-D-0090"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0090-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0090/FDA-2003-D-0090-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:01:16,2025-05-28 03:53:06
989f1a64-e048-4eca-ae86-f669221ed515,USA-FDA,12816d53-5673-4e0e-8014-ae38e9f73538,G_DETAILED_SUMMARY,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004/FDA-2005-D-0028-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products"", ""docket_id"": ""FDA-2005-D-0028"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0028-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:01:38,2025-05-28 03:53:06
98d9b712-81fc-4fdf-9fd5-f37f57bb5466,USA-FDA,a7db29ef-70a5-4dc1-808d-a2254d2a9097,G_DETAILED_SUMMARY,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002/FDA-1999-D-0063-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling"", ""docket_id"": ""FDA-1999-D-0063"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0063-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:47:40,2025-05-28 03:53:06
98ff5a3b-c7fa-4332-8d58-cf2d4e7b4d40,USA-FDA,ad14d5d4-53a4-44a8-8aa1-a35ce49d5cc8,G_DETAILED_SUMMARY,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1529/FDA-2013-N-1529-0023/FDA-2013-N-1529-0023-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""03 Reference 2 Open Public Hearings Guidance - Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: The Open Public Hearing at FDA Advisory Committee Meetings"", ""docket_id"": ""FDA-2013-N-1529"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1529-0023""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1529/FDA-2013-N-1529-0023"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:32:01,2025-05-28 03:53:06
99,,b0fbcc11-08b8-4a84-89e3-e43649847804,G_ACTION_ITEMS_IN,2025-05-12 22:32:25,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,{},"{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2/Guidance_on_qualification_and_classification_of_Annex_XVI_products_-_A_guide_for_manufacturers_and_notified_bodies.pdf"", ""country"": ""EU"", ""agency_id"": ""MDCG"", ""doc_title"": ""Guidance on qualification and classification of Annex XVI products - A guide for manufacturers and notified bodies"", ""docket_id"": ""MDCG-1"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""MDCG-1-2""}","{""aws_key"": ""EU/MDCG/CONTENT/MDCG-1/MDCG-1-2"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-13 05:32:25,2025-05-28 03:53:06
997f76d7-baf7-49e4-9bfc-7d3b8a82c005,USA-FDA,a990b786-9cb5-4bae-bb53-c17a5ad0f10b,G_DETAILED_SUMMARY,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0201/FDA-2007-D-0201-0005/FDA-2007-D-0201-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content and Format of the Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products"", ""docket_id"": ""FDA-2007-D-0201"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0201-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0201/FDA-2007-D-0201-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:46:25,2025-05-28 03:53:06
99aa2a94-dbf1-4283-93f2-1bd33683ff81,USA-FDA,1bf4056e-f776-4759-8a66-0e8fca20b5ff,G_FAQ,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002/FDA-2009-D-0354-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Pharmaceutical Components at Risk for Melamine Contamination"", ""docket_id"": ""FDA-2009-D-0354"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0354-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:02:34,2025-05-28 03:53:06
99c10224-5d2e-43c7-91fa-d1d3fc36572b,USA-FDA,d1803a5f-6a75-4e20-9583-9b42ee7bb5d4,G_DETAILED_SUMMARY,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0002/FDA-2010-D-0503-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Investigational New Drug Applications (INDs)�Determining Whether Human Research Studies Can Be Conducted Without an IND"", ""docket_id"": ""FDA-2010-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0503-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:47:32,2025-05-28 03:53:06
99c4bf43-5b93-4bab-88f6-46926499cbbb,SCHEDULED,f0815cae-bbce-4436-a559-3f5808f03a47,DEVICE_ANALYST,2025-05-27 00:00:04,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Patel"", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": ""Abhishek"", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/f0815cae-bbce-4436-a559-3f5808f03a47"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:26,2025-05-28 03:53:06
99cd1087-cdb5-4e85-9975-e0351668b796,USA-FDA,0e4d99ab-a3b7-49b2-8f5b-cda5cec67366,G_FAQ,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0438/FDA-2004-D-0438-0007/FDA-2004-D-0438-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Time and Extent Applications for Nonprescription Drug Products"", ""docket_id"": ""FDA-2004-D-0438"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0438-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0438/FDA-2004-D-0438-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:47:49,2025-05-28 03:53:06
99eb0262-66fc-47fb-afd4-4be1645a3f81,USA-FDA,37966dbb-1538-4993-80b2-f1d5b8094bff,G_MINI_SUMMARY,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020/FDA-2015-D-1245-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:02:21,2025-05-28 03:53:06
9a21195c-23ba-4651-80db-f11462fd17df,USA-FDA,f33068fb-c41e-4e07-9c86-d95371c40369,G_ACTION_ITEMS,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0056/FDA-1997-D-0056-0002/FDA-1997-D-0056-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Iron-Containing Supplements and Drugs: Label Warning Statements and Unit-Dose Packaging Requirements Small Entity Compliance Guide"", ""docket_id"": ""FDA-1997-D-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0056-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0056/FDA-1997-D-0056-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:16:32,2025-05-28 03:53:06
9a4a1f72-760e-4a9c-b9eb-4f2dcadff9fb,USA-FDA,f5fe3c46-b9bb-41b7-a06d-2c220206eb14,G_ACTION_ITEMS,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-2441/FDA-1999-D-2441-0002/FDA-1999-D-2441-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Dioxin in Anti-Caking Agents Used in Animal Feed and Feed Ingredients"", ""docket_id"": ""FDA-1999-D-2441"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-2441-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-2441/FDA-1999-D-2441-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:00:29,2025-05-28 03:53:06
9a5ab9f4-6ff2-4353-90ac-dac6bc1b7d75,USA-FDA,9d3e641d-3d25-4eb4-8c85-d403fec776fb,G_MINI_SUMMARY,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001/FDA-2020-D-1444-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Safety Information - FDA's Communication to the Public"", ""docket_id"": ""FDA-2020-D-1444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1444-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:16:13,2025-05-28 03:53:06
9a6a3bd4-31e7-4be4-94c0-1900ed0cdb68,USA-FDA,ee71dbc2-7e0c-4a95-baf4-b2ba22f5e3a6,G_KEYWORDS,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007/FDA-2007-D-0149-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff Class II Special Controls Guidance Document: Electrocardiograph Electrodes"", ""docket_id"": ""FDA-2007-D-0149"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0149-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:32:21,2025-05-28 03:53:06
9a6df291-1242-4388-937f-8bb88e86f841,USA-FDA,588c1900-cea2-431d-a1ec-9cda8764151c,G_DETAILED_SUMMARY,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0361/FDA-2008-N-0361-0002/FDA-2008-N-0361-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Standard of Identity for White Chocolate; Guidance "", ""docket_id"": ""FDA-2008-N-0361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-N-0361-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0361/FDA-2008-N-0361-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:15:12,2025-05-28 03:53:06
9aae0e8e-ab0c-4d27-8444-fb33c5d6e9b5,USA-FDA,c19718d6-8fda-4299-bfa9-36537fd8e06e,G_IMPACT_ANALYSIS,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002/FDA-2009-D-0136-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0136"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0136-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:31:41,2025-05-28 03:53:06
9acbddd9-6481-4863-819e-408806b7b8a6,USA-FDA,e6e371db-25b9-420e-bfda-9009b764c216,G_DETAILED_SUMMARY,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009/FDA-2007-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry; Bioequivalence Recommendation for Lenalidomide Capsules"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:13:21,2025-05-28 03:53:06
9afc0f34-571a-40e0-8f11-1b4ad53b660c,USA-FDA,72db51bc-78dd-4552-b9cb-52264a1caad0,G_IMPACT_ANALYSIS,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0003/FDA-2014-D-1525-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Draft Guidance"", ""docket_id"": ""FDA-2014-D-1525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1525-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:02:29,2025-05-28 03:53:06
9b098551-11c0-4b39-b00e-61894b892976,USA-FDA,c8b8bf96-8fff-4579-a297-1916e9b42b07,G_DETAILED_SUMMARY,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0545/FDA-2016-D-0545-0099/FDA-2016-D-0545-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components; Guidance for Industry"", ""docket_id"": ""FDA-2016-D-0545"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0545-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0545/FDA-2016-D-0545-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:30:19,2025-05-28 03:53:06
9b8316ce-c757-407d-b238-e6e11186e8b3,USA-FDA,77c649e4-e7f0-4b5f-afba-5b66e8290da0,G_MINI_SUMMARY,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0002/FDA-2010-D-0503-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Investigational New Drug Applications (INDs)�Determining Whether Human Research Studies Can Be Conducted Without an IND"", ""docket_id"": ""FDA-2010-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0503-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:47:17,2025-05-28 03:53:06
9bb99e6e-b631-4a95-9617-3bab79e6cd57,USA-FDA,2093a53a-009b-4c08-9685-dceb0b71671f,G_DETAILED_SUMMARY,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002/FDA-2011-D-0376-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues"", ""docket_id"": ""FDA-2011-D-0376"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0376-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:00:35,2025-05-28 03:53:06
9bd25152-1ecf-4157-9681-efdd1c7c84d9,USA-FDA,8cfbe12b-bbc9-43fa-9100-be0d2ba3670e,G_FAQ,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-2001/FDA-2015-D-2001-0002/FDA-2015-D-2001-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance Assessment of Male-Mediated Developmental Risk for Pharmaceuticals"", ""docket_id"": ""FDA-2015-D-2001"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-2001-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-2001/FDA-2015-D-2001-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:32:07,2025-05-28 03:53:06
9bd33940-f682-443c-9d94-99cc110760bc,USA-FDA,ac8717b5-cf93-4ba1-9b38-0df68ffdd988,G_IMPACT_ANALYSIS,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1455/FDA-2020-D-1455-0001/FDA-2020-D-1455-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; Early Development Considerations for Innovative Combination Products"", ""docket_id"": ""FDA-2020-D-1455"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1455-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1455/FDA-2020-D-1455-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:17:18,2025-05-28 03:53:06
9bf4adfc-dea5-4057-8f52-d2b85355098d,USA-FDA,e50385d9-def2-483b-8ab1-24fadedb423a,G_DETAILED_SUMMARY,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017/FDA-2010-D-0426-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Bar Code Label Requirements�Questions and Answers"", ""docket_id"": ""FDA-2010-D-0426"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0426-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:33:17,2025-05-28 03:53:06
9bfff0bd-d581-4893-b15d-70249b49e50a,USA-FDA,396ee6b4-5a6f-4ec7-b40b-e5af60cbdeda,G_IMPACT_ANALYSIS,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002/FDA-2009-D-0542-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Factors that Distinguish Liquid Dietary Supplements from Beverages, Considerations Regarding Novel Ingredients, and Labeling for Beverages and Other Conventional Foods; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0542"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0542-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:03:19,2025-05-28 03:53:06
9c11289d-27b2-412e-a377-ddbfc6975ae9,USA-FDA,1fe76e43-c979-4a98-a06e-3b991b00f899,G_IMPACT_ANALYSIS,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0183/FDA-2010-D-0183-0002/FDA-2010-D-0183-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance of Industry; Prevention of Salmonella Enteritidis in Shell Eggs During Production, Transportation, and Storage; Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0183"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0183-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0183/FDA-2010-D-0183-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:00:59,2025-05-28 03:53:06
9c18226e-3e8c-4539-9e94-b810dea70c8f,USA-FDA,a07142c4-1686-4ec5-9588-c7f4818be10d,G_ACTION_ITEMS,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002/FDA-2017-D-6380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric\nSubpopulations of Common Diseases Draft Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:02:05,2025-05-28 03:53:06
9c2c7d19-aec1-4df4-a1c7-e7d19394b347,USA-FDA,c1c6ebe0-7de6-4da5-af58-4cefb587d9d4,G_DETAILED_SUMMARY,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0002/FDA-2004-D-0500-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Help Seeking and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:32:43,2025-05-28 03:53:06
9c2d76d2-9d9e-4faa-ab35-fc47c45a67b0,USA-FDA,752e0854-906e-4d5f-b0ed-eb8530d36d1a,G_ACTION_ITEMS,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1380/FDA-2020-D-1380-0001/FDA-2020-D-1380-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products"", ""docket_id"": ""FDA-2020-D-1380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1380-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1380/FDA-2020-D-1380-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:31:18,2025-05-28 03:53:06
9c311a96-6c2a-4174-94a0-5f1569ff0616,USA-FDA,2314b9c4-7749-4814-ac26-9ebaa23b8ea8,G_ACTION_ITEMS,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0125/FDA-2013-N-0125-0025/FDA-2013-N-0125-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Alternative to Certain Prescription Device Labeling Requirements"", ""docket_id"": ""FDA-2013-N-0125"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-0125-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0125/FDA-2013-N-0125-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:00:29,2025-05-28 03:53:06
9c4c910e-4209-4c10-aa5b-09c9efe80393,USA-FDA,2c10e648-a59d-4943-9d79-d7f8f83ba800,G_FAQ,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004/FDA-2002-D-0298-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition"", ""docket_id"": ""FDA-2002-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0298-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:46:40,2025-05-28 03:53:06
9c5379f7-4dba-4f5d-a8a8-e4656a226990,SCHEDULED,7774398a-6a89-4c4d-8f28-156ae0754771,DEVICE_ANALYST,2025-06-01 00:00:04,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/7774398a-6a89-4c4d-8f28-156ae0754771"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:06,2025-06-01 00:00:06
9c884ab5-3f4a-4602-9509-1008bf0f46d8,USA-FDA,212f3a65-3d7b-4a91-b996-276cd7d39a21,G_FAQ,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002/FDA-2010-D-0395-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Adminstration Staff Recommendation for Premarket Notification for Lamotrigine and Zonisamide Assays"", ""docket_id"": ""FDA-2010-D-0395"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0395-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:00:51,2025-05-28 03:53:06
9c8871fd-8ab9-4c78-82ac-a036da41501f,USA-FDA,9f436c7a-afd9-4883-840c-be2ebfcd888e,G_IMPACT_ANALYSIS,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020/FDA-1992-N-0056-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prescription Drug Marketing Act (PDMA) Requirements; Questions and Answers"", ""docket_id"": ""FDA-1992-N-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0056-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:16:05,2025-05-28 03:53:06
9cc57ff1-f775-4b4f-bcc7-294b078f4e71,USA-FDA,0f82e117-3272-4af6-8d28-4727b73b0797,G_ACTION_ITEMS,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0514/FDA-2011-D-0514-0002/FDA-2011-D-0514-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Industry and Staff; Procedures for Handling Section 522 Postmarket Surveillance Studies"", ""docket_id"": ""FDA-2011-D-0514"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0514-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0514/FDA-2011-D-0514-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:15:54,2025-05-28 03:53:06
9cf10f85-97b7-4e77-8913-48e973c94e72,USA-FDA,4ca31169-29f9-4163-ae58-98d94a3e3f14,G_CONCISE_SUMMARY,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008/FDA-2009-D-0448-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry, MQSA Inspectors and FDA Staffl The Mammography Quality Standards Act Final Regulations: Modifications and Additions to Policy Guidance Help System #13"", ""docket_id"": ""FDA-2009-D-0448"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0448-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:01:45,2025-05-28 03:53:06
9d0d3667-d004-4058-ba1c-e2600eb03653,USA-FDA,8f9a261c-f194-4c9b-9043-aa9e8384e6ac,G_DETAILED_SUMMARY,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0212/FDA-2009-D-0212-0025/FDA-2009-D-0212-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting - Guidance for Industry"", ""docket_id"": ""FDA-2009-D-0212"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0212-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0212/FDA-2009-D-0212-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:47:10,2025-05-28 03:53:06
9d130f7e-a405-4410-b38d-c10dec0e32b0,USA-FDA,0fcf07bc-850c-4fff-a0b3-454543e9d6d9,G_DETAILED_SUMMARY,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002/FDA-2009-D-0198-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain Cochineal Extract and Carmine"", ""docket_id"": ""FDA-2009-D-0198"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0198-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:45,2025-05-28 03:53:06
9d205e0b-5806-4644-baad-38419d1de497,USA-FDA,6a56529c-afeb-4e0a-888b-2682ac08f32e,G_CONCISE_SUMMARY,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005/FDA-2007-D-0205-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:32:42,2025-05-28 03:53:06
9d23c6c5-f971-42a1-b4ae-0f526a6f8d10,USA-FDA,3270d3bb-90d1-48eb-a220-4c9434e24ee0,G_ACTION_ITEMS,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0012/FDA-1998-D-0035-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:16:00,2025-05-28 03:53:06
9d331412-b6ad-4ac0-890d-738852b0d2d3,USA-FDA,d0dc2da1-2e04-4db6-bdc6-e566445d2608,G_MINI_SUMMARY,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0313/FDA-2010-D-0313-0018/FDA-2010-D-0313-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2010-D-0313"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0313-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0313/FDA-2010-D-0313-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:45:12,2025-05-28 03:53:06
9d52fe92-821a-46a0-9392-ad8a0aaa65cb,USA-FDA,9b362da9-18c7-432a-a5e8-d4d12952a071,G_CONCISE_SUMMARY,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001/FDA-2020-D-1945-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a)"", ""docket_id"": ""FDA-2020-D-1945"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1945-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:39,2025-05-28 03:53:06
9d640814-d2f9-451d-95db-e77a7cb20c5c,USA-FDA,bd207355-d1b5-446e-b0be-6d40e69390ad,G_CONCISE_SUMMARY,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002/FDA-2009-D-0136-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0136"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0136-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:30:15,2025-05-28 03:53:06
9d69dd11-9d6c-450e-ab05-dc91bc5e32fa,USA-FDA,e0a49fce-f062-4d38-ab94-1b2ff91d729f,G_MINI_SUMMARY,2025-05-22 18:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1434/FDA-2013-N-1434-0002/FDA-2013-N-1434-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules; Guidance Document"", ""docket_id"": ""FDA-2013-N-1434"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1434-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1434/FDA-2013-N-1434-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:45:24,2025-05-28 03:53:06
9d749057-3997-46db-b875-250d2e23183d,USA-FDA,842bf22c-33cf-4a0e-86af-41fb376d3e96,G_MINI_SUMMARY,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0722/FDA-2011-D-0722-0002/FDA-2011-D-0722-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Implementation of Acceptable Abbreviated Donor History Questionnaire, etc."", ""docket_id"": ""FDA-2011-D-0722"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0722-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0722/FDA-2011-D-0722-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:47:56,2025-05-28 03:53:06
9d7657dc-ac99-4b3d-9250-280412acd66e,USA-FDA,73474938-75b9-4d88-8bb5-c55a78da706c,G_MINI_SUMMARY,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0201/FDA-2007-D-0201-0005/FDA-2007-D-0201-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content and Format of the Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products"", ""docket_id"": ""FDA-2007-D-0201"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0201-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0201/FDA-2007-D-0201-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:46:07,2025-05-28 03:53:06
9d769060-8bf9-4e82-8f85-8b6c4bd36b29,USA-FDA,b693c639-5bcd-4884-a8cb-c82ff898c5b9,G_IMPACT_ANALYSIS,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1960/FDA-2020-D-1960-0001/FDA-2020-D-1960-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on HACCP Regulation for Fish and Fishery Products"", ""docket_id"": ""FDA-2020-D-1960"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1960-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1960/FDA-2020-D-1960-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:02:30,2025-05-28 03:53:06
9d82a1f0-1807-407d-aa3d-b28298e8d6fb,USA-FDA,d315eef3-4f3e-4009-8d4b-ed4c1183e0b1,G_FAQ,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001/FDA-2018-D-3551-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Impact of Certain Provisions of Revised Common Rule on FDA-Regulated Clinical Investigations; Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2018-D-3551"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3551-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:30:35,2025-05-28 03:53:06
9d85415e-37fb-4c52-ad22-5d4a6fd466fd,USA-FDA,27928db8-9180-4d64-ab44-57bc42c96355,G_DETAILED_SUMMARY,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0128/FDA-2008-D-0128-0005/FDA-2008-D-0128-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Guidance for Industry"", ""docket_id"": ""FDA-2008-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0128-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0128/FDA-2008-D-0128-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:47:07,2025-05-28 03:53:06
9dcb0437-d42a-444f-accb-2546743e623d,USA-FDA,2f31b8b4-9f44-4cc6-bef1-e42e36dc277b,G_CONCISE_SUMMARY,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012/FDA-2008-D-0610-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic"", ""docket_id"": ""FDA-2008-D-0610"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0610-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:32:00,2025-05-28 03:53:06
9ddd8ec1-3c5e-4d17-969b-49f2b064c405,USA-FDA,7ce5e6b2-b08e-4cd4-8f2d-6a143df4d108,G_ACTION_ITEMS,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112/FDA-2000-N-0190-0112-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Outdoor Access)"", ""docket_id"": ""FDA-2000-N-0190"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-N-0190-0112""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:03:49,2025-05-28 03:53:06
9df49080-cddf-4109-bbbb-ed01ceaf30d8,USA-FDA,4c704ba8-212b-4589-9a0d-60ca1cfc8983,G_MINI_SUMMARY,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007/FDA-2011-D-0691-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs"", ""docket_id"": ""FDA-2011-D-0691"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0691-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:02:33,2025-05-28 03:53:06
9dfa38d6-b875-4b3b-b29f-6362f3c898dd,USA-FDA,1aa6c6ce-5b8c-4670-b835-e433e8d9ce37,G_IMPACT_ANALYSIS,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0002/FDA-2017-D-6526-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier"", ""docket_id"": ""FDA-2017-D-6526"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6526-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:00:52,2025-05-28 03:53:06
9e1998f7-c081-4422-91ae-42a756422ec9,USA-FDA,ccf324fa-8ac1-4930-8fb2-6c9a67e601ef,G_IMPACT_ANALYSIS,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0201/FDA-2007-D-0201-0005/FDA-2007-D-0201-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content and Format of the Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products"", ""docket_id"": ""FDA-2007-D-0201"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0201-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0201/FDA-2007-D-0201-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:46:57,2025-05-28 03:53:06
9e2c67c3-a1c6-4b03-bd6d-ec21b7c58470,USA-FDA,046fa4a8-7470-4f0b-8320-58e327c60a02,G_DETAILED_SUMMARY,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5140/FDA-2017-D-5140-0002/FDA-2017-D-5140-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Display Devices for Diagnostic Radiology"", ""docket_id"": ""FDA-2017-D-5140"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5140-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5140/FDA-2017-D-5140-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:16:39,2025-05-28 03:53:06
9e474b2b-ec7e-4879-90a8-a2cb296478ad,SCHEDULED,e8028642-d32d-43d4-b5fc-10925220302f,FDA_ALERT,2025-05-21 20:33:25,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/e8028642-d32d-43d4-b5fc-10925220302f"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:46,2025-05-28 03:53:06
9e4b9f5b-2acb-4ade-8273-297e2fc48e9c,SCHEDULED,32a53353-af4f-4f96-9328-b64a2083c161,DEVICE_ANALYST,2025-05-22 00:03:21,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/32a53353-af4f-4f96-9328-b64a2083c161"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:28,2025-05-28 03:53:06
9e5f4126-b55d-47f7-8e86-98c5d918fc38,USA-FDA,0d948cf1-7436-4d9c-b045-4bbdff39da07,G_IMPACT_ANALYSIS,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0523/FDA-2012-D-0523-0012/FDA-2012-D-0523-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; Refuse to Accept Policy for 510(k)s"", ""docket_id"": ""FDA-2012-D-0523"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0523-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0523/FDA-2012-D-0523-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:46:07,2025-05-28 03:53:06
9e8e35c7-9be3-4f2c-9cc6-f5dd358d60c6,USA-FDA,96f4351d-1bb7-4e04-922e-a4f9be06fd51,G_IMPACT_ANALYSIS,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1380/FDA-2020-D-1380-0001/FDA-2020-D-1380-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products"", ""docket_id"": ""FDA-2020-D-1380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1380-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1380/FDA-2020-D-1380-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:31:27,2025-05-28 03:53:06
9ea918ae-3838-4b92-b90f-598879181c8e,USA-FDA,b71de114-1e01-4407-bc7f-5fa698e6a882,G_KEYWORDS,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001/FDA-2016-D-1533-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:03:00,2025-05-28 03:53:06
9eafd9c2-4b3c-4bed-92ca-b7141f26f271,USA-FDA,6c620adb-76c6-4e93-9a45-898a45348136,G_IMPACT_ANALYSIS,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0182/FDA-2004-D-0182-0004/FDA-2004-D-0182-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; ANDAs: Pharmaceutical Solid Polymorphism;\nChemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-2004-D-0182"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0182-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0182/FDA-2004-D-0182-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:30:41,2025-05-28 03:53:06
9ed97c10-929c-4b06-aa4b-79d58306ed3e,USA-FDA,27a72137-e044-4c57-b1e8-d73f6bb29114,G_MINI_SUMMARY,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002/FDA-1997-D-0444-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""FDA Approval of Animal Drugs for Minor Uses and Minor Species; Draft Guidance Document"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:45,2025-05-28 03:53:06
9efb23ec-7f91-4ba5-8e72-fd64b2b844b4,USA-FDA,36fab8fb-de46-4e06-a83f-552bc7291426,G_ACTION_ITEMS,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0199/FDA-2008-D-0199-0002/FDA-2008-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""E15 Pharmacogenomics Definitions and Sample Coding"", ""docket_id"": ""FDA-2008-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0199/FDA-2008-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:32:23,2025-05-28 03:53:06
9f27ff10-fdb8-4136-bfab-b7ae25db21cd,QUEUE,5127178a-0daf-48ce-937e-29bbc2792a33,G_CONCISE_SUMMARY_USER,2025-05-23 14:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""doc_title"": ""FDA-2025-N-0831-0001.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/concise_summary/5127178a-0daf-48ce-937e-29bbc2792a33/FDA-2025-N-0831-0001.pdf.pdf"", ""doc_title"": ""FDA-2025-N-0831-0001.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/concise_summary/5127178a-0daf-48ce-937e-29bbc2792a33"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 14:15:10,2025-05-28 03:53:06
9f2b325e-a3b9-4eca-8022-77367300ec81,USA-FDA,2c86898c-9f89-485b-9735-bd4c8e8a9e6d,G_IMPACT_ANALYSIS,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001/FDA-2020-D-1916-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect -21 CFR 1003.11"", ""docket_id"": ""FDA-2020-D-1916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1916-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:45:34,2025-05-28 03:53:06
9f2d2034-d69c-49a2-b5c8-efcc45c54f5e,USA-FDA,96bb5ef0-b748-4456-a46b-797e33ba0529,G_KEYWORDS,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002/FDA-2018-D-3152-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Postapproval Changes to Drug Substances Guidance for Industry"", ""docket_id"": ""FDA-2018-D-3152"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3152-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3152/FDA-2018-D-3152-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:46:22,2025-05-28 03:53:06
9f672755-33c1-49d4-a54a-ab83ecb9f8d0,USA-FDA,7934102c-7bbb-4e26-b113-422febd31eab,G_ACTION_ITEMS,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001/FDA-2020-D-1945-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a)"", ""docket_id"": ""FDA-2020-D-1945"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1945-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:53,2025-05-28 03:53:06
9f71b4d4-634a-49f8-b9ee-29ceb5e4bb10,USA-FDA,938d0794-9db9-4037-a9ea-31e2b434259a,G_IMPACT_ANALYSIS,2025-05-19 23:42:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001/FDA-2017-D-5478-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""MRCT Draft FDA Guidance Return of Aggregate Results"", ""docket_id"": ""FDA-2017-D-5478"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5478-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 03:43:53,2025-05-28 03:53:06
9f8896b5-56a0-4383-8a65-ddc706410545,USA-FDA,41979484-f993-42e2-93c8-cfe4829c2acf,G_DETAILED_SUMMARY,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0447/FDA-2013-D-0447-0002/FDA-2013-D-0447-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Charging for Investigational Drugs Under an Investigational New Drug Application-Questions and Answers"", ""docket_id"": ""FDA-2013-D-0447"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0447-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0447/FDA-2013-D-0447-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:30:15,2025-05-28 03:53:06
9f8db421-d330-4f7f-b655-d1dbe463fe85,USA-FDA,68c87b1d-07f4-4f8a-b7fc-b1f5aefc469b,G_MINI_SUMMARY,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001/FDA-2023-D-2510-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)"", ""docket_id"": ""FDA-2023-D-2510"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2510-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:30:56,2025-05-28 03:53:06
9f96ea45-6b49-4116-8538-f91bfea9c0b5,CAB,892345cb-d9ab-4e92-bfda-05af8cfe7132,G_TRANSLATE,2025-05-20 09:28:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__to_language__"": ""Italian""}","{""tilte"": ""FDA-2023-N-4225-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""be71a183-8124-4a8f-984c-ce1233023d0a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/be71a183-8124-4a8f-984c-ce1233023d0a/Italian"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:29:41,2025-05-28 03:53:06
9fce506d-cb28-41b0-8575-bfc5faa35d24,USA-FDA,563e83fb-4765-4e2a-93c2-60d4b2a7e64c,G_ACTION_ITEMS,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010/FDA-2011-D-0799-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components Including Source Plasma to Reduce the Risk of Transmission of Hepatitis B Virus"", ""docket_id"": ""FDA-2011-D-0799"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0799-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:02:01,2025-05-28 03:53:06
9fd5e955-0b65-454e-8709-5702f73b1155,USA-FDA,1a23ff01-f546-4608-bbc8-b8286f0b73fb,G_FAQ,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002/FDA-2013-D-0349-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format"", ""docket_id"": ""FDA-2013-D-0349"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0349-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:01:41,2025-05-28 03:53:06
9fdfd782-a75d-428b-8f54-0a0e080cd12e,USA-FDA,6175872f-61d1-4574-9bc7-65bddf0d39c9,G_MINI_SUMMARY,2025-05-22 18:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0880/FDA-2012-D-0880-0007/FDA-2012-D-0880-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Generic Drug User Fee Amendments of 2012: Questions and Answers (Revision 1)"", ""docket_id"": ""FDA-2012-D-0880"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0880-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0880/FDA-2012-D-0880-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:45:10,2025-05-28 03:53:06
a01d397b-5e93-4c1f-970e-c95850cf670b,USA-FDA,847bc388-f8c5-42e6-8b8a-7c5c6fc24b88,G_DETAILED_SUMMARY,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002/FDA-2009-D-0006-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""S9 Nonclinical Evaluation for Anticancer Pharmaceuticals - Draft Guidance"", ""docket_id"": ""FDA-2009-D-0006"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0006-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:00:22,2025-05-28 03:53:06
a08c6bee-975e-4e69-b40b-b31a261b0fb6,USA-FDA,8ad385e5-ab25-4e80-ae2f-e7dd11d7160a,G_ACTION_ITEMS,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005/FDA-2012-D-0419-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for Use in Companion Animals"", ""docket_id"": ""FDA-2012-D-0419"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0419-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0419/FDA-2012-D-0419-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:31:38,2025-05-28 03:53:06
a08de489-f129-4ceb-a96e-a1440a1411b5,USA-FDA,2b9b7a85-6942-46f0-965e-db991839e8e6,G_IMPACT_ANALYSIS,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0258/FDA-2011-D-0258-0002/FDA-2011-D-0258-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 335.700 Surgeons� Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure"", ""docket_id"": ""FDA-2011-D-0258"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0258-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0258/FDA-2011-D-0258-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:47:01,2025-05-28 03:53:06
a09d8b5f-e9d4-4c90-89d1-d3c1810a6f80,USA-FDA,825e7e0d-c1de-44f2-80f2-093d9476f54c,G_DETAILED_SUMMARY,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0533/FDA-2009-D-0533-0009/FDA-2009-D-0533-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application"", ""docket_id"": ""FDA-2009-D-0533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0533-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0533/FDA-2009-D-0533-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:00:19,2025-05-28 03:53:06
a0aeaf9d-3ebc-4c28-8264-f41df7939f98,USA-FDA,4d849fd0-3d33-445d-a314-70e88adb7474,G_DETAILED_SUMMARY,2025-05-20 12:08:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002/FDA-2011-D-0597-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring"", ""docket_id"": ""FDA-2011-D-0597"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0597-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:09:32,2025-05-28 03:53:06
a0ca16fc-7f1a-41a5-9a3b-80b1fb51a887,USA-FDA,7fc6f81f-6799-46e9-bfd4-d0bbc191445f,G_IMPACT_ANALYSIS,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021/FDA-2005-D-0282-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:32:02,2025-05-28 03:53:06
a0fe3f5c-3a3a-4ae8-8f59-ac3738731e4a,USA-FDA,8fc7bf90-70c0-4841-95c5-4cd33e4d8fd6,G_IMPACT_ANALYSIS,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011/FDA-1998-D-0035-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:01:36,2025-05-28 03:53:06
a11e0f6e-dc1d-4c57-bba4-4a8d4b062c54,SCHEDULED,ab2cb785-2184-4bc6-bb38-6abc6518f6a1,DEVICE_ANALYST,2025-05-23 00:00:04,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/ab2cb785-2184-4bc6-bb38-6abc6518f6a1"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:22,2025-05-28 03:53:06
a14e83dc-58ab-4bff-9df8-1f68296d2304,USA-FDA,b3479d5e-13f7-4c61-a30a-e7ddc2d076a9,G_DETAILED_SUMMARY,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2635/FDA-2016-D-2635-0269/FDA-2016-D-2635-0269-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Potential Approach for Defining Durations of Use for Medically Important Antimicrobial Drugs Intended for Use In or On Feed: A Concept Paper"", ""docket_id"": ""FDA-2016-D-2635"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2635-0269""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2635/FDA-2016-D-2635-0269"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:30:35,2025-05-28 03:53:06
a154317e-a66c-45e6-92e4-056b074ed336,USA-FDA,d5f98ac1-b1e2-44d5-9b9d-e89418c1e62f,G_MINI_SUMMARY,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002/FDA-2011-D-0376-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues"", ""docket_id"": ""FDA-2011-D-0376"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0376-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0376/FDA-2011-D-0376-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:00:11,2025-05-28 03:53:06
a15f8906-7029-4db8-b5d7-de8eb3491ea5,USA-FDA,698fde1a-8fee-4343-9133-598f4e94fab8,G_IMPACT_ANALYSIS,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0196/FDA-2009-D-0196-0002/FDA-2009-D-0196-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Arsenic"", ""docket_id"": ""FDA-2009-D-0196"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0196-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0196/FDA-2009-D-0196-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:31:10,2025-05-28 03:53:06
a16953da-5bba-4eb0-9524-4063260a1b8b,USA-FDA,21abfff5-d041-4417-bf17-3ce1e9c5dc53,G_MINI_SUMMARY,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1279/FDA-2013-D-1279-0002/FDA-2013-D-1279-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Development Tools; Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-1279"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1279-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1279/FDA-2013-D-1279-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:00:43,2025-05-28 03:53:06
a1726aa2-b23f-40c2-aefb-ba301634899c,USA-FDA,9222a663-a60c-49ac-afc4-a0794539295f,G_DETAILED_SUMMARY,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011/FDA-1997-D-0444-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance on FDA Approval of New Animal Drugs for Minor Uses and for Minor Species; Guidance Document (Revised May 29, 2008)"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:00:31,2025-05-28 03:53:06
a1e033cb-c622-4b83-adb3-57620755843d,USA-FDA,42646cc1-dbcb-444d-940f-93f150b4716b,G_DETAILED_SUMMARY,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0081/FDA-2012-D-0081-0002/FDA-2012-D-0081-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance; Investigational New Drug Applications for Positron Emission Tomography Drugs"", ""docket_id"": ""FDA-2012-D-0081"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0081-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0081/FDA-2012-D-0081-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:45:23,2025-05-28 03:53:06
a1ed9999-bea7-459c-8775-a7c75d528b12,USA-FDA,1560cdbb-509a-460b-9c1d-ea0829b38ef6,G_ACTION_ITEMS,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0081/FDA-2012-D-0081-0002/FDA-2012-D-0081-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance; Investigational New Drug Applications for Positron Emission Tomography Drugs"", ""docket_id"": ""FDA-2012-D-0081"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0081-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0081/FDA-2012-D-0081-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:45:50,2025-05-28 03:53:06
a1efbc38-bbc7-4f08-b611-1713cf31345d,SCHEDULED,14aa770c-d937-4577-9261-0be1f390ac57,DEVICE_ANALYST,2025-05-25 00:00:04,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/14aa770c-d937-4577-9261-0be1f390ac57"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:11,2025-05-28 03:53:06
a205b10f-823b-46d3-ba8f-d88689441503,USA-FDA,9af0f8bd-befc-441d-a141-dd1e04fbca1c,G_ACTION_ITEMS,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003/FDA-2008-D-0180-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Coronary Drug Eluting Stents- Nonclincal and Clinical Studies; Draft Guidance"", ""docket_id"": ""FDA-2008-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0180-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:01:01,2025-05-28 03:53:06
a20b1e44-a08a-424a-99d3-65d166a1ef5f,USA-FDA,5de86fc1-4b27-429f-aa2c-a7157f1c5380,G_FAQ,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0605/FDA-2011-D-0605-0002/FDA-2011-D-0605-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Scientific Considerations in Demonstrating Biosimilarity to Reference Product"", ""docket_id"": ""FDA-2011-D-0605"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0605-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0605/FDA-2011-D-0605-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:16:28,2025-05-28 03:53:06
a2390a73-402a-4bed-a5ab-3230c8819b90,USA-FDA,93f23018-5738-420c-a584-fa35ab454048,G_IMPACT_ANALYSIS,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0002/FDA-2011-D-0847-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Humanitarian Use Device Designations"", ""docket_id"": ""FDA-2011-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0847-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:45:50,2025-05-28 03:53:06
a266f50b-be46-40e3-a745-5eeec5774f92,USA-FDA,0f32397f-1d7a-4b50-9cba-67c633cb6d89,G_FAQ,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0035/FDA-2003-D-0035-0002/FDA-2003-D-0035-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims"", ""docket_id"": ""FDA-2003-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0035-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0035/FDA-2003-D-0035-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:02:32,2025-05-28 03:53:06
a2682a5e-f0d1-4d72-b4e6-db1d03f82aac,USA-FDA,685fa71f-72c3-4af4-a5f5-86ea8ebb7228,G_ACTION_ITEMS,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0438/FDA-2004-D-0438-0007/FDA-2004-D-0438-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Time and Extent Applications for Nonprescription Drug Products"", ""docket_id"": ""FDA-2004-D-0438"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0438-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0438/FDA-2004-D-0438-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:47:58,2025-05-28 03:53:06
a275368a-0833-42fc-96af-5f6b729ea509,USA-FDA,40ea1ff6-8480-4d5b-bc91-e952a0fc815c,G_IMPACT_ANALYSIS,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0008/FDA-2017-D-2462-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species Guidance for Industry"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:32:55,2025-05-28 03:53:06
a2ae866c-a3e3-4d3e-8128-0f3b43c0a0d7,USA-FDA,76559910-3576-42e7-9436-1bf5dc960da3,G_DETAILED_SUMMARY,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0045/FDA-2013-D-0045-0030/FDA-2013-D-0045-0030-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abuse-Deterrent Opioids-Evaluation and Labeling"", ""docket_id"": ""FDA-2013-D-0045"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0045-0030""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0045/FDA-2013-D-0045-0030"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:45:31,2025-05-28 03:53:06
a2ca4c23-d328-429a-957a-e73f8c7681f2,USA-FDA,a66ab609-80dd-4c16-b3ff-877fba75f0d7,G_ACTION_ITEMS,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610/FDA-2016-D-4414-1610-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nutrition and Supplement Facts Labels: Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals: Guidance for Industry"", ""docket_id"": ""FDA-2016-D-4414"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-4414-1610""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:15:58,2025-05-28 03:53:06
a302fe0a-6fa7-4fa8-8f0a-84b051dd14e7,USA-FDA,b4d8f7fa-3917-44e8-b4e9-5c5fe33d60c2,G_KEYWORDS,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002/FDA-2012-D-0179-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens"", ""docket_id"": ""FDA-2012-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0179-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:01:42,2025-05-28 03:53:06
a32863ef-d813-4b8c-8816-cebccdc8ec9f,USA-FDA,2ddba684-bf3b-4d07-9c77-a9c6a9678fe2,G_DETAILED_SUMMARY,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1120/FDA-2012-D-1120-0002/FDA-2012-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Vaginal Microbicides: Development for the Prevention of Human Immunodeficiency Virus Infection"", ""docket_id"": ""FDA-2012-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1120/FDA-2012-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:46:48,2025-05-28 03:53:06
a32b1bfa-d37e-4711-b71e-22923a73ccba,USA-FDA,1b071681-8975-4e59-81c6-05d3fc4de138,G_DETAILED_SUMMARY,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0592/FDA-2008-D-0592-0010/FDA-2008-D-0592-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Contents of a Complete Submission for the Evaluation ofProprietary Names - Guidance for Industry "", ""docket_id"": ""FDA-2008-D-0592"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0592-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0592/FDA-2008-D-0592-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:17:32,2025-05-28 03:53:06
a34c5aa3-963a-4a71-a3ac-a55ebe88954a,USA-FDA,804202d6-2107-4384-a5c2-fc0c061c3c3f,G_ACTION_ITEMS,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002/FDA-2011-D-0689-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; De Novo Classification Process (Evaluation of Automatic Class III Designation)"", ""docket_id"": ""FDA-2011-D-0689"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0689-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:16:05,2025-05-28 03:53:06
a365c242-442d-4203-91fa-edac2d3df754,SCHEDULED,08f08e2b-5812-47a9-a741-88e1888c58c5,DEVICE_ANALYST,2025-05-22 00:03:21,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/08f08e2b-5812-47a9-a741-88e1888c58c5"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:32,2025-05-28 03:53:06
a367b615-1943-483c-a7c6-86ec43466898,USA-FDA,b9729080-2940-418e-969e-d02251dfc20f,G_FAQ,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005/FDA-2007-D-0205-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:33:13,2025-05-28 03:53:06
a3730643-f1d7-4f6a-97c8-708342064dd0,USA-FDA,141f4a75-c6cf-4e66-8004-e48147f93d07,G_DETAILED_SUMMARY,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0589/FDA-2013-D-0589-0002/FDA-2013-D-0589-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Human Immunodeficiency Virus-1 Infection:  Developing Antiretroviral Drugs for Treatment"", ""docket_id"": ""FDA-2013-D-0589"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0589-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0589/FDA-2013-D-0589-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:01:00,2025-05-28 03:53:06
a37fe7c0-ffde-4220-a70c-971cd02fb35b,USA-FDA,b62e869d-550d-43c6-a4b3-448d6ff88157,G_IMPACT_ANALYSIS,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038/FDA-2008-D-0406-0038-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs; Frequently Asked Questions - Statement of Investigator (Form FDA 1572)"", ""docket_id"": ""FDA-2008-D-0406"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0406-0038""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:17:58,2025-05-28 03:53:06
a38a67fa-d6d5-4e63-87e7-aa88ebf48a0f,USA-FDA,81d781c9-6deb-4ac1-959b-23a95fd10a87,G_CONCISE_SUMMARY,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004/FDA-2002-D-0180-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Q1E Evaluation of Stability Data"", ""docket_id"": ""FDA-2002-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0180-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:45:12,2025-05-28 03:53:06
a39d1afb-6046-451c-96ef-8573aa7fbbd0,USA-FDA,acdae611-7831-4f7a-9157-773e96d3244a,G_IMPACT_ANALYSIS,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0586/FDA-2011-D-0586-0002/FDA-2011-D-0586-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Standards for Clinical Trial Imaging Endpoints; Draft Guidance Document"", ""docket_id"": ""FDA-2011-D-0586"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0586-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0586/FDA-2011-D-0586-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:01:49,2025-05-28 03:53:06
a3a30a61-7950-4fb8-9599-f2533918d0fd,USA-FDA,b88889b1-e061-4764-91c5-3f4acb0b9000,G_DETAILED_SUMMARY,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008/FDA-2009-D-0448-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry, MQSA Inspectors and FDA Staffl The Mammography Quality Standards Act Final Regulations: Modifications and Additions to Policy Guidance Help System #13"", ""docket_id"": ""FDA-2009-D-0448"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0448-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:02:14,2025-05-28 03:53:06
a3e3fbb5-3831-45f8-94dc-c608aa40461f,USA-FDA,1d3c9ccf-ff3b-429d-9d73-51ab32d75d33,G_DETAILED_SUMMARY,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1958/FDA-2020-D-1958-0001/FDA-2020-D-1958-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Seafood HACCP Transition Guidance"", ""docket_id"": ""FDA-2020-D-1958"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1958-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1958/FDA-2020-D-1958-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:02:43,2025-05-28 03:53:06
a43f27a5-a191-4b4e-aaf9-13f08dceb6d3,USA-FDA,91341484-039f-4e1f-a1f0-f663d7eab658,G_IMPACT_ANALYSIS,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1962/FDA-2020-D-1962-0001/FDA-2020-D-1962-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.400 Contamination of Devices Labeled as Sterile"", ""docket_id"": ""FDA-2020-D-1962"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1962-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1962/FDA-2020-D-1962-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:16:37,2025-05-28 03:53:06
a459890a-8b2e-4f33-be62-3cee951ac169,USA-FDA,3fa7fd78-bc68-463c-a4bd-0999d5c9d463,G_DETAILED_SUMMARY,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018/FDA-2012-D-1038-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:30:29,2025-05-28 03:53:06
a478d57c-d70f-4bc4-8423-47733af89128,USA-FDA,650bde3b-6809-4b85-9b5f-4e6be11426ad,G_IMPACT_ANALYSIS,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010/FDA-2011-D-0799-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components Including Source Plasma to Reduce the Risk of Transmission of Hepatitis B Virus"", ""docket_id"": ""FDA-2011-D-0799"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0799-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:02:10,2025-05-28 03:53:06
a47eb95f-6fba-4360-8267-855d29ad34ea,USA-FDA,bdde71d3-e037-42ff-96b2-0a036b27f508,G_ACTION_ITEMS,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0523/FDA-2012-D-0523-0012/FDA-2012-D-0523-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; Refuse to Accept Policy for 510(k)s"", ""docket_id"": ""FDA-2012-D-0523"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0523-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0523/FDA-2012-D-0523-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:45:59,2025-05-28 03:53:06
a48a034f-2994-4c1e-a617-d59a320dee6d,USA-FDA,0c3c9aa6-1f84-4414-bfaf-fc7e747eb8b8,G_IMPACT_ANALYSIS,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0744/FDA-2013-D-0744-0002/FDA-2013-D-0744-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Antibacterial Therapies for Patients With Unmet Medical Need for the Treatment of Serious Bacterial Diseases"", ""docket_id"": ""FDA-2013-D-0744"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0744-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0744/FDA-2013-D-0744-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:17:53,2025-05-28 03:53:06
a4f07bb1-9d3d-4459-a3b4-a5c7968f8a49,USA-FDA,18e56d81-9ba3-4722-87bf-7b9a700a6ae1,G_MINI_SUMMARY,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004/FDA-2010-D-0636-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia Burgdorferi"", ""docket_id"": ""FDA-2010-D-0636"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0636-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:15:08,2025-05-28 03:53:06
a4f84e17-81a6-40ce-b60d-f9723ac450af,SCHEDULED,6b4612e4-4eeb-4d69-bf9e-de95a82cbf96,DEVICE_ANALYST,2025-05-28 00:00:05,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/6b4612e4-4eeb-4d69-bf9e-de95a82cbf96"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:18,2025-05-28 03:53:06
a5065523-538f-4733-81fb-ace7caba13a0,USA-FDA,05e3534f-2f44-489f-8813-ab366dc3d725,G_MINI_SUMMARY,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008/FDA-2009-D-0448-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry, MQSA Inspectors and FDA Staffl The Mammography Quality Standards Act Final Regulations: Modifications and Additions to Policy Guidance Help System #13"", ""docket_id"": ""FDA-2009-D-0448"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0448-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:01:32,2025-05-28 03:53:06
a51bdbf1-7824-46b8-9cca-c298bbc8bd07,USA-FDA,27b24a81-0215-439a-aaeb-5d1cd7f8f9b9,G_IMPACT_ANALYSIS,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002/FDA-2007-D-0202-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting Improving Human Subject Protection"", ""docket_id"": ""FDA-2007-D-0202"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0202-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:02:14,2025-05-28 03:53:06
a52bf505-c7fb-41f6-8c6c-7873f313258d,USA-FDA,54548b73-5c7b-4362-bce6-fcc8210d3375,G_IMPACT_ANALYSIS,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010/FDA-2008-D-0623-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #192 Anesthetics for Companion Animals"", ""docket_id"": ""FDA-2008-D-0623"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0623-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0623/FDA-2008-D-0623-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:02:41,2025-05-28 03:53:06
a5355c79-c51c-45fe-8910-1f0d37c8b5ae,USA-FDA,300b8420-28d4-4bfd-abb7-ddcad569e23f,G_IMPACT_ANALYSIS,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012/FDA-2008-D-0610-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic"", ""docket_id"": ""FDA-2008-D-0610"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0610-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:32:38,2025-05-28 03:53:06
a5440bfe-b37e-47d7-af9d-1db5704dd6dd,USA-FDA,e63778eb-f980-4c1f-b5d5-878a7c9037c5,G_CONCISE_SUMMARY,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001/FDA-2020-D-1925-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations)"", ""docket_id"": ""FDA-2020-D-1925"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1925-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1925/FDA-2020-D-1925-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:45:46,2025-05-28 03:53:06
a55276cc-cdb3-4ac9-babd-d8763490cd4d,USA-FDA,04a9c6ad-f13c-41e7-b419-9b002f03cd31,G_IMPACT_ANALYSIS,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008/FDA-2010-D-0431-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Food and Drug Administration Staff and Tobacco Retailers on Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Revised"", ""docket_id"": ""FDA-2010-D-0431"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0431-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:45:57,2025-05-28 03:53:06
a557a76a-0f40-46e4-b820-b6a3c4001d6f,USA-FDA,9d0cbb14-ea87-47f9-8e57-1c5719501405,G_MINI_SUMMARY,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001/FDA-2020-D-1951-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on Juice HACCP Regulation (2003)"", ""docket_id"": ""FDA-2020-D-1951"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1951-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:30:43,2025-05-28 03:53:06
a594a35e-a90d-40c1-9307-55d56d7e84ff,USA-FDA,fa9b0153-7e8a-4740-a467-05dda259b8cf,G_IMPACT_ANALYSIS,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002/FDA-2012-D-1135-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidances for Industry Limiting Use of Certain Phthalates as Excipients in Center for Drug Evaluation and Research-Regulated Products"", ""docket_id"": ""FDA-2012-D-1135"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1135-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:01:51,2025-05-28 03:53:06
a5ca514f-5c16-4ab8-a3b0-446cc2cabdfd,USA-FDA,9d163360-9405-4022-b10a-90e352853893,G_ACTION_ITEMS,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022/FDA-1999-D-1875-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Extra-Label Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:02:51,2025-05-28 03:53:06
a5f90a65-f105-44ea-b210-bd3d8770ed45,USA-FDA,d408cb1d-f171-4117-988b-5ca0a64814ce,G_KEYWORDS,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001/FDA-2020-D-0367-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""External Guidance Document Submission from Turner Scientific, LLC re: Ototoxicity: Nonclinical Evaluation During Drug Development"", ""docket_id"": ""FDA-2020-D-0367"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-0367-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:33,2025-05-28 03:53:06
a6170423-42f0-4d2d-9985-f514efb1bd3d,USA-FDA,1223475e-0971-48fd-a27e-8033d436f485,G_CONCISE_SUMMARY,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002/FDA-2007-D-0202-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting Improving Human Subject Protection"", ""docket_id"": ""FDA-2007-D-0202"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0202-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:01:28,2025-05-28 03:53:06
a61fb74e-e8c5-4147-bd51-e79c8f7098ea,USA-FDA,20651b03-4463-4fbb-9a0b-6c4c282ee0f3,G_CONCISE_SUMMARY,2025-05-20 12:08:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002/FDA-2011-D-0597-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring"", ""docket_id"": ""FDA-2011-D-0597"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0597-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:09:11,2025-05-28 03:53:06
a646c008-6adc-4a6f-a0d1-82040e521b37,USA-FDA,1a957d02-3b24-49d4-8148-7e49af157969,G_ACTION_ITEMS,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4090/FDA-1999-D-4090-0005/FDA-1999-D-4090-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and for FDA Reviewers Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer"", ""docket_id"": ""FDA-1999-D-4090"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4090-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4090/FDA-1999-D-4090-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:32:12,2025-05-28 03:53:06
a664b24d-62c9-418e-a740-d96e05574642,USA-FDA,185330ab-09f4-4b3f-a0f1-b9b9f7993025,G_IMPACT_ANALYSIS,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-D-0621/FDA-2021-D-0621-0001/FDA-2021-D-0621-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #50 Target Animal and Human Food Safety, Drug Efficacy, Environmental and Manufacturing Studies for Teat Antiseptic Products"", ""docket_id"": ""FDA-2021-D-0621"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-D-0621-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-D-0621/FDA-2021-D-0621-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:01:23,2025-05-28 03:53:06
a6b30886-daf5-4b20-ae70-ef1a553c36ef,USA-FDA,ccd09bd4-bcdf-45a7-9fcf-8646da6824c0,G_IMPACT_ANALYSIS,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0429/FDA-2012-D-0429-0003/FDA-2012-D-0429-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Investigators Meetings with Industry and Investigators on the Research and Development of Tobacco Products"", ""docket_id"": ""FDA-2012-D-0429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0429-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0429/FDA-2012-D-0429-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:00:55,2025-05-28 03:53:06
a6cd0b7c-33c5-430f-974e-d9aefef124fc,USA-FDA,90e71210-93b8-4aff-93af-357889c26c9c,G_ACTION_ITEMS,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0031/FDA-2006-D-0031-0006/FDA-2006-D-0031-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Frequently Asked Questions About Medical Devices:  Guidance For IRBs, Clinical Investigators, and Sponsors"", ""docket_id"": ""FDA-2006-D-0031"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0031-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0031/FDA-2006-D-0031-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:16:27,2025-05-28 03:53:06
a7204f76-47a9-42fe-95b4-57788f40d662,USA-FDA,c7ef287c-4859-4943-b44a-d616eb3de041,G_IMPACT_ANALYSIS,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002/FDA-2008-D-0576-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sponsors, Clinical Investigators, and IRBs - Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials"", ""docket_id"": ""FDA-2008-D-0576"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0576-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:16:56,2025-05-28 03:53:06
a72af07b-de8f-4c36-87a6-a76c5b9564be,QUEUE,394e89ad-3f57-4c4a-8883-f5338eb92d35,G_TRANSLATE,2025-05-29 21:45:06,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""FDA-2008-N-0567-0011_content.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/394e89ad-3f57-4c4a-8883-f5338eb92d35/FDA-2008-N-0567-0011_content.pdf.pdf"", ""doc_title"": ""FDA-2008-N-0567-0011_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/394e89ad-3f57-4c4a-8883-f5338eb92d35"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 21:45:09,2025-05-29 21:45:09
a73a4c60-0f28-4bac-a82a-8a813d4984f9,USA-FDA,ea5317b6-c962-4aac-9818-368be7a76d06,G_IMPACT_ANALYSIS,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-N-0083/FDA-1999-N-0083-0015/FDA-1999-N-0083-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Availability: Reproductive and Developmental Toxicities - Integrating Study Results to Assess Concerns"", ""docket_id"": ""FDA-1999-N-0083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-N-0083-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-N-0083/FDA-1999-N-0083-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:47:14,2025-05-28 03:53:06
a73c9c32-0cba-4460-9218-66b646ff9219,USA-FDA,2459de9a-2ac1-466c-810b-9fd11954917f,G_DETAILED_SUMMARY,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0044/FDA-2009-D-0044-0009/FDA-2009-D-0044-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis "", ""docket_id"": ""FDA-2009-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0044-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0044/FDA-2009-D-0044-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:01:32,2025-05-28 03:53:06
a746e01c-2add-4579-a4f8-e483d88d8666,USA-FDA,1e5b3b1c-b4d5-4530-8b76-4effbb51393a,G_FAQ,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002/FDA-2013-D-0616-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0616-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:33:08,2025-05-28 03:53:06
a75c004d-a551-4de9-bcae-c2101e7d7e35,USA-FDA,37427c75-214c-4899-8908-74ceedabdb40,G_FAQ,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024/FDA-2011-D-0577-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications  - Guidance"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:32:20,2025-05-28 03:53:06
a7a5515f-8b0e-494b-81e3-3acd7f6ef9bf,SCHEDULED,a80011fb-c242-4664-8dae-58bd9049e7d2,FDA_ALERT,2025-05-21 20:33:25,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/a80011fb-c242-4664-8dae-58bd9049e7d2"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:35,2025-05-28 03:53:06
a7c97bf9-8e60-4bba-a209-b695a6d92332,SCHEDULED,7b2c88c2-78ce-4d68-b7c0-fc0eae934a48,DEVICE_ANALYST,2025-05-21 20:33:25,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/7b2c88c2-78ce-4d68-b7c0-fc0eae934a48"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:26,2025-05-28 03:53:06
a7f7e2c1-7b98-49f2-acf7-948581066f35,USA-FDA,6d0ac235-848b-4b6a-8b2c-8d1ba1553782,G_ACTION_ITEMS,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007/FDA-2007-D-0149-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff Class II Special Controls Guidance Document: Electrocardiograph Electrodes"", ""docket_id"": ""FDA-2007-D-0149"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0149-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0149/FDA-2007-D-0149-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:32:10,2025-05-28 03:53:06
a84f0138-a8a7-4a06-8088-516f54212c8e,USA-FDA,2e95e148-f0a9-4c2d-a376-f04363379ded,G_ACTION_ITEMS,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021/FDA-2005-D-0282-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:31:54,2025-05-28 03:53:06
a86e51f0-4142-459f-9113-bdab6ea9283e,USA-FDA,2e4d4e97-40a4-4ad4-b0d6-729ea5a86f45,G_ACTION_ITEMS,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006/FDA-2010-D-0500-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information"", ""docket_id"": ""FDA-2010-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0500-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:31,2025-05-28 03:53:06
a895387d-0464-4f92-9fd3-6038253a6f9e,USA-FDA,3f5a9668-702c-4b6d-a172-1443dafa4249,G_KEYWORDS,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004/FDA-2010-D-0636-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia Burgdorferi"", ""docket_id"": ""FDA-2010-D-0636"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0636-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:15:35,2025-05-28 03:53:06
a8a0a917-4a82-4378-ba63-8253f06c3a5a,USA-FDA,e4202e0c-45a0-4f84-9aa8-6f9aa8e8ab1f,G_ACTION_ITEMS,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003/FDA-2006-D-0231-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds"", ""docket_id"": ""FDA-2006-D-0231"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0231-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:01:09,2025-05-28 03:53:06
a8bd81d9-727e-4015-9e60-b3d27f87657d,SCHEDULED,92d77bc1-d60b-4dfd-873a-dfb52b489ad6,FDA_ALERT,2025-05-30 00:00:04,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/92d77bc1-d60b-4dfd-873a-dfb52b489ad6"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:14,2025-05-30 00:00:14
a8d62dcb-3377-40cb-8553-773f18fd38a2,USA-FDA,4dfa1f18-c4ee-4af0-a2e6-0059b229ab5e,G_ACTION_ITEMS,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0563/FDA-1996-N-0270-0563-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations"", ""docket_id"": ""FDA-1996-N-0270"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1996-N-0270-0563""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0563"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:30:53,2025-05-28 03:53:06
a9127156-d369-4066-9a20-d5da38e078c1,USA-FDA,1f31f9f7-b338-490f-8e61-ed58a3a1c2d0,G_DETAILED_SUMMARY,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0199/FDA-2008-D-0199-0002/FDA-2008-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""E15 Pharmacogenomics Definitions and Sample Coding"", ""docket_id"": ""FDA-2008-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0199/FDA-2008-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:32:04,2025-05-28 03:53:06
a913a8f0-6c7a-4799-a6c5-41e55b587f3c,SCHEDULED,56c880cb-7e34-467a-b24a-16a47b1aab78,DEVICE_ANALYST,2025-06-01 00:00:04,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/56c880cb-7e34-467a-b24a-16a47b1aab78"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:11,2025-06-01 00:00:11
a9190b74-ed86-4883-ab9d-201e18b67a30,USA-FDA,1a11d5bc-6cf6-4597-9539-45b9192f6a28,G_KEYWORDS,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002/FDA-2012-D-0307-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Revised Preventive Measures to Reduce Possible Risk of Transmission of Creutzfeldt-Jakob Disease, etc."", ""docket_id"": ""FDA-2012-D-0307"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0307-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:31:36,2025-05-28 03:53:06
a9318c6f-3cce-4b94-9fd5-fa64ca3ef1c6,USA-FDA,ccf9c2ec-f83e-4830-ada5-b267626eb451,G_MINI_SUMMARY,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002/FDA-2012-D-0022-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Direct-to-Consumer Television Advertisements, etc."", ""docket_id"": ""FDA-2012-D-0022"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0022-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:30:07,2025-05-28 03:53:06
a93eb368-8460-4178-b55b-7f7727522869,USA-FDA,52a720c3-2feb-4308-9aa5-b20039eb0b1c,G_KEYWORDS,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002/FDA-1997-D-0380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation; Guidance"", ""docket_id"": ""FDA-1997-D-0380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:31:38,2025-05-28 03:53:06
a951aa75-e607-4291-9ebc-ba97eeb9721c,USA-FDA,4d282644-d46d-40b6-9238-6e9cbd40f9d7,G_ACTION_ITEMS,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0652/FDA-2011-D-0652-0002/FDA-2011-D-0652-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff The 510(k) Program Evaluating Substantial Equivalence in Premarket Notifications [510(k)]"", ""docket_id"": ""FDA-2011-D-0652"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0652-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0652/FDA-2011-D-0652-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:46:10,2025-05-28 03:53:06
a99d02d2-b847-41a4-bdad-d79014a85a73,USA-FDA,0726b29c-6658-472e-b70a-cf05ab254c64,G_ACTION_ITEMS,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002/FDA-2014-D-1351-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Flow Cytometric Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1351"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1351-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:02:52,2025-05-28 03:53:06
a9a11872-35a4-45d7-a1d3-78aeaa291168,USA-FDA,a1a061a1-970b-4749-be8c-aa7252b10b75,G_DETAILED_SUMMARY,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0509/FDA-2010-D-0509-0002/FDA-2010-D-0509-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Enforcement Policy - OTC Sunscreen Drug Products Marketed Without an Approved Application"", ""docket_id"": ""FDA-2010-D-0509"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0509-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0509/FDA-2010-D-0509-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:01:14,2025-05-28 03:53:06
a9a6941f-070a-4936-a142-1844ee0f80c0,USA-FDA,29d386d7-6f81-4445-aa38-918c9bedd29b,G_MINI_SUMMARY,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0081/FDA-2012-D-0081-0002/FDA-2012-D-0081-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance; Investigational New Drug Applications for Positron Emission Tomography Drugs"", ""docket_id"": ""FDA-2012-D-0081"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0081-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0081/FDA-2012-D-0081-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:45:08,2025-05-28 03:53:06
a9a8e48f-46c3-4cf1-acba-456a89ea5522,USA-FDA,cfcc323d-78a5-45cc-a594-308f749adc7b,G_MINI_SUMMARY,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008/FDA-2010-D-0431-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Food and Drug Administration Staff and Tobacco Retailers on Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Revised"", ""docket_id"": ""FDA-2010-D-0431"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0431-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:45:10,2025-05-28 03:53:06
a9d606a7-c33e-4cfa-8242-eaa0ed2b1b8e,USA-FDA,8bc539ba-8a2f-4e36-b256-ceb04391b171,G_ACTION_ITEMS,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0166/FDA-2010-D-0166-0006/FDA-2010-D-0166-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods (VICH GL-48)"", ""docket_id"": ""FDA-2010-D-0166"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0166-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0166/FDA-2010-D-0166-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:16:13,2025-05-28 03:53:06
a9f32ffe-5f17-46d4-88b2-55786f6842b5,USA-FDA,624e0acd-9b78-44ef-ad65-8c0685e2278f,G_ACTION_ITEMS,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0586/FDA-2011-D-0586-0002/FDA-2011-D-0586-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Standards for Clinical Trial Imaging Endpoints; Draft Guidance Document"", ""docket_id"": ""FDA-2011-D-0586"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0586-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0586/FDA-2011-D-0586-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:01:40,2025-05-28 03:53:06
a9f405db-0353-4e56-bfce-5942aa357e33,USA-FDA,21073dbf-c304-48d1-bc98-47ac84e3cc87,G_ACTION_ITEMS,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0169/FDA-2013-D-0169-0002/FDA-2013-D-0169-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Review Staff: Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling"", ""docket_id"": ""FDA-2013-D-0169"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0169-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0169/FDA-2013-D-0169-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:45:39,2025-05-28 03:53:06
a9f75b54-ec0e-4a1e-a767-925435b5abc5,USA-FDA,4255c3e7-6217-4c61-a1f8-21b4df676ad5,G_MINI_SUMMARY,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029/FDA-2009-D-0179-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0179-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:31:28,2025-05-28 03:53:06
a9fe3fa6-f0be-4c99-a3f6-0e3a6a91a52d,SCHEDULED,548c8799-0063-4b2f-89f8-b30b3bc1334a,DEVICE_ANALYST,2025-05-27 00:00:04,17,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,86583d6a-2c86-4f76-9cb3-2bc933de2ebc,"{""user_id"": 127, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""weekly"", ""last_name"": ""Mandadapu"", ""user_guid"": ""86583d6a-2c86-4f76-9cb3-2bc933de2ebc"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""mandadapu.nandakishore@gmail.com"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/86583d6a-2c86-4f76-9cb3-2bc933de2ebc/AGENTS/device_analyst/548c8799-0063-4b2f-89f8-b30b3bc1334a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:28,2025-05-28 03:53:06
aa157af1-ea27-440b-92fe-a9dd7d2c6160,USA-FDA,41f4d3fa-577d-4e8d-8991-04430b701f54,G_IMPACT_ANALYSIS,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029/FDA-2009-D-0179-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0179-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:32:43,2025-05-28 03:53:06
aa1b6e2b-71e5-4a26-afe7-75d6c3497edf,USA-FDA,5f5497c4-f5bb-47d2-b128-9969424f01d1,G_FAQ,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016/FDA-2014-D-1399-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:15:29,2025-05-28 03:53:06
aa2395ee-3abd-4728-8827-9b3fe3256960,USA-FDA,72fefda6-468e-401f-b983-936c6c491c07,G_IMPACT_ANALYSIS,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0009/FDA-2011-D-0620-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2011-D-0620"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0620-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:00:45,2025-05-28 03:53:06
aa3b266a-1790-4d37-b2b0-83b1104f98cc,QUEUE,db4d9f49-4a89-4354-a229-223c7108c88e,G_IMPACT_ANALYSIS_USER,2025-05-20 10:43:13,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__doc_title__"": ""FDA-2023-N-4225-0001_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/db4d9f49-4a89-4354-a229-223c7108c88e/SRC/db4d9f49-4a89-4354-a229-223c7108c88e.pdf"", ""doc_title"": ""FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/db4d9f49-4a89-4354-a229-223c7108c88e/DEST/impact_analysis.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:43:23,2025-05-28 03:53:06
aa4d5724-3240-4413-927f-8a14b6e37450,USA-FDA,92a56874-55f9-4713-989d-72a1f2206c0c,G_MINI_SUMMARY,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-N-0464/FDA-2005-N-0464-0231/FDA-2005-N-0464-0231-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guideline re Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Drug Establishment Registration and Drug Listing; Availability"", ""docket_id"": ""FDA-2005-N-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-N-0464-0231""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-N-0464/FDA-2005-N-0464-0231"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:17:03,2025-05-28 03:53:06
aa553ecb-12a3-42d3-af5f-78f1ee67a80b,USA-FDA,56b4fa3d-657e-4c27-ac61-cfa997cdebbc,G_ACTION_ITEMS,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0643/FDA-2010-D-0643-0092/FDA-2010-D-0643-0092-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Electronic Source Data in Clinical Investigations"", ""docket_id"": ""FDA-2010-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0643-0092""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0643/FDA-2010-D-0643-0092"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:00:51,2025-05-28 03:53:06
aa56e9a0-4207-427e-84c7-53c62650e00d,USA-FDA,76680ece-6624-4c58-8086-289aa4efd9e1,G_IMPACT_ANALYSIS,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002/FDA-2009-D-0006-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""S9 Nonclinical Evaluation for Anticancer Pharmaceuticals - Draft Guidance"", ""docket_id"": ""FDA-2009-D-0006"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0006-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:01:00,2025-05-28 03:53:06
aa6d44fa-2693-4bc5-9e5d-39a81fd6e518,USA-FDA,d7591ce0-d74e-413b-b04b-4d59895513b0,G_DETAILED_SUMMARY,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002/FDA-2017-D-2462-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:01:15,2025-05-28 03:53:06
aa6f6fe7-aea2-43c5-b99a-b3f785768ef6,USA-FDA,fffb3ef2-5e83-4d56-830e-db604d69f362,G_ACTION_ITEMS,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0005/FDA-2007-D-0433-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bieoquivalence Recommendations for Specific Products"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:01:03,2025-05-28 03:53:06
aa801a74-19b7-491a-b3a2-71340c958841,USA-FDA,ef3cbe1a-1569-4013-8e77-dce3f01c96b1,G_IMPACT_ANALYSIS,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002/FDA-2014-N-1082-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Multiplexed Microbiological/Medical Countermeasure In Vitro \nNucleic Acid Based Diagnostic Devices; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-N-1082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1082-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:01:58,2025-05-28 03:53:06
aabc1abc-1027-44ad-a8ef-49efc2dcf488,SCHEDULED,b0bfaaa8-5469-4415-baee-b1014bf4f0b9,DEVICE_ANALYST,2025-05-27 17:45:03,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/b0bfaaa8-5469-4415-baee-b1014bf4f0b9"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 17:45:05,2025-05-28 03:53:06
aaceff2b-deb1-40c2-a7d4-5ce2a1be2da9,USA-FDA,0a3b3b24-4a2d-4607-87a9-94647764b387,G_DETAILED_SUMMARY,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001/FDA-2020-D-1608-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data"", ""docket_id"": ""FDA-2020-D-1608"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1608-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:46:46,2025-05-28 03:53:06
aacf45d5-bb78-40db-b6b6-072b46d37b8f,QUEUE,2890710a-4869-4bc5-99a5-056aa73b60f0,G_MINI_SUMMARY_USER,2025-05-20 10:45:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__doc_title__"": ""FDA-1983-P-0373-0002_attachment_1.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/2890710a-4869-4bc5-99a5-056aa73b60f0/SRC/2890710a-4869-4bc5-99a5-056aa73b60f0.pdf"", ""doc_title"": ""FDA-1983-P-0373-0002_attachment_1.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/2890710a-4869-4bc5-99a5-056aa73b60f0/DEST/mini_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:45:42,2025-05-28 03:53:06
aae03c93-dc6f-4eac-93dc-682e4129ee0c,SCHEDULED,aa342108-d738-4caf-b5cc-49f22bbe0484,DEVICE_ANALYST,2025-05-25 00:00:04,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": """", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": """", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/aa342108-d738-4caf-b5cc-49f22bbe0484"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:26,2025-05-28 03:53:06
aafb4a2b-bad1-4e3e-8df6-1a7e0bf740ed,USA-FDA,2dbb154f-9149-4580-8efb-d5d8dfec8fd7,G_DETAILED_SUMMARY,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002/FDA-2011-D-0469-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and the Food and Drug Administration Staff: Applying Human Factors and Usability Engineering to Optimize Medical Device Design - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0469"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0469-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:21,2025-05-28 03:53:06
ab1ab7e3-553f-445c-a44e-b8f3dc0a91c1,USA-FDA,91496ce4-7233-47f7-a278-2a9e181ef4aa,G_FAQ,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010/FDA-2004-D-0500-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Consumer-Directed Broadcast Advertising of Restricted Devices; Draft Guidance for Industry"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:02:05,2025-05-28 03:53:06
ab3269bd-0ac5-408a-8450-32c02b2bee60,USA-FDA,575b3cad-c201-4e5d-a51f-97ece479cca1,G_FAQ,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0358/FDA-2014-D-1525-0358-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application"", ""docket_id"": ""FDA-2014-D-1525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1525-0358""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0358"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:02:00,2025-05-28 03:53:06
ab4f95a8-941a-4c18-8707-3038496d25da,USA-FDA,5de29e2b-62fa-40bd-8811-b437baf22bc5,G_KEYWORDS,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005/FDA-2011-D-0643-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; What You Need to Know About Administrative Detention of Foods; Small Entity Compliance Guide; Final Guidance"", ""docket_id"": ""FDA-2011-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0643-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:31:40,2025-05-28 03:53:06
ab503b6b-01d7-4e27-974a-4aee161fa280,QUEUE,f346d913-3ebe-4fa6-9187-d2e0342d5413,G_TRANSLATE,2025-05-30 04:00:15,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""c_986569 (4).pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/f346d913-3ebe-4fa6-9187-d2e0342d5413/c_986569 (4).pdf.pdf"", ""doc_title"": ""c_986569 (4).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/f346d913-3ebe-4fa6-9187-d2e0342d5413"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 04:00:20,2025-05-30 04:00:20
ab758557-77a4-4b4e-a8f6-a0c27c85b8ab,USA-FDA,916df50b-4969-406b-be7e-a0a86067bf1e,G_IMPACT_ANALYSIS,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0391/FDA-2008-D-0391-0014/FDA-2008-D-0391-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Submission of Documentation: Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes"", ""docket_id"": ""FDA-2008-D-0391"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0391-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0391/FDA-2008-D-0391-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:46:37,2025-05-28 03:53:06
ab8e7ba3-f32e-4503-9121-bb1a6d31237f,USA-FDA,c1fcb199-60e5-445a-b4c2-e28680e5e3bf,G_ACTION_ITEMS,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001/FDA-2018-D-0398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions Guidance for Industry and\nFood and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:01:24,2025-05-28 03:53:06
abacd158-abde-4bcd-8348-ff988cc701b6,USA-FDA,ad3edd68-5cd6-4419-86c9-7aa5accdd3d9,G_ACTION_ITEMS,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0490/FDA-2011-D-0490-0002/FDA-2011-D-0490-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that are Color Additives; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0490-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0490/FDA-2011-D-0490-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:16:53,2025-05-28 03:53:06
abb92438-6ca2-4a5c-87aa-dca8ee591788,USA-FDA,14745d49-632e-4dfb-ba22-2bcd59a6d85e,G_FAQ,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0024/FDA-2011-D-0024-0012/FDA-2011-D-0024-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Size of Beads in Drug Products Labeled for Sprinkle"", ""docket_id"": ""FDA-2011-D-0024"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0024-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0024/FDA-2011-D-0024-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:31:35,2025-05-28 03:53:06
abc4a673-96e7-459a-a28b-1d86be4bbdcc,SCHEDULED,df86b242-fa11-49de-b7b5-c785106d36ed,FDA_ALERT,2025-06-01 00:00:04,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/df86b242-fa11-49de-b7b5-c785106d36ed"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:25,2025-06-01 00:00:25
abcf7b2b-1460-478c-930c-cf9eba3de0c1,USA-FDA,5b3bd5fa-d874-49e5-be90-3384bd2ff83c,G_IMPACT_ANALYSIS,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002/FDA-2013-D-0349-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format"", ""docket_id"": ""FDA-2013-D-0349"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0349-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:01:56,2025-05-28 03:53:06
ac2524db-24e7-4423-b6aa-a80e928c40ea,USA-FDA,f6a7be32-e72c-4bb2-8239-91d3f2049143,G_CONCISE_SUMMARY,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004/FDA-2007-D-0375-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Acute Bacterial Sinusitis; Developing Drugs for Treatment"", ""docket_id"": ""FDA-2007-D-0375"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0375-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:30:12,2025-05-28 03:53:06
ac5b4f89-24ba-4d7c-b17a-1da856c0130f,USA-FDA,edf9c321-4ce0-4697-89db-93216aaec54d,G_ACTION_ITEMS,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0487/FDA-2007-D-0487-0005/FDA-2007-D-0487-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec 110.310 Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002"", ""docket_id"": ""FDA-2007-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0487-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0487/FDA-2007-D-0487-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:01:17,2025-05-28 03:53:06
ac7c5c3d-ae68-4bda-971f-7bd90a74652f,USA-FDA,392c0010-f0f1-4d41-9fc7-70b15eb36417,G_CONCISE_SUMMARY,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012/FDA-2003-D-0186-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for InduGuidance for Industry: Cosmetics Processors and Transporters of Cosmetics Security Preventive Measures Guidance"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:00:13,2025-05-28 03:53:06
aca067b9-ee87-4160-9282-975f9d502ec3,USA-FDA,de76a6d8-67ea-4bd2-91f2-e3bfe27cebbb,G_MINI_SUMMARY,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002/FDA-1997-D-0380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation; Guidance"", ""docket_id"": ""FDA-1997-D-0380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:31:10,2025-05-28 03:53:06
aca62bb2-044f-46a4-90df-e371fe35f077,Queue,fa34754c-fcbb-42ab-a16d-3db2ab726897,G_CONCISE_SUMMARY_USER,2025-05-30 09:13:47,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/fa34754c-fcbb-42ab-a16d-3db2ab726897/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/fa34754c-fcbb-42ab-a16d-3db2ab726897"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-30 03:43:53,2025-05-30 03:43:53
acc9a424-c1a7-4c9d-a693-ae6e858ee7be,USA-FDA,5443c035-d45d-4449-b3ae-ce9164c4b4f8,G_MINI_SUMMARY,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022/FDA-2005-D-0282-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Antiviral Product Development - Conducting and Submitting Virology Studies to the Agency Guidance for Submitting Influenza Resistance Data"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:45:52,2025-05-28 03:53:06
acdfa6e2-dc13-4442-97b3-17153751b978,USA-FDA,ef8d3702-9a02-4c8f-bb9a-bdc0bd305ffc,G_KEYWORDS,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001/FDA-2020-D-1397-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Q3A Impurities in New Drug Substances"", ""docket_id"": ""FDA-2020-D-1397"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1397-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:45:54,2025-05-28 03:53:06
ace29d73-e597-4110-a93a-83dec740c7db,SCHEDULED,9d676ff4-6ec5-473d-bede-9e6099cf6d2c,DEVICE_ANALYST,2025-06-02 00:00:04,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/9d676ff4-6ec5-473d-bede-9e6099cf6d2c"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:23,2025-06-02 00:00:23
ad19407d-71b9-4c61-b863-086e56f778c3,USA-FDA,e48a4b73-6f43-4b16-b46a-7f4518d22737,G_MINI_SUMMARY,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0009/FDA-2011-D-0620-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2011-D-0620"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0620-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:00:09,2025-05-28 03:53:06
ad1d495a-ba4e-4289-9d76-70a8c2255a05,USA-FDA,f8e85aeb-c662-4e5a-9b16-d7cd7a3688bd,G_FAQ,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012/FDA-2016-D-1533-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma - Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:47:45,2025-05-28 03:53:06
ad549580-fe5a-4428-a0a8-0ace970330bf,USA-FDA,8b4049ce-b1d9-480e-8442-6d15f497b7f3,G_ACTION_ITEMS,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001/FDA-2020-D-1444-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Safety Information - FDA's Communication to the Public"", ""docket_id"": ""FDA-2020-D-1444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1444-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1444/FDA-2020-D-1444-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:16:51,2025-05-28 03:53:06
ad641d4f-d316-448f-a346-c43f3a49c49c,USA-FDA,835a1302-fbfb-4b3f-8354-b1925641e824,G_IMPACT_ANALYSIS,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0125/FDA-2013-N-0125-0025/FDA-2013-N-0125-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Alternative to Certain Prescription Device Labeling Requirements"", ""docket_id"": ""FDA-2013-N-0125"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-0125-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0125/FDA-2013-N-0125-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:00:36,2025-05-28 03:53:06
ad8955b7-50bc-4f6b-a538-1a19121fb00f,USA-FDA,ca70b795-0e1b-482f-a509-76c4b2b5051c,G_ACTION_ITEMS,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004/FDA-2002-D-0180-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Q1E Evaluation of Stability Data"", ""docket_id"": ""FDA-2002-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0180-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:46:12,2025-05-28 03:53:06
ad9c2d63-8e5d-4519-87e4-10b285a7f3dd,USA-FDA,e6778209-cb2f-42ec-af8c-fc84c3f92387,G_MINI_SUMMARY,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0031/FDA-2007-D-0031-0005/FDA-2007-D-0031-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Integrated Summaries of Effectiveness and Safety:  Location Within the Common Technical Document"", ""docket_id"": ""FDA-2007-D-0031"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0031-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0031/FDA-2007-D-0031-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:00:09,2025-05-28 03:53:06
adaa1c2d-afeb-47a9-9cb5-d6fbcbcb0cae,USA-FDA,52e7f513-cfaa-45ff-83e8-37bbdf001a55,G_DETAILED_SUMMARY,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0024/FDA-2011-D-0024-0012/FDA-2011-D-0024-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Size of Beads in Drug Products Labeled for Sprinkle"", ""docket_id"": ""FDA-2011-D-0024"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0024-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0024/FDA-2011-D-0024-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:31:22,2025-05-28 03:53:06
adaac445-2a24-49f3-a964-2a430379d7b8,USA-FDA,c0be4887-9d98-4719-95ea-5cc9b2d1e2bf,G_CONCISE_SUMMARY,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002/FDA-2018-D-0740-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk Guidance for Industry"", ""docket_id"": ""FDA-2018-D-0740"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0740-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:30:21,2025-05-28 03:53:06
adaf4446-7869-4539-9d7e-6f343f66fc6e,SCHEDULED,4dff1b36-c95a-4950-bf26-1fdffce56fe0,DEVICE_ANALYST,2025-05-27 00:00:04,32,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/device_analyst/4dff1b36-c95a-4950-bf26-1fdffce56fe0"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:30,2025-05-28 03:53:06
adc74712-2e4f-4852-9221-78904aae2cf3,USA-FDA,b24abb4f-0f62-4be6-9a6c-b8a9c363a49d,G_ACTION_ITEMS,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002/FDA-2011-D-0730-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff; Class II Special Controls Guidance Documents: In Vitro Diagnostic Devices for Yersinia Species Detection"", ""docket_id"": ""FDA-2011-D-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0730-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:00:54,2025-05-28 03:53:06
ade32f79-bf6e-43c7-abfb-270f32add3a3,USA-FDA,b2b5931e-f8f9-493e-b825-3033109161e9,G_FAQ,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1978/FDA-2020-D-1978-0001/FDA-2020-D-1978-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects"", ""docket_id"": ""FDA-2020-D-1978"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1978-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1978/FDA-2020-D-1978-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:15:56,2025-05-28 03:53:06
adff6797-0718-4776-9b56-df9a4fac7a93,USA-FDA,fa62ad0d-f4ef-4c5d-816e-c0dd466abca4,G_FAQ,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011/FDA-2001-D-0137-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children"", ""docket_id"": ""FDA-2001-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0137-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:32:34,2025-05-28 03:53:06
ae074220-4b1c-473c-83c8-5065c04b9fce,USA-FDA,f50f7366-c003-4f77-94be-e4642c8232b5,G_DETAILED_SUMMARY,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0476/FDA-2011-D-0476-0010/FDA-2011-D-0476-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Enforcement Policy for Premarket Notification Requirements for Certain In Vitro Diagnostic and Radiology Devices"", ""docket_id"": ""FDA-2011-D-0476"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0476-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0476/FDA-2011-D-0476-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:31:26,2025-05-28 03:53:06
ae11e7f1-eb5e-4628-961e-4c4c7df3a7c6,USA-FDA,9f8c1613-2c15-4622-b98c-4f0104040469,G_FAQ,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001/FDA-2016-D-1533-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:02:43,2025-05-28 03:53:06
ae620f34-fe75-4fbe-8df3-478aad59e536,USA-FDA,5b4fd8d7-e444-4de4-b4b5-595e8d5ae345,G_ACTION_ITEMS,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015/FDA-2010-D-0281-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; ��Harmful and Potentially Harmful Constituents� in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act�"", ""docket_id"": ""FDA-2010-D-0281"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0281-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:23,2025-05-28 03:53:06
ae80c7b1-c992-451b-8e7c-c2de0c24a4e6,USA-FDA,31fdbc30-69c9-4a48-99d6-edb648980c3d,G_CONCISE_SUMMARY,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002/FDA-1997-D-0444-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""FDA Approval of Animal Drugs for Minor Uses and Minor Species; Draft Guidance Document"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:48,2025-05-28 03:53:06
aed35f56-9848-4391-a7eb-cadfcfd82ff0,USA-FDA,9a49491a-7a82-4c36-a8ad-7c358ffa4ce2,G_MINI_SUMMARY,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0080/FDA-2012-D-0080-0005/FDA-2012-D-0080-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Oversight of Positron Emission Tomography Drug Products - Questions and Answers"", ""docket_id"": ""FDA-2012-D-0080"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0080-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0080/FDA-2012-D-0080-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:31:17,2025-05-28 03:53:06
aed56ae0-a816-411a-8e2a-a09ca0a83c76,USA-FDA,4026b71f-27b6-4274-87ff-2429d7a7cc4e,G_MINI_SUMMARY,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0017/FDA-2017-D-6526-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6526"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6526-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:45:55,2025-05-28 03:53:06
af13b9ac-f4c0-417b-be8e-09231c7a925a,USA-FDA,db99d0bd-8827-49d5-a34d-07943f697285,G_IMPACT_ANALYSIS,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0447/FDA-2013-D-0447-0002/FDA-2013-D-0447-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Charging for Investigational Drugs Under an Investigational New Drug Application-Questions and Answers"", ""docket_id"": ""FDA-2013-D-0447"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0447-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0447/FDA-2013-D-0447-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:30:40,2025-05-28 03:53:06
af49cef1-0cdb-4b5a-b0b2-abd2bd1ef962,USA-FDA,7fcdd8db-beed-4feb-addc-ce6c704fd3a4,G_FAQ,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0081/FDA-2012-D-0081-0002/FDA-2012-D-0081-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance; Investigational New Drug Applications for Positron Emission Tomography Drugs"", ""docket_id"": ""FDA-2012-D-0081"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0081-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0081/FDA-2012-D-0081-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:45:40,2025-05-28 03:53:06
af572b64-3804-461d-b9e9-b53e853c7c71,USA-FDA,06f788ac-45db-42f4-9314-9c33d98b091e,G_IMPACT_ANALYSIS,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002/FDA-2009-D-0354-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Pharmaceutical Components at Risk for Melamine Contamination"", ""docket_id"": ""FDA-2009-D-0354"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0354-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:02:46,2025-05-28 03:53:06
af619d83-f087-4a5f-a485-6b6fa75ad0cd,USA-FDA,d5485a50-f199-4248-9bb2-40051434d341,G_FAQ,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010/FDA-2011-D-0799-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components Including Source Plasma to Reduce the Risk of Transmission of Hepatitis B Virus"", ""docket_id"": ""FDA-2011-D-0799"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0799-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:01:54,2025-05-28 03:53:06
af77e871-111c-4b1c-a36c-9e7d46f3d0f0,USA-FDA,9d61aa6e-cf87-4457-8799-01ac746a8a44,G_FAQ,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0563/FDA-1996-N-0270-0563-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations"", ""docket_id"": ""FDA-1996-N-0270"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1996-N-0270-0563""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0563"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:30:49,2025-05-28 03:53:06
af793898-6567-425e-b4ad-e2c75d24aed4,SCHEDULED,3c49d399-28f6-4466-b057-b5ea315ca1fe,FDA_ALERT,2025-05-27 00:00:04,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/3c49d399-28f6-4466-b057-b5ea315ca1fe"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:17,2025-05-28 03:53:06
afa0b26f-a684-4cd5-966e-6bd753dd3958,USA-FDA,2a033560-1d5e-409b-b394-9468adbb4867,G_CONCISE_SUMMARY,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016/FDA-2013-D-0369-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in\nPharmaceuticals to Limit Potential Carcinogenic Risk; International\nConference on Harmonisation; Guidance for Industry"", ""docket_id"": ""FDA-2013-D-0369"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0369-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0369/FDA-2013-D-0369-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:11:20,2025-05-28 03:53:06
afa86a80-3390-4862-b277-01a81e17c3d0,USA-FDA,4f4e9e38-440c-4b4e-be4a-4a61b5229e72,G_IMPACT_ANALYSIS,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0260/FDA-2009-D-0260-0029/FDA-2009-D-0260-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2)"", ""docket_id"": ""FDA-2009-D-0260"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0260-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0260/FDA-2009-D-0260-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:47:51,2025-05-28 03:53:06
afe18320-5655-4b96-a286-91b7ba0b4309,USA-FDA,d0f84b19-d961-4772-b263-c20ac9ba92f6,G_IMPACT_ANALYSIS,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001/FDA-2020-D-1397-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Q3A Impurities in New Drug Substances"", ""docket_id"": ""FDA-2020-D-1397"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1397-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1397/FDA-2020-D-1397-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:45:50,2025-05-28 03:53:06
afe271e3-07e0-4855-9441-c4fb2c1b2b13,USA-FDA,5aae30e7-1126-425c-a6c0-e04464c86699,G_ACTION_ITEMS,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013/FDA-2016-D-2567-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""02-Final Guidance for Industry-E17 General Principles for Planning and Design of Multiregional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:03:31,2025-05-28 03:53:06
afec29ab-6374-49ee-aef4-4fdb37be6c60,USA-FDA,e2791297-3260-4468-be4b-e187f911b760,G_KEYWORDS,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009/FDA-2011-D-0916-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Classification Product Codes; Guidance for Industry and  Food and Drug Administration Staff"", ""docket_id"": ""FDA-2011-D-0916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0916-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:32:56,2025-05-28 03:53:06
b01e4369-c41c-4655-93cf-9a3de7b7c1b9,USA-FDA,33f67222-7045-42c9-8665-140c7f3f28da,G_MINI_SUMMARY,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002/FDA-2009-D-0195-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Uranium"", ""docket_id"": ""FDA-2009-D-0195"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0195-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:30:59,2025-05-28 03:53:06
b021441c-b194-4018-8578-2b29008bc6cd,USA-FDA,e858056a-c29f-4aaf-b6b1-5ae4ea73cc8c,G_FAQ,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0013/FDA-1998-D-0035-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis and Interpretation of Clinical Studies"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:17:54,2025-05-28 03:53:06
b0500507-26e5-43c7-9e99-82aef7bdda89,USA-FDA,45fef250-b0ea-406c-9dc2-e4d2c14edd24,G_MINI_SUMMARY,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001/FDA-2020-D-1945-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a)"", ""docket_id"": ""FDA-2020-D-1945"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1945-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:36,2025-05-28 03:53:06
b05c6813-a3da-43dd-b4df-dce8428f9c17,USA-FDA,ea436e91-0a83-483e-8e03-7a3da42d328a,G_FAQ,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1978-N-0011/FDA-1978-N-0011-0008/FDA-1978-N-0011-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidelines for Effectiveness Testing of O. T. C. Antiperspirant Drug Products"", ""docket_id"": ""FDA-1978-N-0011"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1978-N-0011-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1978-N-0011/FDA-1978-N-0011-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:46:18,2025-05-28 03:53:06
b0725ebb-5537-4b5a-b32a-0447896e3e31,USA-FDA,1413ee84-9486-4cc9-beb3-e63044bcf016,G_DETAILED_SUMMARY,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002/FDA-1997-D-0380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation; Guidance"", ""docket_id"": ""FDA-1997-D-0380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:31:18,2025-05-28 03:53:06
b07aa8ec-83e7-482d-b27c-a0bcb4ac4df4,USA-FDA,43919918-fb35-47fa-8062-2c632dfccdc3,G_ACTION_ITEMS,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0258/FDA-2011-D-0258-0002/FDA-2011-D-0258-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 335.700 Surgeons� Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure"", ""docket_id"": ""FDA-2011-D-0258"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0258-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0258/FDA-2011-D-0258-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:46:53,2025-05-28 03:53:06
b07cf5d3-65c3-4b34-9879-1c9cf439a804,SCHEDULED,866d1d67-73e1-4e96-a983-137aadb123e1,FDA_ALERT,2025-05-30 00:00:04,30,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/fda_alert/866d1d67-73e1-4e96-a983-137aadb123e1"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:31,2025-05-30 00:00:31
b087860e-eed2-454c-8278-eeb1b7bbe876,SCHEDULED,efeef423-2162-44ba-a04f-ff652a589a0a,DEVICE_ANALYST,2025-05-24 00:00:05,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/efeef423-2162-44ba-a04f-ff652a589a0a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:07,2025-05-28 03:53:06
b091de43-cf8b-4010-8c80-092b6c46de4b,QUEUE,d18bba59-e0ee-4b59-a375-40217681ad6c,G_TRANSLATE,2025-05-29 22:15:06,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/d18bba59-e0ee-4b59-a375-40217681ad6c/MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf.pdf"", ""doc_title"": ""MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/d18bba59-e0ee-4b59-a375-40217681ad6c"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 22:15:15,2025-05-29 22:15:15
b0961b67-791d-484d-92ca-268797af13b1,USA-FDA,fdf91f4b-92ff-41a3-9f19-bed8c4ce7961,G_FAQ,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005/FDA-2010-D-0165-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies (VICH GL49)"", ""docket_id"": ""FDA-2010-D-0165"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0165-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:02:09,2025-05-28 03:53:06
b09a9f31-0af3-446a-b4a6-7984310cbe59,USA-FDA,c23c07bb-1be0-488c-af07-20a062ab600a,G_DETAILED_SUMMARY,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004/FDA-2019-D-1372-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Elemental Impurities in Human Drug Products Questions and Answers Proposed DRAFT Guidance for Industry"", ""docket_id"": ""FDA-2019-D-1372"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-1372-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:02:05,2025-05-28 03:53:06
b0a55cf3-5c69-4b20-ba5d-580096d53c07,USA-FDA,7c3533fb-0349-4dba-abbc-e31004ff3e00,G_ACTION_ITEMS,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0029/FDA-2003-D-0029-0003/FDA-2003-D-0029-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Federal Agencies and State and Local Governments Potassium Iodide Tablets Shelf Life Extension"", ""docket_id"": ""FDA-2003-D-0029"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0029-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0029/FDA-2003-D-0029-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:30:31,2025-05-28 03:53:06
b0faa2b8-1868-4735-8893-64d4fd98c359,USA-FDA,fc34e720-b3f5-4c99-bee9-b6c70d89bc5d,G_MINI_SUMMARY,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0447/FDA-2013-D-0447-0002/FDA-2013-D-0447-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Charging for Investigational Drugs Under an Investigational New Drug Application-Questions and Answers"", ""docket_id"": ""FDA-2013-D-0447"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0447-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0447/FDA-2013-D-0447-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:30:08,2025-05-28 03:53:06
b1186478-794d-4ecb-b090-f28124d4e207,USA-FDA,3a3e4cba-4324-4b18-917a-0bb174d05cc7,G_MINI_SUMMARY,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0429/FDA-2012-D-0429-0003/FDA-2012-D-0429-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Investigators Meetings with Industry and Investigators on the Research and Development of Tobacco Products"", ""docket_id"": ""FDA-2012-D-0429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0429-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0429/FDA-2012-D-0429-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:00:09,2025-05-28 03:53:06
b13911f5-96b3-4c91-bf52-2c0e8b259749,USA-FDA,a8cd158a-6b9b-4965-9d00-e8b6c80fbcac,G_KEYWORDS,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005/FDA-2010-D-0163-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (VICH GL46)"", ""docket_id"": ""FDA-2010-D-0163"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0163-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:30:58,2025-05-28 03:53:06
b1611648-90cc-44cd-b0c4-26338824a212,USA-FDA,b0cd1892-3c70-46f4-81c0-7132f3c76268,G_ACTION_ITEMS,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016/FDA-2014-D-1399-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:15:35,2025-05-28 03:53:06
b1912764-2499-4cf4-9352-af93f492bca5,USA-FDA,3e433eb4-babc-42aa-8056-c63676272563,G_ACTION_ITEMS,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0889/FDA-2011-D-0889-0002/FDA-2011-D-0889-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions With GFI #209"", ""docket_id"": ""FDA-2011-D-0889"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0889-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0889/FDA-2011-D-0889-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:31:26,2025-05-28 03:53:06
b2068cc5-c92f-4298-8240-f0e6caa79228,USA-FDA,fa14fdca-6127-4480-82d9-a977df4d3329,G_FAQ,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002/FDA-2011-D-0577-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Factors To Consider When Making Benefit-Risk Determinations in Medical Device Premarket Review"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:48:07,2025-05-28 03:53:06
b22bff0a-bacb-4ea8-a67b-fe6bd16db4bd,CAB,63613683-b0a4-42dd-a276-5100794cc4d9,G_KEYWORDS,2025-05-20 16:33:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2018-F-3757-0019.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2018-F-3757-0019_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""04cb41d6-deff-4cde-83f8-ba7f77069dd4""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/04cb41d6-deff-4cde-83f8-ba7f77069dd4"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:34:12,2025-05-28 03:53:06
b2522c76-2faf-46fd-9ee0-aa31728b7b73,USA-FDA,ae22b3db-22da-443e-a6d7-854c4398ba0b,G_CONCISE_SUMMARY,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002/FDA-2011-D-0689-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; De Novo Classification Process (Evaluation of Automatic Class III Designation)"", ""docket_id"": ""FDA-2011-D-0689"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0689-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0689/FDA-2011-D-0689-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:15:13,2025-05-28 03:53:06
b25f75d7-92ad-485a-be90-5a3454d08d34,USA-FDA,329ddd45-77ac-420b-8707-1a4b08875312,G_KEYWORDS,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002/FDA-2013-D-0749-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implanted Blood Access Devices for Hemodialysis; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0749"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0749-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0749/FDA-2013-D-0749-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:02:21,2025-05-28 03:53:06
b284ecda-7d1f-4755-b52c-7f2469f7ed89,USA-FDA,59f237e4-c41e-48e9-83b6-b3abd7e46958,G_CONCISE_SUMMARY,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001/FDA-2018-D-3551-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Impact of Certain Provisions of Revised Common Rule on FDA-Regulated Clinical Investigations; Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2018-D-3551"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3551-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:30:12,2025-05-28 03:53:06
b28ef4ad-3529-4d64-af05-32126629a055,QUEUE,f48d07bd-b5ec-445f-94b5-3519b5a77aa4,G_SUMMARY_USER,2025-05-20 10:59:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""__doc_title__"": ""EU regulations on medical devices � Update November 2022.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/f48d07bd-b5ec-445f-94b5-3519b5a77aa4/SRC/f48d07bd-b5ec-445f-94b5-3519b5a77aa4.pdf"", ""doc_title"": ""EU regulations on medical devices � Update November 2022.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/f48d07bd-b5ec-445f-94b5-3519b5a77aa4/DEST/detailed_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:59:37,2025-05-28 03:53:06
b2dbf757-82f2-4803-8837-bcd71ea880e7,USA-FDA,912d04d8-b94e-4f7f-bce5-de5f76fc631c,G_MINI_SUMMARY,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010/FDA-2011-D-0799-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components Including Source Plasma to Reduce the Risk of Transmission of Hepatitis B Virus"", ""docket_id"": ""FDA-2011-D-0799"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0799-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:01:09,2025-05-28 03:53:06
b309ad26-ceec-4b29-b0bf-474a4ab56a11,USA-FDA,1d4ede65-30b4-43a7-9728-ba68f6cdb7c8,G_CONCISE_SUMMARY,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005/FDA-2011-D-0112-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Chemistry, Manufacturing, and Controls (CMC)\nInformation � Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use"", ""docket_id"": ""FDA-2011-D-0112"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0112-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:30:13,2025-05-28 03:53:06
b3a5632f-ecd6-4a8e-a23a-083276248456,USA-FDA,2a16a4d5-4c58-4a6d-9f19-33b008a1560e,G_KEYWORDS,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004/FDA-2005-D-0208-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency"", ""docket_id"": ""FDA-2005-D-0208"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0208-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:33:47,2025-05-28 03:53:06
b3a77bf9-ce47-41b0-a65f-3fae1f3dfd4e,USA-FDA,ce208084-4107-4b94-a156-5910f64ae594,G_MINI_SUMMARY,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3443/FDA-2018-D-3443-0002/FDA-2018-D-3443-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-3443"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3443-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3443/FDA-2018-D-3443-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:46:36,2025-05-28 03:53:06
b3b55dde-d086-44b6-ba53-30a9f35b844a,USA-FDA,202dce6f-912c-4154-84cb-a8472a1b8009,G_FAQ,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013/FDA-2009-D-0503-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in - Premarket Notification (510(k)) Submissions; Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0503-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:00:56,2025-05-28 03:53:06
b3ce2eb3-bddd-4830-837a-f35df6a6ec78,QUEUE,b9e1302e-65c9-498b-b67c-7ab0d0945651,G_TRANSLATE,2025-05-30 04:00:11,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""c_986569 (9).pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/b9e1302e-65c9-498b-b67c-7ab0d0945651/c_986569 (9).pdf.pdf"", ""doc_title"": ""c_986569 (9).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/b9e1302e-65c9-498b-b67c-7ab0d0945651"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 04:00:15,2025-05-30 04:00:15
b3e3459a-d458-4163-baee-21614c946645,USA-FDA,2adc8d11-b009-48d3-8ed4-7737343f5fd3,G_DETAILED_SUMMARY,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008/FDA-1999-D-0128-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cooperative Manufacturing Arrangements for Licensed Biologics"", ""docket_id"": ""FDA-1999-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0128-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:31:50,2025-05-28 03:53:06
b3e8a0e2-d589-4525-a70c-43a1a56ff134,USA-FDA,5f70f882-c6ba-4888-b468-91f418050d7f,G_ACTION_ITEMS,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009/FDA-2011-D-0916-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Classification Product Codes; Guidance for Industry and  Food and Drug Administration Staff"", ""docket_id"": ""FDA-2011-D-0916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0916-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0916/FDA-2011-D-0916-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:32:43,2025-05-28 03:53:06
b4151630-d53a-46f2-b960-78e71cc999e1,USA-FDA,f5ccf95e-03f1-4a48-a235-7c7feed1f236,G_DETAILED_SUMMARY,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0030/FDA-2007-D-0030-0002/FDA-2007-D-0030-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Refrigerated Carrot Juice and Other Refrigerated\nLow-Acid Juices"", ""docket_id"": ""FDA-2007-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0030-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0030/FDA-2007-D-0030-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:15:14,2025-05-28 03:53:06
b44f5a99-2f9c-4a88-b301-fe3fb671524b,USA-FDA,e9028097-0913-4775-aaf7-29857d7f4234,G_FAQ,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0008/FDA-2012-D-1083-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff Civil Money Penalties for Tobacco Retailers: Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2012-D-1083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1083-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:15:52,2025-05-28 03:53:06
b47550ea-067b-4de1-9204-48cd12df728d,USA-FDA,4af84404-d00d-4a82-be14-940e625a8ff9,G_FAQ,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0166/FDA-2010-D-0166-0006/FDA-2010-D-0166-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods (VICH GL-48)"", ""docket_id"": ""FDA-2010-D-0166"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0166-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0166/FDA-2010-D-0166-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:16:06,2025-05-28 03:53:06
b478d869-ce21-4090-a5e9-ccd2d3b4180f,USA-FDA,8435053e-43f9-4d10-b443-ac83c941b80a,G_FAQ,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0872/FDA-2011-D-0872-0002/FDA-2011-D-0872-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies"", ""docket_id"": ""FDA-2011-D-0872"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0872-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0872/FDA-2011-D-0872-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:00:38,2025-05-28 03:53:06
b4c3dd54-893a-4b86-9da3-0a503633f782,USA-FDA,c4a72d99-e730-46d2-bc72-5222ac0dbb90,G_ACTION_ITEMS,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0721/FDA-2011-D-0721-0002/FDA-2011-D-0721-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act"", ""docket_id"": ""FDA-2011-D-0721"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0721-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0721/FDA-2011-D-0721-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:30:55,2025-05-28 03:53:06
b4c517a9-1c24-4ee8-847c-819d3213311b,USA-FDA,93b643d9-b5e9-4472-8a76-7129689c6b3b,G_FAQ,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017/FDA-2010-D-0426-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Bar Code Label Requirements�Questions and Answers"", ""docket_id"": ""FDA-2010-D-0426"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0426-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:33:30,2025-05-28 03:53:06
b4d2e5fd-75ec-448d-b010-12dc873ed265,USA-FDA,b2707138-a844-4119-a8c1-72e79db0466c,G_DETAILED_SUMMARY,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002/FDA-2017-D-5525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Statistical Approaches to Evaluate Analytical Similarity Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5525/FDA-2017-D-5525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:31:54,2025-05-28 03:53:06
b4f2114b-ef82-42c1-b55b-a804ab9eff7f,USA-FDA,7f0bc162-b98d-432f-9916-1b385cd4b607,G_ACTION_ITEMS,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001/FDA-2020-D-1944-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives"", ""docket_id"": ""FDA-2020-D-1944"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1944-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:30:31,2025-05-28 03:53:06
b547748c-bf98-422c-9b76-3917a2e19d97,USA-FDA,cc136e5a-1662-48ba-b78d-9c254cf89bf8,G_FAQ,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002/FDA-2013-D-0168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Recommendations for Labeling Medical Products to Inform Users the Product or Product Container Is Not Made With Natural Rubber Latex"", ""docket_id"": ""FDA-2013-D-0168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:16:58,2025-05-28 03:53:06
b5839da1-ab29-4c71-b095-b622c5b4f100,USA-FDA,4d161ec1-7108-4966-b3fd-ead10a671003,G_MINI_SUMMARY,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010/FDA-2004-D-0500-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Consumer-Directed Broadcast Advertising of Restricted Devices; Draft Guidance for Industry"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:54,2025-05-28 03:53:06
b585c65a-7f9d-4285-b141-39f81fa9757a,USA-FDA,1656af52-2ee8-4c78-acd9-a8bb3542e3a2,G_FAQ,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0386/FDA-2009-D-0386-0010/FDA-2009-D-0386-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection, etc., of Human Papillomaviruses"", ""docket_id"": ""FDA-2009-D-0386"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0386-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0386/FDA-2009-D-0386-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:30:16,2025-05-28 03:53:06
b586a7f8-e1e4-4188-8a24-752ee31b2af9,USA-FDA,708220b6-fc57-4612-9ca0-00fab47d7cfa,G_DETAILED_SUMMARY,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0029/FDA-2003-D-0029-0003/FDA-2003-D-0029-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Federal Agencies and State and Local Governments Potassium Iodide Tablets Shelf Life Extension"", ""docket_id"": ""FDA-2003-D-0029"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0029-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0029/FDA-2003-D-0029-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:30:19,2025-05-28 03:53:06
b5ac666e-43b2-4836-a8e5-eb2f521828cd,USA-FDA,93469327-6622-4c2b-b651-29bdf12ebf5b,G_KEYWORDS,2025-05-21 23:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002/FDA-1999-D-0063-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling"", ""docket_id"": ""FDA-1999-D-0063"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0063-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0063/FDA-1999-D-0063-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:48:14,2025-05-28 03:53:06
b5ac95eb-fd33-4a83-bb26-d2b6f3da4600,USA-FDA,b4a9bfd0-306c-448e-bbe4-dc34d5eb6eec,G_MINI_SUMMARY,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0002/FDA-2015-D-1245-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; Draft Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:31:32,2025-05-28 03:53:06
b5bb8de3-d5b8-4ef5-b457-3105b1e8ec41,USA-FDA,b104dbea-3472-452a-b9b9-552c149ba3c2,G_KEYWORDS,2025-05-20 12:08:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002/FDA-2011-D-0597-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring"", ""docket_id"": ""FDA-2011-D-0597"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0597-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:10:31,2025-05-28 03:53:06
b5c8d89a-4ad2-42f8-a020-bb3dc6b5e21a,USA-FDA,45e19bff-a8b3-478e-bf8f-b07e2c48f04b,G_IMPACT_ANALYSIS,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002/FDA-2013-D-0269-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Purchasing Reef Fish Species Associated with the Hazard of Ciguatera Fish Poisoning"", ""docket_id"": ""FDA-2013-D-0269"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0269-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:32:23,2025-05-28 03:53:06
b60f77e6-a33b-454e-a1c4-095b447b22fc,USA-FDA,ba9b4b25-5bae-43df-b260-520b222686b9,G_KEYWORDS,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610/FDA-2016-D-4414-1610-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nutrition and Supplement Facts Labels: Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals: Guidance for Industry"", ""docket_id"": ""FDA-2016-D-4414"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-4414-1610""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:16:10,2025-05-28 03:53:06
b625b5d2-1f07-4df8-9919-aea3322ff6b0,Queue,b9e1302e-65c9-498b-b67c-7ab0d0945651,G_TRANSLATE,2025-05-30 03:54:04,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""c_986569 (9).pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/b9e1302e-65c9-498b-b67c-7ab0d0945651/c_986569 (9).pdf.pdf"", ""doc_title"": ""c_986569 (9).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/b9e1302e-65c9-498b-b67c-7ab0d0945651"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 03:54:03,2025-05-30 03:54:03
b6306ad1-500e-4b26-9616-8e27621a4326,USA-FDA,3f51519f-3f39-4d0b-b2e3-eafb412e35ca,G_IMPACT_ANALYSIS,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0146/FDA-2010-D-0146-0012/FDA-2010-D-0146-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Irritable Bowel Syndrome Clinical Evaluation of Drugs for Treatment"", ""docket_id"": ""FDA-2010-D-0146"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0146-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0146/FDA-2010-D-0146-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:16:37,2025-05-28 03:53:06
b6730aab-1c4a-49f3-a1f7-2c9c51cf4453,USA-FDA,28b58ab0-40da-41b4-a82b-bd2b282f5f51,G_MINI_SUMMARY,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0509/FDA-2010-D-0509-0002/FDA-2010-D-0509-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Enforcement Policy - OTC Sunscreen Drug Products Marketed Without an Approved Application"", ""docket_id"": ""FDA-2010-D-0509"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0509-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0509/FDA-2010-D-0509-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:01:02,2025-05-28 03:53:06
b69d1bd5-fc0c-47bc-9fae-38f5b8049ee7,USA-FDA,0adaf36d-b702-43e3-9af0-b0e5af219140,G_MINI_SUMMARY,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0589/FDA-2013-D-0589-0002/FDA-2013-D-0589-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Human Immunodeficiency Virus-1 Infection:  Developing Antiretroviral Drugs for Treatment"", ""docket_id"": ""FDA-2013-D-0589"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0589-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0589/FDA-2013-D-0589-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:00:50,2025-05-28 03:53:06
b6c0bb75-9ec0-4a5a-9ccf-d2f73fdcf918,USA-FDA,75552c5f-478a-497e-983f-83970ac362b4,G_IMPACT_ANALYSIS,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002/FDA-2011-D-0464-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Low Glucose Suspend (LGS) Device Systems - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0464-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:32:50,2025-05-28 03:53:06
b6c9f8f6-9761-4af2-9801-dd6d0c9887c4,USA-FDA,157fdeff-941e-42e6-ba04-e65791d884a4,G_MINI_SUMMARY,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001/FDA-2020-D-1961-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling"", ""docket_id"": ""FDA-2020-D-1961"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1961-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:31:07,2025-05-28 03:53:06
b6ee055b-5fee-41b5-b9fe-0591cb306058,USA-FDA,43a04765-d664-4fdf-bb3e-cca8360f4fb7,G_KEYWORDS,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002/FDA-2020-D-1640-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance on Cannabidiol"", ""docket_id"": ""FDA-2020-D-1640"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1640-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:16:18,2025-05-28 03:53:06
b73047ff-8b94-42db-b2ca-9e533c29d048,USA-FDA,5c328255-f11a-4dbc-bc5f-40fe4ccb8ea5,G_IMPACT_ANALYSIS,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012/FDA-2003-D-0186-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for InduGuidance for Industry: Cosmetics Processors and Transporters of Cosmetics Security Preventive Measures Guidance"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:21,2025-05-28 03:53:06
b75f364c-5094-495f-808b-d4c41b0357c9,QUEUE,1b167ebd-ddad-45cf-bd1f-3910d06869cc,G_TRANSLATE,2025-05-29 21:30:06,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/1b167ebd-ddad-45cf-bd1f-3910d06869cc/MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf.pdf"", ""doc_title"": ""MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/1b167ebd-ddad-45cf-bd1f-3910d06869cc"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 21:30:13,2025-05-29 21:30:13
b7615fb2-bf58-4d22-9ac2-63cd0237ce13,USA-FDA,f6121cf8-b574-4493-9126-b3313df81582,G_KEYWORDS,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002/FDA-2017-D-3235-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2017-D-3235"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-3235-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:16:21,2025-05-28 03:53:06
b76a5637-8197-48b7-a47f-58ec5583e8c0,USA-FDA,2e938d36-2142-469d-ac22-e9ebd6610839,G_FAQ,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0125/FDA-2013-N-0125-0025/FDA-2013-N-0125-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Alternative to Certain Prescription Device Labeling Requirements"", ""docket_id"": ""FDA-2013-N-0125"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-0125-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0125/FDA-2013-N-0125-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:00:23,2025-05-28 03:53:06
b773aaf7-eda8-46ce-80d6-b57b59583718,USA-FDA,d2e1fe4c-680f-4527-9258-b0022b8ba138,G_DETAILED_SUMMARY,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002/FDA-2020-D-1640-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance on Cannabidiol"", ""docket_id"": ""FDA-2020-D-1640"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1640-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:15:58,2025-05-28 03:53:06
b79579d8-08c5-4d09-a3bd-69386a505fd5,USA-FDA,38c241b5-03f9-4772-908d-583ce48c168a,G_MINI_SUMMARY,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011/FDA-1997-D-0444-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance on FDA Approval of New Animal Drugs for Minor Uses and for Minor Species; Guidance Document (Revised May 29, 2008)"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:00:10,2025-05-28 03:53:06
b7b12af9-56bc-4fdf-a71e-e97f4ea11538,USA-FDA,8c52be4e-bbdb-477a-8e60-940bac4ea8e7,G_FAQ,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002/FDA-2015-D-1309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M8 Electronic Common Technical Document v4.0 Draft Implementation\nGuide v2.0; Electronic Common Technical Document v4.0 Implementation Package Draft Specification for Submission Formats\nv2.0; International Conference on Harmonisation; Draft Guidance for\nIndustry"", ""docket_id"": ""FDA-2015-D-1309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1309/FDA-2015-D-1309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:46:31,2025-05-28 03:53:06
b7bdc876-2e39-4066-bbcd-2b16ee5cd6d0,USA-FDA,023c5c41-57d3-4c71-ba67-decb333b6744,G_MINI_SUMMARY,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004/FDA-2005-D-0028-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products"", ""docket_id"": ""FDA-2005-D-0028"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0028-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:01:25,2025-05-28 03:53:06
b7c597b6-8114-4bd0-bfdb-a6f5c53baf94,USA-FDA,5683f15b-b86b-47bf-891a-af8d091dcc3c,G_DETAILED_SUMMARY,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610/FDA-2016-D-4414-1610-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nutrition and Supplement Facts Labels: Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals: Guidance for Industry"", ""docket_id"": ""FDA-2016-D-4414"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-4414-1610""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:15:23,2025-05-28 03:53:06
b7ed8ff1-305b-45e4-b8fb-0ed5d2ab0de8,QUEUE,5b85962e-5fb3-4489-aebb-c5e88f4dc7b5,G_IMPACT_ANALYSIS_USER,2025-05-20 10:41:59,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__doc_title__"": ""FDA-2024-N-1111-0001_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/5b85962e-5fb3-4489-aebb-c5e88f4dc7b5/SRC/5b85962e-5fb3-4489-aebb-c5e88f4dc7b5.pdf"", ""doc_title"": ""FDA-2024-N-1111-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/5b85962e-5fb3-4489-aebb-c5e88f4dc7b5/DEST/impact_analysis.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:42:08,2025-05-28 03:53:06
b836678d-70dc-4e6e-8dbf-1c0e03d7ef57,USA-FDA,0ca9352b-d7f9-42dd-850a-4874b9f46a52,G_CONCISE_SUMMARY,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002/FDA-2013-N-1429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2013-N-1429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:02:02,2025-05-28 03:53:06
b8815f0a-6f89-497b-9764-bef4ea0c72e6,SCHEDULED,095a1eb0-a1ff-4db5-b52a-f0c1167e54fa,DEVICE_ANALYST,2025-05-19 16:47:53,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-19""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/095a1eb0-a1ff-4db5-b52a-f0c1167e54fa"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-19 20:49:14,2025-05-28 03:53:06
b9320a85-6d3d-4bc4-9377-bace597c5559,CAB,a59605d4-9396-4f1a-bdde-d79384014b9e,G_MINI_SUMMARY_IN,2025-05-20 10:13:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2022-F-1108-0001"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2022-F-1108-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""48b24e3f-2c7d-446d-8ef2-9a788b5abc48""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/48b24e3f-2c7d-446d-8ef2-9a788b5abc48"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:13:27,2025-05-28 03:53:06
b935aff5-069b-44eb-8648-03b72d822066,USA-FDA,5f8f2716-9ed3-422c-9231-af8f514b1156,G_DETAILED_SUMMARY,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1459/FDA-2018-D-1459-0049/FDA-2018-D-1459-0049-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Food Labeling: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics: Guidance for Industry"", ""docket_id"": ""FDA-2018-D-1459"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-1459-0049""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1459/FDA-2018-D-1459-0049"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:30:19,2025-05-28 03:53:06
b9373da9-13fb-41f4-adfe-90d69642d623,USA-FDA,f8fe03f8-66ef-40d2-a965-eaeab30037f5,G_ACTION_ITEMS,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0938/FDA-2012-D-0938-0024/FDA-2012-D-0938-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Guidance on Abbreviated New Drug Applications: Stability Testing of Drug Substances and Products"", ""docket_id"": ""FDA-2012-D-0938"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0938-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0938/FDA-2012-D-0938-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:15:26,2025-05-28 03:53:06
b9394c45-5dea-4e1e-8add-6525ff751e1e,USA-FDA,33414034-c796-4ead-9200-832dfbb35129,G_DETAILED_SUMMARY,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002/FDA-2011-D-0730-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff; Class II Special Controls Guidance Documents: In Vitro Diagnostic Devices for Yersinia Species Detection"", ""docket_id"": ""FDA-2011-D-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0730-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:00:30,2025-05-28 03:53:06
b9604892-6354-4cb0-8933-42d22ace3a21,USA-FDA,5b5b27e0-6d17-44d6-be6c-da8b43323e1a,G_FAQ,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0391/FDA-2008-D-0391-0014/FDA-2008-D-0391-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Submission of Documentation: Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes"", ""docket_id"": ""FDA-2008-D-0391"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0391-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0391/FDA-2008-D-0391-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:46:23,2025-05-28 03:53:06
b9674cd7-da1f-4585-9d09-2289e92f1355,USA-FDA,561e4d65-5fcc-4487-a9d0-8683d12a3434,G_FAQ,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025/FDA-2009-D-0524-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Listing of Ingredients in Tobacco Products"", ""docket_id"": ""FDA-2009-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0524-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:01:41,2025-05-28 03:53:06
b97f9f2e-eb7b-4bf4-b923-5123cc5bb69d,USA-FDA,a0ffc59c-e785-46e7-919c-80c56e9d98aa,G_CONCISE_SUMMARY,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002/FDA-2013-D-0920-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0920"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0920-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:30:56,2025-05-28 03:53:06
b98776cb-f777-44b8-a7d8-1f2150565468,SCHEDULED,8bbbebcd-fce1-4362-8bb4-e1473b1970e4,DEVICE_ANALYST,2025-06-01 00:00:04,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Patel"", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": ""Abhishek"", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/8bbbebcd-fce1-4362-8bb4-e1473b1970e4"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:26,2025-06-01 00:00:26
b98a6930-1a95-4134-86eb-680d763adcbc,USA-FDA,ac9eab78-4f7d-4537-a269-883d0824f26b,G_MINI_SUMMARY,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0002/FDA-2009-D-0568-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:46:35,2025-05-28 03:53:06
b98f38be-2bf4-4c64-bc3c-22656407315c,USA-FDA,4a309173-d3f8-4deb-a259-408f13a5e99c,G_DETAILED_SUMMARY,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0009/FDA-2011-D-0620-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2011-D-0620"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0620-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:00:21,2025-05-28 03:53:06
b99a088b-79d6-4454-a878-52869b907ff3,USA-FDA,9e893f02-0148-4a53-b636-07f7efcded27,G_IMPACT_ANALYSIS,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0295/FDA-2013-D-0295-0002/FDA-2013-D-0295-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Scale-Up and Post-Approval Changes, Manufacturing Equipment Addendum"", ""docket_id"": ""FDA-2013-D-0295"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0295-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0295/FDA-2013-D-0295-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:30:49,2025-05-28 03:53:06
b99f56c1-306c-454d-a0e5-f6505fc6f47d,USA-FDA,c427641c-c9e4-4330-89dc-003c41cf3a27,G_DETAILED_SUMMARY,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002/FDA-2007-D-0205-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]; Draft Guidance"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:02:34,2025-05-28 03:53:06
b9a0b28d-4832-47e9-ad91-1be5da483299,USA-FDA,fc033cf5-feb0-4225-910c-ee1819e8cf31,G_FAQ,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002/FDA-2013-D-0743-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Reporting for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0743"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0743-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:16:12,2025-05-28 03:53:06
b9b48ad4-252f-4655-93e9-db156370d923,Queue,5e10fbd0-6680-40e7-937f-16e1fb4c68eb,G_TRANSLATE,2025-05-29 22:23:46,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""MDCG_Position_Paper_on_the_application_of_Article_97_MDR_to_legacy_devices_for_which_the_MDD_or_AIMDD_certificate_expires_before_the_issuance_of_a_MDR_certificate.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/5e10fbd0-6680-40e7-937f-16e1fb4c68eb/MDCG_Position_Paper_on_the_application_of_Article_97_MDR_to_legacy_devices_for_which_the_MDD_or_AIMDD_certificate_expires_before_the_issuance_of_a_MDR_certificate.pdf.pdf"", ""doc_title"": ""MDCG_Position_Paper_on_the_application_of_Article_97_MDR_to_legacy_devices_for_which_the_MDD_or_AIMDD_certificate_expires_before_the_issuance_of_a_MDR_certificate.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/5e10fbd0-6680-40e7-937f-16e1fb4c68eb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 22:23:46,2025-05-29 22:23:46
b9bf190a-fdd5-452a-975f-b414f8a97534,USA-FDA,ae000384-f43c-4b0c-af50-34ab53bf1713,G_ACTION_ITEMS,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002/FDA-2007-D-0202-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting Improving Human Subject Protection"", ""docket_id"": ""FDA-2007-D-0202"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0202-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:02:06,2025-05-28 03:53:06
b9c210b2-5cd2-49e9-9a83-77c11fa098aa,USA-FDA,ad4dd269-f2d5-4277-bbe3-ccd84ab4cb30,G_MINI_SUMMARY,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005/FDA-2010-D-0165-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies (VICH GL49)"", ""docket_id"": ""FDA-2010-D-0165"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0165-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:01:40,2025-05-28 03:53:06
b9c5c1c2-6bb3-424c-b7d1-fd08383a7a2b,CAB,76be4911-97c2-4a33-b073-c4eae40a06d3,G_ACTION_ITEMS_IN,2025-05-27 02:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-2910-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2024-N-2910-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b3efc128-de32-4064-8905-ee749b8e53b7""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b3efc128-de32-4064-8905-ee749b8e53b7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 02:00:46,2025-05-28 03:53:06
b9c5d3e5-fecf-492b-ab45-caee34180fd8,USA-FDA,7f748912-d077-46a9-93a2-25f1d6ee881e,G_ACTION_ITEMS,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001/FDA-2020-D-1977-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures"", ""docket_id"": ""FDA-2020-D-1977"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1977-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:17:03,2025-05-28 03:53:06
b9dd069b-75f1-4d96-81f5-078088bbde3f,USA-FDA,986530a6-4240-4370-a805-58f19af405df,G_IMPACT_ANALYSIS,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001/FDA-2016-D-1533-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:02:57,2025-05-28 03:53:06
ba056c7e-ca07-4715-810c-f8c2b231c515,USA-FDA,b2bf0014-3048-491c-999f-86c42fa734a5,G_ACTION_ITEMS,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002/FDA-2012-D-0544-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Toll Free Number Labeling and Related Requirements for Over the Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide"", ""docket_id"": ""FDA-2012-D-0544"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0544-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:30:29,2025-05-28 03:53:06
ba1b09be-a895-49c4-9f59-c1242673b206,USA-FDA,728086c0-5c23-40b3-8c01-9bd394b89389,G_IMPACT_ANALYSIS,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0514/FDA-2011-D-0514-0002/FDA-2011-D-0514-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Industry and Staff; Procedures for Handling Section 522 Postmarket Surveillance Studies"", ""docket_id"": ""FDA-2011-D-0514"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0514-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0514/FDA-2011-D-0514-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:16:06,2025-05-28 03:53:06
ba1c099f-592a-41c1-afe5-a68acf704d83,USA-FDA,b017ed3b-be04-4944-886b-18c422fb5f84,G_DETAILED_SUMMARY,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0872/FDA-2011-D-0872-0002/FDA-2011-D-0872-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies"", ""docket_id"": ""FDA-2011-D-0872"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0872-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0872/FDA-2011-D-0872-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:00:20,2025-05-28 03:53:06
ba1f98d9-3b29-402b-b796-830a63224db1,USA-FDA,1c882c3e-51f2-4fc1-a0cd-5a5b7ffa35c6,G_CONCISE_SUMMARY,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018/FDA-2012-D-1038-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:30:17,2025-05-28 03:53:06
ba37587e-8e37-4341-bb29-a1337177615c,USA-FDA,f7343189-79ee-4c06-af5b-afdbc385f7c2,G_MINI_SUMMARY,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005/FDA-2007-D-0205-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:32:37,2025-05-28 03:53:06
ba3a0e1e-b2f0-4f7a-af36-d1308e8404b5,SCHEDULED,46d9432d-8098-4268-ba01-13803dbd59de,DEVICE_ANALYST,2025-05-28 00:00:05,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/46d9432d-8098-4268-ba01-13803dbd59de"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:24,2025-05-28 03:53:06
ba5d2f73-20e2-4757-a425-7e54a91c45cf,USA-FDA,63227f3f-7b33-4a2e-a961-07411cca0955,G_FAQ,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0429/FDA-2011-D-0429-0002/FDA-2011-D-0429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry and Staff: Classification of Products as Drugs and Devices and Additional Product Classification Issues"", ""docket_id"": ""FDA-2011-D-0429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0429/FDA-2011-D-0429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:46:14,2025-05-28 03:53:06
ba6d9dba-225a-4f32-8915-1717c8903873,USA-FDA,3bdf0304-ac68-400d-85a3-936315f1b55e,G_IMPACT_ANALYSIS,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004/FDA-2010-D-0636-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia Burgdorferi"", ""docket_id"": ""FDA-2010-D-0636"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0636-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0636/FDA-2010-D-0636-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:15:32,2025-05-28 03:53:06
ba9776a7-9f4f-4c63-98c5-9b5e255ad2ba,CAB,c344b726-dc90-4c7b-8989-85d778f065c8,G_MINI_SUMMARY_IN,2025-05-20 12:42:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2018-N-3233-0006.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2018-N-3233-0006_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""3f21331b-4399-4219-aa7e-0a5cb7a4ba33""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3f21331b-4399-4219-aa7e-0a5cb7a4ba33"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:43:04,2025-05-28 03:53:06
baa17a25-40e6-4361-a75f-3cc6a219cb25,SCHEDULED,7ae3f776-5bda-474f-ad35-9129a4b2c0fb,DEVICE_ANALYST,2025-05-27 00:00:04,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/7ae3f776-5bda-474f-ad35-9129a4b2c0fb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:23,2025-05-28 03:53:06
bab3bece-ffa5-4cc7-853a-62f979fb4793,USA-FDA,44a3d2dc-f38b-400a-94ee-8c5b8a8ceda5,G_ACTION_ITEMS,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005/FDA-2010-D-0163-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (VICH GL46)"", ""docket_id"": ""FDA-2010-D-0163"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0163-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:30:47,2025-05-28 03:53:06
bad21301-6e61-4fcb-8fc1-b504b40b8e62,USA-FDA,895e988b-2160-4961-bb19-63651da2ce7a,G_FAQ,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002/FDA-2011-D-0480-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products"", ""docket_id"": ""FDA-2011-D-0480"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0480-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:30:37,2025-05-28 03:53:06
baf44812-9bde-4379-928e-64c00e2db4b4,USA-FDA,414566d7-d03d-474f-af71-4d2be7e2b93b,G_MINI_SUMMARY,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015/FDA-2010-D-0350-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Tobacco Retailers on Tobacco Retailer Training Programs"", ""docket_id"": ""FDA-2010-D-0350"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0350-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:02:12,2025-05-28 03:53:06
bb1de219-3638-477c-970f-d7c37e6218a2,USA-FDA,78353ff8-c6b9-4a18-a07c-221eb3bacdea,G_IMPACT_ANALYSIS,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0017/FDA-2017-D-6526-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6526"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6526-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:46:29,2025-05-28 03:53:06
bb2f6d49-2a4d-4443-9cd0-b8ba9f4dc8ce,USA-FDA,55f416bd-54e0-4ad3-9397-1edbd0ba1709,G_FAQ,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0002/FDA-2012-D-1083-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff; Civil Responses to Frequently Asked Question"", ""docket_id"": ""FDA-2012-D-1083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1083-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:04:14,2025-05-28 03:53:06
bb484c60-6a73-444d-9b59-f9362101b4c0,USA-FDA,2e386c08-2d51-4c55-9d2b-d5dba2f91dca,G_KEYWORDS,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002/FDA-2013-D-0349-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format"", ""docket_id"": ""FDA-2013-D-0349"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0349-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:01:59,2025-05-28 03:53:06
bb5fe51b-1340-4fe8-9e0a-932ab4bd7c18,USA-FDA,e502b024-a796-4f23-a8e1-f71ad1f26c4f,G_FAQ,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004/FDA-2005-D-0028-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products"", ""docket_id"": ""FDA-2005-D-0028"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0028-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0028/FDA-2005-D-0028-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:02:12,2025-05-28 03:53:06
bb689eaa-2367-464e-8453-76b86e316595,USA-FDA,4522d62f-4191-4226-9699-439449d6a2e3,G_CONCISE_SUMMARY,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038/FDA-2008-D-0406-0038-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs; Frequently Asked Questions - Statement of Investigator (Form FDA 1572)"", ""docket_id"": ""FDA-2008-D-0406"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0406-0038""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:17:08,2025-05-28 03:53:06
bb91700f-6013-4852-a681-ef196ba09639,USA-FDA,a00b48ca-edfb-43d5-b2aa-a9caeb27dbbe,G_MINI_SUMMARY,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002/FDA-2009-D-0198-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain Cochineal Extract and Carmine"", ""docket_id"": ""FDA-2009-D-0198"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0198-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:37,2025-05-28 03:53:06
bb9f844c-7fb8-483a-aa73-64d6d62871d1,USA-FDA,0dc247f1-765a-41b2-b398-be1d5933047f,G_FAQ,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1924/FDA-2020-D-1924-0001/FDA-2020-D-1924-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry:  Dear Manufacturer Letter Regarding Front-of-Package Symbols"", ""docket_id"": ""FDA-2020-D-1924"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1924-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1924/FDA-2020-D-1924-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:45:22,2025-05-28 03:53:06
bbfa8f4a-373e-4fd2-8bf0-86e6facd0c59,USA-FDA,0599ac16-9b90-4410-9f68-246ee5b276f4,G_IMPACT_ANALYSIS,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0712/FDA-2016-D-0712-0002/FDA-2016-D-0712-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported  Outcome, for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use DRAFT GUIDANCE"", ""docket_id"": ""FDA-2016-D-0712"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0712-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0712/FDA-2016-D-0712-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:16:36,2025-05-28 03:53:06
bc3dd65a-53d0-4606-9c1a-76ec5723af8a,CAB,10848626-3023-4f13-b223-70c1158709c7,G_SUMMARY_IN,2025-05-28 21:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,{},"{""tilte"": ""EU regulations on medical devices � Update November 2022.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/EU regulations on medical devices � Update November 2022.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""0a2f2db4-b308-43a4-9ab5-7be5666e97bb""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/0a2f2db4-b308-43a4-9ab5-7be5666e97bb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 21:30:16,2025-05-28 21:30:16
bc5d3136-958b-4d0f-8fe6-61d235a4626a,USA-FDA,f80b0472-2506-43c1-9459-bc1f10aa4cb7,G_FAQ,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008/FDA-2008-D-0642-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2008-D-0642"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0642-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:32:57,2025-05-28 03:53:06
bc69952f-c475-4ae4-b8ba-45866218cd02,USA-FDA,b201a6a1-8131-465c-9cb7-96c1f93e7034,G_DETAILED_SUMMARY,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0487/FDA-2007-D-0487-0005/FDA-2007-D-0487-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec 110.310 Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002"", ""docket_id"": ""FDA-2007-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0487-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0487/FDA-2007-D-0487-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:00:58,2025-05-28 03:53:06
bc75a929-6435-4743-a4f7-678513ccc9b7,USA-FDA,dede83c7-bf85-493e-a2de-77c68d4ca636,G_DETAILED_SUMMARY,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0017/FDA-2017-D-6526-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6526"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6526-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:46:06,2025-05-28 03:53:06
bc7a8264-e9b5-493a-ac5f-a2995e8c2711,USA-FDA,ee94232f-e67a-459c-9bb6-97deb70178bd,G_ACTION_ITEMS,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0300/FDA-2004-D-0300-0005/FDA-2004-D-0300-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Quality Systems Approach to Pharmaceutical CGMP Regulations"", ""docket_id"": ""FDA-2004-D-0300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0300-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0300/FDA-2004-D-0300-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:01:07,2025-05-28 03:53:06
bc830a6b-6c02-4fb8-ae33-83d8036863cd,USA-FDA,6f06ae94-2d22-402c-920d-88c39ebef598,G_FAQ,2025-05-19 23:42:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001/FDA-2017-D-5478-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""MRCT Draft FDA Guidance Return of Aggregate Results"", ""docket_id"": ""FDA-2017-D-5478"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5478-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 03:43:29,2025-05-28 03:53:06
bc832f72-c7d1-454f-a059-2cfd08ad87fa,SCHEDULED,2dc12fab-5083-4c30-b49b-341278f2ab31,FDA_ALERT,2025-06-02 00:00:04,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/2dc12fab-5083-4c30-b49b-341278f2ab31"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:25,2025-06-02 00:00:25
bc90b64f-b323-47e2-b487-88f64759a0e6,USA-FDA,7edbb74d-ca2f-458c-abcd-165f2c466d22,G_MINI_SUMMARY,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0031/FDA-2006-D-0031-0006/FDA-2006-D-0031-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Frequently Asked Questions About Medical Devices:  Guidance For IRBs, Clinical Investigators, and Sponsors"", ""docket_id"": ""FDA-2006-D-0031"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0031-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0031/FDA-2006-D-0031-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:15:41,2025-05-28 03:53:06
bccdb65d-e6f8-4ade-b6c2-1da697ce66ab,USA-FDA,9a8f25f4-66a3-46d1-b61b-e43a7ef94857,G_IMPACT_ANALYSIS,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002/FDA-2014-N-0829-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Reporting Drug Sample Information\nUnder Section 6004 of the Affordable Care Act"", ""docket_id"": ""FDA-2014-N-0829"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-0829-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:30:50,2025-05-28 03:53:06
bcd0727a-e7bc-4d21-90d3-e808fce2370c,USA-FDA,1ececc24-a500-47a5-a914-37b1e466d0e8,G_FAQ,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0848/FDA-2012-D-0848-0002/FDA-2012-D-0848-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for FDA Staff Compliance Policy Guide Sec. 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products - Hypoglycin A Toxin\nDraft Guidance"", ""docket_id"": ""FDA-2012-D-0848"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0848-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0848/FDA-2012-D-0848-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:30:22,2025-05-28 03:53:06
bced2e51-c748-471c-8f46-f216c2c797f1,USA-FDA,29a81ec6-9251-4779-a5ce-ab3127b3a75c,G_CONCISE_SUMMARY,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002/FDA-2012-D-0307-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Revised Preventive Measures to Reduce Possible Risk of Transmission of Creutzfeldt-Jakob Disease, etc."", ""docket_id"": ""FDA-2012-D-0307"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0307-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0307/FDA-2012-D-0307-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:31:05,2025-05-28 03:53:06
bcfdfcc2-b503-4617-97f9-c3a4043cd000,USA-FDA,6d3f0ef7-b23e-40a8-a4a9-36bd444dc1b5,G_DETAILED_SUMMARY,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001/FDA-2020-D-1945-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a)"", ""docket_id"": ""FDA-2020-D-1945"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1945-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:43,2025-05-28 03:53:06
bd112005-968f-4059-8997-c99561b4c52e,USA-FDA,0de0798d-3da2-417a-a4cb-7d30dac7e834,G_DETAILED_SUMMARY,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002/FDA-2009-D-0542-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Factors that Distinguish Liquid Dietary Supplements from Beverages, Considerations Regarding Novel Ingredients, and Labeling for Beverages and Other Conventional Foods; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0542"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0542-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:02:50,2025-05-28 03:53:06
bd13fbb3-6239-48df-90cd-a48f760633fb,USA-FDA,267fdeff-9d1d-48e3-a400-b3dd83700b4a,G_ACTION_ITEMS,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002/FDA-2012-D-0049-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke UnderSection 904(a)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance"", ""docket_id"": ""FDA-2012-D-0049"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0049-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0049/FDA-2012-D-0049-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:30:55,2025-05-28 03:53:06
bd1a4e6e-faba-42d1-98da-6db3861e091d,USA-FDA,4a69ebf8-03d0-42db-b13b-5d9dcb00b0ed,G_CONCISE_SUMMARY,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002/FDA-2020-D-1877-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Necessary Automated External Defibrillator Accessories: Policy Regarding Compliance Date; Guidance for Industry, Stakeholders, Health Care Professionals, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2020-D-1877"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1877-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:00:54,2025-05-28 03:53:06
bd1ebba8-aa5e-4a67-9a8e-a44e6d83ec59,USA-FDA,05caedd3-b141-4f79-95db-e79d4f1850d8,G_DETAILED_SUMMARY,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1161/FDA-2012-D-1161-0002/FDA-2012-D-1161-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Design Considerations for Devices Intended for Home Use - Draft Guidance"", ""docket_id"": ""FDA-2012-D-1161"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1161-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1161/FDA-2012-D-1161-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:32:54,2025-05-28 03:53:06
bd47da2b-9457-4ac9-bf43-0691f668edcc,USA-FDA,119e3f46-b4d8-490f-add6-6c8f0aa04974,G_IMPACT_ANALYSIS,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015/FDA-2010-D-0281-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; ��Harmful and Potentially Harmful Constituents� in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act�"", ""docket_id"": ""FDA-2010-D-0281"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0281-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:31,2025-05-28 03:53:06
bd90f4e9-9568-4a2a-ac1f-37186ec15abe,USA-FDA,d1d1f8a8-e323-45ed-a66b-1808e7df6952,G_DETAILED_SUMMARY,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0183/FDA-2004-D-0183-0003/FDA-2004-D-0183-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System Guidance for Industry\nand FDA Staff"", ""docket_id"": ""FDA-2004-D-0183"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0183-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0183/FDA-2004-D-0183-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:46:46,2025-05-28 03:53:06
bdb9322c-7e82-415b-ac0e-1ed1d914b7f6,USA-FDA,7a80fe20-9094-4129-8f6b-23b0a89e829d,G_ACTION_ITEMS,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002/FDA-2003-D-0416-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS"", ""docket_id"": ""FDA-2003-D-0416"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0416-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0416/FDA-2003-D-0416-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:47:40,2025-05-28 03:53:06
bdd3ee1c-ab59-438f-9f51-158337342afe,USA-FDA,f99b9f0c-31b9-4315-8eee-39f890127b98,G_DETAILED_SUMMARY,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0744/FDA-2013-D-0744-0002/FDA-2013-D-0744-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Antibacterial Therapies for Patients With Unmet Medical Need for the Treatment of Serious Bacterial Diseases"", ""docket_id"": ""FDA-2013-D-0744"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0744-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0744/FDA-2013-D-0744-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:16:59,2025-05-28 03:53:06
bddb1b92-0165-473e-ae40-d853cfa62363,USA-FDA,06bda4c8-0b6e-4e8b-8877-c284bef8f978,G_KEYWORDS,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002/FDA-2014-D-1891-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD"", ""docket_id"": ""FDA-2014-D-1891"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1891-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:16:24,2025-05-28 03:53:06
bde39360-da6a-45e4-b9a8-b554a3ba8465,USA-FDA,da412e6f-855a-4c98-ae15-f67a30a7c9fc,G_DETAILED_SUMMARY,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0196/FDA-2009-D-0196-0002/FDA-2009-D-0196-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Arsenic"", ""docket_id"": ""FDA-2009-D-0196"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0196-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0196/FDA-2009-D-0196-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:30:52,2025-05-28 03:53:06
be1c2420-dbaa-414b-a8dc-479280540186,USA-FDA,f47fbc01-ca40-4d70-84f7-0eb1eaaf3f47,G_FAQ,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002/FDA-2012-N-1239-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guideline for Industry and Food and Drug Administration Staff; Class II Special Controls Guideline: Temporary Mandibular Condyle Reconstruction Plate"", ""docket_id"": ""FDA-2012-N-1239"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-N-1239-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:32:08,2025-05-28 03:53:06
be2e4842-c2c0-4bc9-a11b-e943bdc67fed,SCHEDULED,2a7b00f1-0c1e-4cb1-baf1-c1a20711fafd,DEVICE_ANALYST,2025-05-29 00:00:04,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/2a7b00f1-0c1e-4cb1-baf1-c1a20711fafd"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:11,2025-05-29 00:00:11
be86bdaa-8e98-4211-b1e5-592c00ef76e3,USA-FDA,3cf26a90-5df1-49c4-baef-df36d509f3ac,G_IMPACT_ANALYSIS,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0013/FDA-1998-D-0035-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis and Interpretation of Clinical Studies"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:18:14,2025-05-28 03:53:06
be8a0d2a-4996-4b39-b719-1354781b528b,SCHEDULED,9e5d9bbe-8ee2-4419-9d91-1553f5246fcf,DEVICE_ANALYST,2025-05-26 00:00:07,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/9e5d9bbe-8ee2-4419-9d91-1553f5246fcf"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:25,2025-05-28 03:53:06
bea0b134-bc3a-4971-880a-f75884609e3a,USA-FDA,f59c2867-8b72-407d-a16b-1d50ddc975fa,G_DETAILED_SUMMARY,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1918/FDA-2020-D-1918-0001/FDA-2020-D-1918-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Food Additive Petition Expedited Review"", ""docket_id"": ""FDA-2020-D-1918"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1918-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1918/FDA-2020-D-1918-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:47:55,2025-05-28 03:53:06
bea59593-3c24-440c-9100-3198a0739d0c,USA-FDA,71b9052c-776f-439c-a254-f7ca5c450fb9,G_KEYWORDS,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002/FDA-2011-D-0602-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industryon Quality Considerations in Demonstrating Biosimilarity to Reference Protein Product"", ""docket_id"": ""FDA-2011-D-0602"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0602-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:35:00,2025-05-28 03:53:06
bebc6ed5-1c04-4b86-bcdb-b18abc8d6787,USA-FDA,c630fed9-f1f7-4d66-a920-854bfd420b8c,G_ACTION_ITEMS,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002/FDA-2013-D-0616-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0616-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:33:14,2025-05-28 03:53:06
bec8ad8c-17f6-48e0-b102-deb861de5f06,SCHEDULED,08092049-d759-404c-9380-65b48e0d9f23,DEVICE_ANALYST,2025-05-26 00:00:07,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/08092049-d759-404c-9380-65b48e0d9f23"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:18,2025-05-28 03:53:06
bed9041e-720d-4b3c-8c6c-6f3b8d8abc16,USA-FDA,7c2e25f9-6bce-48a5-9122-1d5f2b76f5b1,G_FAQ,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0009/FDA-2011-D-0620-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2011-D-0620"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0620-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:00:31,2025-05-28 03:53:06
bf110d3f-4fe3-49f7-9e00-4752108b1e8e,USA-FDA,9e822c9d-5953-40ac-bb98-3d8798fb6d6d,G_ACTION_ITEMS,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-2001/FDA-2015-D-2001-0002/FDA-2015-D-2001-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance Assessment of Male-Mediated Developmental Risk for Pharmaceuticals"", ""docket_id"": ""FDA-2015-D-2001"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-2001-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-2001/FDA-2015-D-2001-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:32:13,2025-05-28 03:53:06
bf13018d-5771-4285-9dbe-8602b755277e,USA-FDA,f9a62e85-8da4-485b-a8f8-8bbc3b69942e,G_CONCISE_SUMMARY,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004/FDA-2019-D-1372-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Elemental Impurities in Human Drug Products Questions and Answers Proposed DRAFT Guidance for Industry"", ""docket_id"": ""FDA-2019-D-1372"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-1372-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:59,2025-05-28 03:53:06
bf4abeeb-b72c-4a9b-b743-de875e9a5604,USA-FDA,034ed666-d8e4-4a16-90a6-576d6c4eb3f1,G_MINI_SUMMARY,2025-05-22 18:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0068/FDA-2013-D-0068-0002/FDA-2013-D-0068-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""International Conference on Harmonisation; Draft Guidance on S10 Photosafety Evaluation of Pharmaceuticals"", ""docket_id"": ""FDA-2013-D-0068"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0068-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0068/FDA-2013-D-0068-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:15:09,2025-05-28 03:53:06
bf60ba52-a0c2-45c4-928d-3c6e5393ca8d,USA-FDA,8db0f660-34fa-4f18-bbe7-60e7bfb2c754,G_CONCISE_SUMMARY,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001/FDA-2020-D-1408-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000; I Introduction"", ""docket_id"": ""FDA-2020-D-1408"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1408-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:39,2025-05-28 03:53:06
bf6a172a-8c6f-45ae-b0c1-07c49c09256b,USA-FDA,6bf3cb0c-7057-4523-9e53-d1a25506ec6d,G_IMPACT_ANALYSIS,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1358/FDA-2013-D-1358-0002/FDA-2013-D-1358-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation"", ""docket_id"": ""FDA-2013-D-1358"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1358-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1358/FDA-2013-D-1358-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:02:34,2025-05-28 03:53:06
bf7e092f-da16-4ec3-80e1-073af05a0e17,USA-FDA,bc752e40-3b7e-4354-b48b-bcfe5f31f866,G_CONCISE_SUMMARY,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002/FDA-2018-D-2583-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products; Guidance for Industry;  Draft Guidance"", ""docket_id"": ""FDA-2018-D-2583"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2583-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:02:37,2025-05-28 03:53:06
bfd7d874-ec6f-4d6f-bd92-7fadeb869a7e,CAB,6dd00847-0b11-4bb5-bce4-4411153b9ad0,G_FAQ_IN,2025-05-20 10:06:57,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,{},"{""tilte"": ""Rapporto_esplicativo_revisione_ordinanze_20240607.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/Rapporto_esplicativo_revisione_ordinanze_20240607.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""fb660f3f-a153-44fa-90cf-7ed1e0478417""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/fb660f3f-a153-44fa-90cf-7ed1e0478417"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:10:22,2025-05-28 03:53:06
bff0db7a-51b5-46ce-8f50-d127da6ea485,USA-FDA,d28a9984-2969-4bf0-af33-f85a27b9e011,G_FAQ,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002/FDA-2018-D-4525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Lactation Studies: Considerations for Study Design; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2018-D-4525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-4525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:17:41,2025-05-28 03:53:06
c0539df3-d4ad-4dc0-b7f0-16267c3539de,USA-FDA,449a3176-2643-40dd-af3d-bfdc12dc958b,G_FAQ,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0476/FDA-2011-D-0476-0010/FDA-2011-D-0476-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Enforcement Policy for Premarket Notification Requirements for Certain In Vitro Diagnostic and Radiology Devices"", ""docket_id"": ""FDA-2011-D-0476"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0476-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0476/FDA-2011-D-0476-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:31:36,2025-05-28 03:53:06
c0799cf1-dec7-4ba1-a05e-e09ea42b9c26,USA-FDA,c197f74b-016e-45ac-9df9-393ae4ac7fb1,G_IMPACT_ANALYSIS,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002/FDA-2011-D-0487-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of Acceptable Full-Length and Abbreviated Donor History Questinnaries and Accompanying Materials for Use in Screening Donors of Source Plasma Draft Guidence"", ""docket_id"": ""FDA-2011-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0487-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:31:31,2025-05-28 03:53:06
c0b78164-5548-49e8-b054-e50038eea70e,USA-FDA,396f38f5-b4a4-401e-907d-c3ac2f433127,G_DETAILED_SUMMARY,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0391/FDA-2008-D-0391-0014/FDA-2008-D-0391-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Submission of Documentation: Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes"", ""docket_id"": ""FDA-2008-D-0391"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0391-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0391/FDA-2008-D-0391-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:46:09,2025-05-28 03:53:06
c0b91354-5240-4e4b-a80d-e95c0110f8d9,Queue,968c7c01-fb02-434d-9911-174101584bbf,G_TRANSLATE,2025-05-30 03:30:16,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""c_986569 (9).pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/968c7c01-fb02-434d-9911-174101584bbf/c_986569 (9).pdf.pdf"", ""doc_title"": ""c_986569 (9).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/968c7c01-fb02-434d-9911-174101584bbf"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 03:30:15,2025-05-30 03:30:15
c0fa8dd5-91ec-4bcf-99ac-a59af1007b00,USA-FDA,eea0045e-de9c-466c-bff6-bd0dff8727e2,G_ACTION_ITEMS,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1318/FDA-2014-D-1318-0002/FDA-2014-D-1318-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1318"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1318-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1318/FDA-2014-D-1318-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:16:46,2025-05-28 03:53:06
c11fd8a2-f0ce-4081-ac37-53724807fbcc,USA-FDA,d3b0869b-0662-4ee0-8fc8-10b4171c8f84,G_FAQ,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-D-0621/FDA-2021-D-0621-0001/FDA-2021-D-0621-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #50 Target Animal and Human Food Safety, Drug Efficacy, Environmental and Manufacturing Studies for Teat Antiseptic Products"", ""docket_id"": ""FDA-2021-D-0621"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-D-0621-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-D-0621/FDA-2021-D-0621-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:01:11,2025-05-28 03:53:06
c121ee02-5feb-42e0-bccb-5251b0a6652a,USA-FDA,c8d46811-e68b-4f7f-93e6-e313fe4d0a5d,G_FAQ,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1189/FDA-2018-D-1189-0002/FDA-2018-D-1189-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Concentrated Caffeine in Dietary Supplements: Guidance for Industry"", ""docket_id"": ""FDA-2018-D-1189"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-1189-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1189/FDA-2018-D-1189-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:33:18,2025-05-28 03:53:06
c12be499-666e-4d2c-a65d-d90560fed1e8,USA-FDA,9cd41a24-9ec1-4820-97fd-b362e13a260c,G_ACTION_ITEMS,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009/FDA-2003-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI"", ""docket_id"": ""FDA-2003-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:31:01,2025-05-28 03:53:06
c135ad9c-0fb8-48de-a5d6-0616dd35c275,USA-FDA,fc6ba039-a4ac-419a-abf7-e9a17d3b13a1,G_FAQ,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001/FDA-2020-D-1945-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a)"", ""docket_id"": ""FDA-2020-D-1945"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1945-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:48,2025-05-28 03:53:06
c14ca752-e976-472c-9f48-8cf4e7d0ad12,USA-FDA,e68fd12f-acf1-4c4d-a317-7c6b28aad04e,G_MINI_SUMMARY,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008/FDA-1999-D-0128-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cooperative Manufacturing Arrangements for Licensed Biologics"", ""docket_id"": ""FDA-1999-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0128-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:31:34,2025-05-28 03:53:06
c191a5db-c22f-4d66-9890-673467cbb94b,USA-FDA,b6c2ae64-d009-485a-aa16-46b04f631de0,G_MINI_SUMMARY,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0146/FDA-2010-D-0146-0012/FDA-2010-D-0146-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Irritable Bowel Syndrome Clinical Evaluation of Drugs for Treatment"", ""docket_id"": ""FDA-2010-D-0146"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0146-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0146/FDA-2010-D-0146-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:16:02,2025-05-28 03:53:06
c198bd46-14af-42a7-9172-df1cf460cc02,USA-FDA,bbe9ffd8-7332-41bd-a91f-1044c67b683e,G_DETAILED_SUMMARY,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002/FDA-2008-D-0576-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sponsors, Clinical Investigators, and IRBs - Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials"", ""docket_id"": ""FDA-2008-D-0576"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0576-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:16:32,2025-05-28 03:53:06
c1c01a1d-100d-469c-9c1c-1f04c94ddb58,SCHEDULED,ba01cfca-4fb5-4633-8809-298b87573c7c,FDA_ALERT,2025-05-29 00:00:04,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/ba01cfca-4fb5-4633-8809-298b87573c7c"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:13,2025-05-29 00:00:13
c1d8cc24-680a-492d-8614-e09fb560a102,USA-FDA,bd9b2409-bcd0-43c9-ac98-ceb7cb53c9d8,G_IMPACT_ANALYSIS,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1978-N-0011/FDA-1978-N-0011-0008/FDA-1978-N-0011-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidelines for Effectiveness Testing of O. T. C. Antiperspirant Drug Products"", ""docket_id"": ""FDA-1978-N-0011"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1978-N-0011-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1978-N-0011/FDA-1978-N-0011-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:46:31,2025-05-28 03:53:06
c1e39bda-0cd1-4110-9459-a99e712a40df,USA-FDA,8f2aa143-842c-4bc4-a27e-21515ddcfa39,G_FAQ,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002/FDA-2011-D-0602-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industryon Quality Considerations in Demonstrating Biosimilarity to Reference Protein Product"", ""docket_id"": ""FDA-2011-D-0602"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0602-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:34:40,2025-05-28 03:53:06
c1e5b1ad-5767-42dd-a2d2-0e914e47a1bf,USA-FDA,7db8ca00-b248-4f81-a0ca-a7ac54b05209,G_IMPACT_ANALYSIS,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005/FDA-2011-D-0112-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Chemistry, Manufacturing, and Controls (CMC)\nInformation � Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use"", ""docket_id"": ""FDA-2011-D-0112"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0112-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:31:35,2025-05-28 03:53:06
c20e0168-24f8-409e-982b-a5643240a4c1,USA-FDA,1ea59747-724a-4817-98a8-a3a137a19e84,G_DETAILED_SUMMARY,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004/FDA-2007-D-0302-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Labeling for Human Prescription Drug and Biological Products � Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information"", ""docket_id"": ""FDA-2007-D-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0302-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:02:59,2025-05-28 03:53:06
c2493748-5232-4a3e-805f-060bae3d5c87,SCHEDULED,5f73fc40-5bb5-4168-99e1-a8bd161c114f,DEVICE_ANALYST,2025-05-25 00:00:04,32,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/device_analyst/5f73fc40-5bb5-4168-99e1-a8bd161c114f"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:28,2025-05-28 03:53:06
c24d04fb-790b-4fbf-bb51-cbdfbe7be339,USA-FDA,90715eca-58a3-4a3e-82db-f630db069d6b,G_CONCISE_SUMMARY,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001/FDA-2023-D-2510-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)"", ""docket_id"": ""FDA-2023-D-2510"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2510-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:31:01,2025-05-28 03:53:06
c27aaa79-98a3-4a63-960d-830eaf5a28c0,USA-FDA,d17378f3-5466-48aa-909d-6c62332870b0,G_KEYWORDS,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002/FDA-2010-D-0395-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Adminstration Staff Recommendation for Premarket Notification for Lamotrigine and Zonisamide Assays"", ""docket_id"": ""FDA-2010-D-0395"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0395-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0395/FDA-2010-D-0395-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:12,2025-05-28 03:53:06
c2f9afba-705c-4756-bb95-a1ed24b7755c,SCHEDULED,09a252d7-5a9e-4c31-8a87-a2425874334d,FDA_ALERT,2025-05-29 00:00:04,30,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/fda_alert/09a252d7-5a9e-4c31-8a87-a2425874334d"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:30,2025-05-29 00:00:30
c3336e4a-7da7-499b-b3a9-08d5e64bdf6f,USA-FDA,a234e5d4-820d-4540-a9f6-af23f1fb4fdc,G_ACTION_ITEMS,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0436/FDA-2011-D-0436-0002/FDA-2011-D-0436-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Q11 Development and Manufacture of Drug Substances; International Conference on Harmonisation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0436"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0436-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0436/FDA-2011-D-0436-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:31:32,2025-05-28 03:53:06
c34d926d-3e94-47bb-8128-dc476268d556,USA-FDA,c31bb93c-4267-430e-bcf2-1e59bcf03f9a,G_IMPACT_ANALYSIS,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0205/FDA-2008-D-0205-0034/FDA-2008-D-0205-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"", ""docket_id"": ""FDA-2008-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0205-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0205/FDA-2008-D-0205-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:47:43,2025-05-28 03:53:06
c372479a-9d28-4c8c-9499-ff76fa0a7b13,USA-FDA,297dd09f-2d1e-466e-a2d8-df2463e37a46,G_ACTION_ITEMS,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0002/FDA-2012-D-1083-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff; Civil Responses to Frequently Asked Question"", ""docket_id"": ""FDA-2012-D-1083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1083-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:04:23,2025-05-28 03:53:06
c3a60b9a-0da1-40fd-9069-2c664bdd5554,USA-FDA,846f1f97-ab59-4753-9a7c-ded1925ecef6,G_DETAILED_SUMMARY,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002/FDA-2018-D-4525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Lactation Studies: Considerations for Study Design; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2018-D-4525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-4525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:17:25,2025-05-28 03:53:06
c3bbed7e-2c3b-4d19-a6b5-e813554ef1e8,USA-FDA,a93d60e2-49f0-4983-9818-977227b22595,G_DETAILED_SUMMARY,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002/FDA-2009-D-0354-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Pharmaceutical Components at Risk for Melamine Contamination"", ""docket_id"": ""FDA-2009-D-0354"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0354-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:02:26,2025-05-28 03:53:06
c3c2e8e3-d655-47f9-8c58-4b138c7a9d9f,USA-FDA,0d800b43-d462-49d7-ae8b-579c097a38fe,G_DETAILED_SUMMARY,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0531/FDA-2004-D-0531-0001/FDA-2004-D-0531-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations to Processors of Apple Juice or Cider on the Use of Ozone for Pathogen Reduction Purposes"", ""docket_id"": ""FDA-2004-D-0531"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0531-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0531/FDA-2004-D-0531-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:15:17,2025-05-28 03:53:06
c3ec4c46-bcdf-45a7-92db-e5ed711712f0,USA-FDA,620ce3c1-79ba-4132-808a-ac4d0fdad0c3,G_IMPACT_ANALYSIS,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004/FDA-2019-D-1372-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Elemental Impurities in Human Drug Products Questions and Answers Proposed DRAFT Guidance for Industry"", ""docket_id"": ""FDA-2019-D-1372"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-1372-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:02:32,2025-05-28 03:53:06
c3ed08a4-2f0c-4f20-b1c8-5755c8b0f772,USA-FDA,a04a6e1d-a720-49ce-a635-e3398754133a,G_ACTION_ITEMS,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0712/FDA-2016-D-0712-0002/FDA-2016-D-0712-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported  Outcome, for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use DRAFT GUIDANCE"", ""docket_id"": ""FDA-2016-D-0712"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0712-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0712/FDA-2016-D-0712-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:16:31,2025-05-28 03:53:06
c4019772-76ad-4c8e-aa0f-645aa5c6e5bd,USA-FDA,124d0046-06f8-45bd-a281-7cdc8d325915,G_IMPACT_ANALYSIS,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002/FDA-2012-D-0022-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Direct-to-Consumer Television Advertisements, etc."", ""docket_id"": ""FDA-2012-D-0022"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0022-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0022/FDA-2012-D-0022-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:30:48,2025-05-28 03:53:06
c40e3f9a-ba6f-4d8e-a7a5-9f58de576743,USA-FDA,2c5016bb-f45a-4772-82ac-0029986bfda5,G_ACTION_ITEMS,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0567/FDA-2011-D-0567-0002/FDA-2011-D-0567-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry, Clinical Investigators and Staff; Design Considerations for Pivotal Clinical Investigations for Medical Devices"", ""docket_id"": ""FDA-2011-D-0567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0567-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0567/FDA-2011-D-0567-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:01:15,2025-05-28 03:53:06
c40f737e-efc5-4a7f-8a04-ee09fa796c80,USA-FDA,09f0fccf-b05b-4a95-8ba7-1c8a2cec5f9f,G_IMPACT_ANALYSIS,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002/FDA-2012-N-1239-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guideline for Industry and Food and Drug Administration Staff; Class II Special Controls Guideline: Temporary Mandibular Condyle Reconstruction Plate"", ""docket_id"": ""FDA-2012-N-1239"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-N-1239-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:32:30,2025-05-28 03:53:06
c4305d4f-cd8e-4743-a6dd-2e12ee50081e,USA-FDA,a53a215d-e6c2-4ca8-9b88-ce65c751172d,G_FAQ,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5960/FDA-2017-D-5960-0002/FDA-2017-D-5960-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5960"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5960-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5960/FDA-2017-D-5960-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:30:58,2025-05-28 03:53:06
c437f19b-89c6-43a6-a8e6-a08fab720ffc,USA-FDA,11a563f9-2134-4787-bb81-d9a584ad018b,G_IMPACT_ANALYSIS,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010/FDA-2004-D-0500-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Consumer-Directed Broadcast Advertising of Restricted Devices; Draft Guidance for Industry"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:02:18,2025-05-28 03:53:06
c4a2b916-e1ca-4c42-8655-f3638f9d6db1,USA-FDA,8f6d88ea-14b8-42d9-8b30-c805f0756d28,G_DETAILED_SUMMARY,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-0298/FDA-2019-D-0298-0002/FDA-2019-D-0298-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Quality Considerations for Continuous Manufacturing; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2019-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-0298-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-0298/FDA-2019-D-0298-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:45:30,2025-05-28 03:53:06
c4ea7e6f-b7df-45a0-b06f-048c7f076606,USA-FDA,8b22031b-aac6-4895-97d5-e79f25ae5af1,G_ACTION_ITEMS,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1935/FDA-2020-D-1935-0001/FDA-2020-D-1935-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 100.550 Status and Responsibilities of Contract Sterilizers Engaged in the Sterilization of Drugs and Devices"", ""docket_id"": ""FDA-2020-D-1935"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1935-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1935/FDA-2020-D-1935-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:46:04,2025-05-28 03:53:06
c4f64b3b-f56a-4230-a7d4-99a7402b47cb,USA-FDA,42e162ad-7e69-4278-902d-31c07fce68d3,G_MINI_SUMMARY,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1978/FDA-2020-D-1978-0001/FDA-2020-D-1978-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects"", ""docket_id"": ""FDA-2020-D-1978"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1978-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1978/FDA-2020-D-1978-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:15:45,2025-05-28 03:53:06
c4ffc42f-019d-412c-9da9-9bd754d9540f,USA-FDA,fe5d38e5-32cb-471f-b487-1ec9cff39d1a,G_DETAILED_SUMMARY,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009/FDA-2011-D-0398-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Questions and Answers Regarding The Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2011-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0398-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0398/FDA-2011-D-0398-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:31:04,2025-05-28 03:53:06
c5004ccb-2e7d-43f3-bfaa-9a1469884372,SCHEDULED,1f5febeb-6610-4500-a919-76b85abe393b,DEVICE_ANALYST,2025-05-21 20:33:25,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/1f5febeb-6610-4500-a919-76b85abe393b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:36,2025-05-28 03:53:06
c51282ab-221d-4589-81db-69f22e0a7439,USA-FDA,7ba415f7-ce82-406f-8cbb-1ee82f5d0012,G_MINI_SUMMARY,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610/FDA-2016-D-4414-1610-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nutrition and Supplement Facts Labels: Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals: Guidance for Industry"", ""docket_id"": ""FDA-2016-D-4414"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-4414-1610""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-4414/FDA-2016-D-4414-1610"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:15:09,2025-05-28 03:53:06
c5180ff0-7abe-43f9-9f5f-6461103fd46f,USA-FDA,942496a9-dcf2-4381-92b0-f4af68d411dc,G_DETAILED_SUMMARY,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1279/FDA-2013-D-1279-0002/FDA-2013-D-1279-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Development Tools; Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-1279"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1279-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1279/FDA-2013-D-1279-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:00:55,2025-05-28 03:53:06
c545bb52-8e1b-4cd4-b7ba-c08cdc94ac77,SCHEDULED,e9a711a6-7ba8-44ac-ab15-5b02cca87489,FDA_ALERT,2025-05-25 00:00:04,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-25""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/e9a711a6-7ba8-44ac-ab15-5b02cca87489"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-25 00:00:25,2025-05-28 03:53:06
c560c5ac-ee1a-41c1-9632-6f4b52fb2d9f,USA-FDA,28a0a6f0-3bee-480c-a76d-be5d3bf4f48f,G_ACTION_ITEMS,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011/FDA-1997-D-0444-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance on FDA Approval of New Animal Drugs for Minor Uses and for Minor Species; Guidance Document (Revised May 29, 2008)"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:00:56,2025-05-28 03:53:06
c5a64637-0ed2-40ab-8378-c8376e705c29,USA-FDA,9d7f2072-65c0-4a44-b4a4-70b022b55794,G_MINI_SUMMARY,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015/FDA-2010-D-0281-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; ��Harmful and Potentially Harmful Constituents� in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act�"", ""docket_id"": ""FDA-2010-D-0281"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0281-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:08,2025-05-28 03:53:06
c5b69271-e399-43bd-b921-382acb10e895,SCHEDULED,a33d8cd7-f066-4b9a-b270-ba43d94eabed,FDA_ALERT,2025-05-20 13:40:01,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-03-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/a33d8cd7-f066-4b9a-b270-ba43d94eabed"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:40:22,2025-05-28 03:53:06
c5c75686-0d96-409b-becb-548f80424f02,SCHEDULED,85430d40-b2c0-45ee-8fa7-7f09b7e93b6b,FDA_ALERT,2025-05-24 00:00:05,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/85430d40-b2c0-45ee-8fa7-7f09b7e93b6b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:20,2025-05-28 03:53:06
c5cb3ae6-daab-4e18-8bfb-d8cb30532d37,USA-FDA,c1ac89b7-f5a8-4b16-95d6-7cc95f2b5cca,G_CONCISE_SUMMARY,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005/FDA-2010-D-0163-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (VICH GL46)"", ""docket_id"": ""FDA-2010-D-0163"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0163-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:30:12,2025-05-28 03:53:06
c5cf5348-3456-45c3-b5ba-8ee8a6259909,USA-FDA,c6b7073d-4268-4e47-8202-f68051283187,G_MINI_SUMMARY,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005/FDA-2010-D-0163-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (VICH GL46)"", ""docket_id"": ""FDA-2010-D-0163"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0163-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:30:08,2025-05-28 03:53:06
c62a208b-f975-4b07-8550-21beb05c03bb,USA-FDA,bf9dd1bf-f67e-4e15-8427-c18780f80db3,G_FAQ,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002/FDA-1997-D-0444-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""FDA Approval of Animal Drugs for Minor Uses and Minor Species; Draft Guidance Document"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:56,2025-05-28 03:53:06
c631913c-2acb-4efa-a469-6ff313186f8f,SCHEDULED,f8a1ed0f-ca74-473d-a5aa-0162614cd463,DEVICE_ANALYST,2025-05-29 00:00:04,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/f8a1ed0f-ca74-473d-a5aa-0162614cd463"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:23,2025-05-29 00:00:23
c63ce7cd-3094-4349-bea9-8f2d9960ede2,USA-FDA,88e71380-2fb0-4a84-8bf6-006858a2475c,G_DETAILED_SUMMARY,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022/FDA-1998-N-0050-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 540.375 Canned Salmon - Adulteration Involving Decomposition Withdrawn 3-22-2010"", ""docket_id"": ""FDA-1998-N-0050"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-N-0050-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-N-0050/FDA-1998-N-0050-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:16,2025-05-28 03:53:06
c6501cbe-2dcf-463b-8f00-1b180a9f0053,QUEUE,87f91274-746a-43be-aac7-274354a5d059,G_MINI_SUMMARY_USER,2025-05-20 10:44:46,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__doc_title__"": ""FDA-2024-N-1111-0001_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/87f91274-746a-43be-aac7-274354a5d059/SRC/87f91274-746a-43be-aac7-274354a5d059.pdf"", ""doc_title"": ""FDA-2024-N-1111-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/87f91274-746a-43be-aac7-274354a5d059/DEST/mini_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:44:50,2025-05-28 03:53:06
c6634c19-3634-4b95-8c93-f0d736d640d8,SCHEDULED,f3fa5001-3ec4-4a36-b5a0-69cd6ebf4221,FDA_ALERT,2025-05-29 00:00:04,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/f3fa5001-3ec4-4a36-b5a0-69cd6ebf4221"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:25,2025-05-29 00:00:25
c6832e22-b012-4f7d-889a-a30ddd1ae5fa,USA-FDA,e0b32dbb-e0b1-4a3f-bb58-a29d6c13c1ed,G_MINI_SUMMARY,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0057/FDA-2011-D-0057-0021/FDA-2011-D-0057-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff ;  Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data"", ""docket_id"": ""FDA-2011-D-0057"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0057-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0057/FDA-2011-D-0057-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:01:51,2025-05-28 03:53:06
c686ab4e-2457-4fba-9c08-a9d1d37998cc,USA-FDA,1c40b52b-d20c-49a8-81ff-bf77c8fe1439,G_IMPACT_ANALYSIS,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1927/FDA-2020-D-1927-0001/FDA-2020-D-1927-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Food Security Preventive Measures Guidance for  Retail Food Stores and Food Service Establishments"", ""docket_id"": ""FDA-2020-D-1927"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1927-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1927/FDA-2020-D-1927-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:01:02,2025-05-28 03:53:06
c69a2e08-e6fe-4160-b6c0-bf11c93f3435,USA-FDA,9e824c62-c0c8-4789-a749-261d2f70b936,G_MINI_SUMMARY,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034/FDA-2002-D-0094-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Food and Drug Administration Advisory\nCommittee Members, and Food and Drug Administration Staff: Public\nAvailability of Advisory Committee Members� Financial Interest\nInformation and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:30:09,2025-05-28 03:53:06
c6b8ab07-f7ae-420d-9691-b63ea1edbf79,USA-FDA,1a2b28a0-b498-4780-b95d-433ba8e3c4a0,G_IMPACT_ANALYSIS,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001/FDA-2020-D-1408-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000; I Introduction"", ""docket_id"": ""FDA-2020-D-1408"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1408-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:01:06,2025-05-28 03:53:06
c6caf44a-0e8d-49f1-865c-d30201995c64,USA-FDA,4ac62993-2194-4374-ad9d-5455bba78af7,G_MINI_SUMMARY,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002/FDA-2011-D-0480-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products"", ""docket_id"": ""FDA-2011-D-0480"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0480-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:30:08,2025-05-28 03:53:06
c7055f18-6eb2-4e6d-8354-531e22d195c4,USA-FDA,5e03dc1f-c9d5-4f34-be20-efbfc2319098,G_MINI_SUMMARY,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005/FDA-1999-D-4079-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling"", ""docket_id"": ""FDA-1999-D-4079"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4079-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:31:48,2025-05-28 03:53:06
c71b7ebe-67d5-4392-91a8-9aff3a65a2a4,USA-FDA,a5351586-56fe-4a50-8155-1f3da857d6f9,G_IMPACT_ANALYSIS,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5140/FDA-2017-D-5140-0002/FDA-2017-D-5140-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Display Devices for Diagnostic Radiology"", ""docket_id"": ""FDA-2017-D-5140"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5140-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5140/FDA-2017-D-5140-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:17:11,2025-05-28 03:53:06
c72e38e3-d3b8-400d-9179-2e71fea5d941,USA-FDA,f985d222-f918-49a7-8232-c24bf8ec45a3,G_MINI_SUMMARY,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0310/FDA-2014-D-0310-0002/FDA-2014-D-0310-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Immunogenicity-Related\nConsiderations for the Approval of Low Molecular Weight Heparin for New Drug Applications and Abbreviated New Drug Applications"", ""docket_id"": ""FDA-2014-D-0310"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-0310-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0310/FDA-2014-D-0310-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:30:54,2025-05-28 03:53:06
c737fbb3-b189-413e-b47a-0fef440da977,USA-FDA,44dace9f-c74b-4a04-a0c1-36d24260de93,G_FAQ,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0201/FDA-2007-D-0201-0005/FDA-2007-D-0201-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content and Format of the Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products"", ""docket_id"": ""FDA-2007-D-0201"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0201-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0201/FDA-2007-D-0201-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:46:41,2025-05-28 03:53:06
c74b2f35-483d-4824-9493-5a18c84119d0,USA-FDA,6964056b-9403-4daa-823f-a53daa289aba,G_FAQ,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021/FDA-2005-D-0282-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:31:48,2025-05-28 03:53:06
c74d231b-bf89-4064-a225-346f8eaee26c,USA-FDA,6250c5a1-cb3e-441a-a812-7ca0feae5a8b,G_FAQ,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011/FDA-1998-D-0035-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:01:16,2025-05-28 03:53:06
c755e9db-c23c-492a-b4e8-2306fafb757b,USA-FDA,de54e478-a563-4a53-a56c-ad41ca1b0efb,G_DETAILED_SUMMARY,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002/FDA-2010-D-0404-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use--Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0404"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0404-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:33:12,2025-05-28 03:53:06
c7aa3013-c26e-4e51-8deb-ee39c0591d3a,USA-FDA,7e6aab90-5ba7-4369-ae78-6460b14a4905,G_FAQ,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0523/FDA-2012-D-0523-0012/FDA-2012-D-0523-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; Refuse to Accept Policy for 510(k)s"", ""docket_id"": ""FDA-2012-D-0523"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0523-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0523/FDA-2012-D-0523-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:45:52,2025-05-28 03:53:06
c7c6fcd8-5846-4fe4-9d45-353e53577ca7,USA-FDA,87753276-dab6-47ae-b5eb-b8a59be80208,G_DETAILED_SUMMARY,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002/FDA-2011-D-0147-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Staff Demonstrating Substantial Equivalence of New Tobacco Product; Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2011-D-0147"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0147-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:30:22,2025-05-28 03:53:06
c80a0629-7bdf-4946-942d-48ff1513c610,QUEUE,628a380b-4a2f-4e6a-bf68-cde055ab72de,G_COMPARE_DOCUMENTS,2025-05-23 18:30:16,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/compare_documents/628a380b-4a2f-4e6a-bf68-cde055ab72de/FDA-2008-P-0086-0037_content.pdf.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""child_document_title"": ""FDA-2008-P-0086-0037.pdf"", ""master_document_title"": ""Provisions for In-vitro Diagnostic Reagent Registration (Abolished).pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/compare_documents/628a380b-4a2f-4e6a-bf68-cde055ab72de/Provisions for In-vitro Diagnostic Reagent Registration (Abolished).pdf.pdf"", ""doc_title"": ""Provisions for In-vitro Diagnostic Reagent Registration (Abolished).pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""doc_compare_title"": ""FDA-2008-P-0086-0037.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/compare_documents/628a380b-4a2f-4e6a-bf68-cde055ab72de"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 18:30:27,2025-05-28 03:53:06
c81f804b-c913-468c-8eca-65c13e796900,USA-FDA,7a794a86-4bd0-43f8-995e-4318b7511743,G_ACTION_ITEMS,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005/FDA-2011-D-0643-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; What You Need to Know About Administrative Detention of Foods; Small Entity Compliance Guide; Final Guidance"", ""docket_id"": ""FDA-2011-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0643-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:31:28,2025-05-28 03:53:06
c82c33f6-9567-46ed-9383-384a651212b8,USA-FDA,4d274ed1-0cd5-4801-b71a-4fcf6156e69d,G_DETAILED_SUMMARY,2025-05-19 23:42:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001/FDA-2017-D-5478-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""MRCT Draft FDA Guidance Return of Aggregate Results"", ""docket_id"": ""FDA-2017-D-5478"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5478-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 03:43:10,2025-05-28 03:53:06
c850d3be-6bc7-45ef-ae41-92c02e61cd26,USA-FDA,53586761-c92f-4cb1-bef9-e4687e5f4cf6,G_MINI_SUMMARY,2025-05-19 23:42:39,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001/FDA-2017-D-5478-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""MRCT Draft FDA Guidance Return of Aggregate Results"", ""docket_id"": ""FDA-2017-D-5478"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5478-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5478/FDA-2017-D-5478-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 03:42:50,2025-05-28 03:53:06
c86f847a-2ea9-49c6-9fe2-8ddb6ddc4f17,USA-FDA,08233184-5500-4aea-b7b8-938c7218e6ae,G_IMPACT_ANALYSIS,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0490/FDA-2011-D-0490-0002/FDA-2011-D-0490-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that are Color Additives; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0490-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0490/FDA-2011-D-0490-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:17:04,2025-05-28 03:53:06
c8754c78-bd6c-48e8-b58b-99868a58c186,Queue,9f591146-c684-48cd-aec4-3d00d59c7e05,G_CONCISE_SUMMARY_USER,2025-05-29 22:15:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""num_paragraphs"": 3}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/9f591146-c684-48cd-aec4-3d00d59c7e05/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/concise_summary/9f591146-c684-48cd-aec4-3d00d59c7e05"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 16:45:16,2025-05-29 16:45:16
c8770871-6d18-4106-9a55-12b43671f656,USA-FDA,5f467987-1214-4144-a27a-9af6ecc8ea8b,G_CONCISE_SUMMARY,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002/FDA-2012-N-1239-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guideline for Industry and Food and Drug Administration Staff; Class II Special Controls Guideline: Temporary Mandibular Condyle Reconstruction Plate"", ""docket_id"": ""FDA-2012-N-1239"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-N-1239-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-N-1239/FDA-2012-N-1239-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:31:46,2025-05-28 03:53:06
c87cb66f-df86-4423-b756-cb0119d1c845,USA-FDA,1a41b6f3-7f31-45b7-bbbf-15c51677b8d3,G_KEYWORDS,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002/FDA-2017-D-2462-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:02:29,2025-05-28 03:53:06
c89678b2-893f-49fc-8751-72d9e61f0201,SCHEDULED,c1086cef-ef6b-4366-8d17-aac7f0cdf12b,FDA_ALERT,2025-05-26 00:00:07,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/c1086cef-ef6b-4366-8d17-aac7f0cdf12b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:22,2025-05-28 03:53:06
c897052e-0675-4b68-96cc-0105156754c5,USA-FDA,c3641ff6-e63f-4343-ba72-fbfe83ede917,G_ACTION_ITEMS,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011/FDA-1998-D-0035-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments"", ""docket_id"": ""FDA-1998-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1998-D-0035-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1998-D-0035/FDA-1998-D-0035-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:01:26,2025-05-28 03:53:06
c8cc5302-3b12-4f6c-b745-8c6c1cb719a1,USA-FDA,ec4bf8fa-1530-415e-acd7-2a18f244a03a,G_FAQ,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008/FDA-1999-D-0128-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cooperative Manufacturing Arrangements for Licensed Biologics"", ""docket_id"": ""FDA-1999-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0128-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:32:08,2025-05-28 03:53:06
c8e6c122-be3a-442a-9564-b80087ff54f0,USA-FDA,e75a51a6-4d73-4846-94c9-9a26f8aa0cff,G_MINI_SUMMARY,2025-05-20 12:08:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002/FDA-2011-D-0597-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring"", ""docket_id"": ""FDA-2011-D-0597"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0597-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:09:02,2025-05-28 03:53:06
c8efed35-cfcd-4fb3-8bbb-56dc43889c19,USA-FDA,fe9b5381-75c3-4ae9-b88c-43c1bb22eee0,G_FAQ,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0545/FDA-2016-D-0545-0099/FDA-2016-D-0545-0099-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components; Guidance for Industry"", ""docket_id"": ""FDA-2016-D-0545"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0545-0099""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0545/FDA-2016-D-0545-0099"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:30:34,2025-05-28 03:53:06
c8f7fa9d-2074-41d3-ba9e-f2f4f8aec93b,USA-FDA,b630d12c-ef82-4763-b645-4cdba0af686d,G_MINI_SUMMARY,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2635/FDA-2016-D-2635-0269/FDA-2016-D-2635-0269-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Potential Approach for Defining Durations of Use for Medically Important Antimicrobial Drugs Intended for Use In or On Feed: A Concept Paper"", ""docket_id"": ""FDA-2016-D-2635"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2635-0269""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2635/FDA-2016-D-2635-0269"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:30:10,2025-05-28 03:53:06
c941f106-30fa-489f-8b61-d8607ef50dcb,USA-FDA,55f9e856-9d9f-4280-9544-471ae648391b,G_ACTION_ITEMS,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0268/FDA-2009-D-0268-0005/FDA-2009-D-0268-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0268"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0268-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0268/FDA-2009-D-0268-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:30:34,2025-05-28 03:53:06
c9a84cdc-8d2b-4965-961c-4e029c4acb72,USA-FDA,97d4e58a-4e7b-487c-9991-291f2e44e6fb,G_MINI_SUMMARY,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012/FDA-2008-D-0610-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic"", ""docket_id"": ""FDA-2008-D-0610"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0610-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:31:55,2025-05-28 03:53:06
c9bb5e9a-4868-41eb-88bc-470dc63b927d,USA-FDA,fda48b50-ccb5-4b1d-a972-76f813382dc9,G_DETAILED_SUMMARY,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001/FDA-2020-D-0367-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""External Guidance Document Submission from Turner Scientific, LLC re: Ototoxicity: Nonclinical Evaluation During Drug Development"", ""docket_id"": ""FDA-2020-D-0367"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-0367-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:15,2025-05-28 03:53:06
c9c200da-a0ad-4432-9ef1-9a160b9ebe39,USA-FDA,9435b2f9-2fc2-427f-9562-3214f907b7c6,G_IMPACT_ANALYSIS,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020/FDA-2015-D-1245-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:03:18,2025-05-28 03:53:06
c9d6c1d6-482b-415f-9f2d-0e89c455d770,USA-FDA,1410996e-95b6-4da1-ad0b-d8bb1da438f5,G_MINI_SUMMARY,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0183/FDA-2004-D-0183-0003/FDA-2004-D-0183-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System Guidance for Industry\nand FDA Staff"", ""docket_id"": ""FDA-2004-D-0183"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0183-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0183/FDA-2004-D-0183-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:46:35,2025-05-28 03:53:06
c9d899ba-9522-42be-bdc4-67bf9d4a7b2f,USA-FDA,ea0731f7-c728-42dc-8e8e-344f71b6b98c,G_FAQ,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-N-0464/FDA-2005-N-0464-0231/FDA-2005-N-0464-0231-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guideline re Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Drug Establishment Registration and Drug Listing; Availability"", ""docket_id"": ""FDA-2005-N-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-N-0464-0231""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-N-0464/FDA-2005-N-0464-0231"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:17:27,2025-05-28 03:53:06
c9dd4d52-cb0a-4d31-9885-9b38b8ea6e9f,USA-FDA,f45bc23a-0a45-4518-8c05-e88708a5c0b4,G_KEYWORDS,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002/FDA-2011-D-0469-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and the Food and Drug Administration Staff: Applying Human Factors and Usability Engineering to Optimize Medical Device Design - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0469"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0469-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0469/FDA-2011-D-0469-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:47:39,2025-05-28 03:53:06
c9e50ff5-1fa1-4945-b99c-87f858f0344f,USA-FDA,c5484c06-a528-4ccc-a234-8a154ce85c17,G_IMPACT_ANALYSIS,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112/FDA-2000-N-0190-0112-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Outdoor Access)"", ""docket_id"": ""FDA-2000-N-0190"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-N-0190-0112""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:03:58,2025-05-28 03:53:06
ca14a2bc-ce14-421f-9b0a-62b7429e802d,USA-FDA,01f40747-3e20-443d-94b1-0179815c2097,G_IMPACT_ANALYSIS,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0002/FDA-2014-D-1399-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Draft Guidance Document"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:16:18,2025-05-28 03:53:06
ca2e0edd-44bd-4642-9528-8527a7affc46,USA-FDA,77e35df9-81c2-4524-ade7-f84cb3444838,G_MINI_SUMMARY,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0205/FDA-2008-D-0205-0034/FDA-2008-D-0205-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"", ""docket_id"": ""FDA-2008-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0205-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0205/FDA-2008-D-0205-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:46:20,2025-05-28 03:53:06
ca5df0e5-c2de-4eee-833f-2888757b40ab,SCHEDULED,56c04275-df1a-4cd5-93cd-bbc4ceadca8e,DEVICE_ANALYST,2025-05-27 00:00:04,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/56c04275-df1a-4cd5-93cd-bbc4ceadca8e"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:11,2025-05-28 03:53:06
ca63d797-87cf-4097-9430-fe6f967c6c45,USA-FDA,1f0a3cf7-2a55-405e-8499-a232e7dae82d,G_ACTION_ITEMS,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002/FDA-2017-D-3235-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2017-D-3235"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-3235-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:16:11,2025-05-28 03:53:06
ca726bc9-21ec-4e7e-8cae-2f31be5fe0df,USA-FDA,88854f55-144b-4f5e-b5c3-3ec0f6cfb2a4,G_FAQ,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0008/FDA-2011-D-0847-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; Humanitarian Use Device (HUD) Designations"", ""docket_id"": ""FDA-2011-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0847-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:30:55,2025-05-28 03:53:06
ca921101-51df-4a5c-8cdf-d9d7285e2f1a,USA-FDA,602dd4f9-fa06-45c0-a00a-2100b3f4ff1d,G_ACTION_ITEMS,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002/FDA-2010-D-0404-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use--Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0404"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0404-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:33:33,2025-05-28 03:53:06
ca9cf80e-e0ff-42c2-a225-ae3e9338befc,CAB,864c5d22-2bb6-4453-bf75-03be7ca4f5d4,G_SUMMARY_IN,2025-05-20 10:06:57,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,{},"{""tilte"": ""Rapporto_esplicativo_revisione_ordinanze_20240607.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/Rapporto_esplicativo_revisione_ordinanze_20240607.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""fb660f3f-a153-44fa-90cf-7ed1e0478417""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/fb660f3f-a153-44fa-90cf-7ed1e0478417"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:09:52,2025-05-28 03:53:06
ca9ea782-aba0-4e64-bf20-8889b084aacf,USA-FDA,de5fad1f-a62d-4bea-b15f-b7e501b327ac,G_MINI_SUMMARY,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0128/FDA-2008-D-0128-0005/FDA-2008-D-0128-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Guidance for Industry"", ""docket_id"": ""FDA-2008-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0128-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0128/FDA-2008-D-0128-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:46:43,2025-05-28 03:53:06
caae2e6d-3998-446e-b618-2973c73476a2,USA-FDA,f7f7feb8-934b-4649-b11d-a7e27dff26e8,G_IMPACT_ANALYSIS,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2635/FDA-2016-D-2635-0269/FDA-2016-D-2635-0269-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Potential Approach for Defining Durations of Use for Medically Important Antimicrobial Drugs Intended for Use In or On Feed: A Concept Paper"", ""docket_id"": ""FDA-2016-D-2635"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2635-0269""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2635/FDA-2016-D-2635-0269"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:31:08,2025-05-28 03:53:06
cab6d7f5-29a6-499f-9373-32e2520f714a,USA-FDA,a984c6e0-4b2c-4a10-85a8-6acd86662214,G_DETAILED_SUMMARY,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002/FDA-2012-D-1002-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Questions and Answers Regarding Food Facility Registration Fifith Edition"", ""docket_id"": ""FDA-2012-D-1002"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1002-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1002/FDA-2012-D-1002-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:46:24,2025-05-28 03:53:06
cac2ea06-b12a-4d0f-8ced-bf08f5eb610d,USA-FDA,9412bb38-bdd0-4f2e-9ea0-34f574f25675,G_FAQ,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002/FDA-2015-D-4380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Best Practices for Communication Between IND Sponsors and FDA\nDuring Drug Development Guidance for Industry and Review Staff"", ""docket_id"": ""FDA-2015-D-4380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:16:59,2025-05-28 03:53:06
cad4f032-7f3d-4160-85de-e78835e13f71,USA-FDA,f1bcad6b-9b6e-46d9-94c7-feee54961385,G_MINI_SUMMARY,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008/FDA-2018-D-2936-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; CDRH Standard Operating Procedures for the Identification and Evaluation of Candidate Consensus Standards for Recognition"", ""docket_id"": ""FDA-2018-D-2936"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2936-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:00:10,2025-05-28 03:53:06
caedb910-e55b-432d-888f-0c3b0628987d,USA-FDA,13f4ac8e-d268-489f-a5cb-f56e85841787,G_ACTION_ITEMS,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1924/FDA-2020-D-1924-0001/FDA-2020-D-1924-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry:  Dear Manufacturer Letter Regarding Front-of-Package Symbols"", ""docket_id"": ""FDA-2020-D-1924"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1924-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1924/FDA-2020-D-1924-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:45:28,2025-05-28 03:53:06
cafd22b3-caa8-44b3-9f73-4cddb926cf16,USA-FDA,71f0bbd5-a504-4201-aac4-8a9d1f5c849f,G_IMPACT_ANALYSIS,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004/FDA-2005-D-0208-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency"", ""docket_id"": ""FDA-2005-D-0208"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0208-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0208/FDA-2005-D-0208-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:33:44,2025-05-28 03:53:06
cb21fdb7-0bfe-4e96-b841-ff2482cfc668,USA-FDA,d860188e-ef47-493b-8162-a2f356676de4,G_MINI_SUMMARY,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002/FDA-2012-D-1135-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidances for Industry Limiting Use of Certain Phthalates as Excipients in Center for Drug Evaluation and Research-Regulated Products"", ""docket_id"": ""FDA-2012-D-1135"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1135-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:01:12,2025-05-28 03:53:06
cb277214-fcb8-4289-8605-d37cc473cb6f,USA-FDA,b9292ec6-5d51-4b79-948d-2b89628877b9,G_CONCISE_SUMMARY,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010/FDA-2004-D-0500-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Consumer-Directed Broadcast Advertising of Restricted Devices; Draft Guidance for Industry"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:57,2025-05-28 03:53:06
cb5d92f7-768d-4a8e-a157-e20cc9bb3a19,USA-FDA,03847a59-ff8d-43b3-a92e-e2a1ae62fb49,G_MINI_SUMMARY,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006/FDA-2010-D-0500-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information"", ""docket_id"": ""FDA-2010-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0500-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:10,2025-05-28 03:53:06
cb5e584d-dde8-4edc-adb2-14a8d285415b,USA-FDA,84d8e9c0-c9c0-4e0d-a27f-83148c97ba1e,G_CONCISE_SUMMARY,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002/FDA-1999-D-1315-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act (PDUFA) Products; Guidance for Industry; Draft Guidance for Industry"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:01:50,2025-05-28 03:53:06
cb604296-9f01-403a-bf35-cb6d46cf36cf,USA-FDA,88a2a5c8-bf7b-4822-ac8a-d47f75b8f36e,G_FAQ,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0306/FDA-2003-D-0306-0002/FDA-2003-D-0306-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Powder Blends and Finished Dosage Units Stratified In-Process Dosage Unit Sampling and Assessment"", ""docket_id"": ""FDA-2003-D-0306"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0306-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0306/FDA-2003-D-0306-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:17:30,2025-05-28 03:53:06
cb607f98-57d4-40a9-902e-c29ad9aabfa6,USA-FDA,db31dfbd-ec92-49cf-a1cd-64856aa22b11,G_MINI_SUMMARY,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0358/FDA-2014-D-1525-0358-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry on Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application"", ""docket_id"": ""FDA-2014-D-1525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1525-0358""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0358"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:01:29,2025-05-28 03:53:06
cba20777-a4d7-4480-8f53-8f800cc2154e,USA-FDA,d97a6856-e472-40d9-9801-e68d2e08d00a,G_DETAILED_SUMMARY,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012/FDA-2003-D-0186-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for InduGuidance for Industry: Cosmetics Processors and Transporters of Cosmetics Security Preventive Measures Guidance"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:00:20,2025-05-28 03:53:06
cbc502d6-7ee7-4c8c-ae2c-911da77874ee,USA-FDA,b0158e4c-d58b-4886-ad6c-2f93e150593a,G_IMPACT_ANALYSIS,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0489/FDA-2011-D-0489-0002/FDA-2011-D-0489-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety of Nanomaterials in Cosmetic Products; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0489"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0489-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0489/FDA-2011-D-0489-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:45:38,2025-05-28 03:53:06
cbda917f-0198-4fb1-b783-a95cda286832,USA-FDA,de43b679-8198-4f35-a2ae-f9faacac1fcc,G_FAQ,2025-05-22 17:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0258/FDA-2011-D-0258-0002/FDA-2011-D-0258-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 335.700 Surgeons� Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure"", ""docket_id"": ""FDA-2011-D-0258"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0258-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0258/FDA-2011-D-0258-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:46:47,2025-05-28 03:53:06
cbee83ea-51e8-4b89-b88a-63d08366eb11,USA-FDA,51f8662a-14b5-435d-9f09-92fe60a5c09a,G_DETAILED_SUMMARY,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112/FDA-2000-N-0190-0112-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Outdoor Access)"", ""docket_id"": ""FDA-2000-N-0190"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-N-0190-0112""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:03:25,2025-05-28 03:53:06
cbf0a4d9-9918-4de4-9ede-65d14184d0d5,USA-FDA,f5b89f37-ae8d-4395-a052-297d14b6352a,G_FAQ,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003/FDA-2008-D-0180-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Coronary Drug Eluting Stents- Nonclincal and Clinical Studies; Draft Guidance"", ""docket_id"": ""FDA-2008-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0180-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:00:43,2025-05-28 03:53:06
cbf8de02-dec9-41a4-b5c9-029cf32a7f79,USA-FDA,4150a783-792b-401a-98d1-7c65fb9af120,G_DETAILED_SUMMARY,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0971/FDA-2016-D-0971-0002/FDA-2016-D-0971-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Infectious Disease Next Generation Sequencing Based Diagnostic Devices Microbial Identification and Detection of Antimicrobial Resistance and Virulence Markers"", ""docket_id"": ""FDA-2016-D-0971"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0971-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0971/FDA-2016-D-0971-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:45:59,2025-05-28 03:53:06
cbfdc74d-1903-415b-9248-00162674d1a5,SCHEDULED,c4a9dab3-7e56-4732-9adf-d254200c7857,DEVICE_ANALYST,2025-05-28 00:00:05,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/c4a9dab3-7e56-4732-9adf-d254200c7857"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:12,2025-05-28 03:53:06
cc542781-baca-453a-9cd8-5898d4b2c33d,USA-FDA,105bb805-e155-4e14-ae97-b610cca1ad8b,G_DETAILED_SUMMARY,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0722/FDA-2011-D-0722-0002/FDA-2011-D-0722-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Implementation of Acceptable Abbreviated Donor History Questionnaire, etc."", ""docket_id"": ""FDA-2011-D-0722"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0722-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0722/FDA-2011-D-0722-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:48:00,2025-05-28 03:53:06
cc749d09-fb27-4038-a89f-981fa8edb982,USA-FDA,f4623dc6-6f4c-4532-ac03-d4501a29e310,G_DETAILED_SUMMARY,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005/FDA-2007-D-0205-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:33:03,2025-05-28 03:53:06
cc778622-2959-4b2c-955e-d041b60273b6,SCHEDULED,4a28ac2e-d6e6-4aad-abd6-ff0a92ebecc7,FDA_ALERT,2025-05-28 00:00:05,29,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""weekly"", ""last_name"": ""Patel"", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": ""Abhishek"", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/fda_alert/4a28ac2e-d6e6-4aad-abd6-ff0a92ebecc7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 00:00:29,2025-05-28 03:53:06
cc85553b-5fcd-48c2-b92b-2e9fbf9c4b5a,USA-FDA,3cc68c8b-d3f3-4c99-bff1-07b6eedf9724,G_IMPACT_ANALYSIS,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015/FDA-2010-D-0350-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Tobacco Retailers on Tobacco Retailer Training Programs"", ""docket_id"": ""FDA-2010-D-0350"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0350-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:03:15,2025-05-28 03:53:06
cc8af1c3-769b-481d-b6f7-96d37ba2bd6b,SCHEDULED,c7da8cde-2ac6-443f-a69f-9207086cac6c,DEVICE_ANALYST,2025-06-02 00:00:04,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/c7da8cde-2ac6-443f-a69f-9207086cac6c"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:21,2025-06-02 00:00:21
cc90fe99-b9d3-4622-bba8-ff6c654b1faf,USA-FDA,6c6970bf-fb59-4897-bc28-0eda5cff5867,G_KEYWORDS,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005/FDA-1999-D-4079-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling"", ""docket_id"": ""FDA-1999-D-4079"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4079-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:32:27,2025-05-28 03:53:06
cc935e0e-a27a-4ea1-9478-e0eb6fd6fabb,SCHEDULED,39255c30-1a80-4f90-b048-3d919b2dc52f,FDA_ALERT,2025-05-26 00:00:07,30,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-26""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/fda_alert/39255c30-1a80-4f90-b048-3d919b2dc52f"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-26 00:00:33,2025-05-28 03:53:06
ccaadb6f-9125-4cf4-9de4-1d2bada4a760,USA-FDA,7ce67e59-d51d-4fb2-8622-36e55fcc9d44,G_DETAILED_SUMMARY,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0132/FDA-2009-D-0132-0012/FDA-2009-D-0132-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cellular Therapy for Cardiac Disease "", ""docket_id"": ""FDA-2009-D-0132"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0132-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0132/FDA-2009-D-0132-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:46:39,2025-05-28 03:53:06
ccb2c1fe-e38a-489b-87a2-0b879ad4c8ae,SCHEDULED,00f5cde6-17a1-4b1e-a085-360e327ff97b,DEVICE_ANALYST,2025-05-21 20:33:25,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/00f5cde6-17a1-4b1e-a085-360e327ff97b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:45,2025-05-28 03:53:06
ccba3a0a-594c-44f6-ad16-9e9cf709ce9e,USA-FDA,566d37f2-3b73-442a-9d8b-f65c212cdc78,G_DETAILED_SUMMARY,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1924/FDA-2020-D-1924-0001/FDA-2020-D-1924-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry:  Dear Manufacturer Letter Regarding Front-of-Package Symbols"", ""docket_id"": ""FDA-2020-D-1924"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1924-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1924/FDA-2020-D-1924-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:45:16,2025-05-28 03:53:06
cccc1ab4-4216-45af-9635-4d626d8b88ef,USA-FDA,22f1e5be-317b-43bb-a367-6841e41292f2,G_FAQ,2025-05-20 11:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005/FDA-2010-D-0163-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (VICH GL46)"", ""docket_id"": ""FDA-2010-D-0163"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0163-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0163/FDA-2010-D-0163-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:30:41,2025-05-28 03:53:06
cce1882b-e15a-4a05-86f4-d70b74f4ecf5,USA-FDA,32a8a64e-e260-47aa-a64e-8536b2a78009,G_IMPACT_ANALYSIS,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011/FDA-1997-D-0444-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance on FDA Approval of New Animal Drugs for Minor Uses and for Minor Species; Guidance Document (Revised May 29, 2008)"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:01:06,2025-05-28 03:53:06
cce5de6c-7131-4304-ad4c-430599a4fa36,USA-FDA,333cbd25-97e9-45e8-b42d-7cf3621c0004,G_IMPACT_ANALYSIS,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0002/FDA-2012-D-1038-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:17:38,2025-05-28 03:53:06
ccfae75c-70f4-4f58-8212-256fcd8555d5,USA-FDA,58ca4bc2-ea78-45b5-9169-1623326fcdbf,G_MINI_SUMMARY,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0002/FDA-2012-D-1083-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff; Civil Responses to Frequently Asked Question"", ""docket_id"": ""FDA-2012-D-1083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1083-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:03:31,2025-05-28 03:53:06
cd516b4a-9df8-4ea3-9cad-cee6d9fe94a6,USA-FDA,ac5d2799-172a-4504-9b06-52062f03f719,G_IMPACT_ANALYSIS,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0077/FDA-2007-D-0077-0003/FDA-2007-D-0077-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Providing Regulatory Submissions in Electronic Format - Receipt Date - Draft Guidance Document"", ""docket_id"": ""FDA-2007-D-0077"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0077-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0077/FDA-2007-D-0077-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:31:14,2025-05-28 03:53:06
cd533ad8-7275-4ffb-9447-fe34b5c5c29d,USA-FDA,0750b457-086f-4a64-8636-138eecb081bd,G_DETAILED_SUMMARY,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0188/FDA-1999-D-0188-0002/FDA-1999-D-0188-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Effect of Anthelmintics : Specific Recommendations for Ovine  VICH GL13 -  Final Guidance 96"", ""docket_id"": ""FDA-1999-D-0188"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0188-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0188/FDA-1999-D-0188-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:16:50,2025-05-28 03:53:06
cd98835e-bc73-4d4d-bf1a-080818748bcf,USA-FDA,52fd8386-836d-4602-9c95-66d6b6355f7c,G_DETAILED_SUMMARY,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022/FDA-2005-D-0282-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Antiviral Product Development - Conducting and Submitting Virology Studies to the Agency Guidance for Submitting Influenza Resistance Data"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:46:03,2025-05-28 03:53:06
cdc9277c-b6c6-4794-ba96-1ce234fa8770,USA-FDA,30becd40-66b7-4786-9b1a-012c9a1d6bdf,G_MINI_SUMMARY,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0309/FDA-2002-D-0309-0002/FDA-2002-D-0309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been ReconditionedDraft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been Reconditioned"", ""docket_id"": ""FDA-2002-D-0309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0309/FDA-2002-D-0309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:15:07,2025-05-28 03:53:06
cddffa4b-0a18-4d02-83b8-bd0b89a27d39,USA-FDA,1d2f394c-55c9-4f61-92e4-d9815ccf1076,G_CONCISE_SUMMARY,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024/FDA-2011-D-0577-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications  - Guidance"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:32:03,2025-05-28 03:53:06
cde40017-1161-4ca3-a7b0-148757bf53ea,USA-FDA,2fee43f5-23ff-4089-a17f-836ef1c5a6fb,G_ACTION_ITEMS,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1067/FDA-2013-D-1067-0002/FDA-2013-D-1067-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products--Content and Format"", ""docket_id"": ""FDA-2013-D-1067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1067-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1067/FDA-2013-D-1067-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:01:38,2025-05-28 03:53:06
cde62405-7cad-41de-9406-aa1571bc08c8,USA-FDA,2c24400c-fe97-4917-97d6-915b06a6556e,G_ACTION_ITEMS,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002/FDA-2009-D-0195-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Uranium"", ""docket_id"": ""FDA-2009-D-0195"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0195-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:31:20,2025-05-28 03:53:06
cde696c3-99f6-4fae-a70a-46bc5501df4f,USA-FDA,483cff5d-27d5-4ed7-92fd-bc6ce6012c08,G_ACTION_ITEMS,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1358/FDA-2013-D-1358-0002/FDA-2013-D-1358-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation"", ""docket_id"": ""FDA-2013-D-1358"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1358-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1358/FDA-2013-D-1358-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:02:24,2025-05-28 03:53:06
ce14f0e0-31f8-4ba7-b405-e6f10e6726e5,USA-FDA,5f627616-fae0-4f26-8976-33a8c543b923,G_ACTION_ITEMS,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001/FDA-2016-D-1533-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:02:49,2025-05-28 03:53:06
ce2ffaa4-c7ad-4431-b8f0-8574cfcb459b,USA-FDA,f00147de-5fc3-4235-8cb3-fc7b3c374a21,G_DETAILED_SUMMARY,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001/FDA-2023-D-2508-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products"", ""docket_id"": ""FDA-2023-D-2508"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2508-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:00:18,2025-05-28 03:53:06
ce31cb42-18d9-4843-902e-1931d2eb9ae3,USA-FDA,49efc2c1-3777-41d0-8840-7428004f9bdb,G_ACTION_ITEMS,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001/FDA-2020-D-2015-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Devices Without a Premarket Notification (510(k)) or an Approved Premarket Approval Application (PMA) REVOKED DOCUMENT"", ""docket_id"": ""FDA-2020-D-2015"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-2015-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:41,2025-05-28 03:53:06
ce33de26-4fc1-4192-88f7-b839569889c6,CAB,ed88978e-8e0d-41c5-a380-d0a1e6d15e04,G_ACTION_ITEMS_IN,2025-05-20 12:42:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2018-N-3233-0006.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2018-N-3233-0006_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""3f21331b-4399-4219-aa7e-0a5cb7a4ba33""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3f21331b-4399-4219-aa7e-0a5cb7a4ba33"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:43:50,2025-05-28 03:53:06
ce357961-9723-4d4d-bb51-f237b94f547e,USA-FDA,da55653c-76e0-47fd-9b64-db10da8386d8,G_IMPACT_ANALYSIS,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0074/FDA-2011-D-0074-0025/FDA-2011-D-0074-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Medication Guide Distribution Requirements and Inclusion of Medication Guides in Risk Evaluation and Mitigation Strategies"", ""docket_id"": ""FDA-2011-D-0074"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0074-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0074/FDA-2011-D-0074-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:01:07,2025-05-28 03:53:06
ce36dcd4-0569-463a-b8c3-56500334f113,USA-FDA,337dd3ae-07ff-4f97-9357-fc881bcc054f,G_FAQ,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001/FDA-2020-D-2015-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Devices Without a Premarket Notification (510(k)) or an Approved Premarket Approval Application (PMA) REVOKED DOCUMENT"", ""docket_id"": ""FDA-2020-D-2015"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-2015-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:37,2025-05-28 03:53:06
ce39828e-0507-4898-952b-2a2ea6e6a89b,USA-FDA,df7c88bc-e7a8-4f38-9cb6-7f8e16483ff0,G_MINI_SUMMARY,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0336/FDA-2005-D-0336-0004/FDA-2005-D-0336-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #176 (VICH GL39) Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances"", ""docket_id"": ""FDA-2005-D-0336"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0336-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0336/FDA-2005-D-0336-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:30:12,2025-05-28 03:53:06
ce4f109b-e50b-43f8-8d5c-bfd68380397c,USA-FDA,f01254e9-7c5d-445e-a98a-237b8004589a,G_FAQ,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0309/FDA-2002-D-0309-0002/FDA-2002-D-0309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been ReconditionedDraft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been Reconditioned"", ""docket_id"": ""FDA-2002-D-0309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0309/FDA-2002-D-0309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:15:28,2025-05-28 03:53:06
ce521156-d95e-40b3-9a78-39f1395d7da4,SCHEDULED,1abd9228-e8bc-4900-962f-4ffd06349502,GLOBAL_ALERT,2025-05-27 10:34:56,8,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-18""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/int_alert/1abd9228-e8bc-4900-962f-4ffd06349502"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 17:35:59,2025-05-28 03:53:06
ce660346-368b-447d-b53d-9fa317c77dfb,USA-FDA,172fdb7b-3347-4ffe-a275-1eecbad125aa,G_IMPACT_ANALYSIS,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0002/FDA-2009-D-0568-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:47:20,2025-05-28 03:53:06
ce6c18d4-93f1-4cea-a01c-3fad373b3168,USA-FDA,14ee75ea-665f-4bac-9285-0bd42ad13a99,G_ACTION_ITEMS,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012/FDA-2008-D-0610-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic"", ""docket_id"": ""FDA-2008-D-0610"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0610-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:32:28,2025-05-28 03:53:06
ce71fe3f-4973-43c4-9275-028775586f8b,SCHEDULED,b6c121f7-9fe2-47a9-b5ee-47fd007b65fa,DEVICE_ANALYST,2025-05-31 00:00:05,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/b6c121f7-9fe2-47a9-b5ee-47fd007b65fa"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:07,2025-05-31 00:00:07
cea5343f-8627-4354-8816-7c265aa0553d,USA-FDA,f0231fe6-2d4c-44e7-982a-d26d89859666,G_IMPACT_ANALYSIS,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002/FDA-2012-D-0179-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens"", ""docket_id"": ""FDA-2012-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0179-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0179/FDA-2012-D-0179-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:01:37,2025-05-28 03:53:06
ceda31b1-436e-4706-ae0f-6bfca82b4024,USA-FDA,e8b961b7-8e4b-4947-993a-df4e76a222f3,G_IMPACT_ANALYSIS,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024/FDA-2011-D-0577-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications  - Guidance"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:32:38,2025-05-28 03:53:06
cf035bc9-ef44-4a30-86c6-acc63dd50400,USA-FDA,71bb90f5-456c-407b-b36b-08914c52fb4c,G_ACTION_ITEMS,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002/FDA-2011-D-0649-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Class II Special Controls; External Pacemaker Pulse Generator"", ""docket_id"": ""FDA-2011-D-0649"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0649-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:01:11,2025-05-28 03:53:06
cf1aa3c4-4839-44e6-beb8-656ad6fb13d8,USA-FDA,df33832c-1d8f-4f47-9cc1-b3b732576afc,G_DETAILED_SUMMARY,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002/FDA-2013-D-0168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Recommendations for Labeling Medical Products to Inform Users the Product or Product Container Is Not Made With Natural Rubber Latex"", ""docket_id"": ""FDA-2013-D-0168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:16:49,2025-05-28 03:53:06
cf22fc86-86d4-46f6-a9fb-9790b4215130,SCHEDULED,61b94b2e-5372-4e66-bcfc-4dad1219be91,DEVICE_ANALYST,2025-05-30 00:00:04,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/61b94b2e-5372-4e66-bcfc-4dad1219be91"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:24,2025-05-30 00:00:24
cf29ea35-bed1-4e0f-93d6-cc422d6aa2b1,USA-FDA,7d13a03e-8213-4592-87fd-0e76dde3a193,G_MINI_SUMMARY,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0033/FDA-2003-D-0033-0003/FDA-2003-D-0033-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff: Food and Drug Administration and Industry Actions on Premarket Notification Submissions: Effect on Food and Drug Administration Review Clock and Performance Assessment"", ""docket_id"": ""FDA-2003-D-0033"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0033-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0033/FDA-2003-D-0033-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:31:50,2025-05-28 03:53:06
cf38e819-c55d-44e3-ac01-98e34ad92a10,USA-FDA,1f18a415-7c64-4aec-981a-75d5b71edfbb,G_IMPACT_ANALYSIS,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1189/FDA-2018-D-1189-0002/FDA-2018-D-1189-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Concentrated Caffeine in Dietary Supplements: Guidance for Industry"", ""docket_id"": ""FDA-2018-D-1189"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-1189-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1189/FDA-2018-D-1189-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:33:34,2025-05-28 03:53:06
cf48da2f-34d9-4337-83d1-3de765577d96,USA-FDA,291ecddd-6544-45cf-9599-f15d4d46c953,G_ACTION_ITEMS,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001/FDA-2020-D-1961-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling"", ""docket_id"": ""FDA-2020-D-1961"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1961-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:31:44,2025-05-28 03:53:06
cf566ddb-be0c-4fbe-9e03-a9d4ad635e5f,USA-FDA,5800e3da-6338-4ada-9676-336674aa1f2c,G_ACTION_ITEMS,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-D-0621/FDA-2021-D-0621-0001/FDA-2021-D-0621-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #50 Target Animal and Human Food Safety, Drug Efficacy, Environmental and Manufacturing Studies for Teat Antiseptic Products"", ""docket_id"": ""FDA-2021-D-0621"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-D-0621-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-D-0621/FDA-2021-D-0621-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:01:15,2025-05-28 03:53:06
cf609bb9-4d32-4757-90e1-bcf642198fcd,USA-FDA,3353a728-f462-4961-82ab-97629b2b159f,G_ACTION_ITEMS,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007/FDA-2011-D-0691-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs"", ""docket_id"": ""FDA-2011-D-0691"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0691-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:03:07,2025-05-28 03:53:06
cfaf9700-adf7-4b49-b416-e82b28dbc03e,USA-FDA,f3bab566-c25d-40d7-be50-70e981d6221f,G_FAQ,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0025/FDA-1999-D-1875-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sec.615.115 Extralabel Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:33:17,2025-05-28 03:53:06
cff7e41d-430e-4598-ae0c-e4e999897ba7,USA-FDA,3e467cb8-c3c4-4ab6-aa23-031f25e27ce1,G_CONCISE_SUMMARY,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013/FDA-2009-D-0490-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff:  Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2009-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0490-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:47:34,2025-05-28 03:53:06
d0051237-ae56-474a-88e1-7035b6d10f7d,USA-FDA,01398be9-f048-4e03-9f7c-747903faf401,G_DETAILED_SUMMARY,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002/FDA-2012-D-0544-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Toll Free Number Labeling and Related Requirements for Over the Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide"", ""docket_id"": ""FDA-2012-D-0544"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0544-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:30:18,2025-05-28 03:53:06
d00e0f29-c298-422f-8560-634a74e53f05,USA-FDA,61ecb7d8-7dfe-4306-81ce-44dc656ff6d4,G_FAQ,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003/FDA-1999-D-0030-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-1999-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0030-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:32:16,2025-05-28 03:53:06
d031967f-2fc8-425f-b65e-fd3f933c2079,SCHEDULED,61cb2aa1-4d98-4345-811f-94f9b7bc8cbf,DEVICE_ANALYST,2025-05-31 00:00:05,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Patel"", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": ""Abhishek"", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-31""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/61cb2aa1-4d98-4345-811f-94f9b7bc8cbf"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-31 00:00:28,2025-05-31 00:00:28
d04e3e9b-49f0-4d53-a1a0-c00fc470e56e,USA-FDA,384157da-db8d-4dcc-a39e-aa2902ff8601,G_MINI_SUMMARY,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002/FDA-2015-D-4380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Best Practices for Communication Between IND Sponsors and FDA\nDuring Drug Development Guidance for Industry and Review Staff"", ""docket_id"": ""FDA-2015-D-4380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:16:28,2025-05-28 03:53:06
d09a7654-67d6-4e26-ac86-e531deda816a,USA-FDA,0dfa2b41-194d-40a8-8315-6cb2902f3d44,G_IMPACT_ANALYSIS,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0719/FDA-2018-D-0719-0002/FDA-2018-D-0719-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)\nGuidance for Industry"", ""docket_id"": ""FDA-2018-D-0719"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0719-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0719/FDA-2018-D-0719-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:31:52,2025-05-28 03:53:06
d0dcf925-08df-4bc8-8c43-42c323711284,USA-FDA,7c5bb369-742a-48a2-8ee4-8c2a5fd2e4ee,G_MINI_SUMMARY,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-D-0621/FDA-2021-D-0621-0001/FDA-2021-D-0621-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #50 Target Animal and Human Food Safety, Drug Efficacy, Environmental and Manufacturing Studies for Teat Antiseptic Products"", ""docket_id"": ""FDA-2021-D-0621"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-D-0621-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-D-0621/FDA-2021-D-0621-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:01:00,2025-05-28 03:53:06
d0f420b4-8874-4438-9a37-fb3f1a05f8b5,USA-FDA,59200f1f-b30b-4101-81ae-f1d28692c558,G_DETAILED_SUMMARY,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008/FDA-2018-D-2936-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; CDRH Standard Operating Procedures for the Identification and Evaluation of Candidate Consensus Standards for Recognition"", ""docket_id"": ""FDA-2018-D-2936"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2936-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:00:19,2025-05-28 03:53:06
d113d0f4-5e08-4703-af67-d1b83213a7c8,USA-FDA,69ac6877-9bf9-47f6-a388-7d4a25cf4bee,G_ACTION_ITEMS,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0447/FDA-2013-D-0447-0002/FDA-2013-D-0447-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Charging for Investigational Drugs Under an Investigational New Drug Application-Questions and Answers"", ""docket_id"": ""FDA-2013-D-0447"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0447-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0447/FDA-2013-D-0447-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:30:32,2025-05-28 03:53:06
d1188bb4-b59d-4705-9d2c-8618faa0ab11,USA-FDA,2032793d-dac7-4692-9336-288ba1c15a01,G_MINI_SUMMARY,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1304/FDA-1999-D-1304-0002/FDA-1999-D-1304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Possible Dioxin/PCB Contamination of Drug and Biological Products"", ""docket_id"": ""FDA-1999-D-1304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1304/FDA-1999-D-1304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:31:40,2025-05-28 03:53:06
d122297e-c885-46b7-9a38-9332437b561f,USA-FDA,a1e86b7f-4f64-484e-ad14-f9b9bb3f54db,G_IMPACT_ANALYSIS,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0652/FDA-2011-D-0652-0002/FDA-2011-D-0652-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff The 510(k) Program Evaluating Substantial Equivalence in Premarket Notifications [510(k)]"", ""docket_id"": ""FDA-2011-D-0652"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0652-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0652/FDA-2011-D-0652-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:46:22,2025-05-28 03:53:06
d16d6fc4-3aa8-46f8-8aee-03263c4b13a9,SCHEDULED,036ac1b2-2682-40ed-ab8d-2d1728067291,DEVICE_ANALYST,2025-05-20 04:13:45,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-20""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/036ac1b2-2682-40ed-ab8d-2d1728067291"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 04:13:52,2025-05-28 03:53:06
d1a1f56e-371e-4d89-9c9e-9e664fc459bf,USA-FDA,7033bd76-6b22-48a9-9989-e804a9727d07,G_KEYWORDS,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002/FDA-2011-D-0164-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:00:31,2025-05-28 03:53:06
d1c56d51-5d53-4003-a792-3d7544b93efc,USA-FDA,fb549586-1474-4ffd-ac8d-2ce8488f6d20,G_MINI_SUMMARY,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001/FDA-2020-D-1408-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000; I Introduction"", ""docket_id"": ""FDA-2020-D-1408"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1408-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:35,2025-05-28 03:53:06
d1d9f4a7-58ba-463a-9888-55e0d7a8d2f0,CAB,932e13fa-9ee3-4a24-a981-7fa834b0884c,G_FAQ_IN,2025-05-20 10:13:24,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2022-F-1108-0001"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/9d6232e0-4b34-4087-9932-5b92e745079f/FDA-2022-F-1108-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""48b24e3f-2c7d-446d-8ef2-9a788b5abc48""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/48b24e3f-2c7d-446d-8ef2-9a788b5abc48"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:13:44,2025-05-28 03:53:06
d2342bba-e66d-4a1c-94f9-dee35e4e3783,USA-FDA,bf577a16-4c04-4963-930a-c2b302e90c9e,G_FAQ,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004/FDA-2007-D-0302-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Labeling for Human Prescription Drug and Biological Products � Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information"", ""docket_id"": ""FDA-2007-D-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0302-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:03:08,2025-05-28 03:53:06
d2343594-c9cd-48dc-864d-c5abff972177,USA-FDA,54a7e34e-2a32-4f18-8006-681740415699,G_ACTION_ITEMS,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038/FDA-2008-D-0406-0038-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs; Frequently Asked Questions - Statement of Investigator (Form FDA 1572)"", ""docket_id"": ""FDA-2008-D-0406"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0406-0038""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:17:50,2025-05-28 03:53:06
d24a9ac0-2632-4aab-a936-9a5882280923,USA-FDA,4393963b-b98c-41ef-b45b-f7d5a52e9c1f,G_CONCISE_SUMMARY,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002/FDA-2010-D-0404-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use--Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0404"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0404-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:33:06,2025-05-28 03:53:06
d24f6775-726b-4b69-b3e6-bcd00130996a,USA-FDA,900657d8-b908-44ef-b4fd-e38820d543ac,G_DETAILED_SUMMARY,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-N-0083/FDA-1999-N-0083-0015/FDA-1999-N-0083-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Availability: Reproductive and Developmental Toxicities - Integrating Study Results to Assess Concerns"", ""docket_id"": ""FDA-1999-N-0083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-N-0083-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-N-0083/FDA-1999-N-0083-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:46:22,2025-05-28 03:53:06
d250d5ce-95c1-48e9-ab5d-2ea82d3765db,SCHEDULED,77941a16-357d-4700-8e1b-19b2857a4811,FDA_ALERT,2025-05-22 00:03:21,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/77941a16-357d-4700-8e1b-19b2857a4811"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:36,2025-05-28 03:53:06
d25ca5c3-2def-49db-9087-eeea9fa08553,SCHEDULED,59c60138-cca4-4efd-a2b5-cc008d662175,DEVICE_ANALYST,2025-05-29 00:00:04,32,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/device_analyst/59c60138-cca4-4efd-a2b5-cc008d662175"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:28,2025-05-29 00:00:28
d268009e-487a-474a-8f3a-4056883f046d,USA-FDA,26558dbd-c634-40a4-8b4e-3d256b4ad449,G_FAQ,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0742/FDA-1999-D-0742-0014/FDA-1999-D-0742-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Financial Disclosure by Clinical Investigators - Draft Guidance"", ""docket_id"": ""FDA-1999-D-0742"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0742-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0742/FDA-1999-D-0742-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:47:05,2025-05-28 03:53:06
d278d87d-6e3a-4a7d-86d6-6b02460b877d,USA-FDA,fa755e81-37b4-4d17-824b-13a04187697b,G_IMPACT_ANALYSIS,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0002/FDA-2004-D-0301-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Fixed Dose Combination and Co-Packaged Drug Products for Treatment of HIV - DRAFT GUIDANCE"", ""docket_id"": ""FDA-2004-D-0301"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0301-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:32:50,2025-05-28 03:53:06
d2be3944-3259-446b-91af-2997225c29a5,USA-FDA,185a90ae-f4c3-4db1-b88f-d22077fc934f,G_ACTION_ITEMS,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0295/FDA-2013-D-0295-0002/FDA-2013-D-0295-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Scale-Up and Post-Approval Changes, Manufacturing Equipment Addendum"", ""docket_id"": ""FDA-2013-D-0295"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0295-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0295/FDA-2013-D-0295-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:30:43,2025-05-28 03:53:06
d2e1d0bf-0ac9-48a4-8fc1-d32ff6a0df81,USA-FDA,c2bd25f1-b1d0-44b3-861b-9c5b2e1e8a0a,G_KEYWORDS,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002/FDA-2011-D-0480-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products"", ""docket_id"": ""FDA-2011-D-0480"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0480-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0480/FDA-2011-D-0480-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:30:55,2025-05-28 03:53:06
d2f9dbeb-dbf4-4d11-bab5-5dbc58bcc193,USA-FDA,a9c8ede1-ccee-4071-84dd-09fcc3301035,G_DETAILED_SUMMARY,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-D-0621/FDA-2021-D-0621-0001/FDA-2021-D-0621-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #50 Target Animal and Human Food Safety, Drug Efficacy, Environmental and Manufacturing Studies for Teat Antiseptic Products"", ""docket_id"": ""FDA-2021-D-0621"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2021-D-0621-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2021-D-0621/FDA-2021-D-0621-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:01:08,2025-05-28 03:53:06
d30070a5-2d37-41bc-bf67-65f96e404fda,USA-FDA,17869dd9-6ec6-4fa4-8b78-c46bc1ad1cf0,G_IMPACT_ANALYSIS,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1161/FDA-2012-D-1161-0002/FDA-2012-D-1161-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Design Considerations for Devices Intended for Home Use - Draft Guidance"", ""docket_id"": ""FDA-2012-D-1161"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1161-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1161/FDA-2012-D-1161-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:33:11,2025-05-28 03:53:06
d310e6ca-c4a4-4dc5-8fa9-e226095b776c,USA-FDA,f86deaaa-6551-47eb-81f5-baa83d1d1b8b,G_DETAILED_SUMMARY,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005/FDA-2010-D-0165-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies (VICH GL49)"", ""docket_id"": ""FDA-2010-D-0165"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0165-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:02:00,2025-05-28 03:53:06
d33a5930-8845-474d-b5e4-d63fb7bffb5a,USA-FDA,12b85319-4af9-4c34-8d3d-4826e451f502,G_MINI_SUMMARY,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0093/FDA-2002-D-0093-0022/FDA-2002-D-0093-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry"", ""docket_id"": ""FDA-2002-D-0093"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0093-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0093/FDA-2002-D-0093-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:32:00,2025-05-28 03:53:06
d34436f9-d420-4328-b5c2-e20c699a3575,USA-FDA,1437996a-daae-46ab-9540-851197c31fe0,G_IMPACT_ANALYSIS,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0090/FDA-2003-D-0090-0002/FDA-2003-D-0090-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate � Labeling Enforcement Policy"", ""docket_id"": ""FDA-2003-D-0090"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0090-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0090/FDA-2003-D-0090-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:01:39,2025-05-28 03:53:06
d347fe57-f7ff-499c-aac3-ea7704bff583,USA-FDA,415f0687-591b-4735-abf4-756ecb36de5c,G_DETAILED_SUMMARY,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0005/FDA-2004-D-0301-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Fixed Dose Combinations, Co-Packaged Drug Products, and Single-EntityVersions of Previously Approved\nAntiretrovirals for the Treatment of HIV"", ""docket_id"": ""FDA-2004-D-0301"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0301-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:01:39,2025-05-28 03:53:06
d34cc884-d1bc-4b6c-8b29-1453065e361d,USA-FDA,cd65486e-4c72-4a6b-84a3-18f9250e658f,G_ACTION_ITEMS,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1529/FDA-2013-N-1529-0023/FDA-2013-N-1529-0023-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""03 Reference 2 Open Public Hearings Guidance - Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: The Open Public Hearing at FDA Advisory Committee Meetings"", ""docket_id"": ""FDA-2013-N-1529"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1529-0023""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1529/FDA-2013-N-1529-0023"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:32:21,2025-05-28 03:53:06
d366e48d-7486-405b-96bc-73572eee5ddd,USA-FDA,074c4c96-3880-4cab-937b-673f1a951be2,G_KEYWORDS,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112/FDA-2000-N-0190-0112-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Outdoor Access)"", ""docket_id"": ""FDA-2000-N-0190"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-N-0190-0112""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-N-0190/FDA-2000-N-0190-0112"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:04:01,2025-05-28 03:53:06
d368c1b0-47df-46ce-acae-a25037c97daf,USA-FDA,e9304a21-c612-49c4-9f66-d21405584153,G_FAQ,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002/FDA-2017-D-3235-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2017-D-3235"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-3235-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:16:05,2025-05-28 03:53:06
d3aa4cc6-40cf-43be-b547-c1d333c2427b,USA-FDA,3667e604-3495-478d-8f6c-4533854a9782,G_IMPACT_ANALYSIS,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0044/FDA-2009-D-0044-0009/FDA-2009-D-0044-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis "", ""docket_id"": ""FDA-2009-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0044-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0044/FDA-2009-D-0044-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:01:50,2025-05-28 03:53:06
d3bfe007-c7a3-4257-92d8-287d94780453,USA-FDA,9513f9ef-586b-4391-9c90-3e47bb0928fb,G_KEYWORDS,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004/FDA-2018-N-4735-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""GFI Safety Labeling Changes Implementation of Section 505(o)(4) of the FDC Act"", ""docket_id"": ""FDA-2018-N-4735"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-N-4735-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:17:03,2025-05-28 03:53:06
d3d7d6d3-de6f-4bb3-a262-29aad26d0570,USA-FDA,278804f1-3aa3-416a-a685-8cc7c9424134,G_ACTION_ITEMS,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002/FDA-2012-D-0304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Claa II Special Controls Guidance Implanted Blood Access Devices for Hemodialysis"", ""docket_id"": ""FDA-2012-D-0304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:01:00,2025-05-28 03:53:06
d3f9182d-9850-4963-bb57-4cfb0c71e67e,USA-FDA,4e8d0607-dca9-4c7b-a9c8-b78eb278bb2b,G_KEYWORDS,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002/FDA-2014-D-1351-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Flow Cytometric Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1351"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1351-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:03:07,2025-05-28 03:53:06
d40308f5-e4a6-49f2-b287-c95d4f8789ae,USA-FDA,61edefc6-3c2e-45fa-be2d-56ddb8b49e2e,G_FAQ,2025-05-22 03:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0002/FDA-2011-D-0847-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Humanitarian Use Device Designations"", ""docket_id"": ""FDA-2011-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0847-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:45:35,2025-05-28 03:53:06
d42878a5-baf1-441c-91ca-8c98f710068d,CAB,1161c3ea-cf5e-4634-80b5-24a4c3a1fb84,G_ACTION_ITEMS_IN,2025-05-20 10:06:57,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,{},"{""tilte"": ""Rapporto_esplicativo_revisione_ordinanze_20240607.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/Rapporto_esplicativo_revisione_ordinanze_20240607.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""fb660f3f-a153-44fa-90cf-7ed1e0478417""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/fb660f3f-a153-44fa-90cf-7ed1e0478417"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:10:30,2025-05-28 03:53:06
d452a66b-b331-4c68-98de-a207a0db8272,USA-FDA,453ca810-534b-424d-8079-1cd48ef42b70,G_IMPACT_ANALYSIS,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1362/FDA-2020-D-1362-0001/FDA-2020-D-1362-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Regulatory Submissions to OFAS, Part VI GRAS Notices"", ""docket_id"": ""FDA-2020-D-1362"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1362-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1362/FDA-2020-D-1362-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:30:34,2025-05-28 03:53:06
d468fb6f-e166-444f-aec9-8f7d3da4308a,USA-FDA,3614f1e7-667a-41ef-86a0-f9869d655705,G_CONCISE_SUMMARY,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002/FDA-2014-N-1082-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Multiplexed Microbiological/Medical Countermeasure In Vitro \nNucleic Acid Based Diagnostic Devices; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-N-1082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1082-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:00:15,2025-05-28 03:53:06
d47df0b6-b44e-450a-9967-ca299fefc7e7,USA-FDA,11ea56e8-0d2b-4e00-89be-fe0dcba369e3,G_FAQ,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001/FDA-2023-D-2508-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products"", ""docket_id"": ""FDA-2023-D-2508"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2508-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2508/FDA-2023-D-2508-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:00:28,2025-05-28 03:53:06
d4af8085-8a2e-4595-be02-81422a24c1bd,SCHEDULED,5920935d-56e8-42e9-9bee-908421c4e874,DEVICE_ANALYST,2025-05-27 18:00:05,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/5920935d-56e8-42e9-9bee-908421c4e874"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 18:00:06,2025-05-28 03:53:06
d4be843a-9adf-4ca0-8f76-5536b4a920b0,USA-FDA,37735cb9-75ce-4040-b9d7-60644f58d0df,G_ACTION_ITEMS,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0057/FDA-2011-D-0057-0021/FDA-2011-D-0057-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff ;  Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data"", ""docket_id"": ""FDA-2011-D-0057"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0057-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0057/FDA-2011-D-0057-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:02:44,2025-05-28 03:53:06
d4dd604e-e015-4d2b-8fd9-d4e9f3bdb639,USA-FDA,982efbe9-5b60-40b9-9408-0df0c1582c29,G_CONCISE_SUMMARY,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007/FDA-2011-D-0691-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs"", ""docket_id"": ""FDA-2011-D-0691"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0691-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0691/FDA-2011-D-0691-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:02:37,2025-05-28 03:53:06
d512ca09-cdc0-4a72-80c0-bbb6a8228cfb,USA-FDA,2923ec64-054e-4f1c-ab0c-b41689dfd47e,G_DETAILED_SUMMARY,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002/FDA-1999-D-1315-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act (PDUFA) Products; Guidance for Industry; Draft Guidance for Industry"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:02:06,2025-05-28 03:53:06
d51a92de-fd89-4e34-a77b-fb32a604e680,USA-FDA,480899b1-5f11-44fb-861b-038028eed5e2,G_CONCISE_SUMMARY,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015/FDA-1999-D-1315-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Formal Meetings With Sponsors and Applicants for PDUFA Products; Guidance Document"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:32:27,2025-05-28 03:53:06
d523d8db-8d97-4bb5-82b2-64c752eac02d,CAB,51d9c60b-e8ae-42cf-8edf-7196063f30fa,G_MINI_SUMMARY_IN,2025-05-20 16:33:48,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2018-F-3757-0019.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2018-F-3757-0019_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""04cb41d6-deff-4cde-83f8-ba7f77069dd4""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/04cb41d6-deff-4cde-83f8-ba7f77069dd4"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:33:52,2025-05-28 03:53:06
d529417f-61d2-4516-b55e-b4331bf1e9e1,QUEUE,5f2bea4a-0742-4ace-84e9-d24940140869,G_SUMMARY_USER,2025-05-29 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/detailed_summary/5f2bea4a-0742-4ace-84e9-d24940140869/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/detailed_summary/5f2bea4a-0742-4ace-84e9-d24940140869"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 16:00:13,2025-05-29 16:00:13
d531f426-52dc-4b55-b5c3-11fc7740ff7f,USA-FDA,c577ac4c-0657-4d63-8612-8d2d7880d46c,G_DETAILED_SUMMARY,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0436/FDA-2011-D-0436-0002/FDA-2011-D-0436-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Q11 Development and Manufacture of Drug Substances; International Conference on Harmonisation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0436"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0436-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0436/FDA-2011-D-0436-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:31:06,2025-05-28 03:53:06
d54b0557-f024-46f9-b500-61fe97e198f9,USA-FDA,72f772ad-2928-484a-8901-8da8f077c4e9,G_MINI_SUMMARY,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0169/FDA-2013-D-0169-0002/FDA-2013-D-0169-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Review Staff: Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling"", ""docket_id"": ""FDA-2013-D-0169"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0169-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0169/FDA-2013-D-0169-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:45:08,2025-05-28 03:53:06
d54defd8-d47b-4765-9cb0-2b71ddb9ac93,USA-FDA,c860a56e-8e17-41e6-afb4-b7912427789e,G_ACTION_ITEMS,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001/FDA-2020-D-1385-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Drug Stability Guidelines; #5"", ""docket_id"": ""FDA-2020-D-1385"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1385-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:32:46,2025-05-28 03:53:06
d5632026-8f73-471e-8f13-556f7e8208a0,USA-FDA,543a1ca2-5783-4994-87a2-26186a32dffd,G_FAQ,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002/FDA-2007-D-0205-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]; Draft Guidance"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:02:52,2025-05-28 03:53:06
d572d124-1cca-4d38-b3ab-6ba03d2c7df5,USA-FDA,e3fefa18-362f-4ba8-a089-23da30f077c5,G_DETAILED_SUMMARY,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001/FDA-2018-D-0398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions Guidance for Industry and\nFood and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:00:38,2025-05-28 03:53:06
d573cda4-daed-4928-9009-c3608f1ecc13,Queue,d18bba59-e0ee-4b59-a375-40217681ad6c,G_TRANSLATE,2025-05-29 22:09:30,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/d18bba59-e0ee-4b59-a375-40217681ad6c/MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf.pdf"", ""doc_title"": ""MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/d18bba59-e0ee-4b59-a375-40217681ad6c"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 22:09:30,2025-05-29 22:09:30
d57890e7-aac8-498f-a433-f4005eacffb1,USA-FDA,66844524-a4c2-4bdb-b25a-69d507f7889f,G_ACTION_ITEMS,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0002/FDA-2011-D-0620-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2011-D-0620"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0620-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:16:48,2025-05-28 03:53:06
d586ae3c-a208-4f5d-a35a-039d3b383ad4,USA-FDA,be3656d7-290d-4adb-bc9b-06f027b7387d,G_IMPACT_ANALYSIS,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002/FDA-2012-D-0304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Claa II Special Controls Guidance Implanted Blood Access Devices for Hemodialysis"", ""docket_id"": ""FDA-2012-D-0304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:01:08,2025-05-28 03:53:06
d5873ead-50e5-489d-b2c3-865b98591195,USA-FDA,c509d226-4692-4c21-8611-6ff118bdb4bb,G_FAQ,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-2441/FDA-1999-D-2441-0002/FDA-1999-D-2441-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Dioxin in Anti-Caking Agents Used in Animal Feed and Feed Ingredients"", ""docket_id"": ""FDA-1999-D-2441"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-2441-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-2441/FDA-1999-D-2441-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:00:24,2025-05-28 03:53:06
d5c2318d-8090-4726-ab8e-cbf32b1ea058,USA-FDA,cc0c332f-ad22-4108-b131-a908bd88b7f3,G_IMPACT_ANALYSIS,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002/FDA-2015-D-4380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Best Practices for Communication Between IND Sponsors and FDA\nDuring Drug Development Guidance for Industry and Review Staff"", ""docket_id"": ""FDA-2015-D-4380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:17:15,2025-05-28 03:53:06
d5e6fd82-a58d-48d0-b294-a20a8c34e2fe,USA-FDA,dccac642-215c-49cc-8b5c-20df2eba1393,G_ACTION_ITEMS,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1918/FDA-2020-D-1918-0001/FDA-2020-D-1918-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Food Additive Petition Expedited Review"", ""docket_id"": ""FDA-2020-D-1918"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1918-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1918/FDA-2020-D-1918-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:48:09,2025-05-28 03:53:06
d601db39-43d4-4b79-a49e-796750e25dd5,USA-FDA,7603d5ae-6db0-4524-8c4b-45f0f7135b7b,G_FAQ,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002/FDA-2009-D-0195-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Uranium"", ""docket_id"": ""FDA-2009-D-0195"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0195-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:31:15,2025-05-28 03:53:06
d602c51e-3346-4b64-94a0-62b621d99cef,USA-FDA,a824611c-545c-49ce-9d62-7529011fd779,G_DETAILED_SUMMARY,2025-05-22 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0429/FDA-2012-D-0429-0003/FDA-2012-D-0429-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Investigators Meetings with Industry and Investigators on the Research and Development of Tobacco Products"", ""docket_id"": ""FDA-2012-D-0429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0429-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0429/FDA-2012-D-0429-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:00:19,2025-05-28 03:53:06
d6210141-7c4a-498c-b675-70a7fc4c932a,USA-FDA,5626c9fd-509c-4379-a97e-d5759dd23fc6,G_KEYWORDS,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002/FDA-2013-D-0616-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0616-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:33:24,2025-05-28 03:53:06
d6271055-8914-428a-88c0-4bdb0c19c13b,USA-FDA,ed6ee0b7-ff7a-437c-8a09-365fac854f9a,G_IMPACT_ANALYSIS,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002/FDA-2011-D-0598-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers Regarding Establishment, Maintenance of Records by Persons Who Manufacture of Records by Persons Who Manufacture, Process, Pack, Transport,Distribute Receive, Hold or Import Food (Edition 5)"", ""docket_id"": ""FDA-2011-D-0598"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0598-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0598/FDA-2011-D-0598-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:32:01,2025-05-28 03:53:06
d6488ddb-ef42-4344-a36a-9c71a9d43b89,USA-FDA,bda3cbc7-3187-4432-abbd-55f932ff7a49,G_KEYWORDS,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002/FDA-2013-D-0168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Recommendations for Labeling Medical Products to Inform Users the Product or Product Container Is Not Made With Natural Rubber Latex"", ""docket_id"": ""FDA-2013-D-0168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0168/FDA-2013-D-0168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:17:13,2025-05-28 03:53:06
d65aae27-d2d8-4151-a610-6d9c3ef3e3b3,USA-FDA,45e0f835-43c7-4a34-9f99-8a56d1925ee2,G_DETAILED_SUMMARY,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1927/FDA-2020-D-1927-0001/FDA-2020-D-1927-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Food Security Preventive Measures Guidance for  Retail Food Stores and Food Service Establishments"", ""docket_id"": ""FDA-2020-D-1927"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1927-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1927/FDA-2020-D-1927-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:00:16,2025-05-28 03:53:06
d6a9a1e1-e96e-4343-90cb-ce50277143be,USA-FDA,6b86e296-bffd-481e-b62c-8d1d2c4c1f1f,G_MINI_SUMMARY,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008/FDA-2008-D-0642-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2008-D-0642"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0642-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:31:25,2025-05-28 03:53:06
d6c81002-4213-47c5-bdc1-eead1bdc427f,USA-FDA,9ef8f197-d7ae-40da-823a-01a2e2ed038a,G_CONCISE_SUMMARY,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002/FDA-2011-D-0602-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industryon Quality Considerations in Demonstrating Biosimilarity to Reference Protein Product"", ""docket_id"": ""FDA-2011-D-0602"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0602-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:33:58,2025-05-28 03:53:06
d6d715b1-6bc5-4c0e-98bd-67a3c5201874,USA-FDA,04499e55-8ead-416b-a999-d0decb267e1f,G_DETAILED_SUMMARY,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008/FDA-2010-D-0431-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Food and Drug Administration Staff and Tobacco Retailers on Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Revised"", ""docket_id"": ""FDA-2010-D-0431"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0431-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:45:23,2025-05-28 03:53:06
d6e0e7e1-62e8-43ac-8135-635386650ed8,USA-FDA,22330d98-bbdf-466c-867a-c049537b1f0c,G_ACTION_ITEMS,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003/FDA-1999-D-0030-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-1999-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0030-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:32:37,2025-05-28 03:53:06
d7140ab8-6801-4a5e-b32d-70b3baa2357f,USA-FDA,02b40269-8612-4c24-87e7-ea82c40303ec,G_ACTION_ITEMS,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010/FDA-2004-D-0500-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Consumer-Directed Broadcast Advertising of Restricted Devices; Draft Guidance for Industry"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:02:10,2025-05-28 03:53:06
d7469c40-66d3-4deb-94d7-7db611bb2e6d,USA-FDA,9d1e17bc-6769-455a-967f-db7a7b77b9c6,G_MINI_SUMMARY,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001/FDA-2020-D-0367-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""External Guidance Document Submission from Turner Scientific, LLC re: Ototoxicity: Nonclinical Evaluation During Drug Development"", ""docket_id"": ""FDA-2020-D-0367"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-0367-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:07,2025-05-28 03:53:06
d750fd63-06a3-486b-9f06-930eab915204,CAB,5a3c3fd7-8966-4d49-80be-9259dbfa12fe,G_IMPACT_ANALYSIS_IN,2025-05-27 02:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-2910-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2024-N-2910-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b3efc128-de32-4064-8905-ee749b8e53b7""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b3efc128-de32-4064-8905-ee749b8e53b7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 02:00:55,2025-05-28 03:53:06
d7679a42-9e71-4f4a-bc36-35a80ae50baf,USA-FDA,7278ff2d-607d-4108-9e7f-c8aa38ff73a6,G_ACTION_ITEMS,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0730/FDA-2013-N-0730-0007/FDA-2013-N-0730-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for Industry: Submitting Requests under 21 CFR 170.39 Threshold of Regulation for Substances Used in Food-Contact Articles"", ""docket_id"": ""FDA-2013-N-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-0730-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0730/FDA-2013-N-0730-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:15:32,2025-05-28 03:53:06
d76af76b-0273-4c1a-be5a-3f11dc1bcb2e,USA-FDA,9e644b21-6167-4152-9755-b670acd724ac,G_IMPACT_ANALYSIS,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0306/FDA-2003-D-0306-0002/FDA-2003-D-0306-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Powder Blends and Finished Dosage Units Stratified In-Process Dosage Unit Sampling and Assessment"", ""docket_id"": ""FDA-2003-D-0306"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0306-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0306/FDA-2003-D-0306-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:17:43,2025-05-28 03:53:06
d777b679-509a-4114-917e-a9a533b0a6f4,USA-FDA,3f5d89af-bf63-4097-8cdd-2fd13818bb42,G_CONCISE_SUMMARY,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002/FDA-2009-D-0195-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Uranium"", ""docket_id"": ""FDA-2009-D-0195"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0195-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:31:03,2025-05-28 03:53:06
d78ec0b9-670a-43d4-9caa-ec937266c73c,USA-FDA,119008cc-2c64-4c31-9ea5-53d9d36273e3,G_CONCISE_SUMMARY,2025-05-21 21:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002/FDA-2014-N-0829-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Reporting Drug Sample Information\nUnder Section 6004 of the Affordable Care Act"", ""docket_id"": ""FDA-2014-N-0829"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-0829-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-0829/FDA-2014-N-0829-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:30:14,2025-05-28 03:53:06
d7b3308e-f57b-4a27-af2e-ae061e1ed264,USA-FDA,941d64d8-1d1d-4130-8a16-d516d8d879c0,G_IMPACT_ANALYSIS,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1529/FDA-2013-N-1529-0023/FDA-2013-N-1529-0023-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""03 Reference 2 Open Public Hearings Guidance - Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: The Open Public Hearing at FDA Advisory Committee Meetings"", ""docket_id"": ""FDA-2013-N-1529"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1529-0023""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1529/FDA-2013-N-1529-0023"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:32:28,2025-05-28 03:53:06
d7c07f05-9c60-4d90-a5db-b99cebea523a,USA-FDA,4b4c9f1e-07d7-4488-ad11-568245b7313c,G_FAQ,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011/FDA-2014-D-2300-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Drug Effects on the Ability to Operate a Motor Vehicle\nGuidance for Industry"", ""docket_id"": ""FDA-2014-D-2300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-2300-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:32:21,2025-05-28 03:53:06
d7d52671-7f59-4924-907f-3dcef34ad4ed,USA-FDA,9884deee-2649-4c75-b957-f5e98a0d7adc,G_MINI_SUMMARY,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0719/FDA-2018-D-0719-0002/FDA-2018-D-0719-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)\nGuidance for Industry"", ""docket_id"": ""FDA-2018-D-0719"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0719-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0719/FDA-2018-D-0719-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:31:00,2025-05-28 03:53:06
d7e92c25-bbeb-45e3-9cc9-47e51fee36e7,USA-FDA,1df3976c-9837-4cb3-b7a2-cead69746931,G_FAQ,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0007/FDA-1992-N-0007-0005/FDA-1992-N-0007-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Industry Supported Scientific and Educational Activities:  Guidance for Industry"", ""docket_id"": ""FDA-1992-N-0007"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0007-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0007/FDA-1992-N-0007-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:16:41,2025-05-28 03:53:06
d8137334-d53b-4915-a5f0-fcf9429e6d3f,SCHEDULED,0b6dc720-b1b7-46a0-9fb1-6b89b3d2cbe1,DEVICE_ANALYST,2025-05-23 00:00:04,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-23""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/0b6dc720-b1b7-46a0-9fb1-6b89b3d2cbe1"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 00:00:24,2025-05-28 03:53:06
d829bc3d-18a9-43f7-b0d7-624417b3f081,USA-FDA,6ec1b2c2-cfc6-4851-9c63-9757aaa4664b,G_ACTION_ITEMS,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0391/FDA-2008-D-0391-0014/FDA-2008-D-0391-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Submission of Documentation: Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes"", ""docket_id"": ""FDA-2008-D-0391"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0391-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0391/FDA-2008-D-0391-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:46:28,2025-05-28 03:53:06
d86bf67f-6cef-4c37-93e6-3aaa4e9af5bf,USA-FDA,47a68067-0952-4825-9f3f-27a4276fbe17,G_CONCISE_SUMMARY,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013/FDA-2016-D-2567-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""02-Final Guidance for Industry-E17 General Principles for Planning and Design of Multiregional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:02:49,2025-05-28 03:53:06
d873d6bc-746b-48dd-a606-b0b49f7e2994,USA-FDA,a34a0e46-b17e-47db-b387-1fc6edbbeb66,G_DETAILED_SUMMARY,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001/FDA-2018-D-3551-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Impact of Certain Provisions of Revised Common Rule on FDA-Regulated Clinical Investigations; Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2018-D-3551"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-3551-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-3551/FDA-2018-D-3551-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:30:21,2025-05-28 03:53:06
d886e99d-ceeb-4e0e-a53a-fcf9a7597dee,USA-FDA,6a17d07d-50c6-4914-8c0a-ef9da92667f8,G_IMPACT_ANALYSIS,2025-05-22 12:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0722/FDA-2011-D-0722-0002/FDA-2011-D-0722-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Implementation of Acceptable Abbreviated Donor History Questionnaire, etc."", ""docket_id"": ""FDA-2011-D-0722"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0722-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0722/FDA-2011-D-0722-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:48:18,2025-05-28 03:53:06
d8927f30-92a1-4c10-9749-5dc35d3a0513,USA-FDA,cd040364-4ac1-47a4-912a-47746c9c1643,G_DETAILED_SUMMARY,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0002/FDA-2012-D-1038-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:17:13,2025-05-28 03:53:06
d8a261c1-a275-4d30-995b-d6789b1d90bb,USA-FDA,25e3d71a-0f24-4d4d-9a19-1cb199c89a43,G_IMPACT_ANALYSIS,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0035/FDA-2003-D-0035-0002/FDA-2003-D-0035-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims"", ""docket_id"": ""FDA-2003-D-0035"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0035-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0035/FDA-2003-D-0035-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:02:46,2025-05-28 03:53:06
d8cbb834-f503-4c44-9363-8bd7fd1f69bd,USA-FDA,bd9fd517-1c83-4da0-9c56-3d030b3fc9f5,G_ACTION_ITEMS,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002/FDA-2011-D-0602-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industryon Quality Considerations in Demonstrating Biosimilarity to Reference Protein Product"", ""docket_id"": ""FDA-2011-D-0602"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0602-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:34:48,2025-05-28 03:53:06
d8db4a63-1c98-4761-bfb5-9970145dbdf3,USA-FDA,025e8a7d-2fcc-490d-80c0-dd36a29191de,G_ACTION_ITEMS,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002/FDA-2009-D-0354-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Pharmaceutical Components at Risk for Melamine Contamination"", ""docket_id"": ""FDA-2009-D-0354"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0354-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0354/FDA-2009-D-0354-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:02:39,2025-05-28 03:53:06
d8e8f06f-d136-4c65-896c-f30d5e81fa8e,USA-FDA,f5941811-bca9-4921-a456-ddcd1cc4a3b7,G_KEYWORDS,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002/FDA-2009-D-0136-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0136"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0136-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:31:44,2025-05-28 03:53:06
d8f8e618-e889-4e66-a930-ce1d874d65a9,USA-FDA,57b29f80-8403-4420-9a65-81bc41551b6d,G_MINI_SUMMARY,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002/FDA-2014-D-1351-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Flow Cytometric Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1351"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1351-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:01:46,2025-05-28 03:53:06
d9073dc0-5cf7-4fe5-a1eb-efe6771ae00c,USA-FDA,01eb8d6c-f816-4d70-a482-950ca8445664,G_KEYWORDS,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004/FDA-2010-D-0249-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Systemic Lupus Erythematosus � Developing Medical Products for Treatment"", ""docket_id"": ""FDA-2010-D-0249"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0249-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:02:23,2025-05-28 03:53:06
d92a5224-7bdd-4df3-bb0b-6967ca60a156,USA-FDA,046f2e51-492b-4e30-96bd-b74ee3b03c29,G_IMPACT_ANALYSIS,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009/FDA-2016-D-2569-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""01 Final Guidance for Industry - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals-Questions and Answers"", ""docket_id"": ""FDA-2016-D-2569"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2569-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2569/FDA-2016-D-2569-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:33:30,2025-05-28 03:53:06
d9430060-fc07-4556-a6d3-e494e8ad133d,USA-FDA,e6b62274-8dcd-40e1-872d-be0f4056e142,G_DETAILED_SUMMARY,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013/FDA-2009-D-0490-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff:  Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2009-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0490-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:47:44,2025-05-28 03:53:06
d95b4ee2-bc57-41ef-aa06-f862ea78e96d,USA-FDA,ff435caa-debc-446f-801e-72cac994b2e5,G_IMPACT_ANALYSIS,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001/FDA-2023-D-2510-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)"", ""docket_id"": ""FDA-2023-D-2510"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2510-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:31:47,2025-05-28 03:53:06
d96c07e9-f037-46ea-8403-bd7aedcabccc,USA-FDA,b611fb2e-caba-4862-931d-b3625791a9df,G_DETAILED_SUMMARY,2025-05-20 05:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002/FDA-2014-D-1351-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Flow Cytometric Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-D-1351"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1351-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1351/FDA-2014-D-1351-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:02:02,2025-05-28 03:53:06
d9aad656-69f9-4d3c-883a-9018258efb1f,USA-FDA,a72198e5-0e3c-4f42-b01b-5ca2381fb5b2,G_ACTION_ITEMS,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0002/FDA-2017-D-6526-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier"", ""docket_id"": ""FDA-2017-D-6526"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6526-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6526/FDA-2017-D-6526-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:00:43,2025-05-28 03:53:06
d9bbecc1-43e2-42d9-8f1f-44a570d92e7f,SCHEDULED,cb697fe5-d147-4e01-a3bc-e8dff81efde7,FDA_ALERT,2025-05-24 00:00:05,30,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/fda_alert/cb697fe5-d147-4e01-a3bc-e8dff81efde7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:31,2025-05-28 03:53:06
d9ec7c6c-dcc7-47b1-ab20-6da7242ad0f2,USA-FDA,3b61ef5a-314c-4cf9-b2c8-e5c8e123defd,G_CONCISE_SUMMARY,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008/FDA-1999-D-0128-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Cooperative Manufacturing Arrangements for Licensed Biologics"", ""docket_id"": ""FDA-1999-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0128-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0128/FDA-1999-D-0128-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:31:39,2025-05-28 03:53:06
d9effde2-034e-491c-b845-ff49681c93be,USA-FDA,ea5aee69-a834-4252-8bde-20e2f7425e57,G_MINI_SUMMARY,2025-05-22 18:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0508/FDA-2009-D-0508-0010/FDA-2009-D-0508-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments"", ""docket_id"": ""FDA-2009-D-0508"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0508-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0508/FDA-2009-D-0508-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:15:20,2025-05-28 03:53:06
da1f44b1-0055-4800-b926-dbec7558efc3,USA-FDA,6cf1a169-0ac3-4bfd-9bda-50fb8b0090dd,G_ACTION_ITEMS,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008/FDA-2008-D-0642-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2008-D-0642"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0642-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0642/FDA-2008-D-0642-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:33:18,2025-05-28 03:53:06
da23e54f-d892-4c54-8f6e-7a585e78f2b9,USA-FDA,491038f4-bd7f-4d59-bef9-756fb6107306,G_DETAILED_SUMMARY,2025-05-22 04:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0310/FDA-2014-D-0310-0002/FDA-2014-D-0310-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Immunogenicity-Related\nConsiderations for the Approval of Low Molecular Weight Heparin for New Drug Applications and Abbreviated New Drug Applications"", ""docket_id"": ""FDA-2014-D-0310"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-0310-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-0310/FDA-2014-D-0310-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:31:06,2025-05-28 03:53:06
da9a8622-dfa8-4a3e-9d74-66ca4baf65f1,USA-FDA,b7225083-a66f-4f83-a65f-4444c6ff384a,G_ACTION_ITEMS,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0002/FDA-2004-D-0500-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Help Seeking and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:32:57,2025-05-28 03:53:06
dac65f20-43eb-4734-b719-f6512e5cc42c,USA-FDA,c3c03ae1-df4e-42e5-b67b-ef3ecb5f9121,G_CONCISE_SUMMARY,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001/FDA-2020-D-1407-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products HCT Ps Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2020-D-1407"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1407-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:27,2025-05-28 03:53:06
dacbd4ea-a40d-49df-aa7d-412d745e658b,CAB,8bd8df7b-e03a-435d-ad69-78c5d36c981e,G_SUMMARY_IN,2025-05-27 02:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-2910-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2024-N-2910-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""b3efc128-de32-4064-8905-ee749b8e53b7""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/b3efc128-de32-4064-8905-ee749b8e53b7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 02:00:31,2025-05-28 03:53:06
dadd6cf1-9b46-4744-b363-c5e9184eeca8,USA-FDA,7f8c0050-9eee-4526-bc0c-393e60ba480b,G_FAQ,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038/FDA-2008-D-0406-0038-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs; Frequently Asked Questions - Statement of Investigator (Form FDA 1572)"", ""docket_id"": ""FDA-2008-D-0406"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0406-0038""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0406/FDA-2008-D-0406-0038"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:17:44,2025-05-28 03:53:06
daf783e2-5338-4aee-a47f-5adc7023bd66,USA-FDA,cf25f4f5-e128-4d8d-81a4-088d860f72a7,G_MINI_SUMMARY,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0847/FDA-2012-D-0847-0002/FDA-2012-D-0847-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for IRBs, Clinical Investigators, and Sponsors; IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed"", ""docket_id"": ""FDA-2012-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0847-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0847/FDA-2012-D-0847-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:15:08,2025-05-28 03:53:06
dafde867-9388-4766-a33d-837e6c2b54c6,USA-FDA,379fdef8-df82-4f6e-b2d5-93aa8015cec7,G_FAQ,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0182/FDA-2004-D-0182-0004/FDA-2004-D-0182-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; ANDAs: Pharmaceutical Solid Polymorphism;\nChemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-2004-D-0182"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0182-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0182/FDA-2004-D-0182-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:30:27,2025-05-28 03:53:06
db09cbe3-3eda-4ada-bece-1514c0563821,USA-FDA,5dcc7abf-d4f4-40db-8b37-6eca44588245,G_DETAILED_SUMMARY,2025-05-22 17:30:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0336/FDA-2005-D-0336-0004/FDA-2005-D-0336-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #176 (VICH GL39) Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances"", ""docket_id"": ""FDA-2005-D-0336"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0336-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0336/FDA-2005-D-0336-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:30:44,2025-05-28 03:53:06
db1ec10c-749a-4217-b803-6e9a79a200a6,USA-FDA,eed1f793-d42e-4077-bf7f-84035245a3b4,G_MINI_SUMMARY,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012/FDA-2003-D-0186-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for InduGuidance for Industry: Cosmetics Processors and Transporters of Cosmetics Security Preventive Measures Guidance"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:00:08,2025-05-28 03:53:06
db6a689e-4f20-4954-99a8-4f3dc6c9572d,USA-FDA,205b6882-9a9f-4b49-a3bb-5374b111a405,G_FAQ,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020/FDA-1992-N-0056-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prescription Drug Marketing Act (PDMA) Requirements; Questions and Answers"", ""docket_id"": ""FDA-1992-N-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0056-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:15:49,2025-05-28 03:53:06
db8f7605-4434-4eb7-91c1-059c03a796df,SCHEDULED,d2bc674d-fb24-4ed6-b078-bea8a88e88ac,DEVICE_ANALYST,2025-05-30 00:00:04,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Patel"", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": ""Abhishek"", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/d2bc674d-fb24-4ed6-b078-bea8a88e88ac"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:27,2025-05-30 00:00:27
dbb8ed7a-173f-4959-942d-7da28a840441,USA-FDA,84c86969-392c-4b61-a088-b8dd6204b85d,G_KEYWORDS,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001/FDA-2020-D-1916-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect -21 CFR 1003.11"", ""docket_id"": ""FDA-2020-D-1916"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1916-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1916/FDA-2020-D-1916-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:45:36,2025-05-28 03:53:06
dbcf64a6-e7eb-4318-b7eb-baa4a027f354,USA-FDA,21383d85-4e60-45d5-8216-93a0aec1fe11,G_ACTION_ITEMS,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1168/FDA-2012-D-1168-0002/FDA-2012-D-1168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Providing Submissions in Electronic Format Summary Level Clinical Site Data for CDER's Inspection Planning"", ""docket_id"": ""FDA-2012-D-1168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1168/FDA-2012-D-1168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:45:29,2025-05-28 03:53:06
dbf3baec-a4c2-4175-8708-f62cb75e4b65,USA-FDA,f5a88c17-3e4a-4a59-a513-ca73fd351353,G_MINI_SUMMARY,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0016/FDA-2010-D-0503-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Clinical Investigators, Sponsors, and Institutional Review Boards on Investigational New Drug Applications--Determining Whether Human Research Studies Can Be Conducted Without an Investigational New Drug Application"", ""docket_id"": ""FDA-2010-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0503-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:45:08,2025-05-28 03:53:06
dc2053a4-5de6-496a-b228-c0a776c3930b,USA-FDA,e60bda22-45cf-43e5-a7da-91b9e26c423b,G_FAQ,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032/FDA-2002-D-0094-0032-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0032""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:02:32,2025-05-28 03:53:06
dc3abe46-aeed-455c-8891-cffe84060165,USA-FDA,d7924152-0c86-4477-9e13-dbf60f20de68,G_FAQ,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0005/FDA-2004-D-0301-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Fixed Dose Combinations, Co-Packaged Drug Products, and Single-EntityVersions of Previously Approved\nAntiretrovirals for the Treatment of HIV"", ""docket_id"": ""FDA-2004-D-0301"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0301-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:01:51,2025-05-28 03:53:06
dc4a3b59-ac58-42f6-b556-0ec587a2c28f,USA-FDA,91fc8fba-aeb1-4c57-a0ce-b5e0d4b63b86,G_MINI_SUMMARY,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1264/FDA-2014-D-1264-0003/FDA-2014-D-1264-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment over the Spectrum of Disease"", ""docket_id"": ""FDA-2014-D-1264"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1264-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1264/FDA-2014-D-1264-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:47:22,2025-05-28 03:53:06
dc511813-ad55-486b-8ab5-3e39b9bbd61c,USA-FDA,601f8672-a14d-42b8-83c3-02445d96f4da,G_MINI_SUMMARY,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002/FDA-2011-D-0147-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Staff Demonstrating Substantial Equivalence of New Tobacco Product; Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2011-D-0147"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0147-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:30:10,2025-05-28 03:53:06
dc5722a3-a71f-4075-ab9a-df8b81e6c136,USA-FDA,bdabdd89-a72c-4786-ba8c-06cebaad1864,G_IMPACT_ANALYSIS,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004/FDA-2002-D-0180-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Q1E Evaluation of Stability Data"", ""docket_id"": ""FDA-2002-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0180-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:46:20,2025-05-28 03:53:06
dcb4fb7a-48c7-4a2e-ad29-03ef65e108c4,USA-FDA,40d311d9-6719-4a98-a718-b6f80ae233c7,G_DETAILED_SUMMARY,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0490/FDA-2011-D-0490-0002/FDA-2011-D-0490-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that are Color Additives; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0490-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0490/FDA-2011-D-0490-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:16:06,2025-05-28 03:53:06
dd0175c0-a003-41fd-b7aa-7a4c7cc1cc2f,USA-FDA,727188d8-be49-481f-97b6-453a818d8ea0,G_KEYWORDS,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009/FDA-2003-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI"", ""docket_id"": ""FDA-2003-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:31:14,2025-05-28 03:53:06
dd13678a-6075-446f-9efd-8d093985abf1,USA-FDA,c0ad50a2-b321-4bea-b3d8-cdfaa3d5d2e3,G_FAQ,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001/FDA-2020-D-1961-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling"", ""docket_id"": ""FDA-2020-D-1961"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1961-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:31:37,2025-05-28 03:53:06
dd2719e4-62bf-4dfa-a013-59a3451c3d47,USA-FDA,84545789-f60e-4bb9-925c-ade8978a0041,G_DETAILED_SUMMARY,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005/FDA-1999-D-4079-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling"", ""docket_id"": ""FDA-1999-D-4079"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4079-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4079/FDA-1999-D-4079-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:31:58,2025-05-28 03:53:06
dd338639-3205-475c-9e55-f370df8a1c2d,USA-FDA,61b31f91-c4a3-444e-a3aa-65da092abb04,G_MINI_SUMMARY,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011/FDA-2014-D-2300-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Drug Effects on the Ability to Operate a Motor Vehicle\nGuidance for Industry"", ""docket_id"": ""FDA-2014-D-2300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-2300-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:31:53,2025-05-28 03:53:06
dd50db4f-d462-4b85-936b-fc996b197685,USA-FDA,8b2ca8e3-0fe9-4361-bbc2-72a086179cde,G_CONCISE_SUMMARY,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002/FDA-2012-D-0304-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Claa II Special Controls Guidance Implanted Blood Access Devices for Hemodialysis"", ""docket_id"": ""FDA-2012-D-0304"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0304-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0304/FDA-2012-D-0304-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:00:19,2025-05-28 03:53:06
dd6d94d5-0292-4af8-b13a-1149f2526d03,USA-FDA,95f63b29-41c4-41c4-a285-e8cdd1de6ea0,G_FAQ,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002/FDA-2018-D-2583-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products; Guidance for Industry;  Draft Guidance"", ""docket_id"": ""FDA-2018-D-2583"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2583-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:02:55,2025-05-28 03:53:06
dd7d4dfe-d6b1-438a-88b2-a7f95dea385e,SCHEDULED,8367a9dd-1e18-405a-8ab3-1a2eb5435e28,DEVICE_ANALYST,2025-05-30 00:00:04,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/8367a9dd-1e18-405a-8ab3-1a2eb5435e28"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:16,2025-05-30 00:00:16
dd8f2974-6586-4996-ab9c-b605cda8dbc3,USA-FDA,5dd1465f-20ea-47a7-8d9d-96007cda27c2,G_MINI_SUMMARY,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0742/FDA-1999-D-0742-0014/FDA-1999-D-0742-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Financial Disclosure by Clinical Investigators - Draft Guidance"", ""docket_id"": ""FDA-1999-D-0742"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0742-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0742/FDA-1999-D-0742-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:46:08,2025-05-28 03:53:06
dd9ef4a5-d14e-43d6-8e00-6c962b9da47a,USA-FDA,79eca29b-29c3-4d71-8179-7198ef1e935d,G_ACTION_ITEMS,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0030/FDA-2007-D-0030-0002/FDA-2007-D-0030-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Refrigerated Carrot Juice and Other Refrigerated\nLow-Acid Juices"", ""docket_id"": ""FDA-2007-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0030-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0030/FDA-2007-D-0030-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:15:28,2025-05-28 03:53:06
dda0f44d-af0c-496a-ba0f-a8a3c88022f2,USA-FDA,958ef2b6-36b5-46cd-8018-2ec538d04628,G_FAQ,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021/FDA-2004-D-0044-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for the Early Food Safety\nEvaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties\nIntended for Food Use; Availability"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:00:29,2025-05-28 03:53:06
dda49cfd-77bb-4800-8159-6530b8fe238c,USA-FDA,15532d99-447b-475f-8ca0-0241ced01f70,G_MINI_SUMMARY,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004/FDA-2010-D-0249-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Systemic Lupus Erythematosus � Developing Medical Products for Treatment"", ""docket_id"": ""FDA-2010-D-0249"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0249-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0249/FDA-2010-D-0249-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:01:13,2025-05-28 03:53:06
dda4e95e-3c0c-4144-a47e-4a1979f80bc1,USA-FDA,7606f0b2-b4f4-4ac2-8281-0fb0bb2d3013,G_DETAILED_SUMMARY,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010/FDA-2004-D-0500-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Consumer-Directed Broadcast Advertising of Restricted Devices; Draft Guidance for Industry"", ""docket_id"": ""FDA-2004-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0500-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0500/FDA-2004-D-0500-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:02:00,2025-05-28 03:53:06
ddc4d131-d80d-4e02-8b04-66ab2786a266,USA-FDA,183e8fd7-f2c7-4d68-93ae-a9767558b05f,G_FAQ,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0592/FDA-2008-D-0592-0010/FDA-2008-D-0592-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Contents of a Complete Submission for the Evaluation ofProprietary Names - Guidance for Industry "", ""docket_id"": ""FDA-2008-D-0592"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0592-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0592/FDA-2008-D-0592-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:17:49,2025-05-28 03:53:06
ddc6c80d-aafe-4465-9c97-f353e0640913,USA-FDA,d5164047-f899-4896-bdeb-f7009768da5c,G_DETAILED_SUMMARY,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0002/FDA-2009-D-0568-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:46:49,2025-05-28 03:53:06
ddd5b533-178e-49ab-88b5-e9767b5f0ad6,USA-FDA,cf321ff3-8dfb-4c67-bf93-f4a98a317b3d,G_MINI_SUMMARY,2025-05-22 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1927/FDA-2020-D-1927-0001/FDA-2020-D-1927-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Food Security Preventive Measures Guidance for  Retail Food Stores and Food Service Establishments"", ""docket_id"": ""FDA-2020-D-1927"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1927-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1927/FDA-2020-D-1927-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:00:09,2025-05-28 03:53:06
dde89361-d841-4a59-b4da-e0aae2384513,USA-FDA,8e25e396-2627-4d67-b1cf-ac56b136614c,G_MINI_SUMMARY,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002/FDA-2014-D-1891-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD"", ""docket_id"": ""FDA-2014-D-1891"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1891-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:15:50,2025-05-28 03:53:06
ddf275a8-ffcf-4900-90b8-fde1e88d34bf,USA-FDA,368ead52-3f6b-47e4-b437-7c35dd889d9a,G_ACTION_ITEMS,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002/FDA-2018-D-4525-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Lactation Studies: Considerations for Study Design; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2018-D-4525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-4525-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-4525/FDA-2018-D-4525-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:17:47,2025-05-28 03:53:06
de27e2e0-72c0-451f-9bac-dcf2927b6464,SCHEDULED,0db7dcbc-72a4-4c6f-9a06-ba937594c0b3,FDA_ALERT,2025-05-20 04:13:45,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-20""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/0db7dcbc-72a4-4c6f-9a06-ba937594c0b3"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 04:13:50,2025-05-28 03:53:06
de36956c-ae79-464c-963e-fa18dd38e8ff,USA-FDA,9506f2de-cbcc-4b7d-9baa-d35b4c96d977,G_ACTION_ITEMS,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0201/FDA-2007-D-0201-0005/FDA-2007-D-0201-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content and Format of the Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products"", ""docket_id"": ""FDA-2007-D-0201"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0201-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0201/FDA-2007-D-0201-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:46:48,2025-05-28 03:53:06
de4c6122-4605-4a37-9ca8-80c94586bf2e,USA-FDA,3d7f8f7e-04a8-45be-945a-9bde8c9947b9,G_IMPACT_ANALYSIS,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1067/FDA-2013-D-1067-0002/FDA-2013-D-1067-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products--Content and Format"", ""docket_id"": ""FDA-2013-D-1067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1067-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1067/FDA-2013-D-1067-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:01:46,2025-05-28 03:53:06
de5a4729-0e15-4d18-b112-fa1de66851d4,USA-FDA,f240b964-c9f8-43ac-a61a-0c524fe06cb7,G_DETAILED_SUMMARY,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001/FDA-2020-D-1961-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling"", ""docket_id"": ""FDA-2020-D-1961"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1961-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1961/FDA-2020-D-1961-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:31:26,2025-05-28 03:53:06
de818956-5017-47f1-9ce3-6cd2304e4746,QUEUE,267fdf06-19c2-44f7-95e9-dab618e05636,G_SUMMARY_USER,2025-05-20 10:44:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""__doc_title__"": ""FDA-2024-E-0438-0006_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/267fdf06-19c2-44f7-95e9-dab618e05636/SRC/267fdf06-19c2-44f7-95e9-dab618e05636.pdf"", ""doc_title"": ""FDA-2024-E-0438-0006_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/267fdf06-19c2-44f7-95e9-dab618e05636/DEST/detailed_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:44:34,2025-05-28 03:53:06
de87b7bf-2c30-4a97-88fe-bbfd7e9ba9fb,USA-FDA,c09b44e6-153f-429a-81f3-1e3ff0498055,G_DETAILED_SUMMARY,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0523/FDA-2012-D-0523-0012/FDA-2012-D-0523-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; Refuse to Accept Policy for 510(k)s"", ""docket_id"": ""FDA-2012-D-0523"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0523-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0523/FDA-2012-D-0523-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:45:24,2025-05-28 03:53:06
de99a273-a8d8-4990-9867-c44ab83aea51,USA-FDA,e9e7a15d-0cc6-4097-b426-b9328e055cf4,G_ACTION_ITEMS,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006/FDA-2005-D-0086-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""uidance for Industry; Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals"", ""docket_id"": ""FDA-2005-D-0086"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0086-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:02:02,2025-05-28 03:53:06
deaf1f2d-780d-4256-a1db-74cb93326d07,USA-FDA,c24205a4-88fb-48fb-9d0a-5d48e91e7d7a,G_IMPACT_ANALYSIS,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0212/FDA-2009-D-0212-0025/FDA-2009-D-0212-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting - Guidance for Industry"", ""docket_id"": ""FDA-2009-D-0212"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0212-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0212/FDA-2009-D-0212-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:47:37,2025-05-28 03:53:06
decbae8b-63dc-4024-837a-fcccb4bf33db,USA-FDA,81801605-37d8-4edf-9633-8cb3cd7671ae,G_CONCISE_SUMMARY,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002/FDA-2011-D-0164-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:00:11,2025-05-28 03:53:06
ded70a31-6551-4305-aed6-f755f1f11d6d,USA-FDA,36c6072d-9724-4e81-a743-e30f51975596,G_DETAILED_SUMMARY,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006/FDA-2005-D-0086-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""uidance for Industry; Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals"", ""docket_id"": ""FDA-2005-D-0086"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0086-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0086/FDA-2005-D-0086-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:01:45,2025-05-28 03:53:06
deda688b-7322-432b-be41-5481a1b6462d,USA-FDA,17063616-fcfc-42f1-afc7-d1d3dbc18366,G_FAQ,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0712/FDA-2016-D-0712-0002/FDA-2016-D-0712-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported  Outcome, for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use DRAFT GUIDANCE"", ""docket_id"": ""FDA-2016-D-0712"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0712-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0712/FDA-2016-D-0712-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:16:26,2025-05-28 03:53:06
dee8d37d-b04a-4b92-8be8-50601389a2b5,USA-FDA,63c192f7-ebaf-4e42-a621-b418bdbb7924,G_DETAILED_SUMMARY,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002/FDA-2007-D-0202-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting Improving Human Subject Protection"", ""docket_id"": ""FDA-2007-D-0202"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0202-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:01:42,2025-05-28 03:53:06
df0a5c3c-dccd-48a2-a0a1-dad4c50a7dc8,USA-FDA,c36085be-09cf-4157-9736-d56464afcb5f,G_ACTION_ITEMS,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0024/FDA-2011-D-0024-0012/FDA-2011-D-0024-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Size of Beads in Drug Products Labeled for Sprinkle"", ""docket_id"": ""FDA-2011-D-0024"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0024-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0024/FDA-2011-D-0024-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:31:41,2025-05-28 03:53:06
df333950-49b1-4df1-8ab7-ae07cbeb5c90,USA-FDA,4f812658-e940-404e-a40d-cd4c7e6ff2c6,G_DETAILED_SUMMARY,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1455/FDA-2020-D-1455-0001/FDA-2020-D-1455-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; Early Development Considerations for Innovative Combination Products"", ""docket_id"": ""FDA-2020-D-1455"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1455-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1455/FDA-2020-D-1455-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:16:39,2025-05-28 03:53:06
df3be7fc-1a68-4386-bdd7-897bc4070514,USA-FDA,47f601f5-f1df-4419-aa62-9150f6a963f7,G_FAQ,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0008/FDA-2017-D-2462-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species Guidance for Industry"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:32:39,2025-05-28 03:53:06
df5273ef-d443-4c82-b2b2-f232d11fd39e,USA-FDA,c3f5938e-c723-4da1-9f14-b6e48743c1c8,G_IMPACT_ANALYSIS,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0605/FDA-2011-D-0605-0002/FDA-2011-D-0605-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Scientific Considerations in Demonstrating Biosimilarity to Reference Product"", ""docket_id"": ""FDA-2011-D-0605"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0605-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0605/FDA-2011-D-0605-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:16:46,2025-05-28 03:53:06
df9d38db-ad70-428f-a7a9-2126c23c3a30,SCHEDULED,729d2b4a-070d-4af6-bd3c-bcb2d9f64929,FDA_ALERT,2025-05-21 20:33:25,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/729d2b4a-070d-4af6-bd3c-bcb2d9f64929"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:39,2025-05-28 03:53:06
dfd43b24-7283-4866-b138-ad86b7855f68,USA-FDA,8fada63f-2a85-4d84-a921-af1f15904eed,G_IMPACT_ANALYSIS,2025-05-22 15:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0246/FDA-2010-D-0246-0014/FDA-2010-D-0246-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Residual Drug in Transdermal and Related Drug Delivery Systems; Guidance for Industry"", ""docket_id"": ""FDA-2010-D-0246"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0246-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0246/FDA-2010-D-0246-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:02:21,2025-05-28 03:53:06
e01a8ba3-0fb1-47f1-8668-8ddc97ac7835,USA-FDA,6171ffc8-1c6f-4e35-a8ce-e6bd496f8a58,G_ACTION_ITEMS,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002/FDA-1997-D-0380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation; Guidance"", ""docket_id"": ""FDA-1997-D-0380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:31:27,2025-05-28 03:53:06
e01e17f1-55b4-4796-8a4e-586b45a8aa34,USA-FDA,2d9337d6-f4af-4d8f-9ebf-2d3d4a671587,G_DETAILED_SUMMARY,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013/FDA-2016-D-2567-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""02-Final Guidance for Industry-E17 General Principles for Planning and Design of Multiregional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:03:07,2025-05-28 03:53:06
e0325ee2-a6ef-469a-b7a1-be4aed594f19,USA-FDA,78c96489-8d4d-4f11-a551-352b36804bf8,G_DETAILED_SUMMARY,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-N-0121/FDA-2011-N-0121-0009/FDA-2011-N-0121-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products; Small Entity Compliance Guide"", ""docket_id"": ""FDA-2011-N-0121"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-N-0121-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-N-0121/FDA-2011-N-0121-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:15:13,2025-05-28 03:53:06
e063a5ae-2351-4664-a39d-f604d64ddd22,USA-FDA,1b6beea9-f7ae-4012-a8de-32158dc40e25,G_IMPACT_ANALYSIS,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0524/FDA-2012-D-0524-0002/FDA-2012-D-0524-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: Acceptance and Filing Review for Premarket Approval Applications (PMAs) - Guidance"", ""docket_id"": ""FDA-2012-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0524-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0524/FDA-2012-D-0524-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:16:35,2025-05-28 03:53:06
e0749d73-0c7f-49ab-83d8-aadc3debde5a,USA-FDA,e25927da-0a16-4bd3-8b86-294c159634d1,G_CONCISE_SUMMARY,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009/FDA-2007-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry; Bioequivalence Recommendation for Lenalidomide Capsules"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:13:16,2025-05-28 03:53:06
e07f976e-942e-45db-9d6c-c269bfc37f21,USA-FDA,b98c987a-4578-41d3-8084-9e7e85b527ab,G_CONCISE_SUMMARY,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002/FDA-2017-D-6380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric\nSubpopulations of Common Diseases Draft Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:01:46,2025-05-28 03:53:06
e09834d3-330c-4cf6-8d3e-8cd0c69f71f8,USA-FDA,d5b82452-bd99-458b-899e-8c4cccb5b1f9,G_IMPACT_ANALYSIS,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3390/FDA-2015-D-3390-0002/FDA-2015-D-3390-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""eCTD TECHNICAL CONFORMANCE GUIDE"", ""docket_id"": ""FDA-2015-D-3390"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-3390-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3390/FDA-2015-D-3390-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:32:38,2025-05-28 03:53:06
e0aa1393-5b85-40a4-abee-a34fa5d2ff55,USA-FDA,60d45d29-a1cd-4796-affc-73c4fdbb05c1,G_IMPACT_ANALYSIS,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1264/FDA-2014-D-1264-0003/FDA-2014-D-1264-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment over the Spectrum of Disease"", ""docket_id"": ""FDA-2014-D-1264"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1264-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1264/FDA-2014-D-1264-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:48:29,2025-05-28 03:53:06
e0c60a23-09aa-4a3f-9aa4-a7dc73b126d1,USA-FDA,633064a1-8512-4fbd-b50a-b8e48c6f1b7d,G_KEYWORDS,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008/FDA-2018-D-2936-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; CDRH Standard Operating Procedures for the Identification and Evaluation of Candidate Consensus Standards for Recognition"", ""docket_id"": ""FDA-2018-D-2936"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2936-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:00:47,2025-05-28 03:53:06
e0da902f-c87b-4258-b5f8-5a28b8243e7a,USA-FDA,54390865-9a45-45cc-bb33-04f7aa6db308,G_FAQ,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-3276/FDA-2016-D-3276-0001/FDA-2016-D-3276-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Investigational Use of Deemed, Finished Tobacco Products That Were on the U.S. Market on August 8, 2016, During the Deeming Compliance Periods; Guidance for Industry"", ""docket_id"": ""FDA-2016-D-3276"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-3276-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-3276/FDA-2016-D-3276-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:17:14,2025-05-28 03:53:06
e0e697cc-5dde-4539-a08e-8d53cedde118,Queue,5f2bea4a-0742-4ace-84e9-d24940140869,G_SUMMARY_USER,2025-05-29 21:25:00,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/detailed_summary/5f2bea4a-0742-4ace-84e9-d24940140869/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/detailed_summary/5f2bea4a-0742-4ace-84e9-d24940140869"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 15:55:08,2025-05-29 15:55:08
e1068a1d-ffc7-49d3-81b9-ee09209d7d05,USA-FDA,92cc165c-c041-4492-ab5e-4eae2360d0d7,G_FAQ,2025-05-22 10:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-0298/FDA-2019-D-0298-0002/FDA-2019-D-0298-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Quality Considerations for Continuous Manufacturing; Guidance for Industry; Draft Guidance"", ""docket_id"": ""FDA-2019-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-0298-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-0298/FDA-2019-D-0298-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:45:54,2025-05-28 03:53:06
e113ddfb-2c0d-4808-97b6-2c8d8b9306de,USA-FDA,e11b4297-0d32-47f6-aba5-f428bba631c1,G_MINI_SUMMARY,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0268/FDA-2009-D-0268-0005/FDA-2009-D-0268-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0268"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0268-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0268/FDA-2009-D-0268-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:30:08,2025-05-28 03:53:06
e12948ad-64ff-4c42-9095-ca3dc279e41b,USA-FDA,d75656b0-c9eb-4677-8d98-65928a0f5c58,G_MINI_SUMMARY,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013/FDA-2016-D-2567-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""02-Final Guidance for Industry-E17 General Principles for Planning and Design of Multiregional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:02:43,2025-05-28 03:53:06
e151f738-8150-4352-a499-4813aa4b589f,USA-FDA,33df0d2e-a4b1-4cca-9f9a-d06f52b77609,G_MINI_SUMMARY,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001/FDA-2020-D-1398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; FDA Approval of New Animal Drugs For Minor Uses and for Minor Species; #61"", ""docket_id"": ""FDA-2020-D-1398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:46:00,2025-05-28 03:53:06
e1600787-0ce8-4140-a643-81aab1bf3abd,USA-FDA,fadb102f-d2c4-47bd-bd28-ce5698928736,G_FAQ,2025-05-20 07:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002/FDA-2011-D-0674-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry FDA Records Access Authority under Section 414 and 704 of the Federal Food, Drug, & Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0674"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0674-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0674/FDA-2011-D-0674-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:01:35,2025-05-28 03:53:06
e1643a0f-cd98-42c6-9360-5485491bfed6,USA-FDA,c0a841e4-8e63-4464-91bd-4f6b30d65b4f,G_KEYWORDS,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013/FDA-2009-D-0503-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in - Premarket Notification (510(k)) Submissions; Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0503-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:01:20,2025-05-28 03:53:06
e19473d3-1e10-45ae-bf21-089ca79ba628,CAB,4b7ee395-8507-4322-8731-0f4cce3a0beb,G_FAQ_IN,2025-05-20 09:31:28,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2024-N-5471-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2024-N-5471-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""efc4cee5-eb06-4edf-b5ae-42564def83b6""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/efc4cee5-eb06-4edf-b5ae-42564def83b6"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:31:39,2025-05-28 03:53:06
e1996c57-73cf-4d16-9a2b-1524a924f66e,USA-FDA,bcf430e2-880c-4dd1-a622-5664018da6d6,G_FAQ,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1459/FDA-2018-D-1459-0049/FDA-2018-D-1459-0049-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Food Labeling: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics: Guidance for Industry"", ""docket_id"": ""FDA-2018-D-1459"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-1459-0049""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1459/FDA-2018-D-1459-0049"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:30:38,2025-05-28 03:53:06
e1bc41e0-e2b2-408f-ba3c-5b406c432479,USA-FDA,f44e6428-39e3-46b6-ae7c-1b4423977340,G_CONCISE_SUMMARY,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005/FDA-2010-D-0165-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies (VICH GL49)"", ""docket_id"": ""FDA-2010-D-0165"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0165-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:01:45,2025-05-28 03:53:06
e1c61f15-00c1-48e4-a125-4687d09f38c3,USA-FDA,ba4c20b0-4611-4d0b-8377-4a934ede2312,G_KEYWORDS,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001/FDA-2020-D-1608-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data"", ""docket_id"": ""FDA-2020-D-1608"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1608-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1608/FDA-2020-D-1608-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:47:18,2025-05-28 03:53:06
e1c6b4c7-20aa-4b0d-bbf5-5c556534c61f,USA-FDA,170d3fc8-6af7-4033-b40a-0ef9af61dabc,G_FAQ,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0436/FDA-2011-D-0436-0002/FDA-2011-D-0436-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Q11 Development and Manufacture of Drug Substances; International Conference on Harmonisation - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0436"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0436-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0436/FDA-2011-D-0436-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:31:24,2025-05-28 03:53:06
e1d74d37-5e2e-468a-a66b-b11da8785929,USA-FDA,4449d85c-efae-41b5-bd6c-a17910c1593f,G_DETAILED_SUMMARY,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002/FDA-2013-N-1429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2013-N-1429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:02:07,2025-05-28 03:53:06
e1e8078d-1db0-49fb-a7ab-43fa130d195b,USA-FDA,c38be025-ad6c-4a21-baf7-a9c936f97cf9,G_ACTION_ITEMS,2025-05-22 12:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0005/FDA-2004-D-0301-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Fixed Dose Combinations, Co-Packaged Drug Products, and Single-EntityVersions of Previously Approved\nAntiretrovirals for the Treatment of HIV"", ""docket_id"": ""FDA-2004-D-0301"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0301-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:02:02,2025-05-28 03:53:06
e22772ff-fa27-445a-abc8-599547b0000c,USA-FDA,47c21409-8f70-42b4-8ac4-144a08a5dc02,G_CONCISE_SUMMARY,2025-05-21 23:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004/FDA-2018-N-4735-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""GFI Safety Labeling Changes Implementation of Section 505(o)(4) of the FDC Act"", ""docket_id"": ""FDA-2018-N-4735"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-N-4735-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-N-4735/FDA-2018-N-4735-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:16:19,2025-05-28 03:53:06
e24307a6-8512-4971-bc73-ef57ea071f42,USA-FDA,314ccc2a-c007-40c4-9233-7603cf3232e1,G_IMPACT_ANALYSIS,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008/FDA-2009-D-0448-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry, MQSA Inspectors and FDA Staffl The Mammography Quality Standards Act Final Regulations: Modifications and Additions to Policy Guidance Help System #13"", ""docket_id"": ""FDA-2009-D-0448"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0448-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0448/FDA-2009-D-0448-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:03:30,2025-05-28 03:53:06
e2613525-044b-40af-95b5-2c7f579ef594,USA-FDA,62233d55-2d5e-4f82-b8d5-53afd932c2ea,G_DETAILED_SUMMARY,2025-05-22 17:00:09,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0005/FDA-2007-D-0433-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Bieoquivalence Recommendations for Specific Products"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:00:50,2025-05-28 03:53:06
e27d114c-123c-4d8d-8cc5-1d22147cff48,USA-FDA,2d004580-6a1c-4f43-b841-91e8ad1139b8,G_DETAILED_SUMMARY,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002/FDA-2011-D-0164-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:00:14,2025-05-28 03:53:06
e28ca2bd-a9fe-41d9-9b91-de015fbb92a0,USA-FDA,31f1004f-823f-4d0e-9b07-ec8450d0165a,G_KEYWORDS,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002/FDA-2010-D-0404-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use--Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0404"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0404-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:33:45,2025-05-28 03:53:06
e2ca54bb-7fd6-4637-b323-572bb5b4fe5d,USA-FDA,ebee8c8f-4e5a-4096-92ea-fd0e0e76a438,G_MINI_SUMMARY,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1161/FDA-2012-D-1161-0002/FDA-2012-D-1161-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Design Considerations for Devices Intended for Home Use - Draft Guidance"", ""docket_id"": ""FDA-2012-D-1161"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1161-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1161/FDA-2012-D-1161-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:32:50,2025-05-28 03:53:06
e2df894a-ade2-49ca-aa5a-bd4c6e45fbd8,USA-FDA,6195e3d5-167e-4911-855e-6b350b3b9487,G_ACTION_ITEMS,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004/FDA-2007-D-0302-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Labeling for Human Prescription Drug and Biological Products � Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information"", ""docket_id"": ""FDA-2007-D-0302"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0302-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0302/FDA-2007-D-0302-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:03:13,2025-05-28 03:53:06
e2e24088-23a3-47a4-b25e-bb965d7a2554,USA-FDA,0f3241df-db13-4405-997a-ba7b14ecdf78,G_ACTION_ITEMS,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1120/FDA-2012-D-1120-0002/FDA-2012-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Vaginal Microbicides: Development for the Prevention of Human Immunodeficiency Virus Infection"", ""docket_id"": ""FDA-2012-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1120/FDA-2012-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:47:12,2025-05-28 03:53:06
e2e87416-e3d4-4ed4-8b69-77b552dd7840,USA-FDA,938f25b6-4bce-4816-a22c-64af539d2cd5,G_IMPACT_ANALYSIS,2025-05-22 06:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0361/FDA-2008-N-0361-0002/FDA-2008-N-0361-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Standard of Identity for White Chocolate; Guidance "", ""docket_id"": ""FDA-2008-N-0361"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-N-0361-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0361/FDA-2008-N-0361-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:15:33,2025-05-28 03:53:06
e3046a99-37af-4546-9bdd-d92a1a9f9798,USA-FDA,643a5af2-e87e-4328-a114-06b43662e794,G_DETAILED_SUMMARY,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0002/FDA-2016-D-2567-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on E17 General Principles for Planning and Design of Multi-Regional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:15:31,2025-05-28 03:53:06
e3084a82-f849-4692-8aae-e5febcda1198,USA-FDA,57743c7b-5068-4f91-a30a-c5d0b646830e,G_KEYWORDS,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001/FDA-2020-D-1950-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 394.500 Importation of Television Products, Microwave Ovens, and Inherent Class I Laser Products for Investigation and Evaluation during Design Development"", ""docket_id"": ""FDA-2020-D-1950"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1950-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:47:54,2025-05-28 03:53:06
e30dbc81-3b4a-43f0-a2de-0d58e4852865,USA-FDA,10313d0e-2ec4-417e-9734-453cc2853041,G_DETAILED_SUMMARY,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0313/FDA-2010-D-0313-0018/FDA-2010-D-0313-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2010-D-0313"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0313-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0313/FDA-2010-D-0313-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:45:27,2025-05-28 03:53:06
e31d9e69-8da9-421a-8848-e4ee1e08fc7e,USA-FDA,9e56c902-ee3a-4704-9981-1b844b7a23cd,G_ACTION_ITEMS,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001/FDA-2020-D-1398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; FDA Approval of New Animal Drugs For Minor Uses and for Minor Species; #61"", ""docket_id"": ""FDA-2020-D-1398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:47:09,2025-05-28 03:53:06
e3b878a9-5b1a-4907-adb3-4433ba450c4a,USA-FDA,a328dc6f-52ce-4f21-917f-490b6c4bd85f,G_FAQ,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0002/FDA-2014-D-1399-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Draft Guidance Document"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:16:03,2025-05-28 03:53:06
e3ecb4fc-d455-49b6-80e8-bbbe5a612582,USA-FDA,23aeadfd-7987-4c6b-8ebc-a17af56f880b,G_MINI_SUMMARY,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0835/FDA-2011-D-0835-0002/FDA-2011-D-0835-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Considerations when Transferring Clinical Investigation Oversight to Another Institutional Review Board; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0835"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0835-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0835/FDA-2011-D-0835-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:46:31,2025-05-28 03:53:06
e454cec2-d267-4068-9e75-0dc107f339d8,USA-FDA,57b2b2e8-6d01-44af-b371-df9c8cc5a2c1,G_MINI_SUMMARY,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0391/FDA-2008-D-0391-0014/FDA-2008-D-0391-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Submission of Documentation: Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes"", ""docket_id"": ""FDA-2008-D-0391"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0391-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0391/FDA-2008-D-0391-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:45:58,2025-05-28 03:53:06
e4621c37-cca4-4a40-824d-07cc7485f7d3,USA-FDA,a25a1f70-163d-4103-8c88-2e654a925935,G_KEYWORDS,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003/FDA-1999-D-0030-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-1999-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0030-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:32:51,2025-05-28 03:53:06
e46881f0-7b30-4f2c-9458-5263ec20dc4b,USA-FDA,dda16f8f-e389-475b-8635-9c6f573ba894,G_KEYWORDS,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013/FDA-2016-D-2567-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""02-Final Guidance for Industry-E17 General Principles for Planning and Design of Multiregional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:03:46,2025-05-28 03:53:06
e4af7cf1-292b-4773-b391-d4cf796c3469,USA-FDA,e3681bee-8dc2-4424-b6d9-c3ec0b8c2c6b,G_FAQ,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008/FDA-2010-D-0431-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Food and Drug Administration Staff and Tobacco Retailers on Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Revised"", ""docket_id"": ""FDA-2010-D-0431"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0431-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:45:41,2025-05-28 03:53:06
e4b7966c-5b95-4520-b7f9-d5468ee92944,USA-FDA,57a620f3-4655-43d4-b4d0-6dba773778c6,G_FAQ,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002/FDA-2016-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Enforcement Policy on National Health Related Item Code and National Drug Code Numbers Assigned to Devices"", ""docket_id"": ""FDA-2016-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:45:31,2025-05-28 03:53:06
e4be8a43-ce1f-4a08-a84e-155a6626c9cf,Queue,f346d913-3ebe-4fa6-9187-d2e0342d5413,G_TRANSLATE,2025-05-30 03:54:54,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""c_986569 (4).pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/f346d913-3ebe-4fa6-9187-d2e0342d5413/c_986569 (4).pdf.pdf"", ""doc_title"": ""c_986569 (4).pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/f346d913-3ebe-4fa6-9187-d2e0342d5413"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 03:54:54,2025-05-30 03:54:54
e4d106ea-3efd-4908-b6d1-59e7141e1251,USA-FDA,a754d884-d81d-412c-881a-8f29728bb95b,G_FAQ,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002/FDA-2009-D-0006-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""S9 Nonclinical Evaluation for Anticancer Pharmaceuticals - Draft Guidance"", ""docket_id"": ""FDA-2009-D-0006"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0006-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0006/FDA-2009-D-0006-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:00:45,2025-05-28 03:53:06
e52cd99f-d2d7-4eaf-9757-e51392397b22,USA-FDA,a2afdbd8-46ac-4732-ad03-41dd1cdb5c3a,G_FAQ,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0643/FDA-2010-D-0643-0092/FDA-2010-D-0643-0092-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Electronic Source Data in Clinical Investigations"", ""docket_id"": ""FDA-2010-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0643-0092""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0643/FDA-2010-D-0643-0092"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:00:42,2025-05-28 03:53:06
e5463af5-a2cf-4acd-9733-1917524a02c1,SCHEDULED,f7268b4f-02f7-4598-89b6-3508d41bf7c7,DEVICE_ANALYST,2025-05-22 00:03:21,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/f7268b4f-02f7-4598-89b6-3508d41bf7c7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:38,2025-05-28 03:53:06
e550ddd3-f8c6-4aaf-82e2-923453637709,SCHEDULED,0718eb0d-c914-4790-b296-9797418760dc,DEVICE_ANALYST,2025-05-24 00:00:05,11,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/device_analyst/0718eb0d-c914-4790-b296-9797418760dc"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:12,2025-05-28 03:53:06
e5795b6d-97e6-4117-b4f4-5c72fc785d33,USA-FDA,64a4a583-1fbf-445e-a69f-61d657c5a857,G_ACTION_ITEMS,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0003/FDA-2014-D-1525-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Draft Guidance"", ""docket_id"": ""FDA-2014-D-1525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1525-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:02:20,2025-05-28 03:53:06
e5a8b4cf-b074-4dda-ba6f-99ae134abfa9,USA-FDA,3bdc349d-62d0-44ab-a592-4a1ffaa5e866,G_DETAILED_SUMMARY,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1978-N-0011/FDA-1978-N-0011-0008/FDA-1978-N-0011-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidelines for Effectiveness Testing of O. T. C. Antiperspirant Drug Products"", ""docket_id"": ""FDA-1978-N-0011"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1978-N-0011-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1978-N-0011/FDA-1978-N-0011-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:46:08,2025-05-28 03:53:06
e5c17fe5-5e63-4c77-9621-e915ebf71271,USA-FDA,0c84d608-6495-455e-9281-02ee7094a556,G_FAQ,2025-05-22 11:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0183/FDA-2004-D-0183-0003/FDA-2004-D-0183-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System Guidance for Industry\nand FDA Staff"", ""docket_id"": ""FDA-2004-D-0183"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0183-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0183/FDA-2004-D-0183-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:47:09,2025-05-28 03:53:06
e5c4529f-2d01-4b4e-bfc0-360a6d950cae,USA-FDA,00ca1ff7-6d11-4ef2-869f-32da73aca442,G_CONCISE_SUMMARY,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001/FDA-2020-D-0367-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""External Guidance Document Submission from Turner Scientific, LLC re: Ototoxicity: Nonclinical Evaluation During Drug Development"", ""docket_id"": ""FDA-2020-D-0367"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-0367-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-0367/FDA-2020-D-0367-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:30:10,2025-05-28 03:53:06
e5d4194c-e15b-4c00-960d-d1ee45853788,USA-FDA,7d953ae0-de7b-4604-8442-df1baa786ce5,G_IMPACT_ANALYSIS,2025-05-20 12:08:30,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002/FDA-2011-D-0597-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring"", ""docket_id"": ""FDA-2011-D-0597"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0597-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0597/FDA-2011-D-0597-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:10:22,2025-05-28 03:53:06
e6723379-ddd2-4caf-afdc-8cfa97c66452,USA-FDA,1fba2696-8a25-4fec-bd98-d192d6170ea5,G_CONCISE_SUMMARY,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009/FDA-2011-D-0164-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Safety Labeling Changes--Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:00:15,2025-05-28 03:53:06
e6843e80-8280-43be-b9f0-520b98c7efb6,USA-FDA,9efc3ac2-6c86-4c12-b5a1-05400953c448,G_IMPACT_ANALYSIS,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009/FDA-2011-D-0164-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Safety Labeling Changes--Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:01:03,2025-05-28 03:53:06
e6ad811a-d4cd-4044-b7e6-cb29bf5b2679,USA-FDA,2f45117d-88fe-4a69-b4f9-67ea18d2be22,G_FAQ,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002/FDA-2009-D-0539-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins; Guidance"", ""docket_id"": ""FDA-2009-D-0539"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0539-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0539/FDA-2009-D-0539-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:31:51,2025-05-28 03:53:06
e6c1e6e4-88e8-4dde-ac52-78f80653392e,USA-FDA,02c33858-856c-453a-bb6e-c28d6ef41098,G_IMPACT_ANALYSIS,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013/FDA-2009-D-0490-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff:  Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2009-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0490-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:48:24,2025-05-28 03:53:06
e6dd3843-741f-43bf-bb5a-7a7a503636e7,USA-FDA,28e0eede-6c17-49c9-8b57-f99dcd3a8887,G_DETAILED_SUMMARY,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0008/FDA-2012-D-1083-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff Civil Money Penalties for Tobacco Retailers: Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2012-D-1083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1083-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:15:16,2025-05-28 03:53:06
e6e6a7ae-a24a-4f06-98e1-85422c11bafd,USA-FDA,72f77639-beba-4698-9aab-48f619931ad6,G_MINI_SUMMARY,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001/FDA-2020-D-1977-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures"", ""docket_id"": ""FDA-2020-D-1977"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1977-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1977/FDA-2020-D-1977-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:16:22,2025-05-28 03:53:06
e6f9e534-e22a-4ea4-86ee-bf1ff6b7fbf2,USA-FDA,2749ccf9-9890-41f4-ac3e-c9af495f341c,G_MINI_SUMMARY,2025-05-20 16:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002/FDA-2009-D-0136-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0136"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0136-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0136/FDA-2009-D-0136-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:30:10,2025-05-28 03:53:06
e727fb70-c404-476a-b683-901219738cd1,USA-FDA,613c2409-4237-4b75-8cc1-525dcc65936d,G_FAQ,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0719/FDA-2018-D-0719-0002/FDA-2018-D-0719-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)\nGuidance for Industry"", ""docket_id"": ""FDA-2018-D-0719"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0719-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0719/FDA-2018-D-0719-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:31:35,2025-05-28 03:53:06
e73cd281-d6dc-4817-b9b3-64f458dfe55b,USA-FDA,00c25e65-4206-43af-8e50-4f9d61e615ab,G_KEYWORDS,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002/FDA-2008-D-0576-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sponsors, Clinical Investigators, and IRBs - Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials"", ""docket_id"": ""FDA-2008-D-0576"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0576-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:17:00,2025-05-28 03:53:06
e765b606-5ba1-421f-8845-e85d8961ef74,USA-FDA,cf1a4640-03e6-48dd-b195-70c9d3fe41a5,G_DETAILED_SUMMARY,2025-05-22 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0182/FDA-2004-D-0182-0004/FDA-2004-D-0182-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; ANDAs: Pharmaceutical Solid Polymorphism;\nChemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-2004-D-0182"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0182-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0182/FDA-2004-D-0182-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:30:17,2025-05-28 03:53:06
e78a9830-d02f-4ca6-abec-5a913b9ef708,USA-FDA,e6a8a5a0-bc6d-4136-b047-e3f80d2aad08,G_IMPACT_ANALYSIS,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013/FDA-2016-D-2567-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""02-Final Guidance for Industry-E17 General Principles for Planning and Design of Multiregional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:03:41,2025-05-28 03:53:06
e7983f74-46e1-4fa8-bc25-1eeb82ffd4b5,USA-FDA,42dfcf0a-ce0a-4a41-947d-2be372486905,G_DETAILED_SUMMARY,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0283/FDA-2009-D-0283-0021/FDA-2009-D-0283-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Postmarketing Stuides and Clinical Trials - Implementation of Section 505 (o)(3) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2009-D-0283"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0283-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0283/FDA-2009-D-0283-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:01:08,2025-05-28 03:53:06
e7b5ae7c-6931-4826-8680-1b570178dfc7,SCHEDULED,5132bf83-4fc8-4791-880d-fc59de96f50b,DEVICE_ANALYST,2025-05-29 00:00:04,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/5132bf83-4fc8-4791-880d-fc59de96f50b"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:06,2025-05-29 00:00:06
e7c4c2ba-45b4-44ff-a0b1-905b5fa7652d,USA-FDA,6ec6b8b5-01da-484d-ad0a-a1341d280c1c,G_FAQ,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1067/FDA-2013-D-1067-0002/FDA-2013-D-1067-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products--Content and Format"", ""docket_id"": ""FDA-2013-D-1067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1067-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1067/FDA-2013-D-1067-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:01:33,2025-05-28 03:53:06
e7e97232-faa3-465f-85cf-da54d153d3c2,USA-FDA,f0882187-cd45-4e44-a70d-821c3d4b8d2e,G_FAQ,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1962/FDA-2020-D-1962-0001/FDA-2020-D-1962-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 300.400 Contamination of Devices Labeled as Sterile"", ""docket_id"": ""FDA-2020-D-1962"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1962-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1962/FDA-2020-D-1962-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:16:25,2025-05-28 03:53:06
e7ed3a32-8999-4d40-8a5f-4461c55e766e,SCHEDULED,7da4bd36-22fa-48b1-9636-fde7f261b9f9,FDA_ALERT,2025-06-02 00:00:04,23,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-04-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/fda_alert/7da4bd36-22fa-48b1-9636-fde7f261b9f9"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:17,2025-06-02 00:00:17
e81bdda2-a19f-46dd-96ca-b02b3cb14cb8,USA-FDA,07a3599c-d4d5-4210-9533-979cc13a64f2,G_MINI_SUMMARY,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004/FDA-2002-D-0180-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Q1E Evaluation of Stability Data"", ""docket_id"": ""FDA-2002-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0180-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0180/FDA-2002-D-0180-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:45:08,2025-05-28 03:53:06
e8226896-4bf1-4ea3-8ec5-f4c6fc2923c1,USA-FDA,5436831b-5f39-4118-b8b1-c355280023e6,G_DETAILED_SUMMARY,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0309/FDA-2002-D-0309-0002/FDA-2002-D-0309-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been ReconditionedDraft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been Reconditioned"", ""docket_id"": ""FDA-2002-D-0309"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0309-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0309/FDA-2002-D-0309-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:15:15,2025-05-28 03:53:06
e858bd3f-62de-41ec-9c28-bc096182835a,USA-FDA,01ec8e21-377a-40e1-b8d6-88b98f83901b,G_MINI_SUMMARY,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5960/FDA-2017-D-5960-0002/FDA-2017-D-5960-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry"", ""docket_id"": ""FDA-2017-D-5960"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-5960-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-5960/FDA-2017-D-5960-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:30:09,2025-05-28 03:53:06
e88f3a32-4c29-4260-9f49-c94c74959499,QUEUE,3ce383c9-d8b1-44a3-a95d-6c6a86a088b8,G_SUMMARY_USER,2025-05-20 10:43:01,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""__doc_title__"": ""FDA-2024-N-3008-0001_content.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/3ce383c9-d8b1-44a3-a95d-6c6a86a088b8/SRC/3ce383c9-d8b1-44a3-a95d-6c6a86a088b8.pdf"", ""doc_title"": ""FDA-2024-N-3008-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/3ce383c9-d8b1-44a3-a95d-6c6a86a088b8/DEST/detailed_summary.md"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 17:43:05,2025-05-28 03:53:06
e8953656-b9eb-4191-9008-5cbafe769fe8,USA-FDA,75fe81ef-9450-4485-b04f-9e3ab220067a,G_FAQ,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002/FDA-2020-D-1640-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance on Cannabidiol"", ""docket_id"": ""FDA-2020-D-1640"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1640-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1640/FDA-2020-D-1640-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:16:03,2025-05-28 03:53:06
e899d05d-732d-4965-bec2-14995db91c13,USA-FDA,fa0d52ac-7d48-4b0d-83e4-ed9240ebdc54,G_IMPACT_ANALYSIS,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001/FDA-2020-D-1398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; FDA Approval of New Animal Drugs For Minor Uses and for Minor Species; #61"", ""docket_id"": ""FDA-2020-D-1398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1398/FDA-2020-D-1398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:47:17,2025-05-28 03:53:06
e8a1c8c6-756a-4170-88bb-e81dcd189a40,USA-FDA,97786708-6460-444c-8a83-8b13c3b0eb67,G_ACTION_ITEMS,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0008/FDA-2012-D-1083-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff Civil Money Penalties for Tobacco Retailers: Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2012-D-1083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1083-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:15:59,2025-05-28 03:53:06
e8ad0448-6bb5-4e20-8701-8cd2282a5942,USA-FDA,ccb37927-492b-4ee0-a62e-ebfc17723774,G_ACTION_ITEMS,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002/FDA-2011-D-0164-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:00:21,2025-05-28 03:53:06
e8ae9a0b-4512-4d36-a129-97de2137e216,USA-FDA,24da0e58-b359-4230-aebd-2d7218004440,G_MINI_SUMMARY,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008/FDA-2004-D-0181-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA)"", ""docket_id"": ""FDA-2004-D-0181"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0181-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:32:09,2025-05-28 03:53:06
e8b072b6-91ce-43c6-9804-ed32b8915a38,USA-FDA,fadd8e4c-782f-45c8-bb4b-5b0bd7f2a77a,G_MINI_SUMMARY,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013/FDA-2009-D-0490-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff:  Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"", ""docket_id"": ""FDA-2009-D-0490"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0490-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0490/FDA-2009-D-0490-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:47:29,2025-05-28 03:53:06
e8f78627-d5a7-4679-9fe5-ed2780cc5811,USA-FDA,29481aed-4dee-4b71-baed-378fe252e24c,G_ACTION_ITEMS,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0002/FDA-2004-D-0301-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Fixed Dose Combination and Co-Packaged Drug Products for Treatment of HIV - DRAFT GUIDANCE"", ""docket_id"": ""FDA-2004-D-0301"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0301-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0301/FDA-2004-D-0301-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:32:39,2025-05-28 03:53:06
e90323d0-e774-46ec-8007-c634bbd45b18,USA-FDA,a4abc8c9-d7ee-4757-86a6-8e78be60c3ba,G_ACTION_ITEMS,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0031/FDA-2007-D-0031-0005/FDA-2007-D-0031-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Integrated Summaries of Effectiveness and Safety:  Location Within the Common Technical Document"", ""docket_id"": ""FDA-2007-D-0031"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0031-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0031/FDA-2007-D-0031-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:00:38,2025-05-28 03:53:06
e905b5e0-7fb1-4b10-aeb9-2943fe820054,USA-FDA,19788718-9356-4c69-a713-56e5c87f1ba3,G_ACTION_ITEMS,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0509/FDA-2010-D-0509-0002/FDA-2010-D-0509-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry Enforcement Policy - OTC Sunscreen Drug Products Marketed Without an Approved Application"", ""docket_id"": ""FDA-2010-D-0509"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0509-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0509/FDA-2010-D-0509-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:01:29,2025-05-28 03:53:06
e918285c-05d4-4cb3-a3e6-c3b858be747b,USA-FDA,2c7d31cc-dfcf-43d4-8a53-3fc15691a74a,G_ACTION_ITEMS,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009/FDA-2007-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry; Bioequivalence Recommendation for Lenalidomide Capsules"", ""docket_id"": ""FDA-2007-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0433/FDA-2007-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:13:32,2025-05-28 03:53:06
e94b590d-9bb6-4498-8186-03c144648120,USA-FDA,374bcc94-af9b-453e-87d3-b9e8d8e48a4a,G_FAQ,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1659/FDA-2015-D-1659-0002/FDA-2015-D-1659-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Established Conditions: Reportable Chemistry, Manufacturing, and\nControls Changes for Approved Drug and Biologic Products; Draft Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1659"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1659-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1659/FDA-2015-D-1659-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:15:25,2025-05-28 03:53:06
e95bc947-a045-4c78-ad88-67a501bbb883,QUEUE,ac42199b-7f78-4853-9370-d34ddaefe108,G_TRANSLATE,2025-05-29 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,1334dc67-da6a-4ce7-bd26-519a044a846d,"{""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""to_language"": ""Dutch""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/translation/ac42199b-7f78-4853-9370-d34ddaefe108/FDA-2017-D-5152-0001-guidance.pdf.pdf"", ""doc_title"": ""FDA-2017-D-5152-0001-guidance.pdf"", ""aws_bucket"": ""lexim-agentic-ai-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/1334dc67-da6a-4ce7-bd26-519a044a846d/AGENTS/translation/ac42199b-7f78-4853-9370-d34ddaefe108"", ""aws_bucket"": ""lexim-agentic-ai-dev""}",Pending,2025-05-29 17:00:40,2025-05-29 17:00:40
e993b775-ae44-45ec-a395-16437c0ac98b,USA-FDA,3d48aea9-fd44-452b-ba6c-789e6638c117,G_ACTION_ITEMS,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0524/FDA-2012-D-0524-0002/FDA-2012-D-0524-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: Acceptance and Filing Review for Premarket Approval Applications (PMAs) - Guidance"", ""docket_id"": ""FDA-2012-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0524-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0524/FDA-2012-D-0524-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:16:27,2025-05-28 03:53:06
e9a037f0-41c7-4016-853f-e3a9bbc13def,USA-FDA,329f4a46-efa9-41b3-b3d9-ee1574737932,G_IMPACT_ANALYSIS,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0188/FDA-1999-D-0188-0002/FDA-1999-D-0188-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Effect of Anthelmintics : Specific Recommendations for Ovine  VICH GL13 -  Final Guidance 96"", ""docket_id"": ""FDA-1999-D-0188"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0188-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0188/FDA-1999-D-0188-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:17:17,2025-05-28 03:53:06
e9af2b94-c14f-4c3b-9ded-cfc8a55cd103,USA-FDA,e33671e9-c5aa-4c14-8486-5ec83be212b1,G_IMPACT_ANALYSIS,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002/FDA-2010-D-0404-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use--Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0404"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0404-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:33:41,2025-05-28 03:53:06
e9daa96d-ccae-4407-8fd4-5d1e0204da42,USA-FDA,3b933e10-901e-411f-934d-88c38b17d8e0,G_ACTION_ITEMS,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0744/FDA-2013-D-0744-0002/FDA-2013-D-0744-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Antibacterial Therapies for Patients With Unmet Medical Need for the Treatment of Serious Bacterial Diseases"", ""docket_id"": ""FDA-2013-D-0744"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0744-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0744/FDA-2013-D-0744-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:17:46,2025-05-28 03:53:06
e9dfb35a-d37e-49f1-b867-bf056d4377b9,USA-FDA,6aaea747-28aa-4011-b835-dc2adfdccd66,G_IMPACT_ANALYSIS,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1168/FDA-2012-D-1168-0002/FDA-2012-D-1168-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Providing Submissions in Electronic Format Summary Level Clinical Site Data for CDER's Inspection Planning"", ""docket_id"": ""FDA-2012-D-1168"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1168-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1168/FDA-2012-D-1168-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:45:37,2025-05-28 03:53:06
e9e28d40-d0b8-44fe-a85d-c955c23cd92c,USA-FDA,7d844216-0462-4c58-a2bb-17b60a55c988,G_ACTION_ITEMS,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002/FDA-2013-N-1429-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2013-N-1429"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-1429-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-1429/FDA-2013-N-1429-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:02:22,2025-05-28 03:53:06
ea1e490d-e41c-4c16-8d87-18a4821733e2,USA-FDA,0be9181e-ee76-4568-96c5-bebd1ddcaf84,G_IMPACT_ANALYSIS,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4561/FDA-2015-D-4561-0005/FDA-2015-D-4561-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Head Lice Infestation: Developing Drugs for Topical Treatment Guidance for Industry"", ""docket_id"": ""FDA-2015-D-4561"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4561-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4561/FDA-2015-D-4561-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:17:31,2025-05-28 03:53:06
ea2644ed-f8af-4a5d-9e9a-d5491e1d903a,USA-FDA,d746de66-aa34-4e61-818b-054e2ab9bcb4,G_FAQ,2025-05-22 16:45:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0313/FDA-2010-D-0313-0018/FDA-2010-D-0313-0018-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation"", ""docket_id"": ""FDA-2010-D-0313"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0313-0018""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0313/FDA-2010-D-0313-0018"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:45:43,2025-05-28 03:53:06
ea7393c7-23e7-4e04-a571-c961447cb54e,USA-FDA,fa2874eb-88f2-41ee-8181-98a443e666d3,G_FAQ,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002/FDA-2012-D-1135-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidances for Industry Limiting Use of Certain Phthalates as Excipients in Center for Drug Evaluation and Research-Regulated Products"", ""docket_id"": ""FDA-2012-D-1135"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1135-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1135/FDA-2012-D-1135-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:01:36,2025-05-28 03:53:06
ea86cdfc-2b15-4fb3-b6f7-bd444c0eda52,USA-FDA,934f2be8-b3bb-4da2-85bc-d78dbcc8b22a,G_DETAILED_SUMMARY,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0002/FDA-2012-D-1083-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff; Civil Responses to Frequently Asked Question"", ""docket_id"": ""FDA-2012-D-1083"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1083-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1083/FDA-2012-D-1083-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:03:40,2025-05-28 03:53:06
ea9b15ce-6d00-48db-930b-3be41fa2b734,USA-FDA,55b77a7d-e266-49c3-883e-1b1b02b7030d,G_IMPACT_ANALYSIS,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002/FDA-2011-D-0164-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:00:29,2025-05-28 03:53:06
eadf038e-599e-47ae-b321-beb1665f41ae,QUEUE,c9e2e403-984f-4f40-b25a-7bea12a72adf,G_TRANSLATE,2025-05-28 22:00:17,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""doc_title"": ""FDA-2008-P-0086-0037.pdf"", ""to_language"": ""French""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/translation/c9e2e403-984f-4f40-b25a-7bea12a72adf/FDA-2008-P-0086-0037_content.pdf.pdf"", ""doc_title"": ""FDA-2008-P-0086-0037.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/translation/c9e2e403-984f-4f40-b25a-7bea12a72adf"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-28 22:00:51,2025-05-28 22:00:51
eae80582-7f8d-4159-a216-96998aaf05c3,USA-FDA,3a3bb553-cda6-47ee-9b54-f2644ecbcd52,G_FAQ,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002/FDA-2000-D-0129-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans - Draft Guidance"", ""docket_id"": ""FDA-2000-D-0129"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-D-0129-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:01:34,2025-05-28 03:53:06
eb22950b-4646-48cc-b7e7-2af0bc79e661,USA-FDA,538ed307-e5da-402c-9d54-95f1259871e2,G_ACTION_ITEMS,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002/FDA-2013-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abbreviated New Drug Application Submissions--Refuse-to-Receive Standards"", ""docket_id"": ""FDA-2013-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:32:45,2025-05-28 03:53:06
eb2d826e-44b0-4c61-93cb-402eab45a20f,USA-FDA,a1221741-1abe-4d84-a25a-ebbde838262b,G_IMPACT_ANALYSIS,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017/FDA-2010-D-0426-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Bar Code Label Requirements�Questions and Answers"", ""docket_id"": ""FDA-2010-D-0426"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0426-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:33:46,2025-05-28 03:53:06
eb2d9555-b90c-47f1-94e5-498e276b4181,USA-FDA,0526dc26-f492-4c55-8262-61ad116536af,G_CONCISE_SUMMARY,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003/FDA-1999-D-0030-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information"", ""docket_id"": ""FDA-1999-D-0030"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0030-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0030/FDA-1999-D-0030-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:31:51,2025-05-28 03:53:06
eb4196bd-25a5-48e1-9c34-9a9df1f6f1f4,USA-FDA,968484c6-cd41-4637-a9c3-36388b04a8ca,G_IMPACT_ANALYSIS,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0592/FDA-2008-D-0592-0010/FDA-2008-D-0592-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Contents of a Complete Submission for the Evaluation ofProprietary Names - Guidance for Industry "", ""docket_id"": ""FDA-2008-D-0592"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0592-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0592/FDA-2008-D-0592-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:18:06,2025-05-28 03:53:06
eb4b056d-8f99-475e-9b88-5c0f322d9219,USA-FDA,84a66e4a-5638-473a-a531-7a674ab66669,G_DETAILED_SUMMARY,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0567/FDA-2011-D-0567-0002/FDA-2011-D-0567-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry, Clinical Investigators and Staff; Design Considerations for Pivotal Clinical Investigations for Medical Devices"", ""docket_id"": ""FDA-2011-D-0567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0567-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0567/FDA-2011-D-0567-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:00:33,2025-05-28 03:53:06
eb53baa2-2f19-495f-b476-e513095d1b48,USA-FDA,6eb98b0c-b1cb-4709-9629-7a643977f67c,G_ACTION_ITEMS,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002/FDA-2007-D-0205-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]; Draft Guidance"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:03:04,2025-05-28 03:53:06
eb7d6838-7ced-4f52-80cd-1ab2add20f97,USA-FDA,d37cfcc8-016a-4805-904c-355433d1a6ba,G_ACTION_ITEMS,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0283/FDA-2009-D-0283-0021/FDA-2009-D-0283-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Postmarketing Stuides and Clinical Trials - Implementation of Section 505 (o)(3) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2009-D-0283"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0283-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0283/FDA-2009-D-0283-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:01:16,2025-05-28 03:53:06
eb89dce2-9bc7-4d06-9158-02e3aa0342c5,USA-FDA,1bf368b2-ae1f-49df-af44-acc1b3f2670c,G_KEYWORDS,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002/FDA-2017-D-6380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric\nSubpopulations of Common Diseases Draft Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:02:16,2025-05-28 03:53:06
eb91b7ef-73a2-45ca-befb-d0ca30316b33,USA-FDA,b1950e52-446f-47a5-8f05-febff4d6c0e3,G_FAQ,2025-05-22 04:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0938/FDA-2012-D-0938-0024/FDA-2012-D-0938-0024-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Guidance on Abbreviated New Drug Applications: Stability Testing of Drug Substances and Products"", ""docket_id"": ""FDA-2012-D-0938"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0938-0024""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0938/FDA-2012-D-0938-0024"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:15:21,2025-05-28 03:53:06
eb99b5fd-1e9a-4c24-991f-412299c446e1,USA-FDA,c559ed28-7dcf-4606-ae82-15aa2593dbb1,G_DETAILED_SUMMARY,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002/FDA-2013-D-0349-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format"", ""docket_id"": ""FDA-2013-D-0349"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0349-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:01:28,2025-05-28 03:53:06
ebb553d1-2630-490d-88ef-caad3be7bf52,USA-FDA,937b2cf6-46a9-4868-bc78-fde797cfbab8,G_ACTION_ITEMS,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002/FDA-1999-D-1315-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act (PDUFA) Products; Guidance for Industry; Draft Guidance for Industry"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:02:27,2025-05-28 03:53:06
ebb8f564-d172-4801-987f-4288a45718c8,USA-FDA,1b0295a5-ed9b-4f4b-883f-9d97dcfe7681,G_MINI_SUMMARY,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0077/FDA-2007-D-0077-0003/FDA-2007-D-0077-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Providing Regulatory Submissions in Electronic Format - Receipt Date - Draft Guidance Document"", ""docket_id"": ""FDA-2007-D-0077"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0077-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0077/FDA-2007-D-0077-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:30:44,2025-05-28 03:53:06
ebc3fa42-8b25-400d-b5df-58484875ca8f,USA-FDA,f795de71-4356-40cf-be47-e209bff4184d,G_FAQ,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0146/FDA-2010-D-0146-0012/FDA-2010-D-0146-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Irritable Bowel Syndrome Clinical Evaluation of Drugs for Treatment"", ""docket_id"": ""FDA-2010-D-0146"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0146-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0146/FDA-2010-D-0146-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:16:21,2025-05-28 03:53:06
ebd56e20-bb10-4f56-b39e-05ba58b92851,USA-FDA,e80bad29-fe0d-4d55-b473-66601f3fc47c,G_ACTION_ITEMS,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013/FDA-2009-D-0503-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in - Premarket Notification (510(k)) Submissions; Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0503-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:01:04,2025-05-28 03:53:06
ebde1c0d-2909-4add-a1cb-3925d6167a7a,USA-FDA,9475de9c-d7fe-426d-9470-fcbda9ee0f6c,G_DETAILED_SUMMARY,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0016/FDA-2010-D-0503-0016-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Clinical Investigators, Sponsors, and Institutional Review Boards on Investigational New Drug Applications--Determining Whether Human Research Studies Can Be Conducted Without an Investigational New Drug Application"", ""docket_id"": ""FDA-2010-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0503-0016""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0016"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:45:21,2025-05-28 03:53:06
ebdfb7fb-bb93-4e67-8510-2e90b71e7821,USA-FDA,81b39340-8714-46c1-9129-5d81b2c298fb,G_FAQ,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0033/FDA-2003-D-0033-0003/FDA-2003-D-0033-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff: Food and Drug Administration and Industry Actions on Premarket Notification Submissions: Effect on Food and Drug Administration Review Clock and Performance Assessment"", ""docket_id"": ""FDA-2003-D-0033"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0033-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0033/FDA-2003-D-0033-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:32:15,2025-05-28 03:53:06
ebf03110-3708-4cd0-9596-f76c76b7269c,Queue,1b167ebd-ddad-45cf-bd1f-3910d06869cc,G_TRANSLATE,2025-05-29 21:25:23,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/1b167ebd-ddad-45cf-bd1f-3910d06869cc/MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf.pdf"", ""doc_title"": ""MDCG_Position_Paper_onUDI_assignment_for_Spectacle_lenses_&_Ready_readers.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/1b167ebd-ddad-45cf-bd1f-3910d06869cc"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 21:25:23,2025-05-29 21:25:23
ec0c82da-781e-4d42-bd3e-61ec91499774,USA-FDA,d9e79c12-d985-401b-bdb5-8f759eedbfeb,G_ACTION_ITEMS,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-N-0121/FDA-2011-N-0121-0009/FDA-2011-N-0121-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products; Small Entity Compliance Guide"", ""docket_id"": ""FDA-2011-N-0121"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-N-0121-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-N-0121/FDA-2011-N-0121-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:15:27,2025-05-28 03:53:06
ec101896-db30-4716-bc43-d8f036f7341d,USA-FDA,1c4377f8-e18f-4652-8e8f-76f3ffd4d659,G_FAQ,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034/FDA-2002-D-0094-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Food and Drug Administration Advisory\nCommittee Members, and Food and Drug Administration Staff: Public\nAvailability of Advisory Committee Members� Financial Interest\nInformation and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:30:32,2025-05-28 03:53:06
ec299251-cf4b-4c95-9401-db6f7bacfa22,USA-FDA,12503645-3580-4a8e-a642-7d1bf8b4aa65,G_ACTION_ITEMS,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002/FDA-2017-D-2462-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species"", ""docket_id"": ""FDA-2017-D-2462"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-2462-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-2462/FDA-2017-D-2462-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:02:13,2025-05-28 03:53:06
ec4ee72b-2e60-4463-8491-4fee3a760944,USA-FDA,7eee9720-6969-4cfa-9422-88b0fe67e67c,G_IMPACT_ANALYSIS,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022/FDA-2011-D-0082-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry , Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling"", ""docket_id"": ""FDA-2011-D-0082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0082-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0082/FDA-2011-D-0082-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:03:47,2025-05-28 03:53:06
ec51b2c8-2123-410b-a43b-95efa249d067,USA-FDA,8495cf8e-3384-4e57-8358-cd60ef5c648f,G_IMPACT_ANALYSIS,2025-05-22 11:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0531/FDA-2004-D-0531-0001/FDA-2004-D-0531-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations to Processors of Apple Juice or Cider on the Use of Ozone for Pathogen Reduction Purposes"", ""docket_id"": ""FDA-2004-D-0531"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0531-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0531/FDA-2004-D-0531-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:15:45,2025-05-28 03:53:06
ec6785ba-f09c-4273-9ea6-1b50a18aa71c,USA-FDA,bb4f6ff7-5349-4d63-9a20-c8b7c2e87a81,G_CONCISE_SUMMARY,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032/FDA-2002-D-0094-0032-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0032""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:02:09,2025-05-28 03:53:06
ec6b9940-dd6f-4614-8bef-8d2e75d86d1c,USA-FDA,3d6122eb-1f41-43c3-9783-a2a9beb2d9f3,G_KEYWORDS,2025-05-20 10:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002/FDA-2018-D-2583-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products; Guidance for Industry;  Draft Guidance"", ""docket_id"": ""FDA-2018-D-2583"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2583-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2583/FDA-2018-D-2583-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:03:14,2025-05-28 03:53:06
ec8770bb-78e9-4c52-ba76-9a1c6ad8c834,USA-FDA,b639aa88-b5cf-4546-95bb-66135ae67e36,G_FAQ,2025-05-22 07:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0002/FDA-2009-D-0568-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products"", ""docket_id"": ""FDA-2009-D-0568"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0568-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0568/FDA-2009-D-0568-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:47:02,2025-05-28 03:53:06
ec93a9f3-9433-44ab-b0b9-02ae78b78a6a,USA-FDA,e54abd09-70fc-4058-b033-48046d4c2666,G_DETAILED_SUMMARY,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034/FDA-2002-D-0094-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Food and Drug Administration Advisory\nCommittee Members, and Food and Drug Administration Staff: Public\nAvailability of Advisory Committee Members� Financial Interest\nInformation and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:30:22,2025-05-28 03:53:06
ece95959-a253-4ce7-ab8c-0d56e686326f,USA-FDA,4644d0ac-6161-4896-a53b-efbfc15425e7,G_IMPACT_ANALYSIS,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002/FDA-2017-D-3235-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2017-D-3235"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-3235-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:16:18,2025-05-28 03:53:06
ed0da467-644d-4c33-b025-e76939dcc029,USA-FDA,77520276-b841-4d9e-b0d0-83d2c4e5df78,G_MINI_SUMMARY,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002/FDA-2018-D-0740-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk Guidance for Industry"", ""docket_id"": ""FDA-2018-D-0740"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0740-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:30:12,2025-05-28 03:53:06
ed0e65a3-6f81-480a-b966-2903f91f6e79,USA-FDA,652b89b2-15c3-41a7-a015-5c1f54defd77,G_DETAILED_SUMMARY,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002/FDA-2017-D-3235-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects Guidance for Sponsors, Investigators, and Institutional Review Boards"", ""docket_id"": ""FDA-2017-D-3235"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-3235-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-3235/FDA-2017-D-3235-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:15:56,2025-05-28 03:53:06
ed11c5db-6c1d-46fa-85b2-7c66dbf88ef1,USA-FDA,97765d8b-8e95-483c-b757-c657da013b4d,G_DETAILED_SUMMARY,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002/FDA-2014-N-1082-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Multiplexed Microbiological/Medical Countermeasure In Vitro \nNucleic Acid Based Diagnostic Devices; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-N-1082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1082-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:00:54,2025-05-28 03:53:06
ed22dff4-4d20-45ea-bc0c-c8675d14d751,USA-FDA,3df2e922-bc12-4582-ade1-c37be8b0d12e,G_FAQ,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002/FDA-2020-D-1877-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Necessary Automated External Defibrillator Accessories: Policy Regarding Compliance Date; Guidance for Industry, Stakeholders, Health Care Professionals, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2020-D-1877"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1877-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1877/FDA-2020-D-1877-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:06,2025-05-28 03:53:06
ed50b93f-38fa-4a27-8cc7-863a56868132,USA-FDA,e6a18677-f32c-4391-a5bd-397d38b73743,G_FAQ,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0652/FDA-2011-D-0652-0002/FDA-2011-D-0652-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff The 510(k) Program Evaluating Substantial Equivalence in Premarket Notifications [510(k)]"", ""docket_id"": ""FDA-2011-D-0652"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0652-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0652/FDA-2011-D-0652-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:45:59,2025-05-28 03:53:06
ed70d1b6-58ba-445f-be64-ed8ccf487bb0,USA-FDA,2b23c78f-34ca-4f6c-bb1d-1d786eb7cfac,G_IMPACT_ANALYSIS,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003/FDA-2008-D-0180-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Coronary Drug Eluting Stents- Nonclincal and Clinical Studies; Draft Guidance"", ""docket_id"": ""FDA-2008-D-0180"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0180-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0180/FDA-2008-D-0180-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:01:14,2025-05-28 03:53:06
ed9368f6-61fd-4561-a72d-2be39bd87bcd,USA-FDA,0eb334aa-f60d-47c0-b385-df59173517b6,G_IMPACT_ANALYSIS,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021/FDA-2004-D-0044-0021-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Recommendations for the Early Food Safety\nEvaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties\nIntended for Food Use; Availability"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0021""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0021"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:00:42,2025-05-28 03:53:06
edb9fd13-e5fe-4211-93f7-f7f6066b177d,USA-FDA,8564ba00-cbf8-43de-a6be-9021f644e38a,G_FAQ,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1358/FDA-2013-D-1358-0002/FDA-2013-D-1358-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry: Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation"", ""docket_id"": ""FDA-2013-D-1358"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1358-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1358/FDA-2013-D-1358-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:02:15,2025-05-28 03:53:06
edf15b30-c8e3-45a7-9a21-578f97839705,USA-FDA,3cfed365-c760-4406-ae05-169b61e5875f,G_IMPACT_ANALYSIS,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0364/FDA-2007-D-0364-0014/FDA-2007-D-0364-0014-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Indexing Structured Product Labeling"", ""docket_id"": ""FDA-2007-D-0364"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0364-0014""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0364/FDA-2007-D-0364-0014"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:01:54,2025-05-28 03:53:06
ee0879dd-09bc-400f-853f-5ef177c38806,USA-FDA,49402488-a8b4-428e-b962-3cd714e9e85d,G_ACTION_ITEMS,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008/FDA-2018-D-2936-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; CDRH Standard Operating Procedures for the Identification and Evaluation of Candidate Consensus Standards for Recognition"", ""docket_id"": ""FDA-2018-D-2936"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2936-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:00:36,2025-05-28 03:53:06
ee205e72-466e-4f4d-80c0-79b57974c4be,SCHEDULED,5ac72785-893e-4dda-aff6-5231592efdab,FDA_ALERT,2025-05-24 00:00:05,20,22e9cbee-8ffd-40b1-ac72-354a385b80f8,a7bbdec2-e205-4363-b6da-a8ca02af38ec,"{""user_id"": 86, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""a7bbdec2-e205-4363-b6da-a8ca02af38ec"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-19"", ""user_email"": ""sij239@nyu.edu"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/a7bbdec2-e205-4363-b6da-a8ca02af38ec/AGENTS/fda_alert/5ac72785-893e-4dda-aff6-5231592efdab"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:14,2025-05-28 03:53:06
ee4beeed-99e9-42b3-8d0a-309aec699efc,USA-FDA,52c051e6-910a-4369-be77-17f8bf686282,G_DETAILED_SUMMARY,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0643/FDA-2010-D-0643-0092/FDA-2010-D-0643-0092-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Electronic Source Data in Clinical Investigations"", ""docket_id"": ""FDA-2010-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0643-0092""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0643/FDA-2010-D-0643-0092"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:00:25,2025-05-28 03:53:06
ee70c769-1e93-4d10-948c-5760059870aa,USA-FDA,e4ed09bc-5662-43b9-9f10-24b9bd7d491f,G_IMPACT_ANALYSIS,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0002/FDA-2010-D-0503-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Investigational New Drug Applications (INDs)�Determining Whether Human Research Studies Can Be Conducted Without an IND"", ""docket_id"": ""FDA-2010-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0503-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0503/FDA-2010-D-0503-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:48:09,2025-05-28 03:53:06
ee73cca3-be26-4fa0-8049-c3a1d7f6b0a6,USA-FDA,14e4e220-88c7-421f-9766-6982be293e14,G_FAQ,2025-05-22 13:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0096/FDA-2012-D-0096-0002/FDA-2012-D-0096-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations"", ""docket_id"": ""FDA-2012-D-0096"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0096-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0096/FDA-2012-D-0096-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:46:56,2025-05-28 03:53:06
ee9d9359-1eda-465b-aff1-5fe335873198,USA-FDA,9b9d8e7e-c57e-4b67-985d-7d31ee91fc8c,G_IMPACT_ANALYSIS,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0790/FDA-2011-D-0790-0002/FDA-2011-D-0790-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff, FDA Decisions for Investigational Device Exemption Clinical Investigations"", ""docket_id"": ""FDA-2011-D-0790"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0790-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0790/FDA-2011-D-0790-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:46:23,2025-05-28 03:53:06
eeabd7df-5e84-4cb9-901f-8866925a5b32,USA-FDA,9d65a7e8-a6ed-451e-9306-ed8445ecfb95,G_KEYWORDS,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002/FDA-2011-D-0464-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Low Glucose Suspend (LGS) Device Systems - Draft Guidance"", ""docket_id"": ""FDA-2011-D-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0464-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0464/FDA-2011-D-0464-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:32:55,2025-05-28 03:53:06
eeae9848-5d8c-42b4-859e-d2026c472cba,USA-FDA,7bee3c90-a9c2-478d-b42c-878439e9aa6b,G_FAQ,2025-05-22 02:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002/FDA-1999-D-1315-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act (PDUFA) Products; Guidance for Industry; Draft Guidance for Industry"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:02:18,2025-05-28 03:53:06
eeaff565-efcb-4f65-8347-5ec37f0c8ca7,USA-FDA,bd9f5c11-b666-42e2-9962-a2be7bfc2ff6,G_KEYWORDS,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001/FDA-2020-D-1385-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Drug Stability Guidelines; #5"", ""docket_id"": ""FDA-2020-D-1385"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1385-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:32:59,2025-05-28 03:53:06
eeb1a160-b985-4acb-a9d1-b8a3d27879e0,USA-FDA,11506cc3-17c4-46c8-80f1-3b1f39b0702a,G_DETAILED_SUMMARY,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0080/FDA-2012-D-0080-0005/FDA-2012-D-0080-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Oversight of Positron Emission Tomography Drug Products - Questions and Answers"", ""docket_id"": ""FDA-2012-D-0080"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0080-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0080/FDA-2012-D-0080-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:31:29,2025-05-28 03:53:06
eeced27e-babc-4fcb-916f-00e06aa476c8,USA-FDA,6485db14-7d0e-4e75-80b2-002354367ae7,G_MINI_SUMMARY,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002/FDA-2018-D-2238-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""2018-125 Guidance GT for Hemophilia_7-09-2018 -508 Compliant"", ""docket_id"": ""FDA-2018-D-2238"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2238-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2238/FDA-2018-D-2238-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:30:08,2025-05-28 03:53:06
eed6ec42-bf5b-4637-96fb-5ea094bc238f,USA-FDA,75656484-1cb0-4251-ad71-d4cf866d5f70,G_MINI_SUMMARY,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0592/FDA-2008-D-0592-0010/FDA-2008-D-0592-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Contents of a Complete Submission for the Evaluation ofProprietary Names - Guidance for Industry "", ""docket_id"": ""FDA-2008-D-0592"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0592-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0592/FDA-2008-D-0592-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:17:23,2025-05-28 03:53:06
eed83d05-1896-46d4-8c75-403803979956,USA-FDA,27f9009f-340c-4056-8ca5-eeea8a2ec02c,G_ACTION_ITEMS,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002/FDA-2013-D-0349-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format"", ""docket_id"": ""FDA-2013-D-0349"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0349-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0349/FDA-2013-D-0349-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:01:49,2025-05-28 03:53:06
eefa0d45-783d-48f6-acc8-8693de91df83,USA-FDA,5a184411-4bf3-41e0-9e29-f8d3fe0d3e19,G_ACTION_ITEMS,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001/FDA-2020-D-1430-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents"", ""docket_id"": ""FDA-2020-D-1430"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1430-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1430/FDA-2020-D-1430-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:18:04,2025-05-28 03:53:06
ef0b854c-ed99-45dc-b9d5-1856a7361f40,SCHEDULED,e1362667-f144-4985-b420-7f8beda503bb,DEVICE_ANALYST,2025-05-19 16:07:33,6,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-01-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/device_analyst/e1362667-f144-4985-b420-7f8beda503bb"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-19 20:09:38,2025-05-28 03:53:06
ef2df1e5-67f5-424d-9bf6-a0685ea1e6c7,USA-FDA,c9999f9a-3071-418f-8a86-acf4d4e72d98,G_DETAILED_SUMMARY,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029/FDA-2009-D-0179-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0179-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:31:49,2025-05-28 03:53:06
ef6b7b3c-d5b5-4c3e-900e-a695074094a5,USA-FDA,6b26c849-4e65-4530-9602-aa13626e8d20,G_FAQ,2025-05-22 04:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0334/FDA-2008-N-0334-0010/FDA-2008-N-0334-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Providing Submissions in Electronic Format - Postmarketing Safety Reports-Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements"", ""docket_id"": ""FDA-2008-N-0334"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-N-0334-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-N-0334/FDA-2008-N-0334-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:01:39,2025-05-28 03:53:06
ef8f670a-de46-46de-940c-aaf01562477e,USA-FDA,fedb4f8f-d1e5-45eb-aa29-2873acf4f927,G_CONCISE_SUMMARY,2025-05-20 19:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002/FDA-2011-D-0730-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff; Class II Special Controls Guidance Documents: In Vitro Diagnostic Devices for Yersinia Species Detection"", ""docket_id"": ""FDA-2011-D-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0730-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0730/FDA-2011-D-0730-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 19:00:17,2025-05-28 03:53:06
ef91dd2a-7b86-4f55-99f1-efabaebad7cb,USA-FDA,5c20e80f-3a5a-40b0-91ab-e8681925122e,G_MINI_SUMMARY,2025-05-22 13:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1067/FDA-2013-D-1067-0002/FDA-2013-D-1067-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products--Content and Format"", ""docket_id"": ""FDA-2013-D-1067"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1067-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1067/FDA-2013-D-1067-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:01:07,2025-05-28 03:53:06
efa6e4ad-dca3-4f93-8905-e38f36552d95,SCHEDULED,b706d323-f6f2-4b07-974c-2df01a2913df,FDA_ALERT,2025-05-27 15:33:48,4,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-04-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-04-28""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/fda_alert/b706d323-f6f2-4b07-974c-2df01a2913df"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 22:33:53,2025-05-28 03:53:06
efaadd99-98a3-4513-affd-65713713c7d6,USA-FDA,1579ce7a-3d61-425c-a3b1-369bc8d3f1b4,G_CONCISE_SUMMARY,2025-05-22 01:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011/FDA-1997-D-0444-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance on FDA Approval of New Animal Drugs for Minor Uses and for Minor Species; Guidance Document (Revised May 29, 2008)"", ""docket_id"": ""FDA-1997-D-0444"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0444-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0444/FDA-1997-D-0444-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:00:15,2025-05-28 03:53:06
efe7f0f7-0e20-4683-9f17-f91470f25b08,USA-FDA,52cfacc7-0608-437d-8c9b-37a461461d56,G_IMPACT_ANALYSIS,2025-05-22 01:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004/FDA-2002-D-0298-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition"", ""docket_id"": ""FDA-2002-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0298-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0298/FDA-2002-D-0298-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:46:56,2025-05-28 03:53:06
eff3c68e-73f3-4357-8107-d39fd67038e3,USA-FDA,eb911c05-3947-4f62-ad73-66e9fa67e4e8,G_DETAILED_SUMMARY,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020/FDA-1992-N-0056-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prescription Drug Marketing Act (PDMA) Requirements; Questions and Answers"", ""docket_id"": ""FDA-1992-N-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0056-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:15:25,2025-05-28 03:53:06
f022fb5c-5efe-48ad-b91b-79af3a04686e,USA-FDA,289c542f-d904-42c7-8c81-f9500e9f2280,G_ACTION_ITEMS,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0790/FDA-2011-D-0790-0002/FDA-2011-D-0790-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff, FDA Decisions for Investigational Device Exemption Clinical Investigations"", ""docket_id"": ""FDA-2011-D-0790"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0790-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0790/FDA-2011-D-0790-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:46:15,2025-05-28 03:53:06
f054369a-ac8c-49d3-a966-7343e8820f46,USA-FDA,9efe8d4d-e8b4-4d26-978f-3dfda5045407,G_CONCISE_SUMMARY,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001/FDA-2020-D-1385-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Drug Stability Guidelines; #5"", ""docket_id"": ""FDA-2020-D-1385"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1385-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1385/FDA-2020-D-1385-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:31:35,2025-05-28 03:53:06
f057ab6a-3112-41ff-b526-bd179ccd1343,USA-FDA,4261ad69-b324-4af6-8dda-f7dd23a119c6,G_FAQ,2025-05-22 04:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1264/FDA-2014-D-1264-0003/FDA-2014-D-1264-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment over the Spectrum of Disease"", ""docket_id"": ""FDA-2014-D-1264"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1264-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1264/FDA-2014-D-1264-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 04:48:02,2025-05-28 03:53:06
f09a9b53-4038-442d-9014-bbe1a74e7cc4,USA-FDA,2e78b5f0-43fe-493d-91cf-2b20085776ea,G_MINI_SUMMARY,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002/FDA-2013-D-0920-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0920"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0920-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:30:51,2025-05-28 03:53:06
f11f1548-6736-4328-a3c3-40f9c4f50981,USA-FDA,6287fa67-5202-4e3f-9121-cd3cee845c55,G_MINI_SUMMARY,2025-05-22 10:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0183/FDA-2010-D-0183-0002/FDA-2010-D-0183-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance of Industry; Prevention of Salmonella Enteritidis in Shell Eggs During Production, Transportation, and Storage; Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0183"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0183-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0183/FDA-2010-D-0183-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:00:09,2025-05-28 03:53:06
f1389224-0deb-4559-b7d0-6967e162e49d,USA-FDA,cbcb1f26-d396-4b50-a620-44bd02df7345,G_MINI_SUMMARY,2025-05-22 08:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0523/FDA-2012-D-0523-0012/FDA-2012-D-0523-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; Refuse to Accept Policy for 510(k)s"", ""docket_id"": ""FDA-2012-D-0523"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0523-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0523/FDA-2012-D-0523-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:45:08,2025-05-28 03:53:06
f13b2e04-fd0f-44c5-a2d4-a7d8ec1eb020,USA-FDA,3eb42638-d9ac-409f-8161-b8f932c93f3a,G_DETAILED_SUMMARY,2025-05-22 05:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0847/FDA-2012-D-0847-0002/FDA-2012-D-0847-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for IRBs, Clinical Investigators, and Sponsors; IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed"", ""docket_id"": ""FDA-2012-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0847-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0847/FDA-2012-D-0847-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:15:17,2025-05-28 03:53:06
f14748cc-a655-451e-b47b-e0ec44a7a53f,USA-FDA,0ce4227f-602b-4a8e-a762-781db2214d55,G_ACTION_ITEMS,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008/FDA-2004-D-0181-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA)"", ""docket_id"": ""FDA-2004-D-0181"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0181-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:32:46,2025-05-28 03:53:06
f14e7fce-1012-4c31-ad38-9b7389f0e962,CAB,c67b59d3-51ca-4068-9c1e-f99761bc10ff,G_KEYWORDS,2025-05-20 12:42:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""__num_keywords__"": 10}","{""tilte"": ""FDA-2018-N-3233-0006.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2018-N-3233-0006_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""3f21331b-4399-4219-aa7e-0a5cb7a4ba33""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3f21331b-4399-4219-aa7e-0a5cb7a4ba33"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:44:11,2025-05-28 03:53:06
f1958c9a-3984-47c9-8e06-47f042dd7773,USA-FDA,c30f4dd4-c5c2-455c-86b4-f8ea3a06c3c7,G_MINI_SUMMARY,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0730/FDA-2013-N-0730-0007/FDA-2013-N-0730-0007-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Final Guidance for Industry: Submitting Requests under 21 CFR 170.39 Threshold of Regulation for Substances Used in Food-Contact Articles"", ""docket_id"": ""FDA-2013-N-0730"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-N-0730-0007""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-N-0730/FDA-2013-N-0730-0007"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:15:10,2025-05-28 03:53:06
f19f1057-ea6d-483b-87b6-85ce45d4cc1e,USA-FDA,4b43452d-52bc-44f9-9f41-d3de430f21e5,G_MINI_SUMMARY,2025-05-22 17:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0056/FDA-1997-D-0056-0002/FDA-1997-D-0056-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Iron-Containing Supplements and Drugs: Label Warning Statements and Unit-Dose Packaging Requirements Small Entity Compliance Guide"", ""docket_id"": ""FDA-1997-D-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0056-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0056/FDA-1997-D-0056-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 17:16:15,2025-05-28 03:53:06
f1ac537f-24bd-4fa4-8aeb-400ddbb9c313,USA-FDA,4dad4935-faf4-4f48-82f6-fe5b2e0daabc,G_CONCISE_SUMMARY,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020/FDA-2015-D-1245-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:02:26,2025-05-28 03:53:06
f1c24ce0-26b6-491e-90f4-21d2b6e0a8eb,USA-FDA,9074a8cd-4616-4127-aa0c-8302cfbd42e4,G_CONCISE_SUMMARY,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002/FDA-2011-D-0487-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Implementation of Acceptable Full-Length and Abbreviated Donor History Questinnaries and Accompanying Materials for Use in Screening Donors of Source Plasma Draft Guidence"", ""docket_id"": ""FDA-2011-D-0487"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0487-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0487/FDA-2011-D-0487-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:31:09,2025-05-28 03:53:06
f1e3913b-6c74-481a-9cd6-786da83c776a,USA-FDA,bf0e7fa2-fcbd-4d39-9a76-9a964ebd60cc,G_ACTION_ITEMS,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3390/FDA-2015-D-3390-0002/FDA-2015-D-3390-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""eCTD TECHNICAL CONFORMANCE GUIDE"", ""docket_id"": ""FDA-2015-D-3390"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-3390-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-3390/FDA-2015-D-3390-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:32:29,2025-05-28 03:53:06
f1ee8b8f-066a-40d8-b10a-187dd50d43dc,USA-FDA,cf7c1f00-581b-4152-8ccc-2e9bdac5102a,G_IMPACT_ANALYSIS,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0002/FDA-2011-D-0620-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2011-D-0620"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0620-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:16:57,2025-05-28 03:53:06
f1f018f6-d36f-4aae-af20-a5eecea55499,USA-FDA,de3c7a5e-8c33-4695-ae02-6a3f9eb4825a,G_IMPACT_ANALYSIS,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013/FDA-2009-D-0503-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in - Premarket Notification (510(k)) Submissions; Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0503"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0503-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0503/FDA-2009-D-0503-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:01:15,2025-05-28 03:53:06
f1f86d97-d821-494a-849a-26514cb0e7d1,USA-FDA,ed82b80b-4841-4436-9aa8-2c702976477a,G_KEYWORDS,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002/FDA-2007-D-0205-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]; Draft Guidance"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:03:17,2025-05-28 03:53:06
f1fcd907-7eca-48ff-bfa4-0da7a3c29d05,USA-FDA,9e81f372-a71a-4dc9-82ff-f661157887ce,G_MINI_SUMMARY,2025-05-22 12:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0002/FDA-2014-D-1399-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Draft Guidance Document"", ""docket_id"": ""FDA-2014-D-1399"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1399-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1399/FDA-2014-D-1399-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:15:45,2025-05-28 03:53:06
f21fa2c7-a32b-470d-9200-0911c832acc3,USA-FDA,ac841a46-a563-474b-8802-2a049a9e201b,G_CONCISE_SUMMARY,2025-05-22 02:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012/FDA-2016-D-1533-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma - Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:47:29,2025-05-28 03:53:06
f222f7be-c27d-4551-98a8-cef53441a75f,USA-FDA,21bc34af-e2b2-4809-936b-d331ac792936,G_FAQ,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001/FDA-2020-D-1951-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on Juice HACCP Regulation (2003)"", ""docket_id"": ""FDA-2020-D-1951"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1951-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:31:11,2025-05-28 03:53:06
f2255fcd-601a-48e6-a3ac-5951bef7ade8,USA-FDA,27d8acf3-8683-4f12-8d28-b9a4a72e0b34,G_DETAILED_SUMMARY,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002/FDA-2016-D-0199-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Food and Drug Administration Staff Enforcement Policy on National Health Related Item Code and National Drug Code Numbers Assigned to Devices"", ""docket_id"": ""FDA-2016-D-0199"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-0199-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-0199/FDA-2016-D-0199-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:45:22,2025-05-28 03:53:06
f227c743-1443-49f0-9bb0-243ef17e05cf,USA-FDA,d02dab26-eff9-4291-8f56-125bd0a137a1,G_ACTION_ITEMS,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002/FDA-2014-D-1891-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD"", ""docket_id"": ""FDA-2014-D-1891"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1891-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:16:13,2025-05-28 03:53:06
f2407c80-d962-4207-bb4b-ab6844191b3e,USA-FDA,eda788f3-3d27-4b7e-ae7b-f9e71da6ba01,G_MINI_SUMMARY,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002/FDA-2014-N-1082-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Multiplexed Microbiological/Medical Countermeasure In Vitro \nNucleic Acid Based Diagnostic Devices; Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2014-N-1082"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-N-1082-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-N-1082/FDA-2014-N-1082-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:00:10,2025-05-28 03:53:06
f272c286-2d59-4bda-9954-71e6bcbeb3b0,USA-FDA,474a3743-5042-4a1d-be9b-78399beb565e,G_MINI_SUMMARY,2025-05-22 13:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0889/FDA-2011-D-0889-0002/FDA-2011-D-0889-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions With GFI #209"", ""docket_id"": ""FDA-2011-D-0889"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0889-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0889/FDA-2011-D-0889-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:30:46,2025-05-28 03:53:06
f27f4044-aa13-48d1-b1d3-52fa80d22d4e,USA-FDA,804c9344-9bb7-4fb2-9f0b-89981551daf1,G_FAQ,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0298/FDA-2006-D-0298-0005/FDA-2006-D-0298-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff: Whole Grain Label Statements"", ""docket_id"": ""FDA-2006-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0298-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0298/FDA-2006-D-0298-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:17:04,2025-05-28 03:53:06
f28a5abd-f6f9-4b63-9e01-ce544fb8adc4,USA-FDA,13523d8f-bb34-4ef2-8c89-6fbb0d7dd6e4,G_DETAILED_SUMMARY,2025-05-20 04:11:10,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002/FDA-2005-G-0193-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Low Energy Ultrasound Wound Cleaner"", ""docket_id"": ""FDA-2005-G-0193"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-G-0193-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-G-0193/FDA-2005-G-0193-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:12:34,2025-05-28 03:53:06
f2922b87-351f-48c4-baaa-72a31536a205,USA-FDA,89a1738a-fbb9-4763-9115-4726ccaea05f,G_ACTION_ITEMS,2025-05-22 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0476/FDA-2011-D-0476-0010/FDA-2011-D-0476-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Enforcement Policy for Premarket Notification Requirements for Certain In Vitro Diagnostic and Radiology Devices"", ""docket_id"": ""FDA-2011-D-0476"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0476-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0476/FDA-2011-D-0476-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:31:42,2025-05-28 03:53:06
f2a09ed4-560c-43d5-9e4b-ca2884ec20c0,SCHEDULED,23f442ce-f71e-4b29-ba56-37cfdd0e2431,GLOBAL_ALERT,2025-05-27 10:34:56,22,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/int_alert/23f442ce-f71e-4b29-ba56-37cfdd0e2431"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 17:37:10,2025-05-28 03:53:06
f2c61332-7667-4585-a80f-a0cdfd0c3d8a,USA-FDA,b76e9de1-9d33-452a-8330-60b284732aab,G_FAQ,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002/FDA-2010-D-0404-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use--Small Entity Compliance Guide"", ""docket_id"": ""FDA-2010-D-0404"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0404-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0404/FDA-2010-D-0404-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:33:25,2025-05-28 03:53:06
f2c6e847-58a6-4343-84a2-2bb616514d6f,USA-FDA,a5a9d959-bdcf-4e92-978c-c92d6c99a35b,G_DETAILED_SUMMARY,2025-05-21 22:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001/FDA-2020-D-1950-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 394.500 Importation of Television Products, Microwave Ovens, and Inherent Class I Laser Products for Investigation and Evaluation during Design Development"", ""docket_id"": ""FDA-2020-D-1950"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1950-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1950/FDA-2020-D-1950-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:47:35,2025-05-28 03:53:06
f2cd196e-e6fb-4677-be24-7e3f5fcb8993,USA-FDA,692484c8-3b1e-4bb1-a5be-abcd30513e49,G_MINI_SUMMARY,2025-05-21 22:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020/FDA-1992-N-0056-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Prescription Drug Marketing Act (PDMA) Requirements; Questions and Answers"", ""docket_id"": ""FDA-1992-N-0056"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1992-N-0056-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1992-N-0056/FDA-1992-N-0056-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:15:08,2025-05-28 03:53:06
f2d2955c-7112-467a-b2a7-00002b153f84,USA-FDA,efc89e00-0ce9-41ea-b4df-3b268f04734f,G_DETAILED_SUMMARY,2025-05-22 14:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0433/FDA-2012-D-0433-0002/FDA-2012-D-0433-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""mHealth Regulatory Coalition (Epstein Becker & Green) - Guidance"", ""docket_id"": ""FDA-2012-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0433-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0433/FDA-2012-D-0433-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:15:20,2025-05-28 03:53:06
f30fad12-0e1e-4672-867c-51577f093e25,USA-FDA,420ccbac-03bc-4902-8746-a64ff06f41b9,G_ACTION_ITEMS,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0893/FDA-2011-D-0893-0002/FDA-2011-D-0893-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidances for Industry and Staff Center for Devices and Radiological Health Appeals Processes"", ""docket_id"": ""FDA-2011-D-0893"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0893-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0893/FDA-2011-D-0893-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:02:43,2025-05-28 03:53:06
f31e55eb-0939-45d9-9fd1-237672c534bd,SCHEDULED,f9b07f36-3aed-42fd-9ab0-5ca327c879a0,FDA_ALERT,2025-05-27 00:00:04,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/f9b07f36-3aed-42fd-9ab0-5ca327c879a0"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:09,2025-05-28 03:53:06
f3265b9f-931f-4c5e-8e48-46094fcbff42,USA-FDA,110a3300-ac3f-4c99-ba9b-e364ed24de8a,G_ACTION_ITEMS,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0298/FDA-2006-D-0298-0005/FDA-2006-D-0298-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and FDA Staff: Whole Grain Label Statements"", ""docket_id"": ""FDA-2006-D-0298"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0298-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0298/FDA-2006-D-0298-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:17:10,2025-05-28 03:53:06
f3273ddc-c0f9-47b4-b4d5-71b1522a2405,USA-FDA,0c60a474-cde2-452c-aa29-5625d519de69,G_DETAILED_SUMMARY,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0093/FDA-2002-D-0093-0022/FDA-2002-D-0093-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry"", ""docket_id"": ""FDA-2002-D-0093"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0093-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0093/FDA-2002-D-0093-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:32:11,2025-05-28 03:53:06
f3358713-af55-4a4d-8f42-7cd1e789a981,USA-FDA,121e9506-38c8-40a5-b794-4ccec79aac25,G_ACTION_ITEMS,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1459/FDA-2018-D-1459-0049/FDA-2018-D-1459-0049-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Food Labeling: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics: Guidance for Industry"", ""docket_id"": ""FDA-2018-D-1459"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-1459-0049""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1459/FDA-2018-D-1459-0049"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:30:44,2025-05-28 03:53:06
f338a510-d94e-49a2-9e1d-95dfe7d6439c,USA-FDA,f92b13e2-32c3-4916-a5e1-96b2ceccdfcd,G_DETAILED_SUMMARY,2025-05-20 18:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010/FDA-2011-D-0799-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components Including Source Plasma to Reduce the Risk of Transmission of Hepatitis B Virus"", ""docket_id"": ""FDA-2011-D-0799"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0799-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0799/FDA-2011-D-0799-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:01:33,2025-05-28 03:53:06
f3dbced7-1876-421c-8017-23323cfaf7c5,USA-FDA,b199eb48-83cd-4ab1-a541-ced62d622177,G_MINI_SUMMARY,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005/FDA-2011-D-0643-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; What You Need to Know About Administrative Detention of Foods; Small Entity Compliance Guide; Final Guidance"", ""docket_id"": ""FDA-2011-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0643-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:30:54,2025-05-28 03:53:06
f3f256c7-7f47-4cb2-8311-b7a3c34f9fc0,USA-FDA,b1456cad-45a6-4db9-bcf8-06c264d92b3a,G_IMPACT_ANALYSIS,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002/FDA-2009-D-0198-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain Cochineal Extract and Carmine"", ""docket_id"": ""FDA-2009-D-0198"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0198-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:31:05,2025-05-28 03:53:06
f407d555-c461-4a70-b6f0-fe33d53e2658,USA-FDA,60642e98-6d44-474b-8290-616bc6118b0d,G_DETAILED_SUMMARY,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0002/FDA-2011-D-0620-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2011-D-0620"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0620-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0620/FDA-2011-D-0620-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:16:23,2025-05-28 03:53:06
f40e81b9-8b71-4e2f-8a2b-a45030c2fd8c,USA-FDA,3df6993d-56d0-44e7-9413-6935bde7e4f4,G_MINI_SUMMARY,2025-05-22 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0024/FDA-2011-D-0024-0012/FDA-2011-D-0024-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Size of Beads in Drug Products Labeled for Sprinkle"", ""docket_id"": ""FDA-2011-D-0024"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0024-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0024/FDA-2011-D-0024-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:31:13,2025-05-28 03:53:06
f434a2d4-b970-448d-a1da-37cb83f6589e,USA-FDA,4e940d92-33eb-4004-a217-eefe494e1237,G_ACTION_ITEMS,2025-05-21 22:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001/FDA-2020-D-1408-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Redbook 2000; I Introduction"", ""docket_id"": ""FDA-2020-D-1408"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1408-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1408/FDA-2020-D-1408-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:00:59,2025-05-28 03:53:06
f43ca761-b831-43be-b138-39b9b2fef061,USA-FDA,d71fd84a-0f56-4c40-8b45-d3778528cf58,G_DETAILED_SUMMARY,2025-05-22 11:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0002/FDA-2015-D-1245-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; Draft Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1245"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1245-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1245/FDA-2015-D-1245-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 11:32:02,2025-05-28 03:53:06
f448ce5a-8a48-4e24-b019-0b97c4818925,USA-FDA,1975c239-e006-4cc4-bc2f-87cd0fbced24,G_MINI_SUMMARY,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022/FDA-1999-D-1875-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Compliance Policy Guide; Extra-Label Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:02:21,2025-05-28 03:53:06
f45800cf-881c-434e-b212-9060b45fbc90,USA-FDA,766924bb-7bff-4c4c-917e-e563fb48dcb0,G_FAQ,2025-05-22 08:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4561/FDA-2015-D-4561-0005/FDA-2015-D-4561-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Head Lice Infestation: Developing Drugs for Topical Treatment Guidance for Industry"", ""docket_id"": ""FDA-2015-D-4561"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4561-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4561/FDA-2015-D-4561-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:17:15,2025-05-28 03:53:06
f459d97e-9bfd-41db-a02c-c7a35bb83067,USA-FDA,0c7569e5-6acd-42bb-836d-008619a84639,G_IMPACT_ANALYSIS,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-3528/FDA-1999-D-3528-0002/FDA-1999-D-3528-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture"", ""docket_id"": ""FDA-1999-D-3528"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-3528-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-3528/FDA-1999-D-3528-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:01:53,2025-05-28 03:53:06
f4809fb8-d43e-4032-a325-21fff7de1978,USA-FDA,5bc45114-d827-447f-8968-a24908f4568a,G_CONCISE_SUMMARY,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022/FDA-2005-D-0282-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Antiviral Product Development - Conducting and Submitting Virology Studies to the Agency Guidance for Submitting Influenza Resistance Data"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:45:57,2025-05-28 03:53:06
f4a5d497-4cd5-4203-a192-80ba0e74b4c8,USA-FDA,942c4ec2-7bdf-4fcb-b89a-182737a76aa4,G_DETAILED_SUMMARY,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002/FDA-2013-D-0920-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0920"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0920-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0920/FDA-2013-D-0920-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:31:04,2025-05-28 03:53:06
f4e8d543-73e7-4dfe-ba7f-89849bc0509a,USA-FDA,c45e21af-84df-4d1a-83aa-7f09a5875ed2,G_KEYWORDS,2025-05-22 00:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005/FDA-2011-D-0112-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Chemistry, Manufacturing, and Controls (CMC)\nInformation � Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use"", ""docket_id"": ""FDA-2011-D-0112"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0112-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0112/FDA-2011-D-0112-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:31:38,2025-05-28 03:53:06
f4ea1635-62f3-4bae-b85c-c26707f5ac46,SCHEDULED,c14d0a8c-4c5b-445c-90d1-6a6b9cda3091,DEVICE_ANALYST,2025-06-02 00:00:04,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Patel"", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": ""Abhishek"", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-06-02""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/c14d0a8c-4c5b-445c-90d1-6a6b9cda3091"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-02 00:00:26,2025-06-02 00:00:26
f50d21bb-71fe-4239-b173-3b7532051388,USA-FDA,79bbe5d3-138e-4447-ab29-fc12c9165d58,G_IMPACT_ANALYSIS,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0008/FDA-2011-D-0847-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; Humanitarian Use Device (HUD) Designations"", ""docket_id"": ""FDA-2011-D-0847"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0847-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0847/FDA-2011-D-0847-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:31:12,2025-05-28 03:53:06
f514073c-e435-4d2e-9199-98de0d9bfb38,CAB,7a64c56c-8b87-4683-96ae-47b91aa8f7f2,G_SUMMARY_IN,2025-05-20 09:28:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2023-N-4225-0001.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3fe2475a-08fd-45e4-b6e8-9b5c7406fb22/FDA-2023-N-4225-0001_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""be71a183-8124-4a8f-984c-ce1233023d0a""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/be71a183-8124-4a8f-984c-ce1233023d0a"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:28:18,2025-05-28 03:53:06
f524fb39-68e3-40a6-a88a-d4a242921046,USA-FDA,5bea285d-d937-4808-be87-b0ce8624e075,G_FAQ,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0002/FDA-2012-D-1038-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:17:26,2025-05-28 03:53:06
f54d9e15-0954-43f0-8513-cd28377dde3b,SCHEDULED,d422fa05-323b-40f7-b824-446863220f1c,FDA_ALERT,2025-05-27 00:00:04,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-27""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/d422fa05-323b-40f7-b824-446863220f1c"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 00:00:19,2025-05-28 03:53:06
f55fb1c2-9000-4524-9801-aec52fc92d60,QUEUE,a0fae055-5d6a-404e-8883-5f2b6d67c3e9,G_TRANSLATE,2025-05-23 02:29:40,0,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""doc_title"": ""MDCG_Position_Paper_on_the_application_of_Article_97_MDR_to_legacy_devices_for_which_the_MDD_or_AIMDD_certificate_expires_before_the_issuance_of_a_MDR_certificate.pdf"", ""to_language"": ""Hindi""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/a0fae055-5d6a-404e-8883-5f2b6d67c3e9/MDCG_Position_Paper_on_the_application_of_Article_97_MDR_to_legacy_devices_for_which_the_MDD_or_AIMDD_certificate_expires_before_the_issuance_of_a_MDR_certificate.pdf.pdf"", ""doc_title"": ""MDCG_Position_Paper_on_the_application_of_Article_97_MDR_to_legacy_devices_for_which_the_MDD_or_AIMDD_certificate_expires_before_the_issuance_of_a_MDR_certificate.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/translation/a0fae055-5d6a-404e-8883-5f2b6d67c3e9"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 06:30:25,2025-05-28 03:53:06
f586814e-8d58-48b6-995b-1afb6c1e1f2f,USA-FDA,f2d3626a-616b-48a9-8633-cc682c3f94bf,G_ACTION_ITEMS,2025-05-22 12:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0025/FDA-1999-D-1875-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sec.615.115 Extralabel Use of Medicated Feeds for Minor Species"", ""docket_id"": ""FDA-1999-D-1875"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1875-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1875/FDA-1999-D-1875-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 12:33:23,2025-05-28 03:53:06
f58c934f-c7bf-47fc-afa4-e70b9ca825d4,USA-FDA,62dace6e-4576-4e18-a6ed-d888b9bb00af,G_KEYWORDS,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002/FDA-2009-D-0137-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Guidance"", ""docket_id"": ""FDA-2009-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0137-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:32:52,2025-05-28 03:53:06
f596921e-7900-4377-8a7f-ea8a7e01ed7b,QUEUE,8a641c1e-e755-4881-82a2-0ff2c9fc9491,G_FAQ_USER,2025-05-27 23:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""doc_title"": ""Provisions for In-vitro Diagnostic Reagent Registration.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/faq/8a641c1e-e755-4881-82a2-0ff2c9fc9491/Provisions for In-vitro Diagnostic Reagent Registration (Abolished) (1).pdf.pdf"", ""doc_title"": ""Provisions for In-vitro Diagnostic Reagent Registration.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/faq/8a641c1e-e755-4881-82a2-0ff2c9fc9491"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-27 23:00:46,2025-05-28 03:53:06
f5b15ea5-2655-4028-9366-417582919cf1,USA-FDA,785f5a0a-3281-4f71-bc5b-77dcd636569b,G_MINI_SUMMARY,2025-05-22 14:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-2441/FDA-1999-D-2441-0002/FDA-1999-D-2441-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Dioxin in Anti-Caking Agents Used in Animal Feed and Feed Ingredients"", ""docket_id"": ""FDA-1999-D-2441"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-2441-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-2441/FDA-1999-D-2441-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:00:09,2025-05-28 03:53:06
f5d5774b-9692-43af-bc09-32acf39f2a80,USA-FDA,26254255-f7f4-4c5a-b094-f4126c202108,G_ACTION_ITEMS,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0033/FDA-2003-D-0033-0003/FDA-2003-D-0033-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff: Food and Drug Administration and Industry Actions on Premarket Notification Submissions: Effect on Food and Drug Administration Review Clock and Performance Assessment"", ""docket_id"": ""FDA-2003-D-0033"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0033-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0033/FDA-2003-D-0033-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:32:21,2025-05-28 03:53:06
f5eaee2a-bd4f-4043-8994-6c8c7b767dcd,USA-FDA,d4075db3-e1cf-4f56-8022-3413a5fd7165,G_ACTION_ITEMS,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022/FDA-2005-D-0282-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Antiviral Product Development - Conducting and Submitting Virology Studies to the Agency Guidance for Submitting Influenza Resistance Data"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:46:18,2025-05-28 03:53:06
f5f76bbf-d5f8-439d-b0a8-fb5e94a57342,USA-FDA,092c6d89-0f1a-40dc-a5e9-fb4779e07c30,G_IMPACT_ANALYSIS,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1978/FDA-2020-D-1978-0001/FDA-2020-D-1978-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects"", ""docket_id"": ""FDA-2020-D-1978"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1978-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1978/FDA-2020-D-1978-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:16:11,2025-05-28 03:53:06
f5fa28ef-2122-4e20-9792-e852d0c6e905,USA-FDA,625b16ac-f8b9-4ae7-a22b-5ea32232dd28,G_CONCISE_SUMMARY,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017/FDA-2010-D-0426-0017-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Bar Code Label Requirements�Questions and Answers"", ""docket_id"": ""FDA-2010-D-0426"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0426-0017""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0426/FDA-2010-D-0426-0017"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:33:07,2025-05-28 03:53:06
f5fadfe8-463b-4740-bec9-bebd3a9c317a,USA-FDA,fe34cd23-45bd-403a-9524-333e1ea2c319,G_IMPACT_ANALYSIS,2025-05-22 15:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0157/FDA-2005-D-0157-0006/FDA-2005-D-0157-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; CGMP for Phase 1 Investigational Drugs"", ""docket_id"": ""FDA-2005-D-0157"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0157-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0157/FDA-2005-D-0157-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:47:03,2025-05-28 03:53:06
f61daf4b-a7e8-45fc-a27c-d16a08581668,USA-FDA,80a41ed5-96a6-4700-8b7f-5ba11fc0475c,G_DETAILED_SUMMARY,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015/FDA-2010-D-0281-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Food and Drug Administration Staff; ��Harmful and Potentially Harmful Constituents� in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act�"", ""docket_id"": ""FDA-2010-D-0281"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0281-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0281/FDA-2010-D-0281-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:30:15,2025-05-28 03:53:06
f64d0358-687a-4391-8ae4-79c0b496fd9a,USA-FDA,b73ca4e8-5f49-469b-aaf7-b59cc59ebe6e,G_MINI_SUMMARY,2025-05-22 05:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0003/FDA-2014-D-1525-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Draft Guidance for Industry Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Draft Guidance"", ""docket_id"": ""FDA-2014-D-1525"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1525-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1525/FDA-2014-D-1525-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:01:44,2025-05-28 03:53:06
f661cab5-cea1-4ee9-847d-55e93ce45798,USA-FDA,d6fbaa02-e039-4caa-848f-b682cb8f3a0a,G_KEYWORDS,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004/FDA-2007-D-0375-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Acute Bacterial Sinusitis; Developing Drugs for Treatment"", ""docket_id"": ""FDA-2007-D-0375"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0375-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0375/FDA-2007-D-0375-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:31:11,2025-05-28 03:53:06
f66e3ffc-cbe9-4008-8bc0-e585db25032c,USA-FDA,a30c1900-dd89-4fe3-90e4-2f62672fe63b,G_DETAILED_SUMMARY,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-N-0464/FDA-2005-N-0464-0231/FDA-2005-N-0464-0231-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guideline re Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Drug Establishment Registration and Drug Listing; Availability"", ""docket_id"": ""FDA-2005-N-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-N-0464-0231""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-N-0464/FDA-2005-N-0464-0231"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:17:14,2025-05-28 03:53:06
f6886001-70e9-41c1-b3da-2ec14e9c6917,USA-FDA,70d0fb95-18f0-46d1-a73d-99efb2db20ca,G_CONCISE_SUMMARY,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002/FDA-2007-D-0205-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Pulse Oximeters - Premarket Notification Submissions [510(k)s]; Draft Guidance"", ""docket_id"": ""FDA-2007-D-0205"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0205-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0205/FDA-2007-D-0205-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:02:18,2025-05-28 03:53:06
f695de90-0bf6-466b-8566-8763204b45c7,USA-FDA,03387625-e78b-4442-9fea-109803776ce9,G_ACTION_ITEMS,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1189/FDA-2018-D-1189-0002/FDA-2018-D-1189-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Concentrated Caffeine in Dietary Supplements: Guidance for Industry"", ""docket_id"": ""FDA-2018-D-1189"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-1189-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1189/FDA-2018-D-1189-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:33:25,2025-05-28 03:53:06
f69a28e1-0103-4189-b683-7fa2b2f746e0,USA-FDA,7d338220-0a18-48b1-9755-5ea3a3866c41,G_KEYWORDS,2025-05-20 17:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003/FDA-2006-D-0231-0003-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds"", ""docket_id"": ""FDA-2006-D-0231"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0231-0003""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0231/FDA-2006-D-0231-0003"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:01:21,2025-05-28 03:53:06
f6ec9999-5298-45e5-8d20-ff2fb4212d6e,USA-FDA,f2547feb-52ae-4ffb-8847-bd40a87d512c,G_KEYWORDS,2025-05-21 22:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001/FDA-2020-D-1945-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a)"", ""docket_id"": ""FDA-2020-D-1945"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1945-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1945/FDA-2020-D-1945-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 22:31:03,2025-05-28 03:53:06
f7029e82-6ed8-43e3-aa0e-14e63e793a87,USA-FDA,80fc2475-198a-4d1b-8051-d318739f5d2a,G_FAQ,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001/FDA-2018-D-0398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions Guidance for Industry and\nFood and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:01:16,2025-05-28 03:53:06
f70a2c53-8df8-4e9f-b5fc-c14aa5103a43,SCHEDULED,0a387330-7b57-4a3e-b5cb-9f610d10d509,DEVICE_ANALYST,2025-06-01 00:00:04,32,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-06-01""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/device_analyst/0a387330-7b57-4a3e-b5cb-9f610d10d509"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-06-01 00:00:28,2025-06-01 00:00:28
f73722a2-44d7-48c5-bfc6-04ff3df74504,USA-FDA,3cd4c9b7-12f6-493a-81ba-5dd8aefda664,G_DETAILED_SUMMARY,2025-05-20 13:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002/FDA-2009-D-0195-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Bottled Water and Uranium"", ""docket_id"": ""FDA-2009-D-0195"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0195-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0195/FDA-2009-D-0195-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:31:08,2025-05-28 03:53:06
f74619ad-f38a-4250-a054-3e2c0d2f4a43,USA-FDA,401df9a6-b13c-4dab-90ca-27da11f81840,G_MINI_SUMMARY,2025-05-22 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0196/FDA-2007-D-0196-0013/FDA-2007-D-0196-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for FDA Advisory Committee Members and FDA Staff : Voting Procedures for Advisory Committee Meetings"", ""docket_id"": ""FDA-2007-D-0196"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0196-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0196/FDA-2007-D-0196-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:00:40,2025-05-28 03:53:06
f74f51a6-d9cc-41c6-94ab-c1f5d40cea09,SCHEDULED,9d743771-83ad-4cdd-a3c4-106bb9b58d1c,FDA_ALERT,2025-05-30 00:00:04,4,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""user_id"": 37, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Bhatt"", ""user_guid"": ""e842a45e-7661-4c8f-a9bd-5885d465872b"", ""first_name"": ""Pat"", ""start_date"": ""2025-04-01"", ""user_email"": ""Pat.Bhatt@lexim.ai"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/e842a45e-7661-4c8f-a9bd-5885d465872b/AGENTS/fda_alert/9d743771-83ad-4cdd-a3c4-106bb9b58d1c"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:08,2025-05-30 00:00:08
f75dabea-f76c-4183-b8fb-8353e657f0fb,USA-FDA,3d3708c4-0b89-44b5-b2b1-651af7712c25,G_FAQ,2025-05-20 16:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006/FDA-2010-D-0500-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information"", ""docket_id"": ""FDA-2010-D-0500"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0500-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0500/FDA-2010-D-0500-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 16:00:26,2025-05-28 03:53:06
f75ff9d4-dfeb-451a-9471-c27bd4a35a43,USA-FDA,5b4744ce-8047-4a6b-a8c8-6a7f3e63cde9,G_CONCISE_SUMMARY,2025-05-21 20:45:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008/FDA-2010-D-0431-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Food and Drug Administration Staff and Tobacco Retailers on Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Revised"", ""docket_id"": ""FDA-2010-D-0431"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0431-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0431/FDA-2010-D-0431-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:45:16,2025-05-28 03:53:06
f76033d1-5aa2-49f4-8466-41f8c7484c7e,USA-FDA,e50676c8-4aee-49e1-ae86-ebc93e0a32d9,G_FAQ,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008/FDA-2018-D-2936-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and FDA Staff; CDRH Standard Operating Procedures for the Identification and Evaluation of Candidate Consensus Standards for Recognition"", ""docket_id"": ""FDA-2018-D-2936"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-2936-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-2936/FDA-2018-D-2936-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:00:29,2025-05-28 03:53:06
f76a5971-5b22-4d63-acef-1906d1db25ab,SCHEDULED,00d407c2-653e-46a3-879b-936562873171,DEVICE_ANALYST,2025-05-24 00:00:05,32,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,bad34868-4f42-466d-9dd2-9d9e1d4ff849,"{""user_id"": 129, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Atreyas"", ""user_guid"": ""bad34868-4f42-466d-9dd2-9d9e1d4ff849"", ""first_name"": ""Ritu"", ""start_date"": ""2025-02-22"", ""user_email"": ""Ritu.Atreyas@gmail.com"", ""next_run_date"": ""2025-05-24""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/bad34868-4f42-466d-9dd2-9d9e1d4ff849/AGENTS/device_analyst/00d407c2-653e-46a3-879b-936562873171"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-24 00:00:29,2025-05-28 03:53:06
f78a5cd6-94b6-4fcf-a86f-a3096611f76c,USA-FDA,9a8ebba4-3655-4f4d-bca9-4c52ff2c9db7,G_DETAILED_SUMMARY,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025/FDA-2009-D-0524-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Listing of Ingredients in Tobacco Products"", ""docket_id"": ""FDA-2009-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0524-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:01:28,2025-05-28 03:53:06
f7d5405c-67b0-4f41-8398-994dc3d79b60,USA-FDA,9cb48ff6-d0a2-4012-87d4-7840fce0e313,G_ACTION_ITEMS,2025-05-22 03:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001/FDA-2020-D-1407-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products HCT Ps Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2020-D-1407"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1407-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1407/FDA-2020-D-1407-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:01:43,2025-05-28 03:53:06
f7f1046f-4f53-47b3-92a8-27171248ed59,USA-FDA,c4910a5a-d775-477c-956f-5088a88d815c,G_MINI_SUMMARY,2025-05-22 09:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0002/FDA-2012-D-1038-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Preclinical Assessment of Investigational Cellular and Gene Therapy Products"", ""docket_id"": ""FDA-2012-D-1038"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1038-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1038/FDA-2012-D-1038-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:17:09,2025-05-28 03:53:06
f7f4fdc9-29e6-4774-bcb4-460accd86331,USA-FDA,8411ef98-29cf-44c1-afc0-2ed80290bf22,G_IMPACT_ANALYSIS,2025-05-22 18:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0541/FDA-2011-D-0541-0002/FDA-2011-D-0541-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance PET Drugs ----- Current Good Manufacturing Practice (CGMP) (Small Entity Compliance Guide)"", ""docket_id"": ""FDA-2011-D-0541"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0541-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0541/FDA-2011-D-0541-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:03:25,2025-05-28 03:53:06
f80b0c35-a8e8-43bd-b1dc-74f79d8a0042,USA-FDA,50d3a560-c7cf-440d-95bd-dac0483d9e8f,G_ACTION_ITEMS,2025-05-22 00:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002/FDA-2013-D-0743-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Reporting for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0743"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0743-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0743/FDA-2013-D-0743-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:16:19,2025-05-28 03:53:06
f823ea05-7705-44db-8835-d65c65b4232f,USA-FDA,0e4e5c31-c6c6-493a-9c8d-da76143e5434,G_KEYWORDS,2025-05-20 14:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005/FDA-2010-D-0165-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies (VICH GL49)"", ""docket_id"": ""FDA-2010-D-0165"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0165-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0165/FDA-2010-D-0165-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:02:29,2025-05-28 03:53:06
f85dbf6f-b631-416d-940f-8311a1ed8600,USA-FDA,8d9e500e-1dab-4fa8-92c1-4a2d0a044027,G_KEYWORDS,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001/FDA-2018-D-0398-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions Guidance for Industry and\nFood and Drug Administration Staff"", ""docket_id"": ""FDA-2018-D-0398"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0398-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0398/FDA-2018-D-0398-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:01:37,2025-05-28 03:53:06
f8748dc4-48d2-4a1d-bfce-fd0b50566110,USA-FDA,17a8eed7-4593-4693-8df4-968edc282914,G_ACTION_ITEMS,2025-05-22 01:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002/FDA-2008-D-0576-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Sponsors, Clinical Investigators, and IRBs - Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials"", ""docket_id"": ""FDA-2008-D-0576"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0576-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0576/FDA-2008-D-0576-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:16:47,2025-05-28 03:53:06
f893d63d-dc7b-443a-b929-1338c934a3b1,USA-FDA,c38dd362-7b42-466c-b1f9-7bbbe22c8d14,G_FAQ,2025-05-22 14:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1010/FDA-2012-D-1010-0002/FDA-2012-D-1010-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Initial Completeness Assessments for Type II Active Pharmaceutical Ingredient Drug Master Files under Generic Drug User Fee"", ""docket_id"": ""FDA-2012-D-1010"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1010-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1010/FDA-2012-D-1010-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 14:48:10,2025-05-28 03:53:06
f8e9778d-9e03-4dec-837d-c60bfb1d067b,USA-FDA,570a2a9c-5082-45de-8e37-f0bb8edfdc09,G_IMPACT_ANALYSIS,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002/FDA-2009-D-0137-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Guidance"", ""docket_id"": ""FDA-2009-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0137-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0137/FDA-2009-D-0137-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:32:47,2025-05-28 03:53:06
f8e9fcd7-aab7-4651-9cbc-b9242225d171,USA-FDA,feea2cdc-f9ac-4e50-aa21-6946ecd7b7f4,G_IMPACT_ANALYSIS,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001/FDA-2020-D-2015-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Devices Without a Premarket Notification (510(k)) or an Approved Premarket Approval Application (PMA) REVOKED DOCUMENT"", ""docket_id"": ""FDA-2020-D-2015"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-2015-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-2015/FDA-2020-D-2015-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:01:48,2025-05-28 03:53:06
f90e0828-ca90-4baa-82b0-0e71af87339e,USA-FDA,615e36cd-d19e-480f-8450-af0ed4526c7d,G_DETAILED_SUMMARY,2025-05-22 05:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0386/FDA-2009-D-0386-0010/FDA-2009-D-0386-0010-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and Staff; Establishing Performance Characteristics of In Vitro Diagnostic Devices for the Detection, etc., of Human Papillomaviruses"", ""docket_id"": ""FDA-2009-D-0386"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0386-0010""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0386/FDA-2009-D-0386-0010"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:30:11,2025-05-28 03:53:06
f91f40ec-3ea5-43a0-be85-d52923629d8d,QUEUE,995e15eb-e84a-4140-9a4e-78fc5c1c61f3,G_COMPARE_DOCUMENTS,2025-05-23 18:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/compare_documents/995e15eb-e84a-4140-9a4e-78fc5c1c61f3/FDA-2022-F-1108-0001_content.pdf.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""child_document_title"": ""FDA-2022-F-1108-0001.pdf"", ""master_document_title"": ""FDA-2008-P-0086-0037.pdf""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/compare_documents/995e15eb-e84a-4140-9a4e-78fc5c1c61f3/FDA-2008-P-0086-0037_content.pdf.pdf"", ""doc_title"": ""FDA-2008-P-0086-0037.pdf"", ""aws_bucket"": ""lexim-cabinet-dev""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/compare_documents/995e15eb-e84a-4140-9a4e-78fc5c1c61f3"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-23 18:30:15,2025-05-28 03:53:06
f9293f51-1eea-4c68-a50f-dee2ebacded6,USA-FDA,7becf36b-de00-441e-baeb-a9147a8f52c2,G_ACTION_ITEMS,2025-05-22 16:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1978/FDA-2020-D-1978-0001/FDA-2020-D-1978-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects"", ""docket_id"": ""FDA-2020-D-1978"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1978-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1978/FDA-2020-D-1978-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:16:02,2025-05-28 03:53:06
f93a300d-e7ee-4731-8526-4d99e8d6d3c1,SCHEDULED,14667eb9-468b-4314-906c-8d193db5a4fa,FDA_ALERT,2025-05-21 20:33:25,12,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,"{""user_id"": 69, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Jain"", ""user_guid"": ""77fcd14d-3764-441c-9570-03e53d871081"", ""first_name"": ""Shanaya"", ""start_date"": ""2025-02-16"", ""user_email"": ""shanayaj45312@gmail.com"", ""next_run_date"": ""2025-05-21""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/77fcd14d-3764-441c-9570-03e53d871081/AGENTS/fda_alert/14667eb9-468b-4314-906c-8d193db5a4fa"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-21 20:33:31,2025-05-28 03:53:06
f93c2459-7edc-4d43-b1f8-a1bd9a491ceb,USA-FDA,748ac472-ee5c-4999-b03e-d5bd7c5bffd1,G_KEYWORDS,2025-05-20 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012/FDA-2008-D-0610-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic"", ""docket_id"": ""FDA-2008-D-0610"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0610-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0610/FDA-2008-D-0610-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:32:43,2025-05-28 03:53:06
f9425e32-1f0d-49ba-ba28-070159dcb89a,USA-FDA,bcd9c632-a917-40df-92aa-2d173499ab86,G_MINI_SUMMARY,2025-05-22 18:15:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0181/FDA-2009-D-0181-0012/FDA-2009-D-0181-0012-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Label Comprehension Studies for Nonprescription Drug Products"", ""docket_id"": ""FDA-2009-D-0181"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0181-0012""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0181/FDA-2009-D-0181-0012"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 18:15:30,2025-05-28 03:53:06
f943a0a7-9c45-492b-9c6c-c4b6b3bb1254,SCHEDULED,070916db-e205-4389-b15b-38b2299c53ff,FDA_ALERT,2025-05-30 00:00:04,21,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-19"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-30""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/fda_alert/070916db-e205-4389-b15b-38b2299c53ff"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-30 00:00:20,2025-05-30 00:00:20
f9559498-99ad-45af-9b82-faf31c63e71e,USA-FDA,13ead7e2-e6b9-4043-ace7-cb97712d7f7d,G_FAQ,2025-05-20 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002/FDA-2018-D-0740-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk Guidance for Industry"", ""docket_id"": ""FDA-2018-D-0740"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-0740-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-0740/FDA-2018-D-0740-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:31:03,2025-05-28 03:53:06
f96d3eeb-11a7-4b11-b908-992c51a98be7,USA-FDA,16a2383e-6321-42e1-98b8-2eaed876f14f,G_KEYWORDS,2025-05-20 14:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002/FDA-2013-D-1120-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Abbreviated New Drug Application Submissions--Refuse-to-Receive Standards"", ""docket_id"": ""FDA-2013-D-1120"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1120-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1120/FDA-2013-D-1120-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 14:32:59,2025-05-28 03:53:06
f97add63-d9cd-465b-b39d-32cc0408c6a9,USA-FDA,1244150a-32d1-49a4-89a0-eed2c8f9d7ec,G_MINI_SUMMARY,2025-05-20 12:00:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002/FDA-2000-D-0129-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry - Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans - Draft Guidance"", ""docket_id"": ""FDA-2000-D-0129"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2000-D-0129-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2000-D-0129/FDA-2000-D-0129-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:00:50,2025-05-28 03:53:06
f97cda9a-fdb2-4090-ab6b-f5df7de01b5f,USA-FDA,c199e219-cb97-43ec-8d22-30ef088b0874,G_DETAILED_SUMMARY,2025-05-22 06:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0031/FDA-2007-D-0031-0005/FDA-2007-D-0031-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Integrated Summaries of Effectiveness and Safety:  Location Within the Common Technical Document"", ""docket_id"": ""FDA-2007-D-0031"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0031-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0031/FDA-2007-D-0031-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:00:18,2025-05-28 03:53:06
f984e728-0ef1-4016-a4d5-8e75706c8763,USA-FDA,44638f08-f12d-4bc1-9d4b-9a8bce0d9ae4,G_IMPACT_ANALYSIS,2025-05-22 13:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1659/FDA-2015-D-1659-0002/FDA-2015-D-1659-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Established Conditions: Reportable Chemistry, Manufacturing, and\nControls Changes for Approved Drug and Biologic Products; Draft Guidance for Industry"", ""docket_id"": ""FDA-2015-D-1659"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-1659-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-1659/FDA-2015-D-1659-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 13:15:41,2025-05-28 03:53:06
f9a2d26a-2f3b-4a63-81cc-6a58d3485e03,USA-FDA,4c1e09ef-9d0b-4317-86eb-16c710c1f36d,G_FAQ,2025-05-20 12:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002/FDA-2011-D-0147-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Staff Demonstrating Substantial Equivalence of New Tobacco Product; Responses to Frequently Asked Questions"", ""docket_id"": ""FDA-2011-D-0147"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0147-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0147/FDA-2011-D-0147-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 12:30:44,2025-05-28 03:53:06
f9a342df-30d7-4152-8ab3-dee870feac8f,USA-FDA,141c8289-2398-45b9-8500-672b45154898,G_DETAILED_SUMMARY,2025-05-20 10:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015/FDA-1999-D-1315-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Formal Meetings With Sponsors and Applicants for PDUFA Products; Guidance Document"", ""docket_id"": ""FDA-1999-D-1315"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-1315-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-1315/FDA-1999-D-1315-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 10:32:37,2025-05-28 03:53:06
f9c29c0b-ae7e-4270-8f04-c6c92aa35406,USA-FDA,23cf9dc2-4fa7-427b-83b6-4b5c98df18d0,G_CONCISE_SUMMARY,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001/FDA-2020-D-1951-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Questions and Answers on Juice HACCP Regulation (2003)"", ""docket_id"": ""FDA-2020-D-1951"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1951-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1951/FDA-2020-D-1951-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:30:47,2025-05-28 03:53:06
f9cf99f5-351c-481a-8235-4560c5780355,USA-FDA,a4252432-395e-43da-ae5f-d887a80a104e,G_ACTION_ITEMS,2025-05-22 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1161/FDA-2012-D-1161-0002/FDA-2012-D-1161-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Design Considerations for Devices Intended for Home Use - Draft Guidance"", ""docket_id"": ""FDA-2012-D-1161"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-1161-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-1161/FDA-2012-D-1161-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:33:03,2025-05-28 03:53:06
f9f1dcf0-de84-463c-8d40-1ef8ad67df35,USA-FDA,e62328b1-26c6-4fe8-8448-6a0266f41ce0,G_KEYWORDS,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015/FDA-2010-D-0350-0015-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Tobacco Retailers on Tobacco Retailer Training Programs"", ""docket_id"": ""FDA-2010-D-0350"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0350-0015""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0350/FDA-2010-D-0350-0015"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:03:19,2025-05-28 03:53:06
fa29b502-f9c3-46ae-8aca-c5d13573cb45,USA-FDA,71e94137-67e8-43b9-b18c-365056dc3169,G_DETAILED_SUMMARY,2025-05-21 23:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002/FDA-2011-D-0602-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industryon Quality Considerations in Demonstrating Biosimilarity to Reference Protein Product"", ""docket_id"": ""FDA-2011-D-0602"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0602-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0602/FDA-2011-D-0602-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:34:14,2025-05-28 03:53:06
fa4da390-5080-4dbf-8f1c-10c886dafca0,USA-FDA,63ca2539-32aa-4eeb-9d3b-9cad3b91f8a6,G_ACTION_ITEMS,2025-05-21 23:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004/FDA-2019-D-1372-0004-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Elemental Impurities in Human Drug Products Questions and Answers Proposed DRAFT Guidance for Industry"", ""docket_id"": ""FDA-2019-D-1372"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2019-D-1372-0004""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2019-D-1372/FDA-2019-D-1372-0004"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 23:02:23,2025-05-28 03:53:06
fa5b232a-bc5a-4ebc-965e-ed98f75f5eff,USA-FDA,bcd3fb39-bf4f-4de3-8ff8-e939e5cedbb8,G_ACTION_ITEMS,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0188/FDA-1999-D-0188-0002/FDA-1999-D-0188-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Effect of Anthelmintics : Specific Recommendations for Ovine  VICH GL13 -  Final Guidance 96"", ""docket_id"": ""FDA-1999-D-0188"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-0188-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-0188/FDA-1999-D-0188-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:17:09,2025-05-28 03:53:06
fa6af0dd-77c4-4904-ae7d-541f0eab1e48,USA-FDA,2b1a3733-84f0-4615-ad71-545593bd215b,G_KEYWORDS,2025-05-22 02:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001/FDA-2020-D-1944-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives"", ""docket_id"": ""FDA-2020-D-1944"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2020-D-1944-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2020-D-1944/FDA-2020-D-1944-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:30:39,2025-05-28 03:53:06
fa9458ad-05a7-4a6f-975c-6ef9d993901a,USA-FDA,93976965-e52d-4095-bd58-5d8ae5b4a649,G_MINI_SUMMARY,2025-05-21 21:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001/FDA-2016-D-1533-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma Guidance for Industry"", ""docket_id"": ""FDA-2016-D-1533"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-1533-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-1533/FDA-2016-D-1533-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:02:25,2025-05-28 03:53:06
faf5460e-088c-4b7b-a884-1042757189ae,USA-FDA,a1411d18-f751-4a8b-8fce-26ea5c1e8692,G_IMPACT_ANALYSIS,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0616/FDA-2010-D-0616-0020/FDA-2010-D-0616-0020-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry on Codevelopment of Two or More New Investigational Drugs for Use in Combination"", ""docket_id"": ""FDA-2010-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2010-D-0616-0020""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2010-D-0616/FDA-2010-D-0616-0020"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:02:31,2025-05-28 03:53:06
fb0fe451-6a29-4c7a-b8ea-37538766f058,USA-FDA,6cb63ca3-9757-4051-bfb2-7e7b67969a62,G_DETAILED_SUMMARY,2025-05-22 10:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0031/FDA-2006-D-0031-0006/FDA-2006-D-0031-0006-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Frequently Asked Questions About Medical Devices:  Guidance For IRBs, Clinical Investigators, and Sponsors"", ""docket_id"": ""FDA-2006-D-0031"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2006-D-0031-0006""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2006-D-0031/FDA-2006-D-0031-0006"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 10:16:04,2025-05-28 03:53:06
fb158713-8f75-4377-88df-d5c493fb24b3,USA-FDA,f34305e7-d8bb-496c-b188-1b0fa1afff9e,G_FAQ,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025/FDA-2004-D-0044-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:15:30,2025-05-28 03:53:06
fb375276-08d2-400d-8ae1-1bbe90d36afd,USA-FDA,6f61bd95-fe98-4903-85b6-e9051b9f2b14,G_ACTION_ITEMS,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034/FDA-2002-D-0094-0034-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Food and Drug Administration Advisory\nCommittee Members, and Food and Drug Administration Staff: Public\nAvailability of Advisory Committee Members� Financial Interest\nInformation and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0034""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0034"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:30:37,2025-05-28 03:53:06
fb6f5c22-3c34-4cb5-b70c-f5870ceede8b,USA-FDA,f21ffa17-2efa-4784-a66b-752d332d4e35,G_KEYWORDS,2025-05-22 00:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002/FDA-2011-D-0577-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Factors To Consider When Making Benefit-Risk Determinations in Medical Device Premarket Review"", ""docket_id"": ""FDA-2011-D-0577"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0577-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0577/FDA-2011-D-0577-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:48:26,2025-05-28 03:53:06
fb80291e-af80-4a6d-afc3-60441fd72565,USA-FDA,13784c13-98dc-4983-b219-1e5172a64a3a,G_ACTION_ITEMS,2025-05-22 00:00:07,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009/FDA-2011-D-0164-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Safety Labeling Changes--Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act"", ""docket_id"": ""FDA-2011-D-0164"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0164-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0164/FDA-2011-D-0164-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 00:00:52,2025-05-28 03:53:06
fbb02cdc-d1bf-4ec4-bc4c-aa6799fc34a7,USA-FDA,508f20e8-0309-4453-a785-0ec2fd47366b,G_DETAILED_SUMMARY,2025-05-22 05:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0790/FDA-2011-D-0790-0002/FDA-2011-D-0790-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff, FDA Decisions for Investigational Device Exemption Clinical Investigations"", ""docket_id"": ""FDA-2011-D-0790"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0790-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0790/FDA-2011-D-0790-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 05:45:55,2025-05-28 03:53:06
fbbb30fb-b81a-44ea-82db-753bc4e783ba,USA-FDA,1f8cd0e1-7f52-4a74-b8ea-c1042e0ca763,G_FAQ,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002/FDA-1997-D-0380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation; Guidance"", ""docket_id"": ""FDA-1997-D-0380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1997-D-0380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1997-D-0380/FDA-1997-D-0380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:31:23,2025-05-28 03:53:06
fbc7cf52-4887-4a3e-85a7-c35a2b5725c9,USA-FDA,637f6fc9-fa81-48bf-8550-23c0fb34b428,G_CONCISE_SUMMARY,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002/FDA-2013-D-0616-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Content of Premarket Submissions for Management of Cybersecurity in Medical Devices; Draft Guidance for Industry and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-0616"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0616-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0616/FDA-2013-D-0616-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:32:54,2025-05-28 03:53:06
fbffda0a-fcb0-4122-83b8-2c0c2ae0dc1d,USA-FDA,75bb4f46-8511-44b6-b58b-152dc60823ea,G_CONCISE_SUMMARY,2025-05-21 20:30:08,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029/FDA-2009-D-0179-0029-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff"", ""docket_id"": ""FDA-2009-D-0179"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0179-0029""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0179/FDA-2009-D-0179-0029"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 20:31:33,2025-05-28 03:53:06
fc039a34-808c-43df-9992-b6c8add330d0,USA-FDA,8ef3e906-619c-4c4e-b753-7745db6b1242,G_MINI_SUMMARY,2025-05-22 06:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0013/FDA-2003-D-0186-0013-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""DRAFT GUIDANCE FOR INDUSTRY COSMETICS PROCESSORS AND TRANSPORTERS: COSMETICS SECURITY PREVENTIVE MEASURES GUIDANCE"", ""docket_id"": ""FDA-2003-D-0186"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0186-0013""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0186/FDA-2003-D-0186-0013"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:30:43,2025-05-28 03:53:06
fc300ce1-6387-4414-a3f4-252f2d0ffb2c,USA-FDA,6c8359df-9710-414e-afcc-d5d230047010,G_IMPACT_ANALYSIS,2025-05-20 04:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002/FDA-2012-D-0544-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry Toll Free Number Labeling and Related Requirements for Over the Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide"", ""docket_id"": ""FDA-2012-D-0544"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2012-D-0544-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2012-D-0544/FDA-2012-D-0544-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 04:30:37,2025-05-28 03:53:06
fc403c4d-e3ce-466e-9fc6-ced22c7e6a92,USA-FDA,f3ac37e4-4b0d-404b-987e-ae5ab27f4f95,G_IMPACT_ANALYSIS,2025-05-21 21:45:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022/FDA-2005-D-0282-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance on Antiviral Product Development - Conducting and Submitting Virology Studies to the Agency Guidance for Submitting Influenza Resistance Data"", ""docket_id"": ""FDA-2005-D-0282"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-D-0282-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-D-0282/FDA-2005-D-0282-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:46:26,2025-05-28 03:53:06
fc726035-b4c8-40b8-9cf7-3759f41ecdd0,USA-FDA,dfcfdb9f-a36e-4806-b3c4-2fcc65c0eedb,G_KEYWORDS,2025-05-20 17:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002/FDA-2009-D-0198-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Small Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain Cochineal Extract and Carmine"", ""docket_id"": ""FDA-2009-D-0198"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0198-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0198/FDA-2009-D-0198-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 17:31:07,2025-05-28 03:53:06
fc72ded2-2aab-4314-8789-38d384d0992b,SCHEDULED,c90fcdd7-a8ec-40aa-9c64-45caad6ba953,DEVICE_ANALYST,2025-05-29 00:00:04,25,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,4e7da00e-1571-4136-80e3-c0ba815996c4,"{""user_id"": 88, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Simpson"", ""user_guid"": ""4e7da00e-1571-4136-80e3-c0ba815996c4"", ""first_name"": ""Kevin"", ""start_date"": ""2025-01-01"", ""user_email"": ""Kevin.Simpson@lexim.ai"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/4e7da00e-1571-4136-80e3-c0ba815996c4/AGENTS/device_analyst/c90fcdd7-a8ec-40aa-9c64-45caad6ba953"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:15,2025-05-29 00:00:15
fc8344f1-692d-4749-aec5-51c21e363272,USA-FDA,9098ef4b-87a2-4272-9df4-f2046b9246e3,G_DETAILED_SUMMARY,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002/FDA-2015-D-4380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Best Practices for Communication Between IND Sponsors and FDA\nDuring Drug Development Guidance for Industry and Review Staff"", ""docket_id"": ""FDA-2015-D-4380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2015-D-4380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2015-D-4380/FDA-2015-D-4380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:16:48,2025-05-28 03:53:06
fca0b138-da20-4350-8645-3d8241337524,USA-FDA,39916c13-c1fa-4f7d-80cc-5f07b0328c8a,G_MINI_SUMMARY,2025-05-20 09:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002/FDA-2017-D-6380-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Clarification of Orphan Designation of Drugs and Biologics for Pediatric\nSubpopulations of Common Diseases Draft Guidance for Industry"", ""docket_id"": ""FDA-2017-D-6380"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-6380-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-6380/FDA-2017-D-6380-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:01:41,2025-05-28 03:53:06
fcd4cb16-b1d9-4d4c-bfeb-71fb72b7bbab,USA-FDA,80e9999e-6b30-4ad3-b4d7-c3c40062ece3,G_MINI_SUMMARY,2025-05-22 15:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0563/FDA-1996-N-0270-0563-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations"", ""docket_id"": ""FDA-1996-N-0270"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1996-N-0270-0563""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1996-N-0270/FDA-1996-N-0270-0563"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:30:38,2025-05-28 03:53:06
fcde3c0c-2f8c-4510-9141-7d1d851a13b6,USA-FDA,1d815778-e23b-4cd1-9fa6-1c8803ac992d,G_IMPACT_ANALYSIS,2025-05-22 08:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4090/FDA-1999-D-4090-0005/FDA-1999-D-4090-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry and for FDA Reviewers Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer"", ""docket_id"": ""FDA-1999-D-4090"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-1999-D-4090-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-1999-D-4090/FDA-1999-D-4090-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:32:22,2025-05-28 03:53:06
fd0a2aae-3bcb-4ffe-bd66-6744f2568b80,USA-FDA,5e82c2df-3be6-48bf-9681-41f6082bc661,G_IMPACT_ANALYSIS,2025-05-22 01:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011/FDA-2001-D-0137-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children"", ""docket_id"": ""FDA-2001-D-0137"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2001-D-0137-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2001-D-0137/FDA-2001-D-0137-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 01:32:49,2025-05-28 03:53:06
fd2aa9b9-f815-4fa2-b1c4-9d92e670d248,USA-FDA,0d820c78-2ce9-4840-883c-273dea43bee9,G_CONCISE_SUMMARY,2025-05-20 07:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_paragraphs__"": 3, ""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008/FDA-2004-D-0181-0008-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA)"", ""docket_id"": ""FDA-2004-D-0181"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0181-0008""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0181/FDA-2004-D-0181-0008"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 07:32:13,2025-05-28 03:53:06
fd5579ca-ff2f-4bb5-82f3-438ff406c990,SCHEDULED,fa0c622e-3d48-49e6-a9c9-d3a950045efd,DEVICE_ANALYST,2025-05-29 00:00:04,28,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,834cbe38-e182-41f8-bc1d-9da61deed4dc,"{""user_id"": 125, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Patel"", ""user_guid"": ""834cbe38-e182-41f8-bc1d-9da61deed4dc"", ""first_name"": ""Abhishek"", ""start_date"": ""2025-02-19"", ""user_email"": ""Abhishek.Patel@lexim.ai"", ""next_run_date"": ""2025-05-29""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/834cbe38-e182-41f8-bc1d-9da61deed4dc/AGENTS/device_analyst/fa0c622e-3d48-49e6-a9c9-d3a950045efd"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-29 00:00:27,2025-05-29 00:00:27
fd57fde9-c1ea-44ce-8900-7fb8a5e84117,USA-FDA,b3e58325-0d7b-401c-af6e-557cc6f9c85e,G_ACTION_ITEMS,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1279/FDA-2013-D-1279-0002/FDA-2013-D-1279-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Medical Device Development Tools; Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff"", ""docket_id"": ""FDA-2013-D-1279"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1279-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1279/FDA-2013-D-1279-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:01:22,2025-05-28 03:53:06
fd6f2e18-08ee-4cf4-b4d1-8f9e93122b98,USA-FDA,df052fd0-6b03-4cb6-958e-e0eab216b8c5,G_ACTION_ITEMS,2025-05-22 09:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0128/FDA-2008-D-0128-0005/FDA-2008-D-0128-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Guidance for Industry"", ""docket_id"": ""FDA-2008-D-0128"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2008-D-0128-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2008-D-0128/FDA-2008-D-0128-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:47:33,2025-05-28 03:53:06
fd853cbf-f98d-4e10-8ad0-1988ddaa727f,SCHEDULED,cc90ff75-bfbf-47c0-a0d1-22d0b813b2d7,DEVICE_ANALYST,2025-05-22 00:03:21,27,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/device_analyst/cc90ff75-bfbf-47c0-a0d1-22d0b813b2d7"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:40,2025-05-28 03:53:06
fd8ee6b1-503f-489d-81df-cff70ad4fe30,USA-FDA,d9f328d4-d1f1-492c-a4d8-07e58ce3b119,G_KEYWORDS,2025-05-22 02:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__num_keywords__"": 10}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025/FDA-2004-D-0044-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use"", ""docket_id"": ""FDA-2004-D-0044"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2004-D-0044-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2004-D-0044/FDA-2004-D-0044-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 02:15:46,2025-05-28 03:53:06
fdb58c08-8418-46f8-8a9a-efebb222ba49,SCHEDULED,cc910f5d-8281-4385-895f-63ebb7e8c836,DEVICE_ANALYST,2025-05-19 19:18:09,19,22e9cbee-8ffd-40b1-ac72-354a385b80f8,f5afaea1-6d6b-42be-af7d-051ae67b2ec2,"{""user_id"": 108, ""org_guid"": ""22e9cbee-8ffd-40b1-ac72-354a385b80f8"", ""frequency"": ""daily"", ""last_name"": ""M"", ""user_guid"": ""f5afaea1-6d6b-42be-af7d-051ae67b2ec2"", ""first_name"": ""Nanda Kishore"", ""start_date"": ""2025-02-18"", ""user_email"": ""nanda.mandadapu@lexim.ai"", ""next_run_date"": ""2025-05-19""}",{},"{""aws_key"": ""ORGANIZATION/22e9cbee-8ffd-40b1-ac72-354a385b80f8/USERS/f5afaea1-6d6b-42be-af7d-051ae67b2ec2/AGENTS/device_analyst/cc910f5d-8281-4385-895f-63ebb7e8c836"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-19 23:18:20,2025-05-28 03:53:06
fddc3941-8d03-4fd4-9a02-c2a7ec3fb850,USA-FDA,cd3db0ed-690f-4f72-aa5a-580c797ab740,G_ACTION_ITEMS,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011/FDA-2014-D-2300-0011-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Evaluating Drug Effects on the Ability to Operate a Motor Vehicle\nGuidance for Industry"", ""docket_id"": ""FDA-2014-D-2300"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-2300-0011""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-2300/FDA-2014-D-2300-0011"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:32:28,2025-05-28 03:53:06
fdde7cc8-6268-4edd-898a-8633d9e1102e,USA-FDA,366bc773-04f7-4f06-9e28-ec14bece8656,G_DETAILED_SUMMARY,2025-05-20 05:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002/FDA-2013-D-0269-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry; Purchasing Reef Fish Species Associated with the Hazard of Ciguatera Fish Poisoning"", ""docket_id"": ""FDA-2013-D-0269"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0269-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0269/FDA-2013-D-0269-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 05:31:58,2025-05-28 03:53:06
fde1fa9d-ecc9-4a8b-a9af-432aab7d146b,USA-FDA,4ae8f4dd-cff9-4bb5-891a-33f22b20b947,G_ACTION_ITEMS,2025-05-22 07:15:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0002/FDA-2016-D-2567-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on E17 General Principles for Planning and Design of Multi-Regional Clinical Trials"", ""docket_id"": ""FDA-2016-D-2567"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2016-D-2567-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2016-D-2567/FDA-2016-D-2567-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 07:16:24,2025-05-28 03:53:06
fe3073ac-36d6-4227-bf7b-430131877d74,USA-FDA,7171ddcf-b4c6-4d77-a6ec-a92fd7eb5c33,G_DETAILED_SUMMARY,2025-05-20 06:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032/FDA-2002-D-0094-0032-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers"", ""docket_id"": ""FDA-2002-D-0094"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0094-0032""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0094/FDA-2002-D-0094-0032"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:02:17,2025-05-28 03:53:06
fe348268-12a7-4dc4-bcb1-a56c5cc5a27a,USA-FDA,ebeb1b03-145f-4b7d-a6d5-0d54300cac2b,G_ACTION_ITEMS,2025-05-22 03:15:03,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002/FDA-2017-D-4359-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry 68 on Small Entites Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors"", ""docket_id"": ""FDA-2017-D-4359"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2017-D-4359-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2017-D-4359/FDA-2017-D-4359-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:15:35,2025-05-28 03:53:06
fe366cf0-b1f9-4579-aa43-8eb2f1a00ed1,USA-FDA,5c63a908-dbec-4ffc-a5c8-5434cbe0cbe4,G_MINI_SUMMARY,2025-05-20 06:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009/FDA-2003-D-0433-0009-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI"", ""docket_id"": ""FDA-2003-D-0433"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2003-D-0433-0009""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2003-D-0433/FDA-2003-D-0433-0009"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 06:30:09,2025-05-28 03:53:06
fe61fb84-7420-4806-bda5-0da04c6ff0ea,USA-FDA,ae41d054-2c19-4e35-929d-e8a173837fe8,G_FAQ,2025-05-20 15:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002/FDA-2007-D-0202-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting Improving Human Subject Protection"", ""docket_id"": ""FDA-2007-D-0202"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2007-D-0202-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2007-D-0202/FDA-2007-D-0202-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 15:01:59,2025-05-28 03:53:06
fe70f62d-64cc-4a55-b1a7-0a009a9fb1b4,CAB,4d5b7c5d-6f46-44d3-b653-2a343d595d94,G_IMPACT_ANALYSIS_IN,2025-05-20 12:42:55,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,77fcd14d-3764-441c-9570-03e53d871081,{},"{""tilte"": ""FDA-2018-N-3233-0006.pdf"", ""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/ROOT_FOLDER/FDA-2018-N-3233-0006_content.pdf"", ""aws_bucket"": ""lexim-cabinet-dev"", ""document_guid"": ""3f21331b-4399-4219-aa7e-0a5cb7a4ba33""}","{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/CABINET/2eba9a63-67da-4153-b366-7e9f93eff485/3f21331b-4399-4219-aa7e-0a5cb7a4ba33"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-20 16:44:03,2025-05-28 03:53:06
fe8cc368-9815-4c7c-b93e-bc9511a2ba3f,SCHEDULED,292a4abe-3dda-4434-a9a6-974a7e1e5082,FDA_ALERT,2025-05-22 00:03:21,26,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,9963625e-c2b2-41ef-8372-9eece67c5cfa,"{""user_id"": 110, ""org_guid"": ""2ba0ac41-b3aa-4b96-ba47-feeddc029ccd"", ""frequency"": ""daily"", ""last_name"": ""Singh"", ""user_guid"": ""9963625e-c2b2-41ef-8372-9eece67c5cfa"", ""first_name"": ""Priya"", ""start_date"": ""2025-02-19"", ""user_email"": ""Priya.Singh@lexim.ai"", ""next_run_date"": ""2025-05-22""}",{},"{""aws_key"": ""ORGANIZATION/2ba0ac41-b3aa-4b96-ba47-feeddc029ccd/USERS/9963625e-c2b2-41ef-8372-9eece67c5cfa/AGENTS/fda_alert/292a4abe-3dda-4434-a9a6-974a7e1e5082"", ""aws_bucket"": ""lexim-cabinet-dev""}",Pending,2025-05-22 00:03:42,2025-05-28 03:53:06
feb026a7-85fd-416a-8d88-0a751b88c7b9,USA-FDA,56a93ee0-53b1-4e81-affb-2d4738255e95,G_ACTION_ITEMS,2025-05-22 09:00:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0589/FDA-2013-D-0589-0002/FDA-2013-D-0589-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on Human Immunodeficiency Virus-1 Infection:  Developing Antiretroviral Drugs for Treatment"", ""docket_id"": ""FDA-2013-D-0589"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-0589-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-0589/FDA-2013-D-0589-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 09:01:32,2025-05-28 03:53:06
feb45451-561e-4b88-bd73-44dc2ded02f4,USA-FDA,c52ae1c8-d8d0-4aba-846a-760024837c8b,G_IMPACT_ANALYSIS,2025-05-20 08:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025/FDA-2009-D-0524-0025-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Listing of Ingredients in Tobacco Products"", ""docket_id"": ""FDA-2009-D-0524"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0524-0025""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0524/FDA-2009-D-0524-0025"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 08:01:57,2025-05-28 03:53:06
fed1d07c-19cd-44be-951d-04643f214be6,USA-FDA,1c675dd7-4bf0-4013-91c6-2e632145b783,G_DETAILED_SUMMARY,2025-05-22 03:30:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1189/FDA-2018-D-1189-0002/FDA-2018-D-1189-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Highly Concentrated Caffeine in Dietary Supplements: Guidance for Industry"", ""docket_id"": ""FDA-2018-D-1189"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2018-D-1189-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2018-D-1189/FDA-2018-D-1189-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 03:33:08,2025-05-28 03:53:06
fed5cdad-79e7-4e1a-b40a-29c448f81e4d,USA-FDA,249b9f7e-2690-4d93-9c31-b5e30313a019,G_FAQ,2025-05-20 11:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002/FDA-2011-D-0649-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry and Staff; Class II Special Controls; External Pacemaker Pulse Generator"", ""docket_id"": ""FDA-2011-D-0649"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0649-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0649/FDA-2011-D-0649-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 11:01:01,2025-05-28 03:53:06
fefaa8a5-a91d-404a-be19-4bffbf049c3a,USA-FDA,9ff37c9c-b43b-46b2-bfce-4cb1bef348ce,G_IMPACT_ANALYSIS,2025-05-22 16:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0093/FDA-2002-D-0093-0022/FDA-2002-D-0093-0022-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry"", ""docket_id"": ""FDA-2002-D-0093"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2002-D-0093-0022""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2002-D-0093/FDA-2002-D-0093-0022"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 16:32:41,2025-05-28 03:53:06
ff01ac0d-740c-4c0a-8aa5-752160e19478,USA-FDA,13621bc5-3b8b-42ae-b8e1-6bca257bdd4c,G_ACTION_ITEMS,2025-05-22 06:45:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0835/FDA-2011-D-0835-0002/FDA-2011-D-0835-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Considerations when Transferring Clinical Investigation Oversight to Another Institutional Review Board; Draft Guidance"", ""docket_id"": ""FDA-2011-D-0835"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0835-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0835/FDA-2011-D-0835-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 06:46:59,2025-05-28 03:53:06
ff05fb4b-029e-4f45-a79e-67a34151c840,USA-FDA,436befe1-fa18-4374-9615-31f8168727f4,G_FAQ,2025-05-20 13:00:05,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002/FDA-2009-D-0542-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Factors that Distinguish Liquid Dietary Supplements from Beverages, Considerations Regarding Novel Ingredients, and Labeling for Beverages and Other Conventional Foods; Draft Guidance"", ""docket_id"": ""FDA-2009-D-0542"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2009-D-0542-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2009-D-0542/FDA-2009-D-0542-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 13:03:02,2025-05-28 03:53:06
ff3941a0-c6b7-4fd1-a754-b41835cc5c56,USA-FDA,b9739d49-915d-4728-865a-b45b822ef5b2,G_IMPACT_ANALYSIS,2025-05-21 21:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002/FDA-2014-D-1891-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Draft Guidance for Industry on How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD"", ""docket_id"": ""FDA-2014-D-1891"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2014-D-1891-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2014-D-1891/FDA-2014-D-1891-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-21 21:16:21,2025-05-28 03:53:06
ff43e6bd-0b90-4360-82f4-0cb1c7041971,USA-FDA,181dc9f4-8412-4f2c-ab75-beb12a6d1973,G_IMPACT_ANALYSIS,2025-05-22 08:00:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1088/FDA-2013-D-1088-0002/FDA-2013-D-1088-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Small Entity Compliance Guide; Declaring Color Additives in Animal Foods; #223"", ""docket_id"": ""FDA-2013-D-1088"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2013-D-1088-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2013-D-1088/FDA-2013-D-1088-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 08:00:38,2025-05-28 03:53:06
ff87a80f-bb07-4ec8-a91a-06b81dfba462,USA-FDA,7bbc3f21-5338-4bb1-b1fe-380649d65c2d,G_IMPACT_ANALYSIS,2025-05-22 15:15:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-N-0464/FDA-2005-N-0464-0231/FDA-2005-N-0464-0231-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guideline re Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Drug Establishment Registration and Drug Listing; Availability"", ""docket_id"": ""FDA-2005-N-0464"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2005-N-0464-0231""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2005-N-0464/FDA-2005-N-0464-0231"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-22 15:17:44,2025-05-28 03:53:06
ff99f302-d136-45a8-9913-9684ccb47ece,USA-FDA,c85df18e-cc5a-47fd-9311-def4bea67156,G_MINI_SUMMARY,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002/FDA-2011-D-0733-0002-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; Evaluating the Safety of Flood-affected Food Crops for Human Consumption"", ""docket_id"": ""FDA-2011-D-0733"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0733-0002""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0733/FDA-2011-D-0733-0002"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:30:09,2025-05-28 03:53:06
ff9d35e9-1db2-46f1-b282-58bba143302c,USA-FDA,35e2e6b7-684f-4bf1-a08d-f4280fcd02f6,G_IMPACT_ANALYSIS,2025-05-20 18:30:06,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005/FDA-2011-D-0643-0005-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Guidance for Industry; What You Need to Know About Administrative Detention of Foods; Small Entity Compliance Guide; Final Guidance"", ""docket_id"": ""FDA-2011-D-0643"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2011-D-0643-0005""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2011-D-0643/FDA-2011-D-0643-0005"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 18:31:37,2025-05-28 03:53:06
ffb37ffb-a052-470f-8008-38c3605d189b,USA-FDA,37548d3d-2c1a-473c-b870-7b07e2b718cc,G_DETAILED_SUMMARY,2025-05-20 09:30:04,0,2ba0ac41-b3aa-4b96-ba47-feeddc029ccd,e842a45e-7661-4c8f-a9bd-5885d465872b,"{""__document_heading__"": ""Health and Human Services or Food and Drug Administration""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001/FDA-2023-D-2510-0001-guidance.pdf"", ""country"": ""USA"", ""cfr_part"": null, ""doc_type"": ""Other"", ""agency_id"": ""FDA"", ""doc_title"": ""Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)"", ""docket_id"": ""FDA-2023-D-2510"", ""aws_bucket"": ""lexim-ai-dev"", ""document_id"": ""FDA-2023-D-2510-0001""}","{""aws_key"": ""USA/FDA/CONTENT/FDA-2023-D-2510/FDA-2023-D-2510-0001"", ""aws_bucket"": ""lexim-ai-dev""}",Pending,2025-05-20 09:31:09,2025-05-28 03:53:06
